0.9422845100	calcium carbonate
0.9407662298	erythema nodosum
0.9401582448	carbon tetrachloride
0.9400609794	bipolar disorder
0.9388110005	mood stabilizers
0.9387298171	collecting duct
0.9387272715	hydrogen cyanamide
0.9386211327	corn oil
0.9383244116	alkaline phosphatase
0.9382870608	green tea
0.9381438074	dba 2j
0.9379008922	myasthenia gravis
0.9378223782	vital signs
0.9377748905	staphylococcus aureus
0.9376915483	superoxide dismutase
0.9376540668	hibiscus rosa sinensis
0.9375484671	gum arabic
0.9372946296	sensorineural hearing loss
0.9372295752	coenzyme q10
0.9372001015	acetylsalicylic acid
0.9371890574	hemorrhagic cystitis
0.9370634978	downbeat nystagmus
0.9370336922	calcium chloride
0.9368379583	arginine vasopressin
0.9368038196	positron emission tomography
0.9366503989	odds ratio
0.9366395994	frontal lobe
0.9366211327	nonketotic hyperglycinemia
0.9366038196	blot hybridization
0.9365604741	birdshot retinochoroidopathy
0.9363043426	tranexamic acid
0.9362816495	daucus carota
0.9362292578	ad libitum
0.9360735166	cesarean section
0.9359073982	folic acid
0.9358995596	optical coherence tomography
0.9358938074	caesarean section
0.9358698069	c57bl 6j
0.9358324371	dp dtejc
0.9354588843	piperacillin tazobactam
0.9354014387	smooth pursuit
0.9354014387	apoe epsilon4
0.9353511408	guinea pig
0.9348178318	world health organization
0.9348152222	cyproterone acetate
0.9346438074	vena cava
0.9346387866	attentional modulation
0.9340604741	ulcerative colitis
0.9340104038	substantia nigra
0.9339828852	mossy fiber sprouting
0.9339104411	weight gain
0.9336130576	erectile dysfunction
0.9335564662	reactive oxygen species
0.9334997610	blurred vision
0.9334619325	tardive dyskinesia
0.9334356707	nitrous oxide
0.9333410090	alanine transaminase
0.9332070460	gustatory hyperhidrosis
0.9331556052	physical examination
0.9331437843	panic attacks
0.9330438990	triphasic waves
0.9329847720	polyethylene glycol
0.9329688303	passive avoidance
0.9326514387	question arises
0.9326439866	beats min
0.9323901966	ejection fraction
0.9323216918	rheumatoid arthritis
0.9323017240	lipid peroxidation
0.9322800092	vasoactive intestinal polypeptide
0.9322313491	spastic paraparesis
0.9322313491	pyrrolidine dithiocarbamate
0.9321667087	tonotopic organization
0.9317662311	partner preference
0.9317372686	35s tbps
0.9317318833	white matter
0.9316675688	dna fragmentation
0.9315686417	informed consent
0.9313362080	cerebral haemorrhage
0.9312604856	morris water maze
0.9312347720	endoplasmic reticulum
0.9311667087	pleural effusions
0.9310967236	localized scleroderma
0.9310740763	indocyanine green
0.9309140535	end points
0.9308667627	visual acuity
0.9308285918	valproic acid
0.9307887153	orthostatic hypotension
0.9307075986	optical density
0.9306588973	psychomotor retardation
0.9305765595	linear regression
0.9302586490	hypersecretory states
0.9300906297	chest pain
0.9300705931	ethinyl estradiol
0.9300421899	uric acid
0.9299552342	sodium bicarbonate
0.9299380277	hemolytic anemia
0.9298626394	nephrotic stage
0.9297599648	neurotoxic esterase
0.9297541139	creatinine clearance
0.9296789365	heparan sulphate
0.9296108913	glyceryl trinitrate
0.9294956710	aplastic anemia
0.9294702817	choline acetyltransferase
0.9293538693	aspartate aminotransferase
0.9293441540	ovarian cancer
0.9293409511	corpus callosum
0.9293409511	speaking aloud
0.9293181053	cholesteryl hemisuccinate
0.9290914404	breast cancer
0.9287707780	puromycin aminonucleoside
0.9286874948	hot plate
0.9286523374	computed tomography
0.9285370647	subarachnoid hemorrhage
0.9285151907	pertussis immunization
0.9284906374	antithymocyte globulin
0.9283342490	cognitive impairment
0.9282235408	spontaneous alternation
0.9280759686	cardiogenic shock
0.9280351424	d2 occupancy
0.9279574243	luteinizing hormone
0.9278706689	fusidic acid
0.9277756811	hoehn _ yahr
0.9276321037	ionizing radiation
0.9273564862	virgaurea extract
0.9273247118	intraocular pressure
0.9272867390	working memory
0.9271919875	cognitive deficits
0.9271694059	left ventricle
0.9271085338	membranous glomerulonephritis
0.9270068403	mefenamic acid
0.9269823100	prostaglandin e1
0.9267089804	platelet aggregation
0.9266686944	gall stones
0.9266555915	carbonic anhydrase
0.9265427218	ymdd motif mutants
0.9263327728	deoxycholic acid
0.9262683501	mass spectrometry
0.9259747456	diabetes mellitus
0.9259622845	ng ml
0.9258509597	eslicarbazepine acetate
0.9257545154	magnetic resonance
0.9256210510	qt prolongation
0.9256012004	macaque monkeys
0.9254786760	hepatocellular carcinoma
0.9254408021	dp dt
0.9254034615	optic neuropathies
0.9253739207	visual hallucinations
0.9253360199	optic nerve
0.9252655692	orthotopic liver transplantation
0.9251214082	alanine aminotransferase
0.9250519028	optic neuropathy
0.9249167445	cholestatic hepatitis
0.9245742501	cesarean delivery
0.9245347165	mycophenolate mofetil
0.9245347165	polyarteritis nodosa
0.9245347165	vasurix polyvidone
0.9243952187	magnetic resonance imaging
0.9243909820	eye drops
0.9242416828	qtc interval
0.9241256811	palpebral twitching
0.9240753521	urticaria angioedema
0.9240264671	anecdotal reports
0.9238209507	status epilepticus
0.9236256797	mm hg
0.9235584531	acute lymphoblastic leukemia
0.9235486517	forward scatter
0.9235236427	cluster headache
0.9234645623	treadmill exercise
0.9233943030	allergic reaction
0.9233564277	oral contraceptives
0.9231914811	healthy volunteers
0.9231243732	reflex bradycardia
0.9230230464	baep waveforms
0.9229343264	nitric oxide
0.9229206270	smooth muscle
0.9227901113	histamine release
0.9227862893	neuromuscular blockade
0.9227257527	liposomal daunorubicin
0.9227164029	remained unchanged
0.9226071916	pulmonary edema
0.9225642779	bone marrow suppression
0.9224929342	guinea pigs
0.9224550503	adverse event
0.9224197242	ventralis intermedius
0.9224181590	differential diagnosis
0.9224025375	frontal lobe oxygenation
0.9223953607	microglial activation
0.9223578817	pallidal stimulation
0.9222781814	intracerebral hemorrhage
0.9222188836	case summary
0.9221256811	pueraria thunbergiana
0.9221256811	2b1 2b2
0.9220598004	choreoathetoid movements
0.9220067745	clavulanic acid
0.9219706871	ribosomal rna
0.9219348395	polymorphous ventricular tachycardia
0.9219192934	platelet count
0.9219060102	wild type
0.9218966178	human immunodeficiency virus
0.9218553874	peripheral neuropathy
0.9218276854	growth delay
0.9216743807	blood vessels
0.9216504239	prostate cancer
0.9215945362	radionuclide angiography
0.9213453345	complete remission
0.9213361264	microangiopathic hemolytic anemia
0.9213060772	subtenon carboplatin
0.9212832742	nephrotic syndrome
0.9212136483	sodium retention
0.9212104796	cardiac output
0.9211973573	cerebrospinal fluid
0.9211256811	halogenated hydroxyquinolines
0.9210432705	lactic acidosis
0.9210341397	yellow phosphorus
0.9209886398	baboon syndrome
0.9208986635	coronary spasm
0.9208299177	leucocytoclastic vasculitis
0.9208129399	vacuous chewing
0.9207232535	laser pointer
0.9205822691	hippocampal dbs
0.9205668917	appetite suppressants
0.9205419823	contralateral rotation
0.9205340139	cognitive functions
0.9204831062	amyloid beta peptide
0.9202742156	ethacrynic acid
0.9202335412	thymus weight
0.9200867213	substance abuse
0.9200720833	post hoc
0.9200354923	electron microscopy
0.9199729990	diabetes insipidus
0.9199630123	bone marrow
0.9197033494	myocardial ischemia
0.9196989820	body mass index
0.9196509610	bzds rds
0.9196399201	supraventricular tachyarrhythmias
0.9196256811	foramen ovale
0.9196256811	fruit juices
0.9196256811	butylated hydroxyanisole
0.9196256811	homonymous hemianopsia
0.9196256811	stippled epiphyses
0.9196256811	f1 hybrid
0.9196256811	rp 67,580
0.9196256811	radiocalcium uptakes
0.9196256811	vice versa
0.9196256811	bevacizumab irinotecan
0.9196256811	dura mater
0.9196256811	pyeloureteritis cystica
0.9196256811	photorefractive keratectomy
0.9196256811	maculopapular eruption
0.9196256811	anabolic androgenic
0.9196256811	waldenstrom macroglobulinaemia
0.9195837095	prostaglandin e2
0.9195738507	hearing loss
0.9195085351	lumbar plexus
0.9194103478	diabetic nephropathy
0.9194087681	diastolic bp
0.9192684285	cholesteryl ester accumulation
0.9192677158	ventricular arrhythmias
0.9190771174	1mg kg
0.9190297344	tricyclic antidepressants
0.9190154925	ergotamine caffeine
0.9189946820	mutual potentiation
0.9189550752	hip fracture repair
0.9189099335	grade iii
0.9188019020	marker enzymes
0.9186929504	creatine monohydrate
0.9186256811	moles glomerulus
0.9185772795	calcineurin inhibitors
0.9185740066	rem sleep
0.9185247525	local anaesthetic
0.9185067465	brain regions
0.9184367009	intensive care unit
0.9182443251	metabolic acidosis
0.9181826478	emergency physician
0.9181741562	phosphodiesterase inhibitor cilostazol
0.9181390974	biopsy specimens
0.9181061848	thiobarbituric acid reactive substances
0.9178751834	qt interval
0.9178627042	mitral valve prolapse
0.9178582525	brachial artery
0.9177937006	reference range
0.9177876621	procedural sedation
0.9175645976	liposomal doxorubicin
0.9173523985	oxidant stress
0.9173050174	cholestatic jaundice
0.9172985536	oxygen consumption
0.9172706775	garcinielliptone fc
0.9171882335	coronary arteries
0.9171838706	lipid emulsion
0.9171354407	respiratory chain
0.9170880272	overnight memory consolidation
0.9170780154	paranoid exacerbations
0.9170397550	sinus rhythm
0.9170289418	interstitial fibrosis
0.9170286183	sexual dysfunction
0.9170137619	folinic acid
0.9168109694	glial fibrillary acidic protein
0.9166370703	primary dysmenorrhea
0.9165808348	pulmonary hypertension
0.9164713276	odds ratios
0.9163767004	bone resorption
0.9163481741	set shifting
0.9163307998	mantle cell lymphoma
0.9162637551	steady state
0.9162422282	persistent sterile leukocyturia
0.9161755450	mental confusion
0.9161030227	carried forward
0.9160916526	contrast medium
0.9160803547	left ventricles
0.9160091495	auditory location discrimination
0.9159740493	adverse reactions
0.9159710338	mast cell
0.9158896575	hearing impairment
0.9158549267	nonsmall cell lung carcinoma
0.9157808653	tobacco smoking
0.9156610558	histological examination
0.9156136911	peritubular capillary basement
0.9155926882	lupus erythematosus
0.9155503932	emergency department
0.9155307995	color vision
0.9154392518	cytosine arabinoside
0.9154158773	atrial natriuretic factor
0.9152892919	visual field
0.9152835116	meth mouth
0.9152192735	oral contraceptive
0.9151479707	proximal tubular
0.9151419572	alcohol consumption
0.9151376509	conscious shr
0.9150534220	pupil size
0.9150440954	red cell
0.9149519329	coronary cta
0.9149462975	sexual behavior
0.9148690754	basal ganglia
0.9148162090	bladder irrigation
0.9148076969	antitumor activity
0.9147653830	controlled trials
0.9147237016	skin rash
0.9146596607	nitric oxide synthase
0.9146105946	foot process effacement
0.9145526437	100mg kg
0.9145386672	cerebral infarction
0.9145204711	interstitial nephritis
0.9145059874	multiple myeloma
0.9144961298	oxidative stress
0.9144187720	repetitive transcranial magnetic stimulation
0.9143389338	soyabean oil
0.9143389338	bronchial asthma
0.9142198862	procedural sedations
0.9141525836	seizure susceptibility
0.9139998379	supplemented diets
0.9139982967	neuroleptic malignant syndrome
0.9139824355	hypertensive crisis
0.9139673264	ventricular fibrillation
0.9139620554	light microscopy
0.9139483996	surgical procedures
0.9139312810	myocardial infarctions
0.9139022560	apparent diffusion coefficient
0.9138389338	healthcare professionals
0.9138389338	cholesteryl esters
0.9138355397	sinoatrial node
0.9137629244	bs synthesis
0.9136076441	inulin clearance
0.9135565530	local anesthetic
0.9135319334	creatine kinase
0.9135177020	inflammatory infiltrate
0.9134971023	timolol gellan
0.9134936110	gene expression
0.9134353807	glomerular filtration rate
0.9134187720	suicidal erythrocyte death
0.9134178466	body temperature
0.9134171548	hbv reactivation
0.9133156780	newly synthesized
0.9133081397	nephrogenic diabetes insipidus
0.9132812362	thymidylate synthase
0.9132309690	malignant hyperthermia
0.9131966304	mitral annuloplasty
0.9131966304	mitral annulus
0.9131911644	migraine attack
0.9131869337	fanconi syndrome
0.9131843637	tenofovir disoproxil fumarate
0.9130988007	medical records
0.9130577244	maternal deprivation
0.9129490580	beagle dogs
0.9129232767	lymphoproliferative disorder
0.9128925154	lowering surgeries
0.9128156780	endoscopic sympathectomy
0.9127347927	molecular weights
0.9126802377	depressed mood
0.9126633870	mmse sum
0.9126073608	sigma1 receptors
0.9125659866	atrioventricular block
0.9125354423	ultrasound production
0.9124932449	calcium channel blockers
0.9124061456	pinealectomized chick
0.9123784397	mental status
0.9123637296	substituted benzamide
0.9123119672	ecstasy users
0.9123091582	orbital soft
0.9122871759	atrial conduction
0.9122812362	prostate adenocarcinomas
0.9122362960	myelodysplastic syndrome
0.9122278677	adverse experiences
0.9121835107	inflammatory cytokines
0.9121835107	inflammatory mediators
0.9121043582	immunoprecipitation western blotting
0.9120748798	coronary vasospasm
0.9120365699	chemotherapeutic agent
0.9120282600	ecstasy polydrug
0.9119942741	light microscopic
0.9119618839	p450 monooxygenases
0.9119011649	diabetic kindreds
0.9118952278	bile canaliculi
0.9118952278	bile diversion
0.9118885695	evans blue
0.9118774737	premature ventricular contractions
0.9118644002	physical exam
0.9117066100	teaching hospital
0.9116817521	pneumocystis pneumonia
0.9116773569	calcineurin phosphatase
0.9116687697	excitatory amino acid
0.9116264990	supraglottic resistance
0.9115591582	monoamine oxidase
0.9115338447	clinical practice
0.9114974823	vasogenic edema
0.9114629096	eosinophilic myocarditis
0.9113747069	amino acid
0.9113525900	neuroactive steroids
0.9112902925	epithelial cell
0.9112658023	epithelial cells
0.9111873669	sodium nitroprusside
0.9111326440	visual electrophysiology
0.9110818555	soft tissue
0.9110558057	atrial fibrillation
0.9109823447	chick embryo
0.9109673001	myoclonic jerks
0.9109506612	hepatocellular necrosis
0.9109161704	reye syndrome
0.9108410593	channel blockers
0.9107972930	migraine headache
0.9107883007	bladder irritation
0.9107702129	base line
0.9107622775	motor fluctuations
0.9107043093	cb1 ko
0.9106497409	inferior colliculus
0.9105392048	cardiopulmonary resuscitation
0.9105164076	p24 antigen
0.9105046342	salvianolic acid
0.9104830802	thermal enhancement
0.9104536482	statistical significance
0.9104296745	generic haart
0.9102961404	sexual desire
0.9102751439	biological abstracts
0.9102740570	sinoatrial block
0.9102284209	extrapyramidal symptoms
0.9102060833	lithium carbonate
0.9101585318	converting enzyme
0.9101128083	local anesthetics
0.9100958430	systolic blood pressure
0.9100778866	jak stat3 pathway
0.9100705691	masseter spasm
0.9100124220	polymer dextran
0.9099808931	postoperative myalgia
0.9099044999	locomotor activity
0.9098357236	bacterial infections
0.9098030544	halogenated anesthetics
0.9097761765	atrial flutter
0.9097542631	vitamin b12
0.9097497946	medical history
0.9097497518	symptom progression
0.9097211122	contrast material
0.9096720323	irritable bowel syndrome
0.9095777756	mg bid
0.9095379721	botulinum toxin
0.9095375255	thrombotic microangiopathy
0.9095247409	spinal transection
0.9094830893	adult offspring
0.9094776491	angina pectoris
0.9094129424	executive functioning
0.9094129424	glioblastoma multiforme
0.9093980384	lateral epicondylitis
0.9093949731	cycle length
0.9092660141	organ transplantation
0.9091984560	ventricular tachyarrhythmias
0.9091718315	tongue protrusions
0.9090688669	gallbladder contractility
0.9090056005	hemopoietic progenitor
0.9090056005	solute diuresis
0.9089392577	facial dysmorphism
0.9088806087	coronary ligation
0.9088159662	muscle rigidity
0.9088022864	p53 inhibition
0.9087955234	myocardial infarction
0.9087821585	glucose effectiveness
0.9085481985	thyroid stimulating hormone
0.9085073669	abdominal pain
0.9084622565	aortic segments
0.9084369726	virus infection
0.9083154917	ventricular tachycardia
0.9082388375	visual field constriction
0.9081837572	taurocholic acid
0.9080709635	end point
0.9080590339	coronary angiogram
0.9080470036	systolic bp
0.9080379721	slurred speech
0.9080379721	intraplatelet camp
0.9079996344	healthcare providers
0.9079056422	ocular motility
0.9078560334	muscle fasciculation
0.9077399204	ldlr transcript
0.9077399204	microbiologic eradication
0.9077010628	central sensitization
0.9076875541	sirius red
0.9076186821	carbon dioxide
0.9075572885	atypical antipsychotic
0.9075350789	dry mouth
0.9075182545	hepatic injury
0.9075132034	predisposing factor
0.9074319711	statistical analysis
0.9074012073	predisposing factors
0.9073131762	cuprolinic blue
0.9073131762	goldmann perimetry
0.9071624696	granule cell
0.9070983285	colon cancer
0.9070765569	mole fraction
0.9070020487	panic attack
0.9069624255	accurate diagnosis
0.9069428948	retention deficit
0.9069400582	direct thrombin inhibitor
0.9069009306	glutathione reductase
0.9068528409	ic50 values
0.9068380003	dopaminergic neurotransmission
0.9068361172	gingival hyperplasia
0.9068361172	brainstem dysgenesis
0.9068273650	circumflex artery
0.9067728199	oleic acid
0.9066587047	obsessive compulsive
0.9065650129	pituitary tumors
0.9065388313	graft loss
0.9065339426	quinacrine hydrochloride
0.9064877039	bilateral vagotomy
0.9064259306	allergic rhinitis
0.9064113338	prospectively evaluated
0.9063286346	unified parkinson
0.9062899204	necrotising fasciitis
0.9061926449	percutaneous mechanical thrombectomy
0.9061186821	steering accuracy
0.9060861677	dilated cardiomyopathy
0.9060615203	unfractionated heparin
0.9059868871	micrograms t.i.d
0.9059260247	se survivors
0.9058612210	cingulated cortex
0.9057957972	action potentials
0.9057948894	sinus bradycardia
0.9057853487	fibrin sealants
0.9057182681	angio oedema
0.9057147943	mumol kg
0.9057106145	gall bladder
0.9056795114	ctni elevations
0.9056676664	concentrating defect
0.9056186821	jaw stiffness
0.9056186821	myotonia congenita
0.9055990406	pkca ko
0.9055549421	multivariate analysis
0.9054283414	chorioretinal atrophy
0.9054251419	taurodeoxycholic acid
0.9053856506	releasing hormone
0.9053632865	phenytoin sodium
0.9053132021	divalproex sodium
0.9053128286	sympathetic outflow
0.9052927835	life threatening
0.9052847606	lateral epicondyle
0.9052490273	sinus node
0.9052247039	angiotensin converting enzyme
0.9052042516	therapeutic option
0.9051300698	microg ml
0.9050662784	enos mrna
0.9050511156	lymph node
0.9049616928	multivariate regression analysis
0.9048780823	prospectively collected
0.9048612210	leukocytoclastic vasculitis
0.9048555966	carotid arteries
0.9047934481	ventricular pacing
0.9047707635	optic atrophy
0.9046780696	bipolar mania
0.9045511156	fluocinolone acetonide
0.9045306173	qt interval prolongation
0.9044718538	ocular myasthenia
0.9043336946	tyrosine phosphatase
0.9042740460	solid organ
0.9042360785	chronically instrumented
0.9041863727	norepinephrine spillover
0.9041714123	metastatic breast cancer
0.9040846377	intragastric pressure
0.9040646901	thrombotic events
0.9040387315	pre existing
0.9040362805	17beta estradiol
0.9040230573	aspartate transaminase
0.9039820197	cerebral vasculitis
0.9039044003	intermittent claudication
0.9037889265	salvage therapies
0.9036985882	general practitioners
0.9035392109	pleural effusion
0.9034544186	chemical bioactivation
0.9034038043	confocal microscopy
0.9032853487	plasminogen activator
0.9032742071	coronary stenosis
0.9032676886	autoimmune diseases
0.9030482405	computerized tomography
0.9030338423	podocyte injury
0.9030217736	movement disorders
0.9030133051	cpa ee
0.9029673582	ng dl
0.9029213423	gouty arthritis
0.9028698852	platelet counts
0.9028652125	physiological saline
0.9028608833	heroin addicts
0.9028104421	urine volume
0.9027753837	liver transplantation
0.9027151270	marmara university
0.9027050533	randomly allocated
0.9026999023	zinc acetate
0.9026795701	cardiac myocytes
0.9026132877	iodinated contrast medium
0.9025737009	sleep deprivation
0.9025105185	hodgkin lymphoma
0.9023575311	muscular incoordination
0.9022493871	drinking water
0.9022049820	signal intensity
0.9021639911	supraventricular tachycardia
0.9021484660	deep vein thrombosis
0.9021348521	cardiopulmonary bypass
0.9021157172	metastatic nsclc
0.9020764009	pyrrolidine ring
0.9020561930	serum cholinesterase
0.9020429245	galanthamine hydrobromide
0.9020429245	sr 48,968
0.9019690293	globus pallidus
0.9018131762	nonlactating nonpregnant
0.9017766065	skin reactions
0.9016582585	exo utero
0.9016543197	10mg kg
0.9015957289	lpo generation
0.9015765031	topical papaverine
0.9014845987	abstract truncated
0.9014677568	previous reports
0.9014578942	midline b3
0.9014329558	ace inhibitor
0.9014093552	prostaglandin d2
0.9014085164	mitral regurgitation
0.9013877973	systemic lupus erythematosus
0.9013656013	nonionic contrast media
0.9013022727	temporal lobe
0.9012707808	psychological distress
0.9012676858	intramural vasoconstriction
0.9012153137	neurocritical care
0.9011698062	grand mal seizures
0.9011596309	micrograms b.d
0.9010912426	capillary leak syndrome
0.9010357953	exclusion criteria
0.9009441667	open label
0.9008885176	psychiatric disorders
0.9007408012	gross haematuria
0.9007284016	milk alkali syndrome
0.9007161999	preterm infants
0.9007099545	etiologic factors
0.9006888724	av node
0.9006827053	serotonin reuptake inhibitors
0.9006749072	alpha1 adrenoceptor
0.9006582585	von frey
0.9005088629	lipid peroxide
0.9005039007	convincing evidence
0.9004503642	paracellular permeability
0.9004470409	cardiovascular collapse
0.9004461557	hips cms
0.9003665141	antiglobulin test
0.9003627429	lemon essential oil
0.9003121089	cortical dysplasia
0.9002929760	chest discomfort
0.9002849384	body weight
0.9001810611	cardiac arrest
0.9001763840	ventral lesion
0.9001256414	vegf vpf
0.8999704576	neuronal loss
0.8999670627	catheter ablation
0.8999569849	lateral ventricle
0.8999566832	body surface area
0.8999223285	preterm labor
0.8998775016	peripheral iron dextran
0.8998619756	congestive heart failure
0.8998479367	qs qt
0.8998327226	polymerase chain reaction
0.8998222435	guinea pig ileum
0.8998018659	hepatocyte tjs
0.8997997855	antirifampicin antibodies
0.8997980073	lichenoid dermatitis
0.8997688227	autonomic neuropathy
0.8997201060	receptor antagonist
0.8996862533	gspe preexposure
0.8995970188	real rtms
0.8993933492	premature neonates
0.8993504474	developmental anomalies
0.8993456119	takotsubo syndrome
0.8993362633	left ventricular
0.8992928735	ischemic colitis
0.8992774198	type iia
0.8992304506	ammonia coma
0.8991058659	sound source location
0.8990743109	western blotting
0.8990283647	wt mice
0.8990054937	logistic regression
0.8989804622	microvascular permeability
0.8988521601	lipid metabolism
0.8988092148	nocturnal asthma
0.8987980073	hbeag negativity
0.8987691021	ldl cholesterol
0.8987593457	special reference
0.8986623275	oral contraception
0.8986437432	stabilizing action
0.8986334471	clomiphene citrate
0.8986072243	cells microl
0.8986020455	anti hbe
0.8985466707	pulse power analysis
0.8984980211	left ventricular ejection fraction
0.8984725115	cm h2o
0.8984528541	blood urea nitrogen
0.8984242242	cytochrome p450 3a4
0.8983989526	birth defects
0.8983826361	kainic acid
0.8982702726	middle ear
0.8982665649	cholesterol rich
0.8982648319	mouse strain
0.8982282690	driving simulator
0.8982166819	swiss webster mice
0.8982119108	intravenous ribavirin
0.8981689394	cochrane library
0.8981359968	prostaglandin synthesis
0.8981196946	primary pulmonary hypertension
0.8980825009	golgi cisternae
0.8980749302	antiarrhythmic agent
0.8980668875	qrs prolongation
0.8978625605	antineutrophil cytoplasmic
0.8977242358	digit span
0.8976951300	gamma hch
0.8976559996	4,000 micrograms
0.8976182326	opioid abusers
0.8976135907	wilms tumor
0.8975927929	alternation behavior
0.8975611572	terminalia chebula
0.8975611572	cranberry juice
0.8974857264	axillary block
0.8974540837	symptom severity
0.8974335079	hydrogen peroxide
0.8974242242	dorsal root ganglia
0.8973123077	band keratopathy
0.8973123077	polymyositis dermatomyositis
0.8973105210	st segment
0.8972789940	pharmacokinetic pharmacodynamic
0.8972263851	passive avoidance paradigm
0.8971827279	intracranial pressure
0.8971825735	serotonergic antidepressants
0.8971116474	major depressive disorder
0.8971094492	epsilon aminocaproic acid
0.8971092418	pregnenolone sulphate
0.8970982032	pure red cell aplasia
0.8970962716	fluocinolone acetonide implant
0.8970906131	mg m2bsa
0.8969517539	neurotransmitter overflow
0.8969298494	tyrosine kinase
0.8969298494	dentate gyrus
0.8968173833	extrahepatic tissues
0.8967930660	blood coagulation
0.8967885151	rosaceiform dermatitis
0.8967746415	acetic acid
0.8967416156	blood samples
0.8967293357	glutamate uptake
0.8967165463	dobutamine infusion
0.8967055904	temporal lobe epilepsy
0.8966964773	chart review
0.8966905899	pupillary oscillation
0.8966743231	dna synthesis
0.8965379014	disodium edetate
0.8965293111	dopaminergic neurones
0.8965020128	breast carcinoma
0.8964884400	cognitive processes
0.8964857264	postoperative emetic
0.8964580363	fractional shortening
0.8964282985	vocal cord function
0.8964277271	bristol myers squibb company
0.8963390984	panic disorder
0.8961796049	suicide attempt
0.8961386902	fulminant hepatic failure
0.8960279511	adversely affected
0.8960229263	real world
0.8959877832	hepatorenal syndrome
0.8959769015	renal insufficiency
0.8959708648	cardiac arrhythmias
0.8958602960	granulocyte colony stimulating factor
0.8958422097	adjusted odds ratio
0.8958210340	crack cocaine
0.8958112443	causality assessment
0.8957806263	purkinje cells
0.8957487510	electron dense
0.8957420244	secretory granules
0.8957343856	portal tracts
0.8957279425	percutaneous coronary intervention
0.8956987086	severe malaria
0.8955921605	syncopal attacks
0.8955607451	sodium valproate
0.8955361674	diclofenac sodium
0.8954649440	cognitive development
0.8954511547	peri operative
0.8954150437	verbal fluency
0.8953701595	viral replication
0.8953661499	estrogen replacement
0.8953586865	healthy subjects
0.8952395325	mood switches
0.8952313349	exaggerated adrenergic response
0.8951809557	visual disturbances
0.8951595472	long standing
0.8951433442	mono infected
0.8951405050	bone marrow transplantation
0.8951387379	past users
0.8951244600	parathyroid hormone
0.8951227632	delusional parasitosis
0.8951220558	epsilon4 allele
0.8950811803	frequently sampled intravenous glucose tolerance test
0.8950746054	superior sagittal
0.8950622840	perhexiline maleate
0.8950377303	stevens johnson syndrome
0.8950234634	intrathecal adenosine
0.8950036487	tissue oxygenation
0.8948637519	leukemoid reaction
0.8948471155	transketolase abnormality
0.8948083499	visual deficits
0.8948046345	pupil diameter
0.8948038502	lopinavir ritonavir
0.8947903410	phase iii
0.8947849999	systemic sclerosis
0.8947423570	resolved completely
0.8947379499	compression neuropathy
0.8947077985	respiratory failure
0.8947069797	enac subunits
0.8946523589	locus coeruleus
0.8945748341	rebound phenomenon
0.8945698835	pseudomonas aeruginosa
0.8945080671	unrecordable blood
0.8944398881	hemolytic anemias
0.8943623352	extended interval
0.8943249593	type iib
0.8943020158	personality disorder
0.8942736576	climbing behavior
0.8942538625	blood collection
0.8942344209	gamma vinyl gaba
0.8942292752	oversulfated chondroitin sulfate
0.8941782055	bile duct
0.8941780397	cannabis users
0.8941523589	liquid chromatography
0.8941375778	neutrophil count
0.8941330744	sodium deoxycholate
0.8941157471	blood flow
0.8940496462	lactic acid dehydrogenase
0.8940208952	stimulant action
0.8940097395	cervical cord
0.8939974460	cell cultures
0.8939333809	nerve fiber layer
0.8939124498	blood dyscrasias
0.8938943520	disease progression
0.8938588450	controlled trial
0.8938240715	cardiac hypertrophy
0.8938165223	hazard ratio
0.8938113496	transmission electron microscopy
0.8937852631	nonsteroidal antiinflammatory
0.8937791617	brachial plexus
0.8937745229	focal segmental glomerulosclerosis
0.8937637879	capillary walls
0.8937518774	nick end
0.8937453315	bone formation
0.8937428963	bispectral index
0.8937395410	alkylating agents
0.8937389923	brain natriuretic peptide
0.8937296681	visual disturbance
0.8937095692	randomised clinical trials
0.8936106027	bcnu solvent
0.8936098598	exposed newborns
0.8935960528	north carolina
0.8935953277	home cage
0.8935929245	1a1 1a2
0.8935703564	tyrosine hydroxylase
0.8935614554	substantia nigra pars reticulata
0.8935125467	transforming growth factor beta1
0.8934814149	ectopic hilar granule cells
0.8934558317	sodium citrate
0.8934469164	birth weight
0.8933580158	synaptic markers
0.8933416407	deliberate hypotension
0.8933269979	gall stone
0.8932849422	epidural steroid injections
0.8932684970	transcription factor
0.8931391737	apical ballooning
0.8930776838	osmotic fragility curves
0.8930642576	protocol violation
0.8930610766	aggressive behavior
0.8930481146	sleep disturbance
0.8929874989	daucus carota seeds
0.8929586291	leg cramps
0.8929216990	repeat words read
0.8929081932	sarcomeric actin
0.8929023729	receptor agonist
0.8928903283	buffered lidocaine
0.8928665684	renal allograft
0.8928594981	angioneurotic edema
0.8928455739	muscle fasciculations
0.8928431076	nuclear factor kappab
0.8927899795	albumin excretion
0.8927746054	carotid endarterectomy
0.8926534727	northern blot
0.8926325009	orphanin fq
0.8926325009	zymosan opsonized
0.8926227496	rating scale
0.8926124490	achr expression
0.8926111100	glutamic acid decarboxylase
0.8925241219	signal intensities
0.8924760146	gamma aminobutyric acid
0.8924595283	tgf beta1
0.8924225858	transgenic mice
0.8923751587	urinary tract
0.8923631622	clinical trials
0.8923475031	transfusion reaction
0.8922935697	urinary concentrating ability
0.8922843781	inbred mouse strains
0.8922076468	cleft lip
0.8921956061	marrow grafting
0.8920134534	myopic excimer laser
0.8919874022	cognitive function
0.8919779932	calcium gluconate
0.8919493730	stress incontinence
0.8918999779	duchenne dystrophy
0.8918030632	aminoglycoside antibiotics
0.8917380814	cubic phases
0.8917159532	a2a receptor agonist
0.8916965369	long lasting
0.8916779559	monosodium glutamate
0.8916464604	immune mediated
0.8916437164	intrahepatic cholestasis
0.8915746585	water intoxication
0.8915177590	tacrolimus ointment
0.8915037433	poorly understood
0.8914133545	late onset
0.8913523638	blood cultures
0.8913210911	antigen assay
0.8912762406	thoracic aortic aneurysm
0.8912527313	axonal neuropathy
0.8912221212	fluorescence microscopy
0.8912029359	neuropathic pain
0.8911423364	cross sectional
0.8911262115	upper lid
0.8911181128	spinal needle
0.8909559085	posttransplant anemia
0.8909443264	exploratory box
0.8909379013	cerebral edema
0.8908971893	protein adducts
0.8908404541	antisocial personality
0.8908258205	nmda receptor
0.8908230162	niacin extended release lovastatin
0.8908044089	pallidal neurotensin
0.8907931873	pair fed
0.8907436811	chronic allograft nephropathy
0.8907426588	cm h2o cpap
0.8907202553	protease inhibitor
0.8907077132	tricuspid valve
0.8907076933	ultra short acting beta adrenergic blocking
0.8906558911	freely moving
0.8905411912	metabolic derangement
0.8904891449	mood stabilizer
0.8904778732	urinary nox excretion
0.8904771211	pelvic radiotherapy
0.8904691071	sustained release
0.8904443264	trabecular meshwork
0.8904254946	passive avoidance apparatus
0.8903743799	alkaline diuresis
0.8903404541	pars reticulata
0.8902891497	hbs ag
0.8902698155	bundle branch block
0.8902590844	interlobular bile ducts
0.8901995232	nerve growth factor
0.8901683434	older age
0.8901494629	copolymer conjugates
0.8901065925	juxtacanalicular tissue
0.8899472640	gamma hexachlorocyclohexane
0.8899174095	natriuretic peptide
0.8898555982	lipid nanosphere
0.8898555982	polysomnographic sleep
0.8898127767	dialytic support
0.8897884982	sprague dawley
0.8897579349	swiss albino
0.8897571024	pg ml
0.8897480361	post operative
0.8897325629	meta analysis
0.8895406099	cerebral hemispheres
0.8895197699	trough concentrations
0.8894233645	perfusion defects
0.8893668016	pneumocystis carinii pneumonia
0.8893625545	creatine phosphokinase
0.8893533611	mg tid
0.8893445463	fibrin thrombi
0.8892957479	coronary sinus
0.8892520550	mglu7 receptor
0.8892343337	lv diameters bw
0.8891635138	glutathione peroxidase
0.8890421396	late stage
0.8890289802	halothane anesthesia
0.8890209417	yellow card records
0.8889631503	eye movements
0.8889138397	weight loss
0.8888813797	dna damage
0.8887939447	acute promyelocytic leukemia
0.8886534727	spasmodic dysphonia
0.8885096576	calcineurin inhibitor
0.8884859567	spectrum disorders
0.8883595845	luminal hemoglobin content
0.8883213101	arterial pressure
0.8882887443	information exists
0.8882535634	piriform cortex
0.8881919810	attention deficit hyperactivity disorder
0.8880849166	sham operated
0.8880830033	inflammatory bowel disease
0.8879381974	platypnea orthodeoxia
0.8879241503	iron overload
0.8878381111	affective temperament interview
0.8875224621	highly selective
0.8875193624	medial preoptic area
0.8874148703	double blinded
0.8873316086	brush evoked
0.8872688669	liquid crystalline cubic phases
0.8872513288	dobutamine stress
0.8872509537	thiazide diuretics
0.8872210318	chromosome substitution strains
0.8872164199	hepatocyte tight junctions
0.8871918608	neuromuscular monitoring
0.8871625514	semantic verbal fluency
0.8871205556	endogenous antioxidants
0.8871068544	neurologic examinations
0.8871024211	single photon emission tomography
0.8871011017	adp ribose
0.8870067099	lvdp dt
0.8868898011	pulse rate
0.8868764753	cumulative dose
0.8868471227	fibrous myopathy
0.8868366001	apical ballooning syndrome
0.8868044507	maximum urethral pressure
0.8868026526	racemic metoprolol
0.8868018756	closely monitored
0.8868018756	monitored closely
0.8866531176	pupillary dilation
0.8866019403	bilateral abductor paralysis
0.8865413213	rifle criteria
0.8865029824	micrograms ml
0.8864942836	extrapyramidal syndrome
0.8864785001	immunocompromised children
0.8864537887	sympathetic tone
0.8864275186	calcium channel
0.8864267112	statistically significant
0.8863999476	squamous cell carcinoma
0.8863403863	pro fi les
0.8862505210	variant ventricular tachycardia
0.8861866436	epileptiform activity
0.8861654223	nicotinic acid amide
0.8861528885	acute interstitial nephritis
0.8861164640	graft versus host disease
0.8859786164	visual field defects
0.8859604087	electrolyte imbalance
0.8859471797	eating hot spicy
0.8859055969	sensory neurons
0.8859015405	osmolar contrast medium
0.8858969994	infusional cyclophosphamide
0.8858744517	vacuolar degeneration
0.8858336232	bile duct injury
0.8858296356	nmda nr1
0.8857821740	relative risk
0.8856996812	inclusion bodies
0.8856808367	electromyographic activity
0.8856697084	extracellular matrix
0.8856601501	literature review
0.8856419743	perfusion cultured human eyes
0.8856103997	rostral ventrolateral medulla
0.8855788529	sensorimotor axonal polyneuropathy
0.8855504817	5,7 dht
0.8855423542	beta blockers
0.8854962583	facial twitching
0.8854511836	sexual arousal
0.8854338413	pressor responsiveness
0.8854271435	venous thromboembolism
0.8854153392	free radical
0.8854031176	processing speed
0.8853561874	acute bacterial sinusitis
0.8853225060	heparin products
0.8852856694	scleroderma renal crisis
0.8852623675	plasma aldosterone
0.8851566946	spontaneous ventilation
0.8851342055	sleep architecture
0.8851192545	manic episodes
0.8851160423	selective serotonin reuptake inhibitors
0.8851079694	forearm vascular resistance
0.8850915060	lvpw index
0.8850445253	remained sedentary
0.8850391101	rhesus monkeys
0.8850160447	urine nag activity
0.8850127863	tetanic tensions
0.8849560160	cerebral microbleeds
0.8849501254	progressive supranuclear palsy
0.8849477468	solid tumors
0.8849308029	nf kappab
0.8848984099	ischemic stroke
0.8848899658	cysteine protease
0.8848467379	randomly selected
0.8848375581	daytime sleepiness
0.8848047847	tie2 cre
0.8847492617	summed stress
0.8847245065	intrauterine growth retardation
0.8846710295	object recognition
0.8846674411	heart rate variability
0.8846118712	basal tear secretion
0.8845768370	serum creatinine
0.8845429420	gall stone dissolution
0.8844095691	monophasic action potential
0.8844073850	beta adrenoceptor
0.8843304420	somatostatin analog
0.8843215314	health care
0.8841841859	fatty acids
0.8841197431	hiv p24
0.8839692309	glomerular tuft
0.8839496812	trigeminal neuralgia
0.8839271979	dopaminergic neurons
0.8838901574	nasal hypoplasia
0.8838669558	overactive bladder
0.8838610513	antioxidant properties
0.8837998288	delayed onset
0.8837372127	end tidal
0.8837272458	lung cancer
0.8836239162	st elevation
0.8835972212	chinese hbsag carriers
0.8835025558	intravenous fluids
0.8834576525	prejunctional beta adrenoceptor
0.8834455461	picrorrhiza kurroa
0.8834130259	spinal anaesthesia
0.8833983986	endothelial cells
0.8833691018	behavioral despair
0.8833307322	green fluorescent protein
0.8833095558	gamma knife
0.8833047847	kruskal wallis
0.8832694127	remained unaffected
0.8832646965	biogenic amines
0.8832353955	nasal cavity
0.8832336262	striatal 3h spiperone binding sites
0.8831900372	secondary hyperparathyroidism
0.8831118182	mg t.i.d
0.8831070049	humoral immunity
0.8830747054	cmax mic
0.8830652548	topical glycopyrrolate
0.8830505462	cranial decompression
0.8830260683	noxious thermal
0.8829711751	cure rate
0.8829637721	hyperpolarization activated cyclic nucleotide gated
0.8829009556	hot spicy food
0.8828911900	morphologic damage
0.8828692265	sudden death
0.8828546789	ache activity
0.8828261217	beta ar
0.8828176957	intractable atrioventricular reentrant tachycardia
0.8827831719	hand foot syndrome
0.8827708850	bone marrow transplant
0.8827516444	poorly characterized
0.8827470960	correlation coefficient
0.8827202988	osmotic gradient
0.8826498187	anabolizing agent
0.8826273460	dose escalation
0.8826151371	bone turnover
0.8825761668	kearns sayre syndrome
0.8825194862	vacuous chewing movements
0.8824539625	att alf
0.8824455195	static grip force
0.8823881801	hpma copolymer conjugates
0.8823376627	clozapine olanzapine risperidone
0.8822928980	lumbar puncture
0.8822560131	depolarization velocity
0.8822313018	ipratropium bromide
0.8822152260	laryngeal mask
0.8821763564	disseminated necrotizing leukoencephalopathy
0.8821756801	congenital anomalies
0.8821592551	univariate analysis
0.8821268366	alpha2 adrenergic
0.8821241096	heart failure
0.8820508526	past cip
0.8820508526	colour vision
0.8820028477	multichannel blockers
0.8819801698	atrial thrombosis
0.8819565515	cell line
0.8819394043	cognitive abilities
0.8819268263	case description
0.8818954984	continuous ambulatory peritoneal dialysis
0.8818361386	affective disorders
0.8818304420	macrolide antimicrobials
0.8817900050	muscle weakness
0.8817471054	segmental necrotizing glomerulonephritis
0.8817300532	fear recognition accuracy
0.8817288318	autophagic cardiomyocyte death plays
0.8816958996	mfl regimen
0.8816917921	pay close attention
0.8816695237	retinal vein occlusion
0.8815134343	ectopic granule
0.8815079758	bradyarrhythmia requiring
0.8814876568	bladder inflammation
0.8814842468	retrospective case series
0.8813956670	oral galactose
0.8813812994	anionic sites
0.8813719521	gallbladder function
0.8813375442	messenger ribonucleic acid
0.8813304420	dexamphetamine stereotypy
0.8812736716	connecting tubule
0.8812468513	partial remission
0.8812175171	case series
0.8812050925	loaded nanoparticles
0.8811756801	nasal mucosa
0.8811746938	segmental necrotising
0.8811588635	cibenzoline suppressed
0.8811231628	hormonal replacement therapy
0.8809107750	leucovorin rescue
0.8808304420	endotracheal tube
0.8807718058	gallbladder disease
0.8807652509	case reports
0.8807575177	repetitive stimulation
0.8807464838	plasma exchange
0.8807027505	post training
0.8806653359	peripheral nerves
0.8806097125	upper limbs
0.8805538569	val hctz
0.8805128709	morphometric analysis
0.8804062969	myotonic dystrophy
0.8803901574	organophosphate insecticide
0.8803186644	pyeloureteral filling defects
0.8802949596	epileptic foci
0.8802120212	bipolar ii
0.8801951330	memory retention
0.8801599135	upper airway obstruction
0.8801240888	hemolytic uremic syndrome
0.8800583721	electron microscopic
0.8800089039	dose dependently
0.8800071837	leukemic infiltration
0.8799504918	oxidative phosphorylation
0.8798901574	mssa bacteremia
0.8797981778	baseline values
0.8796703474	contractile element shortening velocity
0.8796604131	alpha hydroxymetoprolol
0.8796574016	qtc prolongation
0.8796078629	temporary ipsilateral vocal
0.8795405192	antihyperalgesic effect
0.8795361547	nutritional deprivation
0.8795173415	dobutamine stress echocardiography
0.8794142838	caudate putamen
0.8793901574	gel electrophoresis
0.8793251396	anginal attacks
0.8792454449	panic disorders
0.8792426065	disappeared spontaneously
0.8791407411	dorsal horn
0.8791359630	beta carboline
0.8791136725	upper limits
0.8790598646	alpha lipoic acid
0.8790587997	fractional overflow
0.8790047488	alpha1 adrenergic
0.8789594329	diffusion weighted imaging
0.8789309168	respiratory rate
0.8788752468	malignant neoplasms
0.8788719885	pegylated interferon
0.8788653302	tricyclic antidepressant
0.8788470867	preventive services task force
0.8787909428	intravascular coagulation
0.8787690040	fa intravitreal implant
0.8787122104	mitochondrial injury
0.8787008183	intra arterial
0.8786863710	hepatic failure
0.8785356674	femoral nerve palsy
0.8784778369	humphrey visual field
0.8783914503	malignant glioma
0.8783851138	internal carotid artery
0.8783423990	30mg kg
0.8783423990	reference values
0.8783239774	3h spiperone binding
0.8782546844	nursing staff
0.8782546844	indolent lymphomas
0.8782098746	spinal cord ischemia
0.8781909681	systemic vascular resistance
0.8781693433	mpo anca
0.8781489655	ed50 values
0.8781231323	hyperplastic nodules
0.8780864496	atrial tachycardia
0.8780814927	obsessive compulsive disorder
0.8780419134	transaminase elevations
0.8780143459	hippocampal ltp
0.8779844066	dilated golgi cisternae
0.8779180402	renal papillary necrosis
0.8779155416	vocal cord paralysis
0.8779107750	burning sensations
0.8778527629	specific gravity
0.8778388760	long evans
0.8778309956	cerebellar sensory processing
0.8777646635	urothelial cancer
0.8775908484	sagittal sinus
0.8775750040	131i hsa
0.8775387083	fourth edition
0.8775376940	urine osmolality
0.8774873007	mood rating
0.8774820454	lymphoblastic lymphoma
0.8774471861	benzene hexachloride
0.8774332909	nag isoenzyme
0.8774187824	visual field loss
0.8773714595	coronary aneurysm
0.8772793189	generation progestagens
0.8770337080	dopamine d4
0.8770022759	pregnant jersey cows
0.8769576848	thyroid function
0.8769476599	slimming pills
0.8769083445	electron microscopy disclosed
0.8768767451	ccl2 expression
0.8768412923	grape seed
0.8768135326	il 1beta
0.8767438959	prophylactic lamivudine
0.8766615809	adverse events
0.8766371470	resolve spontaneously
0.8766287374	cgi sf
0.8766035862	pr3 anca
0.8765995560	mental slowing
0.8765906379	d2 receptor
0.8765865301	liver enlargement
0.8765499948	intrathecal cytarabine
0.8765027522	newer oral contraceptives
0.8764827094	coronary artery disease
0.8764697164	ritodrin hcl
0.8764423816	cis platin
0.8763329445	amino acids
0.8763322337	international normalized ratio
0.8763212791	posteroventral medial pallidotomy
0.8762774223	hyperammonemic encephalopathy
0.8761589968	major bleeding
0.8761519051	multifocal erg
0.8761125067	fluocinolone acetonide intravitreal implant
0.8761046116	body weights
0.8760795648	sinusoidal obstruction syndrome
0.8760160165	bone mineral density
0.8759615608	timolol solution
0.8759080923	50mg kg
0.8758711875	coronary artery
0.8758235138	generation cephalosporins
0.8758227953	cross tolerance
0.8758107119	pathophysiological mechanisms
0.8757910969	contractile element shortening
0.8757894253	arteriovenous malformations
0.8756805835	enzymic antioxidants
0.8756710389	visual analog scales
0.8756521888	continuously nebulized albuterol
0.8756089954	stz icv
0.8755906110	tricuspid regurgitation
0.8754699000	p450 isoenzymes
0.8754107750	denervation supersensitivity
0.8754107750	multifocal electroretinography
0.8753720752	mononuclear cells
0.8753104094	coronary occlusion
0.8752948862	bladder wet weight
0.8752830232	bladder cancer
0.8752065993	standard operating procedures
0.8751961138	escalating paclitaxel doses
0.8751853322	cutaneous contact
0.8751123090	lateral antebrachial cutaneous
0.8750037649	static perimetry
0.8749917859	case summaries
0.8749300437	bort dex
0.8748969350	chloroform adrenaline
0.8748873822	autologous stem cell transplantation
0.8748422373	gamma glutamyltransferase
0.8747836989	focal nodular hyperplasia
0.8747769086	close vigilance
0.8747454881	evoked peak twitch
0.8747405965	interscalene brachial plexus block
0.8746822997	gram negative
0.8746681035	small amounts
0.8745917247	cholecystokinin octapeptide
0.8745870830	cyp3a4 inhibitors
0.8745751248	preexisting complete left bundle branch block
0.8745714301	thromboembolic complications
0.8745643010	cardiovascular malformations
0.8745223168	spinal cord
0.8745089677	3,4 methylenedioxymethamphetamine
0.8744843410	post mortem
0.8744309576	alpha tocopherol
0.8743331411	fallopian tube cancers
0.8742103997	biochemical analysis
0.8741895302	oxygen supply
0.8741709791	king fahad national guard hospital
0.8741528470	hit type ii
0.8741335651	artery calcification
0.8741182166	nadh dehydrogenase
0.8741177829	trimethoprim sulfamethoxazole
0.8741162342	cytochrome p450
0.8740914825	low frequencies
0.8740419382	middle aged
0.8740030463	short term
0.8738556718	naturally occurring
0.8738165291	normotensive reperfusion
0.8738132163	reverse transcriptase
0.8737920893	3h tbob
0.8737814129	elimination half life
0.8737735674	sporadic alzheimer
0.8737385462	main outcome measure
0.8737348705	doca salt
0.8737348705	pencil point
0.8736746551	liver function tests
0.8735100407	local anesthesia
0.8734261121	malignant mesenchymal
0.8734121488	dapsone exposed ae rbcs
0.8733629636	epithelial sodium channel
0.8733609510	beta blocking
0.8733047146	blood pressure
0.8731536454	liver adducts
0.8731510733	adductor spasmodic dysphonia
0.8731508348	ma abusers
0.8730914915	liver enzymes
0.8729991149	urine samples
0.8729415291	gastric adenocarcinoma
0.8729052729	prostaglandin synthetase inhibitors
0.8727764585	constipation predominant
0.8726989528	cisapride versus placebo
0.8726955521	amoxicillin clavulanate
0.8726846008	fasting serum insulin
0.8726210453	risk factors
0.8725733788	myocardial injury
0.8725539669	lymphocytic leukemia
0.8725539669	dominant combinations
0.8725309067	er stress
0.8725022176	tubular necrosis score
0.8724540087	tail flick
0.8724463397	secondary hyperalgesia
0.8723819048	wistar rats
0.8723634347	neurological signs
0.8723511993	penicillin derivatives
0.8723411921	dentate nuclei
0.8722385970	extremely rare
0.8722265371	sigma receptor agonist
0.8721083566	supplementary motor area
0.8721017174	anterior wall
0.8720794964	response rates
0.8720584635	coronary artery spasm
0.8720492844	hematologic toxicity
0.8719952254	long acting
0.8719446855	aminonucleoside nephrosis
0.8718946628	renal catecholamine stores
0.8718471038	organic personality syndrome
0.8718378888	psychotropic drugs
0.8718033734	mhc cb7
0.8717464772	restless legs syndrome
0.8716955415	allogeneic bone marrow transplantation
0.8716598496	retrospective chart review
0.8716389128	volunteer apheresis
0.8715751614	involuntary movements
0.8715309326	blocking agent
0.8715246122	5,7 dihydroxytryptamine
0.8715006971	high affinity
0.8714604678	mtdna encoded
0.8714535221	red blood cells
0.8713608661	haematopoietic stem cell transplantation
0.8712712180	basic fibroblast growth factor
0.8711594363	arterial oxygen saturation
0.8711477473	highly active antiretroviral
0.8711029685	glutamatergic blockage
0.8710411814	regression line
0.8709852065	hamster renal carcinomas
0.8709601560	double blind
0.8709214273	receptor antagonists
0.8709007943	premature ventricular contraction
0.8708596474	proliferating cell nuclear antigen
0.8708575020	tubular basement membrane
0.8708115526	renal failure
0.8707810630	d2 receptor occupancy
0.8705752325	japanese man
0.8703650887	transient evoked otoacoustic emissions
0.8702194517	coronary computerized tomography angiography
0.8701920313	board certified
0.8701631167	low density lipoprotein
0.8701009216	signaling pathway
0.8700988681	echothiophate iodide
0.8700680152	vanishing bile duct
0.8699813194	central chemosensitivity
0.8698532073	alpha gst
0.8698123334	spinal cord injury
0.8697821395	subarachnoid haemorrhage
0.8697254286	advanced parkinson
0.8695793644	adenosine a2a
0.8695688168	growth retardation
0.8695051496	terminal differentiation
0.8694441326	cerebral perfusion spect
0.8693784737	sural nerve sap amplitude reduction
0.8693214682	myocardial stunning
0.8692320146	consecutive days
0.8691429517	central executive
0.8691096346	speckle tracking echocardiography
0.8691032516	adrenoceptor desensitization
0.8690840641	st depression
0.8690564469	st segment elevation
0.8690249839	antiepileptic drug
0.8689587560	aryl piperazine
0.8689534721	extended coagulopathy
0.8689460743	male wistar rats
0.8688564447	antimicrobial agents
0.8688008830	seizure inducing agents
0.8687848496	stained microglia cells
0.8687701667	heavy proteinuria
0.8686789020	sustained ventricular tachycardia
0.8686396767	epidemiological studies
0.8685682363	microg kg
0.8684525825	beating rat heart myocyte cultures
0.8683939391	cardiac enzymes
0.8683283435	crescentic glomerulonephritis
0.8682992088	outer medullary
0.8682944795	embolic events
0.8682820375	therapeutic modalities
0.8682528315	generation antipsychotics
0.8681654239	dsm iv
0.8681626845	fatty acid
0.8681418065	righting ability
0.8680632379	accelerated junctional rhythms
0.8680552648	psychotic symptoms
0.8680028238	fluid attenuated inversion recovery
0.8679511884	alpha methyldopa
0.8679310688	early life ias exposure
0.8679285734	aortic valve
0.8679157143	alpha tc
0.8678731253	gc ht
0.8678455120	blocking action
0.8677314198	african american
0.8676469046	tafi antigen concentrations
0.8675894809	transitional cell carcinoma
0.8675203794	depressant actions
0.8675142125	long term potentiation
0.8673908017	histamine h2
0.8673369677	lactate dehydrogenase
0.8673152649	myeloperoxidase antineutrophil cytoplasmic antibody
0.8672253045	tail suspension test
0.8672243434	cis ra
0.8672162285	healthy controls
0.8671536710	sestamibi single photon emission computed tomography
0.8670711677	rabbit syndrome
0.8670449968	apheresis platelet
0.8670437459	segmental dystonia
0.8669269936	diastolic blood pressure
0.8668536924	coronary angioplasty
0.8668520026	preneoplastic nodules
0.8668290877	serum pth levels
0.8668219366	visual loss
0.8667554718	child pugh
0.8667353801	cauda equina syndrome
0.8666600367	cranial nerve
0.8666396710	medical conditions
0.8665630663	bell shaped
0.8665630663	2,3,5 triphenyltetrazolium
0.8665534719	arterial spasm
0.8665476284	palpable purpuric lesions
0.8665398105	4r apdc
0.8665028869	high performance liquid chromatography
0.8663712395	hypertrophic cardiomyopathy
0.8663681068	muscle relaxants
0.8663122388	advanced inoperable
0.8662081386	perceived pain intensity
0.8661414353	ih636 grape seed proanthocyanidin extract
0.8661376362	pr3 anca titer
0.8661041541	medical research council
0.8660159168	placebo controlled
0.8657642870	seizure susceptibility loci
0.8657065929	electroconvulsive therapy
0.8656418693	aqueous suspension
0.8656106631	individual variation
0.8655816879	peroxisome proliferator activated receptor alpha
0.8655710862	heart rate
0.8655630663	macro papular
0.8655324861	alpha2abc knockout
0.8654166524	animal model
0.8652646267	systolic orthostatic hypotension
0.8652502685	ventricular ectopic beats
0.8652277854	japanese population
0.8652230145	follicular cell lymphoma
0.8652206781	idiopathic epilepsy
0.8651278790	group ii mglurs
0.8650702832	chest wall
0.8650347837	fear potentiated startle
0.8650156016	zollinger ellison syndrome
0.8648206011	heart size
0.8648040715	platelet serotonin
0.8647007917	insulin resistance
0.8646839327	spinal segments
0.8646389418	dietary sodium restriction
0.8646126893	outcome measures
0.8645289929	mental calculation
0.8644750096	dopamine turnover
0.8644624790	tubulo interstitial
0.8644571727	parent rating scale revised
0.8644332048	acute liver failure
0.8643482695	dna sbs
0.8643013296	myxedema coma
0.8642999525	prenatal protein deprivation
0.8642608010	passive avoidance conditioning
0.8642593922	ganglionic blockade
0.8642437355	observation period
0.8642388282	uiu ml
0.8642174396	evidence based
0.8641600596	abductor paralysis
0.8640424131	hmg coa reductase inhibitors
0.8639793539	slow release theophylline
0.8639671056	sound silence discriminations
0.8638796458	exposed workers
0.8638400016	tris salt
0.8637928145	fenoterol hydrobromide
0.8637880334	quinidine phenylethylbarbiturate
0.8636543606	open chamber
0.8636205530	nonketotic coma
0.8635281647	cardiovascular thrombotic events
0.8635235553	coronary blood flow
0.8633837610	iv astrocytomas
0.8633771724	beta ccm
0.8633730316	positive vasculitis
0.8633182550	attention deficit disorder
0.8633178934	cell loss
0.8633051075	gnrh neurons
0.8632920795	serum transaminases
0.8632915294	visual field testing
0.8632874325	hyper locomotion
0.8632064486	impaired fear recognition
0.8631874957	alpha fluoro beta alanine
0.8631082548	matrix gla protein
0.8630788123	terminated prematurely
0.8630788123	amn082 reverses
0.8629571970	heart transplantation
0.8628985111	vitamin d3
0.8628921348	diffusion weighted
0.8628500408	memory performance
0.8628335435	volumetric bmd
0.8628065462	normal saline
0.8627914344	offspring cerebellum
0.8627864252	differential sensitivities
0.8626979550	triamterene nephrolithiasis
0.8626870904	cyclic adenosine monophosphate
0.8626870904	purkinje cell synapses
0.8626214982	kinetic analysis
0.8626214982	wise analysis
0.8625062011	fetal growth
0.8624543846	atypical cholinesterase
0.8623186831	te peak
0.8622194358	cholinergic convulsant sensitivity
0.8619723830	anti arrhythmic
0.8619153307	tmp smz
0.8619137793	living donor
0.8619134756	2c receptors
0.8618537645	heart weight
0.8618165234	perinuclear staining antineutrophil cytoplasmic
0.8618031726	mg m2
0.8617794740	jejunal motility
0.8617703631	serotonin reuptake blockers
0.8617521814	cox regression
0.8617475823	crossover study
0.8616198710	cytoplasmic microtubules
0.8615926730	ct scan
0.8615016087	bpt clz
0.8614906370	dramatically improved
0.8614084223	healthy male volunteers
0.8613787983	hematology oncology population
0.8613778816	epidural blood flow
0.8613493907	npy immunoreactivity
0.8613332420	clinical picture
0.8611786882	puromycin aminonucleoside nephrosis
0.8611745795	inhibitory cerebellar stimulation
0.8611252164	alpha smooth muscle actin
0.8611032241	alpha bungarotoxin binding
0.8610809670	targeted antioxidant
0.8610771725	lp bm5
0.8610451849	functional somatotopy
0.8610363546	regained baseline mental status
0.8608206189	mitochondrial electron transport chain
0.8608054134	preventive measures
0.8607399114	electro oculography
0.8606813975	t2 weighted image
0.8606789193	electrical field stimulation
0.8606573708	terminal fragments
0.8606286905	cyclooxygenase inhibitors
0.8606259319	progression free survival
0.8606007766	continuous subcutaneous apomorphine infusions
0.8605008231	vanishing bile duct syndrome
0.8604882363	ae rbcs
0.8604704269	nos ir
0.8604117453	oxidative damage precedes nitrative damage
0.8603759480	previous studies
0.8603341568	dental practitioners
0.8601728237	venous discomfort
0.8600115386	excited delirium
0.8600030727	antiepileptic drugs
0.8600011970	synthase inhibition
0.8599791068	vocal fold palsy
0.8599626796	dyne x sec cm5
0.8599551820	quit drinking
0.8598745646	pentobarbital anesthetized
0.8598694730	nondepolarizing neuromuscular blocking agents
0.8598656824	patients undergoing fess
0.8597849700	increased incubated heinz body formation
0.8597343330	5,7 dcka
0.8596473482	wolff parkinson white
0.8596258985	epinephrine dysrhythmogenicity
0.8595872628	endothelial mesenchymal transition
0.8595858015	extracted data
0.8595816575	anti hbs
0.8595789667	erosive cystitis
0.8595173078	cortical spreading depression
0.8594821667	protein kinase
0.8594473509	matrix assisted laser desorption ionization
0.8593893404	loxp egfp
0.8593410944	homosexual men
0.8593343795	psycho active drugs
0.8593161695	epicardial mapping
0.8593079599	bile duct hamartoma
0.8592513325	internal carotid
0.8592093180	llc pk1
0.8591877028	sudden cardiac death
0.8591844566	temporal delay
0.8591601372	gene targeted mice lacking sgk1
0.8590857670	widely prescribed
0.8590478297	double masked
0.8590364473	clear cell adenocarcinoma
0.8590130754	immunodeficiency virus
0.8590069572	venous thrombo embolism
0.8589664914	main outcome measures
0.8589549038	branch retinal vein occlusion
0.8589354399	combined androgen blockade
0.8587630607	poorer prognosis
0.8587510592	coronary artery bypass
0.8587497214	mosmol kg
0.8587467619	protective effect
0.8586538156	motor behavior
0.8586364202	afferent inputs
0.8585436554	respiratory insufficiency
0.8585435629	cognitive deterioration
0.8585082802	accidental intrathecal
0.8584850903	magnesium sulfate
0.8584612847	ppm corticosterone
0.8584324529	mood disorder
0.8584094349	population spike
0.8583452158	direct thrombin inhibitors
0.8583047273	histamine h1
0.8583047273	systematic reviews
0.8582949685	mip synthase
0.8582112847	paw preference
0.8582030857	nonhematologic toxicities
0.8581360149	adjunctive bupropion
0.8580944226	nissl staining
0.8580732448	99mtc glucarate
0.8580618011	adynamic bone disease
0.8580554051	remained stable
0.8579571909	hiv infected individuals
0.8579028312	lca hca
0.8578855393	anesthetized rats
0.8578845206	nonionic contrast medium
0.8578066153	antioxidant defense
0.8578061195	semi quantitative scoring
0.8577429419	oxitropium bromide
0.8576975929	postsynaptic striatal d2 da receptors
0.8576741710	mini mental state examination
0.8576620320	induced lh surge
0.8576236765	fast moving
0.8573428145	infarct avid
0.8573301995	average platelet counts
0.8573292229	endoscopic procedures
0.8572847120	verbal memory
0.8572388312	left ventricular dysfunction
0.8572326683	reaction probability scale
0.8572030620	zung conde scales
0.8572005335	endogenous lysozyme
0.8571751279	idiopathic generalized epilepsies
0.8570970509	t1 weighted
0.8570185866	clinically significant riha
0.8569746140	glutamate supplementation
0.8569353070	myocardial electrical excitability
0.8569249036	early postoperative delirium
0.8568821724	facial mucosa increases intracranial blood flow
0.8568376991	knockout mice
0.8567561460	ursodeoxycholic acid
0.8567473947	hemodynamic variability
0.8567291016	neuronal cell death
0.8567189677	elderly females
0.8566573429	emotional states
0.8566428028	remained constant
0.8565782622	urinary sodium excretion
0.8565643421	csf methotrexate concentrations
0.8564548319	american society of anesthesiologists
0.8564421442	pb exposure
0.8564327747	m1 plasticity
0.8563587958	concentrating ability
0.8563502504	escape latency
0.8562736766	bone mineral
0.8562142521	older adults
0.8561909965	serum lactate dehydrogenase
0.8561907414	acid protease
0.8561764285	1,3 butadiene
0.8561560871	sarcolemmal integrity
0.8560586135	native kidneys
0.8560572987	aminobutyric acid
0.8560337705	proximal tubular damage
0.8558969721	statistically significant decreases
0.8558944440	marked behavioral modifications
0.8557331347	immune mechanisms
0.8557049227	catheter directed thrombolysis
0.8556401000	veno occlusive
0.8556005045	hospitalized elderly patients
0.8555920183	adverse effects
0.8555589392	bone scans
0.8555468530	nonsteroidal anti inflammatory
0.8554379692	angiotensin converting enzyme inhibitors
0.8554119518	fas ligand
0.8553684905	takotsubo cardiomyopathy
0.8552894448	ed1 ed4
0.8552804102	ad libitum chow
0.8552317337	superoxide production
0.8550336861	hereditary angioedema
0.8550286757	middle cerebral artery occlusion
0.8550073719	fourteen healthy
0.8549314439	contrast media
0.8548472577	postalcoholic wernicke korsakoff syndrome
0.8548416462	post transplant
0.8548339810	cortical laminar
0.8548290602	adenovirus pneumonia
0.8547932714	urine sediment score
0.8547753199	magnesium supplementation
0.8547708223	ethanol withdrawal severity
0.8547613483	bilateral subthalamic nucleus stimulation
0.8547250079	serotonin syndrome
0.8546925647	spontaneous movement
0.8546263226	sexual excitement
0.8545942311	moderate mdma users
0.8545445327	emergency room
0.8545399758	17alpha ethinylestradiol
0.8544016339	dna repair
0.8543086468	erectile function
0.8543012102	toxic optic neuropathy
0.8542082675	sodium nitrite
0.8542015133	atrioventricular nodal
0.8541837793	purkinje cell
0.8539332440	renal tubules
0.8538334290	cerebral hemisphere
0.8538268709	n10 propargyl 5,8 dideazafolic acid
0.8538077874	hepatocellular carcinomas
0.8538050348	endometrial cancer
0.8537887318	polymorphic ventricular tachycardia
0.8536991385	kinin b2 receptor
0.8535663970	anti inflammatory
0.8535559523	acute kidney injury
0.8535100352	seizure threshold
0.8534806881	substance specific differences
0.8534202964	mg dl
0.8533805315	incomplete cerebral ischemia
0.8533699789	hd mtx
0.8533463361	a2a receptor antagonists
0.8532023910	administered intravenously
0.8530554345	autologous stem cell transplant
0.8529604896	sham stimulation
0.8529585740	nicotinic receptors
0.8528886239	primary open angle glaucoma
0.8528777183	nutritional deficiency
0.8528710667	postural tremor
0.8528163370	chronic post herpetic neuralgia
0.8527747646	detailed spectral
0.8527744278	word recall
0.8527743473	pre operative
0.8525696796	plasma samples
0.8525207576	randomly assigned
0.8525126342	regression models
0.8524978713	mumol liter plasma
0.8524638495	hbsag positive
0.8524435953	outflow facility
0.8524190895	liposome encapsulated doxorubicin
0.8524157942	corneal ulcers
0.8523263988	human corticotropin
0.8523201264	polymer bound dox
0.8523168423	ut a1
0.8522698184	male sprague dawley rats
0.8521929190	vasodilatory effect
0.8521624187	protein expression
0.8521170353	red eyes
0.8520829107	fresh frozen plasma replacement
0.8520642935	primary hypercholesterolemia
0.8519812326	pressor action
0.8519508810	capillary leak
0.8519330053	ck mb
0.8518987130	cell lines
0.8518228976	postinfarction ventricular septal
0.8518174230	positive necrotizing glomerulonephritis
0.8517612281	newborn piglets
0.8517402935	hepatic lipid homeostasis
0.8517315620	venlafaxine overdose
0.8517255138	barbiturate narcosis
0.8517217700	cognitive functioning
0.8516909526	beta blocker
0.8516463583	nfkappab activity
0.8516335059	soluble fas
0.8516201665	hepatocyte proliferation
0.8515753435	alternative anticoagulants
0.8514269452	immune escape
0.8514182588	chi square test
0.8514038069	spatial learning capacity
0.8513714288	recombinant human erythropoietin
0.8512941090	potassium losing diuretic
0.8512270894	beta2 adrenoceptor
0.8512197314	regular recreational cocaine
0.8511876379	native kidney
0.8511748312	bp reductions
0.8510948022	mitogen activated protein
0.8510861447	tumor regression
0.8510758810	anterior cingulate
0.8510036036	died suddenly
0.8509731202	routine plasma screening
0.8508376497	population based
0.8508185933	poor metabolizer
0.8508150534	fetal kidneys
0.8507862180	writhing tests
0.8507675006	angiogenesis soluble markers
0.8506859598	conduction delay
0.8506025133	insulin sensitivity index
0.8505910420	neuro ophthalmologic
0.8505701309	permanent pacemaker
0.8505320048	posterior leukoencephalopathy
0.8505054140	mtdna deletion
0.8505003571	locomotor hyperactivity
0.8504032705	endoscopic sinus surgery
0.8503749581	autologous transplant
0.8503419397	partially reversed
0.8503267196	anticonvulsant actions
0.8502797224	main characteristics
0.8502605681	atrial beating
0.8501505619	percutaneous coronary
0.8501260324	cardiac catheterization
0.8500658493	half life
0.8500420394	extrapyramidal signs
0.8499726422	sensori motor neuropathy
0.8499711454	mast cells
0.8499128327	acute myeloid leukemia
0.8498611209	intestinal transit
0.8498538913	definitive diagnosis
0.8496979725	tail cuff method
0.8496884902	poorly controlled
0.8496703769	intramuscular hbig
0.8496366458	myocardial oxygen consumption
0.8496011054	metastatic breast carcinoma
0.8495190452	dependent manner
0.8495162733	ischemic injury
0.8494948544	drug interactions
0.8494802003	histologic examination
0.8493832767	hypoxia responsive
0.8492625688	canine ventricular
0.8491852600	iso osmolar
0.8491317763	wild type littermates
0.8491235403	animal studies
0.8490657578	free np
0.8490388769	visual analog scale
0.8490002664	consecutive cohort
0.8489927719	nonalcoholic fatty liver disease
0.8489633138	systolic pressure variation
0.8489584853	separate occasions
0.8489152101	total cholesterol
0.8487579791	modestly elevated
0.8487361039	circulatory failure
0.8487269710	scanning electron microscopy
0.8484557242	normal tissue toxicities
0.8484479706	open angle glaucoma
0.8484233262	ventricular septal
0.8484182797	renal function
0.8484097928	chelating agents
0.8482394291	adverse reaction
0.8479799924	masseter muscle rigidity
0.8479737940	alpha2 adrenoceptors
0.8479710643	vascular endothelial growth factor
0.8475845144	fundus angiography
0.8475260213	refractory mcl
0.8475233243	gall bladder stones
0.8475048433	label restricted
0.8474991631	social interaction
0.8474635115	nicotine polacrilex
0.8474542788	social and emotional judgement processes
0.8474365757	nicotine sulfate treated chicks
0.8474048433	vigabatrin attributed
0.8472204304	differential sensitivity
0.8471994395	cell types
0.8471954940	diastolic depolarization
0.8471778192	cohort study
0.8471550195	unexpected diagnosis
0.8470888427	electron microscope
0.8470805250	future research
0.8470730376	ipsilateral vocal cord paralysis
0.8470700370	cholinergic agonist pilocarpine
0.8470396000	epicardial coronary
0.8470016761	peripheral blood
0.8469798404	rapa conversion
0.8469517964	light enhanced startle
0.8469383123	nonhematologic toxicity
0.8468489154	sodium salicylate
0.8468447314	rat prostate lateral lobe
0.8468138711	inf mi
0.8468138711	ant mi
0.8467739987	stroke volume
0.8467042560	pituitary growth
0.8467033096	mg kg b.w
0.8466792507	skin lesion
0.8466771777	necrotizing myopathy
0.8466770155	wistar albino rats
0.8466187387	af promotion
0.8465847882	lethal anuria
0.8464654718	bladder carcinomas
0.8464113268	muscarinic receptors
0.8463737454	inhaled beta agonists
0.8462939844	psychotic features
0.8462176584	brain stem
0.8461468619	left ventricular function
0.8461378807	energy metabolism
0.8460336823	anti hiv
0.8460297551	stopping selegiline
0.8459135326	beta lactam
0.8458628326	basal body temperature
0.8458547374	prostaglandin f2 alpha
0.8457075620	dna cleavage enhancing drugs
0.8456835131	cognitive dysfunction
0.8456705046	protective properties
0.8456245584	ipsilateral dyskinesias
0.8456124528	water maze task
0.8456062516	inflammatory mediator
0.8455821059	anabolizing steroids
0.8454496668	structural lesions
0.8453165367	physical activity
0.8453055086	pbo + li dvp
0.8452561661	advanced gastric cancer
0.8452281888	serum prolactin levels
0.8451906908	immunoallergic mechanism
0.8450371431	laser scanning
0.8449430491	amiodarone induced myxoedema coma
0.8449402958	negative mucosal potential
0.8449339191	renal dysfunction
0.8449289036	endometrial hyperplasia
0.8448624838	ace inhibition
0.8448515994	variant angina
0.8448270921	ltg exacerbated
0.8447626710	fresh frozen plasma
0.8447148775	discharged home
0.8446569705	angiotensin ii
0.8446300177	electro diagnostic
0.8445950501	memory retrieval
0.8445721080	calcium channel blocker
0.8445350478	hemoglobin assay
0.8444844316	forced hydration
0.8444428881	positive mothers
0.8444230634	carefully monitor
0.8444045791	epidemiologic findings
0.8441990066	citrate dialysate
0.8441343991	nacl treated segments
0.8440139786	interstitial matrix
0.8439959651	locomotor stimulatory
0.8439158772	light chain
0.8438504484	pulmonary shunt
0.8437572681	local anesthetic kindled
0.8437215287	tissue injury
0.8436601422	val hctz combinations
0.8436558647	marital happiness
0.8435701809	ppm quinacrine hydrochloride
0.8435085307	olanzapine versus risperidone
0.8434589814	hiv infection
0.8434555810	pg mg protein
0.8433055831	forestomach tumors
0.8432079168	adverse drug reactions
0.8431798361	seizure duration
0.8431451069	medical record
0.8430696690	propylthio uracil therapy
0.8430259240	autoimmune disease
0.8430258734	partial thromboplastin
0.8429885722	skeletal muscle
0.8429817987	air conduction
0.8429494543	generalized slowing
0.8429311742	developed hind limb paralysis
0.8428994619	butyrylcholinesterase gene
0.8428394098	mortality rate
0.8428281006	25mg kg
0.8428040098	drug efflux transporter
0.8427960483	apomorphine induced climbing
0.8427020626	chemical exposures
0.8426140389	anesthetized dogs
0.8425447170	cell death
0.8423976767	place preference
0.8423303657	startle response
0.8423047135	relapsed refractory
0.8422589887	intra hisian
0.8422517561	reduced glutathione
0.8421955648	cutaneous lesions
0.8421555574	essential hypertension
0.8421521093	hypoplastic left heart syndrome
0.8420703774	serotonin reuptake inhibitor
0.8419762620	regional citrate
0.8419384354	tubular transporters
0.8419313401	synthase inhibitor
0.8418014216	adult male
0.8417827256	depressed outpatients
0.8417820531	serotonin 1a
0.8417782918	immunosuppressive agent
0.8417031970	amphetamine abuse
0.8416886976	deep venous thrombosis
0.8416834032	granulosa cell
0.8416346394	orofacial dyskinesia
0.8415607011	marked reductions
0.8415582915	cytostatic action
0.8415338100	low ph normal saline
0.8415164971	deep coma
0.8414671988	partial hepatectomy
0.8414462391	activated peripheral blood
0.8414029847	physical provocation
0.8413683357	safely discharged
0.8413404938	salvage chemotherapy
0.8413173348	apoptotic cell death
0.8412717688	transthoracic echocardiography
0.8412324939	smooth muscle cells
0.8411071785	mg kg sc
0.8410982807	calcitonin gene related peptide
0.8410384685	total extractable myocardial
0.8410100478	dog heart lung
0.8409268628	milk fever
0.8409005880	abnormal behaviors
0.8408895123	prenatal dexamethasone
0.8408369322	eastern cooperative oncology group
0.8408270798	prehospital care
0.8407884662	developing countries
0.8407776507	task employing
0.8407271697	ventricular septal defect
0.8406626208	fatal aplastic anemia
0.8406519106	motor impairment
0.8406382296	granulomatous tissue
0.8406336614	dyskinesia severity
0.8406262235	akathisia rating scale
0.8406232241	hbeag positive
0.8405657287	bis score
0.8405603502	urinary protein excretion
0.8405056304	hospital stay
0.8404924301	muscle spasms
0.8404328866	high fat diet
0.8404266196	left ventricular end diastolic pressure
0.8403465419	skin tests
0.8403105933	contraction characteristics
0.8403003733	continuous ambulatory ecg monitoring
0.8402727459	memory processes
0.8402694639	mt induction
0.8402192943	preexisting renal disease
0.8402115662	affected workers
0.8401601473	media degeneration
0.8401452928	14th days
0.8400032992	hemorrhagic blood volume
0.8398861553	high density lipoprotein
0.8398706808	schizo affective disorder
0.8398579434	blood loss
0.8398018893	renovascular hypertension
0.8397280667	pharmacological differentiation
0.8396678238	south african patients
0.8396410894	heinz body hemolytic anemia
0.8396015063	blockers concentration dependently
0.8395528219	cocaine diazepam intoxications
0.8394768200	drug interaction probability scale
0.8394679761	intermediate caudal
0.8394572676	hcv infection
0.8393720814	mechanism underlying
0.8393383711	widely accepted
0.8393126963	english literature
0.8392979348	abnormal involuntary
0.8392705881	h2 histamine
0.8392129900	ventricular wall
0.8391894036	naranjo adverse drug reaction probability scale
0.8391827750	lysosomal enzymes
0.8390989380	adenosine triphosphate
0.8390939783	specific platelet activating factor
0.8390647463	oral thrush
0.8389368196	dbp reduction
0.8389045706	retinal toxicity
0.8388940618	tubular damage
0.8388484538	plasma renin activity
0.8388185253	pkc alpha
0.8387954935	total peripheral resistance
0.8387820064	partial remissions
0.8387287218	focal cerebral ischemia
0.8386941369	acute tubulo interstitial nephritis
0.8386763892	5mg kg
0.8386339016	occupational exposure
0.8386001415	data suggest
0.8385928280	valvular heart disease
0.8385590239	lamivudine na ve hbv
0.8385426918	metabotropic glutamate
0.8385092945	search strategy
0.8384989590	oral contraceptive steroids
0.8384665934	fetal growth measures
0.8384393435	serum urate
0.8383748629	granulocyte macrophage
0.8383468628	double blind trial
0.8382600647	pediatric oncology
0.8382198243	remission inducing drugs
0.8382127924	microgram kg min
0.8382064521	nitro l arginine methyl ester
0.8382045853	cardiovascular complications
0.8381623055	renal transplant recipient
0.8380599558	ifosfamide related encephalopathy
0.8380405000	minor neurological dysfunction
0.8379492235	fluorescein angiography
0.8379368753	invasive procedures
0.8378484473	motor cortex
0.8378362011	inhibitory potency
0.8377983542	fixed dose
0.8376968972	microgram ml
0.8376172064	corticosteroid glaucoma
0.8376029900	memory impairment
0.8375740576	infected untreated animals
0.8375642816	emergency physicians
0.8375129644	axonal degeneration
0.8374353305	prostacyclin analogue
0.8374328789	nucleus accumbens
0.8374291854	dosing regimen
0.8373937959	calcium influx
0.8373701530	rate pressure product
0.8373670362	complete resolution
0.8373440030	post synaptic neurotoxicity
0.8372597110	frequency bands
0.8372337113	antibody titer
0.8371453096	granule cells
0.8371309057	secondary pinprick hyperalgesia
0.8370957921	histochemical injury
0.8370369443	conventional cocs
0.8370355491	pilo injected animals exhibited
0.8370129644	venous route
0.8369916221	human bone marrow progenitor
0.8369444020	prepulse inhibition
0.8368869383	serum fbal concentration
0.8368336420	coronary arterial
0.8367932447	male albino swiss mice
0.8367556221	antioxidant enzymes
0.8367347127	anionic site surface
0.8366175801	respiratory distress
0.8365736174	urotensin ii
0.8365666015	statistical model
0.8365487745	lethalities occurred
0.8365396774	intra arterial pge2
0.8364116583	cell cycle
0.8364062918	urine pge
0.8364048908	vegf vpf protein expression
0.8363728098	borderline hypertensive
0.8363622824	mg crea
0.8363161186	thyroxine abuse
0.8362985702	memory impairments
0.8362618082	paw withdrawal
0.8362455477	immunohistochemical studies
0.8362093344	negatively affect
0.8361964811	thrombotic complications
0.8361512380	cell culture
0.8361266030	tumor necrosis factor alpha
0.8360762155	delayed reactions
0.8360718417	dipivalyl epinephrine
0.8359366707	circumflex coronary
0.8358933512	nephrogenic di
0.8357953938	proteinase 3 antineutrophil cytoplasmic antibody
0.8357153408	spontaneous resolution
0.8356293072	cystic hyperplasia
0.8355189434	clinically significant
0.8354305289	allograft rejection
0.8354170207	tricyclic antidepressant desipramine
0.8353766080	high flux hemodialysis
0.8353660092	remarkably safe
0.8353242874	contrast echocardiography
0.8352944158	basilar artery
0.8352924815	levodopa induced oromandibular dystonia
0.8352455335	anticonvulsant activity
0.8352436801	fractalkine receptor
0.8352150809	alcohol withdrawal
0.8352127145	lobund wistar
0.8351940823	genuine stress incontinence
0.8351124959	prompt recovery
0.8350929080	fulminant liver failure
0.8350232564	dose reduction
0.8350205292	inspired concentration
0.8349591536	neuraxial anesthesia
0.8349253890	propafenone overdose
0.8349008483	neuraxial morphine
0.8348907101	staphylococcal infections
0.8348633396	hypersensitivity reactions
0.8348363375	channel blocker
0.8348209751	apoptotic cells
0.8348201167	potentially lethal
0.8348201167	ros production
0.8347508226	danish national
0.8347226573	eeg recordings
0.8347082927	midpontine activation
0.8346388083	left ventricular wall
0.8346308973	bipolar normocalcemic patients
0.8346271210	muscular dystrophy
0.8346092172	mm hg diastolic
0.8345598099	maximum contraction
0.8345493260	obstructive sleep apnea
0.8344619239	congenital heart disease
0.8344214916	basic antibiotics
0.8343582310	intracranial bleeding
0.8343446886	hbv lamivudine resistant strains
0.8343160048	blood pressures
0.8342550279	minutes postdose
0.8342430930	operations lasting
0.8342385136	menopausal women
0.8342157062	adenovirus hemorrhagic cystitis
0.8341758203	ldlr expression
0.8341076091	beta adrenergic antagonist
0.8340275880	anti diuretic hormone
0.8339703404	water maze
0.8339494328	chloride channel
0.8339271550	clinical features
0.8338312897	global hyperkinesia
0.8338172474	sustained release bupropion
0.8338128544	hospital admission
0.8337990443	median age
0.8337803617	lh rh
0.8337311773	emax model
0.8337096859	contrast sensitivity
0.8336984937	valvular heart
0.8336939500	cd36 mrna
0.8336617954	aorta serum ratio
0.8336235212	intermittent rifampin therapy
0.8335459461	animal models
0.8334890029	hyperalgesic effect
0.8334557027	renal allografts
0.8334492705	b3 cells
0.8333427419	facial mucosa
0.8333361394	small arteries
0.8333281294	subtoxic bupivacaine
0.8332442342	dl sotalol
0.8332202544	successfully managed
0.8332044128	fungal infection
0.8331950562	aggressive prostate cancer
0.8331772567	intradermal capsaicin injection
0.8331428360	lipopolysaccharide pretreatment
0.8331343587	biochemical mechanisms
0.8331222217	lesioned rats
0.8330942233	early recognition
0.8330780318	axonal polyneuropathy
0.8329019880	liver parenchyma
0.8327984902	withdrawal emergent rs
0.8326992074	animal behavior
0.8326607293	plasma concentrations
0.8326397167	transgenic aids mice
0.8326021352	abnormal cerebrospinal
0.8325780785	progressive disease
0.8325501277	ventricular pacemaker
0.8325342914	general anaesthesia
0.8324653678	psychotic disorders
0.8324570090	spontaneously hypertensive rats
0.8324094115	renal cortical malondialdehyde content
0.8324005195	hemoglobin level
0.8322444359	superoxide and hydrogen peroxide production
0.8321834741	gastrointestinal motility
0.8321771044	citrate toxicity
0.8321692899	dose dependent
0.8321338346	artery thrombosis
0.8319693030	iqr range
0.8319359656	glucocorticoid induced glaucoma
0.8319350662	potential confounders
0.8319222428	abnormal movements
0.8319198859	advanced breast cancer
0.8319062290	intrarenal noradrenaline infusion
0.8319033527	ovariectomized female
0.8319024528	antimicrobial induced mania
0.8318067227	kidney perfusion
0.8317649784	adrenoceptor blockade
0.8317138873	memory updating
0.8317093878	homer1 gene
0.8316791111	clinical manifestations
0.8316717149	mu opioid receptor
0.8316093878	bupropion sr
0.8315892973	penicillin anaphylaxis
0.8315741488	pattern visual evoked potentials
0.8315548947	post lesion
0.8315410268	healthy subject
0.8314926858	induced penile erections
0.8314750270	beta lactam antibiotics
0.8314489926	biochemical alterations
0.8314453341	facial telangiectasia
0.8314369808	tibialis muscle
0.8314262335	life long
0.8313407284	endocrine screening
0.8313096759	progressive fsgs
0.8311733421	single blind
0.8311566025	low testosterone
0.8311336841	swallowing induced atrial tachyarrhythmia
0.8310250795	plasma corticosterone level
0.8309113774	peripheral nerve
0.8309056869	cell membranes
0.8309015289	developing cochlea
0.8308525876	cell proliferation
0.8308503903	cingulate cortex
0.8308393233	cross sectional echocardiography
0.8308322092	case illustrates
0.8308290858	impaired consciousness
0.8308230241	central venous
0.8308041062	colorectal cancer
0.8307714266	rapidly reversed
0.8307091741	acquired aplastic anemia
0.8306820962	median survival
0.8306405916	visual fields
0.8306189317	varying degrees
0.8305874527	adenovirus infection
0.8305659388	auditory thresholds
0.8305410041	onset age
0.8305087226	heart hypertrophy
0.8304942241	computerized image
0.8304874624	total cholesterol hdl
0.8304689711	significant positive correlations
0.8304515822	maximal contraction
0.8303673805	pyramidal cells
0.8303582986	case report
0.8302582712	ischaemic strokes
0.8302394280	anca positive carbimazole induced vasculitis
0.8302136005	tam induces
0.8302001214	basement membranes
0.8301779555	open field
0.8301180569	lamina densa and lamina rara interna
0.8301009603	neurologic deterioration
0.8300612784	heparin induced thrombocytopenia
0.8300399426	cardiac dysfunction
0.8300347796	mania rating scale
0.8299672241	promote af
0.8299471412	sap amplitude
0.8299413809	ketamine catatonia
0.8298372606	rough endoplasmic reticulum
0.8298219519	rem sleep deprivation
0.8297617317	general safety
0.8297403332	rt pcr
0.8297274062	favourable outcome
0.8296947004	remains unclear
0.8296246942	parent compound
0.8296063465	topiramate induced nephrolithiasis
0.8295289881	earlier studies
0.8295216817	f2 pituitaries
0.8294622016	partial response
0.8294426067	action potential
0.8294283419	femoral area
0.8294276110	blood sample
0.8294228990	antimicrobial agent
0.8293917620	erythroid cells
0.8293581010	air conduction audiograms
0.8293056674	lymph node biopsies
0.8292918987	genetic influences
0.8291912352	neuropsychiatric symptoms
0.8291428319	bladder tumors
0.8290944964	electrophysiological recordings
0.8290240329	pressure rise
0.8290220889	pregnant rats
0.8290168803	induced pluripotent stem cell derived cardiomyocytes
0.8289987160	reporting rate
0.8289986782	laboratory tests
0.8289957136	low molecular weight heparin
0.8289645228	advanced ovarian cancer
0.8289254947	central vein thrombosis
0.8288381577	growth hormone
0.8288043236	ng mouse
0.8287617970	muscle biopsy
0.8287417542	anxiogenic drugs
0.8286698480	head twitches
0.8286569003	urinary sediment
0.8285511192	caffeine challenge test
0.8284720066	affective disorder
0.8284589189	chronic active hepatitis
0.8284525022	standard treatments
0.8283792454	cardiovascular dynamics
0.8283459733	undergoes extensive
0.8283397172	brain damage
0.8283229575	gastric acid back diffusion
0.8283185440	coronary angiography
0.8282464251	convulsive action
0.8282053540	cerebral hemorrhage
0.8281747286	arthralgia myalgia syndrome
0.8281202808	health history
0.8280890081	prescribed cephalexin
0.8280688560	outer medulla
0.8280625358	rhuepo beta
0.8280549664	neural correlates
0.8280301050	valve regurgitation
0.8279985992	spinal anesthesia
0.8279977913	therapeutic window
0.8279797539	heart mitochondria
0.8279494518	extensive literature
0.8279095045	acute corticosteroid myopathy
0.8279086810	delivery hospitals
0.8279040752	mitral valve
0.8279023402	significantly lower
0.8278637416	mtdna encoded respiratory chain
0.8278250290	iu kg
0.8278203158	epileptic woman
0.8278134630	permeability transition
0.8277558577	epidemiologic studies
0.8277327882	urodynamic studies
0.8277305629	apigenin delays
0.8276447842	cerebral arteries
0.8276152058	unilateral spinal anaesthesia
0.8274780018	intracavitary chemotherapy
0.8274716181	renal biopsy
0.8274577991	clonic convulsions
0.8274190631	week intervals
0.8274074677	serum creatinine level
0.8273786604	percent inhibition
0.8273055947	clonic seizure
0.8272766710	maintenance steroids
0.8272667490	hepatic veno occlusive disease
0.8272621486	liver transplant
0.8271983152	action potential generation
0.8271344411	nkcc2 expression
0.8270763516	isoenzyme pattern
0.8270739964	methamphetamine dependence
0.8270176595	pharmacological actions
0.8269956877	recreational cocaine users
0.8269719615	liver injury
0.8269617226	memory deficit
0.8269594154	shorter median
0.8269341638	taking continuous combined ht
0.8268669580	advanced kaposi
0.8268623065	juvenile rheumatoid arthritis
0.8268595933	d1 receptor agonists
0.8267741773	systolic arterial pressure
0.8267673496	3alpha hydroxy
0.8267499619	delayed maturation
0.8267344526	ma abuse
0.8266639529	myocardial hypertrophy
0.8266358469	physical status
0.8264781704	mm hg systolic
0.8264526947	gamma gt
0.8264429804	diarrhoea predominant
0.8263745181	constipating effects
0.8263613593	serum chemistry
0.8263332398	pro apoptotic
0.8263316873	vessel wall
0.8262907720	calcium channels
0.8262743551	creatinine concentration
0.8261881359	facial expression
0.8261416916	significantly attenuated
0.8260717197	urinary incontinence
0.8260044180	postoperative delirium
0.8258896419	visual analogue
0.8258413049	initial evaluation
0.8258098616	tumor growth
0.8257607079	serum levetiracetam
0.8257243502	cognitive measures
0.8256993419	recreational ecstasy
0.8256643155	life saving
0.8256471070	viral hepatitis
0.8256370664	withdrawal seizure prone
0.8255220144	previously reported cases
0.8255052880	diabetic neuropathy
0.8254841498	fracture reduction
0.8254468244	bile flow
0.8254432019	transient neurological deficit
0.8254186724	hematoma volume
0.8254009574	antithyroid drugs
0.8253114512	myocardial contrast echocardiography
0.8252391654	left ventricular ejection
0.8252362813	subcutaneous heparin
0.8251478744	maximum osmolality
0.8251294717	selection criteria
0.8251181652	fatty acid oxidation
0.8250141145	historic control
0.8250112897	pupil dilation
0.8249783874	tumor tissue
0.8249237098	endothelial cell
0.8249057894	renal artery stenosis
0.8248799968	reached statistical significance
0.8248752976	bile diverted rats
0.8247940251	left sided
0.8247681450	free water
0.8247258559	electrographic seizure
0.8246792896	dietary sodium chloride
0.8246667278	intensity weighted lifetime days
0.8246474300	nuclear number
0.8246095686	lv end diastolic pressure
0.8245928460	carbidopa levodopa
0.8244494621	bladder afferent
0.8244355766	bilateral nephrectomy
0.8243567666	dopamine beta hydroxylase
0.8242416747	long term
0.8242192230	ketamine doc
0.8241303058	renal artery
0.8241269068	moderate degree
0.8241015688	behavioral states
0.8240816615	survival rate
0.8240179823	associative learning
0.8239996794	thrombotic risk
0.8239526636	epileptic seizures
0.8239254009	venous complications
0.8238962408	recurrence rate
0.8238749891	avoidance task
0.8238449227	upper abdominal pain
0.8237767550	positive reaction products
0.8237665379	retinal vasculitis
0.8237337626	glibenclamide sensitive
0.8237059491	progressive decline
0.8237019385	anticholinergic challenge
0.8236592260	thyroid illness
0.8236417454	visual function
0.8236332939	mature male
0.8236260282	von frey gauges
0.8235409953	mechanical ventilation
0.8234058546	acquired long qt syndrome
0.8233979613	fewer cardiovascular
0.8233975658	osmolality contrast medium
0.8232490186	estrogen binding sites
0.8232397786	operative field
0.8232008688	lateral antebrachial cutaneous neuropathy
0.8231626686	body potassium
0.8231358500	safety profiles
0.8231031683	hepatocellular pattern
0.8230632535	selective serotonin uptake inhibitor
0.8230280070	remission induction
0.8230141913	kidney function
0.8229830298	rat ventricular myocytes
0.8229725882	antisocial personality disorder
0.8229503453	disulfiram intoxication
0.8229482766	dilevalol antigens
0.8229445109	parkinsonian motor disability
0.8228951546	auditory brainstem
0.8228532264	induced hypertension instituted
0.8228351057	gsh stability
0.8228209339	periodic acid
0.8227346739	dopamine agonists
0.8227205859	masseter muscle
0.8226722885	lung mass
0.8226438270	4hne protein adducts
0.8226413948	halothane hepatitis
0.8226160322	hemolytic anemia crisis
0.8226102992	mitochondrial dna
0.8225725601	primary care
0.8225615980	sd rats
0.8225328811	chinese man
0.8225184873	glomerular sclerosis
0.8224795802	epidural steroid injection
0.8224717273	anti hcv
0.8224051432	recent onset atrial fibrillation
0.8223691424	behavioral approach
0.8223215738	tonic clonic convulsions
0.8223024617	transporter promoter gene
0.8222967511	remain unknown
0.8222256970	collagenase induced intracerebral hemorrhage
0.8221821694	potentially life threatening
0.8221769978	experimental conditions
0.8220214396	outcome scale
0.8220159774	public health
0.8219770423	glucose metabolism
0.8219757897	mhc cb7 mice
0.8219625345	atypical plasma cholinesterase
0.8219623392	passive avoidance behaviours
0.8219147031	perinatal complications
0.8218959196	alpha bungarotoxin
0.8218767700	clinical evaluation
0.8218574119	mg ml h2o
0.8218551336	continue combination therapy
0.8217811463	vocal fold
0.8217492892	cb1 receptors
0.8217311634	endometrial cancer diagnosed
0.8216698826	sympathetic stimulation
0.8216284621	duration longer
0.8215852220	electrical stimulation
0.8215550330	fetal pulmonary hypertension
0.8215358360	total bilirubin
0.8213584709	a1 receptor agonist
0.8213450738	wall motion
0.8213380021	generalized tonic clonic seizure
0.8212939797	left ventricular filling
0.8212927317	reverse transcriptase inhibitor
0.8212882531	intestinal ischemia reperfusion injury
0.8212614234	transplant recipients
0.8212417425	benzodiazepine gaba chloride channel macromolecular complex
0.8212055189	nerve fiber
0.8210877908	seed extract
0.8210171008	body weight gain
0.8210110802	receive tamoxifen
0.8210106522	axial symptoms
0.8209413050	unusual complications
0.8209228431	grade ii
0.8208789129	respiratory paralysis
0.8208040935	snp infusion
0.8207892415	highly suspected
0.8207661542	micrograms mouse
0.8207655755	abnormal cardiac adrenergic neuron activity
0.8207157504	dopamine agonist
0.8206781921	flecainide plasma concentrations
0.8205584296	marrow suppression
0.8205434693	plasma membrane sodium channels
0.8204888622	lymphocyte transformation
0.8204517529	seizure activity
0.8204421613	orally active
0.8204142523	immunoreactive corticotropin releasing factor
0.8203735388	systemic plasma vegf165 levels
0.8203500553	retrospective review
0.8203471320	bpo pll
0.8203058966	safety profile
0.8202900695	cardiovascular diseases
0.8202816216	cardiac events
0.8202597697	gastrointestinal bleeding
0.8201599043	quinine infusion
0.8201456644	spinal block
0.8201282860	neurogenic di
0.8200565791	wall thickening
0.8199700883	hemorrhagic ulcer
0.8198868892	multivariate logistic regression
0.8198713944	pulse frequency
0.8198480655	acetic acid induced writhing
0.8198271894	clinically reversible
0.8197241498	retrospective comparative study
0.8197130027	tubular atrophy
0.8196418495	nonsteroidal anti inflammatory drugs
0.8196290937	sodium channel density
0.8196141236	pre bed
0.8195780243	alcohol intake
0.8195519615	causally related
0.8195422685	glomerular hypertrophy
0.8195350634	junctional rhythms
0.8195230124	major depression
0.8194240162	grip force
0.8194133415	spring allergic rhinitis
0.8193699742	potassium loss
0.8192265706	nonimmune women
0.8192265706	hysterectomised women
0.8191961200	comparable antitumor efficacy
0.8191337241	papillary damage
0.8191131909	retrospective analysis
0.8190987928	psychopathological symptoms
0.8190632159	ami gi
0.8190344803	pharmacologic agents
0.8190170974	autoimmune complications
0.8190144096	hypotensive episodes
0.8189611538	female sex
0.8187989606	minor neurological dysfunctions
0.8187814961	bladder hyperactivity
0.8187684115	antitumor effect
0.8187641849	kg b.w
0.8187161441	alpha adrenoceptor
0.8186584725	respiratory pattern
0.8186422748	foot processes
0.8186062491	picture resembling
0.8184845112	histological evidence
0.8184766150	adrenergic mechanism
0.8183739864	hepatic failure necessitating liver transplantation
0.8183006089	similar reductions
0.8182852634	adriamycin mediated antitumor
0.8182210647	recurrence rates
0.8181929768	neurological evaluation
0.8180889624	estimated glomerular filtration rate
0.8180245537	standard deviation
0.8180149119	placebo controlled trial
0.8178959730	unit collagenase
0.8178764391	antagonist fluphenazine
0.8178460162	toxic deaths
0.8178297108	average age
0.8178087797	barium exposed rats
0.8178006934	group ii
0.8177833237	neuroimaging data
0.8177829406	1,2 dihydro 2 acenaphthylenyl
0.8177435697	da d2
0.8176944872	left ventricular papillary
0.8176908746	hypersensitivity reaction
0.8176867890	motor disability
0.8176581419	multiple dosing paradigm
0.8176471679	conscious dogs
0.8175703119	high frequency
0.8175510087	atrial tachyarrhythmia
0.8175121158	prophylactic measures
0.8175086474	fda recommended
0.8174848522	mm hg sem
0.8174606917	nmda receptors
0.8173875976	serum ferritin
0.8173864928	elevated reactive oxygen
0.8173088517	controlled hypotension anesthesia
0.8172873499	alcohol intoxication
0.8172314820	nonanemic controls
0.8171845027	renal tubule
0.8171654178	long qt syndrome
0.8170405333	obstructive coronary
0.8169968633	epileptogenic properties
0.8169864710	vincristine sulfate
0.8169490570	mild type chronic fk506 nephropathy
0.8169193055	urothelial toxicity
0.8168112781	protein excretion
0.8168043856	anti amnesic effect
0.8167993553	clinical trial
0.8167461998	dose limiting
0.8167429207	respiratory arrest
0.8167127535	recovered completely
0.8167027279	liver regeneration
0.8166965821	acetazolamide induced gerstmann syndrome
0.8166687856	p450 2b1 2b2
0.8166229123	urinary ph
0.8165643661	lasted longer
0.8164770729	bmc treated epileptic animals
0.8164180050	healthy young volunteers
0.8163658880	trials register
0.8163589364	cerebral artery
0.8163571878	tubulointerstitial injury
0.8162925142	cardiovascular functions
0.8162153963	cardiac pacing
0.8161684748	gap43 ir
0.8160443159	sex hormones
0.8160373412	randomised trial
0.8160221260	alpha coma
0.8160042819	posterior wall thickness
0.8159189724	compensatory mechanism
0.8157901247	exercise performance
0.8157860021	gemfibrozil lovastatin
0.8157407119	intraperitoneal infusion rates
0.8154899106	low dose
0.8154873775	basal creatinine
0.8154612675	acute tubular necrosis
0.8154205418	aortic pressure
0.8154074214	contrast enhancement
0.8153741219	sphincter of oddi spasm
0.8153455147	femoral nerve
0.8153202829	highly sensitive
0.8152814191	liver cirrhosis
0.8152594357	hepatitis b immune globulin
0.8152075939	concentration defect appeared
0.8151994516	binding site
0.8151712187	acetylcholine receptor
0.8150796334	thallium 201 single photon emission tomography
0.8150581581	trimethaphan induced hypotension
0.8150431849	airway management
0.8150312120	lower limb
0.8150219533	absence epilepsy
0.8149615953	baseline startle
0.8147957137	ventricular septal defects
0.8147599516	seizure thresholds
0.8147436259	aggressive behaviors
0.8147379833	high dose cytosine arabinoside
0.8146780571	subacute diazinon
0.8146463372	dose inhaled salbutamol
0.8146320033	brain biogenic amines
0.8144978742	serum marker enzymes
0.8144687552	sugar access
0.8143867309	fasl tg
0.8143515344	tonic dopaminergic stimulation
0.8143503382	fulminant hepatitis
0.8143295450	streptozotocin induced diabetic nephropathy
0.8142416854	optimal medical
0.8142001505	mitochondrial oxygen
0.8141761639	rapidly progressive glomerulonephritis
0.8141441498	left atrial
0.8140988877	haemorrhagic myocarditis
0.8140706472	intravitreal implant
0.8140466643	mg kg
0.8140424596	neuromuscular block
0.8140077557	climacteric women receiving oestrogen therapy
0.8139671142	advanced pregnancy
0.8139624513	severe bradyarrhythmia
0.8138675010	etomidate induced myoclonus
0.8138583763	mitochondrial dysfunction
0.8138356202	sodium excretion
0.8138347629	point scale
0.8138152595	retrospectively reviewed
0.8138024006	clomipramine ingestion
0.8137534663	toxic metabolite
0.8137292580	antiretroviral therapy
0.8136337480	wsp mice
0.8135621231	cardiovascular disease
0.8135237688	brain edema
0.8135007583	highly effective
0.8134942991	ticlopidine induced aplastic anemia
0.8134901973	neuropsychological testing
0.8134005345	tubular necrosis
0.8133404672	dopaminergic systems
0.8132751375	systemic absorption
0.8131813489	hearing threshold
0.8131532088	consecutive weeks
0.8130872250	white matter abnormalities
0.8130323714	subclinical heart failure
0.8129865363	epidural block
0.8129699907	central cholinergic
0.8129280088	atropine sulfate
0.8129005501	massive transfusion
0.8127631612	trihexyphenidyl hydrochloride
0.8127067759	rapidly progressive
0.8126079306	tubular epithelial
0.8125946754	stat3 activation
0.8125836845	end stage renal disease
0.8125452271	acute renal failure
0.8125018830	dipyridamole induced hyperemia
0.8124857853	previous evidence
0.8124209708	requiring hospitalization
0.8124028897	plasma noradrenaline
0.8123417795	rat atrial spontaneous
0.8121379727	postoperative convulsive
0.8121325979	posterior reversible encephalopathy syndrome
0.8120915878	massive intestinal bleeding
0.8120168129	sinus arrest
0.8120090289	muscle fibers
0.8118866597	plasma apolipoprotein
0.8118160889	microscopic evaluation
0.8118031160	single agent
0.8117742951	upper abdominal
0.8117495691	high grade
0.8117484913	postoperative analgesia
0.8117311322	based immunosuppression
0.8117129998	chronically infected
0.8117089140	visceral afferent
0.8116543405	valproate induced hyperammonemic
0.8115722216	bupropion hcl
0.8115720474	multivariate logistic regression analysis
0.8115431123	low cost
0.8115302976	pan glomeruli
0.8115082218	chronic prazosin treatment
0.8114979955	dna cleavage
0.8114564736	canine ventricular arrhythmias
0.8113837820	real inhibitory cerebellar stimulation
0.8113756679	nociceptin orphanin fq and nocistatin
0.8113753116	bladder pathology
0.8112419539	calcium concentrations
0.8110867551	surgical conditions
0.8110735603	malignant mesenchymal tumors
0.8110405987	gestational age
0.8110224810	immune hemolytic anemia
0.8109408897	lr132 significantly attenuated
0.8109334664	total rna
0.8109157899	neuropathic symptoms
0.8108634962	type passive avoidance
0.8108393798	ao mrna levels
0.8108035322	antithrombotic users
0.8107850818	lsd abuse
0.8107335685	marked differences
0.8106469459	laboratory values
0.8106418217	esophageal carcinoma
0.8106359046	combination chemotherapy
0.8106119649	biopsy samples
0.8105909083	red cells
0.8105810579	morphological alterations
0.8105482220	broad spectrum
0.8105410571	free interval
0.8105361645	young adults
0.8105285491	bladder epithelium
0.8105112083	promoter gene
0.8104578082	glucose tolerance
0.8103836966	equivalent doses
0.8103761085	pacemaker channels
0.8103692788	median progression free survival
0.8103498876	longer acting
0.8102835209	monophasic action potential duration
0.8102592413	previously unreported
0.8102086740	pentazocine induced fibrous myopathy
0.8101845353	nitroprusside infusion
0.8101040620	high pressure liquid chromatography
0.8101005266	undergoing apoptosis
0.8099230191	minocycline induced vasculitis
0.8098548266	inflammatory diseases
0.8098104755	bilateral abductor
0.8097890422	medical center
0.8097870560	ecstasy polydrug users
0.8095975916	nmol min
0.8095958651	extrapyramidal symptom
0.8094852665	tubular injury
0.8094084910	adverse drug reaction
0.8093087854	acetylcholinesterase inhibitor
0.8092434350	vagal mechanism
0.8092362097	treated segments
0.8091957206	developed complete av block
0.8091698365	toxic effects
0.8090732172	headache intensity
0.8090406697	combined continuous ht significantly increased
0.8090168114	hepatic tissue
0.8090142083	free recall
0.8089841471	stem cell transplantation
0.8089752566	ultrasound examinations
0.8089335037	intrathecal methotrexate
0.8089098141	ventricular arrhythmia
0.8088519961	oral bisphosphonate
0.8088404418	potassium deficit
0.8087729418	preneoplastic liver
0.8087375565	propofol infusion
0.8087366409	hepatic dysfunction
0.8086931560	l1 l2 and l6 s1
0.8086679490	auditory nerve
0.8086178432	apical targeting
0.8085996844	systolic left ventricular posterior wall dimension
0.8085774685	recent evidence
0.8084392393	myocardial ischaemia
0.8083878377	experimental glomerulonephritis
0.8083606164	cervical carcinoma
0.8083259689	reversible inferior colliculus lesions
0.8082736028	high doses
0.8082229234	control subjects
0.8081274839	suspected idiopathic epilepsy
0.8081241126	valproate encephalopathy
0.8081082091	female gender
0.8080917686	attributable risk
0.8079764068	capillary endothelial cells
0.8079513892	based chemotherapy
0.8078537349	liver failure
0.8078022196	chemotherapeutic agents
0.8077240115	renal tubular acidosis
0.8075892397	injected intravenously
0.8075852612	tertiary care
0.8075828271	neonatal apnea
0.8075662426	srl conversion
0.8075083606	blood vessel
0.8074536749	therapeutic strategies
0.8073978302	serum sfas
0.8073079515	thromboembolic events
0.8072542142	acute hepatitis
0.8072045917	exposed neonates
0.8071543286	urinary ngf
0.8071321701	brain sections
0.8070925232	prenatal screening
0.8070724906	distance traveled and average speed
0.8070188295	idiopathic orthostatic hypotension
0.8069900134	conventional medical
0.8069695862	serum bilirubin
0.8069388223	metronidazole induced encephalopathy
0.8068719077	immunohistochemical analysis
0.8068515903	immunosuppressive agents
0.8067974027	rheumatologic diseases
0.8067938682	midline b3 serotonin
0.8067244913	histopathological alterations
0.8066323725	altered bbb
0.8066259143	eyes task
0.8066240176	stage d1
0.8065205444	congenital heart
0.8064459875	sinus thrombosis
0.8062681789	abnormal physical examination
0.8062246793	motor signs
0.8061778908	count decrease
0.8061689942	general anesthesia
0.8061641374	potential therapeutic
0.8061488563	drug adsorption
0.8061459318	oliguric renal failure
0.8061283679	recent studies
0.8061165299	major health problem
0.8061010650	allograft function
0.8060833727	prospective study
0.8059674227	intrarenal angiotensinogen expression
0.8059249069	partly mediated
0.8058601555	poly l lactid acid nanoparticles
0.8058466265	acetylcholine receptor antibody
0.8058237786	intraperitoneally injected
0.8058237786	injected intraperitoneally
0.8057636860	ng kg min
0.8057606781	systolic blood pressures
0.8057592539	histological characteristics
0.8057243897	antinociceptive effect
0.8057138559	endometrial carcinoma
0.8057123293	urodynamic parameters
0.8056814164	mrp2 antibody
0.8055497793	adult males
0.8054829449	levodopa equivalent
0.8054767767	chf development
0.8054705788	myocardial scintigraphy
0.8054572437	cell layer
0.8054549981	illicit drug
0.8053796336	intensive topical
0.8053409198	liver sections
0.8053263140	strong support
0.8050858249	cerebral vasospasm
0.8050797371	wall motion abnormalities
0.8050260626	histopathological examination
0.8049821622	compartment model
0.8049438870	healthy elderly
0.8048304148	multiple cytotoxic
0.8047687587	organic mental disorder
0.8047192506	food intake
0.8047163293	serum concentrations
0.8046931753	occurring simultaneously
0.8046813545	sensory action potential
0.8046741795	filling pressure
0.8046121662	intrathecal chemotherapy
0.8045467370	aortic atherosclerosis
0.8044306265	hippocampal dependent
0.8043972746	clinical outcome
0.8043244713	transplant recipient
0.8042814886	coronary heart disease
0.8042665788	positive foci
0.8042661380	molecular mechanisms underlying
0.8042472583	levodopa induced dyskinesias
0.8042344962	progenitor cells
0.8042333831	nonsteroidal anti inflammatory drug
0.8041182473	marked polyuria
0.8040870231	cortical homogenates
0.8040373687	magnetic resonance imaging scans
0.8040269168	generalized seizures
0.8040112362	heart valves
0.8039936086	passive avoidance test
0.8039858576	gentamicin sulfate
0.8039634778	anticataleptic effects
0.8039183345	central cholinergic functioning
0.8038307669	intermittent dobutamine
0.8037422980	focal segmental
0.8037047559	underlying diseases
0.8036522617	flurothyl seizure testing
0.8036294931	magnetic resonance angiography
0.8035378089	tonic convulsions
0.8035231890	cell samples
0.8035066667	hbv mutants
0.8034981720	regional anesthesia
0.8034709530	stable angina
0.8034613272	glomerular size
0.8033754044	contralateral eyes
0.8032812209	catecholamine release
0.8032022212	university affiliated
0.8031670034	free radical generation
0.8030938119	basal membrane
0.8030674565	intravenous conscious sedation
0.8030487721	altered mental status
0.8029494987	minimal model analysis
0.8029176529	generally small
0.8028923937	injection drug users
0.8028871041	cholinergic transmission
0.8028785515	cerebral white matter
0.8028766783	combined oral contraceptives
0.8028566647	immunodeficiency syndrome
0.8028261062	focal glomerulosclerosis
0.8028233197	plasma lipoproteins
0.8027956470	serum magnesium
0.8027886237	serotonin nerves
0.8027871931	unmask seizures
0.8027849332	alkylating agent
0.8027339720	completely prevent
0.8026234982	family history
0.8026019050	acetylcholinesterase activity
0.8025816604	ilk liver mice
0.8025159459	cost effective
0.8024425404	capillary wall
0.8023636404	mammalian target of rapamycin
0.8023270462	permanent neurological
0.8022761882	cytotoxic chemotherapy
0.8022360197	alpha2abc mice
0.8022221295	septal defects
0.8022166884	hyperbaric oxygen
0.8021046167	pharmacological profile
0.8020021653	minor motor
0.8019481982	intermittent schedule
0.8017666067	previous exposures
0.8016872713	occurs frequently
0.8016798848	cochlear hearing loss
0.8016628527	pan nephrosis
0.8015981062	brain cholinesterase activity
0.8015531263	ovulation induction
0.8014501539	significant statistical
0.8014384113	psychiatric rating scale
0.8014335985	cardiac dysrhythmias
0.8014218501	impaired cognitive functions
0.8013711377	ad libitum fed rats
0.8013032739	offer protection
0.8012701603	monthly intervals
0.8012411097	sural nerve
0.8012319574	steroid myopathy
0.8012300337	visual analogue scale
0.8012157279	pharmacological characteristics
0.8011722708	respiratory depression
0.8011711824	dsm iii
0.8011164454	target tissues
0.8010956921	antagonist yohimbine
0.8010655091	left gastrocnemius
0.8010548029	chronic hyperprolactinemia
0.8010203664	standard prophylaxis
0.8010121721	tj damage
0.8009928458	special attention
0.8009806241	hypotensive action
0.8009000902	high performance liquid
0.8008539174	sensitivity analyses
0.8008305479	prevent hypokalemia
0.8007535175	focal calcification
0.8007164454	needed dialysis
0.8006858985	renal tissue
0.8006703969	biosynthetic pathways
0.8006694387	mouse lines
0.8006280959	baseline ejection fraction
0.8006093015	anxiogenic effect
0.8005865097	subtenon carboplatin chemotherapy
0.8005629554	immune escape variants
0.8005625116	antihyperalgesic activity
0.8005416534	upper limit
0.8003698177	renal injury
0.8003345834	occupancy levels
0.8003205934	small bowel
0.8003087829	standard lidocaine
0.8002645105	cold pressor
0.8002067789	advanced age
0.8000330321	plasma malondialdehyde
0.7999871958	training naloxone
0.7999740266	nacl solution
0.7999653972	amino acid neurotransmitters
0.7999566386	myometrial cells
0.7999531619	tumor angiogenesis
0.7998741944	clinical research center
0.7998438683	histologic features
0.7996584560	pulmonary vascular smooth muscle
0.7996560197	verapamil stimulation test
0.7995238429	clinical success
0.7995028593	hiv disease progression
0.7993493891	vt appeared
0.7992902905	chemical cystitis
0.7992784763	early onset migraine
0.7991887196	squamous cell
0.7991154722	neurological manifestations
0.7991110385	valdecoxib doses
0.7990959003	glepp1 expression
0.7990700711	mg b.d
0.7990566659	nitrative damage
0.7990542951	renal cell carcinoma
0.7989308632	tonic clonic seizures
0.7989238657	lv dp dt
0.7989237109	arterial diameter
0.7987569593	niacin extended release
0.7987542694	male rats
0.7987277323	radial nerve
0.7987174221	continuous infusion
0.7986949712	ischemic brain injury
0.7986626381	abnormalities correlated
0.7986354172	tam induced hemolysis
0.7986335252	gastric acid
0.7986326295	biochemical liver function tests
0.7985894323	transient hemiparesis
0.7985591289	fetal alcohol
0.7985579735	amphetamine induced hyperactivity
0.7985337170	chronic obstructive pulmonary disease
0.7984890418	glycine site
0.7984816327	hiv protease inhibitor
0.7984371159	urinary bladder
0.7984166216	septal rupture
0.7983185029	growth hormone secretion
0.7983068067	poor risk
0.7982998961	seizures mo
0.7982474332	nigrostriatal dopamine
0.7982274574	spontaneous circulation
0.7981913995	proliferating cell
0.7981866952	patients undergoing hip
0.7981844286	high frequencies
0.7981549420	map kinase related pathways
0.7981534892	tobramycin sulfate
0.7981451183	mmol kg
0.7981390971	gaba transaminase
0.7980903787	hemodynamic parameters
0.7980251678	evoked potentials
0.7979311052	da pool
0.7978909288	success rates
0.7978420023	open arm
0.7977746061	unusually high
0.7977746061	unexpectedly high
0.7976007470	ocular hypertension
0.7975929650	bladder retention
0.7975681228	opioid receptors
0.7975323775	mediated signaling
0.7975035654	serum aminotransferase levels
0.7974353797	peripheral blood stem cell
0.7973853008	muscle tone
0.7973756447	disabling dyskinesia
0.7972915494	cocaine users
0.7972665619	atrial natriuretic peptide
0.7971842895	lv hypertrophy
0.7971252952	compensatory mechanisms
0.7971167038	alpha benzene hexachloride
0.7970968797	beta adrenergic
0.7969847252	fibrinolysis inhibitor
0.7969458417	muscarinic cholinergic
0.7969404313	delayed feedback
0.7969326603	ppa caffeine
0.7969257863	surface antigen
0.7969199457	low grade
0.7968936142	intraoperative dialysis
0.7968747132	infected individuals
0.7968241281	cn pretreatment
0.7968100657	laboratory variables
0.7967617157	metabolic disturbances
0.7967163964	segmental glomerulosclerosis
0.7965860772	intradermal capsaicin
0.7965717228	human subjects
0.7965159272	hiv positive persons
0.7965143979	primary end point
0.7964394034	sulfasalazine induced lupus
0.7964359988	b2 receptors
0.7964178899	bile salt
0.7963859212	depressive disorders
0.7963505794	nicotinic receptor blockade
0.7962347257	multicenter study
0.7962236746	urinary bladder function
0.7962071191	noradrenergic signaling
0.7961927507	brain areas
0.7961695333	adriamycin nephrosis
0.7961442707	human cloned
0.7961409001	apomorphine induced aggressiveness
0.7961280823	functional magnetic resonance imaging
0.7961134166	hemorrhagic strokes
0.7960296702	echocardiographic screening
0.7960125955	methadone dose
0.7959485382	precurarizing dose
0.7958681408	beta adrenergic receptors
0.7958115337	brain mr
0.7958089893	antithyroid agent
0.7956568166	hepatic function
0.7956565725	mdma polydrug users
0.7956546803	acute flank pain syndrome
0.7955892803	escape latencies and traveled distances
0.7955779501	retrospective study
0.7954909571	prescribed telithromycin
0.7954393055	adverse effect
0.7954358777	adherence group
0.7954159809	naloxone reverses
0.7954094661	mild ptcr
0.7953945477	controlled challenge tests
0.7953771721	vacuous chewing movements and tongue protrusions
0.7952256030	qtp + li dvp
0.7952067093	androgen independent prostate cancer
0.7951794453	surgery radiotherapy
0.7951748428	spontaneous respiration
0.7951713304	depressive symptoms
0.7951333634	race ethnicity or obesity
0.7951189466	intracranial surgery
0.7950875595	neuromuscular blocking
0.7950165592	converting enzyme inhibitor
0.7949693138	intrarenal angiotensinogen
0.7949371862	controlled release
0.7948857840	opioid analgesics
0.7948470710	peritoneal dialysis
0.7947875876	regular ecstasy users
0.7947388934	serum calcium
0.7947058315	fluctuating parkinson
0.7946581291	chemical analysis
0.7945673788	activated clotting
0.7945492818	min intervals
0.7945431934	prenatal cocaine exposure
0.7945030142	mm nh4ac
0.7943769648	activated protein kinase
0.7943309419	months post cab
0.7942089762	negative myoclonus
0.7942036716	infants born
0.7941804965	recreational drug
0.7941184855	benzodiazepine antagonist
0.7941109027	systemic corticosterone
0.7941077114	therapeutic tool
0.7940693525	encoded subunits
0.7940328127	data collection
0.7940133874	versus similar sized placebo groups
0.7939919653	perfusion technique
0.7938759379	produce neurological complications
0.7938641335	proximal tubular necrosis
0.7938236233	potential confounding factors
0.7938012617	open chest dogs
0.7937999239	hit antibody
0.7937962007	locomotor stimulation
0.7937820871	hepatic veins
0.7937587381	soluble markers
0.7937297764	injected subcutaneously
0.7936929446	preoperative values
0.7936869626	maintenance dose
0.7936352974	complete blood cell counts
0.7935709026	ml min
0.7935338126	atp synthesis
0.7935002090	liver biopsy sample showed
0.7934966175	hippocampus improves
0.7934121247	recent data suggest
0.7934067187	cardiomyocyte degeneration
0.7933276341	d2 antagonist
0.7933024703	dopamine transporter
0.7932999867	markedly reduced
0.7932719181	field defects
0.7932261445	cerebral blood flow
0.7931937646	red blood cell
0.7931180713	central cholinergic systems
0.7930886556	potentially toxic
0.7930637284	renal fibrosis
0.7930511124	prolactin signaling
0.7929894314	combined levomepromazine fluvoxamine treatment
0.7929620821	f2 alpha
0.7929102947	rg1 restored
0.7929052929	persistent hiccups
0.7928796320	conventional neuroleptics
0.7928401941	progressive muscular dystrophy
0.7927623366	modestly reduced
0.7927495728	highest risk
0.7927480292	mild aortic regurgitation
0.7927410879	pathophysiologic mechanisms
0.7927282041	late conversion
0.7926824072	pressure dynamic
0.7926620731	pge2 synthesis
0.7926372329	methamphetamine induced nigrostriatal
0.7926320516	yellow phosphorus poisoning
0.7925816822	slight improvement
0.7925193760	dopamine release
0.7924373802	cell number
0.7922724813	des arg10 hoe 140
0.7922672146	immunosuppressive therapy
0.7922596065	recent users
0.7922221658	bcnu exposed
0.7921906441	dopaminergic activation
0.7921101439	open chest
0.7920916969	angiotensin ii receptor antagonist
0.7920029627	body weight loss
0.7919700931	surgical interventions
0.7918848520	antagonist sulpiride
0.7918514735	severely depressed
0.7918512376	acute pain models
0.7918481727	conscious spontaneously hypertensive rats
0.7918245773	negative inotropic
0.7917485549	divided doses
0.7917404525	recommend caution
0.7917350529	endothelial function
0.7917067510	frontal cortex
0.7916552682	nnos activity
0.7916508559	transient visual disturbances
0.7915892799	recovery room
0.7915778782	gradually improved
0.7915589993	selective alpha1 adrenoceptor
0.7914847115	timolol maleate
0.7914227946	liver disease
0.7914154907	injected bilaterally
0.7914065036	trihexyphenidyl anticholinergic
0.7913801593	anti hypertensive
0.7913800142	atypical antipsychotic agents
0.7913065036	chinese herbal
0.7912488577	achieved complete remission
0.7912315728	receptor binding
0.7911341291	neurotransmitter systems
0.7910880012	retrospective cohort study
0.7910272701	young volunteers
0.7910029068	antitumor efficacy
0.7909461668	cardiovascular outcomes
0.7909457937	inpatient setting
0.7909328299	initiated hepatocytes
0.7908841891	spinal surgery
0.7908752154	metformin hydrochloride
0.7908649340	muscular rigidity
0.7908580352	microg kg min
0.7908305100	mortality rates
0.7908183829	safety population
0.7907183314	glomerulosclerosis index
0.7907143711	signaling pathways
0.7907077476	hemodynamic measurements
0.7905945755	left ventricular posterior wall
0.7905893649	previous investigations
0.7905106816	liver biopsy
0.7904783374	acetylcholine receptor expression
0.7904514263	handling proteins
0.7903553287	gene targeted mice
0.7903297486	antagonist ro4368554
0.7903084939	mesangial cells
0.7902453607	tail withdrawal
0.7901973841	academic medical
0.7901809740	hippocampal ach
0.7901714893	chelating agent
0.7901341587	myeloid leukemia
0.7900194926	coagulation factors
0.7900094422	hematologic toxicities
0.7898488119	nicotinic receptor
0.7898158424	oral cavity
0.7897908376	regional cerebral blood flow
0.7897063826	absolute risk remained
0.7895769048	plasma lactate
0.7895489012	dobutamine stress testing
0.7894735086	haloperidol induced catalepsy
0.7894496679	reflex responses
0.7894462599	hiv infected patients
0.7893509978	antiinflammatory agents
0.7892934858	pulmonary arterial
0.7892447230	cardiac failure
0.7892405103	updrs scores
0.7890720808	organ transplant
0.7890683627	ich deterioration
0.7890614874	tacrine loaded
0.7890407877	evaluation revealed
0.7890317238	renal damage
0.7890112845	based regimens
0.7890043674	folic acid supplementation
0.7889911123	central excitatory actions
0.7888731815	massive rhabdomyolysis
0.7888097015	advanced metastatic renal cell
0.7887680157	male ds
0.7887208238	gynecologic procedures
0.7887059167	positive inotropic
0.7885690473	micturition reflex
0.7885408857	hepatic triglyceride
0.7884925858	vascular smooth muscle
0.7883636209	sleep latency
0.7882245347	pap formation
0.7882214670	recombinant human
0.7882082487	atherosclerotic rats
0.7882039612	significantly reduced
0.7879111427	antineutrophil cytoplasmic antibody
0.7878523329	papillary necrosis
0.7877877655	ecstasy specific
0.7877712562	total daily levodopa dose
0.7877318263	renal calculi
0.7876912615	cardiovascular toxicity
0.7876265300	periportal hepatocytes after bdl
0.7875924652	gad mrna
0.7875773643	spontaneous pain behaviors
0.7875583557	sulpiride induced tardive dystonia
0.7875381707	prevent milk fever
0.7874423220	chronic urticaria
0.7874365155	urine toxicology
0.7874165191	mg kg bw
0.7873499420	diet fed
0.7873259127	nerve conduction studies
0.7872703600	low sexual desire
0.7871973991	conscious rats
0.7871863445	labeled neurons
0.7871753717	seizure frequency
0.7871386519	low bone turnover
0.7870552102	early identification
0.7870258253	visual field abnormalities
0.7869303574	autoimmune hemolytic anemia
0.7868604837	carmofur induced leukoencephalopathy
0.7868333831	pilocarpine induced electrographic
0.7867547148	cerebellar cortex
0.7867254050	anti epileptic drugs
0.7866987570	bupropion hydrochloride
0.7866773805	passive avoidance task
0.7866765605	isph induced mi
0.7865995769	beta adrenoceptors
0.7865974875	tissue damage
0.7865860851	central venous pressure
0.7865821300	detecting dobutamine induced myocardial ischemia
0.7865528976	wall thickness
0.7864127796	noxious stimulation
0.7863783513	granisetron doses
0.7862754313	hbv dna
0.7859838513	therapeutic hypothermia
0.7859730076	mechanistic studies
0.7858996019	capsaicin induced secondary hyperalgesia
0.7858682619	fatty liver
0.7858576806	hippocampal neurons
0.7858239827	neuropsychological tests
0.7858182365	double blind fashion
0.7857914657	lead induced hypertension
0.7857334096	continuously monitored
0.7856506657	procainamide induced polymorphous ventricular tachycardia
0.7855472109	plasma albumin
0.7855232873	eastern cooperative oncology group performance status
0.7855160816	heparin exposure
0.7854752487	transient neurologic symptoms
0.7854356343	plasma argatroban
0.7854105909	angiotensin ii receptor
0.7853412512	total anionic site surface
0.7853307565	end diastolic
0.7853224813	beta adrenergic blocking
0.7852216612	peripheral blood mononuclear cells
0.7851391378	generation ocs
0.7850930425	low incidence malformations
0.7850608250	renal plasma flow
0.7850470572	adverse ocular reactions
0.7849687836	conduction defects
0.7849083611	kidney transplantation
0.7848582098	auditory discrimination
0.7847760526	chronic liver disease
0.7846868338	glomerular filtration
0.7846830698	latent disease
0.7846721794	hs diet
0.7846410573	completely abolished
0.7844978531	heart diseases
0.7844615310	cardiac toxicity
0.7843590185	streptozotocin induced hyperalgesia
0.7843309069	conduction velocity
0.7842465696	serum aminotransferase
0.7842273513	antibody gnc92h2
0.7842087823	median seizure frequency
0.7841813737	partially prevented
0.7841748773	ug ml
0.7841567242	outcome variable
0.7841409102	protein synthesis
0.7840693872	vgb users
0.7840646523	potent immunosuppressive agent
0.7840597173	concurrent intrathecal
0.7840470432	spontaneous recurrent seizures
0.7839975736	adrenergic neuron
0.7839519548	plasma potassium
0.7838237515	end systolic
0.7836448204	free field
0.7836288472	left ventricular end diastolic volume fell
0.7836272938	ophthalmologic examinations
0.7835789653	oral ursodeoxycholic acid
0.7835496854	lithium pretreated
0.7834692843	severely impaired
0.7834636445	hippocampal amino acid neurotransmitters
0.7833166657	primary motor cortex
0.7831660292	nitroprusside induced hypotension
0.7831547171	intracranial blood flow
0.7831539727	vinorelbine related cardiac events
0.7831487660	cyp2d6 inhibitors
0.7831035689	capsaicin injection
0.7830350715	stalk effect
0.7830170263	previously reported
0.7829513876	beta4 subunits
0.7829266950	cardiac disturbances
0.7829098148	calcium antagonist
0.7828974552	anticholinergic drug
0.7828639922	antiplatelet agent
0.7827072636	stimulant drug
0.7826885717	locomotor activities
0.7826817778	herbal products
0.7826664273	total fasciculation score
0.7826662998	complicating hypertrophic cardiomyopathy
0.7826020100	neuronal damage
0.7825868315	resistant strains
0.7825857206	repeated measures
0.7825673510	immunohistochemical staining
0.7825016655	treated chicks
0.7822377182	gastrointestinal tolerability
0.7821372240	mrna levels
0.7821231495	brain metastases
0.7821152414	consistently higher
0.7820885247	maximal platelet aggregation
0.7820651725	sensory neuropathy
0.7820522112	case fatality
0.7820173560	venous blood
0.7819438703	analyzed separately
0.7819301669	mm st
0.7819000636	sodium chloride diet
0.7818561004	adrenaline infusion
0.7818360696	white matter hypertrophy
0.7818335950	abdominal site
0.7818101085	intestinal bleeding
0.7817950565	mouse strains
0.7817902019	pressor effect
0.7817835534	pegylated interferon alpha 2b
0.7816941772	force excess
0.7815375746	ck mb mi
0.7815336538	glomerular capillary pressure
0.7814445101	epinephrine infusion
0.7814377990	plasma argatroban concentration
0.7814252580	circulating lysosomal
0.7814043677	care center
0.7813924632	significantly decreased
0.7813457946	brain stem activation
0.7812872089	chemotherapeutic drugs
0.7812336372	cold pressor test
0.7812201816	intracranial aneurysms
0.7811873556	dex ht
0.7811624606	moderate mitral regurgitation
0.7811109985	gastric hemorrhagic
0.7810910910	basic sinus
0.7810057488	plasma h2o2
0.7809938614	hemoglobin concentrations
0.7808533406	hypersensitivity myocarditis
0.7808506287	secondary pinprick
0.7808339463	delayed leukoencephalopathy
0.7804195787	cortical epileptic activity
0.7804015556	morning dosed modafinil
0.7803063713	isotonic sodium chloride
0.7801332984	tubular epithelial cells
0.7801220351	previous observations
0.7800720259	interferon alpha 2b
0.7800407629	alpha tac
0.7800182627	sprague dawley rats
0.7800169086	mg kg body wt
0.7799794799	related deaths
0.7799724844	pkca ko mice
0.7799280555	age specific mortality rates
0.7798918374	medical intensive care unit
0.7798578773	striatal da
0.7795800738	nonsteroidal antiinflammatory agents
0.7795082045	opioid agonists
0.7794829595	ace inhibitors
0.7794603291	early detection
0.7793986867	significantly higher
0.7793956151	aortic regurgitation
0.7792323989	hormone replacement therapy
0.7791988165	acute myocardial infarction
0.7791877486	single center
0.7790669344	logistic regression analysis
0.7790284071	epileptic discharges
0.7789652777	lv diameters
0.7788810703	phase ii trials
0.7788549412	systemic anticoagulation
0.7787650042	lifetime exposure
0.7787438367	median progression free
0.7786951337	neuromuscular blocking agents
0.7786171326	early afterdepolarization
0.7786096575	pathologic findings
0.7785455083	post transplantation
0.7785289964	receiving tacrolimus
0.7784684184	histopathological analysis
0.7784667321	immunomodulatory agent
0.7784652396	mg kg s.c
0.7784142513	exposed children
0.7783982931	blood transfusion
0.7783486039	left ventricular filling pressure
0.7782623978	healthy men
0.7782072187	b2 receptor antagonist
0.7780352667	target controlled
0.7779757548	lymphocyte transformation test
0.7779552816	prevention study
0.7779197051	elderly woman
0.7778710372	relapsed refractory multiple myeloma
0.7778691198	high dose
0.7778511340	pacemaker insertion
0.7778151047	fewer cns
0.7777227511	serum potassium level
0.7777125252	aminotransferase levels
0.7776193303	marrow transplantation
0.7776052233	35s tbps binding
0.7775263668	insulin like growth factor
0.7774643821	complete response
0.7773620603	cholinergic mechanisms
0.7773053956	withdrawal resulted
0.7772926568	receptor occupancy
0.7772690716	nicotinic acetylcholine
0.7772647018	minute assessment
0.7772483117	residual serum
0.7772456277	refractory multiple myeloma
0.7771723663	immune complex mediated
0.7771652337	mortality rate ratio
0.7771320574	careful attention
0.7770703613	sensory fibres
0.7770649490	ocular dyskinesias
0.7770550987	functional indices
0.7769856843	hematological disorders
0.7769787763	treatment options
0.7769160695	alternating sinus rhythm and intermittent sinoatrial
0.7769083086	marked visual field constriction
0.7768988109	stage ii
0.7768110888	nonmalignant disease
0.7767721396	undergone recent
0.7767117009	mg kg i.p
0.7766949197	skin biopsy
0.7766889922	causative agent
0.7765857326	preliminary findings
0.7765687982	chronic cbz
0.7765315711	demographic data
0.7764885723	effective refractory period
0.7764816481	dilevalol intake
0.7764567646	plasma epo
0.7764464795	intraventricular conduction
0.7763633568	ureteric obstruction
0.7763498154	captopril overdose
0.7762653761	neuroleptic induced akathisia
0.7762309209	verapamil responsiveness
0.7761869470	iron staining
0.7761756894	punctate evoked hyperalgesia significantly
0.7759660594	target heart rates
0.7759235855	positive skin tests
0.7758835098	hbv related cirrhosis
0.7758764017	ischaemic heart disease
0.7758636002	rna content
0.7758405123	underlying conditions
0.7757963507	beta blockade
0.7757506385	observational study
0.7757221801	abnormal involuntary movements
0.7756830656	aortic occlusion
0.7756612892	randomized phase ii
0.7756380471	tremor severity
0.7755810327	da neurotransmission
0.7755728414	musculoskeletal pain
0.7755465760	malignant bone
0.7754442702	receptor ligands
0.7754000522	adult population
0.7753699926	remained depressed
0.7752586535	methamphetamine induced psychosis
0.7752344988	alcohol nicotine
0.7752030693	nonantithrombotic users
0.7751595557	liver mitochondria
0.7751478433	driving simulator performance
0.7750648217	nephrotoxic effects
0.7750619780	ischemia occurring
0.7750609916	dipyridamole induced myocardial ischemia
0.7750074172	normal tissues
0.7750066627	baseline renal ace
0.7749470763	direct relationship
0.7749435315	kidney tubular dysfunction
0.7747995763	peripheral dopamine d2
0.7746870377	ischemic st
0.7746220151	dopamine d2 receptor antagonists
0.7744641308	lithium induced polyuria
0.7743361290	cerebral sinus thrombosis
0.7743142768	dihydropyridine calcium
0.7742695370	cerebellar sensory processing function
0.7741958730	cya dosage
0.7741496882	d1 d2
0.7741429103	undergoing cardiac angiography
0.7741068779	torsade de pointes
0.7739714748	liver transplant recipients
0.7739672293	nerve conduction velocity
0.7739505166	trough tac
0.7739286607	oxidative damage
0.7739142468	pretreated rats
0.7738748338	nephrotic range proteinuria
0.7738000381	fatality rate
0.7737660377	halothane induced antibodies
0.7737223342	severe neutropenia
0.7736566570	residual confounding
0.7736415095	spatial learning
0.7736007272	epileptic control group
0.7735580877	highly active antiretroviral therapy
0.7735196038	fixed coronary artery stenosis
0.7735191754	heart tissues
0.7735098722	rebound hypertension
0.7734139453	primary tumor
0.7733349021	antidepressant drugs
0.7733052576	cocaine induced anxiety
0.7732802577	rats circled
0.7732802577	hooded rats
0.7731554578	psychiatric symptoms
0.7730981457	colony stimulating
0.7730387430	inhibit dipyridamole induced coronary hyperemia
0.7730240799	alpha 2b
0.7730038058	genetic variants
0.7729990807	devoid diet
0.7728552782	type chronic fk506 nephropathy
0.7727963205	renal lesions
0.7727949079	methamphetamine induced nigrostriatal dopamine neurotoxicity
0.7725955879	thirty minutes
0.7725429120	insulin dependent
0.7725219302	postmenopausal women
0.7725195666	correctly identified
0.7724156910	autonomic blockade
0.7723404229	left temporal
0.7723333461	drug naive
0.7722985641	adenosine antagonists
0.7722723898	significantly improved
0.7721364768	valproate induced encephalopathy
0.7720498618	channel blockade
0.7720424639	lung cancer risk
0.7719402870	gi aes
0.7719157026	receptor subtypes
0.7719015134	rat pituitaries
0.7718895624	higher serum phosphate
0.7717952350	cancer incidence
0.7717858130	fluoxetine induced akathisia
0.7716752671	halothane anesthetized dogs
0.7716491130	skin test antigen
0.7714548296	provide empirical
0.7714272983	effective renal plasma flow
0.7712947849	anti oxidant
0.7712713585	sodium channel blocker
0.7711709049	flow rate
0.7711003766	impaired memory
0.7710041679	oral prednisone
0.7709686056	coronary vessels
0.7709540894	chronic er stress
0.7709313792	prior zidovudine therapy
0.7709201873	heparin remains
0.7709108089	young asymptomatic chronic cocaine users
0.7709081059	visual evoked potentials
0.7708715608	stage iv disease
0.7707652424	polydrug users
0.7707226813	tricyclic antidepressant induced hypotension
0.7706157409	neurological deficits
0.7705918750	neurological complications
0.7705665861	generation pills
0.7705091933	selective serotonin reuptake inhibitor
0.7704800253	beta carboline derivative
0.7704680357	association remained
0.7704389518	antineoplastic agent
0.7704380016	clinical usefulness
0.7703777636	cardiac tissue
0.7703690203	cytolytic hepatitis
0.7702966690	fluoxetine induced penile erections
0.7702133868	brain injury
0.7701834555	rat prolactinoma cells
0.7700985432	left ventricular systolic pressure
0.7700805140	group ls
0.7700619822	iop lowering medication
0.7700604085	iso infusion
0.7700357162	glial activation
0.7699948651	lometrexol plasma
0.7699819362	england activities of daily living
0.7699410956	ptu therapy
0.7699237220	opiate induced rigidity
0.7699223014	hepatic damage
0.7698456840	passive avoidance response
0.7697928194	significantly shorter
0.7697166641	oral diuretic
0.7696503325	functional impairment
0.7696141129	transfusion dependent
0.7695135460	potential atypical antipsychotic agents
0.7694791700	beta enac
0.7693559170	intravenous desferrioxamine
0.7693323327	ethyl alpha p chlorophenoxyisobutyrate
0.7693239512	phasic pain
0.7692974640	dipyridamole induced coronary hyperemia
0.7692915488	apoptotic pathways
0.7691853722	higher preoperative
0.7691832114	cardiac marker enzyme
0.7691339763	renal blood flow
0.7690399247	cardiovascular event data
0.7688816501	stimulation evoked
0.7688398037	intra arterial bcnu
0.7688280486	acid secretion
0.7688273228	nmda receptor activation
0.7686884433	wt control versus
0.7686344190	morphine antinociception
0.7685715449	showed significant difference
0.7684084744	pathogenetic mechanisms
0.7683357008	standard pattern
0.7682201711	micrograms kg min
0.7681304202	animals surviving
0.7681302150	generalized tonic clonic seizures
0.7680544917	myocardial metabolism
0.7679628907	end diastolic volume
0.7677349500	mrp2 deficient
0.7677333268	hemodialyzed patients receiving
0.7676748821	dyskinetic movements
0.7676357451	decreased auditory function
0.7675300739	antihypertensive medication
0.7674624677	interstitial cystitis
0.7674275983	ultrastructural damage
0.7674044497	reduce mortality
0.7673291523	treated animals
0.7672683081	salt depleted
0.7672607947	cell count
0.7672017358	nicotine lozenge
0.7672014766	warfarin induced artery calcification
0.7671991834	maximum urethral
0.7671946439	tubular dysfunction
0.7671101913	adenovirus disease
0.7670941843	associative memory
0.7669963865	liver tumors
0.7669890691	nerve stimulation
0.7669684066	norepinephrine transporter
0.7669581068	cardiovascular disease mortality
0.7669083694	women receiving hormonal
0.7667862958	partial coronary stenosis
0.7667171593	intravenous fluorescein
0.7666916998	conventional antiarrhythmic
0.7666318013	hodgkin disease
0.7666023356	adrenoceptor agonist
0.7665797938	symptom onset
0.7665247385	cardiac surgery
0.7664323477	saline solution
0.7664152382	contributing factor
0.7663186148	iop lowering
0.7662522623	age matched
0.7661216169	overt disease
0.7658888012	mitochondrial impairment
0.7658636095	cd4 + lymphocyte subset count
0.7657967254	intravenous nitroglycerin
0.7657819314	left pawed
0.7657715480	strongly inhibited
0.7657495568	morning dosed
0.7657111212	smooth muscle cell
0.7656628017	afferent neurons
0.7656173993	high flux
0.7655644934	medullary interstitial
0.7655464715	pharmacokinetic parameters
0.7654058684	female rats
0.7653984459	standard bolus
0.7653929306	torsades de pointes
0.7653627707	mptp exposure
0.7653303955	cp induced behavioral modifications
0.7652916993	sustained release nifedipine
0.7652823794	antithyroid drug
0.7652821101	anti tumor
0.7652677563	direct action
0.7651736176	antiarrhythmic effect
0.7651516153	root mean square
0.7650550227	hepatocellular damage
0.7650292359	water intake
0.7649033356	advanced androgen independent prostate cancer
0.7648984329	mediated protection
0.7648912714	human temporal lobe epilepsy
0.7647976497	age dependent
0.7647234248	micrograms dl
0.7645651125	anesthetic management
0.7645441133	lifetime captopril
0.7645241939	cocaine abusers
0.7644545955	prl content
0.7644452077	diagnostic marker
0.7644132783	male wistar albino rats
0.7643842889	laboratory findings
0.7642396993	creatinine ratios
0.7641549458	trough tac level
0.7641320726	gastrocnemius muscle
0.7641014018	respiratory control ratio
0.7639890998	chronic fk506 nephropathy
0.7639675578	isoproterenol pretreatment
0.7638604464	intravenous pamidronate
0.7637987857	standard risk
0.7636882225	psychological health
0.7636812786	initial diagnosis
0.7635264225	idiopathic generalized
0.7632788185	salt loaded
0.7632386379	penile pain following intracorporeal injections
0.7631457311	choline devoid
0.7629935206	cultured human
0.7628684084	multiple regression
0.7628285497	sleep apnea
0.7628210556	motor activity
0.7627757256	potent antioxidant
0.7626513435	reverse sedation
0.7626493705	beta receptor blockers
0.7625913586	white man
0.7625538590	treated rats
0.7625335213	infusion pump
0.7625004114	oral hydrocortisone
0.7624869500	renal hemodynamics
0.7624782197	spinal injection
0.7623560527	thyroid disease
0.7622607765	propofol remifentanil
0.7620978794	adenosine receptor agonists
0.7620651912	peak grip force
0.7620406592	immunosuppressive drugs
0.7620355376	randomized controlled trial
0.7619663586	venous sinus
0.7619232297	binding capacity
0.7619056489	cerebral haemorrhages
0.7618695342	extended release
0.7618661478	toxic effect
0.7615505819	menopausal symptoms
0.7614360400	plasma creatinine levels
0.7613045508	resolved spontaneously
0.7611714873	elderly women
0.7611001228	generalized seizure
0.7610722159	simvastatin ezetimibe
0.7610529962	cerebellar atrophy
0.7607272839	steroid therapy
0.7607029709	convulsive dose
0.7606087638	cs mediated protection
0.7605964605	lower limbs
0.7605716147	cd4 cells
0.7605422510	nicotine induced hyperactivity
0.7604369754	hbv dna levels
0.7603586113	crossover design
0.7603040925	distal tubular
0.7602813230	dfp atropine
0.7602796312	allergic reactions
0.7602466087	hemorrhagic fever
0.7602431616	cerebellar volume
0.7601952841	dna content
0.7601810674	dopamine precursor
0.7601465424	adverse cardiac effects
0.7601405917	coronary artery stenosis
0.7599583752	penile pain
0.7599141934	myocardial damage
0.7597871103	dose reductions
0.7595986092	proliferating cell nuclear antigen positive
0.7595892059	cardiovascular event
0.7595601154	maltolyl p coumarate
0.7595040910	analogue scale
0.7594849559	complete responses
0.7594389833	postural hypotension
0.7593751574	antidepressant activity
0.7591620630	choline devoid diet
0.7591455750	larger doses
0.7590717604	commonly encountered
0.7590269055	left bundle branch block
0.7589412162	valve surgery
0.7588909569	safe alternative
0.7587617141	changed significantly
0.7584597055	general practice
0.7584551870	myocardial cell apoptosis
0.7583846101	impaired renal function
0.7583673874	learning impairment
0.7583346869	antiplatelet users
0.7582482839	occurs primarily
0.7582136806	antimuscarinic drug
0.7582136806	anticholinesterase drug
0.7581204252	corticosterone treatment
0.7580684717	neurologic symptoms
0.7579955909	myocarditis complicating hypertrophic cardiomyopathy
0.7579881099	acute toxic dosage
0.7579877178	contrast enhanced
0.7579331424	4hne protein
0.7576771275	venous thrombosis
0.7575093727	transient hyperammonemic encephalopathy
0.7573654943	d2 receptor blockade
0.7573458940	plasma cgrp concentration
0.7573098209	retrospectively evaluated
0.7571159463	sodium chloride
0.7570843181	sigma2 receptors
0.7570828644	st segment depression
0.7570704595	beneficial clinical
0.7569733151	hd mtx therapy
0.7568063087	corticosteroid therapy
0.7567547339	postoperative variables
0.7567243295	unilateral pallidotomy
0.7566966798	insulin treatment
0.7566346763	drug drug interactions
0.7565312869	younger women
0.7565104440	immediately repeat
0.7565077024	improve exercise
0.7564997958	high signal intensity
0.7564293081	clinically apparent
0.7563897149	hyperbaric 5 lignocaine
0.7562926857	cortical laminar necrosis
0.7561787764	voltage dependence of inactivation
0.7561541606	controlled conditions
0.7561476732	cerebral cortex
0.7560413480	micturition pathways
0.7559264799	hypoxic cortical
0.7558481202	transplant deaths
0.7556486394	naphazoline and xylometazoline
0.7556306767	beating rat heart
0.7556204818	systemic lipopolysaccharide pretreatment
0.7555955785	renal transplantation
0.7555481401	pulmonary tuberculosis
0.7555011144	cocaine abuse
0.7554559347	month long
0.7554047675	increased simvastatin exposure
0.7552096097	reference group
0.7551974745	pressure volume
0.7550616331	bolus mmc
0.7550447034	reversible inferior colliculus
0.7550162712	systemic lipopolysaccharide
0.7550015765	systemic heparin therapy
0.7548560474	cgi sf score
0.7548259179	health problem
0.7547854217	terbutaline concentrations
0.7547676503	high dose daptomycin
0.7546968944	post lt
0.7546657886	topical beta blockers
0.7546430261	ventilated dogs
0.7545069153	chelation improves
0.7544874152	hypotensive effects
0.7543441170	molecular weight
0.7543179840	sodium 2 mercaptoethane sulphonate
0.7542996642	continuous subcutaneous
0.7542786655	closely related
0.7542697527	heart disease
0.7542434147	hormone therapy
0.7542256330	efferent activity
0.7542104764	basal activity
0.7542090210	immune complex
0.7541360643	auditory dysfunction
0.7541034936	arterial smooth muscle
0.7540993980	chronic renal failure
0.7540291606	health status
0.7539531507	anotia and taussig
0.7539196608	movement disorder
0.7537006027	pretreatment characteristics
0.7536275806	end stage
0.7534922426	methadone maintenance
0.7534181478	stage iv nsclc
0.7534015428	late cardiotoxicity
0.7533614069	ophthalmic surgery
0.7532894861	toxic reaction
0.7532862791	interferon alpha
0.7532763597	activated receptor alpha
0.7531927829	combination therapy
0.7531766128	blood brain barrier permeability
0.7531725144	cell population
0.7531637492	hunt and hess grade
0.7531551925	acute renal insufficiency
0.7530645083	independent risk factor
0.7530602389	pegylated interferon alpha
0.7528605629	cell counts
0.7528561964	tumor cells
0.7528367726	intrathecal vincristine
0.7527929667	clear pharmacological
0.7527514251	1,000 mg
0.7527466906	abnormal liver function tests
0.7526501226	postsynaptic dopamine
0.7525960079	ku70 and ku80
0.7525958400	molecular weight class
0.7524899564	toxic hepatitis
0.7524392738	mentioned parameters
0.7523947009	neuronal nitric oxide synthase
0.7523697825	confounding factors
0.7523524642	spontaneous seizures
0.7522811482	adverse cardiorespiratory effects
0.7522794492	kidney biopsy
0.7522617746	fed diet
0.7522381658	bpa exposure
0.7522024075	receiving deferoxamine
0.7519056356	ring metabolites
0.7517755716	protective action
0.7517204710	bile acid
0.7516942029	participants completed
0.7516935400	nf kappab inhibitor
0.7516366205	fetal measures
0.7516261598	nonsteroidal antiinflammatory drugs
0.7514579509	sensory motor
0.7514229859	heart rates
0.7514053477	lifetime captopril treated spontaneously hypertensive rats
0.7513984418	mr imaging
0.7512274193	total auc
0.7512023403	pain sensitivity
0.7511462262	greatest risk
0.7511213669	general practice in hong kong
0.7510662747	adjusted rate
0.7510561628	sodium pentobarbital
0.7508938494	white woman
0.7508877501	improvement resolution
0.7508645668	audiovisual toxicity
0.7508626208	cd4 + lymphocyte subset
0.7508587519	etomidate injection
0.7508413779	paclitaxel carboplatin
0.7508132698	volume retention
0.7507636167	modulates motor
0.7506853018	drug intoxication
0.7506780200	persistent paralysis
0.7504446837	dopaminergic stimulation
0.7503882592	vascular resistance
0.7503555417	chemical stimulation
0.7503047988	gi bleeding
0.7502976314	aminocaproic acid therapy
0.7502338602	antiinflammatory drug
0.7501978628	warfarin induced cerebral haemorrhages
0.7501671238	kidney syndromes
0.7501303337	dose lisinopril
0.7500645441	acute cholecystitis
0.7498997987	control cows
0.7498354014	anesthetic procedure
0.7498071694	direct evidence
0.7497487201	onset diabetes
0.7497472652	anticonvulsant effects
0.7496684960	channel inhibition
0.7496469501	pregnant women
0.7496071220	independent risk factors
0.7495196344	substantially improved
0.7494891349	findings support
0.7494881226	blocker hexamethonium
0.7494552912	mg kg body weight
0.7494350976	salt sensitive
0.7494104947	isolated perfused
0.7493070401	serum urea
0.7491346172	primary culture
0.7490649652	ntg + nimo
0.7490518420	dose schedule
0.7487843983	ma administration
0.7487689511	high dose methotrexate
0.7487313499	absolute risk
0.7487112148	totally prevented
0.7486767533	medical literature
0.7486497793	partial recovery
0.7485878807	laboratory evaluations
0.7485024398	acute lymphoblastic
0.7484879876	antagonistic activity
0.7484208412	selective beta blocker
0.7483140328	swiss mice
0.7482122381	mitochondrial respiratory function
0.7480812242	coronary heart events
0.7480729137	gad activity
0.7479090332	structurally related
0.7478484204	recent preclinical
0.7478239506	typical absence seizures
0.7478147684	paclitaxel doses
0.7476804212	sodium channels
0.7476691420	event rate
0.7476476999	lowering blood pressure
0.7475879458	aspirin treated jj
0.7475222908	locally injected
0.7475154017	hemodynamic effects
0.7474864555	response rate
0.7472849898	betaenac and gammaenac
0.7472267094	fatal outcome
0.7471583037	reversible myocardial hypertrophy
0.7470631944	cardiac history
0.7470297339	controlled hypotension
0.7469741173	contrast induced nephropathy
0.7468035554	mg kg p.o
0.7467895975	necrosis markers
0.7465563764	systolic hypertension
0.7463953627	confounding variables
0.7463829731	mal seizures
0.7463239358	serum creatinine levels
0.7463123018	induction chemotherapy
0.7462258913	ventricular fibrillation threshold
0.7461764501	renal ace activity
0.7461015403	cell production
0.7459619382	av block
0.7459558687	remains unknown
0.7458418406	completely blocked
0.7457855023	experienced sudden
0.7457818920	future studies
0.7457230118	radiocontrast nephropathy
0.7457159976	neurological dysfunctions
0.7456832932	a1 receptors
0.7456240162	urine nitrite levels
0.7455616490	increase persisted
0.7455090273	conventional spinal anaesthesia
0.7454511753	severe agitation
0.7452964098	dopaminergic neurotoxicity
0.7452681249	testosterone replacement
0.7452506888	quetiapine monotherapy
0.7452443859	cardiovascular variables
0.7451728256	adc map
0.7451421175	high resolution
0.7450292824	neuroleptic induced catalepsy
0.7449737334	propofol sedation
0.7447628420	semi quantitative
0.7446147570	treatment modalities
0.7442563055	weight change
0.7442348552	sensorimotor plasticity of m1
0.7442159976	cyclic adenosine
0.7442005893	obstetric and gynecologic procedures
0.7441020740	cisplatin based chemotherapy
0.7441016202	dyskinetic parkinsonian patients
0.7440904433	data acquired
0.7440267300	irreversible injury
0.7440236896	brain tissue
0.7436875994	binding sites
0.7436230165	norepinephrine uptake
0.7435933355	hdl cholesterol
0.7435121807	developmental toxicity
0.7434863768	elevated iop
0.7434774065	washout period
0.7433604875	bn 52021
0.7433571048	pediatric heart
0.7432971061	related complications
0.7431691171	initially appeared
0.7430048602	serum transaminase activities
0.7429091562	laboratory testing
0.7428919332	tetra and pentaglutamate
0.7428501635	short term adverse
0.7428000606	na channel
0.7425679197	kaufman assessment battery for children
0.7425297299	life threatening complication
0.7424979424	tubular lesions
0.7424619382	spontaneous beating
0.7424405322	drug users receiving methadone
0.7422513762	times higher
0.7422322912	prospective studies
0.7422032339	mixed pattern
0.7422020736	protein content
0.7418841133	renal function remained impaired
0.7418217161	complete protection
0.7417577015	examined individually
0.7416587754	treat cancer
0.7414833255	motor function
0.7413957093	tumor necrosis factor
0.7413663046	androgen independent
0.7413137421	apoptotic protein
0.7413092458	auditory neurotoxicity
0.7410987927	adrenergic agonist
0.7410443001	cancer development
0.7406958241	significant fixed coronary artery stenosis
0.7405897179	calcium binding protein
0.7404979835	ticlopidine induced cholestatic hepatitis
0.7404799706	cd 832
0.7404328515	cardiomyocyte apoptosis
0.7404147120	clinically important
0.7404056070	metabotropic glutamate receptors
0.7403526212	hr post
0.7403448278	membrane potential
0.7403441904	dose adjustment
0.7402128046	careful observation
0.7401564251	peripheral adrenergic
0.7400509012	isoflurane concentration
0.7399561097	motor neuropathy
0.7399497341	blood urea
0.7399141304	intracorporeal injections
0.7399048809	cyclosporine induced tma
0.7398067174	fasl tg mice
0.7397438296	common event
0.7396210084	memory deficits
0.7396127799	neuroprotective effects
0.7396073732	binding protein
0.7393975278	target ce
0.7393948527	ns 718
0.7393717102	absence seizures
0.7392531481	tumor bearing
0.7391504426	sulpiride induced tardive
0.7391365284	young female
0.7391047006	behavioral models
0.7388987342	lymphadenopathy and pure red cell aplasia
0.7387984573	muscle mass
0.7387723238	nephrotoxic potential
0.7386868574	imaging studies
0.7386841494	active treatments
0.7385127133	complete atrioventricular
0.7384410353	vacuous chewing movements and tongue
0.7383257870	liver cancer
0.7383218474	clinical congestive heart failure
0.7382489943	patients taking hydroxychloroquine
0.7382293877	conflicting results
0.7381942836	mrna expression
0.7381656302	rls symptoms
0.7381535859	imaging findings
0.7381344300	cell proliferation rate
0.7380674024	maximum tolerated dose
0.7379526443	adequate sedation
0.7379492466	briefly discussed
0.7377655392	depression scale
0.7376938025	common complication
0.7376552688	low serum albumin levels
0.7374929622	drug withdrawal
0.7371782589	negative correlation
0.7371259309	ribavirin reduction
0.7370961070	neurological symptoms
0.7370038638	recorded continuously
0.7369478779	oab symptoms
0.7368081913	chx + pilo
0.7367515831	arrhythmia models
0.7367485850	adult male wistar rats
0.7367122120	hemodialyzed patients receiving desferrioxamine
0.7365539591	regular intervals
0.7364993143	rat heart
0.7364572057	trials comparing
0.7364237417	granule cells and mossy fibres
0.7363603525	combined ht
0.7363058057	tremor and clonic tonic convulsions
0.7361924289	ck mb mass and ck
0.7361734287	adult female
0.7361266001	zymosan opsonized with alf
0.7360240239	rat model
0.7359845388	cimetidine clearance
0.7359405901	seized mice
0.7358675737	spontaneous reporting
0.7358105625	permanent damage
0.7357994555	lv dysfunction
0.7357729743	cholinergic receptors
0.7357352621	patient developed weakness
0.7356960136	clinically important adverse effect
0.7356778884	desipramine toxicity
0.7354718162	glomerular epithelial
0.7354718162	glomerular capillary
0.7354117945	brain da
0.7353802252	gamma enac
0.7353281311	undergoing carotid endarterectomy under local anesthesia
0.7352678292	nonsteroidal anti inflammatory agents
0.7352646387	albino rats
0.7352461183	induced behavioral modifications
0.7352068578	kainic acid induced limbic
0.7348399284	memory formation
0.7348233423	oxidase inhibitor
0.7347628106	hoe 140
0.7347306885	administered isotonic sodium chloride
0.7344899024	high dose methylprednisolone
0.7344696963	previous experiments
0.7344349624	ut a1 expression
0.7343370652	complete recovery
0.7342998712	cab induced anemia
0.7342213593	higher baseline blood pressure
0.7340918541	dna values
0.7340506330	short acting
0.7338897927	drug metabolism
0.7338545707	cardiac troponin
0.7336427115	recently published
0.7335703370	dopamine receptor subtypes
0.7335234007	psoriatic patients
0.7334843270	fk 506
0.7333593896	dose response relationships
0.7333223552	cyp induced cystitis
0.7333096237	underlying disease
0.7331297834	adult patients undergoing
0.7330387865	cell volume
0.7330217496	nicotine gum
0.7328001377	scoline pain
0.7327572844	performance status
0.7326737763	beneficial effects
0.7326313520	administered orally
0.7325575617	fixed dose combination
0.7325089205	normokalemic patients
0.7324745113	hour infusion
0.7323851303	international society of pediatric oncology
0.7323480287	visual recovery
0.7322055330	induced lung toxicity
0.7321123077	progressive muscular
0.7320540366	penicillamine related
0.7320237364	dose response curves
0.7320135457	double blind randomized trial
0.7319788354	lower doses
0.7319725436	receptor agonists
0.7317097512	renal medullary
0.7316480045	malignant hypertension
0.7313535603	bzds rds before admission
0.7313025406	fatal carbamazepine induced
0.7312660219	borderline subjects
0.7312016926	major toxicities
0.7310795838	control versus cyp treatment
0.7309967618	inflammatory responses
0.7309357890	stz injected rats
0.7309103689	mechanical hyperalgesia
0.7308318547	saline control
0.7306110505	peak dose dyskinesia
0.7305496057	intravenous diltiazem
0.7305326421	left ventricular apical ballooning syndrome
0.7304426814	bradykinin receptors
0.7302591104	muscle atrophy
0.7301594406	persistent bradycardia
0.7301362210	subcutaneous injections
0.7301252961	acc 9653
0.7300736660	randomly assigned to receive
0.7299973208	caffeine doses
0.7299869325	stable disease
0.7299439550	oxidative stress markers
0.7299084143	histamine antagonists
0.7298986991	action potential duration
0.7298823856	metoprolol plus glucagon
0.7297812855	illicit drugs
0.7297735318	correlated significantly
0.7297421145	apomorphine induced aggressive behavior
0.7296779040	kidney tissue
0.7294567818	induced neurodegeneration
0.7294302528	swiss albino mice
0.7294093415	fluoxetine exposure
0.7294035636	cochrane central register of controlled trials
0.7293348631	ballistic and choreic dyskinesia
0.7291834458	cibenzoline on canine ventricular arrhythmias
0.7291739621	serotonin release
0.7291221587	major cardiovascular
0.7290684967	acute cholestatic hepatitis
0.7290247424	cholinergic systems
0.7287723356	significantly greater
0.7287512499	normal coronary angiogram
0.7286603288	healthy male subjects
0.7286389281	sex matched
0.7285867291	test conditions
0.7285584401	blocker haloperidol
0.7285492938	double blind study
0.7284444437	neurocognitive effects
0.7283617961	quipazine induced
0.7283212483	loading dose
0.7281114525	selective d1
0.7279970854	phase iii studies
0.7279916575	significant insulin resistance
0.7279771310	acute cytolytic hepatitis
0.7279390825	lithium induced nephrogenic diabetes insipidus
0.7279020715	flk 1 kdr
0.7278716595	cochrane menstrual disorders and subfertility group
0.7278660962	activation state
0.7278591247	cardiac biomarkers
0.7278229761	eps related adverse events
0.7277669473	nmda receptor antagonist
0.7276927599	lower relative
0.7276766207	nitro l arginine
0.7276602853	cb 3717
0.7274808201	head up tilt
0.7274117463	rat dentate gyrus
0.7272585629	daily subcutaneous
0.7272321365	adrenaline induced reflex bradycardia
0.7271947879	early conversion
0.7268953756	reduction in sural nerve sap amplitude
0.7268780146	mg od
0.7268493293	platelet factor
0.7268279536	control animals
0.7268235853	fk506 plus srl
0.7267862124	potential complication
0.7267426747	doxorubicin induced cardiotoxicity
0.7266452509	ly 171555
0.7266295293	hippocampal injury
0.7265348816	post training naloxone
0.7263167100	glyceryl trinitrate infusion
0.7262299786	renal impairment
0.7261919849	chronic active
0.7261607698	thai women with overactive bladder
0.7260942523	dox control mice
0.7260170769	differential impact of immune escape
0.7259954728	produce antiparkinsonian
0.7259782686	urinary enzymes
0.7259758660	urinary output
0.7259620127	median disease duration
0.7259349616	unilateral pallidotomy and subthalamotomy
0.7259247618	study investigates
0.7258829710	bilateral leg compartment syndrome and myonecrosis
0.7257542601	high dose intravenous methotrexate
0.7257526281	recognized complication
0.7255927921	oral anticoagulant
0.7254378620	long term prognosis
0.7251023037	pegylated ifn alpha 2b and ribavirin
0.7250339990	group np
0.7249935086	alpha tc and dfo
0.7249882832	memory function
0.7249113351	diastolic pressure
0.7247320033	alpha enac
0.7245521262	histopathological examination revealed
0.7243977542	platelet function
0.7242913050	adult wistar rats
0.7242801028	group pr
0.7242689230	acute hypersensitivity myocarditis
0.7242437877	white cell
0.7240327106	prospectively performed
0.7239927809	rare complication
0.7238611456	isotonic sodium chloride with diltiazem
0.7237528786	hepatitis b surface antigen
0.7237322938	iatrogenically induced
0.7237164433	angiotensin converting enzyme inhibitor
0.7237075022	pathological findings
0.7236977065	diethylstilbesterol induced
0.7236538752	protective agent
0.7236470385	difference scores
0.7236067587	prolonged analgesic treatment
0.7235798372	laboratory parameters
0.7234507059	antidepressant fluoxetine
0.7234297428	oncological patients
0.7234297428	eucalcemic patients
0.7233902498	mannitol concentrations
0.7232343968	respiratory dysfunction
0.7232031013	gfc effects
0.7229884203	sulfate or tobramycin sulfate
0.7229801553	mk 801
0.7229706121	group fm
0.7229578611	creatine kinase levels
0.7229302019	potential antipsychotic
0.7229273890	clinical observations
0.7228455784	high grade proteinuria
0.7227756171	hospital of eastern ontario pain scale
0.7227608462	mg tablets
0.7226035354	alcohol exposure
0.7225431118	endometrial disease
0.7224598980	turnover rate
0.7224004760	diastolic dysfunction
0.7223644569	adrenergic antagonists
0.7223483614	brush evoked and punctate evoked hyperalgesia
0.7223071063	mg ml
0.7221714253	da d1 receptor
0.7221636510	iron binding
0.7221581644	case control study
0.7220280867	cooperative group
0.7220258813	mc versus
0.7219174871	rs4704559 g allele
0.7218183870	intravenous nimodipine
0.7218029543	previously untreated patients
0.7217661730	tumor free
0.7217658947	active drugs
0.7216905028	acute spinal cord injury
0.7216810105	induced diabetes insipidus rat
0.7215610070	ns nsaids
0.7215477059	positive direct
0.7214728888	group ps
0.7214509748	folinic acid infusion
0.7213294970	botox dose
0.7213068175	heart block
0.7213065475	hirsutism or pcos
0.7213046113	relapsed or refractory hl
0.7212441898	structural damage
0.7212322868	cardiac performance
0.7212153497	systemic lupus
0.7211153208	central action
0.7210920816	ps exposure
0.7210305114	acute noxious stimulation
0.7209371900	memory enhancing
0.7207647011	castrated rats
0.7207416323	direct neurotoxicity
0.7206194491	controlled studies
0.7206158197	nicotine induced nystagmus
0.7206001988	renal replacement therapy
0.7205399279	withdrawal emergent
0.7203678070	experimental design
0.7202677361	panic disorder with agoraphobia
0.7201935739	long term associative memory
0.7201581572	tested in photocell cages
0.7201400913	decreased left ventricular systolic
0.7201239794	renal cortical
0.7199721328	auc greater than mic
0.7197224075	sedation depth
0.7195124619	cortisol induced hypertension
0.7192771899	significantly increased
0.7192290030	male f344 rats
0.7191128690	antihypertensive effects
0.7190507943	clinically significant proteinuria
0.7189596800	loxp egfp mice
0.7189238957	exercise induced tachycardia
0.7188960568	middle ear surgery
0.7188757811	cell damage
0.7188393219	blocking agents
0.7188182489	mg daily
0.7188076263	dxr dose
0.7187370924	cyclophosphamide induced hemorrhagic cystitis
0.7186813675	long acting non sh group angiotensin
0.7186619276	treated pkca ko
0.7186375629	norfloxacin treated rats
0.7186046318	functional abilities
0.7185301113	aggressive disease
0.7185023064	lesion volume
0.7184630478	treated stz injected
0.7183328390	cardiac morbidity
0.7183303488	totp or dfp
0.7182956336	role function
0.7182733835	kidney injury
0.7182296477	adenosine a2a receptor antagonist
0.7181810254	serum samples
0.7181461839	toxic myopathy
0.7179455791	patients developing esrd
0.7179035466	postoperative pain control
0.7178858084	pan temocapril
0.7178554595	dosing regimens
0.7178457202	end systolic left
0.7177454678	open label study
0.7177408885	sustained hypertension
0.7176752333	hepatitis attack
0.7173844481	real time polymerase chain reaction
0.7173591010	thalassemic patients
0.7172400970	myocardial oxygen
0.7171878383	central retinal
0.7171640710	acromegalic patients
0.7170965435	thiopental produced
0.7170870482	drug induced hemolytic anemias
0.7170719654	free radical scavengers on gentamicin
0.7170195983	central nicotinic
0.7166533123	acute rejection
0.7165166700	serum albumin
0.7164738278	kindled seizures
0.7163883310	concentration dependent manner
0.7162500775	mri findings
0.7161683119	hepatic adenoma
0.7161174046	reserpine treated mice
0.7161005209	proliferation rate
0.7160637300	nicotinic receptor concentration
0.7160283637	sedation depth during spinal anesthesia
0.7159827815	kidney cancer
0.7158950081	university hospital
0.7158412707	long lasting effect
0.7158121001	levodopa responsiveness
0.7156267624	p100 group
0.7156132356	intravenous methylprednisolone
0.7155373949	higher terbutaline
0.7153916035	age matched controls
0.7152170004	clinical presentation
0.7151769829	cardiac fatty acid oxidation
0.7151208919	higher baseline serum
0.7149776826	acute coronary syndrome
0.7149753779	salvage treatment
0.7149628413	oestrogen therapy
0.7148765270	underlying mechanism
0.7147175646	intermittent intravenous
0.7146444591	sympathetic nervous system activity
0.7146164461	bipolar patients
0.7146079827	elevated intraocular pressure
0.7145963809	restricted diet
0.7145086560	control values
0.7145039725	intention to treat
0.7145033871	antipsychotic agent
0.7144950333	normal salt
0.7144007571	skf 38393
0.7143535048	lower extremities
0.7141262843	pediatric oncology group
0.7140961582	growth inhibited
0.7140737784	receptor blocker
0.7140671582	antiparkinsonian effects
0.7139823946	clinical significance
0.7139289007	outpatient setting
0.7138086096	memory scores
0.7137582013	acute bipolar mania
0.7137331307	clonidine induced bradycardia
0.7137252053	local anesthetic seizures
0.7137228593	na ve
0.7136701788	cardiovascular risk
0.7135834291	neuronal death
0.7135282495	bone marrow endothelial cells
0.7134818571	systemically administered
0.7134814201	sufficiently severe
0.7134699342	massive proteinuria
0.7134456798	renal vascular resistance
0.7133643007	showed marked visual
0.7132954342	atypical agents
0.7132274284	brain tumor patients
0.7132134465	auditory toxicity
0.7131192271	lou m wsl
0.7129359193	gr 55562
0.7128939662	cb1 ko mice
0.7128697247	carotid endarterectomy under local anesthesia
0.7127998303	sphincter of oddi dyskinesia
0.7126259010	presumed plus documented
0.7125478416	contractile responses of bladder body strips
0.7123522093	induced parkinsonian catalepsy
0.7123479568	iso infusion with stenosis
0.7121825556	histopathological findings
0.7121434979	dose dependent manner
0.7120512322	vitamin b12 and folinic acid supplementation
0.7118492760	underlying mechanisms
0.7118491454	blood brain barrier
0.7118319561	ck mb criteria for mi
0.7117449442	receiving mitral
0.7116664443	optic nerve toxicity
0.7115501521	cardiac conduction
0.7115189026	negative coronary cta
0.7113698920	low ph
0.7113219727	mg kg ip
0.7113163602	pilot study
0.7112860771	renal pathology
0.7112559300	renal fanconi syndrome
0.7112108612	induced immune hemolytic anemia
0.7112057111	mitochondrial function
0.7111244622	experimental data
0.7111097758	secondary outcome
0.7110515845	clinical consequences
0.7109875189	injection intracortically
0.7109762248	cows treated with vitamin d3
0.7109264498	identify risk factors
0.7107894430	pain tolerance
0.7107500359	infrequently reported
0.7107415351	triglyceride levels
0.7107128057	intra individual
0.7106313331	therapeutic approach
0.7105434495	potassium level
0.7102566117	adenosine a2a receptor
0.7101503709	rating scale parts ii and iii
0.7100797454	marked reduction
0.7098938604	central excitatory
0.7098844144	functional antagonism
0.7098077010	psychosis and disruptive behaviors
0.7097944757	jj rats
0.7097260803	ratings of mental slowness
0.7097159680	pharmacological effects
0.7096714765	lw rats
0.7096334583	severe polyneuropathy
0.7095033993	antigen concentrations
0.7094989749	general toxicity
0.7094097295	adherence to sops
0.7093221540	dependent behaviors
0.7092709882	cortisol levels
0.7091553698	levodopa induced dyskinesia
0.7091076205	low density
0.7090287583	cns complications
0.7090263868	human platelet
0.7086627005	pressure change
0.7086466824	nik 247
0.7084202815	liver biopsy showed
0.7083738281	cancer patients receiving single agent cisplatin
0.7083239334	disulfiram for alcohol dependence
0.7082142572	osteoarthritis and rheumatoid arthritis
0.7076625011	subcutaneous apomorphine
0.7075453873	phenytoin medication
0.7073142433	neuronal and extraneuronal uptake
0.7072609772	study participants
0.7071891009	rat strain
0.7071198374	agoraphobia with panic
0.7071104742	cardiovascular alterations
0.7070725787	groups exhibited similar
0.7070487375	heart transplant
0.7070137201	graft function
0.7070087607	heart tissue
0.7069842113	neuropathic damage
0.7069320473	pd female rats
0.7068941289	bilateral retinal artery and choriocapillaris
0.7066170156	isolated hit
0.7065846546	sigma receptors
0.7064309842	remifentanil infusion
0.7063767052	pulmonary toxicity
0.7062428272	replication of lam resistant
0.7062023069	evaluable patients
0.7061414213	cardiac arrhythmia
0.7060768586	experimental nephrotic syndrome
0.7060465564	toxic neuropathy
0.7060104377	supportive therapy
0.7059558054	serum alpha gst
0.7059491592	mda concentration
0.7059377140	saline pretreated
0.7057566881	dose range
0.7056896577	aortic blood pressure
0.7055968601	nitrite levels
0.7055844969	epileptic women
0.7055023193	severe citrate toxicity
0.7052793947	brain capillary endothelial cells
0.7052321215	symptoms persisted
0.7051476757	calcium values
0.7049832590	urinary protein
0.7049183542	d2 receptor antagonist
0.7047561964	cerebral ischemic
0.7046451882	lesion of rostral ventrolateral medulla
0.7045591248	deficient hypertension
0.7043792437	deprived groups
0.7042732424	bladder function
0.7042546310	calcineurin inhibitor induced pain syndrome
0.7042384934	prolactin determination
0.7039359705	tincture of crataegus
0.7037296958	probable cases
0.7036589924	treatments produced
0.7036337948	therapeutic index
0.7036158904	stage iiib or iv nsclc
0.7036047688	preliminary studies
0.7034912248	products of lipid peroxidation
0.7034851734	cocaine dependent participants
0.7034797986	renal transplant recipients
0.7033789076	role of xanthine oxidase
0.7033741747	morphine analgesia
0.7033369993	paclitaxel refractory disease
0.7032782162	minimal type
0.7030814416	risperidone induced hyperprolactinemia
0.7029220766	icrf 187
0.7028772050	hepatitis b vaccine birth dose
0.7028751778	kidney disease
0.7028699041	common pathway
0.7027844678	gestodene or desogestrel
0.7025723075	underwent angiography
0.7024700406	adenosine receptors
0.7024256054	coenzyme q10 treatment
0.7024053292	respiratory paralysis produced by thiopental
0.7023752069	skilled in airway management
0.7023234725	hippocampal stimulation
0.7021898958	marked improvement
0.7021816514	antibody positive
0.7021737686	min recovery period
0.7020862132	dysfunction characterized
0.7019555093	adverse cardiovascular effects
0.7018290419	hbv viral
0.7016671721	bupropion hcl 120 mg kg
0.7016217834	analgesic agents
0.7016142571	aqp2 and ut a1
0.7015597355	rs and nmdars
0.7014729282	sensitivity to cholinergic convulsants
0.7014386939	helodermin produced
0.7013949980	phase ii trial
0.7012631909	cardiac functions
0.7011489314	end stage liver disease
0.7011413862	serum collected
0.7011208355	dopamine d2 receptors
0.7008742512	antineoplastic activity
0.7008594555	nicotine sulfate
0.7008092163	sc 48334
0.7007499080	dose response relationship
0.7007220062	brain magnetic resonance imaging
0.7006640679	adr nephropathy
0.7004859512	bladder pressure
0.7004853320	low molecular weight
0.7004600427	urinary nox
0.7004000120	greater severity
0.7003745045	ribavirin induced hemolytic anemia
0.7003463961	severe immune hemolytic anemia
0.7002257220	cumulative incidence of persistent sterile leukocyturia
0.7002057014	qt syndrome
0.7000928595	potential confounding
0.7000112569	cns toxic
0.6995790701	hypertensive rats
0.6994245263	receptor selective antagonist
0.6994169128	significantly impaired
0.6993733697	clinical implications
0.6993611472	pilocarpine induced status epilepticus
0.6993172984	laboratory data revealed
0.6992776987	syndrome of inappropriate antidiuretic hormone secretion
0.6991948341	clinical interpretation
0.6991864561	conscious mice
0.6991729476	bendrofluazide treatment
0.6991499341	negative chronotropic
0.6991213258	rarely reported
0.6990740947	measured simultaneously
0.6990027605	population responses
0.6988899428	age adjusted
0.6988165164	oral amiodarone therapy
0.6988091265	dup 753
0.6986128390	significant predictors
0.6984815210	open label trial
0.6984337324	patient controlled analgesia
0.6984218753	erythema multiforme and hypersensitivity myocarditis
0.6984048963	glepp1 protein and mrna
0.6983867085	high frequency hippocampal
0.6983805822	postoperative nausea and vomiting
0.6981332454	present ecstasy users
0.6981308094	ro15 1788
0.6981049456	phenothiazines or tricyclic
0.6981043527	coenzyme q10 significantly
0.6979927418	ntg immediately after learning
0.6979571100	renal toxicity
0.6979230722	systematic study
0.6978614647	extremely low
0.6978212115	young children
0.6976388660	pan nephropathy
0.6976113923	creatinine concentrations
0.6974388260	intervention group
0.6971205832	local anesthetic induced convulsions
0.6969636426	reversible valproic acid
0.6968481024	tonic seizures
0.6965698967	amphetamine induced locomotor activity
0.6964699869	transformation from exencephaly to anencephaly
0.6964338077	double blind crossover
0.6963653546	received ketanserin
0.6962566526	total fasciculation
0.6961289268	contraceptive therapy
0.6961267640	patient controlled analgesia morphine
0.6958421874	small increase
0.6957193999	altered distribution patterns of vessels
0.6957030714	findings suggest
0.6956389113	dose limiting nephrotoxicity
0.6956213936	vas scores
0.6954814883	met ck mb criteria for mi
0.6954445037	hepatic enzyme
0.6952918064	ncq436 and ncq344
0.6952359183	myocardial biopsy
0.6951991999	thallium 201 spect
0.6951672393	cocaine dependent
0.6950112980	delta 9 tetrahydrocannabinol
0.6950090663	versus placebo
0.6948655062	troleandomycin induced acute hepatitis
0.6948314805	lead treated group
0.6947098388	clinical usage
0.6946563721	cgs 21680
0.6945551760	pgf2alpha and pgi2
0.6945551760	aqp1 and oat
0.6945551760	lexical and semantic
0.6944696850	chemotherapy naive patients
0.6943628376	experimental thrombosis
0.6943288123	botox injections for adsd
0.6942565821	dopamine d2
0.6941037675	cardiotoxic effects
0.6940962910	previously documented
0.6940397390	seizure disorder
0.6940238444	significant reductions
0.6939446609	urine albumin
0.6939381442	age matched control
0.6937801861	fenfluramine or dexfenfluramine
0.6937330218	fracture or dislocation
0.6936035720	objective response rate
0.6935759053	beta agonist
0.6935535139	urine protein
0.6935196061	wsr mice
0.6935020347	salvage therapy
0.6933391254	drug resistant
0.6933050518	skf 82958
0.6931849227	saline injected
0.6928466964	pb exposed
0.6928285276	female wistar rats
0.6928113054	partial responses
0.6927564969	participants underwent
0.6923265291	days earlier
0.6922320770	completely reversible
0.6922043118	risk factor
0.6921341906	acute cardiovascular events
0.6918509362	anthracycline induced cardiotoxicity
0.6918050518	abbott 53693
0.6918050518	wr 2721
0.6918037842	pegylated interferon and ribavirin
0.6917577940	controls received saline
0.6916889802	continuous infusion cimetidine
0.6913136214	neurotoxicity incidence
0.6912163497	bearing dogs
0.6910339453	adrenergic receptors
0.6910146990	myocardial necrosis
0.6909360799	posterior reversible
0.6908988035	induction agent
0.6907976737	analgesia in difficult pain syndromes
0.6907891193	galactose dose
0.6907516102	nsc 343499
0.6905126017	heparin induced thrombocytopenia type ii
0.6904804034	beta adrenoceptor antagonists
0.6903507980	scopolamine induced amnesia
0.6901011104	abdominal surgery
0.6900645496	beta blocking agents
0.6899597369	dl sotalol and azimilide
0.6899469661	significantly changed
0.6898863434	group differences
0.6898483268	nineteen patients
0.6897403978	brain imaging
0.6896813001	endocrine therapy
0.6896236751	acute oliguric renal failure
0.6895090507	strongly suggests
0.6894318696	central dopamine d2 receptor
0.6894003287	antihypertensive drug
0.6892659814	fold increase
0.6891095656	surveillance study
0.6888956156	administration of egg white lysozyme
0.6888186860	additional risk factors
0.6888046144	cocaine induced mood disorder
0.6887322724	continuous i.v
0.6886698201	diabetic subjects without autonomic neuropathy
0.6886378009	hepatitis after needle stick exposure
0.6884888090	thirty days
0.6884533721	alpha mediated
0.6883908504	hemoglobin concentration
0.6883667224	therapeutic response
0.6883463894	behavioral effects
0.6882956441	disruption of prepulse inhibition
0.6881606435	complete heart block
0.6879204039	experienced fewer
0.6878945377	da d1
0.6878815724	healthy middle aged and older adults
0.6878586017	asymptomatic chronic cocaine users
0.6878209115	free survival
0.6877733005	rat urinary bladder
0.6877243330	dsm iv diagnosis of cimd
0.6876347159	positive donors
0.6875019206	cell membrane
0.6872396908	proliferative response
0.6872067013	antihypertensive effect
0.6871946447	refractory hypotension
0.6870674577	d1 receptor
0.6868846739	tumor bearing rats
0.6868788204	prostigmine morphine administration
0.6868533916	nicotine and 3h spiperone binding
0.6867997237	brain tumors
0.6867884259	memory impaired
0.6866863037	highest level
0.6866589614	cambodian woman with hemoglobin e trait
0.6866219962	statistically significant greater
0.6865209105	clinical experience
0.6862906882	mediated nephropathy
0.6862040327	pan induced nephrotic syndrome
0.6861242754	change cardiac output or qs qt
0.6860953692	beta 2 microglobulinuria
0.6857512741	lna + hca
0.6856478348	fetal rat
0.6852489500	prescription of appetite suppressants
0.6851810192	bupivacaine arrhythmogenicity
0.6851346580	bolus group
0.6851007599	randomly allocated to receive
0.6850683977	follow up mris
0.6849980772	deep sedation
0.6847569916	including akathisia
0.6846965954	reversible cerebral
0.6846286496	plasma calcitonin gene related peptide
0.6845995238	acute cisplatin nephrotoxicity
0.6845124222	ribavirin induced anemia
0.6843796921	improved rapidly
0.6843786116	rat hearts
0.6843437923	taking hydroxychloroquine
0.6842170468	serum transaminase
0.6842073858	peripheral neurotoxicity
0.6841878710	severe psoriasis
0.6840419737	dipyridamole thallium 201 imaging
0.6838595134	ecstasy users demonstrated
0.6835030455	oral penicillin
0.6834596755	mitochondrial respiratory
0.6832537910	brain serotonin
0.6831536082	cost of treating riha
0.6830605394	induced hyperlocomotion
0.6830168845	activities of daily living
0.6829398826	epilepsy model
0.6829095165	maximum heart rate
0.6827293429	antihypertensive drugs
0.6825107768	normal subjects
0.6821342955	peak dose
0.6821189356	severe hypertension
0.6820558819	prolactin levels
0.6819409943	urine sodium
0.6818311717	ethinyl estradiol treatment
0.6816498951	produced lasting
0.6816014589	mptp treated
0.6814618154	frontostriatal dopaminergic and serotonergic
0.6812405084	low toxicity
0.6811137795	anti cocaine effects
0.6808274886	prl secretion
0.6808026115	anticholinergic drugs
0.6807628880	chronic morphine administration
0.6807340046	recent studies suggest
0.6806870598	peak concentrations
0.6806717523	low risk
0.6805283802	examined histologically
0.6803855551	phase 2 early afterdepolarization
0.6802349596	ethopropazine and benztropine
0.6801976941	cardiac transplant patients
0.6801723636	llc pk1 cells
0.6800974631	plasma renin
0.6800926958	lna + lca
0.6800753482	morphine rg1
0.6800277504	renal transplant patients
0.6799679355	allergic to beta lactam antibiotics
0.6799037714	plasma cortisol
0.6798999093	hour heart rate
0.6798905314	foot process
0.6798787783	severe hemodynamic
0.6798691044	receptor blockade
0.6798496644	mm versus
0.6798167108	prolactinoma cells
0.6798034617	beta adrenergic blocking agent
0.6797625811	aggravate proteinuria
0.6797171125	thrombocytopenia and haemolytic anaemia
0.6797007332	plasma cholinesterase
0.6794751526	renal angiotensin ii
0.6793774629	stroke rate
0.6792440322	vpa induced encephalopathy
0.6791551177	attenuates tubulointerstitial nephritis induced by gentamicin
0.6791201461	prolonged cholestasis
0.6788489802	free dox
0.6788486490	stage ii hypertension
0.6788273789	urine output
0.6785870562	normal sinus rhythm
0.6785208805	serum prl levels
0.6784794254	antiviral effect
0.6784720890	etoposide therapy for malignant glioma
0.6783384456	beta adrenergic receptor antagonist
0.6781033172	end stage liver disease score
0.6779966378	coniine and nicotine sulfate
0.6777753655	urine volumes
0.6777384454	adjusted to achieve activated
0.6776496706	death rate
0.6776291828	cumulative doses
0.6776031781	drug delivery
0.6775906825	nk1 and nk2 receptors
0.6775375916	clinical benefit
0.6774307964	d2 receptors
0.6772928336	ht for menopausal symptom control
0.6772844152	splenic and bone marrow
0.6772142504	recommended doses
0.6771834579	total power of pupillary oscillation
0.6771260437	cis ra administered
0.6770559015	analgesic and antiinflammatory activities
0.6769171499	chronic cyp administration
0.6769099801	folinic acid supplementation in preventing
0.6768593922	treated females
0.6768423580	isoproterenol induced tachycardia
0.6768196997	spectral analysis
0.6766988712	ci 921
0.6766579238	anti inflammatory agents
0.6764799696	lithium therapy
0.6764497819	cell free
0.6761363213	lower baseline
0.6760218766	head up tilts
0.6757667087	receptor mediated hypotension
0.6757398604	fr 139317
0.6757355912	high dose intravenous calcium
0.6756708451	antinociceptive and antiamnesic
0.6755540021	transient hypotension
0.6755237902	mazindol treated
0.6755115380	steady state level
0.6753553560	renal sodium excretion
0.6753200293	trough levels
0.6752872584	lithium maintenance therapy
0.6752126722	papillary muscle contractile responses to isoproterenol
0.6750430346	adriamycin induced cardiomyopathy
0.6750085816	higher cumulative dose
0.6749604888	evaluation suggested
0.6748493582	increased urine output
0.6746840162	extracellular dopamine
0.6745781057	dox injections
0.6745127886	completely resolved
0.6744249251	enhancing effect
0.6741730525	homeostasis model assessment of insulin resistance
0.6741448569	dose response effect
0.6740377800	clinical utility
0.6740071202	single agent cisplatin
0.6739846089	open label trial of galantamine
0.6739757500	reported previously
0.6739555054	cya cardiotoxicity
0.6739222710	multivariate analysis showed
0.6738765099	tic like symptoms
0.6738069265	adverse renal effects
0.6737355876	users demonstrated elevated
0.6737048031	sympathetic activity
0.6736311709	inotropic effect
0.6736212732	lv function
0.6735482619	immunoblotting and immunohistochemistry
0.6732117499	showed significant increases
0.6731905572	peripheral vascular
0.6730869173	biopsies showed
0.6730019406	opioid induced hyperalgesia
0.6729609094	cardiorespiratory effects
0.6729197837	95 percent confidence interval
0.6728967896	hpma copolymer and free dox
0.6728832725	reversible left ventricular dysfunction
0.6727931657	prolonged qt
0.6727749301	left ventricular end diastolic volume
0.6727647408	standard dose
0.6727170107	levodopa induced
0.6726845847	histological studies
0.6725658855	peak dose dyskinesias
0.6725448643	seizures induced by maximal electroshock
0.6724633863	vitamin d3 toxicity
0.6723619319	human erythrocytes
0.6722444918	liver biopsies
0.6721835743	ovx rats
0.6721835743	obese rats
0.6721434212	genetic control
0.6717702492	wild type controls
0.6717632285	randomized clinical trials
0.6717436370	creatinine values
0.6715755270	tubular cells
0.6713111137	double dose study
0.6712874420	significant improvements
0.6710357134	plasma ammonium
0.6710203729	central retinal vein occlusion after
0.6710074294	pharmacokinetic studies
0.6709436977	blood level
0.6707968222	peak concentration
0.6707575806	nuclear factor kappa b
0.6707328020	paclitaxel refractory
0.6705723119	major surgery
0.6705537834	angiotensin converting enzyme inhibitor therapy
0.6704092561	isradipine treatment
0.6703836984	moderate dose
0.6701268783	chloroform and galactosamine
0.6700227687	freely moving rats
0.6699734038	induced myocardial stress
0.6699682653	improves cognitive outcomes in pb
0.6699408264	transient anuria
0.6698321282	skin test
0.6696617131	comparative study
0.6696474725	child with cerebral palsy
0.6694945050	immunosuppression in renal transplant recipients
0.6694901899	heparin induced
0.6693487996	brain activation
0.6691732100	healthy women
0.6691690006	muscle fasciculations caused by suxamethonium
0.6690232595	elderly patients
0.6687210063	nephrotic range
0.6685462161	hoehn and yahr scale
0.6685082660	cis ra levels
0.6684658007	hbv hiv co infected patients
0.6684137574	haematological toxicity
0.6684068866	published cases
0.6683747286	mrna level
0.6683226721	acetaminophen induced alf
0.6682772487	current medications
0.6681988603	beta carboline 3 carboxylate
0.6681642230	significantly lowered
0.6681492894	dopamine receptors
0.6680546714	cck 8
0.6680534254	interstitial nephritis and autoimmune hemolytic anemia
0.6677518902	pinealectomized or hypophysectomized
0.6677077750	pilocarpine model of temporal lobe epilepsy
0.6676859457	dopaminergic function
0.6676416608	neuropathy model
0.6676126018	normal adc
0.6675305547	women with genuine stress incontinence
0.6675108887	metabolite levels
0.6674839435	parallel groups
0.6674541151	induced amnesia
0.6674178768	renal interstitial
0.6673868838	interstitial fibrosis and tubular atrophy
0.6673163022	schizophrenic patient
0.6671955455	inhibitory effects
0.6670064805	significant benefits
0.6669237734	precordial pain
0.6667402577	repeated treatment with fluvoxamine
0.6667360134	drug related
0.6666262056	axonal damage
0.6665926603	mitochondrial abnormalities
0.6665434213	pressor response
0.6664745785	smoking of crack cocaine
0.6664502402	pseudolithiasis in paediatric surgical patients
0.6663845293	annexin v binding
0.6662671572	sodium channel beta
0.6662087827	2a receptors
0.6660006374	mice lacking
0.6659260503	catechol and hydroquinone
0.6658515025	deteriorating effect
0.6656617155	carboline 3 carboxylate
0.6655402827	intradermal injection of mu
0.6653743107	pharmacological response
0.6653507170	cp 93129
0.6652716862	androgen therapy
0.6651864286	sm 5887
0.6650995205	cd4 + t cell counts
0.6649839097	parkinsonian symptoms
0.6645660255	daily oral
0.6644548597	related behaviors
0.6643878938	animal groups
0.6643494938	maintenance therapy
0.6637440531	nra0160 and clozapine antagonized
0.6637113132	potential hepatotoxicity
0.6636613210	phase ii study
0.6635450836	ro 40 5967
0.6634675665	hiv positive
0.6631549595	experimental animals
0.6631213100	low dosage
0.6629579275	hepatic necrosis
0.6628234087	p2x3 and nk1 receptors
0.6626805732	muscle pain
0.6626449849	nephrotoxic drug
0.6626008744	neurologic toxicity
0.6625582070	adult age
0.6625194071	high dose etoposide therapy
0.6624761308	low functional programming of renal at2r
0.6623482549	gyki 41 099
0.6623223629	biopsies performed
0.6621331209	anca positive
0.6620409374	long term basis
0.6619773556	dyskinesia among multiethnic
0.6614962424	conventional chemotherapy
0.6614953750	b2 receptor
0.6614424221	stage iiib or iv
0.6613727100	solidago virgaurea extract on
0.6612053420	dose response study
0.6612005155	caffeine free
0.6611754210	anticancer drugs
0.6611146096	adrenergic receptor
0.6609269769	suppression of hbv dna
0.6608547147	severe mr
0.6608460460	hypertensive response
0.6607924044	plasma tafi
0.6605619848	significantly elevated
0.6605018778	pg 9
0.6599100354	ventricular tachycardia or ventricular fibrillation
0.6598917564	exo utero development system
0.6598622714	glial activation and post synaptic
0.6597429293	background aims
0.6597312495	hepatitis b virus
0.6597271898	human plasma
0.6594979960	administration of isosorbide dinitrate
0.6593395966	lifetime captopril treated
0.6593078959	lamivudine resistant hepatitis b virus
0.6592877861	drug action
0.6592733208	liver damage
0.6592314987	chronic cocaine users
0.6591231713	healthy male
0.6590902705	bcnu exposed group
0.6590770455	prostigmine morphine
0.6590400799	cardiac event
0.6589846198	multiple mechanisms
0.6589178996	icp and cvp
0.6588449965	carbamazepine neurotoxicity
0.6587583986	cimetidine associated mental confusion
0.6587380629	light sedation
0.6587348253	chronically treated
0.6587225422	total dose infusion
0.6586466881	free drug
0.6584048841	actions of flurazepam
0.6583091306	mild anemia
0.6583074763	levodopa induced motor fluctuations
0.6581584515	retention or retrieval
0.6580491945	blood pressure and heart rate
0.6579899753	relapsed disease
0.6578707087	elevated tissue
0.6578697873	pharmacologic doses of pyridoxine
0.6575173777	consecutive patients
0.6575071726	procedural sedation with propofol
0.6567367406	weight ratio
0.6565179472	patient history
0.6564771180	group reported significantly
0.6564266227	focal seizures
0.6563671966	cocaine induced hyperactivity
0.6562401743	nontraumatic dissecting aneurysm of
0.6561767529	remained elevated
0.6561358833	antituberculosis therapy
0.6561156564	total score
0.6558972359	significantly smaller
0.6558928034	experimentally induced
0.6558439499	non steroidal anti inflammatory drugs
0.6558153565	infection occurred
0.6557760082	regulation of hippocampal net
0.6556935499	neuroleptic drugs
0.6556870366	catalepsy tests
0.6556048882	blood brain barrier during acute hypertension
0.6551995047	predicting cardiac
0.6551859320	pain intensity
0.6551843133	tumor necrosis
0.6551014097	upregulation of intrarenal angiotensinogen
0.6551010402	chemotherapy regimen
0.6549927701	drug induced
0.6547837011	age range
0.6546663502	bcl 2
0.6546121786	fatty liver induced by tetracycline
0.6545665255	acute heart failure
0.6545044058	drug free
0.6544887410	delayed anemia
0.6544310817	ovulation induction with cc
0.6543536994	positive cells
0.6541656927	tri given repeatedly
0.6537658456	gentamicin mediated
0.6536166914	male ds rats
0.6536050634	significantly longer
0.6535240916	chronic nephrotoxicity
0.6533963609	evidence suggests
0.6533778614	receptor type
0.6533224745	seizure free
0.6532587461	lou m wsl rat
0.6531905494	individual differences in renal ace activity
0.6531766974	pilocarpine model
0.6530046542	inducing seizures
0.6529719548	csa plus srl
0.6529637352	mg kg prednisolone
0.6527574469	pre test morphine
0.6526810621	patient died
0.6526371780	intracoronary administration of methylergonovine
0.6525760211	high frequency stimulation
0.6524911657	cocaine induced vasoconstriction
0.6524680432	p2x3 and nk1 receptors antagonists
0.6521225599	apomorphine induced hyperactivity
0.6520530357	atherosclerosis in postmenopausal women
0.6519362118	ptra group
0.6519247760	rapid infusion
0.6516652853	dyskinesia score
0.6516323770	278 consecutive renal specimens
0.6515198496	recently demonstrated
0.6514831940	oedema related
0.6513638848	mg doxorubicin kg
0.6511666658	clinical characteristics
0.6511413543	half normal
0.6510709006	ro 13 5057
0.6509327846	symptoms improved
0.6508044954	pallidal neurotensin on haloperidol induced parkinsonian
0.6507684024	induced nephrogenic di
0.6506812467	maximal decrease in ccr
0.6503273573	serum prolactin
0.6503248945	threefold more potent
0.6501706089	perinatal hepatitis b and rubella prevention
0.6500932919	fef25 75
0.6498655778	widely used chemotherapeutic agent
0.6498153507	medications included
0.6497877272	pci group
0.6497655809	total body
0.6497078219	vip concentration
0.6496582104	lamivudine untreated chronic hepatitis b patients
0.6495006340	adrenaline hypertension
0.6494156455	paracetamol overdose
0.6492897266	phenytoin administration
0.6492641922	serotonin antagonists
0.6492359083	td group
0.6491766468	serum and glucocorticoid inducible kinase
0.6491455506	microglia cells
0.6491233843	interleukin 6
0.6489708599	diuretic therapy
0.6488447422	severe rheumatoid arthritis
0.6488239508	type ii
0.6487183729	pethidine and norpethidine
0.6484842253	multiple doses
0.6484829243	neurotoxic effects
0.6484264834	glomerulonephritis with crescents
0.6483745308	phase ii
0.6483638459	plasma bupivacaine levels
0.6483037521	developed complete heart block
0.6480780919	intravenous infusion
0.6477754358	randomised double blind trials of ht
0.6476327919	alcohol related
0.6475938746	chronic cyp
0.6474889834	significantly reduces
0.6474689964	radiation therapy
0.6473590761	nra0160 and clozapine significantly
0.6473318120	undergoing procedural sedation with propofol
0.6469308408	human immunodeficiency virus type 1
0.6469273348	microscopy demonstrated
0.6468214146	transplant free survivors of paracetamol
0.6468122475	inducible type of nitric oxide
0.6467360954	months postoperatively
0.6463469978	severe adenovirus disease
0.6462411228	direct evidence from intracellular
0.6462140374	adjuvant chemotherapy
0.6460933920	folate concentrations
0.6460928785	haloperidol catalepsy
0.6459549008	sch 23390
0.6457861640	bia 2 093
0.6457479139	netilmicin and piperacillin
0.6456699495	severe myalgia
0.6456332874	warrants further investigation
0.6455697179	anti inflammatory drugs
0.6455605898	wt animals
0.6455338652	recovery period
0.6451756563	included nausea
0.6448517385	dopa treated
0.6448362089	severe hypotension
0.6446785327	syndrome of inappropriate anti diuretic hormone
0.6446183305	remained normal
0.6445023205	oral mesna
0.6443444963	cardioprotective effects
0.6443330809	fs containing tamca
0.6443079552	respiratory function
0.6441528420	mtx administration
0.6440946785	p300 protects cardiac myocytes from
0.6439664164	consolidation therapy
0.6438916063	chronotropic effects
0.6438700078	previously healthy
0.6438414968	locf and mmrm
0.6438120704	early stress
0.6437615918	occurred rapidly
0.6437454291	cytochrome p 450 3a4
0.6435395163	cardiac evaluation
0.6434333831	january 2009
0.6433784971	dose level
0.6433596998	smoking during pregnancy
0.6433575979	serum blood urea
0.6432958087	chronic infection
0.6432855604	ventricular posterior wall dimension at
0.6431583465	intravenous metoprolol
0.6431346044	cardiac arrest after diltiazem overdose
0.6431299594	synthase activity
0.6430768015	isoflurane induced hypotension
0.6429958325	antinociceptive effects
0.6429925936	bolus injection
0.6429522776	study design
0.6428872789	ascites and hydrothorax
0.6428212096	behavioural effects
0.6425645703	study suggests
0.6425131874	population based study
0.6423103260	renal carcinomas
0.6421217900	acute experiment
0.6421061658	multiple daily
0.6419784880	persistent pain
0.6419732816	depression with panic attacks
0.6417243442	corticosterone infusion
0.6416787886	total cumulative
0.6414742306	symptomatic hypotension
0.6414409059	significant rise
0.6414009529	methamphetamine induced dopaminergic
0.6413807071	treated metastatic breast cancer by mitoxantrone
0.6413547519	diabetic rats
0.6410896122	exhibited higher
0.6410774502	major adverse events
0.6410694261	cytochrome c oxidase
0.6410180186	nicotine induced locomotor
0.6410097100	formation of free radicals
0.6409718671	naloxazone significantly
0.6406621989	net function
0.6406138407	ocular adverse effects
0.6406089998	perimenopausal and postmenopausal women
0.6405859853	ph 7.4
0.6405372438	mitomycin c
0.6403430776	tissue enos and inos expression
0.6403290036	specific inhibitor
0.6401870305	tissue concentrations
0.6399957427	parenteral administration
0.6399686117	significantly faster
0.6397802155	antibiotic treatment
0.6397618153	fk506 nephropathy
0.6396795777	increased tremor severity
0.6395619624	paclitaxel cisplatin
0.6395351755	decrease in percentage segmental shortening
0.6395255768	nitrendipine treated
0.6394870790	cases demonstrate
0.6394004838	untreated controls
0.6393992065	groups r4 and r6
0.6393578825	chronic puromycin aminonucleoside
0.6392886309	direct toxic
0.6392774952	experimental studies
0.6391021977	hoehn and yahr
0.6390821710	cocaine induced locomotor
0.6390820014	visceral pain
0.6390788714	multiple outcomes of raloxifene evaluation
0.6390274999	lnna rats
0.6389804832	receiving desferrioxamine
0.6387781609	lifetime days
0.6386728605	intramuscular administration
0.6385141200	induce apoptosis in hbmp cells
0.6384354595	long term timolol treatment
0.6383664423	doses tested
0.6382155239	beta adrenergic blocking drugs
0.6381922432	continuous intravenous
0.6381728329	antagonism of sigma receptors
0.6379880584	severe congestive heart failure
0.6379140591	animals became somnolent
0.6379109116	nag activity
0.6378918388	immunohistochemical study
0.6378695018	receptor activation
0.6378365195	release rate
0.6378030926	young women
0.6377483680	cbdca administration
0.6376575414	antipsychotic like profile
0.6376514187	protective effects of free radical scavengers
0.6376385931	hb levels
0.6375547924	similar decreases
0.6375240892	preclinical studies
0.6374689077	kidney damage
0.6372819337	medical treatment
0.6372365473	scattered or focal
0.6372271071	folate levels
0.6370395549	abstract truncated at 250 words
0.6370269261	tet and fan
0.6370136047	intravenous morphine
0.6369866721	pparalpha mice
0.6368985467	activated partial thromboplastin time
0.6367234330	mtdna levels
0.6366613663	total dosage
0.6366228689	examination including
0.6366224803	reversible anemia
0.6365880067	liver function
0.6365865384	gastrointestinal symptoms
0.6365236705	cytostatic and anti angiogenic effects
0.6363897320	p450 2e1
0.6363807320	cardiovascular alterations in rat fetuses exposed
0.6362990179	applicators in iowa and north carolina
0.6361537892	hypotensive group
0.6360694894	acute reserpine and subchronic haloperidol
0.6360625387	anticonvulsant effect
0.6360467760	normal volunteers
0.6360220214	adr + los
0.6359869758	aerosolized crack cocaine use
0.6358803841	december 2010
0.6357536190	dipyridamole thallium 201
0.6356572518	recently identified
0.6355779181	required to maintain sleep
0.6355646177	scr increases
0.6354464836	ethinyl estradiol treated rats
0.6354042278	serum levels
0.6352993464	oxidative stress and mitochondrial dysfunction
0.6352273758	deoxycorticosterone and 11 deoxycortisol
0.6351670250	sham operated rats
0.6351410992	suspected myocardial infarction
0.6351135487	patients showed delayed
0.6351092952	isolated rat
0.6348844148	experienced clinically
0.6348333187	mg amlodipine
0.6346322460	estrogen induced rat
0.6345091907	busulfan dose
0.6342939509	nmol 0.5 microl
0.6341033839	cardiac tissues
0.6339537579	estrogen induced tumor
0.6339099138	isoproterenol induced acute myocardial
0.6337344410	rose significantly
0.6336293117	dox induced cardiotoxicity
0.6336119083	prostate cancer patients without bone involvement
0.6335674540	non small cell lung cancer
0.6331978289	previous findings
0.6331758573	steroid groups
0.6330119425	e2 exposure
0.6330034444	vocalization and fighting
0.6329809966	glomerulosclerosis in adult offspring
0.6329413085	plasma ratio
0.6328834604	chronic methamphetamine
0.6327718833	underwent surgery
0.6327006525	increased cell proliferation
0.6326751175	systemic toxicity
0.6325359503	daily smokers of crack cocaine
0.6324602756	clonic seizures
0.6324379926	regions of myocardial underperfusion
0.6324167022	hcfcs 123 and 124
0.6322622384	experienced grade
0.6322030093	ouabain administration
0.6322007132	central dopamine
0.6320063609	neuronal no synthase
0.6318179401	blocker therapy and higher ejection fraction
0.6317588870	included excessive
0.6316975919	inhibitory concentration
0.6316904453	studies of 1,3 butadiene
0.6315412283	mg kg i.v
0.6314829010	vascular disease
0.6313831743	saline solution of tacrine
0.6313172512	carried out
0.6313091848	renal involvement
0.6312752747	values measured
0.6311932441	number of previous manic episodes
0.6311890243	bzd rd
0.6311182197	drug induced liver injury
0.6311048235	pre test
0.6309286152	transgenic rats with low brain angiotensinogen
0.6304407177	patients with argentine hemorrhagic fever
0.6302854631	inhibitory effect
0.6302655919	female mice
0.6300775820	man developed acute
0.6299333838	danish women
0.6296186136	bilateral optic neuropathy
0.6296175927	decreased arterial blood pressure
0.6296097260	lithium treated
0.6294827810	hyperbaric bupivacaine
0.6294751119	blood volume
0.6294714764	rs6275 and taqia
0.6294689499	drug drug interaction
0.6293601323	control group
0.6292461600	clinical studies
0.6292106962	scopolamine induced impairment
0.6289599968	effect relationship
0.6289573299	clinical signs
0.6288848115	atra therapy
0.6287896021	ovariectomized rats
0.6286794179	cardiac angiography
0.6286677591	terfenadine and terodiline
0.6282586841	glial activation and post synaptic neurotoxicity
0.6280791404	severe hypercalcemia
0.6280098354	um 272
0.6279719199	cisplatin induced nephrotoxicity
0.6278756051	toxicity profile
0.6278225137	amiodarone related
0.6276759513	isoproterenol injection
0.6275532872	liver toxicity
0.6275127152	fs containing aprotinin
0.6274316739	succimer treatment
0.6273060395	patient compliance
0.6270987527	isolated hit patients
0.6270132246	caffeine exposure
0.6267196439	infused rats
0.6266772763	pawed animals
0.6266036955	june 2004
0.6265252145	generally well tolerated
0.6265245917	sm 21
0.6262158060	subcutaneous apomorphine treatment
0.6258362585	cardiac damage
0.6257600851	placebo controlled study
0.6256198810	headache free
0.6255992963	matched case control study
0.6255549169	wild type mice
0.6255042435	atorva + dex
0.6254784481	cardiac function
0.6254706980	significantly enhanced
0.6253936187	rare adverse effect
0.6253786187	methadone maintenance patients
0.6250123571	phenylephrine induced hypertension
0.6249477948	prior chemotherapy
0.6249477948	combined chemotherapy
0.6246179202	initial dose
0.6243688496	littermates received
0.6243407919	adverse effects include
0.6242668204	pulse amplitude and frequency
0.6241909611	serial studies
0.6240397705	prolonged apnea
0.6239121832	previously shown
0.6238804208	control rats
0.6238647107	memory retrieval by pre test morphine
0.6238082217	studies demonstrate
0.6236403819	mechanical hyperalgesia and allodynia
0.6235012303	complained of penile pain
0.6234877590	isoproterenol induced
0.6234549725	calcium antagonists
0.6234034148	combined effects of prolonged prostaglandin e1
0.6233728404	included hypercalcemia
0.6232603174	etoricoxib and diclofenac
0.6228157989	carbachol and eserine
0.6228107849	polyethylene glycol 400
0.6227951878	main results
0.6227476767	striatal dopamine
0.6226600026	cyclophosphamide induced cystitis
0.6226552854	behavioral seizures
0.6226327998	high dose cyclophosphamide
0.6224900395	atorvastatin prevented and reversed
0.6224068784	mssbp and msdbp
0.6223235006	cromakalim and pinacidil
0.6222991739	total cardiovascular disease
0.6222534801	gap43 ir band in
0.6222380946	early life
0.6221235943	anesthetic induced damage
0.6221016636	peg 400
0.6220392004	drug hypersensitivity
0.6219264643	clozapine vs risperidone
0.6218066111	total cell
0.6217986258	impairment in word recall
0.6217820570	commercially available
0.6216335428	hepatic impairment
0.6214676291	ymdd motif mutants in lamivudine untreated
0.6214218906	maximum urinary
0.6213938675	exposed to tmp smz
0.6211539604	lesioned animals
0.6211253131	serum sodium
0.6210842293	measurements and main results
0.6210387803	infected children treated with indinavir
0.6209950697	week treatment period
0.6209579503	erk1 2
0.6209529575	significantly suppressed
0.6208745037	doxorubicin induced apoptosis
0.6208018104	mmp 9
0.6206559841	mg kg pdtc
0.6206377875	cocaine toxicity
0.6205992728	prior regimens
0.6205305562	related to lopinavir ritonavir therapy
0.6205076022	mean lowest bis score
0.6204270390	male mice
0.6204170597	serum protein
0.6203444514	eligible patients
0.6201911817	drug induced acute liver injury
0.6198846804	oral contraceptive therapy
0.6198394755	intravenous conscious sedation with diazepam
0.6198106920	famotidine associated delirium
0.6195769698	mitochondrial damage
0.6194585725	clinical condition
0.6194319593	case control studies
0.6194061229	thoracic hematomyelia secondary to
0.6194028600	recurrent myocardial infarction
0.6193903318	analysis identified
0.6193584208	cardiorespiratory arrest and death
0.6193456527	months duration
0.6192108968	head and neck carcinoma
0.6191928589	beta blocker therapy
0.6191012648	postoperative myalgia after succinylcholine
0.6190511883	double blind crossover study
0.6189713839	prior doxorubicin
0.6188692423	syndrome and idiopathic dilated cardiomyopathy
0.6187615700	post operative period
0.6187157394	adriamycin treated group
0.6187064936	significantly correlated
0.6186854994	pharmacokinetic study
0.6186695030	locomotor response
0.6183382725	cya dose
0.6183176777	inducible no synthase
0.6182192030	paclitaxel infusion
0.6180439961	postoperative pain
0.6180345126	receiving nifedipine
0.6180314414	spontaneous pain
0.6177974084	superior to ergotamine caffeine
0.6177598936	seizure development
0.6176125337	drug intake
0.6175663374	hypomethylation of dna
0.6173139700	competitive antagonist of nmda receptors
0.6172774732	sucrose and chow
0.6171974221	experimental myocardial infarction
0.6171794237	synthesis and preliminary pharmacological
0.6171508294	symptoms resolved
0.6171079324	vt or vf
0.6170590992	animal models of parkinson
0.6168964934	diabetic subjects with autonomic neuropathy
0.6168666879	control groups
0.6168305943	fischer 344 rats
0.6167991384	chronic hbv
0.6164898818	dobutamine induced myocardial ischemia
0.6163741538	primary motor
0.6162310698	administered intraperitoneally
0.6161459299	bromocriptine induced tachycardia
0.6160384910	differential effects
0.6160326595	left ventricular pressure
0.6159603909	cells mm3
0.6158640383	depending upon
0.6158482349	ocular pain
0.6157518112	signs of vitamin d3 toxicity
0.6154833168	nx and sham dogs
0.6154401088	strongly reduced
0.6154241776	gastrointestinal toxicity
0.6154206331	methamphetamine induced neurotoxicity
0.6150762373	case report of myxedema coma
0.6150160115	independent predictors of postoperative seizures
0.6149840139	drug abuse
0.6149744315	study confirms
0.6148596744	ventricular rate
0.6148555442	da neurons
0.6147193478	systolic function
0.6147046900	fold higher
0.6146069381	middle and high molecular weight
0.6145753283	migraine with aura
0.6145500290	significantly reducing
0.6142313978	abnormal eeg
0.6140335743	fusidic acid treatment
0.6139619178	intra accumbens shell
0.6139526051	severe exacerbations of asthma
0.6138725871	reports suggest
0.6137746500	studied retrospectively
0.6137701924	clinical symptoms
0.6135418386	late effects
0.6134794876	ht and 1637 taking oestrogen
0.6134301534	patients with coronary spastic angina
0.6133886829	phenylephrine infusion
0.6131379203	haloperidol induced parkinsonian catalepsy
0.6131133523	steroid injection
0.6130776754	results provide evidence
0.6129251334	treatment arms
0.6127728962	hyperkalemia and renal insufficiency
0.6127191705	early onset
0.6124529159	ifosfamide chemotherapy
0.6124291091	patients with recurrent cervical carcinoma
0.6123553977	dose dependence
0.6123011600	castrated and noncastrated
0.6119299386	vomiting or retching
0.6117303424	etomidate 0.3 mg kg
0.6117192158	effective chemotherapy
0.6116395557	renal vascular
0.6115388333	high risk
0.6113453865	treated patients
0.6113151335	controlled design
0.6112039067	fourth group
0.6112032101	patients receiving
0.6110810132	long term survivors of childhood cancer
0.6108062661	december 2006
0.6105995172	age related
0.6105795724	heparin induced platelet aggregation
0.6104611799	treated groups
0.6102354155	slightly increased
0.6100141903	physical abilities and cognitive function
0.6099954127	controlled study
0.6099925104	optic and peripheral neuropathy
0.6099633092	degeneration of spinal motor neurons
0.6099493903	expression of neuronal nitric oxide synthase
0.6097177887	stz and castration induced memory impairment
0.6094405556	treated mice
0.6093895811	intravenous caffeine
0.6091544492	response remained
0.6091125433	cumulative doxorubicin dose
0.6090110222	renal cell
0.6089445472	enalapril treatment
0.6087238708	degrees of coronary stenosis
0.6086452120	slow wave sleep time
0.6084532071	vascular events
0.6083991549	striatal l 3h
0.6082960029	confocal microscopy and real time pcr
0.6081953338	cocaine overdose
0.6080746351	progressive renal failure
0.6080125878	locomotor stimulatory effects of cocaine
0.6077498135	vitamin d2 and cholesterol
0.6077360221	light and electron microscopic
0.6073971657	long term mortality
0.6073401858	increases in hdl cholesterol
0.6073365433	patients undergoing
0.6072627083	male sd
0.6072126295	adenosine in cerebrospinal fluid
0.6072085349	fourth patient
0.6071897019	morphine inhibited
0.6069631445	effect of humoral modulators
0.6069627645	woman years
0.6068839320	igf il 3
0.6065928071	dose limiting toxicity
0.6065899109	adriamycin induced renal damage
0.6064586496	propofol in medialipid
0.6063015014	hypothyroid patients
0.6062475938	subjective assessment of sexual
0.6062330479	refractory to conventional antiarrhythmic drugs
0.6062093927	free concentrations
0.6061516925	folic acid administration
0.6061009184	diet l 485
0.6060260314	decreased renal function
0.6059846667	long term cardiac transplant patients
0.6058988374	dendrin and plekhh2
0.6056364780	3d gradient echo
0.6056061330	propofol in intralipid
0.6055847691	nicotine induced locomotor stimulation
0.6055162276	fanft induced
0.6055085227	ptrend =
0.6053255708	ht significantly increased
0.6052962165	gyki 41
0.6052789317	dopamine d2 and d3
0.6051836694	mpges 1
0.6050319592	cardiovascular events
0.6050275946	mdma + users
0.6049601653	underwent coronary
0.6047299235	free concentration
0.6046904374	chronic hepatitis b patients
0.6046621560	500 cd4 cells mm3
0.6046424277	indian patients with stage ii hypertension
0.6045534962	renin angiotensin system
0.6045129913	total dose
0.6044935894	factors contributing to ribavirin
0.6043810392	patients with aneurysmal subarachnoid hemorrhage
0.6043593504	induced hypotension
0.6043267663	association between metolachlor
0.6042849252	physical therapy
0.6042112661	abstract truncated at 400 words
0.6041501581	challenge tests
0.6041289239	micrograms kg
0.6039400037	acute thrombotic
0.6039303027	analgesic and nonsteroidal anti inflammatory
0.6038490805	selective antagonists
0.6038447551	extrapyramidal side effects
0.6037865022	p10 group
0.6036960081	mg iv
0.6036046420	centrally administered
0.6035710490	case controlled
0.6035586718	randomly received
0.6035484868	d1 and d2 dopamine
0.6032512036	cocaine abuse during pregnancy
0.6032315238	transient renal failure
0.6030360240	antagonist sch 23390
0.6029311491	vitamin e supplementation
0.6027676546	anxiety like behavior
0.6027005227	mk 212
0.6026551390	iohexol and metrizoate
0.6025322190	intravenous amiodarone
0.6025267583	systemic vascular resistance and cardiac output
0.6025151713	systolic and diastolic blood pressures
0.6024735864	treated jj
0.6024718091	median duration
0.6024502615	all trans retinoic acid
0.6023801380	acute toxicity
0.6023236425	primary efficacy
0.6021413523	glyburide therapy
0.6021404531	glomerular disease
0.6021279272	stratum 1
0.6020933727	cardiac complications
0.6020350974	levels accompanied
0.6019809265	receiving ifosfamide
0.6019022280	elevated plus maze test
0.6018872699	cells mm3 at week
0.6018847344	targeting of alpha enac
0.6018743672	serum potassium
0.6016336064	terfenadine and citalopram
0.6015802009	untreated mice
0.6015738274	expression in micturition reflexes
0.6013348864	f344 rats
0.6013274248	marrow toxicity
0.6013085175	amphetamine free
0.6011076142	underwent echocardiography
0.6009808135	nmda antagonist
0.6009177223	subcutaneous injection of isoproterenol
0.6009014918	reversible encephalopathy syndrome after liver transplant
0.6007687502	production of reactive oxygen species
0.6005369612	gabapentin reduced
0.6005265176	positive rate
0.6005172211	decreased expression of na
0.6004935434	cerebral edema and intracranial hypertension
0.6003087300	early development of diabetic nephropathy
0.6002954720	related peptide
0.6000722588	women with moderate hypercholesterolemia
0.5999844741	haptoglobin and angiogenesis
0.5999467628	dosed as initial therapy
0.5996565828	convulsive activity
0.5996565828	antiarrhythmic activity
0.5995446934	open study
0.5995201333	clinical and histologic picture
0.5994269699	resistant hepatitis b virus
0.5991743926	long term memory
0.5991634149	hypotensive response
0.5989963175	induction and emergence times
0.5983579180	oncology group
0.5978132913	psychiatric co morbidity
0.5978044625	group consisted
0.5976547771	drug induced vasculitis
0.5974974334	hiv co infected
0.5974409418	95 confidence interval ci
0.5974152021	thirteen patients
0.5972744672	dph treatment
0.5972464955	multidrug therapy
0.5971604941	women with eating disorders
0.5970769808	d glucarates
0.5970750245	single dose studies
0.5970374963	cardiac transplantation
0.5968999964	requires further investigation
0.5968008153	cardiac marker
0.5967206762	compared with seized mice
0.5966719868	cck 8 ns
0.5965304243	protected rats
0.5964391345	bolus or short term
0.5962779481	catalepsy induced by dopamine antagonists
0.5962251065	3h l arginine
0.5962058587	intervention study
0.5961961818	protein levels
0.5961679525	mtx + 5 fu + cy
0.5961232995	fully developed
0.5961104585	decreases in food intake
0.5959517365	ischemic lesions
0.5959344697	rapid reversal of anticoagulation
0.5957168818	motor complications
0.5955818095	beats per minute
0.5955486191	highest dose
0.5954884480	neurotoxic potential of thalidomide
0.5951419106	clinical setting
0.5950774855	carrageenan induced
0.5947482111	continuous subcutaneous administration of mesna
0.5946662230	duration of levodopa therapy
0.5944312792	cranial to body growth
0.5943783506	pulmonary and renal insufficiency
0.5943553229	normal and central sensitization states
0.5940541877	serum potassium levels
0.5939278813	important untoward effects of heparin therapy
0.5938793446	pathways of bile salt
0.5938664870	decreased significantly
0.5937692978	effect of retinyl acetate
0.5937255090	clinical recovery
0.5936637530	drug exposure
0.5936039597	cigarettes per day
0.5935947183	cocaine induced seizures
0.5935810776	generally lower
0.5934696117	chronic non malignant pain
0.5932917112	nrf2 levels
0.5932549489	ocular toxicity
0.5932518276	inhibition of prostaglandin synthesis
0.5932345860	beat min 1
0.5931841562	sufficient to raise
0.5931291095	simultaneously with diethylnitrosamine
0.5930059390	disulfiram like syndrome
0.5926035872	gentamicin nephrotoxicity
0.5924599600	epileptic activity
0.5924504700	des treated
0.5924358521	severe hepatitis
0.5923757071	follow up visit
0.5923484026	april 2004
0.5922987498	elderly patients with advanced nsclc
0.5921363401	case of central retinal vein occlusion
0.5918901963	cardiovascular disease risk
0.5917883197	mediated inhibition
0.5917002864	ciprofloxacin and norfloxacin
0.5915336560	patients with inoperable lung cancer
0.5914838605	nadph d
0.5914329865	trial analysed subgroups of 2839
0.5913438214	high dose testosterone
0.5913411007	increases in prl secretion
0.5913282606	aor =
0.5912962823	drug condition
0.5911725718	phenobarbitone and carbamazepine
0.5911636383	current evidence
0.5911478307	intravenous propranolol
0.5909788345	streptomycin induced
0.5909481845	asthmatic patients
0.5908005848	man with renal amyloidosis
0.5904506624	experimental findings
0.5904193429	large amounts of calcium
0.5903398109	aimed at investigating
0.5903007012	mitomycin c associated hemolytic uremic syndrome
0.5902501727	survivors of acute liver failure
0.5902168911	selective inhibition
0.5900576197	high dose intravenous methylprednisolone
0.5898415142	sod and dmtu
0.5897296917	glycine transporter 1
0.5896170793	chemotherapy combinations
0.5895257590	chelation therapy
0.5893075034	ischemic lesions and fibrosis
0.5891821719	indicator of anthracycline induced cardiotoxicity
0.5891375097	reduced predominantly
0.5890060780	limbic seizures and status epilepticus
0.5889990663	selective cox 2 inhibitors
0.5888869963	receptor expression
0.5888662472	inner molecular layer
0.5888464059	cocaine induced increases in nucleus accumbens
0.5888190094	total daily dose
0.5884484735	developed acute renal failure
0.5884447170	high dose cytosine arabinoside treatment
0.5882943303	cardiac outcomes
0.5882563625	outcomes for patients transplanted
0.5881520888	mechanisms underlying
0.5879754165	case report suggests
0.5879647452	glomerular injury
0.5878362813	propofol injection pain in ambulatory patients
0.5878291723	adverse events related to eps
0.5877899322	ethambutol and optic neuropathy
0.5876574021	cdt with alteplase
0.5875810116	hyperprolactinemia and amenorrhea
0.5875668796	oral verapamil
0.5875264506	head and neck cancers
0.5875039412	cytotoxic drugs
0.5874345287	azt induced anemia and leukopenia
0.5874034632	additional studies
0.5873303935	effectively reduced
0.5872910408	significantly increases
0.5871722242	crude relative risk =
0.5870878493	warfarin and warfarin drug interactions
0.5870246691	risk for hemorrhagic strokes
0.5870040030	tdp occurred
0.5869761081	responses to isoprenaline
0.5868023236	mediated synaptic inhibition within
0.5867776295	indian patients
0.5867738408	acc 9653 and phenytoin sodium
0.5866828740	vitamin k antagonist
0.5865363437	prostaglandin e2 induced
0.5865185222	complications of indocyanine green
0.5864798727	baroreflex control of heart rate
0.5864566433	myocardial hypertrophy induced by tacrolimus
0.5863299898	urinary potassium
0.5861691922	metabolic studies
0.5861018827	response curve
0.5860536724	rat models of intrahepatic
0.5859592042	per cent
0.5859332129	migraine without aura
0.5859286752	significant disease
0.5858475740	precurarizing dose of rocuronium
0.5858392434	amitriptyline therapy
0.5858192324	normal renal function
0.5854938724	hepatitis b vaccine
0.5854441936	left atrial and left ventricular
0.5853215649	plasma cgrp
0.5851962747	disease status
0.5850919218	chronic nicotine
0.5849187644	l noarg
0.5849165538	type chronic fk506 nephropathy group
0.5848312560	long term ht on mortality
0.5848184489	head and neck cancer
0.5848165976	cardiac disease
0.5847162227	adverse symptoms
0.5846429044	deferoxamine therapy
0.5845817953	absolute risk of vte
0.5845731296	serum bfgf and vegf
0.5845013870	igg and c3
0.5844939331	renal recovery
0.5842875796	progression or unacceptable toxicity
0.5842609843	amphotericin b
0.5841847013	remained similar
0.5837637173	protects against doxorubicin induced
0.5837190029	induced hamster renal carcinomas
0.5834786990	de novo
0.5834732932	adult male and female wistar rats
0.5834605331	september 2012
0.5832284457	marked hypotension
0.5830962541	cisplatin chemotherapy
0.5830738925	systemic chemotherapy
0.5829790210	diazinon exposure
0.5829674420	b cell gastric lymphoma
0.5828913724	mice genetically engineered to
0.5828848100	thymidine incorporation into
0.5828505632	induced bone marrow suppression
0.5827172736	clinical examination
0.5826443953	catalepsy induced by haloperidol
0.5825964262	cancers including
0.5825571456	high dosage
0.5824748769	intracarotid injection of carboplatin
0.5824622215	milligrams per kilogram of body weight
0.5824083533	potential for qt prolongation
0.5823762476	abnormalities occurred
0.5822946742	rhuepo treatment
0.5822709227	preceded by monoher
0.5821599417	micrograms kg 1 i.v
0.5821251204	multiple dosing
0.5820928835	increasing evidence
0.5820731142	blood urea nitrogen and serum creatinine
0.5819514071	animal and clinical studies
0.5819416910	human serum
0.5819045476	primary loss of dystrophin
0.5817803154	incontinence while taking
0.5814053745	evoked by dce
0.5812968027	defined as msdbp 90 mm hg
0.5812799415	analysis revealed
0.5812374731	aza patients
0.5811777425	outcomes included
0.5810014929	beta adrenergic blocking drugs and verapamil
0.5809931698	iu l
0.5808275867	receptor antibodies
0.5808012778	vegfr 2
0.5804998710	myocardial metabolic
0.5802290481	cerebellar and oculomotor
0.5801587068	normal salt rats
0.5801417225	patients showed improvement
0.5799820847	epidemic of liver disease
0.5799543744	cox 2 gene expression
0.5795736923	study end
0.5794518915	stratum 2
0.5794345291	weight control
0.5793582227	neuropsychiatric like behaviors
0.5792867189	severe and clinically evident anemia
0.5792703889	steroid treatment
0.5791192326	the buschke selective reminding test
0.5791113604	selective da
0.5790393886	concentrations increased significantly
0.5789990330	treatment strategies
0.5787693845	alcohol consumption and depression
0.5787129904	drug induced de novo absence seizure
0.5786537184	brain ischemic
0.5786285445	rapid systemic
0.5785661290	igf i
0.5785411167	asymptomatic chronic
0.5785116777	nondyskinetic patients
0.5785116777	cirrhotic patients
0.5784979800	tacrine and e 2020
0.5784975273	interleukin 3
0.5784758858	induced neurotoxicity and microglial activation
0.5783048429	cortex and brain stem
0.5781613886	csa or tac
0.5780254650	higher concentrations
0.5778620969	children with severe adenovirus disease
0.5777313109	induced blood dyscrasias
0.5776886606	central nervous system
0.5776494742	dopamine receptor
0.5776290974	subcortical white matter of
0.5774486742	l arginine
0.5774372368	received docetaxel
0.5774170751	drug toxicity
0.5773746308	drug induced hiccups
0.5773273624	unpaired t tests
0.5773019141	l nil
0.5772791325	treated rats exhibited
0.5770949404	patients with mechanical heart valves
0.5770559125	lidocaine level
0.5769966364	simvastatin ezetimibe induced
0.5768853430	cholesterol levels
0.5767862310	development of puromycin aminonucleoside induced nephrosis
0.5767445197	predictive value
0.5767006036	mild to moderate hypertension
0.5766340388	patients with primary systemic amyloidosis
0.5765273542	urinary sodium
0.5764759930	left ventricular systolic and diastolic dysfunction
0.5763852335	coadministered with cinacalcet
0.5763659779	altered liver
0.5763030504	treatment emergent
0.5761651895	saline treated rats
0.5760732955	cck 8 se
0.5759205870	data demonstrate
0.5759143459	high sensitive cardiac troponin t
0.5758886044	pain models
0.5758272573	cancer patients undergoing
0.5754496196	prevented by rhuepo
0.5754388797	group iii
0.5754350221	higher activity
0.5752692498	type b hepatitis after needle stick
0.5752529727	amounts of alphaenac
0.5749519532	long term sequelae
0.5745074052	hypertensive animals
0.5744817394	cardiovascular depression
0.5744159580	male cd 1 mice
0.5743571466	fan showed
0.5742815705	protective effects
0.5741918987	dose related
0.5740656617	levels of wild type hbv
0.5739832643	amantadine treatment
0.5739241663	dose effect and structure function relationships
0.5737736734	mg kg doxorubicin given i.v
0.5737073887	mechanisms involved
0.5735655140	chronic rejection
0.5734681714	doxorubicin cardiomyopathy
0.5734473758	opioid receptor
0.5734116987	propranolol therapy
0.5733188942	den + pb
0.5732780917	analgesic treatment
0.5732073047	history of lsd abuse
0.5727122180	diabetes insipidus like syndrome by amiloride
0.5726958431	kidney adverse effects
0.5726148531	step down
0.5725814415	hippocampus in adult male mice
0.5720392994	ritonavir treatment
0.5719484600	curcumin administration
0.5719197590	sevoflurane on lidocaine induced convulsions
0.5717377303	multiple dose
0.5716325033	structural and functional impairment
0.5716122769	levodopa dose
0.5714179066	cholinergic receptor
0.5713490770	recent preclinical and clinical
0.5709968029	sub tenon
0.5709903167	treated group
0.5709537387	dsm iii criteria for
0.5706537285	low frequency of extrapyramidal symptoms
0.5705368222	patients with chronic tension type headache
0.5704980467	estrogen receptor
0.5704858232	temsirolimus therapy
0.5703802073	tnf and paf
0.5703453885	patients with newly diagnosed mm
0.5702886216	achieve and maintain
0.5699156943	nicotine induced seizures
0.5698611541	antiparkinsonian effects of levodopa
0.5697723495	azathioprine therapy
0.5697646536	threat to life
0.5697470274	novel selective adenosine a2a receptor antagonist
0.5693920816	blood concentrations
0.5693776239	line treatment of metastatic breast
0.5692124340	ccr2 and ccl2
0.5691026735	renal disease
0.5690332046	response to von frey
0.5689967181	age and sex matched
0.5689212976	selective antagonist
0.5686071780	x ray
0.5685860679	714 creatine phosphokinase levels
0.5683693519	vulnerable to seizure induced damage
0.5682864738	bradycardia induced by beta adrenoceptor antagonists
0.5680762604	versus control
0.5679473105	modafinil on sleep
0.5678960045	received concurrent
0.5678801816	cns toxicity
0.5678403927	mmol l
0.5677782908	mortality from cardiovascular disease
0.5677297614	animal models of schizophrenia
0.5674894399	study objective
0.5674012291	treatments with n nitroso n methylurea
0.5672966161	doxorubicin by significantly reducing
0.5672690753	results suggest
0.5670529940	acting alpha 2 antagonist
0.5670293573	data suggests
0.5667017350	ii trial
0.5666384616	isoproterenol induced myocardial infarction in rats
0.5665066099	published report
0.5664582975	developed prostate cancer
0.5663286485	sodium and volume depleted rats
0.5663207731	progressive loss of vision
0.5663069692	rats and guinea pigs
0.5663059228	penicillin induced
0.5660969079	antioxidant status in isoproterenol
0.5659119186	omission of fentanyl
0.5658796176	central nervous system toxicity
0.5656510187	induced orofacial dyskinesia
0.5655864318	association with pph
0.5654896035	coronary disease
0.5651554127	nimesulide or paracetamol
0.5651122073	activation of nf kappab
0.5648332866	centers for disease control
0.5647987640	low doses
0.5645872492	injection site
0.5644693609	humphrey 10 2 visual field
0.5643781692	in situ hybridization histochemistry
0.5643697814	neurocritical care patients
0.5643593096	compared to normal rbcs
0.5642842631	received coronary cta
0.5642591135	cocaine induced
0.5642099476	differential diagnosis of hyperprolactinemia
0.5638815260	higher doses
0.5638325472	laboratory data
0.5637675434	brain and spinal cord
0.5635931684	dosages of mipafox
0.5634790539	hospitalization for ami
0.5633875799	rate ratio of vte
0.5633313040	cardiac surgical patients
0.5632988677	balb c mouse
0.5630807877	complication of rifampicin therapy
0.5629167189	determine if prenatal
0.5628505981	data collection and analysis
0.5628092157	vein four times
0.5627367777	patients randomly assigned to enalapril
0.5626982614	long term administration of digoxin
0.5626329708	determined by radioimmunoassay
0.5625600015	without clear intraventricular conduction
0.5622596293	ug.kg 1
0.5621497327	cases per 1 million children
0.5620547284	associative learning in healthy subjects
0.5620335452	prescribed trimethoprim alone
0.5619777200	clinical outcomes
0.5619178417	ece 1
0.5618456019	acute infarction
0.5617020234	logistic regression showed
0.5615871427	dimer x
0.5615016517	responding patients
0.5614752127	motor dysfunction
0.5614265448	patients with cocaine related aneurysms
0.5612191971	macroscopic and microscopic
0.5610983247	cholesterol level
0.5610931200	person years of exposure
0.5609851408	insight into
0.5608950578	ac cck 2 8 se
0.5607717927	serum calcium levels
0.5607072277	inhibition studies
0.5606782610	vehicle treated
0.5605657305	hippocampus treated with gfc75 plus p400
0.5605380207	70 nmol kg ip
0.5602223026	24 hour holter monitoring
0.5601710257	seizures produced by pilocarpine
0.5601688048	anti human
0.5600421148	mice with bladder inflammation
0.5599020410	receptor gene
0.5597909505	epinephrine treated animals
0.5597559737	meq l
0.5597211545	glomeruli of pan rats
0.5596096908	dexamethasone before succinylcholine
0.5593610057	normal findings
0.5593588249	grade 4 neutropenia
0.5592941131	severe left ventricular dysfunction
0.5592739052	subjects received
0.5592611012	dothiepin and amitriptyline
0.5591580004	active hepatitis
0.5590517493	oxytocin administration during saline induced
0.5590299917	hypaque 76
0.5589984102	expression of vascular endothelial growth factor
0.5589880451	13 cis retinoic acid
0.5589794639	dogs with partial coronary stenosis
0.5589613488	patients with relapsed refractory multiple myeloma
0.5588169959	vitamin d
0.5587939231	implantation of electrodes
0.5585850452	baseline levels
0.5585584328	cardiac muscle
0.5585246001	adverse effects included
0.5584886954	apomorphine induced
0.5584113685	dyskinetic patients
0.5583659399	long term steroid therapy
0.5582750524	drug history
0.5582528626	cgrp concentration
0.5581219174	amisulpride and tiapride
0.5580736858	children with acute lymphoblastic leukemia
0.5579244029	blood and brain ammonia
0.5579047098	frequently administered
0.5577855681	bronchoscopic removal of
0.5577622377	completing of remd
0.5575671849	supplemental vitamin c
0.5575163544	bun and cpk
0.5574233490	potential role of prostaglandins
0.5572668099	elevated plus maze
0.5570855560	patients experienced grade
0.5568344944	the swedish pharmaceutical insurance
0.5568155534	pilocarpine produced
0.5567946217	vitamin c intake
0.5565460915	epilepsy related side effects
0.5562994150	diets containing
0.5562764391	august 2007
0.5562200735	bromocriptine induced tachycardia in conscious rats
0.5561411344	significant fall in heart rate
0.5560650245	induced convulsions
0.5559490505	scheduled to receive
0.5557516749	parallel treatment
0.5557104198	important to recognize
0.5554630121	cardiac beta
0.5552379019	revealed markedly
0.5552156096	injection immediately
0.5551949506	rate ratio
0.5551635527	hours after instillation
0.5551473194	susceptibility to pilocarpine induced seizures
0.5550953802	depression disorder
0.5549428823	patients with suspected allergic
0.5549287591	significantly reversed
0.5548535254	hydroxy 5beta pregnan 20 one
0.5547758180	dopamine neurons
0.5546052060	positive patients with rheumatologic
0.5543504961	treatment groups
0.5541736716	detection and prompt treatment
0.5539574074	ouabain induced
0.5538922396	markedly elevated
0.5538454768	widely used analgesic
0.5537226048	model of visceral pain
0.5536510797	renal complications
0.5536325555	clinical monitoring
0.5534074942	non hodgkin
0.5533615899	staining revealed
0.5533583789	tonic pain
0.5533396441	creatinine levels
0.5533346861	the naranjo probability scale
0.5529679462	heart failure patients treated with spironolactone
0.5529619783	mitochondrial activity
0.5525915921	y mrs total score
0.5525086417	behavioral parameters
0.5524421561	hs diet for 4 wk
0.5523437507	drug conditions
0.5522800565	delirium during clozapine treatment
0.5522384423	infant rats
0.5521453542	atrial fibrillation on warfarin
0.5520111492	cimetidine in icu patients
0.5519883070	number of ecg abnormalities
0.5519202436	cytochrome c release
0.5516695479	myoclonus after etomidate
0.5514901254	acute period of status epilepticus
0.5514900914	case of lithium induced diabetes insipidus
0.5511472779	high protein
0.5511068270	food and drug administration
0.5510098235	sphenoidal segment of
0.5509260942	standard or low dose haloperidol
0.5508219836	normal limit
0.5507936104	levels of cardiomyocyte apoptosis
0.5505266653	research design and methods
0.5505062784	oncology patients
0.5504633908	administered simultaneously
0.5504045264	month period
0.5502927180	androgen and corticosteroid
0.5502077186	myocardial function
0.5501920823	interaction between warfarin and levofloxacin
0.5501291738	retinal vein occlusion associated with clomiphene
0.5501118573	nausea and vomiting
0.5497272069	mumol l
0.5495511299	drug regimen
0.5494463148	severe motor
0.5494264375	cumulative doxorubicin
0.5493326385	olanzapine vs risperidone
0.5491604246	induced lethality
0.5491469813	a trigemino parasympathetic reflex
0.5490962273	the french pharmacovigilance database
0.5490389524	creatinine level
0.5489338210	phasic and tonic pain
0.5488905622	associations of ozone
0.5488578290	well demarcated
0.5487916342	lower urine
0.5485665352	reduce potassium requirements and
0.5485202362	positive test
0.5484894991	a1 and a2
0.5484314296	related cirrhosis
0.5484295634	n acetyl beta d glucosaminidase
0.5483966219	significantly higher with etoricoxib
0.5483570859	learning and memory
0.5483429692	behavioral seizure
0.5480767153	methoxy 4
0.5480607441	vitamin e
0.5478740702	dose dependency
0.5475512081	accumulation of triglyceride
0.5475123777	recently reported
0.5474634125	pilocarpine and kainic acid induced
0.5473439646	transiently increased
0.5472888725	ocular and orbital toxicity
0.5472755873	case of veno occlusive
0.5472312330	treatment related toxicity
0.5472166765	calcium channel blockers on bupivacaine induced
0.5471259992	number of gad mrna containing neurons
0.5469842091	antipsychotic drugs
0.5469367445	limbic seizures
0.5466069224	patients with psychiatric histories
0.5465769699	infusion rate
0.5465440632	diffuse skeletal pain after
0.5464862124	treatment discontinuation
0.5464360889	induce catalepsy
0.5464117983	adjunct to phenobarbital treatment in cats
0.5462322420	increased significantly
0.5461836232	carbamazepine and vigabatrin
0.5461737188	cohort analysis and case control study
0.5461669029	systemic adverse effects
0.5461021156	receptors in mediating nicotine induced
0.5460972471	severe complications
0.5459511425	55 lifetime tablets
0.5459479436	serum phosphate
0.5459377436	rast for ax
0.5458189880	post exposure
0.5457999920	serotonin 5 ht2
0.5456749044	cellular mediated immunity in
0.5456740689	seizures after cardiac surgery
0.5454341324	potentially serious complication
0.5453841042	cortisol treatment
0.5453789750	loss of creativity
0.5452215851	ifs induced
0.5452149462	behavioral studies
0.5451160774	highly significant
0.5449404864	peak serum
0.5449266398	magnesium levels
0.5448038211	131 heptadecanoic acid
0.5447502707	ionic and non ionic
0.5446693728	chronic heart failure
0.5446566037	blood urea and creatinine
0.5446286336	the human jaw stretch reflex
0.5445677000	n methyl d aspartic acid
0.5445024662	long term lithium treatment
0.5441439231	avp and anp
0.5440462009	ecg test
0.5439939160	saline and apigenin treated
0.5439221081	chronic pre treatment with metformin
0.5439137055	480 mg
0.5438295845	tacrolimus related
0.5437891745	designed to investigate
0.5437866400	ctni and ctnt
0.5437591126	bipolar patients with lithium
0.5435694281	crf or esrd
0.5435390342	yr old man
0.5434502081	interaction between flecainide
0.5433780310	the hypophysial portal circulation
0.5432262899	l 3h nicotine binding sites
0.5429709956	positive and negative syndrome scale
0.5429611746	inflammatory cells
0.5428408058	ciprofloxacin induced
0.5427008726	behavioral toxicity
0.5426806217	treatment of malignant gliomas
0.5426391870	clinical improvement
0.5426154488	manic or mixed
0.5425826826	eaca therapy
0.5424921269	the haemolytic uraemic syndrome
0.5424867186	experimental models
0.5422982707	immunostaining for 7h6
0.5421318908	severe heart failure
0.5421092836	qt interval returned to normal
0.5420880290	hemorrhage occurred
0.5420428448	foci cm2 in
0.5420098187	low back pain
0.5417946158	the rho rock pathway
0.5417683945	injury induced by isoproterenol
0.5417398697	levodopa adverse effects
0.5414627512	microg 0.5 microl
0.5414552935	stimulation on cortical epileptic
0.5414079543	enos and inos expression
0.5412240926	risk for valvular heart disease
0.5410479935	protective effects of misoprostol
0.5410173252	micrograms.kg 1
0.5409589650	fluctuating patients
0.5407931577	recurrent seizures
0.5407867552	sulphasalazine treatment
0.5405084395	patient population
0.5404881178	induced experimentally
0.5404852620	urinary n acetyl beta d glucosaminidase
0.5404525519	formerly rapamycin
0.5403869788	treated eyes
0.5403119264	causal relationship between
0.5402196016	patient compliance to treatment
0.5401357903	metabolic abnormalities
0.5401001414	mepivacaine with adrenaline
0.5400459664	undertaken to determine
0.5399715390	n phenylimide herbicides
0.5399509789	and terminal deoxynucleotidyl transferase
0.5399128786	median follow up period
0.5398606394	mm for control subjects
0.5398296500	cumulative incidence of persistent
0.5397946158	the adenylate energy charge
0.5394676710	10 12h post training period
0.5394255374	vitro showed
0.5393262229	new macrolide antibiotic
0.5392321092	hr prior to amphetamine
0.5391659948	adducts in mitochondria
0.5391574144	neuroleptic induced
0.5391573043	brain dopamine
0.5390663442	n butyl deoxynojirimycin
0.5390365333	respiratory control
0.5390330257	partial seizures
0.5390109771	similarity between
0.5388375669	meth induced
0.5388218265	cox 2 inhibitors
0.5387608676	progressively developed
0.5385826066	cpap during nitroprusside
0.5385515864	castrated and noncastrated rats
0.5384957065	and fine particulate matter
0.5382506337	dox rats compared with controls
0.5382039955	argatroban therapy in hit
0.5382010578	veno occlusive disease of
0.5381221575	possible contributing factors
0.5378340428	chronic administration of lf
0.5376612018	week trial
0.5374844101	protrusion and duration of facial twitching
0.5374182025	hctz therapy
0.5373536352	high cumulative
0.5371843426	withdrawal seizure
0.5371760061	bcnu administration
0.5371573206	effects of 17alpha ethinylestradiol
0.5371428879	a paclitaxel eluting stent
0.5371309324	organ transplant patients
0.5370626596	reductions from baseline
0.5370060053	dosage groups
0.5369223761	stimulus induced
0.5368898268	primary objective
0.5366734705	indirect methods
0.5365590982	ngf and pgs
0.5365527229	proliferation of peroxisomes
0.5364195731	hiv disease
0.5363274475	les and fps
0.5361494627	conversion to cya
0.5360902166	examination showed
0.5360321569	increases in dural
0.5359941388	systolic and diastolic left ventricular function
0.5359794987	memory impairment in male rats
0.5359498109	reversible encephalopathy
0.5357631312	remarkably abundant in ed 1
0.5355759256	high incidence of thrombophlebitis
0.5355131044	infusion of noradrenaline caused
0.5354709639	argatroban concentration
0.5353971201	acute myopathy
0.5352337029	randomly divided into three groups
0.5351527998	orally once daily
0.5351168643	injection duration
0.5350005919	potential duration
0.5349947037	selectively increased
0.5348729924	tobramycin and piperacillin
0.5346106666	healthy subjects and stroke patients
0.5346080507	matched controls
0.5345979789	succinylcholine associated myalgia
0.5343189386	resistant cardiac
0.5342387846	hepatitis c virus
0.5339475605	low frequency
0.5338845334	lv systolic and diastolic
0.5336424087	mg kg daily
0.5334185314	increasing pain
0.5334105189	confirmed by histology
0.5333212212	incidence and risk factors
0.5332577856	d1 and d2 dopamine receptors
0.5331435333	new york heart association
0.5331139551	unaffected by d pen
0.5330938023	glomerular and tubular injury
0.5330146468	c reactive protein
0.5329252717	mmp 2
0.5326965568	solution and chow
0.5326923226	woman with ebstein
0.5325629636	ultrasound showed
0.5325625681	streptozotocin induced
0.5324914601	anesthesia induced hypotension
0.5323880065	renal and liver function
0.5323179298	mrna and protein expression
0.5322065529	frequency of venous thromboembolism
0.5321937219	7alpha hydroxylation of
0.5320062935	congestive heart failure caused
0.5317541297	control of arterial blood pressure
0.5315779220	glutathione levels
0.5315464543	normal wistar rats
0.5315388501	large dose
0.5314550444	pai 1
0.5313138721	patients with recurrent squamous cell
0.5310850247	min before training
0.5310103539	large and small coronary
0.5309582525	patients with advanced nsclc
0.5307973915	bladder afferent cells in
0.5306343498	experimental arrhythmia
0.5306120622	age groups
0.5304947970	lozenge and 4 mg nicotine gum
0.5303223306	massive focal calcification of
0.5302332110	mild to moderate
0.5300263625	induced sensitization of lidocaine
0.5296302893	premature ventricular complexes in
0.5295817902	pleural and pericardial
0.5295702893	aimed to investigate
0.5295485979	9.2 + 0.2
0.5295172128	sham treated
0.5295051439	interstitial cells
0.5293954745	test dose of morphine
0.5291979280	dependent behavioral
0.5291869022	behavioral cross sensitization to
0.5290554566	secondary to zolmitriptan
0.5289824118	the simpson angus scale
0.5289172477	length of stay
0.5288979325	ami and dox
0.5285999203	paracetamol treated rats
0.5284645224	risk for cataracts
0.5284528030	implicated in epileptogenesis
0.5283921245	wk group
0.5282548003	female patient with stable
0.5280971649	induce or aggravate
0.5280745408	1,000 patient admissions in
0.5280681642	5 ht 2a 2c receptor antagonist
0.5279893794	the septo hippocampal cholinergic pathway
0.5279660400	bfgf and vegf
0.5279571031	hypophysectomized chick and
0.5276792491	act synergistically on
0.5275869380	chronic pan
0.5275573785	glutamate receptors
0.5275012769	central effects of scopolamine
0.5274880952	y mrs
0.5274877996	6 ohda
0.5274739406	ara c
0.5273731711	caspase 3
0.5272979846	levels returned
0.5272227207	clonidine induced hypotension and bradycardia
0.5270943655	flexure contracture of
0.5266372613	myocardial dysfunction
0.5265798131	oral thalidomide
0.5264979611	group adr + los
0.5264797302	c57bl 6 mice
0.5264098288	morphine induced sphincter of oddi spasm
0.5263952720	3 alpha hydroxy pregnane
0.5263139895	microinjection of methyldopa
0.5262843269	interfering behaviors in children with autism
0.5261258021	excretion of total protein
0.5260438337	times control
0.5259301265	abilities and cognitive function
0.5259278816	developed renal insufficiency
0.5259080197	neuropeptide y
0.5258869380	selective dopamine
0.5258507313	higher doses in young children
0.5257710349	positive urine
0.5255562583	isoniazid therapy
0.5255221446	sensory and motor dysfunction
0.5255166144	symptoms disappeared
0.5252558925	treated with gfc75 plus p400 showed
0.5251109009	a tracheal foreign body
0.5250440642	suppressed baseline startle in
0.5250328469	al patients
0.5249494055	agranulocytosis and thrombocytopenia
0.5248853120	nicotine induced seizures and hypolocomotion
0.5248545363	chronic phase
0.5248299913	the hilar ectopic granule cell population
0.5248146137	girl with turner syndrome and graves
0.5246466949	ketoprofen group
0.5246317702	splenic and bone marrow bfu e
0.5246222518	cross reactivity between
0.5244793026	acute renal failure following rifampin
0.5244066862	loss of consciousness
0.5244011957	incorporating amphotericin b
0.5243004256	nitrogen and serum creatinine levels
0.5241387993	surgery under epidural
0.5240843052	serum testosterone
0.5240798422	6 thioguanine
0.5240463954	quantitative and qualitative
0.5239535948	micrograms kg per min
0.5238634866	high dose cisplatin
0.5237645574	nonsteroidal anti inflammatory drug induced
0.5236817051	patients and methods
0.5235167006	the glomerular basement membrane
0.5234905847	glutamate receptor
0.5234153312	a laser pointer technique
0.5232106940	mol l
0.5231810494	widely used for controlling menopausal symptoms
0.5230776527	receiving d penicillamine therapy
0.5229501195	5alpha pregnan 20 one
0.5229212486	male and female
0.5229196436	acute cocaine induced seizures
0.5229062152	statistically significantly
0.5228363989	intracollicular microinjection of
0.5227036830	low incidence
0.5225959615	weeks prior to presentation
0.5224412550	mild hypertension
0.5222434878	ng.ml 1
0.5222323573	ndma d
0.5220648117	apoptosis in hl60
0.5219834752	materials and methods
0.5219726874	noxious chemical stimulation of
0.5219139178	significant protective effect
0.5219017002	bsc 1
0.5218553061	na + binding
0.5218120433	zidovudine related side effects
0.5217576466	2 chloroprocaine ce
0.5217364136	s perillyl alcohol
0.5216823977	within normal limits
0.5216743005	the mpo anca titre
0.5215594070	cardiac rate and ultrasound production
0.5213144551	suxamethonium induced
0.5212346706	epileptic animals
0.5211448386	recovery of renal function
0.5210544902	gem p
0.5209944917	dopamine antagonist
0.5209801134	wolff parkinson white syndrome and
0.5209155802	in metastatic squamous cell esophageal carcinoma
0.5208908062	hiv seroconversion among
0.5208585859	elevated blood
0.5206121668	strain rats
0.5206114107	failed to prevent
0.5205935059	6 hydroxydopamine
0.5205723938	ecg monitoring
0.5204616126	levodopa therapy
0.5203167717	concomitant administration
0.5203164011	serum level
0.5202515334	induced abortions
0.5202468708	non indexed journals and conference abstracts
0.5202300790	potential risk factors
0.5202214259	netilmicin and tobramycin
0.5200677399	core study
0.5200069329	increased incidence of myoclonus
0.5198316392	intensity of muscle fasciculations
0.5197987735	pn 30
0.5197143642	lenalidomide and dexamethasone
0.5196256033	014 unit
0.5195738980	igf il 3 and epo
0.5195558057	intraperitoneal administration of atropine
0.5193366207	effective in suppressing
0.5193281206	5 hydroxytryptamine
0.5193260531	stimulus induced overflow in
0.5192379592	research group
0.5192100927	beta 2 adrenoceptor
0.5191610192	refractory to medical treatment
0.5190059553	received enalapril
0.5188023961	selected patients with severe
0.5184238460	low dose haloperidol
0.5183894001	antagonism by metoprolol
0.5182624402	protective activity
0.5182194719	atpase activity
0.5181118905	high dose 5 fluorouracil
0.5180926154	november 2005
0.5179938278	alpha 2 adrenoceptor
0.5179843807	1.44 + 0.6
0.5179799335	daily dosage
0.5179732545	striatum and amygdala
0.5179692934	min post
0.5179360493	t cell lymphoblastic
0.5178774583	the mpo anca titres
0.5178357693	amphetamine induced
0.5178141297	acute encephalopathy
0.5177712274	recent chemotherapy
0.5177327092	cp 200 mg
0.5177048167	asp70gly p
0.5176785318	prl levels
0.5175488203	control rats received
0.5175027880	sufferers of migraine with aura
0.5175019131	reduces levodopa
0.5174523468	safe administration
0.5174165786	missed 40
0.5173622739	mg for untreated rats
0.5170982035	morning and evening
0.5170788935	induce tdp
0.5170305608	exacerbation or de novo
0.5170290540	periods and amplitudes
0.5170196382	dynamic response of blood
0.5169726095	carteolol did not evoke
0.5169273504	rate decrease
0.5168690480	designed to evaluate
0.5167563839	learning and memory performance
0.5165838313	safe and effective
0.5165133053	infusion rates
0.5162520624	drug induced dyskinesias
0.5162466215	pilocarpine induced
0.5161874643	enflurane or isoflurane
0.5161282908	d med
0.5161187489	13 psychometric measures
0.5158459200	intolerant to zidovudine
0.5157040162	ds rats
0.5155554693	years or older
0.5154742337	adam 10 and adam 17
0.5153827403	severe bradycardia
0.5152429119	significant proteinuria
0.5151301641	concomitant use of qt interval prolonging
0.5150901314	total peripheral
0.5148506606	neutrophils stimulated with
0.5148221594	the debrisoquine sparteine type
0.5148120411	days postoperatively
0.5147721947	taken appetite suppressants
0.5145314924	extrapyramidal side effect
0.5145120316	dose per body surface area
0.5144708598	clozapine and olanzapine
0.5144062226	malignant syndrome probably caused by methylphenidate
0.5142806025	genotyped for 5 httlpr
0.5142501593	alf patients
0.5142377993	caused by serotonin reuptake blockers
0.5140865872	positively correlated with
0.5139732513	substantial clinical
0.5139458085	losartan administration
0.5138955876	received bupropion
0.5136838189	experimental myocardial
0.5136801319	toll like receptor 4
0.5135977400	green tea and vitamin e
0.5135549021	produced massive
0.5132650091	tricyclic antidepressant induced
0.5132575639	antidepressant therapy
0.5132384644	glutamate n methyl d aspartate
0.5131971590	data obtained
0.5131311658	passive avoidance task in rats
0.5130987934	the sa node artery
0.5130783085	anxiogenic potential of ciprofloxacin and norfloxacin
0.5130037135	diazinon induced
0.5129912259	hospitalised patients with cancer
0.5129452100	correlation exists between
0.5126205160	pain score
0.5125424596	sub chronic low dose gvg
0.5125333500	divided into
0.5125172565	degenerative changes
0.5124797471	plasma concentration
0.5124461013	years post
0.5123674900	showed statistically significant
0.5123177755	studies demonstrated
0.5120675931	capable of inducing
0.5120468310	adult patients
0.5118933697	5 azc
0.5117546901	reported earlier
0.5116110354	born to hepatitis b surface antigen
0.5115429399	reduction in glomerular number
0.5114495560	injected rats
0.5114308085	sed +
0.5114216659	micromol l
0.5114045779	dynamic response of blood vessels
0.5113602104	prothrombin time
0.5112886005	apoptosis of lesional
0.5109779530	in hospital postpartum rubella
0.5109436577	polydipsia and polyuria
0.5109112684	progression of weakness in duchenne dystrophy
0.5109028396	served as controls
0.5108629357	deaths from breast cancer
0.5105784343	trained to approach
0.5104888137	third generation progestagens
0.5104445566	polyuric despite
0.5104131136	limiting side effect
0.5103242785	myocardial cells in culture
0.5102808131	degrees c
0.5101982865	effects by ro15 1788
0.5101767285	peak increase
0.5101551075	induced locomotor hyperactivity
0.5101245007	physicians caring for
0.5099515589	fasciculation and myalgia
0.5098483399	factors including
0.5097738958	scattered degeneration in
0.5097705579	intranasal dexmedetomidine for
0.5097433259	tgf b
0.5095753071	sirolimus therapy
0.5095382944	of integrin linked kinase
0.5094308937	substance p antagonist
0.5093689361	severe facial
0.5093140894	y maze
0.5092661798	liver dysfunction
0.5092278433	beta 1 adrenoceptor
0.5092235072	the apoe epsilon4 allele
0.5089700790	morphine infusion
0.5087788028	l dopa
0.5087313411	analgesic and antiinflammatory
0.5086913581	600 mg m2 busulfan
0.5086141891	mitochondria isolated from
0.5085966954	mhb former
0.5083520222	enflurane and isoflurane
0.5082400870	therapeutic doses of paracetamol
0.5081036605	dose combinations
0.5080117197	induced narcosis
0.5077628971	comprised 40 patients
0.5077324481	kanamycin and netilmicin
0.5077169832	pre treatment
0.5076054789	the lamina rara externa
0.5075328491	a broad spectrum antiepileptic drug
0.5074663966	induced nephropathy
0.5074206930	isoproterenol treated rats
0.5073567328	exposure to tobacco
0.5073478151	paroxetine and alprazolam
0.5072225834	diclofenac 75 mg
0.5071850466	management of riha
0.5071596430	ki =
0.5071506548	reversed by insulin treatment
0.5071195075	protects against
0.5069641427	acute renal dysfunction
0.5069350629	reserpine induced orofacial dyskinesia and
0.5068694281	dose dependently increased
0.5066905431	undergoing chemotherapy
0.5064209770	conventional doxorubicin
0.5063952445	aimed to evaluate
0.5061715538	subjective effects
0.5060990286	brain oxidative stress
0.5060612599	mg kg per dose
0.5060062761	systematic review of published and unpublished
0.5058391845	drug monitoring
0.5058339071	att alf patients
0.5057622231	flexion extension of
0.5057138431	carboplatin and liposomal doxorubicin
0.5057065155	average ejection fraction of
0.5057029105	grip force in on state
0.5056396440	intravenous calcium
0.5055074852	il 6
0.5053611835	allocated to receive
0.5053092010	saline injection
0.5052890572	placebo vs active
0.5049679171	000 ng mouse
0.5049499991	acute liver injury
0.5048072262	enalapril treated
0.5047348107	intravenous injections
0.5047007738	n methyl d aspartate
0.5046108012	adult rat
0.5045058287	got and gpt
0.5044876873	ventricular function
0.5044820712	the ceruleo cerebellar pathway
0.5044315343	a bulbospinal serotonergic pathway
0.5043832746	the hole board test
0.5041892957	annexin v
0.5037462078	d penicillamine
0.5036019898	formulation of adenosine
0.5035869992	adult mice
0.5034822359	health effects
0.5034818261	alpha and beta
0.5034166809	significantly prevented
0.5033506067	model for studying
0.5033300083	standard clinical
0.5032803219	total protein
0.5032576387	a smoking cessation aid
0.5032308545	nms like
0.5032118845	static and dynamic
0.5029533842	prenatal dexamethasone on days
0.5029177784	pilocarpine injection
0.5028845073	women aged
0.5027847238	carmofur induced
0.5027359301	receiving concomitant
0.5027134909	critically ill patients
0.5026580812	decrease in arterial blood pressure
0.5025448474	the clinical global impressions scale
0.5025250030	ability to repeat
0.5024333444	i 131 ha
0.5023485362	serum concentration of cimetidine
0.5022576387	a major healthcare network
0.5022380917	myocardial cell
0.5021006790	concerns about
0.5019440869	pre treatment levels
0.5019340793	550 mg m2
0.5019293796	succinylcholine induced
0.5019089988	relapsed or refractory
0.5018810587	induction therapy
0.5017847238	troleandomycin induced
0.5017798219	rat models
0.5015868104	clinical parameters
0.5011387778	step through
0.5011244370	the hiv protease inhibitor ritonavir
0.5009383534	et al
0.5009084791	median overall survival
0.5008710044	second generation ocs
0.5008042536	heparan sulphate associated anionic sites in
0.5007731744	on initial mr images
0.5006955362	years of age
0.5006145967	mefenamic acid induced
0.5006067124	complications of levodopa therapy
0.5005043210	the neonatal intensive care unit
0.5004760844	cyp induced
0.5004432791	added to valproate
0.5003696350	convulsive seizures
0.5002912856	chronic low dose
0.5002750954	hepatotoxicity with sulfasalazine
0.5002497136	cross over study
0.5001916265	critically ill
0.5001331711	acetaminophen induced
0.5001234635	behavioral and biochemical
0.5001147804	rhigf i
0.5000740279	therapeutic doses
0.5000021192	heart syndrome
0.4999969602	zo 1
0.4999845157	adjusted relative risks of
0.4999252804	l arginine extraction
0.4999008536	published and unpublished
0.4998647378	animals receiving
0.4991939998	bfu e
0.4990211715	controlled clinical
0.4990095404	drug concentrations
0.4986479677	ranging from
0.4985265700	burn patients
0.4985221511	pain memory
0.4985210290	postoperative delirium in elderly patients
0.4984146480	s granulomatosis
0.4984047214	neuropsychiatric side effects
0.4983102875	4 damp
0.4981765816	administered safely
0.4981472730	potent and selective
0.4981353523	study population
0.4980881796	signs of dopaminergic activation
0.4980566755	7 ni
0.4978108586	stroke and gallbladder disease
0.4977805469	enos and inos
0.4977044652	heart failure induced by adriamycin
0.4976255713	nephrotic rats
0.4971690587	lower concentrations
0.4971539371	abnormal ocular motility in
0.4971220328	ecg abnormalities
0.4971123265	high dose carboplatin
0.4970562209	examination revealed
0.4968642885	confirmed at echocardiography
0.4968178618	cross over trial
0.4966259613	respiratory and cardiovascular
0.4965472282	numbers of nos
0.4965382650	whole body hyperthermia
0.4964964663	stz induced
0.4963750926	the l6 s1 drg
0.4963460762	fenoldopam and theophylline
0.4963271131	p aminophenol
0.4963127535	4 dichlorophenyl
0.4962859478	ranitidine induced acute interstitial nephritis in
0.4962362855	isoproterenol induced myocardial infarction
0.4962308771	induced seizures
0.4960911624	developing acute renal failure
0.4960807041	aimed to compare
0.4959512430	injury in chronic puromycin aminonucleoside
0.4959217549	induced dopaminergic neurotoxicity
0.4959011769	reduction in mssbp
0.4957918293	lithium level
0.4957917168	increased subjective
0.4957743108	sirolimus associated proteinuria
0.4956385374	1993 1997
0.4955207688	anterior and posterior
0.4955103391	co trimoxazole
0.4953551171	anticoagulant therapy
0.4951099055	normal control group
0.4950003539	acute nephrotoxicity
0.4949671441	patients undergoing chemotherapy
0.4948196396	spironolactone 100 mg
0.4948174762	autophagic vacuoles in
0.4945921284	of fat free dry weight
0.4941732211	hypertensive controls
0.4941625697	the granule cell layer
0.4940219491	reduce mean arterial pressure
0.4940030379	acute renal failure induced by gentamicin
0.4939829354	da receptors
0.4939538073	hyperprolactinemia in youth
0.4939207481	cardiac mitochondria
0.4937967243	efficacy and safety
0.4937020097	triglyceride and ldl
0.4936781960	stress test
0.4936112306	and maximum cystometric capacity
0.4934885637	hemodynamic and antiadrenergic effects of dronedarone
0.4933284597	lowering na o to 78 mm
0.4932083950	lovastatin and simvastatin
0.4931848301	misoprostol therapy
0.4931110195	induced optic neuropathy
0.4931067487	varies among
0.4930210383	high mortality
0.4929900149	users vs nonusers with ich
0.4929786055	dexmedetomidine or propofol
0.4929727518	magnesium administration
0.4928235536	nested within
0.4926199278	model of temporal lobe epilepsy
0.4926194205	blocking drugs
0.4926119900	cyclosporine and tacrolimus
0.4924924596	014 unit collagenase
0.4924887376	heart rate and rate pressure product
0.4924476101	previously demonstrated
0.4921726233	in recreational ecstasy polydrug users
0.4921709661	drugs of abuse
0.4921672382	among pesticide applicators
0.4921516317	echocardiography and radionuclide
0.4921292450	oral drug
0.4920430079	disease activity
0.4919596861	myocardial disease
0.4918736793	yohimbine increased
0.4917586757	renal function and hemodynamics
0.4917297914	sodium level
0.4916870618	gentamicin treated rats
0.4916032451	severe anemia
0.4915641841	first episode schizophrenia
0.4915290939	clinical variables
0.4915186608	diazepam than propranolol
0.4913156735	correlates with dose per body surface
0.4912632627	risk of pacemaker insertion
0.4911728457	evaluable for response
0.4911624646	ethambutol and isoniazid
0.4910192646	chronic coronary artery disease
0.4908966622	electrocardiogram showed
0.4908611302	direct inhibition of cardiac
0.4908102836	granulosa cell tumor of
0.4907408830	role of nrf2 against diabetic nephropathy
0.4904596550	thirty six
0.4903808027	isg in preventing type b hepatitis
0.4903733925	csa and fk506
0.4902248449	mechanism of action
0.4901293374	4 dihydroxyphenylacetic acid depletions
0.4901288475	mice with azidothymidine
0.4900926776	high sensitive
0.4898929237	digitalis and adrenaline induced
0.4898833259	regulation of alphaenac
0.4898701408	months after temsirolimus
0.4897677199	mg per deciliter
0.4894847749	hepatic toxicity
0.4894824716	needed to confirm
0.4894269372	effective doses
0.4892236357	significant mortality
0.4890789417	uni and bilateral
0.4890250449	determined by measuring
0.4889957760	bradycardia occurred
0.4889659713	central and peripheral
0.4888706056	per deciliter 95 percent confidence interval
0.4888669874	min 1 epinephrine
0.4888408618	nmol l
0.4888393965	l sotalol
0.4888217397	terbutaline treatment
0.4883929940	risk of breast cancer
0.4882965832	withdrawal of selegiline
0.4880457234	prl r
0.4879897362	saline treated
0.4879551105	mi rats
0.4879230771	meth significantly increased
0.4877521303	crf and esrd
0.4877517953	and summed difference scores
0.4875049257	diazepam induced
0.4874809461	scopolamine induced
0.4871780920	the acetic acid induced writhing test
0.4871685982	concurrent treatment
0.4868486206	5 azacytidine
0.4867877293	n ethylcarboxamidoadenosine
0.4866508362	low sodium
0.4864415067	d tubocurarine dosing
0.4864357104	indistinguishable from
0.4862460796	atp sensitive k
0.4861071994	initiation of levetiracetam treatment
0.4859138976	the remnant kidney model
0.4858734938	preliminary study
0.4856169159	children treated with indinavir
0.4856023017	warfarin related
0.4854968165	l arginine uptake
0.4854613336	head twitches in rats
0.4854352214	emotional lability and
0.4852221076	published studies
0.4852221076	studies published
0.4851444357	diseases such as alzheimer
0.4851218386	ranitidine and cimetidine
0.4851099981	pretreatment with ramh
0.4851072927	mk 801 binding
0.4849104656	tropyl 2
0.4848321649	synthesis release of bradykinin to activate
0.4848204243	renal function in liver transplant recipients
0.4847211953	adriamycin mediated antitumor activity and
0.4847204298	bolus dose
0.4846841324	repeated administration of cocaine
0.4846825793	release of ach
0.4844956133	raloxifene treatment
0.4844850331	neurotensin induced
0.4844090797	findings showed
0.4843376773	dose intensity
0.4843262800	experimental groups
0.4842381144	de novo synthesis
0.4841256212	s anomaly
0.4840796588	independent effects
0.4840306835	cimetidine levels
0.4840244312	hyperkalaemia following
0.4839459395	patients with rheumatoid arthritis
0.4838421608	allergic reactions other than thrombocytopenia
0.4838103508	binding studies
0.4837167110	c57bl 6
0.4835318426	cancer patients
0.4834789472	rhabdomyolysis and acute renal failure
0.4834646274	l arginine transport
0.4834483541	history of wernicke
0.4834037553	improve blood pressure
0.4833661188	ephedrine to propofol
0.4833608994	ao mrna levels did not change
0.4828543161	neurons and astrocytes
0.4828106380	206 dogs
0.4826684958	episodes of cardiac arrest
0.4825882375	near syncope
0.4825729945	renin and aldosterone
0.4824846553	quality of life
0.4824203231	motor activity induced by morphine
0.4820089881	u ml
0.4817817706	therapeutic effects
0.4817711315	serum proteins
0.4814849089	125 mg i.v
0.4811426514	indomethacin induced
0.4810005525	non hydrolyzable
0.4807667171	levels obtained
0.4806897023	shown to protect
0.4806708843	increase in heart size
0.4806173416	treatment schedule
0.4805060523	induced hemorrhagic cystitis
0.4804861972	clinical research
0.4803900455	transmural propagation of
0.4803899758	cyclophosphamide at 900
0.4803841557	a cadaveric renal allograft
0.4802318165	drug interaction
0.4801919278	broadly used
0.4800301259	infusion of sodium nitroprusside
0.4800292146	metoprolol and terbinafine
0.4799256492	induced anemia in prostate cancer patients
0.4799198415	randomized study
0.4799192710	rare but potentially
0.4799155614	insights into
0.4797922386	a face learning task
0.4796630742	moderate to severe
0.4796540604	indinavir therapy
0.4794901946	given intra arterially
0.4794607136	ir in drg
0.4792773626	standard deviation of mean arterial pressure
0.4792441334	concentration time curve
0.4789834130	cyp treatment
0.4789594193	mg protein
0.4789587472	women on cocs
0.4788772512	methods and results
0.4788260593	latency to step
0.4786475018	a timely eeg evaluation
0.4784028065	randomly divided into
0.4782862091	status epilepticus induced by pilocarpine
0.4781286730	2 thiazolyl formamide
0.4781284906	infected with hepatitis c virus
0.4781272560	dose dyskinesias
0.4780242563	venous thrombosis not otherwise specified
0.4779144487	injected with saline
0.4778443431	responder rates at
0.4778220335	randomized to receive
0.4777474687	cancer patients receiving
0.4776494847	lisinopril and survival
0.4774529255	tests with ax
0.4773435879	for potentially nephrotoxic antibiotics
0.4772867799	treatment regimens
0.4771673030	the dihydropyridine calcium channel blockers
0.4771219178	laboratory studies
0.4771156888	clearance of fluorescent
0.4770248771	japanese patients
0.4768259997	reversed by naloxone
0.4768041017	world health organization grade 3 4
0.4767149640	single dose
0.4766846694	5 ht1b receptor ligands microinjected into
0.4766472804	22 oxacalcitriol
0.4765540840	methyldopa induced hemolytic anemia in
0.4764126876	significantly attenuated cocaine induced convulsions and
0.4761631747	mixture of hpma copolymer and free
0.4761176748	safety of capecitabine
0.4759283357	bupropion and carbimazole
0.4759166731	receiving amb and spironolactone
0.4758259165	severe neurotoxicity
0.4757655003	renal disease developed
0.4755971493	examined by immunohistochemistry
0.4755369678	exposed group
0.4753969962	used poisson regression
0.4753449928	cocaine associated chest pain
0.4752002246	diet free of precursors of nad
0.4750572269	degeneration of dopaminergic neurons
0.4749776842	assessed by measuring
0.4747699631	octreotide therapy
0.4745239141	starting dose
0.4744646026	thirty nine
0.4744100662	mean arterial blood pressure
0.4743585194	occurrence of aki
0.4743103244	morphine induced
0.4741285545	an antisense oligodeoxynucleotide
0.4736709200	therapeutic dose
0.4735004924	thrombocytopenia after liver transplantation
0.4734789212	ethyl 4
0.4732638510	type of ssri
0.4732535556	potassium levels
0.4732380544	a previously healthy person
0.4730944990	indomethacin and naproxen
0.4730772515	acute neurologic
0.4730412079	taking propranolol
0.4730318098	cck 5 8
0.4728294841	determination of malondialdehyde
0.4727838657	patients presenting
0.4725596680	follow up
0.4724925829	uraemic syndrome after treatment with metronidazole
0.4722682687	in dahl salt sensitive rats
0.4722501206	bradykinesia and rigidity
0.4721921879	95 confidence interval
0.4721764964	haloperidol induced
0.4719644143	intracavitary application of paclitaxel and carboplatin
0.4719589098	not fully understood
0.4717185903	0.9 nacl
0.4716595695	structural and functional
0.4716537095	cardiac adrenergic neuron activity in
0.4716194165	seizures and status epilepticus
0.4715240805	synergy between
0.4714731154	pain control
0.4714004509	including torsade de pointes
0.4713100204	night time
0.4712371260	extrapyramidal motor system
0.4710863927	memory test
0.4709974195	rizatriptan 10 mg
0.4709221421	desipramine and 6 ohda
0.4709132397	treated rats presented
0.4707061857	chickens given
0.4706753550	u ii
0.4705825777	heart rate and cardiac output
0.4705533825	5 hydroxytryptophan
0.4705504218	1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine
0.4705275809	young and aged mice
0.4703478961	chronic carbamazepine
0.4702770006	nonusers of aspirin
0.4702671265	ovarian cancer patients
0.4702472205	remarkably abundant in ed 1 positive
0.4701129719	injected with gr 55562
0.4698153247	carcinoma after hodgkin disease in childhood
0.4695982670	placebo treated patients
0.4695521328	third generation oral contraceptives
0.4695241881	gspe + drug
0.4693753661	observations suggest
0.4691593694	4 aminopyridine
0.4690580069	high dose ara c
0.4689762677	induced by chronic barium
0.4689555684	infusion of aminophylline
0.4688717018	days after hospitalization
0.4688005974	assessment revealed features of
0.4687452822	deterioration of renal function
0.4687301983	na + k + atpase
0.4685575192	treated dogs
0.4685093682	regulation of signal
0.4684055246	decrease in gls
0.4684039355	morbidity and mortality
0.4683811273	chemotherapy with epirubicin
0.4683250314	unpaired t
0.4682876701	glycopyrrolate and atropine
0.4681184861	treated patients demonstrated
0.4679644303	1,500 g
0.4679206546	reduction in glomeruli
0.4678958139	patients referred
0.4677121304	evoked pain
0.4676561186	binding of 3h
0.4676297601	previous study
0.4673109210	abnormalities in mtdna
0.4672874934	heart damage
0.4672708206	6 ohda lesioned
0.4672080469	higher risk
0.4672035153	this potentially lethal complication occurred
0.4671455495	induction of anesthesia
0.4668901755	the calcium channel blocker nitrendipine
0.4668598235	reference lists of
0.4668263152	p 0.0005
0.4667711717	ex vivo
0.4667351176	containing multivitamin supplementation
0.4667215567	ethanolic extract of
0.4663341487	increased liver neoplasms in
0.4662994365	timing of ribavirin
0.4662055658	reporting of syncope
0.4661697256	patient with hepatocellular carcinoma
0.4659692049	information regarding
0.4659631232	cross tolerant to
0.4659484238	chemotherapy regimens
0.4658873505	sorafenib induced
0.4658224833	patients and controls
0.4656109301	glucagon 1 mg
0.4653080576	induced locomotor response
0.4652492982	inversely correlated with
0.4651909529	propofol and remifentanil
0.4650206827	creatinine and urea
0.4648985169	balb c mice
0.4647675503	dexmedetomidine and propofol
0.4646224080	increases blood pressure
0.4646138252	valproate therapy
0.4645436014	postoperative course
0.4644976125	doxorubicin cardiotoxicity
0.4644752456	increase in left ventricular systolic pressure
0.4643003491	dose of carbon tetrachloride
0.4642676596	paraplegia following
0.4642324747	intrathecal administration
0.4641903449	cytosolic ca 2 + activity
0.4640607807	nd nmba
0.4640355410	presence of central nervous system leukemia
0.4640145388	cannabis use
0.4637915556	concentration of tamca
0.4637777845	extracted from
0.4637657293	mibg accumulation in
0.4636440516	continuous intravenous infusion of
0.4636367288	levels of cpap
0.4635264901	measures of psychological
0.4633659991	pain related
0.4633392726	mitochondrial toxicity
0.4632616065	inner medulla
0.4632453144	stratified by antithrombotic use
0.4632444679	vitamin c
0.4632056849	shell or core
0.4631451358	volume of distribution
0.4631341368	mechanisms of fk 506 induced hypertension
0.4629818176	deterioration of vision
0.4627748344	hyperalgesia and allodynia
0.4626386444	a reality check
0.4625866666	women with oab
0.4625317272	induced epithelial
0.4625152307	locomotor activity and increased
0.4624660455	ibs patients
0.4624588161	oral galactose treatment
0.4622840508	strains of mice
0.4621595558	calcium levels
0.4621011469	the median forebrain bundle
0.4620621421	noradrenaline levels
0.4620547419	the agricultural health study
0.4620515648	education about
0.4620012754	the obstructive sleep apnea syndrome
0.4618876593	received bromocriptine
0.4617435449	and tumor growth factor beta1
0.4615351406	animal study
0.4615235765	thalidomide 200 mg
0.4614845590	outside japan
0.4614584248	daily administration of desipramine
0.4613226902	cancer risk
0.4611138197	previously treated with chemotherapy
0.4610827100	320 12.5
0.4609213770	effect of alpha tocopherol
0.4608899394	all adenosine receptor agonists
0.4608260260	ranged from
0.4607110464	per kilogram
0.4606542490	male wistar rats received
0.4606222308	a triple sequential high dose regimen
0.4606091564	rat fetuses exposed to
0.4605874976	u wave
0.4605503386	initial potassium loss and
0.4605047177	displacement time
0.4604850318	dexamethasone induced
0.4604194516	randomly assigned to
0.4603514717	daily levodopa
0.4602503762	behavioral effects of caffeine
0.4602344958	well differentiated
0.4601441249	significantly increased risk
0.4601239724	epinephrine treated rats
0.4600957363	neuropathy in patients treated
0.4600382536	t1 2
0.4599801690	range 0.7
0.4599436308	everolimus and tacrolimus
0.4599361219	doses of vitamin d3
0.4598659769	returned to dialysis
0.4598288668	two independent observers
0.4597815905	massive right to left
0.4596923426	treatment regimen
0.4596048217	chlorpromazine induced
0.4595148895	no antiemetic rescue
0.4594797858	palliative benefit and
0.4594696510	phenobarbitone induced enlargement of
0.4593890116	d pen
0.4590024833	temporal association between
0.4589737934	disease duration
0.4587542481	clinical evidence
0.4587111567	amb and spironolactone
0.4586686747	week prior to admission
0.4584394488	amiodarone induced
0.4583117031	still unclear
0.4582801905	duration of action
0.4580988245	cyclosporine or tacrolimus
0.4580588586	increased nicotine exposure from
0.4579232952	combination therapy with tetrabenazine and tiapride
0.4578161676	glutamate and aspartate
0.4577580838	topotecan in combination with radiotherapy
0.4577086295	history of nsaid
0.4573191031	injection of puromycin aminonucleoside
0.4572560080	returned to normal
0.4571476093	altered disposition of
0.4571381994	acute renal injury
0.4570878403	cardiac death
0.4570595724	cross react with
0.4569173563	brain activity
0.4566723122	way analysis of variance
0.4565232739	the kinin b1 receptor
0.4564706887	treatment with high dose inhaled salbutamol
0.4564676321	yr old
0.4564164114	non txg
0.4563980672	low concentrations
0.4563198490	cyclooxygenase 2
0.4561338183	fentanyl administration
0.4561080449	concentration dependent
0.4560066827	the normalized reflex amplitude
0.4560062536	tolerated dose
0.4558331381	vigabatrin therapy
0.4557516410	myocardial contrast enhancement and
0.4555867871	effective in preventing
0.4555417606	inflammation and apoptosis
0.4554696673	type 2 diabetes
0.4554322860	5 fu
0.4553004367	trial of mazindol
0.4552768607	ifosfamide induced
0.4552206235	acting alpha 2
0.4552011228	elevation of intracellular
0.4551635901	cocaine kindled seizures in
0.4550695112	glycine and gaba
0.4550682636	experimental pain
0.4548744433	ocd like
0.4548640166	patients receiving heparin
0.4546723433	possibly related
0.4546207658	yr old man developed
0.4546103081	g ethinyloestradiol
0.4545817363	forestomach carcinogenesis of
0.4545768111	neutrophil and platelet
0.4545648975	185 mg m2
0.4544941883	study comparing
0.4543135977	drug challenge
0.4542802121	epileptic patients
0.4542681348	remained significant
0.4542402867	mc patients
0.4540203048	alternative to pallidotomy
0.4539975588	elevated levels of serum
0.4538237994	paroxetine and alprazolam treatment
0.4538079146	developed neuroleptic malignant syndrome
0.4537805919	the newer macrolides
0.4537320833	reduction of glomerular filtration
0.4537278549	after orthotropic liver transplantation
0.4536420057	687 days
0.4536210075	randomized double blind
0.4535122967	second generation pills
0.4534946650	effects of dehydroepiandrosterone
0.4534398413	caspase 3 activity
0.4533348657	drug combination
0.4533174613	striatum and hippocampus
0.4532040007	reduce bf by
0.4531924952	severe complication
0.4531131472	preliminary results
0.4529878403	case suggests
0.4527761055	measured during testing for handling
0.4527521661	fluoxetine effect
0.4527218054	days of e2 exposure
0.4526371585	presence of mb
0.4526187714	dopamine receptors in mediating nicotine induced
0.4526168199	selected controls
0.4525299050	ex mdma
0.4523516747	odds ratio =
0.4523245751	dependent effect of amantadine on motility
0.4522807970	reduce cocaine
0.4520992649	detection of apomorphine induced
0.4518742568	repair synthesis induced by
0.4517796713	glycopyrronium 5 micrograms kg 1
0.4516599826	minutes later
0.4515535055	output of triglyceride
0.4514349295	peripheral effect
0.4512959160	24 hour ambulatory
0.4511680159	magnitude and duration
0.4511296945	de novo absence
0.4511082237	histological and immunohistochemical
0.4511057308	arrest associated with continuous infusion cimetidine
0.4510447769	receiving fluoxetine
0.4509503352	children with autism
0.4509007397	systolic and diastolic dysfunction
0.4508574644	s limonene
0.4508270392	corneal ulcers associated with drug abuse
0.4507018178	advantages over
0.4505680285	food and water
0.4504111767	patient with rheumatoid arthritis
0.4503568896	frequency of micturition
0.4503308548	resting and peak
0.4502752258	yohimbine treatment
0.4502498336	week period
0.4501491352	bladder and forestomach
0.4501091503	injected with cyp
0.4500734004	revealed significant
0.4499786258	continuous infusion of 5 fluorouracil
0.4497854630	focusing on
0.4497654942	injection of carboplatin for recurrent glioblastomas
0.4495399221	immunostaining for 7h6 and zo 1
0.4493424317	4 diazabicyclo
0.4493185619	absence of mr
0.4492770283	failure of ancrod
0.4492328351	in dade county
0.4491262006	maximum and minimum
0.4490909966	reduced latency
0.4490854209	cases of antibiotic induced
0.4490098686	hemodynamic changes occurred
0.4489553407	aimed to determine
0.4489358181	wt with cyp
0.4488910344	high dose ifosfamide
0.4488191824	reduced by lithium treatment
0.4487331820	cauda equina syndrome after
0.4486628350	and abnormal visual evoked potentials
0.4485566882	na o to 78 mm
0.4483611627	mm hg and or diastolic bp
0.4482701962	dexamethasone induced ocular hypertension in
0.4482574956	intradermal injections of glutamate and capsaicin
0.4480204650	90 htn
0.4479769130	histological and biochemical
0.4479169087	the ventral basal ganglia
0.4478411436	wky and shr
0.4474619710	pain model
0.4474568826	score before surgery
0.4474312745	major cardiac
0.4473791085	fourteen patients
0.4473569678	micrograms kg hr and
0.4473320064	depressive like behaviour in mice
0.4472790906	systolic and diastolic
0.4471709884	risk of cad
0.4471541213	lithium pilocarpine
0.4471336794	exencephalic tissue at
0.4470566460	suffering from
0.4468058175	developed vte
0.4467474065	ml kg
0.4465775185	significant differences between clozapine and risperidone
0.4465343701	commencement of clozapine
0.4465221908	motor symptoms
0.4464374060	starting therapy
0.4463908353	clinical and biochemical
0.4462353408	hbv related
0.4461899650	mexiletine and placebo
0.4461493516	women with acne
0.4461359116	beclin 1
0.4460636539	pooled data from
0.4459114470	lost to follow
0.4459024908	close follow up
0.4457599276	mg week
0.4457549441	produced by carbachol and eserine
0.4456909315	ra co
0.4455840070	low dose groups
0.4455614041	fk 506 induced hypertension in rats
0.4455318803	adverse interaction between clonidine and verapamil
0.4453612414	non interventional
0.4451424691	2.0 mg trihexyphenidyl
0.4450780428	effects of nik 247 on cholinesterase
0.4449996637	time frame
0.4449124863	material and methods
0.4447617637	receptor mediated
0.4446694430	carefully consider
0.4446018551	low back
0.4444983346	epinephrine induced
0.4443253172	blood cells
0.4442595017	and schwab england
0.4442595017	and diaphragmatic hernia
0.4441900723	evaluation included
0.4440806104	case of venlafaxine overdose
0.4438921937	good performance status
0.4438638011	right leg
0.4438636962	per se
0.4438587991	anesthesia with etomidate
0.4438078498	well documented
0.4437631560	acute and chronic
0.4436843148	clonidine induced hypotension
0.4436797210	physicians and patients
0.4436690539	inner ear
0.4435372040	sedation for pediatric
0.4435112783	the kinin b2 receptor antagonist
0.4434873160	the electrical field stimulation evoked
0.4434463244	hepatic and extrahepatic
0.4434303525	significantly and dose dependently
0.4433713092	received intradermal injections of
0.4433393198	dronedarone and amiodarone
0.4432454840	motor control
0.4432076314	preoperative and postoperative
0.4432075241	patients with chronic coronary artery disease
0.4432008259	second line
0.4431346230	chow followed by amphetamine injection
0.4428071248	drug interaction between flecainide and paroxetine
0.4427680612	type 2 serotonin
0.4427499553	hypotension and haemodilution
0.4425220773	rna and dna
0.4425151110	versus vip
0.4425033975	methimazole induced
0.4424907286	s 23121
0.4424907286	s 312
0.4424660448	symptoms of rls
0.4424046694	patient receiving
0.4423689557	dox rats
0.4422192955	episode of generalized
0.4421611743	following intestinal ischemia reperfusion injury
0.4421583588	pn 11 to 14
0.4420986350	significant bradycardia
0.4420784437	antagonized by prior
0.4419756427	min of reperfusion
0.4419587448	train of four stimulation
0.4418842593	age and sex
0.4418580549	randomly allocated into
0.4417768034	increase in intragastric pressure
0.4417288627	microinjected into
0.4416569501	developed fulminant
0.4416449786	placebo group
0.4414024359	induced by pilocarpine injection
0.4413516500	w ich
0.4412725991	related to dili
0.4410852905	pgp in brain
0.4410757695	no statistically significant differences
0.4410392649	previously treated
0.4407780722	severe adverse
0.4406786793	2 chloroethyl
0.4406121363	aminonucleoside induced
0.4405784550	maternal smoking on
0.4404730263	imaging study
0.4403085802	high dose busulfan in
0.4402452474	min after succinylcholine
0.4401583070	hyperlocomotion in rats
0.4401378099	cardiac injury
0.4399705044	5 ht1a
0.4399665662	di o
0.4398734242	infant with multiple
0.4397288725	control eyes
0.4395599486	the calvert formula
0.4395431050	protection against
0.4395276292	l name
0.4393302936	psychosis in patients with methamphetamine dependence
0.4391814413	patients with ischaemic heart disease
0.4389583962	thirty five patients
0.4389484224	stomach and small
0.4387901496	material and method
0.4386088349	a transient tonic pupillary response
0.4386014019	synthetase inhibitors on
0.4385537229	increased susceptibility to seizures
0.4385045349	co morbid
0.4384598091	amnesia induced by scopolamine
0.4383522195	pre treated
0.4382663958	in freely moving mice
0.4381542435	socs 3
0.4378752843	0.1 kpa
0.4377642775	or functional stalk effect
0.4374549704	immunohistochemistry revealed
0.4373881375	fluoxetine treatment
0.4373825772	in war tropical
0.4373782921	percutaneous absorption of
0.4373620696	mg kg for i.v
0.4373211847	receiving multiple
0.4372995112	a statistically significant reduction
0.4372486762	induced kindling
0.4371652940	ml min kg in
0.4370629493	non acetaminophen induced alf
0.4369435871	cisplatin and amifostine
0.4369061794	neurologic and psychiatric
0.4365725029	benign and malignant
0.4365616228	induced apoptotic death in
0.4364656899	thrombocytopenia with thrombosis
0.4364494993	induced muscle rigidity in
0.4363557326	minutes per patient per hour
0.4362900347	users of fenfluramine and dexfenfluramine
0.4361732816	deciliter or more
0.4361334150	interferon and ribavirin
0.4361009619	mr study
0.4357585290	clinical data
0.4355670663	mg.kg 1
0.4355231015	unclear whether
0.4354937482	prior therapy
0.4353925978	160 12.5
0.4353677652	propranolol and biperiden
0.4353628131	deficient rats
0.4353117468	tolerance and antiviral effect of ribavirin
0.4350999704	succinylcholine 1.5
0.4350447933	mbp and hr
0.4350423201	oxytocin administration
0.4348394092	head and neck
0.4348098278	induced liver injury
0.4347985822	pentylenetetrazole induced
0.4347675757	mice hippocampus
0.4347535892	treatment with bevacizumab
0.4346285890	balb c
0.4346088043	patients recovered
0.4345967582	stz treatment
0.4345384910	role of mangiferin
0.4343904883	long term survivors of
0.4343621471	norepinephrine and epinephrine
0.4342803015	follow up period
0.4342193408	seventy five
0.4341280290	clonidine and methylphenidate
0.4341177076	methamphetamine induced striatal dopamine and 3
0.4340562313	high risk patients
0.4340065967	0.7 mv
0.4339907514	ocular and orbital toxicity after intracarotid
0.4339800216	4 diphenylacetoxy n methylpiperidine
0.4339439669	e 2020
0.4339413016	per os
0.4338442918	antiarrhythmic activity against
0.4337799665	high serum
0.4337459469	assessable for toxicity
0.4337240852	3.8 mm hg
0.4335625975	pre and post
0.4333543499	mptp induced
0.4333289864	0.1 micromol 10 microl
0.4332752737	mortality and morbidity
0.4332442040	the co2 response curves
0.4330611899	225 mg m2
0.4329989865	675 mm
0.4329348112	ns 718 treated rats
0.4328858376	spironolactone induced
0.4328858376	des induced
0.4328789733	76 yrs
0.4328256660	ninety nine
0.4328014354	patients with variant angina
0.4327250467	non enzymic antioxidants
0.4327091346	tongue protrusion and
0.4326704541	odds of convulsions
0.4325973610	expression of p300
0.4325808348	versus 5.9
0.4325768093	suffers from
0.4324827261	dose effect
0.4324609003	and uric acid levels rose
0.4323398623	negative effect
0.4321784450	conversion to cyclosporine
0.4321084313	exposure to vgb
0.4318401567	impairments in learning
0.4316996968	iii and iv
0.4314555078	0.15 mg bid
0.4314369400	second generation
0.4313869766	alpha 2 agonist
0.4313345304	mg 100 g body wt
0.4313232718	cathepsin d
0.4311599315	p nitrophenyl
0.4311258209	this paper reviews
0.4310671700	the adr nephropathy group
0.4309365916	predictors of dyskinesia
0.4308653485	slightly but significantly
0.4307506420	measures for women
0.4307457614	single intraperitoneal injection of
0.4306525177	systolic and diastolic function in humans
0.4305602356	objective responses
0.4305360835	self limited
0.4304528739	so far
0.4303716963	patients received
0.4300350980	new hampshire
0.4299500961	tended to reduce
0.4299237456	self rating
0.4297563132	de novo absence seizure
0.4296520624	morphological changes
0.4295201071	role in epileptogenesis
0.4294994579	biopsy revealed
0.4294712636	ribavirin dose
0.4294341825	r wave
0.4293701532	novel sigma receptor
0.4292508596	prevention of breast cancer
0.4291944457	induced acute interstitial nephritis and
0.4291916169	ed 1 positive
0.4291769411	excretion of potassium
0.4290638178	41 099
0.4290285648	glucocorticoid induced
0.4289475040	peripheral and central
0.4288340788	observed positive
0.4288096495	acute confusion induced by
0.4286663816	effective in controlling
0.4286143562	injection of puromycin
0.4285500882	motor and sensory
0.4285423394	response and stabilization
0.4284569324	aged 76 and older
0.4284318009	complications related
0.4282558708	1.55 g m2 d
0.4281222182	long term safety
0.4280177848	the cocaine metabolite benzoylecgonine
0.4278218637	acute onset
0.4277828232	after high dose melphalan
0.4277596382	in cx3cr1 knockout mice
0.4276594931	animals received
0.4276507434	single and multiple
0.4274549202	corresponding figures
0.4273150120	5 hiaa
0.4272718306	twice daily
0.4272314853	antipsychotic like
0.4271381635	the ultradistal radius
0.4271018528	regulation of mhc i expression
0.4270174499	areas of secondary hyperalgesia and allodynia
0.4269963986	signs or symptoms
0.4268980066	health of women with hiv
0.4268644737	series of experiments
0.4268220781	gentamicin induced
0.4267385403	second cycle
0.4267311154	83 boys
0.4267025090	learning and memory impairment
0.4265461817	other mood disorders
0.4265286707	in ringers lactate
0.4264757865	the basic sinus cycle
0.4264658740	the multiple sleep latency test
0.4263620362	ca + 2 atpase
0.4262493051	severe enough to require
0.4261812625	the interpeduncular nucleus
0.4259647065	dopaminergic and serotonergic
0.4258338326	standard therapy
0.4257279785	3tc + d4 t +
0.4255374724	number and size
0.4253993340	developed hyperkalemia
0.4253262153	superior to placebo
0.4252817198	3 week sulphasalazine syndrome
0.4252221488	antagonism of diazepam
0.4251851838	acid secretion in patients with gastric
0.4250207174	h sod1
0.4248886707	and rb1 ginsenosides
0.4248709072	8 hourly
0.4248466006	0.24 + 0.06
0.4248414000	comparison of developmental
0.4247408369	combined treatment
0.4245313255	vancomycin therapy
0.4245179794	pd patients
0.4243885729	120 min
0.4243578609	did not reach statistical significance
0.4242591142	electrocardiographic changes
0.4242566332	acute myocardial
0.4242346357	users with ich
0.4240808843	hours after admission
0.4240291638	related cardiotoxicity
0.4240241480	every 28 days
0.4240191698	effectiveness and safety
0.4238694703	untreated animals
0.4238227052	adrenaline induced
0.4237702068	differences in renal ace activity
0.4237027475	tachycardia to bradycardia
0.4234150685	these murine strains
0.4233721372	embryonic day
0.4233104389	normal range
0.4233090578	the nitrendipine treated group
0.4233059753	propylthiouracil induced
0.4231860809	arterial and venous
0.4229406617	cocaine concentration
0.4229290741	u l
0.4229247922	5 hydroxyindoleacetic acid
0.4229136727	tremor side effects of salbutamol
0.4227914876	the protracted infusion schedule
0.4226868508	sought to determine
0.4224701050	mg 100 ml
0.4224562314	myocardial ischemia induced by epinephrine
0.4224250355	weeks of gestation
0.4224204485	propofol injection pain in
0.4223287175	divided into three groups
0.4222258737	protection against doxorubicin
0.4221224674	objective and subjective
0.4220917764	5 htp
0.4220761721	diclofenac 75
0.4220471530	coniine and nicotine
0.4220266693	two dimensional
0.4219581989	study period
0.4218736458	once daily
0.4218518656	grade 3 or 4
0.4218086138	chronic propranolol
0.4217421948	low dose of amphetamine
0.4216457189	azathioprine and cyclophosphamide
0.4216365979	limited by adverse effects
0.4215500781	patient n degree
0.4214976700	hypersensitivity to carbamazepine
0.4214264934	depending on
0.4214098203	signs and symptoms
0.4213475350	month old rats
0.4212519007	development of glomerular sclerosis
0.4211901486	small but significant
0.4211616940	asenapine at 5 mg bid
0.4210974593	cck 2 8
0.4210884427	experienced seizures
0.4210830940	conversion to sirolimus
0.4210750396	second generation oral contraceptives
0.4210352696	without reducing albuminuria
0.4209931962	pretreatment levels
0.4209896945	and selected birth defects
0.4206382382	with metastatic androgen independent
0.4206180464	independent predictor of
0.4205954149	adaptive changes
0.4205360425	following cochlear hearing loss
0.4205171602	matched for age
0.4204647395	list of drugs
0.4204517018	this paper presents
0.4204446365	consumption and activity of respiratory complex
0.4204076646	severe enough
0.4204072690	catalepsy induced by morphine
0.4203813439	the snap index
0.4202839744	marker of inflammation
0.4202571989	deduced from
0.4202571989	withdrew from
0.4202571989	drainage from
0.4202278891	for cn poisoning
0.4201627606	gastric hemorrhage and
0.4200559206	amlodipine 5 mg
0.4200290203	osteoporosis and dementia in older women
0.4199932239	etoposide and cyclophosphamide
0.4198130894	a single pediatric institution
0.4197670503	doses daily
0.4197670503	daily doses
0.4197586879	right atria
0.4196209439	800 micrograms
0.4194971224	predictors of outcome
0.4193659679	significant complications
0.4193235569	il 3 and epo
0.4193231795	dexamethasone on days 15 and 16
0.4192435870	s sarcoma
0.4192160517	the intravesical route
0.4191083170	liver failure due to paracetamol overdose
0.4188986842	l dopa induced dyskinesia
0.4188914488	proliferation and survival
0.4187613294	an eastern cooperative oncology group study
0.4187523129	data revealed
0.4187030067	allopurinol plus
0.4186112664	received tamoxifen
0.4184941934	all von frey gauges
0.4184701050	mg x kg
0.4184457905	age 70 years
0.4184299505	incidence of subependymal
0.4183972526	combination of fentanyl and midazolam
0.4183660431	interaction with simvastatin
0.4182602649	bruising and pain
0.4182386693	always preceded
0.4181356241	injected into
0.4181323587	mg kg intravenously
0.4180895882	combination therapy of interferon and ribavirin
0.4180600874	questions about
0.4180370004	per minute per gram of dried
0.4179800096	neuropathic damage in rats
0.4179201854	born between
0.4178408210	72 hours
0.4177827492	dogs experienced
0.4177586879	0.025 capsaicin
0.4177030884	after pediatric lt
0.4176647047	in chronic prazosin treated shr
0.4176299125	acute liver
0.4176118700	increase in glomerular filtration
0.4175157806	features of encephalopathy
0.4174196166	the flavonoid apigenin
0.4174099026	cibenzoline for digitalis and adrenaline induced
0.4173015711	alfentanil 50 micrograms kg 1
0.4171768991	0 mg kg bw
0.4170629202	r = 0.95
0.4169884143	timolol and pilocarpine
0.4169815078	hepatitis b
0.4168788942	analysis of penicillin induced
0.4167575900	treated with pergolide
0.4164967009	non invasive
0.4164248412	dna in chinese
0.4163228726	reduction in gfr
0.4162750323	prolonged but reversible
0.4162347133	600 mg m2
0.4162239422	the nigrostriatal daergic
0.4162189197	this potentially fatal complication
0.4161603667	induction of apoptosis
0.4161000228	greater than
0.4160826166	history of cocaine abuse
0.4159496038	0.4 fold
0.4159478886	induced status epilepticus
0.4158008008	action of calcitonin
0.4157876135	drug administration
0.4156988435	brain expression of p glycoprotein
0.4156042631	signs of cardiovascular disease
0.4155783355	for intraocular retinoblastoma
0.4155438910	p bromophenyl
0.4154873266	against chemotherapy induced neurotoxicity
0.4154118816	patient controlled
0.4151502914	previous work
0.4150340111	an oral caffeine challenge test
0.4150242910	serve as
0.4149416916	5 ht1b receptors
0.4149396782	assessed by echocardiography
0.4149248909	diabetic nephropathy patients
0.4148674118	protected against
0.4148075143	blood pressure remained
0.4146852484	complication of treatment with tacrolimus ointment
0.4146674908	identifiable cause
0.4146462924	followed by prolonged anicteric cholestasis
0.4144561786	endothelin 1
0.4144246855	dramatic improvement in
0.4142898970	heart rate and blood pressure
0.4142191082	treatment for w ich
0.4141771289	preclinical and clinical studies
0.4141441568	these results extend previous
0.4141262873	levels of ldlr
0.4139725313	glycine site of nmda receptors in
0.4138384899	risk of venous thromboembolism
0.4138335492	significantly prolonged
0.4137965997	diagnosis of wegener
0.4137082314	performed continuous
0.4136902995	minutes after dobutamine
0.4136198653	platelet factor 4
0.4135547665	design and analysis
0.4135262220	increased risk of venous thromboembolism
0.4134846870	clinical trials comparing vnr with other
0.4134375968	epileptic rats
0.4133943222	bortezomib and dexamethasone
0.4133013195	mrna containing neurons within
0.4132927125	pethidine via
0.4132554075	a solitary kidney
0.4130968455	patients with idiopathic parkinson
0.4129492375	1.0 mg doxorubicin kg
0.4129276553	received 1.0 mg
0.4128658458	whole body
0.4128307012	reversal of hyperalgesia
0.4127488529	inflammatory and neuropathic
0.4125609139	derivatives of cck 5 8
0.4125519686	highly effective in protecting against pilocarpine
0.4125154890	evidence indicates
0.4125059325	increased in urothelium
0.4124487125	mg kg 1 i.v
0.4123974509	and managed aggressively
0.4123855559	divided into 4 groups
0.4123839595	cacl2 and 4 aminopyridine
0.4121867904	increased density
0.4121631434	acute stage
0.4121426059	preceded by
0.4121392827	combination with cnsb002
0.4120635670	naproxen seemed to
0.4120508994	urodynamic parameters in patients with oab
0.4119617195	dba 2
0.4119359301	5 ht2
0.4119254870	considerably less
0.4119161398	shortly after
0.4118703106	the perfusion defect correlated
0.4117779432	d amb
0.4117221003	plasma and urinary
0.4116789245	high dose dexmedetomidine as
0.4114996342	whole brain
0.4114530792	inhibitor of inducible no synthase
0.4114073567	incidence of ventricular arrhythmias
0.4113678341	international society of
0.4113506128	a healed myocardial infarction
0.4113126945	a prothrombotic mutation
0.4110900188	dose dependently decreased
0.4110822271	median survival time
0.4108822567	0 tetrahydropyranyladriamycin
0.4107615422	amino 5
0.4106729577	renal dysfunction in well compensated
0.4106488329	the ischemic territory
0.4105275141	induced de novo absence
0.4102029376	tolerability of nimesulide and paracetamol
0.4101892621	occurred more frequently
0.4100390057	p = 0.049
0.4098095366	ii to iv
0.4097964702	in women taking combined continuous ht
0.4097946144	clinical and laboratory
0.4097834896	depression of output of triglyceride
0.4097452521	caused by ampicillin
0.4096522623	mean pulmonary arterial pressure
0.4095806470	l dopa + benserazide
0.4095026417	dba 2 mice
0.4094398570	third generation
0.4093672795	withdrawal of amiodarone
0.4091107663	treatment with mefloquine
0.4090467307	52.7 u ml
0.4090380741	adverse drug
0.4088003827	toxicity of amb
0.4087814727	expression of vegf
0.4087655115	gad mrna containing neurons in
0.4086643714	cisplatin nephrotoxicity
0.4086335169	7h6 and zo 1
0.4085556897	pilocarpine induced seizure in
0.4085455088	rr =
0.4085098937	2 trifluoroethane
0.4084807137	the volar forearm
0.4082719113	inhibition of nos
0.4082178354	progression of weakness
0.4081941037	kg of metformin
0.4080928475	related to motor control
0.4080421456	almost completely abolished
0.4080126695	compared with control rats
0.4079839889	the ant mi group
0.4079661418	sub chronic
0.4079086790	loss of dystrophin
0.4077974317	p = 0.003
0.4074326778	effect of calcium chloride
0.4073195712	of iron dextran
0.4071955711	l med
0.4071897322	rodent models of
0.4071854505	shown to inhibit
0.4071732239	grade 3 4 neutropenia
0.4071321511	investigate whether
0.4071237195	this article
0.4070495745	plus maze test
0.4070339784	sensitive and resistant
0.4070119384	and urine concentrating ability
0.4069374732	versus 43
0.4068432387	pb treated rats
0.4068402529	potassium and calcium
0.4068336809	the mouse passive avoidance test
0.4065718094	effective and safe
0.4065661391	reduction or discontinuation
0.4064054385	with right bundle branch block
0.4063289560	hca =
0.4061957109	l sotalol for sustained ventricular tachyarrhythmias
0.4061658978	110 mm hg
0.4060226493	30 min before spontaneous alternation performance
0.4059771636	optimal treatment
0.4058072897	d ribose
0.4058038840	deliberate hypotension induced by labetalol with
0.4056086011	in adult emergency department seizure patients
0.4055996581	strokes in women
0.4055738967	= 0.58
0.4055137101	studies of left ventricular dysfunction
0.4055021026	240 min
0.4054859271	against isoproterenol induced myocardial
0.4054730650	patient experienced
0.4052661647	ca o
0.4052578321	total sleep time
0.4051891196	12 h access
0.4051856918	15 htn
0.4051771014	taken into account
0.4051729615	efficacy and tolerability
0.4051206324	dopaminergic therapy
0.4051078484	glutamate and capsaicin
0.4050924647	the 160 f2 pituitaries
0.4049053159	in streptozotocin diabetic rats
0.4048460416	results confirm
0.4046297192	in amygdala kindled rats
0.4046186352	median time to progression
0.4045894908	6 hydroxydopamine lesion
0.4042558502	the lithium pilocarpine model
0.4042243901	structurally different
0.4042156568	accounting for
0.4042079694	pretreatment with remifentanil
0.4041824983	5 fu fa
0.4037973806	in submitochondrial particles
0.4037115294	tolerance of pg
0.4033791264	and supraoptic nuclei
0.4033560177	nicotine and caffeine
0.4032429952	histamine h
0.4029709084	a phase iii clinical trial
0.4027650309	adult rats
0.4025811949	addition of phenylephrine
0.4023686775	types of epilepsy
0.4021919169	effective in decreasing
0.4021769625	patients without heart failure
0.4020884344	eighty seven
0.4020185317	good graft function
0.4019758481	prolonged duration of action of succinylcholine
0.4017907795	cyclophosphamide therapy
0.4017827405	progression of renal failure
0.4017330912	tetrameric enzyme in
0.4016580769	a minimally invasive
0.4016085022	failed to affect
0.4016027248	users of third generation
0.4015901739	reserpine and haloperidol
0.4014605912	both genotypes
0.4014105239	15 db
0.4012744417	estrogen induced
0.4012652396	ketoconazole treatment
0.4011062889	peripheral nervous system
0.4009404507	280 + 17
0.4009220959	reduced by 68
0.4009180767	cisplatin administration
0.4009013901	refractory to conventional
0.4008976268	siadh associated with vincristine
0.4008973614	subcutaneous administration
0.4008121399	a double blind placebo controlled
0.4007792656	and stevens johnson
0.4007651049	st changes
0.4007482993	l alpha gfc
0.4007060600	e antigen
0.4005898745	administered five times
0.4005614654	this cross sectional study
0.4005508976	dogs receiving
0.4005350146	weeks of age
0.4004587006	95 ci
0.4004461965	concern about
0.4004318338	the human cloned dopamine
0.4003576098	through 2010
0.4002876004	increased bladder
0.4001686237	defense system
0.4001300854	accompanied by
0.4001034181	epo and il 3
0.4000221569	grade 1 or 2
0.3998843201	hyperplastic changes
0.3998806683	acute and chronic nephrotoxicity
0.3997566503	na o and ca o
0.3997206611	closely correlate with
0.3997004402	moderate or severe
0.3996288966	mg dose of immediate release oxycodone
0.3996235577	alternate day
0.3995354464	cases of thrombotic microangiopathy
0.3994938321	fractures and quality of life
0.3993841818	thirty five
0.3993388469	induced hypertension
0.3993153879	per body surface area
0.3993129763	the opioid antagonist naloxone
0.3991860986	increased risk
0.3991748520	s psychiatric rating scale
0.3991177706	+ 0.3 kpa
0.3990579210	and bay k 8644
0.3989329101	information about
0.3986056287	in advanced idiopathic parkinson
0.3985138769	the isolated perfused rat kidney
0.3984444682	in urethane anesthetized rats
0.3984361311	ranged between
0.3983911606	induced pressor effect
0.3982427871	treatment with sulfadiazine
0.3982001783	treatment with gum arabic
0.3981497900	ifosfamide related
0.3981436358	masseter muscle rigidity during
0.3981417487	undertaken to investigate
0.3981171847	compared to controls
0.3979731897	a muscarinic cholinergic receptor
0.3979490766	atpase and mg + 2 atpase
0.3978928086	l dopa induced peak dose dyskinesia
0.3978576673	low and similar with quetiapine
0.3978481704	kg in td
0.3977609487	years after onset of lithium therapy
0.3975472215	mice treated with dox
0.3974985396	exercise and dobutamine
0.3974892843	or matched cohorts
0.3974127985	appears to represent
0.3972402124	right eye
0.3971637246	il 2
0.3971131052	respiratory paralysis produced by
0.3970814565	antithrombotic users vs
0.3970507365	past and present
0.3970181436	induced by chronic administration of desipramine
0.3968942385	doxorubicin treatment
0.3968086692	d glucosaminidase
0.3967992606	dosage of cm
0.3967920433	developed sudden
0.3967510018	the plain choline
0.3966906513	socs 1
0.3965816743	receptor mechanisms
0.3965386441	lithium treatment
0.3964708302	hyperactivity induced by d amphetamine
0.3963573289	initial value
0.3963217529	a hypocellular marrow
0.3962539384	analyses showed
0.3961855977	and salt loaded rats
0.3960603248	optical isomers of
0.3959935762	renin and endothelin 1
0.3959604460	abductor paralysis after botox injection for
0.3959448411	spinal cords of
0.3958707498	early and late
0.3958556275	risperidone induced
0.3955214733	good compliance
0.3954185586	diagnosed and treated
0.3954165918	recovery from anaesthesia
0.3954092823	recall after one week
0.3952986317	higher plasma
0.3951867784	risk of venous thromboembolism in women
0.3950457862	the urine albumin creatinine
0.3949998205	isomers of propranolol
0.3949640729	the l6 s1
0.3949563753	arterial blood pressure
0.3949508640	expression of p2x3 and nk1 receptors
0.3949265178	rise in serum creatinine
0.3949160084	mg m
0.3945534244	5 ht 2a
0.3945533876	fifty eight
0.3944693677	07 versus 0
0.3943772000	in chinese acromegalic patients
0.3943729531	5 fluorouracil
0.3943236315	azt treated
0.3943071787	95 confidence
0.3942864201	0mg kg for
0.3942693279	noradrenergic involvement in
0.3941426123	blood pressure 120
0.3940752131	than free dx
0.3940423216	management and prevention of cardiovascular disease
0.3940422658	an undiagnosed case of myotonia congenita
0.3940034572	routes of administration
0.3939149294	return to baseline
0.3938057140	d4 t
0.3937510018	the lumbar spine
0.3937115236	literature regarding
0.3936028780	the posterior sub tenon
0.3934485861	cocaine associated stroke
0.3934113824	ca1 region of
0.3933706187	elevated levels
0.3933183368	induced climbing
0.3932776887	responsible for
0.3930712287	before bone marrow transplantation
0.3930513636	effect of misoprostol on indomethacin induced
0.3929797359	a diagnostic dilemma
0.3927963363	induced lupus
0.3926646124	interactions between
0.3926511531	rats induced by adriamycin
0.3926046204	epo alone
0.3924390735	relapsed disease 10
0.3924085936	without known cvd
0.3923127432	chemotherapy for metastatic
0.3922214379	increased anxiety like behavior
0.3921603268	right lacnp
0.3921418804	products containing
0.3921334472	induced cardiotoxicity in mice
0.3921230793	patients receiving high
0.3920878765	risk for torsades de pointes
0.3920363113	relationships between
0.3919847184	became confused
0.3919441548	myocardial ischemia due to coronary
0.3919188581	children and adolescents
0.3918616579	influence of smoking
0.3918350204	increases in tremor and catalepsy
0.3917932884	complemented by
0.3917165172	d penicillamine induced aplastic anemia
0.3915928799	0.59 mg
0.3915580242	marked hypertension
0.3915397393	under general anesthesia
0.3915174383	s 53482
0.3913897923	risk of renal impairment
0.3913622622	p = 0.000
0.3912973423	with persistent sterile leukocyturia more frequently
0.3911705245	resulted in decreases in body weight
0.3910663254	pretreatment group
0.3909616241	ml 100 g min
0.3908830002	median duration of response
0.3908489754	well tolerated
0.3908420852	therapeutic targets for
0.3907307704	a synergistic nephrotoxic effect
0.3907088847	injection of thrombin
0.3906253799	paid to cardiac
0.3905102358	g dl
0.3904608220	a diminished tdr
0.3901900849	statin induced
0.3901564467	2.5 mg b.d
0.3900729107	methylprednisolone recommended by
0.3900253851	the left coronary artery
0.3900088360	0.1 vol
0.3899701167	patients developed
0.3898831583	renal or hepatic
0.3898797570	owing to
0.3898655812	patients with panic disorder
0.3898353245	distinguish between
0.3897606495	following molindone administration
0.3896369161	botox injections for
0.3896278217	formulation of propofol
0.3895545743	metolachlor use
0.3894636223	invasive carcinoma of
0.3894275492	habitual use of acetaminophen
0.3893477659	back pain
0.3893357457	g body wt
0.3893131219	parkinsonian like
0.3892925391	higher serum
0.3892597794	correlations between
0.3891988437	trazodone at 2.5 20 mg kg
0.3890353286	occurrence of serious signs of poisoning
0.3890073667	200 microg
0.3889905053	cardiovascular effects
0.3889265945	l 3h nicotine and 3h spiperone
0.3889095853	differ among
0.3888574439	background and purpose
0.3884550567	pinealectomized or
0.3884293812	prior to discharge
0.3883816843	beneficial effects of vitamin c administration
0.3883554359	case study
0.3882704879	effect of 5 httlpr or gender
0.3881966556	prompt discontinuation of
0.3881480186	a selective serotonin reuptake inhibitor
0.3881314118	regarded as
0.3879649166	a beta adrenoceptor antagonist
0.3879459818	scr increases or = 25
0.3878497542	cocaine injected
0.3877190049	chronic low
0.3876329135	phenobarbital therapy
0.3875815037	learning in healthy subjects and stroke
0.3874115857	experimental period
0.3873259661	in therapy na ve
0.3872912949	mean cmax mic
0.3872433612	sensitive indicator of
0.3872289154	5 nitro 2 furyl
0.3871562357	brain function
0.3871349504	underwent echocardiography before
0.3871114242	serious adverse drug reaction
0.3871101715	chronic epinephrine
0.3870609534	a long lasting depressive
0.3870008410	serum chemistry changes
0.3869626348	repeated doses of suxamethonium in children
0.3868981478	improved cardiac function and
0.3868898545	local anesthetic induced
0.3868548678	melatonin upon
0.3868544184	dfmo plus sulindac compared with
0.3868538887	normal controls
0.3865870341	echocardiographic data from
0.3865742214	using flexible
0.3864330480	susceptibility to subsequent
0.3864281989	gds 6 to 17
0.3863221009	patients with bipolar mania
0.3863031560	5 httlpr
0.3862762121	aor = 2
0.3862537358	saline or nicotine
0.3860980153	ml min at 4 months
0.3860922497	grade 3
0.3860265851	low level
0.3860078707	and 2e1 isoenzymes
0.3859605889	l w
0.3859371617	incremental doses of
0.3859264344	combination of carboplatin and liposomal doxorubicin
0.3859199233	and cis mrna levels
0.3858168770	a low osmolar
0.3857780797	relatively mild
0.3856808208	unmasked by
0.3856571945	studies confirmed
0.3855744759	octreotide induced
0.3854650169	non selective cox
0.3854078719	x 10
0.3853801025	captopril treatment
0.3853626787	ph 7
0.3853615857	cardiac mitochondrial
0.3852932311	combinations of ketamine and morphine
0.3852550514	testosterone and prolactin
0.3851412576	postoperative seizures
0.3850882950	the upper normal limit
0.3850719838	with high dose inhaled salbutamol
0.3848003877	received prophylactic
0.3847909109	day postlesion
0.3846098645	mean blood pressure decrease
0.3845574397	total doses
0.3844743933	maximum dose
0.3844260749	potentially useful
0.3843393471	the apical plasma membrane
0.3842902452	effect of modafinil
0.3842714066	effect of sm 5887
0.3842187975	ages 15
0.3841873948	full recovery
0.3840912806	hour continuous infusion of
0.3838522871	a significantly higher incidence
0.3837504249	inhibitor of angiotensin
0.3836884077	immediate release oxycodone in healthy
0.3833940523	maleate induced
0.3833551838	background and aim
0.3833321244	during alfentanil induced rigidity
0.3832163098	catalepsy and tremor
0.3829771099	this work evaluates
0.3827845893	treatment of hyperthyroidism
0.3826905309	the primary valve surgery
0.3826136816	decreased in lesioned
0.3825526780	produced significant
0.3824923190	a retrospective chart
0.3824837492	h norepinephrine uptake
0.3824661054	3 weekly bolus
0.3824411626	increase in locomotor activity of mice
0.3823898301	microinjection of ritanserin into
0.3823600374	dopamine levels
0.3823274825	single dose of dox
0.3823192698	in situ hybridization
0.3822491495	growth and development
0.3822245047	5.0 nmol mouse 1
0.3821891314	against pilocarpine induced seizure
0.3821506986	12 wk
0.3820843935	6 week double blind
0.3820793764	upper and lower
0.3819961016	acute or chronic
0.3818033579	induced by isoproterenol in rat heart
0.3817743863	induced encephalopathy
0.3816869499	administered dermally to
0.3816420769	days after se
0.3816286807	including age
0.3815706413	102 untreated
0.3815545450	actions of caffeine
0.3814072777	a greater opse
0.3813407211	chromosomes 10 and 18
0.3812750024	in myocyte cultures
0.3812478652	and lam resistance
0.3812407919	diagnosis of bipolar disorder
0.3812219253	resolved spontaneously following
0.3811627578	pain period
0.3811324692	320 25 mg
0.3810024411	more pronounced
0.3809324927	samples obtained from
0.3809114286	in salt loaded rats
0.3807932214	new referral
0.3806119641	schizophrenic patients
0.3805716782	dba 2 and c57bl 6 female
0.3805461280	data showed
0.3803949428	95 ic
0.3802239936	zidovudine and placebo
0.3801912517	year old boy
0.3801747972	rats treated with ee
0.3801287001	4 dihydroxyphenylacetic acid
0.3801080715	ninety six
0.3800469387	relationship between
0.3800329159	risk of bladder cancer
0.3800268885	antibiotic induced
0.3800031233	divided into four groups
0.3799073701	area under
0.3798858833	pre therapy
0.3798218502	2 dmh
0.3797454214	cyclosporine patients
0.3797317777	administration to rats
0.3795201759	2 hydroxypropyl
0.3795201759	2 propylpentanoyl
0.3795187640	after restarting
0.3795156167	adriamycin induced
0.3794839274	dexamethasone in combination with mesna
0.3794366241	the deep sedation group
0.3793547231	well established
0.3793329470	almost completely
0.3792827644	under neuraxial anesthesia
0.3791525612	exercise induced
0.3791069722	at repeat determination
0.3790019199	atypical antipsychotics such as
0.3789949357	of patients receiving high dose
0.3789203705	on male sexual dysfunction
0.3788956625	dex increased
0.3788322022	the pan temocapril group
0.3788013613	dsm iv diagnosis of
0.3787392317	clinical and experimental
0.3786920570	rats received
0.3786697749	these pollutants
0.3786184608	an outpatient basis
0.3785621588	symptoms of nms
0.3783895324	electrophysiological recording in
0.3783206837	more common adverse effects
0.3782697666	dependent effect
0.3782164919	greater deficits than
0.3780886459	compared to control mice
0.3779695651	induced by aconitine or ouabain
0.3778487352	increase in ve
0.3778424650	atra induced
0.3777482430	pain on injection
0.3777340482	intracerebroventricular injection of
0.3775633005	performed significantly
0.3774949190	male subjects
0.3774165679	excess of mb in warfarin
0.3771653145	ph 3
0.3771014601	the proximal tubules
0.3770724196	0 nonane
0.3770461695	proteinuria after conversion
0.3769171793	increased extracellular
0.3768450261	puromycin aminonucleoside induced
0.3767725333	year old women taking combined continuous
0.3767550459	commonly reported
0.3767449271	1 yl
0.3767048795	reported in association with cyclophosphamide treatment
0.3766324828	eighty one
0.3766063533	warfarin therapy
0.3765994903	patients receiving lithium
0.3765804622	sympathectomy or
0.3765585909	prenatal exposure to
0.3765375659	dynamic responses of
0.3764369909	binding and decreased
0.3763780683	study included
0.3763567542	increased oxidative stress
0.3763396111	patients with acute myocardial infarction
0.3762973846	a warfarin drug interaction
0.3762436104	real time
0.3761937470	structural elements of
0.3760662764	a nested case control
0.3759840557	receptor stimulating behavioral signs such as
0.3759662114	anemia while receiving
0.3759362537	a highly significant correlation
0.3758361641	cocaine related
0.3757384894	gastrointestinal side effects
0.3757142046	measured daily
0.3755759101	self limiting
0.3755415499	cox 2
0.3754735242	drug treatments
0.3753476746	contained significantly more cc than
0.3753311050	induced by kainic acid
0.3752968533	bromocriptine treatment
0.3752884249	present case
0.3751956591	180 min
0.3751571604	multiple modes of
0.3751327268	hepatitis b and rubella
0.3749534790	300 micromol
0.3749365499	decreased creatinine clearance
0.3749112354	the present study investigates
0.3748732336	substitute for
0.3748562058	0.5 microg kg min
0.3745888634	sumatriptan use
0.3744347352	long term hormone therapy for
0.3744302262	risk for developing
0.3742314140	the acetylcholine releaser
0.3742199156	flow and metabolism
0.3741253149	phenyl 2
0.3740193879	effects of pallidal neurotensin on haloperidol
0.3739621704	total intravenous
0.3739406839	phase b
0.3738639354	greater than or equal to
0.3738576312	80 mg valsartan
0.3738328880	transducer and activator of transcription 3
0.3735038934	functional and structural
0.3734903765	mg 24 hr
0.3734600942	density and or size
0.3734458012	year old girl
0.3734182698	drug induced hepatitis
0.3733879839	subcutaneously injected with
0.3733669761	250 mg m2
0.3732563874	characterized by
0.3731925230	taken together
0.3731661393	similar studies
0.3730081130	taking lithium
0.3729910440	hundred fifty
0.3729558409	activity in anesthetized
0.3729542561	immediate allergic
0.3728754319	exposed to cocaine
0.3728626839	objective response
0.3728600819	r units
0.3727951612	return to normal
0.3727458280	highly effective in protecting against
0.3725482018	the confusion assessment method
0.3724796904	during repair synthesis
0.3724658254	subjected to
0.3724577178	developed torsade de pointes
0.3724406837	increases in heart rate
0.3723334053	conventional treatment
0.3722571178	interact with
0.3721812536	days later
0.3720473739	0.3 micrograms
0.3719926706	patients with asthma
0.3718303095	explained by
0.3718276078	4.5 microg 0.5 microl
0.3717494225	as follows
0.3717234076	occurs more often
0.3717185631	expression in micturition
0.3716866514	des treatment
0.3716697749	5 mo
0.3716621234	acute myocardial ischemia
0.3715955615	to manage vasospasm
0.3715541714	compatible with
0.3713974776	leading to
0.3712277553	4 mg nicotine gum
0.3710678366	high rate
0.3710603041	clinical efficacy
0.3709834573	contribute to
0.3709499843	sexual side effects
0.3708893163	relation to cyclophosphamide
0.3708593272	did not reoccur
0.3708066660	preclinical and clinical
0.3707727052	antagonists on cyclophosphamide
0.3706204894	history of heparin induced thrombocytopenia
0.3706056823	fas in patients with acute liver
0.3704743193	45 126
0.3704698503	induced paw
0.3704197771	receiving cisplatin
0.3704013860	ethambutol therapy
0.3702469157	24 hours
0.3701402643	aged mice
0.3700548770	subgroup of patients
0.3698196617	patients with hemolysis during combination therapy
0.3697933279	b 24 76
0.3697790709	results in enhanced
0.3697398217	a persistent pain model
0.3697036160	na and ca
0.3696603641	this report describes
0.3694013860	srl therapy
0.3693550254	coincident with
0.3693231701	positive and negative
0.3692356717	loading capacity and
0.3692016145	aimed to
0.3691432105	gene and protein
0.3691334747	identified 27
0.3689931261	the sole sedative
0.3689488025	liver or kidney
0.3689209177	500 ng
0.3688853751	disappeared within 3 months
0.3688824960	a high sodium chloride diet
0.3688362103	of phase ii block
0.3688269687	+ 0.4
0.3687765113	onset of esrd
0.3686257950	a patient taking diphenylhydantoin
0.3685912576	frequently observed
0.3685373540	incontinence secondary to
0.3684891608	30 seconds
0.3684658254	tended to
0.3683077786	morphometric studies of
0.3683043548	patient with heparin induced
0.3682389100	an adherence
0.3682269329	resulting in symptomatic
0.3681467506	glomerular and tubular
0.3680927944	sodium and volume
0.3680298729	role of naloxone
0.3679667235	the exencephalic head
0.3679544715	immediately before
0.3679242664	the pre treatment evaluation
0.3679169916	microg side
0.3678918972	above mentioned
0.3678496365	phase 2 trial
0.3677964237	coincided with
0.3677925282	in rat substantia nigra
0.3677089904	a nerve conduction study
0.3676553918	models of inflammatory and neuropathic pain
0.3675940993	prerequisite for
0.3675940993	compensates for
0.3675642060	rats and dogs
0.3674562744	ii and iii
0.3674457399	2 minute bolus
0.3674078049	the maximum nonsedating doses
0.3673706084	defined as
0.3672947916	potential adverse effect of
0.3672912414	24 hour continuous infusion
0.3672622980	the doxorubicin treated group
0.3672554275	a perfusion defect
0.3670817518	neuropsychiatric like
0.3670666518	5 ht
0.3670538606	bipolar i
0.3670485710	treated successfully with
0.3668207687	effects of atorvastatin
0.3667797549	encephalopathy and cerebral
0.3666855568	months after starting
0.3666315444	neither verapamil nor
0.3665394196	cases with prolactin
0.3664422187	range proteinuria
0.3664137427	model of epilepsy induced by pilocarpine
0.3663750292	amiodarone therapy
0.3663189255	expression of fas
0.3662863102	glial changes
0.3662251191	and dc electrical
0.3662020841	using enzyme linked
0.3661495370	fatal myeloencephalopathy due to
0.3661065571	serum total
0.3660419519	tuberculosis patients
0.3659789975	effects did not exceed 50
0.3659351224	renal functional
0.3659218235	contributes to
0.3658207687	administration of rhigf
0.3658146320	that propranolol antagonizes
0.3656406384	40 50 per cent
0.3655460983	patients treated with haloperidol
0.3654837759	mg twice daily
0.3654314742	weeks of observation
0.3652674427	the perfusion defect
0.3652651104	headache and nausea
0.3652500340	presented with generalized
0.3652406818	well recognized
0.3652098774	down regulation
0.3649608935	adult outpatients with
0.3649430158	the prophylactic lamivudine group
0.3648686604	p 0.0001
0.3648517477	obstruction in patients with hiv
0.3648074591	containing regimen
0.3646594852	hypotension induced by labetalol with isoflurane
0.3646058415	the blood brain barrier
0.3645920158	did not modify
0.3645512173	acetazolamide induced
0.3645319410	deterioration of vision occurred despite
0.3645085823	failed to produce
0.3644912240	medial changes
0.3643348810	approximately 60
0.3643318486	models of hyperactivity
0.3642461105	induced burning
0.3641732340	history of cardiac disease
0.3640524426	a dose dependent fashion
0.3639353638	3.4 + 0.2
0.3638738558	agent in metastatic
0.3638176971	these variables returned
0.3638092245	latency to first seizure
0.3637607150	symptoms and signs
0.3637190522	significant clinical
0.3637152138	terbutaline on pn 2 to 5
0.3636886248	the propranolol insulin group
0.3632334837	on mouse motility
0.3632105377	300 mg kg
0.3632046031	measured again
0.3632006761	bipolar i vs
0.3631879501	major determinant of
0.3630642107	central and peripheral effects of nsaids
0.3627943622	sham rats
0.3627745207	widely available
0.3625742082	control serum
0.3625520697	developed thrombosis within
0.3624802139	quinine and 4 aminopyridine
0.3624140876	disease control
0.3623688423	the prostigmine morphine induced
0.3623241978	depressive like
0.3623113669	g m2
0.3623027618	the light sedation group
0.3621869583	significantly higher than
0.3621669224	the drd2 gene
0.3621255960	mental status changes
0.3619479620	range 18
0.3618800078	model of inflammatory
0.3618732264	induce hypotension
0.3618510944	infusion groups
0.3615830209	a dose dependent manner
0.3615510158	these findings demonstrate
0.3615479921	et 1
0.3615439463	iii r
0.3615411240	cells in culture
0.3615039583	receiving continuous infusion of 5 fu
0.3614701466	patients meeting
0.3614589225	selective and non selective cox 2
0.3614395965	women with hiv
0.3613106549	animals and humans
0.3610834943	hepatotoxicity associated with sulfasalazine
0.3610793938	micrograms h 1
0.3609639259	150 200 g
0.3609497398	per minute
0.3608716768	cystitis in humans
0.3608003224	case of propylthiouracil
0.3607098631	mental status returned to normal within
0.3605227312	the temporal quadrant
0.3604993516	divided over
0.3604977903	intravenous injection
0.3603906091	the normal sodium group
0.3603664610	7.5 15 microg 0.5 microl
0.3602613325	the adriamycin treated cells
0.3602224744	methylphenidate intake in
0.3601739425	the low sodium group
0.3601140952	including hypotension
0.3600487163	brought about by
0.3600176339	chronic alpha 1
0.3600067542	with paws and claws
0.3599168310	patients with newly diagnosed
0.3597955098	mg day for 9 weeks
0.3597839600	+ 0.003
0.3596064742	leading causes of death
0.3595552327	between june
0.3595386817	recently become
0.3591843372	molecular layer of
0.3591775656	mp before and after tdi
0.3591672168	self reported
0.3591643650	grade 3 4
0.3590651965	increased risk for torsades de pointes
0.3590133923	rats exhibited
0.3589985824	served as
0.3589889800	subjected to surgery
0.3588397317	deoxycholic acid than
0.3587275563	n pyrimidinyl 2
0.3586734655	the test environment
0.3584707081	protection against doxorubicin induced
0.3584055185	0.25 per cent
0.3583612050	showed abnormal
0.3583309528	in hiv positive patients
0.3581821965	receiving amiodarone
0.3581137922	hepatotoxicity of amiodarone
0.3580955277	dyskinesias in parkinson
0.3580171676	gentamicin nephrotoxicity in rats
0.3579013203	mesenchymal tumors in
0.3579012785	medical therapy
0.3578415290	rigidity and behavior
0.3576283158	p 0.01
0.3575362932	effect of glyceryl trinitrate
0.3574276779	scr increases or = 0
0.3573026667	therapy for parkinson
0.3572668457	relatively safe for healthy younger women
0.3572311842	second experiment
0.3571094604	related adverse events
0.3570090772	patients suffering from severe
0.3569287088	anticoagulated with
0.3569287088	dealing with
0.3569270764	passage of mannitol into
0.3568892690	and prior myocardial infarction
0.3568826138	metabolite of cocaine
0.3568581378	acute coronary
0.3567642526	role of oxidative
0.3567199763	help prevent
0.3567087574	p less than 0.005
0.3566614768	studies revealed
0.3566324321	tacrolimus side effects
0.3565861897	exposure to diazinon
0.3565552827	urea and creatinine
0.3564446994	48 h
0.3564370523	aor = 3
0.3562402983	the amphetamine induced locomotion
0.3561843789	caused significant
0.3560446426	conducted to examine
0.3560087225	l dopa induced dyskinesias
0.3560074018	iii v
0.3559410742	choice for
0.3558968774	distinguished from
0.3555865480	association between
0.3555772418	the minimum effective plasma
0.3555445495	receiving heparin
0.3554663212	attributed to
0.3554002714	a passive avoidance task
0.3553121280	cases of vte
0.3552274507	reduced locomotor activity
0.3551291342	cefonicid or cefazedone to
0.3551034045	chemically related to
0.3549702455	resulting from
0.3549694881	question as
0.3549411576	bradycardia and hypotension
0.3549409791	patients with coronary disease
0.3549356526	induced cardiomyopathy
0.3549327080	second episode
0.3548926923	strain of mice
0.3548879661	hypotension and bradycardia
0.3547554786	5.6 on pod
0.3547531366	treated and untreated
0.3547276808	cocaine or amphetamine
0.3546294935	even though
0.3546022676	types of experimental
0.3545634079	contrast induced
0.3545287474	patients receiving amb and spironolactone
0.3543984833	both sides
0.3543949695	side effects
0.3543368903	a 86929
0.3543049303	patients with fulminant hepatic failure
0.3542887275	sodium and potassium
0.3542043015	+ 5 mumol mg crea
0.3541652821	of implanted eyes
0.3541547498	biochemical and behavioral
0.3540089820	serious adverse events
0.3539012375	difference regarding
0.3538564057	progression of nephropathy
0.3538326929	extreme caution in
0.3537674047	third line therapy
0.3537048279	16 mg kg total dose
0.3536167257	threshold for pilocarpine
0.3535797902	lethal doses of
0.3535644306	this question
0.3535079725	drop in blood pressure
0.3534660596	decreased plasma
0.3534256355	approximately 40
0.3533277579	risperidone and haloperidol
0.3533076568	warfarin treatment
0.3532930502	practical considerations of argatroban therapy in
0.3532487896	significantly more likely to experience
0.3531637322	in normal conscious rats
0.3531625176	mz use
0.3530752872	important cause of morbidity and mortality
0.3530098495	300 mg m2
0.3529811300	2002 and december
0.3529318928	sequential observations of
0.3529241234	determined only in cases of low
0.3529070023	in chronically treated rats
0.3528817061	the multiple dose study
0.3528782982	commonly used
0.3527266686	the initial mr study
0.3526294774	compared to amiloride
0.3525956416	p 0.001
0.3525027831	atropine like
0.3524495637	and arousal regulation
0.3524368327	g dl hemoglobin
0.3524232683	designed to determine
0.3522486876	of tacrolimus induced neurotoxicity
0.3521796607	alf due to paracetamol
0.3521349333	exhibited similar
0.3521132734	markers of myocardial
0.3520090925	tam induced
0.3519997266	the sole sedative for pediatric mri
0.3519853686	animals without seizures
0.3519747913	rare side effect
0.3519378714	induced nephrotic syndrome
0.3519344225	small numbers of
0.3518393828	the novel exploratory box
0.3517723228	a actinin
0.3515764306	6 months post cab
0.3515508838	rather than
0.3515149745	control women
0.3514968034	form of stress
0.3512567506	dexamethasone treatment
0.3512408113	locomotor activity in animals
0.3512252072	5 ht1b
0.3511454720	aimed at
0.3511208737	the present report describes
0.3510925693	poly l
0.3510893928	mediated through
0.3510627632	cocaine and ethanol
0.3510137989	s disease rating scale
0.3510111303	mean arterial pressure
0.3509844565	history of underlying
0.3509287221	of timolol hydrochlorothiazide
0.3508147004	ml min at 6 months
0.3507747644	ethyl 2
0.3507399739	potentially serious
0.3507370760	10 sucrose
0.3506953906	total cumulative dose of
0.3506518278	mrna and protein
0.3506469286	urinary symptoms and quality of life
0.3505993234	amiodarone treatment
0.3505501757	induced by l norepinephrine
0.3505078731	link between
0.3504781735	relatively short
0.3504419259	480 mg caffeine
0.3504092467	penicillin g
0.3504062675	diagnostic value
0.3502276740	renal function in patients with chf
0.3501752743	treatment with antithrombin
0.3501717625	cross over
0.3501694881	created by
0.3501008990	follow up data
0.3500428084	sixty percent
0.3500392099	severe progressive
0.3500206445	twice daily regimen
0.3499955179	st t
0.3499436575	rapid adjustment to
0.3499381747	old girl
0.3499361804	loss of vision
0.3498397752	first line
0.3497868873	pain free
0.3497044612	a cross sectional study
0.3496190063	hypokalaemia during
0.3494521691	an infrequent complication
0.3494137496	the heavy drinkers
0.3493488238	urgent need for
0.3493426693	developed severe
0.3492660392	differentiation between
0.3492540791	epinephrine treatment
0.3491613394	the activity increasing effects of morphine
0.3491463350	phenylephrine induced
0.3491202406	resolved upon
0.3491003665	novel compound
0.3490968636	levetiracetam treatment
0.3490687030	men and 6 women
0.3488385307	1.5 and or 5.0 nmol mouse
0.3487724468	users of aspirin
0.3486414832	a calcification inhibitor
0.3485647351	reduced cardiotoxicity
0.3484712574	5 fluorouracil folinic acid
0.3484586073	times higher than
0.3484417886	cin developed
0.3484005562	both timolol solution and timolol gellan
0.3483573417	warfarin induced
0.3483458137	hypotension or bradycardia
0.3482439405	seventy nine
0.3482259196	most commonly
0.3481562694	days of age
0.3478692591	1500 mg
0.3477887463	dexamethasone induced hypertension in
0.3476946734	n = 200 ears
0.3476890664	commonly prescribed for
0.3475741562	well compensated
0.3475736517	this country
0.3473775813	unable to
0.3472508781	chronic oral
0.3470650023	induced liver damage
0.3470074938	known coronary artery disease
0.3469774678	the emergency nurse
0.3468905625	model group
0.3468509740	haloperidol administration
0.3467852186	risk of rhabdomyolysis
0.3467671095	immediate headache
0.3467090146	blood pressure and plasma
0.3466116467	types of human
0.3465590903	the contralateral limbs
0.3465585126	1000 micrograms
0.3464738551	na + k +
0.3464692151	decided to
0.3464692151	predispose to
0.3462222900	led to
0.3462017522	a lesser extent
0.3461841199	woman developed
0.3461543639	methyl 6
0.3461480308	rate of 70 min
0.3460513942	the maximum nonsedating
0.3459596729	compared with
0.3458824514	co morbidity
0.3458405496	lipoproteins during
0.3458367989	control and experimental
0.3457051103	prior dosing with
0.3456585661	w v
0.3456533435	renal and hepatic
0.3456333071	result from
0.3456259251	more influenced by adenosine receptor agonists
0.3456220690	year old caucasian woman
0.3455502434	susceptible patients
0.3454822055	prolonged administration
0.3454788042	learning of rats
0.3453770840	complained of
0.3453372074	average follow up
0.3453318937	patients with md
0.3452673414	anxiogenic effects of
0.3452243416	infections in cancer
0.3452127089	82 evaluable patients
0.3451978815	after treatment with injectable artesunate
0.3451928031	treatment for breast cancer
0.3451700773	drug delivery system
0.3451227266	low risk patients
0.3445435569	onset of action
0.3444221411	days of des
0.3442501028	did not recur
0.3442370155	mother to infant infection by
0.3441390034	focus on
0.3440438403	characterized by marked
0.3439691467	stage iii and
0.3439658286	calculated based on
0.3439566893	during halothane anaesthesia
0.3438564976	hour period after
0.3437946676	approximately 12
0.3437760734	nimo alone
0.3437745706	caused by metoclopramide
0.3437666233	rise in blood pressure
0.3437258747	25 microgram ml
0.3436339795	inability to
0.3435302199	rats and mice
0.3434275169	p = 0.005
0.3434251302	revealed severe
0.3433091469	prevalence rates and
0.3432004293	thrombosis in patients with heparin induced
0.3431766575	responses to calcium
0.3430958750	an irritant
0.3430840376	increased with age
0.3429491533	bis score corresponding to
0.3429470950	400 micrograms
0.3428905048	protect against
0.3428408924	oc use
0.3428265542	induced aplastic anemia
0.3427310280	includes over
0.3425919793	propranolol and b 24 76
0.3424586856	s hind foot to passive
0.3424302920	switchers from
0.3424089493	in inflamed preparations
0.3424031527	and oxygen saturations
0.3423014035	paid to
0.3422706521	120 minutes
0.3421469585	by intratympanic instillation of lignocaine
0.3419103842	months of hyperprolactinemia
0.3419069781	differ between
0.3418793574	l type ca
0.3417697536	the lateral position
0.3417694155	the phasic component
0.3417317734	1.5 fold
0.3416675323	high doses of cimetidine
0.3416313355	the median dose intensity
0.3416238393	oral administration of
0.3414819764	model of epilepsy
0.3414532361	combination of cocaine and diazepam
0.3414293305	did not differ
0.3414243451	very good partial response
0.3413955513	protect against peripheral neurotoxicity of
0.3413855531	following penicillin g injection
0.3412762090	association of alcohol
0.3411858082	and small coronary arteries
0.3410649216	an inflammatory origin
0.3408683718	inhibited mean nte activity in
0.3408293835	drug treatment
0.3406879121	differences between groups
0.3406776224	decreased blood pressure and heart rate
0.3406722961	hours after exposure
0.3405892779	5 mg kg i.v
0.3405093009	p p interval
0.3404704733	interferes with
0.3404646323	male patients
0.3404079210	ethyl 1
0.3403468843	facilitation of memory retrieval by
0.3401943635	0.1 1 mg kg p.o
0.3401586726	severity of succinylcholine
0.3401039786	secondary to lithium therapy
0.3400726192	at 4000hz
0.3400726192	at enrollment
0.3400530941	an urgent need to raise awareness
0.3400127328	higher than
0.3400049044	irreversible damage to
0.3399956961	1 instance
0.3398993216	non txg mice
0.3397375661	associations between
0.3396944709	in heart failure patients
0.3396754573	intravenous administration of
0.3395582462	and amphetamine induced locomotor
0.3395453949	twenty nine
0.3393283747	injection of u ii
0.3393121083	approximately 50
0.3392562643	pentazocine induced
0.3391843782	caused by hyperkalemia
0.3391722893	few reports
0.3391193879	known to block voltage
0.3389253192	1 good quality
0.3387486670	slightly less
0.3386664523	all reported cases
0.3386124827	induced peripheral neuropathy
0.3385435203	plasma level
0.3385062664	increase in breast
0.3384806187	rate of ymdd motif mutants in
0.3384691427	studied in cats
0.3384300873	admitted to hospital
0.3384167472	grade 3 4 neutropenia and thrombocytopenia
0.3384018854	induced by ifs
0.3384017271	maximal ctnt and
0.3383968944	intrathecal injection of
0.3382894637	relatively healthy
0.3382549454	than placebo treated patients
0.3382520718	selective and non selective
0.3381457956	amnesia produced by
0.3381455962	stopped treatment
0.3381416274	mean sitting
0.3380275106	troponin i
0.3380056612	x minute
0.3379527786	based on
0.3379520095	analgesic nephropathy in
0.3378621890	pathological changes
0.3378130331	a poor prognosis
0.3378013834	45 min
0.3376802428	10 mg kg sc
0.3374582302	elevations greater than
0.3374347428	symptom duration prior to initiation of
0.3373486583	smaller than
0.3373219301	basal functioning of
0.3371718730	long term treatment with
0.3371549855	antiviral therapy
0.3370746983	induced myocardial damage
0.3370668265	key factors in
0.3368618459	needed to determine
0.3368302521	intake at doses of 100
0.3366058537	three carcinogens
0.3364295918	t cell stimulation
0.3363566440	mg day
0.3362718406	the ventricular tachyarrhythmia
0.3361667163	mg m2 on days
0.3361627274	p 0.005
0.3361272761	effective and well tolerated
0.3360462449	phase i
0.3359354974	soon after
0.3358798829	a noncompetitive n methyl d aspartate
0.3358718872	non transgenic
0.3358472116	nausea prior to discharge from
0.3358277664	induced torsades de pointes
0.3357679006	alcohol use
0.3357321197	allocated to
0.3356235966	depend on
0.3356063807	this article reports
0.3355862636	years previously
0.3355340785	per cycle
0.3354083810	correlated with
0.3352823465	proteinuria and acute renal failure
0.3352778699	380 mg kg
0.3352692705	suggested to model
0.3352585221	staining for serum
0.3351453236	the hemorrhagic phenotype
0.3350726925	s 312 d
0.3350498459	groups ii
0.3350349351	pravastatin associated
0.3350001204	initial treatment
0.3349949870	pilocarpine induced seizures in
0.3349677227	residual confounding by
0.3349501119	hippocampus and cortex
0.3348327041	resulted in
0.3346831810	cases of breast cancer
0.3346799673	predisposes to
0.3346799673	elected to
0.3346799673	preferable to
0.3346799673	responds to
0.3346055837	0.5 mg doxorubicin kg
0.3345336695	arteritis induced in rats by
0.3344976126	and punctate evoked
0.3344938018	24 hour
0.3342600288	hypertensive patients
0.3342498392	= 0.61
0.3342266501	active drug
0.3341863120	successfully treated with
0.3341705822	ed 1 positive cells on
0.3341422749	showed significant
0.3341266594	reduced compared to controls
0.3341204936	pooled analysis of
0.3340829172	no prior psychiatric
0.3339644760	safe and well tolerated
0.3338831191	no significant differences
0.3338435771	contribution of
0.3338335440	focal lesions in
0.3337923411	0.9 saline
0.3336773039	toxicity of high dose
0.3335770123	tamoxifen use
0.3335390324	widespread use
0.3335114807	subacute exposure to
0.3334415154	na o
0.3333711114	investigated whether
0.3332933535	clinicians need to
0.3331332653	increase of il 6
0.3331182488	60 minutes
0.3329901493	120 mg m2
0.3329146869	following cta
0.3329057275	two mouse lines
0.3328934411	women with diabetes
0.3327626685	diuretic use
0.3327390209	t wave
0.3327246418	an eastern cooperative oncology group
0.3326631536	succinylcholine administration
0.3326466110	non reactive
0.3326152213	the iohexol group
0.3325216356	a newborn infant
0.3323890465	plasma and tissue
0.3323187205	cognitive and functional
0.3321946168	further confirmed by histopathological examination
0.3321109237	oral exposure
0.3320320357	habituated to
0.3320320357	fails to
0.3320320357	apply to
0.3320320357	wanted to
0.3319272128	1994 to 2003
0.3318203104	difference between
0.3318119249	potentiation of morphine
0.3318107845	attributable to
0.3317748693	225 mg
0.3317668289	induced by haloperidol
0.3317408048	depends on
0.3317355316	reduced blood pressure
0.3316013159	increased serum
0.3315997537	hemoglobin e
0.3315294242	p = 0.036
0.3315294242	p = 0.007
0.3314418857	much less
0.3313982049	replaced by
0.3312756873	similarities between
0.3310708083	high dose intravenous
0.3310548901	occurring during
0.3309372842	age of 50 years
0.3308639444	patients evaluable for response
0.3308281196	decreased locomotor activity
0.3308037476	six cases of cauda equina syndrome
0.3306962158	interfere with
0.3306713717	or photophobia
0.3306642484	drug therapy
0.3306209934	vaccinated in
0.3305877947	exhibited significantly
0.3305516324	13.3 days
0.3304854394	findings indicate
0.3304122712	preservation of
0.3303778506	aminoglycoside induced
0.3303320446	twice daily dosage
0.3302875147	toxicity studies
0.3301787605	s fire
0.3301747236	treatment mortality
0.3301644193	bupivacaine levels
0.3301575691	containing cocs
0.3301278706	fold more potent than
0.3300378244	induction of anaesthesia
0.3299332896	these two paradigms
0.3298650359	80 minutes
0.3298601563	given orally
0.3297359177	p = 0.027
0.3297359177	p = 0.006
0.3297043900	lower than
0.3296148920	alpha t
0.3296065393	desipramine induced
0.3295630057	proteinuria associated with srl
0.3295420056	groups revealed
0.3295150917	latent period and
0.3294698092	well understood
0.3294688078	chronic amphotericin b
0.3293954198	some neuroactive steroids
0.3292521100	groups 3 and 4
0.3291334439	this case documents
0.3289777689	tremor and catalepsy
0.3289777689	ratio of cimetidine
0.3289750067	of gad mrna containing neurons
0.3289202092	relationship between nicotine induced seizures and
0.3289008895	lithium and pilocarpine
0.3288510213	93 mg dl
0.3288055594	p p intervals
0.3286818406	increase in electromyographic activity
0.3286410239	synthesize dna in response to
0.3285614893	patients with fibrinolytic
0.3285507823	potentiation of bupivacaine
0.3285469157	plasma levels
0.3285385737	mug g
0.3284830812	+ 17.9
0.3284811962	treated with propylthiouracil
0.3284011079	the anti amnesic
0.3283822535	significantly greater with asenapine at
0.3283631359	indicative of
0.3283232778	298 + 7 vs
0.3282032535	three times
0.3281758880	human renal
0.3281196953	aconitine induced
0.3281091754	treatment with ciprofloxacin
0.3280723749	+ 0.9
0.3279294715	lithium levels
0.3279057034	cardiac dilation and
0.3278581373	of isoproterenol induced myocardial
0.3278545949	cord damage in
0.3278541608	published data on
0.3277591780	j mice
0.3277363493	in dexamethasone induced hypertension
0.3277228758	developed acute
0.3276959762	5 mg amlodipine
0.3276533037	reduction in body weight
0.3276435377	did not alter
0.3274558317	frequently in young
0.3274375874	administration of rifampicin
0.3274369517	indomethacin therapy
0.3274222609	the pan group
0.3274140323	located at terminals of
0.3273697730	effect of lindane
0.3273422202	adr induced
0.3271753028	interaction between
0.3271253565	clotting time
0.3270908443	decreases in arterial blood pressure and
0.3270603966	antiarrhythmic effects of
0.3270557131	classified as
0.3270176797	a double blind multicenter study
0.3270131564	rat brain
0.3268877081	year old japanese
0.3267768794	after dacarbazine
0.3267768794	after commencing
0.3267754132	sudden onset of
0.3267348072	level of potassium
0.3266241161	histological changes
0.3265841692	other organs
0.3265526741	kg per min
0.3263101590	risk of switching
0.3262889427	very rarely
0.3262774536	the short term safety
0.3262601798	very carefully
0.3262336877	almost restored
0.3261662249	fell from
0.3260492483	52 weeks
0.3260489240	cessation of therapy
0.3260071776	right lateral
0.3259095120	requirement for
0.3258873778	rosaceiform dermatitis as
0.3257147126	dose levels
0.3257021558	children with wilms tumor of
0.3256843850	intraperitoneally for 3
0.3256549690	sensory and motor
0.3256322208	these findings suggest
0.3256045958	outcomes of interest
0.3255786647	vpa treatment
0.3254870493	mv s
0.3253594275	induced polyuria
0.3251885011	p 0.05
0.3251784315	lead to
0.3251307185	dyskinesias in patients with parkinson
0.3251293126	in special populations
0.3250576884	patients with relapsed refractory
0.3250021252	carbamazepine therapy
0.3250019633	high dose infusion
0.3249810047	useful for identifying
0.3249740029	desipramine alone
0.3249623325	300 micromol l
0.3249598380	200 micrograms
0.3249123424	pupillary response to
0.3247226626	depletion of dopamine in
0.3247073609	case report and review of
0.3246757967	stimulant use
0.3246552074	after pan injection
0.3246369617	induced morphologic changes
0.3246105444	hyperactivity in rats
0.3245733429	normal diet
0.3245164232	sulfasalazine induced
0.3244462629	beneficial effect of
0.3244161109	cholesterol decreased
0.3244030144	stroke like
0.3242724376	rates of events
0.3241702578	b2 receptors in disruption of
0.3241454921	weekly doses of 4
0.3240458652	in susceptible persons
0.3240332938	embryopathy with
0.3240332938	linearly with
0.3239730990	significant differences between
0.3238807238	during organogenesis
0.3238752447	days after stz
0.3238451338	approximately 30
0.3237769253	the anatomic area at risk
0.3237650957	repeat users of
0.3237449999	p = 0.035
0.3237449999	p = 0.009
0.3237449999	p = 0.014
0.3237449999	p = 0.017
0.3236147826	210 cases
0.3236038245	paclitaxel and cisplatin
0.3235975171	failed to
0.3235495256	primarily from muscle atrophy and
0.3235347060	heart and liver
0.3233948192	200 mg ketoconazole
0.3233404766	patients taking
0.3233134629	month later
0.3231935898	significant protection against
0.3230485996	ovarian failure after
0.3230468086	plasma and urine
0.3230432940	the open field test
0.3230389258	signs of milk fever during
0.3229777833	hemolysis and acute renal failure following
0.3229498192	p = 0.016
0.3229193755	significantly lower than
0.3229038563	to classic nsaids
0.3227596787	between july
0.3226341118	stimulation revealed
0.3225729916	stress incontinence while
0.3225657486	relatively healthy 50 to 59
0.3225242198	acetylcholine induced
0.3225168087	between january
0.3223923215	the rc group
0.3222499081	diet containing
0.3221499180	an autoimmune hemolytic anemia
0.3221034936	secretion associated with desvenlafaxine
0.3220553845	off period
0.3219929893	amb alone
0.3219886676	azidothymidine induced
0.3219886676	muscimol induced
0.3219514934	p = 0.020
0.3219029274	incidence and severity
0.3218406047	injection of suxamethonium
0.3214933887	did not affect
0.3212561703	cocaine use
0.3211559793	and extrahepatic cholestasis
0.3211470416	physiology and
0.3211019917	72 h
0.3210881469	new or worsening
0.3210609747	a statistically significant decrease
0.3210336331	fifty one
0.3209011959	amelioration of
0.3208793061	patients with inoperable
0.3207660535	crack cocaine use
0.3207157801	among non users of aspirin
0.3206963061	urinary excretion of
0.3206777725	patients with essential hypertension
0.3206516512	liver and muscle
0.3206471792	the lithium induced diabetes insipidus
0.3206443684	dose of clarithromycin
0.3206345650	cardioprotective effect of
0.3206310125	sensitive k
0.3206022440	pretreated with saline
0.3205941413	an interesting
0.3204923164	declines in
0.3204444173	pulmonary and renal
0.3203931221	1.25 mg
0.3203908443	control dogs and
0.3203810866	7931 +
0.3203810866	8.8 +
0.3203810866	33.6 +
0.3203763826	20 g ethinyloestradiol
0.3203107742	haematuria and
0.3202974459	currently undergoing
0.3201811903	severe toxicity
0.3201231669	not otherwise specified
0.3200866215	24 h after gamma hch
0.3198641178	participate in
0.3196852298	stimulant induced
0.3196706194	clinical course
0.3195561611	effect of l dopa
0.3195426526	the inclusion criteria
0.3194715786	order to evaluate
0.3193839557	aged 18
0.3193668128	lidocaine in patients with cocaine
0.3193572337	expression of beclin 1
0.3193469625	4 week cycle
0.3192537940	gradually returned to
0.3192268791	completely antagonized by
0.3192180311	0.6 mmhg
0.3191947322	treated with
0.3191122797	increase in heart rate and
0.3189613278	in micturition reflexes
0.3188573085	the other hand
0.3188343894	kidney perfused with
0.3187599622	doses of mz
0.3187311782	saline or morphine
0.3186784315	appears to
0.3186423169	following bone marrow transplantation
0.3185978831	360 mg
0.3185850502	effects of magnesium
0.3185807666	transplant patients treated with
0.3185358308	ammonium levels and
0.3184500487	four point scale by one investigator
0.3184152861	developed large
0.3183227573	relative to baseline
0.3182799041	valproate induced
0.3182021625	thought to
0.3181612020	consistent with
0.3181042023	the present study
0.3180343841	shown to block
0.3180245357	through central alpha
0.3180073387	minutes after administration
0.3179966384	treated rats compared with controls
0.3179230176	h after exposure to gamma hch
0.3179203545	more potently than
0.3179064205	long term intake of
0.3178894848	morphological analysis of
0.3178603272	termination of
0.3178532028	on cardiovascular function
0.3177934431	patients with cocaine
0.3177125871	large doses of
0.3177057060	irrespective of
0.3174649213	psychiatric patients
0.3173960050	injections of meth
0.3173047021	infusion group
0.3171080516	oral administration
0.3170903092	and functional impairments
0.3170879569	clinical effects
0.3170028692	infusion of ifosfamide
0.3170025875	the experimental environment
0.3169849189	determination of plasma
0.3169368389	non convulsant
0.3168719347	differences between
0.3168581814	parts of
0.3168513394	duration of treatment
0.3168170097	protein abundance of
0.3168167129	disorder caused
0.3166522294	proteinuria appeared in
0.3166454717	levels of cholesterol
0.3165989404	add on
0.3164940507	pain responses
0.3164775935	penicillamine and chloroquine therapy for
0.3164743358	and serotonergic neurotransmission
0.3164686769	these results suggest
0.3164509451	clinical pain
0.3164270041	patients with hyperthyroidism
0.3163167420	older patients
0.3163154527	sought to
0.3162882393	administration of nefiracetam
0.3162744508	effects of antithrombin
0.3161521630	marketed in
0.3161491682	equally effective in
0.3161215647	s space
0.3160708140	of crocus sativus l
0.3160338179	developed moderate to severe
0.3160217921	the volume density of secretory granules
0.3160147664	to 80.0
0.3159543773	effects of isotonic sodium chloride with
0.3159255894	reported herein
0.3158826935	activity of caspase 3
0.3158380018	female rats showed
0.3157488013	risk of vte
0.3157098200	leads to
0.3157019322	subarachnoid injection of
0.3156125953	mg kg iv
0.3155768754	commencement of therapy
0.3154715053	female patient
0.3154600779	case control
0.3154235187	cases of confusion
0.3153832766	exposure days
0.3153255261	cocaine and amphetamine
0.3152496121	the entire cohort
0.3152078630	different lobular distributions of
0.3151656375	ipsilateral vocal cord paralysis in
0.3151170536	haloperidol produced
0.3150246596	mm hg sem to
0.3149858847	effects differ for
0.3149616130	chronic hepatitis c
0.3149194200	young and old
0.3148747315	patients with pre existing
0.3148052439	pilocarpine treated and
0.3147809997	to date
0.3146423169	and analgesic requirements
0.3146343268	week 24
0.3145583716	immediately after injection
0.3144664355	every other day
0.3143990519	contributor to
0.3143960755	rats results in
0.3143569430	no significant difference
0.3143347060	microinjections of
0.3142138219	heart rate and decreased
0.3141432925	killed before
0.3140902058	and n acetyl beta glucosaminidase
0.3140828815	differential response to
0.3140526482	inoculation of
0.3140101730	induced myocardial infarction in rats
0.3139701989	a 77636
0.3139456859	oral and parenteral challenges with
0.3138569787	for pediatric mri
0.3138562454	reports indicate
0.3137982689	hepatic and renal
0.3137919213	significant increases
0.3137778723	under local anesthesia
0.3137472235	avoided if
0.3137316458	time intervals
0.3136726402	more widespread
0.3136222130	3.2 mg kg
0.3135352023	the passive avoidance task
0.3133414000	contribution to
0.3132185560	hypotension occurred
0.3132147687	the catechol and hydroquinone metabolites
0.3132013343	to better understand
0.3131993850	cytochrome c
0.3131984675	capable of
0.3131308773	pituitary response to
0.3131221798	interactive effects of
0.3130634769	most likely
0.3130433301	stage c
0.3130395638	reduction of ribavirin
0.3130337473	other countries
0.3129686841	long term effects of vincristine on
0.3129593337	tacrolimus therapy
0.3129471972	p less than 0.01
0.3129306997	duration of therapy
0.3129151663	delay between
0.3129020106	increase of plasma
0.3128859450	versus 21
0.3128051990	feature of
0.3126997363	administration of alendronate
0.3126822798	32 episodes
0.3126811545	patients on long term
0.3126800562	containing multivitamin
0.3126000062	clipping of
0.3124862724	similar results
0.3122115545	rifampicin associated
0.3121531863	p less than 0.05
0.3120642395	a low yield
0.3120459854	days after transplantation
0.3120432668	still evident
0.3119403583	a potential hazard
0.3119344670	normal tissue
0.3118038824	by prejunctional
0.3116565663	entered into
0.3114639041	mediated acute
0.3114204581	psychosis patients
0.3113349017	adriamycin dose
0.3113152447	on conditioned place preference and
0.3112123596	present study
0.3111744587	prior to admission
0.3111295798	without aggravating
0.3110915591	extracellular concentrations of
0.3109961134	patients with advanced parkinson
0.3107535945	reported with liver
0.3106867105	patients with advanced age
0.3106606391	patients transplanted at
0.3106332472	persistence of
0.3105789559	intracoronary infusion of
0.3104866778	reflected by
0.3104511957	f 344 rats
0.3104418351	serum lithium
0.3103617141	intracoronary injection of
0.3103415556	co infection
0.3103228993	provision of
0.3103154085	migraine with aura and migraine without
0.3103127025	without aura
0.3103107354	20 microl
0.3103106260	after discontinuing
0.3102694506	versus 19
0.3102217432	patient suffering from
0.3101206539	per 100 gm
0.3100764353	this case emphasizes
0.3100749339	independent predictors of
0.3100668186	mediated by
0.3100536100	acute renal
0.3100505555	specific clinical
0.3100076707	relatively safe
0.3099568173	vitamin c administration
0.3098545183	micrograms kg 1
0.3098068919	adverse interaction between
0.3097311245	antibodies against
0.3096867513	intraperitoneal administration of
0.3096587736	the molecular layer
0.3095760044	pronounced increase in
0.3095436212	for melanoma
0.3095436212	for 21days
0.3094818807	integration of
0.3094818807	patency of
0.3094818772	demonstrated elevated
0.3094576621	these results provide
0.3093815247	like behaviors
0.3093723976	+ 0.11
0.3093136862	randomized to receive 10 mg
0.3092789356	complete restoration of
0.3091986189	very few
0.3091977213	results demonstrate
0.3091640906	10 cm h2o
0.3091124292	beginning at 8
0.3090990302	disappearance of seizures
0.3090936811	the risk of venous thrombo embolism
0.3090782102	upper limit of normal occurred in
0.3090132107	used second generation oral contraceptives
0.3089166080	response test
0.3088969080	the midazolam group
0.3088573653	and fluid restriction
0.3087692915	examination of kidney
0.3087615109	very rare
0.3087112880	overexpression of
0.3086417268	the predictive accuracy
0.3086321162	in vitro and in vivo
0.3086077122	adult smokers with
0.3084882391	50 mg kg
0.3083069535	motor seizures
0.3082864070	initiating treatment
0.3082726118	continued until
0.3081858553	patients with severe neutropenia
0.3081290705	participates in
0.3081266930	younger than
0.3080406348	vpa therapy
0.3080314477	non selective
0.3079163428	in male sprague dawley
0.3076302960	sub chronic low dose
0.3075591432	dose calculated on
0.3074852483	relatively healthy women
0.3074832938	40 micrograms
0.3073956186	severe thrombocytopenia and
0.3073482406	under spinal anesthesia
0.3071189517	least toxic
0.3070979096	evidence of renal damage
0.3068769189	hepatic and brain
0.3068036286	significant adverse effects
0.3066801485	provide new
0.3065786595	separated by
0.3065602100	two sided
0.3064680582	some contraindication to receiving cisplatin
0.3064600152	the high risk surgery
0.3064086682	+ lvdp dt
0.3063985474	reintroduction of
0.3063985474	discontinuance of
0.3063985474	details of
0.3063893920	result in serious liver
0.3062860444	for preterm labor
0.3061347632	intravenous administration
0.3061128838	six month
0.3060532235	urinary excretion and
0.3060472545	96 h
0.3059543896	weeks later
0.3057613413	the direct cost of treating
0.3056694619	patients with chronic hepatitis b
0.3056113359	all mouse strains
0.3055519585	precipitated by
0.3055519585	supported by
0.3055495287	analysis showed
0.3055234331	safety and efficacy
0.3054924649	cardiac dysfunction in patients
0.3053752190	caused by
0.3053029407	p less than 0.001
0.3052493004	compared with placebo
0.3052004561	both isomers
0.3051904669	lower accumulation in
0.3049929224	the reader
0.3048876468	coadministered with
0.3047022061	intravenous administration of high dose
0.3045833310	prophylactic treatment
0.3045173172	good risk
0.3044793524	g cm
0.3043971467	morphine administration and
0.3043648565	reduction of glutamate and aspartate
0.3043339675	so called
0.3043059418	a nonfatal
0.3042912636	displayed increased
0.3042828152	assigned to
0.3042740656	given intraperitoneally
0.3042739588	prior to levodopa
0.3042595658	subset of
0.3041836098	completion of chemotherapy
0.3041140092	an inspired
0.3040924010	metabolized by
0.3040452978	regulation of mhc i
0.3040033818	autonomic control in
0.3039668701	a non steroidal anti inflammatory
0.3038512276	a non alcoholic
0.3037652342	widely used
0.3037455649	15 minute
0.3037445408	20 hbv hiv co infected patients
0.3036668368	a timi
0.3035517589	all trans retinoic acid induced
0.3034968999	identification of
0.3034887966	t cell
0.3034839999	not yet fully
0.3034671174	varied between
0.3034593976	normal heart
0.3034331145	at 250 words
0.3034143226	before nitroprusside infusion
0.3032950721	uni and
0.3032156979	at least partly
0.3031559525	the erythrocyte membrane
0.3031103003	lithium induced
0.3030767830	delayed toxicity
0.3030166997	behavioral and cardiorespiratory responses to
0.3030014331	patients requiring
0.3029947013	applications of
0.3029354248	considerably lower than in
0.3029348229	100 mm3
0.3028852583	drug effects
0.3028740838	200 ppm
0.3028325385	numbers of bfu e and
0.3027896137	required therapy
0.3027607125	15.0 mg
0.3027341793	severe atherosclerosis of
0.3026236888	15 minute infusion
0.3026161731	to proceed
0.3026161731	to obviate
0.3026154628	induced by intracerebroventricular
0.3025683796	clinical findings
0.3024164903	ketoconazole induced
0.3023880663	iso induced
0.3023837948	larger than
0.3023644780	year overall survival
0.3023482206	lack of vitamin e
0.3023355561	more frequent
0.3023328953	different dosages
0.3022721835	men and women
0.3022531387	the arteriolar wall
0.3022440836	n methyl d aspartate receptors
0.3021009275	mg kg day
0.3020350045	8 bromo
0.3020076802	all participants exhibited
0.3019986564	60 min
0.3019642678	130 mg dl
0.3019593219	this unusual complication
0.3019395246	prediction of
0.3018779212	substance use
0.3018264422	4.0 mg
0.3014889687	500 ppm
0.3014881286	data also suggest
0.3011760093	emphasis on
0.3011427309	effective drug
0.3009956031	from january
0.3009714736	side effect
0.3008970044	effective dose
0.3008632260	mg s 1
0.3008563234	require further
0.3007879755	relatively few
0.3007106158	type 1 receptor
0.3006899934	related to
0.3006891447	administration of aprotinin
0.3006548808	beginning on day
0.3006090654	ultrastructural changes
0.3004607343	increased expression and
0.3004279504	mediated by central
0.3003772280	11 529 patients
0.3003201776	alpha 2b and ribavirin for
0.3003156929	these data demonstrate
0.3003111760	prostate cancer patients
0.3002763004	received bupivacaine
0.3002607125	most pronounced
0.3002473034	ketamine and lidocaine on
0.3002162628	a narrow therapeutic
0.3001852086	a 4
0.3000905525	nephrotoxicity and metabolism
0.3000787759	cardiac work
0.2999303120	effect occurred
0.2996714318	p = 0.0001
0.2996510767	800 mg daily
0.2996316241	azathioprine induced
0.2995990592	describes two
0.2995748760	beneficial effect in
0.2994653363	the isolated perfused rat
0.2994145375	convulsion following
0.2993764511	increased excitability of
0.2992670534	impairment of learning
0.2992067727	20 or 40 mg
0.2991724546	an angiotensin converting enzyme inhibitor
0.2991705012	the iodixanol group
0.2991526325	treated with intravenous ribavirin
0.2989872699	possible risk factors
0.2989683657	p 0.025
0.2989673692	severe acute
0.2989171788	100 nm
0.2988906201	80 mg
0.2988830362	prl r expression and
0.2988253879	135 mm
0.2986752417	this case represents
0.2986735065	mean + sd
0.2986431829	suffer from
0.2986143861	although several new anticoagulant drugs
0.2986138470	fluoxetine induced
0.2985691097	prevalence of heart disease in
0.2983982080	consisted of
0.2983122817	50 mg
0.2982781521	infants exposed to
0.2982126264	kg 1
0.2981869441	as ks group
0.2981243726	intracarotid injection of
0.2981190344	1 chloro
0.2980699092	100 micrograms
0.2980401071	very low
0.2978873968	1000 mg
0.2978092442	patients with chf
0.2977649828	studied in rats
0.2977363993	patients with congestive heart failure
0.2976997624	a lesser degree
0.2975746833	the ganglionic blocker
0.2975669606	findings do
0.2974028558	co trimoxazole treatment
0.2973269101	overexpression of pgp in
0.2973131792	results provide
0.2971323285	patients with coronary artery disease
0.2971120121	a 10
0.2971014739	the present study examines
0.2970970419	during static and dynamic exercise
0.2969703342	did not impair
0.2969625993	administration of ouabain
0.2969419682	less pronounced
0.2969238669	patients receiving tacrolimus
0.2969159624	severe ocular and orbital toxicity after
0.2969043388	positivity in
0.2969043388	activations in
0.2968686283	fs containing
0.2968684516	long term oral
0.2967657090	one hundred sixty
0.2967443705	hemoglobin content and
0.2967301731	memory impairment induced by scopolamine in
0.2967232451	to repeat words
0.2966854085	the combination and zidovudine groups
0.2965998246	courses of doxorubicin
0.2965617791	lidocaine and cocaine
0.2965464109	severe glomerulonephritis with
0.2965214944	showed elevated
0.2964831172	0.1 mg kg 1 i.p
0.2964594286	the m1 selective
0.2963943628	pattern of kidney
0.2963785428	a 63 year old caucasian
0.2963654225	on myocardial oxygen supply and demand
0.2963344588	mediated mechanisms in
0.2962926455	3000 mg
0.2962859791	using transthoracic echocardiography
0.2962759765	returned to baseline
0.2962676155	rats with streptozotocin
0.2962616622	dilated cardiomyopathy related to
0.2962018374	the high frequency range
0.2961668495	160 mg m2
0.2961484260	these data suggest
0.2961422057	patients aged 18
0.2961094541	sub effective
0.2961017234	the current study
0.2960766078	reproduced in
0.2960766078	replicated in
0.2960766078	overactivation in
0.2960185312	pain free at 2 h
0.2960102335	the primary outcome
0.2960020334	the fischer 344
0.2959225100	the upper limit of normal
0.2959118171	or rb1
0.2959114903	ich vs
0.2959011067	design and methods
0.2958863503	cholinergic system
0.2958715430	likely mechanism
0.2956964954	the hypercapnic ventilatory response in humans
0.2955938098	and responder rates
0.2955937626	prolonged apnea after
0.2955571583	the bladder wall
0.2953560006	began within
0.2953182896	per 10 000 women years among
0.2952980940	increased resistance
0.2952354724	no long term sequelae
0.2951740312	mg per deciliter or more
0.2950920978	every 3 weeks until disease progression
0.2949522313	acute stroke
0.2949119584	overall health
0.2948761720	does aspirin
0.2948457372	engaged in
0.2948457372	ions in
0.2947965226	more closely
0.2947817513	peaked at
0.2947680992	observations indicate
0.2947619164	a retrospective cohort
0.2947611437	treatment protocol with
0.2947578102	instability during
0.2946922943	renal functional and structural injury in
0.2945534189	group of rats
0.2944744117	0.3 micrograms kg
0.2944687660	the apoe epsilon4 allele only
0.2944377758	new onset
0.2943978555	groups exhibited
0.2943807351	chronic pain
0.2943681154	induced hepatotoxicity
0.2942468408	median time to
0.2941834982	discontinuations from
0.2941494443	prevalence of depression
0.2941484240	pleural and
0.2941334626	mean alt
0.2941252589	induced bradycardia
0.2940295112	every 3 weeks
0.2939812891	runs of
0.2939812891	proof of
0.2939812891	aspect of
0.2939718750	with desipramine reversed
0.2939390612	c terminal
0.2939336447	morphologic changes in
0.2939219366	these results demonstrate
0.2939114736	400 mg kg
0.2938903760	cholinergic activity and
0.2938744473	in very low birth weight infants
0.2938689084	effect level
0.2937664481	first degree
0.2937215107	100 mg
0.2936402010	the atypical antipsychotics
0.2935010470	history significant for
0.2933757367	y old
0.2932667771	users vs nonusers with
0.2932031021	significantly more
0.2931849667	under investigation
0.2931368165	a much lesser
0.2931076794	seizures produced by pilocarpine in rats
0.2930573318	severity of postoperative nausea and vomiting
0.2930455992	by high pressure liquid chromatography
0.2930320092	during dobutamine stress echocardiography
0.2929561610	treated with carbamazepine
0.2929464373	induced catalepsy
0.2926818948	angiotensin converting enzyme inhibitors or
0.2926448360	blocked by
0.2925774670	completion of
0.2925153664	mm hg or more
0.2924478514	the entire procedure
0.2924252923	significantly smaller than
0.2924046654	the minimum effective plasma concentrations
0.2923763532	rats with lithium
0.2923668295	thirty minutes after
0.2923220938	blood and urine
0.2922372493	alterations observed
0.2921172003	development of apomorphine induced
0.2921005407	80 160 mg kg
0.2920796894	act on
0.2920056178	cyclophosphamide treatment
0.2920037836	caffeine induced
0.2919480359	pilocarpine seizures
0.2919448469	admitted to
0.2919258209	co infected patients
0.2918884963	median dose
0.2918338865	for middle ear surgery
0.2917683158	seventy one
0.2917240518	rats treated with morphine
0.2917181717	arm time and
0.2916961703	in recent years
0.2916878040	patients with wegener
0.2915059141	twenty four hours
0.2914509845	an alkylating
0.2913179375	data obtained using
0.2912677257	rate control
0.2911791177	patients with chronic kidney disease
0.2911392880	report 4 cases
0.2911241764	fragmentation of
0.2911168930	5 dimethyl
0.2910816156	the ventral
0.2910693366	novel proteins
0.2910435188	and midline defects
0.2910358301	pretreatment with isoproterenol
0.2910054253	steroid induced
0.2909731013	0.5 mg
0.2908989845	induced vasoconstriction in
0.2908532501	a trend toward
0.2908531373	seizures and death
0.2908375126	nmdar and
0.2908271920	and intensity weighted
0.2908269455	used oral contraceptives
0.2908094644	median number of courses of
0.2907964408	the convulsive threshold
0.2906787945	presented here
0.2906647559	drug susceptibility of
0.2906384908	a large population
0.2906238625	product use
0.2906207473	parp 1 + +
0.2903231068	55 mmhg
0.2902977283	injected with gentamicin
0.2902470365	rheumatoid arthritis patients
0.2901774376	in doses exceeding
0.2901504622	normal rats
0.2900462951	symptoms of pd
0.2900452219	the present results suggest
0.2900385705	11.8 months
0.2899965009	the increase of 35s tbps binding
0.2899895377	infusion produced
0.2898470881	dissatisfaction and
0.2898470881	myelination and
0.2898470881	synaptophysin and
0.2898470881	apex and
0.2898420251	reversal of catalepsy
0.2897974448	long term lithium
0.2897631837	diazepam alone
0.2897008182	the tg + haart cohort
0.2895435682	first time ratings
0.2895008391	sc injection of
0.2894636545	data regarding
0.2894188701	did not produce
0.2893764677	x + se
0.2893508129	diazinon use
0.2892998338	physical changes
0.2891593715	differs from
0.2891125772	immediately after
0.2890706989	0 microgram kg min
0.2890193570	palpitation and
0.2890143160	either active drug
0.2889133935	the lv base
0.2887584706	provides additional
0.2886820073	off dosing
0.2885861291	animals exhibited
0.2885731613	non users
0.2884957272	limited to studies
0.2884538634	3379 patients randomly assigned to
0.2884494570	contraindication to
0.2883401717	chronic pre treatment with
0.2882826797	effective against
0.2882712141	work up
0.2882334743	overall survival
0.2882183290	the entire
0.2881380777	graded doses of
0.2881023902	ethinyloestradiol and
0.2880916713	referred to
0.2880814297	seizure like
0.2880632020	treated with beta blockers
0.2880157074	the b3 serotonin
0.2879927119	skills and
0.2879671318	asked to
0.2878346439	s isomer
0.2878341930	of spontaneous alternation and passive avoidance
0.2877052955	intraperitoneal injection of
0.2876159595	effect of crocin
0.2875960085	a local surveillance
0.2875571929	0.2 mm
0.2874853895	enlargement of
0.2874853277	the globus pallidus
0.2874820572	long term follow up
0.2873469519	on cortical epileptic
0.2870677479	anxiety and depression
0.2870213585	q 4 weeks
0.2869573182	mitomycin c treatment and
0.2869061786	ecg changes
0.2867549002	decreased glucose
0.2866848031	time to first dysrhythmia occurrence
0.2865773284	a reductase inhibitor
0.2865303509	captopril induced
0.2865241058	acted as
0.2865065633	showed statistically
0.2865020072	to maintain
0.2864611794	levels of superoxide
0.2864257593	two step
0.2863852606	a 25 gauge
0.2863319873	disappeared within
0.2862661922	recordings showed
0.2862465099	case of fluconazole associated
0.2862380952	no further sequelae
0.2861995437	dependent upon
0.2861832243	s disease
0.2861675642	cocaine administration
0.2861367191	randomized to receive either
0.2861198445	protective effect of verapamil on
0.2861111163	those receiving amb alone
0.2861097290	volumes than
0.2860675046	compared with control
0.2860461608	irritation of
0.2859999398	adherence to
0.2859886376	subjective assessment of
0.2859283121	developed acute hepatitis
0.2858055355	major hemorrhage and stroke in
0.2857512720	s 53482 and s 23121
0.2857164213	like behavior
0.2855488124	the sedentary
0.2854910660	rr 0
0.2854906188	continuous infusion of 5 fu
0.2853846403	packing and
0.2853721098	verapamil o
0.2853343626	affected by
0.2852770450	by polymerase chain reaction
0.2852060005	median follow up
0.2851691109	the dfmo plus sulindac group
0.2851351337	with newly diagnosed
0.2851203563	elevation of plasma
0.2851047544	eeg and mental changes
0.2850773997	cocaine induced increases in
0.2850719902	this unwanted effect
0.2850700845	injection pain
0.2850647415	hb mean value of
0.2850010668	warrant further
0.2849062819	hormone use
0.2847393119	complete disappearance of
0.2845938886	more tolerable
0.2845938886	more subtle
0.2844479557	alleviation of
0.2843390631	compared to control
0.2843205993	9.1 0
0.2842661153	alpha3 +
0.2842619405	methylation of
0.2841328844	and fundus examination
0.2840924913	a suppressive effect on inos expression
0.2840318726	patients with pd
0.2839697300	received rd
0.2838775363	200 mg m2
0.2838745831	increase in da concentrations in
0.2838587118	dose groups
0.2837912115	an interesting case
0.2836626576	190 mg kg
0.2833550480	serum and heart
0.2833439343	pegylated interferon alpha 2b and
0.2832979582	prior to presentation
0.2832850497	identify patients at
0.2832600740	reported so far
0.2831636169	a young woman
0.2830710473	1200 mg day
0.2830279507	ischemia produced by
0.2829467639	240 mg
0.2828991512	rough endoplasmic reticulum and
0.2828321322	at least partially
0.2828093422	non mi group
0.2828087817	did not retard
0.2827177574	three complete responses
0.2826690879	tolerance study of
0.2826420386	responses to isoproterenol
0.2826238162	+ standard deviation
0.2825081848	asenapine at 5 mg
0.2824962448	or unacceptable toxicity
0.2824813806	twenty three
0.2824500516	most clearly
0.2824041073	a curvilinear
0.2823891286	combined with carboplatin
0.2823671854	induced by scopolamine
0.2823369379	10 mg
0.2823150051	dobutamine induced
0.2822629584	ambulatory patients
0.2822514942	98 days
0.2821696312	people aged
0.2821133760	development of nephrotic syndrome
0.2821028739	patients with convulsive
0.2820452542	the tonic component
0.2819882113	like receptor agonist
0.2819412170	survival time
0.2819258341	models of pd
0.2819225950	tended to increase
0.2818835474	during isoflurane induced hypotension
0.2818680693	dox induced
0.2818416768	failed to increase
0.2818327230	a medical intensive care unit
0.2818324701	mean age
0.2817659525	in diabetics
0.2817237329	patient exhibited
0.2816948650	nearly complete
0.2816057462	r r
0.2815892640	levels of serum creatinine and
0.2815041452	three sessions
0.2815008780	discussed and treatment
0.2814789902	disease occurred
0.2814643772	study suggest
0.2814223750	eeg changes
0.2813814873	treated with igf il 3
0.2813443559	the 30 second injection
0.2812515433	mmol on day
0.2812329914	and average volume per micturition
0.2811615390	aware of
0.2811564470	similarity to
0.2809852558	significant increase
0.2809743541	15 minutes
0.2809623037	elevation of serum
0.2809502766	the ischemic core
0.2809089746	the accumbal shell
0.2809036577	and somatic development
0.2808994146	composed of
0.2808994146	placement of
0.2808994146	isolation of
0.2808994146	coexistence of
0.2808994146	mode of
0.2808362322	therapy in very low
0.2808207794	the sympathetic nervous system contributes
0.2807565574	overshooting of
0.2807565574	coarctation of
0.2807222959	a generalized tonic clonic seizure
0.2806932571	each animal
0.2806897901	the same
0.2806198524	high doses of intravenous
0.2806104607	to 2.31
0.2805695949	100 mm hg
0.2805014996	group b
0.2804808450	decrease in systolic blood pressure
0.2804176195	dox treatment
0.2803630740	induced by fluphenazine
0.2802917227	the long term safety of danazol
0.2802879509	increasing recognition of
0.2802620587	similar to amphetamine
0.2801013023	plasma and liver
0.2800883307	significant decreases of
0.2800761915	locomotor activity in mice
0.2800620821	on follow up images
0.2800501285	do not require
0.2798912575	10 micrograms kg min
0.2798774633	q t
0.2798473434	r =
0.2797746738	consisted mainly of
0.2797720403	cisplatin induced
0.2797344146	clonidine and verapamil
0.2797276992	penicillamine induced
0.2797167791	hypothyroidism developed in
0.2796656615	the formation of autophagic vacuoles
0.2796594879	ventricle to
0.2795813549	150 micrograms
0.2795572020	30 micrograms kg min
0.2795528699	a cocaine metabolite
0.2795464180	an elderly man
0.2795089639	any calcineurin inhibitor
0.2793612420	levels of 15 f
0.2792705779	thirty patients
0.2792668655	referred from
0.2792656314	treated with cabergoline
0.2791994499	cocaine and diazepam
0.2791600335	the mtd of cis ra
0.2790907832	time points
0.2790782182	to 32.6
0.2790568732	within subject
0.2790114140	in azt treated mice
0.2788953133	on two separate occasions
0.2788429706	focused on
0.2787556590	potentiated by
0.2786823946	drug drug interactions related to
0.2786506266	in cco activity
0.2785610946	p = 0.002
0.2784986841	150 mg
0.2783702346	capsaicin induced
0.2783408720	36 micrograms
0.2783161589	in isolated myocytes
0.2782678122	p or = 0.001
0.2782513843	and nucleosides
0.2782509574	produced by morphine
0.2782150666	fhf from acetaminophen and
0.2782010409	+ 0.8
0.2781537157	compared to
0.2780843804	induced hypotension and haemodilution on
0.2780321820	4 aminopyridine sensitive k
0.2779382611	lidocaine and cocaine induced
0.2778791832	lidocaine induced
0.2778772932	and intracranial vascular
0.2776257181	mediated by mechanisms
0.2776149840	risk of renal failure
0.2775834334	cancer therapy
0.2775554039	mean daily dose
0.2775479021	fold over
0.2774789654	therapy for primary
0.2774446288	doses of cya
0.2774384658	serum creatinine levels of 50 above
0.2772058559	response to ketamine
0.2771976325	reports about
0.2771939336	opioid use
0.2771544275	between february
0.2771234258	did not prevent
0.2770986004	micrograms kg per
0.2770969988	pb administration
0.2770060401	following anesthesia induced hypotension
0.2769830804	effects of metolachlor
0.2769414268	observed between dose of tetracycline and
0.2768546779	10 micrograms kg
0.2768249606	ccl2 and
0.2767464166	0.1 mg kg
0.2767396142	mdma use
0.2766864117	caused acute
0.2766352493	anp did not
0.2766233563	of unknown origin
0.2765065577	persistent paralysis after
0.2764920613	sodium channel blocker with
0.2764770255	the non competitive nmda receptor antagonist
0.2764342233	markedly different
0.2764184930	in addition
0.2763897496	provides adequate
0.2763729643	short p p intervals and
0.2762941096	descriptions of
0.2762941096	continuation of
0.2762941096	redistribution of
0.2762941096	drawback of
0.2762795477	motor side effects
0.2762035656	two hundred
0.2761975077	systemic side effects
0.2761789997	trial of paclitaxel
0.2761611283	pharmacological effects of other
0.2761503703	induced by d amphetamine or
0.2761341807	inhibitory effect on
0.2761039491	women receiving
0.2760958127	line treatment
0.2760890377	the chlorthalidone phase
0.2760401275	during cesarean section
0.2760336995	train of
0.2760336995	propagation of
0.2759785314	and heavy methamphetamine
0.2758315169	44 micromol l
0.2758024664	24 hour heart rate
0.2757804038	cardiotoxicity after treatment
0.2756752828	a clinically relevant
0.2755447814	to void
0.2755447814	to enable
0.2755447814	to resuscitate
0.2755413399	exposure of rats to
0.2754885970	mrna containing neurons in
0.2754249440	20 ones
0.2753921035	given simultaneously with den
0.2753764898	not justified
0.2753670013	in turn
0.2753663695	n terminal
0.2753365007	an increased risk for venous thromboembolism
0.2751543956	among chf patients
0.2750153437	for example
0.2749009919	screened for
0.2748705165	48 week
0.2747803625	patients evaluable for
0.2746214300	risk of development
0.2745596901	day isoproterenol pretreatment
0.2745381376	resulted from
0.2744833770	treatment results in
0.2744327681	infusion of fentanyl
0.2743931905	dexmedetomidine alone
0.2743048893	involved in catalepsy
0.2742124972	without affecting
0.2741291978	a descriptive
0.2741291978	a lot
0.2741212066	on continuous ambulatory peritoneal dialysis
0.2740513993	a genetic association
0.2740475638	significant decreases in
0.2740246625	becoming more
0.2739477955	10 sucrose and chow
0.2738867896	artery calcification in rats
0.2738595009	the idea
0.2738391232	without hiv co infection
0.2737609983	did not antagonize
0.2737161277	weeks of treatment
0.2737151549	300 mg
0.2737012211	intravenous and oral administration of
0.2736759052	and peripheral muscles
0.2735901337	a dual adenosine
0.2735247434	serious bleeding
0.2734716229	several benzodiazepines
0.2733958325	nifedipine induced
0.2733810121	200 mg iv
0.2733657320	the aortic wall
0.2733413635	like illness
0.2733073335	the gamma aminobutyric
0.2732716757	2.0 mg
0.2732661749	recreational use of
0.2731870415	patients pretreated with saline
0.2731836974	decrease in percentage segmental shortening from
0.2731099986	in vivo microdialysis
0.2730275452	and shortened latency
0.2729448014	a challenging clinical
0.2728075822	switched from cyclosporine to
0.2727968153	male patient
0.2727906307	fewer than
0.2727804927	acute toxic
0.2727627800	hundred fifty five
0.2726667103	significant difference between groups in
0.2726499560	the pressor response to i.c
0.2726402772	age 70
0.2723779411	syndrome of inappropriate secretion of
0.2723593184	fed rats
0.2722959267	locomotor hyperactivity induced by
0.2722896940	neurones in
0.2722740360	and protein expressions
0.2722227711	reaction characterized by
0.2721680660	the aap induced
0.2721663399	effect of aspirin on
0.2721194768	seizures and status epilepticus in mice
0.2721088770	n methyl n
0.2720813970	of avp gene
0.2720254636	usually well tolerated
0.2720166858	effect of carteolol
0.2720011833	a considerable number of peroxisomes
0.2718763940	10 mg kg
0.2718387954	against doxorubicin induced cardiotoxicity
0.2717349619	in utero
0.2715261785	administration of ibuprofen
0.2715051677	during unilateral and conventional spinal anaesthesia
0.2714796322	ketamine and morphine
0.2714279343	in fischer 344
0.2714167002	doses of ephedrine
0.2714046631	recurred after
0.2713354240	an urgent need
0.2713316206	12 hour
0.2713276842	a population without known risk factors
0.2712668944	year old woman
0.2712509442	acute reversible
0.2712093457	mean + se
0.2711817115	study of thalidomide
0.2711718963	the close temporal
0.2711393017	still unknown
0.2711389497	complicated by
0.2710510094	remained well
0.2709727881	parkinsonian patients
0.2708898044	enzyme levels
0.2708883782	2.5 mg kg
0.2708337397	during cardiopulmonary resuscitation
0.2707750667	effect of bis
0.2707564649	50 above normal
0.2707279756	occurred more frequently in patients
0.2706149748	more frequently
0.2706124238	and right brachial
0.2705654822	effect of nitroglycerin
0.2705103331	induced se
0.2704249183	24 h retention
0.2703713489	after flumazenil administration
0.2703325176	the periconception period
0.2703313349	nor did
0.2703045196	the radiofrequency group
0.2703031690	shared by
0.2702495001	injection of amphetamine
0.2701663399	effect of vitamin d dose on
0.2700485682	with bacl2
0.2700070840	receiving long term
0.2699585538	2.5 times
0.2697551595	30 micrograms kg
0.2697513754	the antidepressant trazodone
0.2697254173	15 microg 0.5 microl
0.2696610380	predictors of response
0.2696592956	dose of trazodone
0.2696261569	daily for 3 weeks
0.2695969553	a permissive
0.2695969553	a viable
0.2695969553	a shrunken
0.2694751634	1 pyrrolidinyl
0.2694398620	serious adr
0.2693800156	only statistically significant benefits of ht
0.2693161345	the developing chick
0.2693153809	perfusion of bladder with
0.2693059485	the saralasin treated
0.2692439015	s disease lid
0.2691811824	17 measures
0.2691554488	implications for
0.2690527766	the accumbens shell
0.2690373805	antidepressant use
0.2688627824	various degrees
0.2687573288	shortly after initiation of
0.2687074799	compared with saline
0.2686093277	this report demonstrates
0.2685646584	proliferative response to
0.2685628459	well defined
0.2685403117	do not
0.2684300006	80 mg kg
0.2683783224	the insulin group
0.2683075532	induced hepatitis
0.2682695568	2005 and june
0.2681106207	developed neurologic
0.2680985266	sub effective doses of ketamine
0.2680966704	rate of adverse
0.2680953597	p = 0.36
0.2680799219	consistent with drug induced
0.2680497277	follow up studies
0.2680459377	possibly through
0.2679403707	doses of 0.25
0.2678492877	well known
0.2678008154	morphine and fentanyl
0.2677173381	72 years
0.2676835596	ten years
0.2676298275	7 ac cck 2 8 se
0.2676266597	adjunct to
0.2675986429	or anemia related
0.2675582245	the 4 mg nicotine
0.2675502393	the norepinephrine content
0.2674597947	the memory enhancing effects of pregs
0.2673820089	five cases of encephalitis
0.2673783224	the gm induced
0.2673763332	migraine patients
0.2672798461	cases reported
0.2672520815	almost always
0.2672284784	23 hours
0.2671672249	induced dyskinesias in parkinson
0.2671346455	and elisa tests
0.2669659796	enhancement of morphine
0.2669172074	years after receiving
0.2668913530	five courses
0.2668878221	length of treatment
0.2668388551	correlation between
0.2668095085	100 mg kg
0.2667771514	an average
0.2667514549	not exceed
0.2665347542	use of bzds rds
0.2665306474	year old female
0.2664779665	l2 and
0.2664706137	the locomotor stimulant
0.2663240695	control value
0.2662457450	mice tested
0.2661801413	prevention and treatment of
0.2661562316	suggestive of
0.2661280823	b cell
0.2661276002	effect of amantadine
0.2661037220	500 mg kg
0.2660623777	latency time
0.2659872351	n = 114
0.2659073597	the appearance of mpo anca
0.2658988527	2 weeks apart
0.2658398323	protrusions and
0.2658323491	group performance
0.2658288202	peroxisomes in
0.2657599636	four times daily
0.2657463206	at rest
0.2657250159	0.75 mg
0.2657050589	report 3 cases
0.2656494879	a nonepileptic patient
0.2656394400	convulsant dose of
0.2655440247	of iodinated contrast
0.2655361178	cardiovascular responses to
0.2654783178	affinities for
0.2654451438	induced by
0.2654071685	group received
0.2653326027	fdc of t +
0.2653211094	thus far
0.2653098530	mg day for 2 weeks
0.2652583735	+ dex group
0.2652545266	200 mg kg
0.2650843673	the untreated shr
0.2649582015	and gastrointestinal toxicities
0.2649400644	secondary to
0.2648056902	the 4 mg nicotine lozenge
0.2647216922	this study
0.2647017285	eradication of
0.2647017285	description of
0.2646959887	the chlorpheniramine group
0.2646310195	modes of
0.2646310195	sides of
0.2646310195	titres of
0.2645670140	the training session
0.2645606266	the dex + ato group
0.2645573597	5 mg kg
0.2645528177	two studies evaluated
0.2644651996	dose of 12 mg kg
0.2644569263	overall response rate
0.2644505699	greater than or equal to 3
0.2643754544	the selective blockade of a2 adenosine
0.2643750193	long term therapy with
0.2643274740	a phase ii study
0.2642479480	reversal of hypotension
0.2642385855	the muscular rigidity produced by morphine
0.2642237960	plasma catecholamines and
0.2642226342	did not augment
0.2642127354	pretreatment with acetaminophen
0.2641539889	a wide range of biological
0.2640751857	the molecular basis
0.2640663929	toxic hepatitis induced by
0.2638440255	highest dose given
0.2638080117	tested whether
0.2637913653	treatment with quetiapine
0.2637861055	compared to placebo
0.2637333220	a 2 week rest period
0.2636877146	and testicular
0.2636842203	sixty nine
0.2636372422	assessed by
0.2636289639	relation between
0.2635857433	pretreated with nicotine for
0.2635278316	rats per group
0.2634671246	from june
0.2634220736	six inbred
0.2634208532	potential risk factors for
0.2634125538	treated and control
0.2633752284	non cardiac surgery
0.2633539376	dual effect of
0.2633355493	treated with saline
0.2633153250	recovery of blood pressure
0.2633045196	the mexiletine group
0.2632825421	a massive lesion
0.2632564395	treatment with captopril
0.2632408728	on gd 21
0.2632338276	100 g body wt
0.2631292875	elevations in serum
0.2630953633	symptoms and quality of life
0.2630935268	combined with other drugs
0.2630530506	25 mg kg i.p
0.2630486475	after tolterodine treatment
0.2630135644	n = 94
0.2629935834	a 3
0.2629792361	factors associated with nephrotoxicity
0.2628844340	lithium maintenance therapy on
0.2628788552	the patient recovered
0.2628787851	h delay
0.2628038574	third group received
0.2628025967	20 mg
0.2626907296	a strong association
0.2626731176	the icu scale
0.2626394178	weeks after discontinuation of
0.2626061469	upregulation of renal
0.2625912190	central nervous system side effects
0.2625731629	il 3
0.2625475332	an inducer of p450
0.2624579832	differ in
0.2623582600	completely upon
0.2623294401	600 mg
0.2623216809	bruising and pain following
0.2621639543	an independent risk factor
0.2620725481	the inf mi group and 61
0.2620121545	treated with epo and
0.2619771064	on beta blocking agents
0.2619755850	last two doses of mesna
0.2617964718	1 nitrosourea
0.2617845625	five hundred
0.2617592960	lack of
0.2617535088	placebo groups
0.2617498989	catalepsy induced by
0.2616955319	35 ng
0.2616676174	sex differences in
0.2615815424	a temporal relationship
0.2615642349	reported here
0.2615387317	alternation and
0.2615369378	experimental and clinical
0.2614741660	not necessarily
0.2614741660	not simply
0.2614589303	differ from
0.2614454206	year by perimenopausal or postmenopausal women
0.2613147758	the bche gene
0.2611910536	affinity for
0.2611038866	10 seconds
0.2609979036	2.5 micrograms
0.2609811469	probably best
0.2609684488	the right radial nerve
0.2609550587	one hundred
0.2608881845	levels of 50 above normal
0.2608778604	+ 0.7
0.2608311543	type of damage
0.2607651770	mechanisms of myocardial ischemia induced by
0.2607488351	+ 0.57
0.2607128152	sixty seven
0.2607082767	days 5 and 10
0.2606895200	p 0.002
0.2606678377	among humans
0.2605635488	in brain membranes
0.2605367375	induced by tacrolimus and
0.2604981695	at baseline
0.2603505967	0.5 microl
0.2603383686	toxic side effects
0.2602330147	90 min
0.2600908234	to determine
0.2600572249	cholesterol less than
0.2599779264	according to
0.2599462205	to assess
0.2598892052	results obtained
0.2598837501	concomitant use of
0.2598809299	no synthase
0.2598694552	directly into
0.2598633100	since 2005
0.2598613670	mg kg 1 i
0.2598532621	increased from 0.19 to
0.2597197365	treatment with corticosteroids
0.2596840868	randomly selected from
0.2596733274	cortical laminar necrosis in
0.2596463880	expressed as
0.2596365777	+ 0.3
0.2596124573	six cases with blood loss
0.2595290308	reabsorption and accumulation of
0.2595137840	and frequency of sexual relations
0.2594908811	treatment with metformin
0.2594523144	hemodynamic changes
0.2594274183	multiple episodes of
0.2592508319	the investigator
0.2592298574	an attempt
0.2592274894	vulnerability to
0.2592264112	30 nmol
0.2592162739	reported to reduce
0.2592070618	patients aged
0.2592035671	than amphetamine induced hyperactivity
0.2590632576	included age
0.2590459073	typical signs of
0.2589222992	last word recalled from prior to
0.2589053839	p less than 0.025
0.2588988468	different treatment regimens
0.2588482642	indicator of
0.2588451622	the dexamethasone treated
0.2587675561	ii study
0.2586865924	discontinued therapy
0.2586808424	normal human
0.2586713564	physiological effects of
0.2586456923	catalepsy in mice
0.2586318685	the molecular mechanisms
0.2585904546	of d tubocurarine
0.2585341923	without altering
0.2585009395	the li treated rats
0.2584865368	no migraine attack
0.2584338731	after multiple injections of meth
0.2583432992	until progression
0.2582320235	a 20
0.2582192653	r = 0
0.2581943351	among women
0.2581736997	background and objectives
0.2581382705	the renin angiotensin
0.2580332658	500 mg
0.2579257047	p less than 0.02
0.2577856473	few hours
0.2577021329	the predictive accuracy of identifying
0.2576284917	to seizure induction
0.2576126375	effects of cd 832
0.2576077405	clinical effect
0.2575916083	tissue levels
0.2575856545	increased proteinuria
0.2575523718	24 hour period
0.2575123392	designed to
0.2574356289	for administering vincristine and intrathecal
0.2574120204	activity against
0.2573558791	perceived pain intensity in
0.2572823877	in aging rats
0.2572798634	growth and vitamin d
0.2572764966	immediate and delayed
0.2571177050	induced by pentylenetetrazole
0.2570855973	indirectly by
0.2570855973	simulated by
0.2570849589	in order to elucidate
0.2570729508	the contrary
0.2570594255	patient presented with
0.2569774812	by body surface
0.2569672185	induced by cromakalim
0.2569373397	processed for
0.2569116332	1 hyperbaric bupivacaine
0.2568877932	efficient than
0.2568548356	8 days of des exposure
0.2568065109	demonstrated significant
0.2567897612	well below
0.2566558897	rats fed
0.2565238946	96 weeks
0.2564871110	resulting in
0.2564111443	predictor of
0.2563994162	before age 50 years
0.2563699256	end of treatment
0.2563519813	in vitro
0.2563345569	suffered from
0.2563019323	treated with ccnu
0.2562836762	in nx dogs
0.2562053646	assessable for
0.2562027242	5.6 years
0.2561654327	the 8 week core study
0.2561599665	1.5 mg kg
0.2560796936	locomotor response to
0.2560781226	upregulation of
0.2560770095	the critical care
0.2560744743	self report
0.2560643198	the 15 htn group
0.2560471791	act as
0.2560098434	in very low birth weight
0.2559955376	l type calcium
0.2559423737	the treatment of peptic ulcer disease
0.2559198331	administration of methylprednisolone and gentamicin into
0.2558077818	duration of use
0.2557338748	this paper
0.2556848314	100 micrograms kg
0.2556620105	one or more recurrences
0.2556509462	concentration of dopamine
0.2555769411	the retention test
0.2555501029	risks and benefits of
0.2555121464	immunohistochemical staining for
0.2554974861	in d amb treated rats
0.2553976372	triggered by
0.2553388496	treatment with enalapril
0.2553337037	to evaluate
0.2553103428	the dosing schedule
0.2552935665	saline group
0.2552220613	etoposide and cyclosporin a
0.2552131973	determinant of
0.2552131973	domains of
0.2551738309	cohort of patients
0.2551500368	in 1
0.2550724378	in dex treated
0.2550443604	week 16
0.2549775610	remarkable for
0.2549469793	significantly less
0.2548763523	long term efficacy and
0.2548603108	administration of mtx
0.2547851274	effect of d glucarates
0.2545717943	the retina and optic nerve
0.2544327345	by den alone
0.2543429180	not tolerate
0.2543050820	the optical isomers of propranolol
0.2542735458	p less than 0
0.2542265429	an iv infusion
0.2541143243	phase of proteinuria associated with
0.2540325248	800 mg
0.2540317413	2 g dl decrease
0.2540208188	s disease + lid
0.2539865258	dramatically from
0.2539837574	the bezold
0.2539827901	submitted to
0.2539536063	week old
0.2539507855	100 microm
0.2539443155	3.5 years
0.2539213646	up regulation
0.2538172423	the convulsant activity
0.2538061445	rapid reversal of
0.2538035319	the remainder
0.2537965268	useful in preventing
0.2536923317	much higher
0.2536655309	70 mg m2
0.2536462921	daily dose of
0.2536340874	1000 ml
0.2535505091	non ischemic
0.2535042015	l on pod
0.2534867062	400 mg
0.2533538048	this case illustrates
0.2533462690	created in
0.2533054171	and 10
0.2532031110	to investigate
0.2531421651	8 sevoflurane
0.2531388965	time interval between monoher and dox
0.2531304189	or coronary event
0.2531294045	produced by
0.2531194000	a delayed and protracted pressor effect
0.2530651328	able to
0.2530374706	non endothelial
0.2529714993	sagittal and
0.2529605643	sch 23390 or
0.2529322311	a non randomised clinical study
0.2529170905	p 0
0.2529080189	patients with diabetes
0.2529017705	the 5
0.2528876875	osteoarthritis and
0.2528195411	times per day
0.2528116106	25 and 50mg
0.2527400441	compared with diclofenac
0.2526794252	non ecstasy
0.2526736411	carteolol did not
0.2524942994	formed only in
0.2523619953	the immunosuppressive regimen
0.2523617478	patients with sah
0.2522448970	stem cell transplantation for
0.2522334735	studies of human
0.2522101517	timing of ribavirin reduction in
0.2521807908	other beta blockers
0.2521805808	levels remained
0.2521458481	exposed rats
0.2521000161	25 32
0.2520940906	the purpose of
0.2519943596	and growth status
0.2519867178	the right coronary artery
0.2519491221	the exact mechanism
0.2519169744	35 mm
0.2518815770	diminished over
0.2518237591	received single
0.2517849652	ci =
0.2517235875	the most common pathogens
0.2516726883	dose of 200 mg kg
0.2516539621	deterioration of renal
0.2516491252	but side effects do exist
0.2516436879	the untreated eyes
0.2516232713	the long term use of minoxidil
0.2516211194	drug levels
0.2516068184	high levels of
0.2515856149	tumor size and
0.2515490501	contributed to
0.2515181257	endometrial hyperplasia or
0.2514179868	the high dose group
0.2513744845	the artery media
0.2513098740	induced locomotion
0.2512869571	determined by
0.2512778332	similar to
0.2512768491	reports of myocardial
0.2512477541	against diabetic nephropathy
0.2512233587	brain and liver
0.2511403126	symptoms of parkinson
0.2510989790	gnc92h2 as
0.2510017038	call attention to
0.2509983337	and 0
0.2508954729	the critical mechanism
0.2508483022	obtained from
0.2508214858	an 11 year old boy
0.2507050190	per day
0.2506839944	resurgence of
0.2506839944	participation of
0.2506724585	n =
0.2506469881	and decreased thymus
0.2505722725	remains under
0.2505655340	forty four
0.2504650988	myocardial infarction in rats
0.2504574737	induced delirium
0.2504070254	to synthesize
0.2503901722	liver mice
0.2503844736	refractory cases of
0.2503448003	due to
0.2503333611	after etomidate administration
0.2503329958	evidence of peripheral
0.2503177134	a patient with primary biliary cirrhosis
0.2502554941	demonstrated to occur in
0.2502453985	prior to
0.2502122086	24 h
0.2501843801	for primary prevention
0.2501344795	piperacillin induced
0.2500624189	pretreatment of rats with
0.2500579543	sixty eight
0.2500356042	+ 0.2 versus
0.2499940399	50 effective dose of d tubocurarine
0.2499350600	pre treatment with
0.2498966086	inhibition of human
0.2498962915	20 mg kg
0.2498474809	cardiac symptoms
0.2498239504	administration of phenytoin
0.2497138423	reversible on cessation of
0.2497113467	after bdl
0.2497050945	end of dose
0.2496031328	significantly reduced in rats treated with
0.2496012555	evidence of hepatotoxicity
0.2495642833	carbimazole induced
0.2495642056	a 72 year old
0.2495082377	cytotoxicity of cyclophosphamide in
0.2494041469	other antiepileptic drugs
0.2493719029	induced cardiac dysfunction
0.2493188123	known about
0.2492877362	and immunoglobulins
0.2492750183	an unusual
0.2492440007	these findings
0.2492243399	observed between
0.2492079102	one half
0.2491645539	in older children
0.2489883965	vessels after 7 days of
0.2489503502	disappearance of
0.2489179128	one month
0.2488465441	produced increases in
0.2488448131	the 8 aminoquinoline
0.2488433574	possible complication
0.2488246075	12 lead
0.2488164682	thus preventing
0.2487940901	an effective antiarrhythmic
0.2487592232	of exencephalic tissue
0.2485396626	groups r4 and r6 than in
0.2484998401	less than or equal to
0.2483478222	a pharmacokinetic drug interaction with paroxetine
0.2482575330	data indicate
0.2482538528	08 ml
0.2482268155	completely blocked by
0.2481994826	this case
0.2481892220	early stage of
0.2481842918	and nacl treated
0.2481661983	on renal protein reabsorption and accumulation
0.2481492877	greater than 35
0.2481067311	map kinase related pathways in
0.2480660832	effects of aminophylline on
0.2480247503	a choline devoid diet
0.2480209628	stiffness and
0.2480103759	prophylactic use of
0.2480020699	patients on cyclosporine
0.2479646595	does not
0.2479481129	carbamazepine treatment in
0.2478554718	action of morphine
0.2478394665	vitamin c intake and mortality from
0.2476769599	and 2
0.2476452191	30 mug
0.2476224978	a greater extent
0.2476035212	more slowly
0.2475332017	comparison of
0.2475307550	effects of ouabain
0.2475178164	a transient neurological deficit
0.2474696893	15 44 of sgk1
0.2473482938	resolution of symptoms
0.2473060102	contrary to
0.2472585730	admission and with
0.2471445128	treated with risperidone
0.2471019486	model to test
0.2470952249	patients with schizophrenia
0.2470809756	relative to
0.2470511860	patients with
0.2470468269	induced limbic
0.2470011704	haloperidol and placebo
0.2469890710	and nimesulide
0.2469522654	7.7 +
0.2469517101	serotonin 6
0.2469008904	the risk of bradyarrhythmia requiring
0.2468975221	this complication
0.2468644957	an elderly patient
0.2468322481	an additive effect
0.2468187567	treatment reduced
0.2467882638	revealed positive
0.2467187770	60 g m2 of ifosfamide
0.2467178191	exposed to
0.2467004375	easy to
0.2467003328	induced by bupropion
0.2466482771	drug efflux transporter in
0.2465982179	by bone marrow transplantation
0.2465826139	group f
0.2465567113	resistant to lithium
0.2465554402	levodopa administration
0.2464610923	treatment resistant
0.2464238279	the svc and central veins
0.2464064844	and apo a ii
0.2463098188	months of age
0.2462571426	pilocarpine alone
0.2462238473	95 ci =
0.2461532194	the vasomotor
0.2461510289	75 mg kg
0.2461037692	from diabetic rats to nerve stimulation
0.2460678035	used with extreme caution
0.2460337095	reaction time
0.2459664993	drug of choice
0.2458917690	and spontaneously hypertensive
0.2458865553	possible underlying
0.2458556451	800 mg kg
0.2458410574	a similar pattern
0.2458339636	did not tolerate
0.2458014811	19 mm
0.2457864402	returned to
0.2457119648	prevented by
0.2456743027	oral manifestations of
0.2456464284	achieved at least
0.2456120069	paracetamol induced
0.2455782323	the locus coeruleus
0.2455555710	either blood pressure or heart rate
0.2455475588	and histological findings
0.2455475397	2 adrenoceptors
0.2455108241	day cycle
0.2454975982	pressure decrease from
0.2454574737	induced hippocampal
0.2454562688	locomotor time
0.2454412739	high doses of
0.2454129461	essential for
0.2453298428	explanation for
0.2453125996	and delayed recall
0.2453038182	nerve conduction velocity in
0.2452996279	mg kg per day
0.2452864212	haloperidol and in
0.2452719581	the prevalence of postoperative delirium
0.2452138906	did not
0.2451317141	the ventralis
0.2450116928	a new galenic formulation of propofol
0.2449945807	patient also received
0.2449650439	risk of subsequent
0.2448464984	each subject
0.2447799477	vigabatrin associated
0.2447317278	an alpha and beta adrenergic
0.2447256541	acute myocarditis associated with
0.2445142881	1.3 mg m
0.2445116903	surgical treatment of
0.2444909652	30 min
0.2444240709	histopathological examination of
0.2443906960	in neutropenic patients on amb treatment
0.2443848711	vas response to
0.2443233588	oxytocin administration during
0.2443022186	high and low
0.2442891148	the alfentanil group
0.2441923737	the management of cognitive dysfunctions
0.2441685420	a 2
0.2441430044	the first trimester
0.2441076003	died within
0.2441009585	and mild type
0.2440420224	features of severe
0.2440368465	+ 0.6
0.2440304966	increase in left ventricular
0.2440242212	48 hours
0.2439178905	number of drugs
0.2438904146	response and toxicity
0.2438127694	requires further
0.2437158380	k atpase
0.2436921452	from april
0.2436548872	this pilot
0.2436135355	without tg
0.2435921072	the prevention of radiocontrast nephropathy
0.2435859027	alpha 2
0.2435793125	the conventional group
0.2435309679	among women with cardiovascular disease
0.2434734190	safely to patients with
0.2434067523	effect of dopamine on
0.2433918687	as well as
0.2433906960	the pce group
0.2433443015	used to treat
0.2432893511	p = 0.39
0.2432678210	ecg alone
0.2432463234	experienced severe
0.2432343832	100 microg
0.2431540833	prevented by low
0.2431481962	parp 1
0.2429791623	the first word recalled
0.2429496471	under isoflurane
0.2429145133	these data indicate
0.2429121172	s 100 protein
0.2428681437	did not change
0.2428279843	to avoid
0.2427987262	transferred to
0.2427335906	weeks and then randomized to
0.2426825247	four weeks
0.2426421978	receptor antagonist l
0.2426144729	the area of histochemical
0.2425084336	usually reversible
0.2424614288	patients with ovarian
0.2424395173	both lines
0.2424089874	standard of care for
0.2423972334	association with
0.2423621088	both sexes
0.2423138761	dynamic response of blood vessels during
0.2422664459	15 mg paclitaxel
0.2422547829	progressive deterioration of
0.2422147148	percent of patients
0.2422076599	histopathological evidence of
0.2420748188	the recent literature
0.2420450324	50 mg kg i.v
0.2420413083	administration of flumazenil
0.2420412104	before surgery
0.2420366200	150 mg kg
0.2420044541	seizures group
0.2419163402	reduction of cyclosporine
0.2418943076	data from
0.2418519110	very good
0.2418440552	a new angiotensin ii antagonist
0.2418330231	the exencephalic tissue
0.2416561784	an alkylating agent
0.2416328838	a central role
0.2415182387	to achieve
0.2414788876	to evaluate seizure susceptibility
0.2413157631	known risk factors
0.2412276237	previously described
0.2412195501	in spontaneously hypertensive
0.2411925178	both peptides
0.2411521437	these latter
0.2410783235	each challenge
0.2410295823	measured using
0.2410036213	several types
0.2409704359	a lethal dose
0.2409599018	with or without progestogens
0.2408990829	with d tubocurarine
0.2408748611	the association between antibacterial
0.2408343034	0.04 mg kg
0.2408026101	in hbmp cells
0.2407986269	catalepsy in rats
0.2407629941	this case highlights
0.2407453726	a visual analogue scale
0.2406783619	the intensive diagnostic and treatment unit
0.2406463492	after operation
0.2405891348	in 7
0.2405815568	detachment of
0.2405618280	risk of nephrotoxicity
0.2405207075	administration of avp
0.2405191046	a 73 year old woman
0.2405111165	did not evoke
0.2404644919	clinical response
0.2404569624	effective therapy for
0.2404464036	half time of
0.2403312314	effect of adriamycin
0.2402565278	most often
0.2402555629	the od group
0.2402398228	associated with permanent visual loss
0.2402193608	n = 10
0.2401957423	the seizures persisted
0.2401877558	352 patients
0.2400537692	from cardiac cells
0.2399936062	vitamin c intake from
0.2398859332	during puberty
0.2398722650	doxorubicin and cyclophosphamide
0.2398076308	history or suspicion of cocaine or
0.2397625728	inulin and
0.2397340498	induced arrhythmia
0.2397149288	the contrast injection
0.2396882970	extracts from
0.2396383351	myocardium during
0.2396308431	to 8
0.2396127646	risk of decreased renal function in
0.2395683588	sixty five patients
0.2395530433	a double blind randomized trial
0.2395305860	peripheral neuropathy caused by
0.2394996031	1 microgram kg min
0.2394822683	a patient with hypoparathyroidism
0.2393851555	in hl60 and hbmp cells
0.2393404953	performance status of 0
0.2393063028	100 ng
0.2392653418	6 days after gentamicin administration
0.2392637172	most frequently
0.2392294175	more intense
0.2392287690	scheduled for
0.2391877558	262 patients
0.2391770269	from pueraria thunbergiana
0.2391371026	at high concentrations
0.2391184106	mp before and
0.2390125254	spontaneously within
0.2390038214	the 8 wk group
0.2389169728	chronically treated with
0.2388387093	dox alone
0.2388228489	between treatment arms
0.2388037667	the body surface
0.2387661678	epidemiology of
0.2387661678	periphery of
0.2387437742	experimental model for
0.2386685960	4 amino
0.2386301705	evoked increases in
0.2385807407	after dipyridamole infusion
0.2385655211	administration of quinidine
0.2385546724	the clinical effects of heparin
0.2384497345	the protective role of mangiferin
0.2384321180	65 years
0.2383743443	0.8 mg
0.2383277421	triad of
0.2383209141	patients with aids
0.2382844664	induced cystitis
0.2382596427	60 epileptic
0.2382494553	azt induced
0.2382430169	the present experiments
0.2382083033	= lna +
0.2381771471	a novel bche
0.2381542462	effects of
0.2381032407	chinese patients
0.2380810250	four groups of mice received
0.2380584052	such reactions
0.2380581857	randomly allocated to four
0.2380294020	treatment of chronic hepatitis c
0.2379257574	a negative coronary cta
0.2378791891	p = 0.02
0.2378628860	5 fu infusion
0.2377317642	habitual use of
0.2377219092	and laminin
0.2377219092	and upright
0.2376578603	0.2 mg kg
0.2376556937	well tolerated regimen
0.2376449294	treatment of type 2 diabetes with
0.2376442829	symptoms of toxicity
0.2376358436	treated with methylphenidate
0.2375769960	findings show
0.2375162921	derived from
0.2374573756	from 109 +
0.2374451791	the total population
0.2373765772	into account
0.2373351426	increased plasma
0.2373196451	to estimate
0.2372959170	showed minimal
0.2372922812	7.9 vs
0.2372792393	reactivation in
0.2372714540	a positive correlation
0.2371803579	patients with oab
0.2371579537	the loss of righting reflex
0.2371489910	relieved by
0.2371387969	account for
0.2371180215	animals pretreated with nicotine for
0.2371101327	4 microg 0.5 microl
0.2371078881	accounted for
0.2370571122	demonstrated increased
0.2370386264	with 30
0.2370254699	resolved after discontinuation of
0.2369526923	used with caution
0.2369335209	non lithium treated
0.2369328885	years of follow up
0.2369245916	assessed by cardiac
0.2369223839	the p100
0.2369107531	these data
0.2368380863	during pregnancy
0.2368336573	results showed
0.2368094008	occurring in association with
0.2367096556	the pallidotomies
0.2367096556	the estrogenic
0.2366103936	rats died
0.2365495566	occurred in 78 of
0.2364457210	an important
0.2364058266	experimental study
0.2363875738	caffeine administration
0.2363584267	the non competitive nmda
0.2363285842	at e18
0.2362729095	end of study
0.2362489720	interest as
0.2361986677	the ilk liver
0.2361759836	only partially
0.2361061992	atrial fibrillation following
0.2360700988	mice received
0.2360067165	risk group
0.2359903666	assessed using
0.2359720079	in malaysia
0.2359250743	the degree of anaemia observed
0.2359186601	excess of mb in
0.2358493050	the pentose phosphate shunt activity of
0.2358146134	p 0.02
0.2357952593	concurrent use of
0.2357686635	p =
0.2357596601	these data support
0.2357376340	the hypotensive effect of levodopa
0.2356889813	able to reverse
0.2355546724	the cognitive impairment and decreased
0.2355030323	a cardiac transplant
0.2354909837	status returned to
0.2354681178	given intravesically
0.2354632147	study group
0.2354442666	a 43 year old man
0.2354004012	occurred significantly more often
0.2353834862	each time point
0.2353298794	cardiovascular effects of
0.2352910216	effect of amphetamine
0.2352858345	a risk factor for hiv infection
0.2352750998	significant increases in
0.2352603603	a beneficial effect
0.2352534505	with respect to
0.2351828045	twenty four
0.2351371208	the 4 wk group
0.2350951976	tolerant to
0.2349849856	treated with dex alone
0.2348593767	and 20
0.2348572489	observed in 84 of
0.2348533808	administration of suxamethonium
0.2348281925	a 57 year old
0.2347978252	daily dose
0.2347534160	to treat
0.2346191122	due to gi aes
0.2346096665	severe adenovirus disease in
0.2346026774	studied in 41
0.2345737038	a 76 year old man
0.2345421909	a non competitive antagonist
0.2344564004	probability of
0.2343923835	l min
0.2343537692	an equal volume of saline
0.2343436584	examine whether
0.2342656601	collected from
0.2342319336	180 mg
0.2342177011	days after initiation of
0.2341681005	consisted of 50
0.2341408544	aspirin use
0.2341370719	a drug delivery system to promote
0.2341317157	the propranolol group
0.2340355462	topical papaverine for
0.2340249282	an 84 year old male
0.2339411435	5 mg kg dox
0.2338231536	induced headache
0.2338037728	finger to
0.2337866606	compared to baseline
0.2337649210	5 ht receptors
0.2336819719	the total grade of fibrosis
0.2336505521	further studies
0.2336008143	clinical study of
0.2333967535	during bladder irrigation
0.2333874948	0.05 0.25 mg kg
0.2333570582	incidence of myoclonus after
0.2333505121	severe headache and
0.2333101659	impairments in rats
0.2332991644	fatal aplastic anemia due to
0.2332827425	16 months
0.2332006474	the subcutaneous injection of heparin
0.2331706899	nephrotic syndrome induced
0.2331572794	dbh +
0.2330646625	the 5 minute assessment
0.2330275681	+ 0.001
0.2329625173	the enalapril group
0.2328399202	after dilevalol intake
0.2328135433	majority of
0.2327794645	impairment in rats
0.2327717606	and 6
0.2327257271	diet free of
0.2327044442	cumulative doses of
0.2327007593	the cumulative doses of levobupivacaine
0.2326510342	in fruit
0.2326022629	normal plasma
0.2325462618	implicated in
0.2324755836	exacerbations of
0.2324577678	receptor agonist n
0.2324231569	received combination
0.2324182573	modulation of
0.2323207686	n = 6
0.2323085313	in 3
0.2322996239	postoperative day
0.2322839919	decreased arterial
0.2322767838	11 eyes
0.2321526726	during rest
0.2321051510	effect of
0.2321032844	the management of clinical myoclonus
0.2320519243	under methadone
0.2319964077	without prior chemotherapy
0.2319871486	per patient per hour
0.2319504393	an 18 month
0.2319057651	excluded from
0.2317546724	the initiation of heparin therapy
0.2316122941	higher levels of
0.2315391148	the control and r2 groups
0.2315159958	patients suffering from
0.2314472994	at enrolment
0.2313928731	occurred within
0.2313264611	in high risk patients
0.2313120078	the reference
0.2312662699	patients with parkinson
0.2311997258	200 mg daily
0.2311660188	micrograms day
0.2311659324	response to
0.2311650884	isoflurane induced
0.2311108553	little information
0.2310381794	cases of acute renal failure
0.2310317641	0 mg kg ip
0.2309930785	both eyes
0.2309836740	locomotor activity in rats
0.2309345787	5 hz
0.2308566131	male sprague dawley rats treated with
0.2308219838	do so
0.2307847969	induced manic
0.2307530931	the piriform cortex
0.2307258477	did not improve
0.2306633287	the treatment of choice
0.2303984519	0.64 to
0.2303113731	min later
0.2302831160	and cerebral metabolic
0.2302783795	the routine management of chronic disease
0.2302149329	dose of cyclophosphamide
0.2301649583	in mixed cocaine
0.2301353935	did not reach
0.2300876046	examined whether
0.2300739323	daytime sleepiness in
0.2300321749	rats with low
0.2298560487	in severe cases
0.2298500945	less frequent
0.2298190402	0.7 mg
0.2298089785	produced by pilocarpine
0.2297544023	shown to
0.2297492777	a cohort analysis
0.2297233387	plasma levels of
0.2296408972	in renal transplant
0.2296081939	involved in
0.2295640938	the snp group
0.2295458406	the placebo group
0.2295383554	used successfully
0.2295253154	5 mg kg ip
0.2295232687	patients with advanced
0.2294770155	a potentially fatal
0.2294628437	both groups
0.2294091669	p for trend 0.01
0.2293675626	and gemcitabine combination
0.2291462380	presenting as
0.2291403750	15 min
0.2290816249	in warfarin users
0.2290778217	eight hours
0.2290332152	year old
0.2290252172	of 6
0.2290083147	a marker of glucocorticoid activity
0.2289757113	the human form
0.2289511598	selective blockade of
0.2289479218	the superficial cells
0.2289050835	5 x minute
0.2288442858	timolol treatment
0.2288174495	estimated using
0.2287650556	neuroleptic malignant syndrome induced by
0.2287216140	levels of estradiol
0.2287089542	forty nine
0.2286630417	a variety of
0.2286317208	a potent immunosuppressive agent
0.2286154211	concentration of gaba
0.2285224458	among inbred
0.2284660616	comparable between
0.2283256938	massive doses of
0.2283049086	showed normal
0.2282915862	hepatitis c
0.2282631903	an elderly woman
0.2282114928	patients with head and neck
0.2282046985	6 months
0.2281695290	analysed using
0.2281609459	developed jaundice
0.2281525972	1 mg kg ip
0.2281259638	bpm after
0.2280766431	the only significantly increased risk reported
0.2280724807	hypertension and renal injury in
0.2280327355	the retina
0.2280325218	high dose 5 fu
0.2280271517	and fluid attenuated inversion recovery
0.2280115157	and hexamethylmelamine
0.2280115157	and bethanechol
0.2280115157	and euthymia
0.2280115157	and bodyweights
0.2280115157	and ap7
0.2279958417	with advanced androgen independent prostate cancer
0.2279434620	use of cocaine and or amphetamine
0.2279269633	in protecting against pilocarpine
0.2279225826	120 mg
0.2279159605	did reduce
0.2279147572	and erythroblastocytopenia
0.2278449469	following status epilepticus
0.2278161293	a protective role
0.2277779648	year old male
0.2276630417	in terms of
0.2275557057	further research
0.2275236127	while taking
0.2275186607	allergic reactions to
0.2274885880	three deaths
0.2274542929	19 mg l x
0.2274055629	in older children and adults
0.2273954243	measurement of
0.2273770762	the maintenance of renal blood flow
0.2273728507	24 hr
0.2273591608	common among patients and
0.2272708251	qt prolongation induced by
0.2272467218	peripheral resistance and
0.2271857089	doxorubicin induced cardiotoxicity by
0.2271399275	apart from
0.2270900869	the treatment of spring allergic rhinitis
0.2270770819	prolactin greater than
0.2270638178	correlates with
0.2270449755	option for
0.2270345711	did not influence
0.2269879542	the heart of f 344 rats
0.2269107990	evaluation of
0.2269051043	10 mul of saline
0.2268561979	in patients with supraventricular
0.2268191763	administered rats
0.2268124136	in contrast
0.2268120662	connected to
0.2267573407	cefotetan induced
0.2266807152	use of serum cholinesterase in succinylcholine
0.2266549217	+ 6
0.2266524620	6 hours
0.2266150446	disruption of
0.2265461340	the emergency department
0.2264881850	four separate
0.2264865636	of 12 drivers
0.2264815774	believed to
0.2264616289	daily injections of
0.2263525988	plus epinephrine
0.2263455656	randomly allocated to
0.2263050957	chronic seizures
0.2262736779	900 mg m
0.2262392193	in view of
0.2262167200	twenty seven patients
0.2261169239	infants born to
0.2260676484	terminated because of
0.2260661802	15 ng ml
0.2260200015	patients showed
0.2259836080	development of
0.2259745043	p less than 0.03
0.2259560575	a 1
0.2259456354	or 40 micrograms kg
0.2259341083	muscular rigidity by
0.2259262284	impairment of learning and memory
0.2259245714	+ sd
0.2257989043	or 1
0.2257962651	significantly lower in group p
0.2257788803	completion of treatment
0.2257775213	a 63 year old
0.2257368542	effects of metformin
0.2257349256	toxicity in dogs
0.2257177159	renal damage induced by
0.2257147388	thirty three
0.2256985753	treatment period
0.2256642588	contributing to
0.2256546730	in vivo
0.2255778230	normal serum
0.2254880750	p = 0.004
0.2254832960	reduction in renal function
0.2254704277	the present experiment
0.2254162257	the congo
0.2254162257	the paraventricular
0.2254162257	the derangements
0.2254059310	within 48 hours
0.2254006607	75 min
0.2253815355	compared to wt
0.2253587192	renal patients
0.2253043786	the left kidney
0.2252487141	the offending
0.2252424235	respond to
0.2252253235	0.5 mg kg
0.2252139597	a positive control
0.2252096135	renal papillary necrosis or
0.2251837846	and ln
0.2251837846	and abrupt
0.2251837846	and fangchinoline
0.2251837846	and dicyclomine
0.2251837846	and gait
0.2251674337	tgr than in
0.2251234231	every 21 days
0.2251196115	10 g dl
0.2250710955	between 1999
0.2250178035	genes involved in
0.2249588198	different epilepsy
0.2249561692	post therapy
0.2248585214	the incidence of lindane induced convulsions
0.2248132224	after stopping
0.2247904011	man developed
0.2247786258	selected patients
0.2247704852	result in
0.2247634153	enough to
0.2247491361	used ma
0.2247237054	incidence of death
0.2247178154	and gellan
0.2246978964	with qtp + li dvp
0.2246802810	one patient
0.2246180193	does not affect
0.2246107958	5 ht 6 receptor antagonist
0.2246048323	p = 0.001
0.2245285467	and thyrotropin
0.2245195275	induced acute hepatitis
0.2245015967	in intact rats
0.2244890520	induced catalepsy in rats
0.2244633492	patients with psoriasis
0.2244534187	said to
0.2244247656	alternation of
0.2243669983	l alpha
0.2243550553	the middle cerebral
0.2243490398	studies showed
0.2242916372	doxorubicin treated
0.2242862313	combined with
0.2242785568	20 day old rats
0.2242483031	the haemodynamic effects
0.2241473595	severity of pain
0.2241167310	a university affiliated
0.2240783560	significantly better
0.2240501082	higher rates of
0.2240467363	varying degrees of
0.2239871044	almost complete
0.2239671155	in patients
0.2238968187	repeated administration
0.2238539729	only during central sensitization
0.2238442858	developed signs
0.2238282973	the anterior cerebral
0.2237825029	the dex only group
0.2237706984	the patient
0.2237463645	and increases in fluid consumption
0.2235706244	+ 4.6
0.2235702304	doses of 2.5
0.2235567101	than jj rats
0.2234734142	450 mg kg
0.2234416687	did not correlate with
0.2234154732	evidence for
0.2234091019	topical treatment
0.2234026994	and 40 micrograms kg
0.2233833996	600 mg day
0.2233520903	some degree
0.2233253164	received atropine
0.2233120624	cases of hyponatremia and or siadh
0.2232992166	15 institutions
0.2232777434	900 mg kg
0.2232740352	than cn
0.2231974990	weekly for up to
0.2231590829	chronic treatment
0.2230914323	commencement of
0.2230544331	250 mg
0.2230432206	in face of chronic renal failure
0.2230176466	fibrin thrombi in patients with
0.2229664206	of experiments examined
0.2229603719	different biochemical
0.2228433799	amount of precurarizing dose of rocuronium
0.2227725375	the high dose d med
0.2227558668	treatment with high doses
0.2225975880	and n acetyl
0.2225908455	treatments prior to
0.2224984198	the majority
0.2224584425	absence of significant
0.2224064067	ribavirin treatment
0.2222942360	and d tubocurarine
0.2222337614	ethambutol associated
0.2222211934	after consuming
0.2221618178	a case control study
0.2221485929	group 2
0.2221096688	daily for 7 days
0.2220115050	the hypertensive group
0.2219945335	only slightly
0.2219737219	the expression of frataxin
0.2219673828	induced by pilocarpine
0.2219512817	a four point scale
0.2217834115	animals showed
0.2217744048	a protective role of nrf2
0.2217581205	a 5
0.2217285867	reduction in patients with hemolysis during
0.2217043907	implicated as
0.2215802855	these questions
0.2215622994	the lozenge and gum
0.2215546781	6 sevoflurane
0.2215502872	coadministration of
0.2214940502	divided into two
0.2214582215	against methamphetamine induced
0.2214056975	500 mg m2 d
0.2213716089	8 per cent
0.2213528697	in patients unable to exercise
0.2212958000	all cause mortality
0.2212451455	but not exclusively
0.2212365397	selective inhibitor of
0.2212210385	0 mg kg dose
0.2212163947	model for study of
0.2211833936	34 months
0.2211615469	g body weight
0.2211210327	occurred after
0.2211175610	80 mg daily
0.2210879483	renal and liver
0.2210395264	phenytoin treatment
0.2210205398	and beyond 3 years
0.2209876716	the present study demonstrates
0.2209493234	neurons appear to
0.2209341614	and plasminogen
0.2209132730	and taqia
0.2209132730	and stl2
0.2208346074	a tertiary care
0.2208108905	a 5 year old girl
0.2208096306	time point
0.2207764627	dox administration
0.2207739441	a 28 year old man
0.2207546171	a treadmill
0.2207196871	pan rats
0.2207040508	induced by nicotine
0.2206929209	of 100
0.2206149832	the motor score
0.2205694990	the control group
0.2205438187	in stratum
0.2204660234	by 8 mg kg i.v
0.2203862979	kinase 1
0.2203784045	n = 8
0.2203599606	of 2
0.2203248015	an additional
0.2202945463	indications for
0.2202650539	important because
0.2202596251	this pilot study
0.2201073581	induced acute liver failure
0.2200860598	lymphocytes from
0.2200774075	more potent
0.2200543674	most sensitive
0.2200525218	3 hydroxy
0.2200301745	l noarg treatment
0.2199970251	patient with hepatic
0.2199216159	differential effects of
0.2199077257	+ 2 mmhg on days 4
0.2199054659	the short p p intervals
0.2198907321	continued for 3
0.2198014280	recently described
0.2197976876	ischemia via
0.2197752210	the midline
0.2197686998	and 5
0.2197670559	+ 3tc +
0.2197649683	withdrawn from
0.2197391399	doxorubicin induced
0.2197276902	the lumbosacral
0.2197276902	the chronological
0.2196413016	in pediatric patients
0.2196309316	the flexural
0.2196309316	the unmatched
0.2196309316	the 11th
0.2196309316	the anticocaine
0.2196309316	the proinflammatory
0.2195502465	an update
0.2195139721	treatment of parkinsonism
0.2194991337	na k
0.2194620638	followed by amphetamine injection
0.2194612656	the sixth
0.2194612656	the subcortical
0.2194229566	3 and cis
0.2192997132	cause delirium
0.2192721499	the function of p2x3
0.2192655844	inhibitors such as
0.2192580378	p = 0
0.2191826027	susceptible to
0.2191696651	of 14
0.2191674214	46 months
0.2191437002	group of 45
0.2191211345	the 5 wk group
0.2190867922	n = 12
0.2190669959	the exencephalic
0.2190569071	less than
0.2190435279	such effects of thp
0.2190121542	210 patients
0.2189644919	intravenous dose
0.2189413651	loss of
0.2188842302	p difference = 0.01
0.2188806673	more aggressive
0.2188698474	a trigger to initiate
0.2188659387	risk factors for
0.2188337254	resulted in fatal
0.2188311650	recovery in 3
0.2188062715	in 20
0.2187966535	stimulatory effects of
0.2187837534	evidence of
0.2187410993	beta 2
0.2186619857	needed to
0.2186324282	disease patients
0.2186131396	mg kg i
0.2186106147	chinese patients with
0.2185741468	an open label
0.2185560948	potential mechanisms of
0.2185332674	previous exposure to
0.2184541867	administration of naloxone
0.2183994531	a case report
0.2183705473	the conners
0.2183705473	the intraarterial
0.2183705473	the acoustic
0.2183503746	calculated using
0.2183086200	report of two cases
0.2183007365	signaling via
0.2182843115	incidence of bradycardia
0.2182713979	groups of mice
0.2182417634	the general medical
0.2182221805	cardiac contractility and
0.2182012680	cardiac effects
0.2182002572	at least
0.2181989390	at autopsy
0.2181782268	the cardiovascular system to sodium pentobarbital
0.2181765429	incidence rate of
0.2180831047	high dose group
0.2180642897	decrease in glutamate
0.2180412752	reactivity to
0.2179731107	0 6.1
0.2179516262	intragastric pressure during
0.2179008278	treatment related
0.2179007577	compared with group 4
0.2177614332	at various time intervals
0.2177313145	1 microgram kg
0.2176776851	and infiltration of inflammatory cells
0.2176413032	effect profiles of
0.2176206927	a receptor complex
0.2175323925	with or without
0.2175029982	20 fold
0.2175003926	successful treatment
0.2174763420	siadh associated with vincristine use
0.2173653594	breast cancer patients
0.2172592445	documented history of
0.2172356536	under close
0.2172117982	+ 0.03
0.2171321021	the lung tissue
0.2170802135	in spontaneously hypertensive rats
0.2170103729	the most common manifestation
0.2168857715	does not inhibit
0.2168785459	corneal ulcers associated with
0.2168716881	effects of mk 801 on
0.2168703138	cases of drug induced
0.2167730188	evidenced by
0.2167110024	h in td
0.2166499229	reduction of
0.2166374203	an increased risk of pacemaker insertion
0.2164098166	epinephrine alone
0.2163990813	functional and structural changes
0.2163880179	the patient felt
0.2163642193	the existence of
0.2163612748	new evidence
0.2163353911	chemotherapy naive patients with
0.2163305910	the hematology oncology population
0.2163293186	the sarcolemma of cardiomyocytes
0.2163070611	one minute
0.2162927073	the recurrence of tma
0.2162675856	a favorable response
0.2162570048	cessation of
0.2161838932	with nimesulide
0.2161272586	85 mg kg
0.2161012062	bupivacaine arrhythmogenicity in
0.2160969550	a 1 year period
0.2160915157	forty five
0.2159774473	the world
0.2158824686	short period of
0.2158803917	antidepressant induced
0.2158266431	the kidney during induced hypotension
0.2158100750	the possibility
0.2157995865	the mean contraction
0.2157167714	twenty patients received
0.2156962304	evaluated using
0.2156818878	the protective activity of loreclezole
0.2156720886	and 3 years postimplant
0.2156377776	occur in patients
0.2156073435	induced by reserpine
0.2155535378	responded to
0.2155397009	after adjusting for
0.2155158461	40 mg
0.2154964970	the dentate gyrus
0.2154007530	the most common
0.2153281327	diagnosed as
0.2153183015	neural correlates of
0.2153174142	correlated with blood
0.2153127728	a 31 year old female
0.2150468106	no significant differences between groups
0.2150459618	a 51 year old man
0.2150191850	the preceding months
0.2150010554	after high dose intravenous methylprednisolone
0.2149774889	compared with 3 5
0.2149600789	5 dextrose
0.2149507755	renal effects
0.2149196525	followed by asystole
0.2148777784	studies suggest
0.2148595135	a 40 year old woman
0.2148591605	kg in od vs
0.2148175243	10 micrograms.kg 1
0.2148124608	induced locomotor activity
0.2148020148	n = 7
0.2147547938	of 20
0.2147446096	performed before
0.2147382270	widely used in clinical
0.2147335654	unresponsive to
0.2146502464	therapy for chronic
0.2145946651	in 16
0.2145343702	same dose
0.2145221447	this study investigates
0.2144939918	these drugs
0.2144652732	in conjunction with
0.2144637802	treated with intravenous
0.2144626062	3 and 49 days post administration
0.2144408105	1 mug
0.2144335813	as late as
0.2144175553	caused by high dose
0.2144167134	the dog heart
0.2144124286	and predictors of levodopa induced
0.2143772931	non specific
0.2143259787	to examine
0.2143085214	the intracoronary infusion of cocaine
0.2142897426	on gd 9
0.2142314599	a 63 year old caucasian man
0.2141976582	effect of nifedipine on
0.2141312068	used to monitor
0.2140435830	treatment response
0.2140294099	twenty five
0.2140159167	a short duration
0.2139846750	not affected by ee
0.2139730068	these observations
0.2139669687	also received intravenous
0.2139541030	seems to
0.2139270828	complications during treatment of
0.2138809137	a 61 year old
0.2138803917	nitroprusside induced
0.2137993541	treatment of schizophrenia
0.2137342100	group t
0.2137071425	by examining
0.2136899596	a 77 year old woman
0.2136617230	a meta analysis of
0.2136245298	during dose reduction of risperidone
0.2136140008	group 3
0.2135810489	the periphery
0.2135625552	induced torsade de pointes
0.2135599946	coupled with
0.2135449840	two canine
0.2135309486	significant alteration in
0.2135141619	many tissues
0.2134560232	did not induce catalepsy
0.2133601776	an academic
0.2133331683	a 30 year old caucasian man
0.2132594531	monkeys with different
0.2132359333	pretreatment with
0.2131678316	without mesna
0.2131658973	induction and maintenance of
0.2131187180	toxic dosage of
0.2129931158	3 and 6 months post cab
0.2129748421	female patients with
0.2129631281	forty six
0.2129540169	an increased cardiac output
0.2129413582	ticlopidine induced
0.2129295651	after liver transplantation
0.2128835813	not different between
0.2128729529	regardless of
0.2128693225	time course
0.2128532598	the context of
0.2128385240	followed by
0.2127996905	a cause and effect
0.2127979551	of myocardial cells
0.2127903309	then bcnu
0.2127371283	sulpiride induced
0.2127369982	a murine model of
0.2126793141	administration of
0.2126458521	gentamicin administration
0.2126214762	and functional events
0.2126138467	cyclophosphamide induced
0.2126014690	dose of 20 mg
0.2125732197	1000 mg kg
0.2125515222	add to
0.2124981623	sirolimus use
0.2123806492	these mitochondrial abnormalities
0.2123559420	further investigations
0.2121503686	used to manage
0.2121434704	the circadian
0.2121404390	+ 7
0.2121031880	70 years
0.2120929393	significantly less in patients
0.2120576565	this cohort
0.2120429415	25 35
0.2120408777	response to amphetamine
0.2120369982	in spite of
0.2120271793	a blocked cystic duct and
0.2119953110	methamphetamine induced
0.2119881505	4 fold increase
0.2119213235	infection received
0.2119213031	two patients developed
0.2118028937	a phase ii trial
0.2117902770	the sa
0.2117493054	a resurgence
0.2117405107	doses of morphine
0.2116964674	increased risk of
0.2116953418	times per
0.2116504854	and 4
0.2116385158	increase in creatinine
0.2116338942	of 1
0.2116144201	the intensive care unit
0.2115587947	patient with chronic
0.2115553890	groups showed
0.2115351148	in rat liver
0.2115344684	the basal map
0.2114976498	presents as
0.2114603876	for 4
0.2114290133	significant decline in
0.2114228658	influenced by
0.2114190893	given intravenously
0.2113865422	act by
0.2112537934	+ 0
0.2111674214	61 women
0.2111643589	the attending
0.2110914465	not find
0.2110846696	amnesia caused by
0.2110776383	repeated exposure of
0.2109937953	confirmed by
0.2109491218	an idiosyncratic
0.2109308726	the glomerulus
0.2109308726	the inability
0.2109308726	the bar
0.2109056359	serious morbidity and mortality
0.2108913016	the rate of major hemorrhage
0.2108547341	a useful marker
0.2108496963	a concentration dependent manner
0.2108353439	postoperative day 1
0.2107459686	to explore
0.2107262883	the regulation of muscle tone
0.2107115954	a 69 year old man
0.2106734814	4 mg kg body weight
0.2106556607	motor system
0.2105804194	not receiving methadone
0.2105728977	the offending drugs
0.2105274922	renal injury induced by
0.2103575010	1 year survival
0.2103326334	also raises
0.2102970562	in order to
0.2102885849	early phase of
0.2102682399	d 1
0.2102607073	5 mg
0.2102312331	sensitized to
0.2101428915	seven days
0.2101222885	under 600 mg m2
0.2099714927	seem to affect
0.2099485394	a 58 year old man
0.2099026394	a significant decrease
0.2098662940	before conversion
0.2098530484	the substantia nigra
0.2098096400	after sacrifice
0.2098037683	the toxicity of lometrexol
0.2097737317	to compare
0.2097605742	in 6
0.2097481086	six times
0.2097253606	time to and incidence
0.2096810154	10 and 20 mg kg
0.2096701512	significant difference between
0.2096668893	despite adequate
0.2096478911	members of
0.2096389018	the epm test
0.2096345213	ribavirin therapy
0.2096326667	100 mg daily
0.2095821766	a 15 year old boy
0.2095696458	resulted in death
0.2095559119	free radical generation and
0.2095335182	the striatum
0.2095227295	selective involvement of
0.2095094887	before and after
0.2094810422	a 37
0.2094447406	amount of bleeding
0.2094434661	an adverse drug reaction
0.2094157803	each group
0.2094111861	the authors
0.2093517344	group exhibited
0.2093191556	a 24
0.2092694532	structurally related to
0.2092336290	to identify
0.2091943828	minutes before
0.2091423701	both beta blockers
0.2091387474	in vitro data suggest
0.2091239076	dysfunction characterized by
0.2091186546	these results indicate
0.2090896030	2 mg kg i.v
0.2090755592	using in situ hybridization
0.2090484287	patients develop
0.2090042603	a single icv
0.2089147189	39 + 10
0.2088373973	a level of 0
0.2088141007	oxidative stress in rats
0.2087961411	adjustment for
0.2087702669	helpful in
0.2087213374	but in none of
0.2085123356	1.5 mg x kg
0.2084846118	this study shows
0.2084723938	the drug
0.2084390218	to detect
0.2084224343	observed in 73
0.2083637420	900 mg day
0.2083043729	of 5
0.2081707015	co administration
0.2081609352	an unacceptable
0.2081326515	in cases of low sexual desire
0.2081156002	the b3 serotonin neurons in
0.2080938495	these differences
0.2080574011	no correlation
0.2079356393	these experimental conditions
0.2078903041	chemotherapy including
0.2078883848	the hepatocarcinogenicity of
0.2078744341	and time to asystole
0.2078679131	these patients
0.2078428324	following unilateral
0.2078184678	each subject and compared among groups
0.2078132684	female patients
0.2077673391	47 year old
0.2077539092	4 and 6 weeks
0.2077288973	though short term use appears to
0.2076875892	every 8 h
0.2076616564	while swallowing
0.2076325565	mouse model of
0.2076169513	19 months
0.2075971839	given lead
0.2075433075	first published
0.2075137764	the normal state
0.2075089026	case reported
0.2074652854	protective effect of
0.2074199680	a 62 year old man
0.2074170715	pentobarbital induced
0.2073931813	10 and 50 ng of avp
0.2073908253	developed clinical
0.2073810975	of 4 mg kg doxorubicin
0.2073547681	the sum of
0.2073393998	a double blind
0.2073169209	to 10
0.2073011613	changes occurring
0.2072919912	seizure induced
0.2072502091	the specific aim
0.2072426663	direct effect on
0.2072014382	by consensus
0.2071630508	risk increased with
0.2070963275	inappropriate use of
0.2070554128	the supplementary
0.2070554128	the adenylate
0.2069931069	phase 0
0.2069683975	accompanied by decreased
0.2069514256	beneficial effects on
0.2069481468	by 5
0.2068434158	to elucidate
0.2068397094	and focal nodular hyperplasia of
0.2068104987	cardiovascular system
0.2068078968	severe pain in
0.2067941278	toxicity included
0.2067683808	following ritonavir treatment
0.2067369131	ml 100
0.2067279444	15 mm
0.2067212794	months later
0.2067005588	onset of symptoms
0.2066847179	+ 4 mm hg
0.2066805699	intravenous infusion of
0.2066322885	severe side effects
0.2066065944	with increasing frequency
0.2065736822	an inhibitor of angiotensin converting enzyme
0.2065665796	months of therapy
0.2065602060	an open field
0.2064557789	rats treated with
0.2064418909	these observations suggest
0.2063724978	75 years
0.2062654179	no deaths from breast cancer
0.2062505583	in north carolina
0.2062311877	re exposure
0.2062290593	developed left
0.2061672066	treatment failure
0.2061201797	a double blind placebo
0.2060696261	1 mg
0.2060511234	a biphasic effect
0.2060447536	of thymidine
0.2060405424	20 ng
0.2060370600	this class of compounds
0.2059984648	associated with
0.2059659006	injected through
0.2059435385	an alternative
0.2058738475	a trend
0.2058738475	a nested
0.2058690331	treatment with
0.2058370907	effect on
0.2058100579	particularly suitable for
0.2057979966	seizures induced by
0.2057849742	2.1 +
0.2057829300	after 3 and 5 days
0.2057567404	in humans
0.2057398387	both hepatitis b surface antigen
0.2057351065	a physician
0.2056994775	not less than 18 months
0.2056080637	the presence or absence of
0.2055705492	patients experiencing
0.2055633848	the ecg of
0.2055629418	this syndrome
0.2054733364	clinical activity
0.2054257877	the rat
0.2054217481	observed in
0.2053185588	seizures produced
0.2052587806	determined using
0.2052517260	activity nor
0.2052186742	mean age 70
0.2051906358	induction treatment
0.2051817863	in 60
0.2051666088	erythrocytes from
0.2051619982	a sample of
0.2051577056	an effective
0.2051357758	the causes of thrombotic microangiopathy
0.2051163933	off period score for
0.2051023800	the naranjo adverse
0.2050886284	reduced doses
0.2050519451	such as
0.2049543170	ranged from 3
0.2049060013	not well understood
0.2047729102	this study supports
0.2046725200	young patients
0.2046717369	p = 0.03
0.2046568766	achieved within
0.2046120469	this effect
0.2046092294	inhibited by
0.2045170058	20 micrograms kg 1 i
0.2045024243	following phenytoin treatment
0.2044988531	vcm induced
0.2044715335	short term effects of
0.2044600420	of juvenile rheumatoid arthritis
0.2044593676	a 3 week
0.2044440480	a wide range of
0.2043758575	and historic
0.2043698962	treatment of cancer
0.2043671625	the latter
0.2043597826	then tested
0.2043402247	appear to
0.2043318026	the setting of
0.2043185241	several reports
0.2042916406	impairment of renal
0.2042764241	observed in wt
0.2041811348	a 15 year old girl
0.2041432204	of yellow phosphorus poisoning
0.2041205304	compared with controls
0.2041057739	dose of 400 mg
0.2039777098	6 or 12
0.2039509965	six hours
0.2039390985	a 45 year old male patient
0.2038361056	differential changes in
0.2038340318	serum levels of
0.2038302304	group 1
0.2037461076	every 4 weeks
0.2037294408	the initial stage
0.2036827557	long term use of
0.2036578671	the authors present
0.2036329149	the literature
0.2036227154	t tests
0.2035980026	1 apraclonidine
0.2035898455	testing showed
0.2035872922	appeared to
0.2034671953	after transfer
0.2034293138	a 50
0.2033549690	and plekhh2
0.2033237206	the ovary
0.2033112448	the expression of p2x3
0.2033028023	decrease in heart rate
0.2032651348	forty eight hours after
0.2032533801	groups 1 and 2
0.2032020508	difficult to
0.2031848693	and 60
0.2031814485	in rats with chronic pan nephropathy
0.2031062668	drug concentration in
0.2030124777	administration of desipramine
0.2029791153	the optic
0.2029711247	compared with baseline
0.2029402899	this study demonstrates
0.2029207688	hypotension induced by
0.2029156774	+ 4
0.2028872545	h mk 801 binding in
0.2028861366	endometrial carcinoma after
0.2028699779	operated on
0.2028522302	group m
0.2028036732	treated with d penicillamine
0.2027711171	young women on
0.2027604740	effects of adriamycin
0.2027453552	intravenously into
0.2027434186	in males than females
0.2027428022	week later
0.2027314465	impact on
0.2026812683	livers from
0.2025585258	of 50
0.2025571705	not suffering from chronic
0.2024843324	received high doses of
0.2024819880	years old
0.2024719275	study showed
0.2024628403	worsening of
0.2023755082	1.2 mg
0.2023247964	a matched case control study
0.2023211219	a 15
0.2022648064	frequently used
0.2022587896	2 h after mcao
0.2022579989	interest in
0.2022158307	to 25 mg kg per dose
0.2021982683	resistant to
0.2021890884	12 27
0.2021321697	twice daily for 14 days
0.2019361286	patients with non hodgkin
0.2019333671	this patient
0.2019278258	the masseter
0.2019260687	80 years
0.2018824344	type 6
0.2018668760	25 mg kg
0.2018537365	dealt with
0.2018214676	manifested by
0.2017682556	one hour
0.2017374213	by means of
0.2017162594	the 13th
0.2017162594	the sarcolemma
0.2017162594	the seriousness
0.2017162594	the cavernous
0.2017063078	hyper or
0.2015673170	dopamine and 3
0.2015318272	vte in users of
0.2015016938	patients with cin
0.2014864019	in allografts and native
0.2014792283	a battery of neuropsychological
0.2014542961	prior history of
0.2014235412	presented with relatively
0.2014092379	administration of metoclopramide
0.2013586389	the median number of prior
0.2013475892	5 fluorouracil and folinic acid
0.2013386234	accepted as
0.2012953402	200 mg
0.2012939866	in suppressing
0.2012939866	in youth
0.2012592757	a single
0.2012475932	experimental group of
0.2011898628	both lifetime
0.2011555311	and cd4 + t cell
0.2011439441	the 7
0.2011225400	this animal model
0.2010827582	until now
0.2010791018	therapeutic approach to
0.2010410152	in 10
0.2010089606	a bipolar
0.2009833606	patients with arthritis
0.2009427387	to 10 micromol
0.2009314628	17 and 18
0.2008761438	an experimental model
0.2008164982	effect of captopril
0.2008114884	2 1 block
0.2007633848	the therapy of
0.2006344021	a group
0.2006261664	these findings indicate
0.2006075971	administration of levobupivacaine
0.2005696031	9 nm
0.2005244481	the respective controls
0.2005047532	targeted at
0.2004722017	mg per day
0.2004707151	s fractures in
0.2004608929	unilateral spinal anaesthesia with
0.2004457379	the physician
0.2004309321	until then
0.2004003820	rigidity produced by
0.2003437337	0.5 mg dl
0.2003264239	prolonged depletion of dopamine in
0.2003231937	bupropion use
0.2002896348	or tap water for 15 days
0.2002700545	a 27 year old
0.2001990276	off time
0.2001345662	isolated from
0.2001103433	high frequency stimulation of
0.2000870543	for ovulation induction
0.2000565927	without sequelae
0.2000562147	in patients receiving
0.2000414252	na +
0.2000378650	closely related to
0.2000282201	and succinylcholine 1.5 mg x kg
0.1999612344	to determine whether
0.1998996851	8 fold
0.1998946763	exposed to lithium
0.1998702106	the lamina rara externa of
0.1998652994	differences in
0.1998530622	use of benzodiazepines or related drugs
0.1998380453	time curve
0.1998153352	the duration of apnea
0.1997725012	role in
0.1997412062	detected in
0.1996635940	continued treatment
0.1995958381	behavioral effects of
0.1995711082	increased heart rate
0.1994665418	increased by 50
0.1994637295	with 2 drug therapy
0.1994244341	and partial recovery in 3
0.1994107871	acetaminophen group
0.1993568014	7 days prior
0.1993350271	administration of azt
0.1992797773	used alone or with methylphenidate
0.1992541812	4 mg kg
0.1991898596	infusion time
0.1991498964	reduced in animals treated with
0.1991444756	a normal sodium
0.1991242538	a hot
0.1991220855	of potentially useful anti
0.1991124478	able to prevent
0.1991095656	of matrix gla protein
0.1990941025	in hemodialyzed patients receiving desferrioxamine
0.1990561278	onset time
0.1990404437	cp induced
0.1989994341	the change of pressure in gentamicin
0.1989853349	these agents
0.1989369617	prevention of hepatitis b
0.1988851586	of 4
0.1988477032	for pulmonary tuberculosis
0.1988210669	cells per
0.1988086462	evoked by
0.1987909323	+ 0.2
0.1987874528	expression level of
0.1986733250	range 1
0.1986700206	the p10 or s groups
0.1986658132	55 years
0.1986610598	cases of delayed
0.1986473728	inhibition of cardiac
0.1986247344	forty eight
0.1986110729	group showed
0.1986031155	+ 1.5
0.1985914781	4 micrograms.kg 1
0.1985597396	drug effect
0.1985584328	time to progression
0.1985154573	2 microg 0.5 microl
0.1985116607	an accurate
0.1984858623	in 40
0.1984736078	in rats
0.1984589993	the following databases
0.1984360556	the occurrence of pvc
0.1984317995	the 2
0.1983601554	effects of caa on
0.1983266358	a 30 year old caucasian
0.1983203119	before lt
0.1982083608	effects of sirolimus
0.1982005588	to prevent
0.1981635940	estradiol treatment
0.1981509652	the study
0.1981370600	10 weeks after conversion
0.1981360889	induced neurotoxicity
0.1980446605	in salt depleted
0.1980363123	10 and 50 ng
0.1980008966	some case reports
0.1979829566	increased numbers of
0.1979293583	the delta down
0.1979143676	effects of melatonin
0.1978482261	and memory induced by scopolamine
0.1978317754	susceptibility to
0.1977970282	considered as
0.1977890495	in group
0.1977171860	given gm
0.1977147243	most important
0.1976538750	drug use
0.1976199675	from 107
0.1976154408	either free dox or
0.1976081957	administered to rats
0.1975964485	the dural
0.1975731589	that seen after exercise
0.1975730920	impaired patients
0.1975664835	plus sulindac
0.1975436106	the democratic republic of
0.1974410228	other factors
0.1974317815	0.9 mg
0.1973814818	administration of methylprednisolone
0.1973572029	for unilateral spinal anaesthesia
0.1972529985	of 12
0.1972400799	maximum doses of
0.1972303022	acts as
0.1971975019	considered in patients
0.1971936896	alone or in combination
0.1971580393	one week later
0.1971477931	these observations indicate
0.1970867883	complete heart block with
0.1970818696	measured in plasma and
0.1970679648	on postnatal day
0.1970672281	two groups
0.1969808286	at regular intervals
0.1969606487	a mixture of
0.1969534050	the number of nadph
0.1969416513	the question
0.1969116564	one month later
0.1968938043	7 g dl
0.1968891121	the release of acetylcholine
0.1967715833	in north
0.1967621397	30 mg kg
0.1967245855	cross tolerance to
0.1966030839	did not change significantly
0.1965204981	despite extensive
0.1964970212	the same experimental model
0.1964581207	group of animals
0.1964270470	inhibition of
0.1964260783	the most commonly prescribed
0.1964258681	for cluster headache
0.1964183286	higher doses of
0.1963422974	blood pressure became
0.1963344326	the prognosis for
0.1962593379	dogs under
0.1962477240	induced map
0.1962326674	need for additional
0.1962303974	this phenomenon
0.1961911477	p = 0.015
0.1961860474	neither patient
0.1961491537	doses of 200 mg
0.1960988375	in experiment set up
0.1960715747	does not seem
0.1960434358	the aim of
0.1960173624	carcinoma developed
0.1959800187	and 21
0.1959427351	all patients recovered
0.1958854508	16 ml 100 g min 1
0.1958813676	used to measure
0.1958687546	a brief observation period
0.1958354211	remained unaffected by
0.1958080032	the dorsal root ganglia
0.1957751049	6 fold
0.1956972800	all patients
0.1956784345	mm hg sem in
0.1956429035	the creatinine concentration of 0.5
0.1956080205	significantly greater with asenapine at 5
0.1955600063	ten subjects
0.1955376102	the neutral and acidic
0.1955359409	the cataleptogenic effect of
0.1955158812	months of follow up
0.1954956805	or 10
0.1954557446	testosterone therapy
0.1954509934	consists of
0.1954464428	exposure to
0.1954229008	weeks after initiation of
0.1953498180	in 2
0.1953367302	developed grade 3
0.1952956955	induced myoclonus
0.1952727027	a 45 year old man
0.1952173290	terminated 3
0.1951519304	p or = 0.01
0.1951465096	ml 100 g min 1
0.1950976921	enhancing effects of
0.1950833557	muscle mass or
0.1950721032	sixty two patients
0.1949447568	phase 4
0.1949382357	8 wk
0.1949100083	and agoraphobia
0.1948701430	+ 0.06
0.1948549260	the gamma knife
0.1948079104	s level of consciousness
0.1947214175	an important role
0.1946631840	of interlobular bile ducts
0.1946387119	deaths related to
0.1945682636	onset of seizures
0.1945567067	20 mg kg i.p
0.1945409256	the three treatment groups
0.1945151867	the protective role of nrf2
0.1944973907	within 30 minutes
0.1944757291	any behavioral effects
0.1944068738	both phasic and tonic
0.1943254496	without neurological
0.1943241217	10 40 mg kg 1
0.1943101418	+ 2 mm hg
0.1942810323	0.3 mg
0.1942359154	2 g dl
0.1942348283	a reference
0.1941248629	negative effects on
0.1940712582	p for trend
0.1939981081	the patients with clinical and subclinical
0.1939575146	d amphetamine
0.1939513909	cd4 +
0.1939262112	reported in 11
0.1939256776	confined to
0.1939256776	progressing to
0.1939095039	treatment with amiodarone
0.1939059738	animals treated with
0.1938819972	time course of lipid peroxidation
0.1938619970	30 mug of morphine
0.1938504469	in 2 cases
0.1938487511	effects of exercise on
0.1938276696	vs 34
0.1938056664	+ 13
0.1938029475	the main outcome
0.1937769769	reduced progression of
0.1937566204	as early as 3 hours
0.1937028958	the progression of diabetic nephropathy
0.1937004195	at 5
0.1935963259	frequency and severity of
0.1935879771	the steady state level of
0.1935877533	liver disease caused by
0.1935096949	occurred in
0.1935094772	a mouse model
0.1935001917	a patient treated with rifampin
0.1934985970	550 mg m2 d
0.1934620594	the optical
0.1934613022	to beta lactam antibiotics
0.1934498396	the last few years
0.1934141436	days after treatment
0.1934105101	10 micrograms
0.1934006303	the hypothesis
0.1933528724	5 min
0.1933510219	infections than
0.1932214877	effect on plasma
0.1932177614	history of hypertension
0.1931755031	concomitant treatment with
0.1931457919	measured before and
0.1930981577	did not induce
0.1929929929	the third cycle
0.1929677254	as anticipated
0.1929423783	and electrophysiological findings
0.1929416878	min 1
0.1929315645	respiratory changes
0.1929129312	four patients died
0.1928983262	of 30
0.1928818783	the unilateral group
0.1928485019	and histochemical
0.1928104558	measured by
0.1926736147	four hours
0.1926177889	of patients
0.1926076576	the sphincter of oddi
0.1925424111	60 and 90
0.1924817541	the incidence of subependymal cysts in
0.1924332768	this patient population
0.1923920277	some individuals
0.1923506520	the thermal sensitivity test and
0.1922980922	30 minutes
0.1922658023	received saline
0.1922587652	models of pain
0.1922122980	0.05 mg kg
0.1921975946	effects of ecstasy
0.1921649131	48 weeks
0.1921620952	use of antibacterials
0.1921283503	studied in female
0.1920742543	the control
0.1920631680	resolution of symptoms following
0.1920398083	from 1 9 renal transplant patients
0.1920278311	dose of 200 mg
0.1919390973	years since
0.1919021611	mean peak
0.1918972527	acute effect
0.1918833571	of pallidal
0.1918615251	dose of 4 mg kg
0.1918153814	the co2 response
0.1917690674	in men and women taking
0.1917514149	this model
0.1917395370	slices from
0.1916982928	or testosterone less than 4 ng
0.1916885678	mediated via
0.1916492599	reduced plasma
0.1916433905	+ 1
0.1916411153	severe renal
0.1916371037	a dose dependent delay in
0.1916334311	possible mechanisms
0.1916167289	in pigs
0.1916100625	3 years
0.1915971487	treated with corticosteroids
0.1915824093	other side effects of heparin therapy
0.1914809705	in good condition
0.1914781334	344 rats
0.1914028714	than quetiapine
0.1913539320	a patient with ileostomy
0.1912880009	the relationship of
0.1912550143	a renal transplant patient with
0.1912426575	elicited by
0.1912003311	the main
0.1911969107	elevation of
0.1911274640	assigned to group
0.1910785859	a total of
0.1910716987	occurred in 4 patients
0.1910557838	and 8
0.1910359120	for 28 days
0.1909987935	within 24 h
0.1909950526	over 3 hours
0.1909747906	six months
0.1909670613	reductions in
0.1908992130	presented with
0.1908490440	number of
0.1908160748	week of therapy
0.1907779487	did not find
0.1907619660	on bupivacaine arrhythmogenicity
0.1907371486	and associated risk factors
0.1907232925	+ 12
0.1907014329	a case of
0.1906999974	at various times
0.1906374024	serum samples from
0.1905546389	animal models of
0.1905215320	35 days
0.1904148749	forty three
0.1903497436	induced in rats by
0.1902913455	of 8
0.1902679012	or 2
0.1902582780	for non acetaminophen induced
0.1901633944	structural damage to
0.1900351684	patients tested
0.1900292138	in mice
0.1899966154	only minor
0.1899419977	doses of cimetidine
0.1899347215	for 10
0.1899281918	treated only with
0.1899029969	g day
0.1898691899	the relation between vitamin c intake
0.1898651247	the clinical global
0.1898383627	phase ii study of
0.1898242383	of peroxisomes
0.1897786066	and 24 hour urine
0.1897275160	relatively high
0.1897146645	five minutes
0.1897065312	these cases
0.1896539293	seizure patients
0.1896134199	in protecting
0.1896124003	a permanent pacemaker
0.1895910326	this latter
0.1895719791	and 9
0.1895265181	by measuring
0.1894921556	to 1200 mg
0.1894330481	treated with methadone
0.1894324753	to obtain
0.1893899633	belonging to
0.1893899633	dropped to
0.1893899633	proportional to
0.1893899633	attempts to
0.1893380284	the heart
0.1893354820	in 68 of patients
0.1892609599	or sm 5887
0.1892063458	and p = 0
0.1891952169	or 2.5 mg
0.1891322341	correlated significantly with
0.1890760242	for over 6 months
0.1890171161	during 5 fu infusion
0.1889923617	patients underwent
0.1889694841	a and fk506
0.1889213305	to ensure
0.1889213305	to differentiate
0.1889018663	postmenopausal women with
0.1888824968	1 mg kg i.p
0.1888488592	combined therapy
0.1888097226	= 70 years
0.1887848328	oral d
0.1887454898	randomized comparison of
0.1887324147	stimulant effect of
0.1887129006	with prolactin greater than 35 ng
0.1886115829	decreased from
0.1886016855	statistical significance at
0.1885802605	and higher baseline
0.1884717785	42 days
0.1884421169	warfarin patients
0.1884259578	worsening after
0.1882681710	the inhibitory effect of
0.1882509477	6 weeks
0.1882349327	other body
0.1881933116	a retrospective cohort study
0.1881337888	old male
0.1881080656	response to isoproterenol
0.1880537478	this drug
0.1879989651	12 subjects
0.1879903635	further observations
0.1879632594	or placebo
0.1879402375	cyclophosphamide associated
0.1879078234	increase in
0.1878900159	patients with chronic hepatitis c
0.1878765576	different rates
0.1878757363	3 hour infusion followed
0.1878296450	challenged with
0.1877965853	an antimicrobial
0.1877818832	patients at risk
0.1877531155	blood brain barrier in
0.1877530379	a pilot study
0.1877465743	60 mg m2
0.1877381913	twenty eight patients
0.1876013220	2.5 years
0.1875331667	the right and left ventricular wall
0.1875302223	particularly in older
0.1874896506	during reperfusion
0.1874853931	doses of pilocarpine
0.1874660932	a passive avoidance task induced
0.1874582336	doses of
0.1874311121	a mixed pattern
0.1874255119	patient years
0.1873865124	350 mg kg
0.1873713342	in mmecs and in
0.1873681595	a subset
0.1873318824	bortezomib and dexamethasone as
0.1873116296	47 mg
0.1873114061	a patient
0.1873089543	old female
0.1872651888	but did not significantly alter
0.1872590913	five patients receiving
0.1872316978	and function in neurons in vivo
0.1871250678	the brain
0.1871177827	a high
0.1869923284	in order to clarify
0.1869800942	a statistically significant greater mean
0.1869781838	study assessed
0.1869185254	1 h after ingestion
0.1869105331	bupivacaine administration
0.1868647410	a 67 year old man
0.1868588402	by ly274614
0.1868527698	a 30
0.1868340103	pretreated with
0.1868049066	two neonates
0.1867948471	treated with rifampin
0.1867941854	the middle
0.1867720708	a 2 day period
0.1867251755	more common among
0.1866976002	nephrotic syndrome induced by
0.1866488808	for four days
0.1866210619	administered in high
0.1866122575	genetic variants of
0.1865975445	action of
0.1865885567	a single oral dose of
0.1865788671	safety of lidocaine in
0.1865714589	dose of 1 mg kg
0.1864763562	the most frequent
0.1864210769	3 year follow up
0.1863937476	reversal of
0.1863876368	on vision and driving
0.1863636065	administered alone
0.1863577144	efficacy and toxicity of
0.1863256069	respiratory arrest with
0.1863220941	with and without chronic prazosin
0.1862741278	an urban
0.1862705340	and 16
0.1862703083	participated in
0.1862673255	to 7
0.1862528310	and 15
0.1861386572	and 30
0.1861239809	syndrome characterized by
0.1860799741	the improvement in lid
0.1860705289	after conversion
0.1860263261	the diagnosis of reye syndrome
0.1860024043	by 6
0.1860006422	associations with
0.1859924996	the ma induced
0.1859299485	a patient controlled analgesia
0.1858298637	expression and activity of
0.1858186823	more relevant
0.1857210495	of levodopa induced dyskinesias by
0.1857188250	busulfan induced
0.1856799518	six areas
0.1855543807	the basis of body surface area
0.1855279256	before and after tdi
0.1855258902	an outpatient
0.1855258902	an irreversible
0.1854185745	increased anxiety
0.1854056708	carried out using
0.1854049900	and intervention groups
0.1853965670	while decreasing
0.1853726826	patients in group 2
0.1853680996	an increase in
0.1853564723	a prospective study
0.1853347951	5 glucose
0.1853270164	a probable relationship between
0.1852924091	seven men
0.1852680468	treated with bromocriptine
0.1852297938	the p100 group than in
0.1852067131	after 5
0.1852040289	n = 36
0.1851998302	kg per day
0.1851703308	the patient developed acute
0.1851284135	with gum arabic on
0.1851283259	or cp 93129
0.1850496766	the spinal cord
0.1850414282	dose of pilocarpine
0.1849586544	long term administration
0.1849396903	sufficient to
0.1849225159	included patient
0.1849199745	reason for
0.1848907811	the patients
0.1848864495	the decrease of mbp and hr
0.1848647410	a 54 year old man
0.1848439232	remained significant after
0.1847219237	250 mg m
0.1847055026	3 2
0.1846779880	increase in blood
0.1846552311	showed increased
0.1846418998	each patient
0.1846346074	evaluated by
0.1845830537	in 12
0.1845640363	10 40
0.1845593087	20 microg
0.1845384220	in 24
0.1845361695	and brush
0.1845215333	day schedule
0.1844872766	a single bolus
0.1844275749	a 50 year old woman
0.1844192431	younger patients
0.1844000826	a 45 year old
0.1843787927	60 years of age
0.1843508063	lower in groups
0.1843335531	sodium increased
0.1842360974	killed at
0.1842326533	two control groups
0.1842009613	this reaction
0.1841981119	drug interaction between
0.1841954498	treated with tamoxifen
0.1841720506	for acute promyelocytic leukemia
0.1841545711	s hospital
0.1841279982	for metastatic breast cancer
0.1841024007	the primary prevention of cardiovascular
0.1840940409	six additional
0.1840830044	the combination of gem and vnb
0.1839863585	and behavioral abnormalities
0.1839333021	the observation test
0.1839208520	after sectioning of
0.1839169514	a significant relationship
0.1839148141	before 5 fu infusion
0.1839008667	the ventricular fibrillation threshold
0.1838977878	significantly superior to
0.1838922814	negative effect on
0.1838381676	more than
0.1838129754	the hepatotoxic effects of
0.1837790059	an additional risk
0.1837646683	1 year
0.1837627486	most probably
0.1837506834	right heart
0.1836787622	new agent
0.1836342620	anxiety and depression than
0.1836118025	while receiving
0.1836080229	the c + e group
0.1835942955	away from
0.1835936951	the reuptake
0.1835824093	to 2.5 mg
0.1835566801	blood pressures at
0.1835553193	of 7
0.1834400748	the spontaneous reporting system
0.1834361397	induced breakdown of
0.1834347585	e i
0.1834112452	of 160 patients
0.1833695720	+ 1.1
0.1833547509	control patients
0.1833490054	administered immediately after
0.1832960108	a postdose scr increase or =
0.1832855321	the supplementary motor area
0.1832237849	the above mentioned
0.1832144342	17 months
0.1832116593	of 15
0.1831805502	the hippocampus
0.1831068123	and 50
0.1830315795	two cases of propylthiouracil
0.1830249812	clinical seizures in
0.1830104267	suppression of
0.1829997303	both types
0.1829929978	15 and 30 mg kg
0.1829698080	bupivacaine induced
0.1829526027	to 3
0.1829288245	treatment increased
0.1829268922	+ sem
0.1829226200	s lymphocytes
0.1829172708	the respective groups
0.1829057843	a 70 year old
0.1828944541	the center of snr
0.1828820610	hyperactivity induced by
0.1828818636	diagnosed with
0.1828814196	in japan
0.1828500856	activity in renal
0.1828485852	even with low doses
0.1828333018	a 12
0.1828159514	in 14
0.1827573380	the carbamazepine dose
0.1827204452	for five consecutive days
0.1826999113	signs of
0.1826855268	gap43 ir in
0.1826687653	these effects
0.1826222274	an inverse
0.1825987125	before admission
0.1825567575	term treatment with
0.1825503772	for four consecutive days
0.1825199864	before starting
0.1824965926	an uncommon
0.1824511752	a ten year
0.1824359505	30 and 45 minutes
0.1824280981	at different times
0.1824131427	the present
0.1824099119	chronic administration
0.1824025318	of immediate release oxycodone in
0.1823940860	an increase of serum creatinine
0.1823166021	12 healthy
0.1822110826	and olanzapine and risperidone
0.1821999304	a newly described
0.1821861913	twenty six
0.1821397529	forms of
0.1820976634	5 mg dl
0.1820769869	the kinin b2 receptor
0.1820724757	subacute effects of
0.1820693626	2.5 20 mg
0.1820176256	administered once
0.1820147578	revealed normal
0.1820066664	for bipolar
0.1819891315	further deterioration
0.1819472272	dose of metoprolol
0.1819393563	to analyze
0.1819325604	a 65 year old woman
0.1818726115	further investigation
0.1818681050	injury in rats
0.1818513684	patients treated with
0.1818510627	presence of
0.1818411024	normal renal
0.1816429390	the dysrhythmogenicity of subsequent
0.1816385408	of bcl 2 and
0.1816250737	a 49 year old woman
0.1816233664	for 5 weeks
0.1816161228	of ectopic hilar granule cells
0.1815949013	the timing
0.1815817720	a useful animal model
0.1815207592	varied from
0.1814448596	a dose dependent increase in
0.1813837831	second day of treatment
0.1813568015	the role of
0.1813526172	into 4 groups
0.1813376494	the objective of
0.1813327313	did not attenuate
0.1813004862	but not
0.1812871736	results of clinical
0.1812741452	14 days
0.1812694033	subscale with
0.1812612385	apomorphine treatment
0.1812612385	pan treatment
0.1812401634	ameliorated by
0.1812085016	using cocaine and or amphetamine
0.1811815245	assessment of
0.1811177438	if confirmed
0.1810786210	the asenapine at 5 and 10
0.1810372937	blockade of
0.1810258635	of other enzymes
0.1809872640	no deficient rats
0.1809817307	renal allografts with
0.1809634002	increased from
0.1809605474	the basis of
0.1809323676	of tet and fan in mice
0.1809102000	of cocaine
0.1808849207	the end of
0.1808769998	this clinical case
0.1807689433	used to evaluate
0.1807566692	the amount of daily urinary protein
0.1807342903	at e13
0.1806536779	serious adverse effects
0.1806263281	two distinct
0.1806239091	of hibiscus rosa sinensis
0.1805973501	on pod
0.1805562356	expression of
0.1805506361	propensity for
0.1805506361	substituted for
0.1805332640	patients achieved at least
0.1805209311	on gestational
0.1804899121	the lithium concentration in
0.1804585207	in 5
0.1803939713	48 h after surgery
0.1803765489	15.3 +
0.1803673521	40 mm hg
0.1803650181	intravenous injection of
0.1803611489	n = 17
0.1803179730	normal control
0.1803075259	clinical experience with
0.1802939035	a dopamine beta
0.1802889721	the potential role
0.1802215774	15 mg kg
0.1801493398	100 mm
0.1801456403	90 min before
0.1801354426	during angiotensin converting enzyme
0.1801005938	fas ligand in
0.1800151739	an important role in
0.1799486842	other diseases
0.1799472272	dose of fentanyl
0.1799186950	these models
0.1799088687	160 mg m2 d
0.1798777493	the mean body weight of dogs
0.1798672938	administration of sirolimus
0.1798618999	acetate in combination with
0.1798431938	adverse effect of
0.1798091081	severe alterations in
0.1797614942	localization of
0.1797526005	for 8
0.1797507825	amphetamine use
0.1797469131	the first published case
0.1796702355	titrated to
0.1796629564	50 mg kg per dose
0.1796304865	antagonized by
0.1796162075	effect of norepinephrine
0.1795800311	in 55 patients
0.1795327334	at diagnosis
0.1794428257	mg per deciliter in
0.1793491307	these studies suggest
0.1793473789	a prospective
0.1793320449	patients with atypical
0.1793002165	patients experienced
0.1792910097	three hours later
0.1792494513	= 0.01
0.1792338761	in allografts
0.1792177191	an acute hepatitis like
0.1791493729	provide evidence for
0.1791203952	various concentrations
0.1791062715	four control groups
0.1790446477	and urine sediment score
0.1789906305	or = 1000 ml
0.1789701195	used for comparison
0.1789535254	a single dose
0.1789508477	the mechanism of cs
0.1789395898	pairs of
0.1789367405	five patients with idiopathic
0.1789287836	a cluster of seizures
0.1789103909	some features
0.1788959888	shifts in
0.1788807494	10 min
0.1788590088	the 10 monkeys developed
0.1787624666	anaesthetised with
0.1787271778	10 and 30 mg kg
0.1787040362	modified by
0.1786650075	10 mg bid
0.1786559462	alfentanil induced
0.1786554472	day 7
0.1786395147	open label trial of
0.1786394089	this association
0.1785750446	a short period
0.1785641849	drug drug
0.1785603239	the presence of autonomic blockade
0.1785550882	and midline
0.1785347847	pathways following
0.1784968646	prove to
0.1784835676	changes occur
0.1784814754	eight and thirty three
0.1784493117	induced toxicity
0.1784370311	manifestation of
0.1784281413	multiple cases of
0.1784074348	bromocriptine induced
0.1783721707	+ 3
0.1783698818	placebo controlled trial of
0.1783452361	no apparent
0.1783307813	+ 2
0.1783239221	eligible for
0.1782534333	a 49 year old
0.1782381219	more likely to develop
0.1782367530	evaluated in rats
0.1781053908	1 mg.kg
0.1780883690	decrease in blood pressure
0.1780865330	1 microgram
0.1780798568	seven years
0.1780781754	nine days later
0.1780744981	located on
0.1780660284	and 1 case
0.1780653842	selective injection of
0.1780378804	consisting of
0.1779791146	for severe adenovirus disease
0.1779714826	control mice
0.1778248036	amounts of
0.1778002824	treatment of parkinson
0.1777211123	a man test
0.1777175154	p = 0.09
0.1776985600	to december 2010
0.1776206882	a 23 year old
0.1775972971	the treatment
0.1775361031	or 5
0.1775221098	the results
0.1775193404	the increased
0.1774823096	increased sensitivity to
0.1773824113	12 week
0.1773775831	as 3
0.1773625545	weeks of therapy
0.1773606528	this retrospective study
0.1773480069	in patients following renal transplantation
0.1773208187	to 6
0.1773196417	and nk1 receptor
0.1773096723	13 months
0.1771991365	rr 1
0.1771819971	of 10
0.1771631249	on neuroleptic induced catalepsy
0.1771442693	or 3
0.1771379244	to convert
0.1770600370	the sa node of
0.1770239459	especially in older patients
0.1769944676	s encephalopathy
0.1769865856	activation of
0.1769713596	the period 1993
0.1769447006	5 years
0.1769244896	effect of morphine
0.1769015682	and patch tests to
0.1767465919	continue to
0.1767454082	an alcoholic
0.1767109455	in drinking water
0.1766120886	induced cardiotoxicity
0.1766013003	in rats treated with 6 ohda
0.1765806844	to 14
0.1765412978	several weeks
0.1764994893	a pediatric patient
0.1764915970	among applicators with
0.1764575064	a 41 year old
0.1763856752	initiation of therapy
0.1763713048	+ 8
0.1763289604	incidence of
0.1763216586	reduction in
0.1762644831	the liver
0.1762597458	occurs following
0.1762534333	a 52 year old
0.1762369557	for confounding variables
0.1761754173	pharmacodynamics of
0.1761415113	a long lasting
0.1760848459	and 11
0.1760365651	to 2
0.1760196630	in conscious spontaneously hypertensive rats
0.1760116437	different mechanisms
0.1759438861	an increase in tdr
0.1759375362	12 hours
0.1759158188	resolved after therapy with
0.1758751874	and 3
0.1758416843	even at low
0.1758326654	received dox
0.1758075505	these complications
0.1757592938	transplant recipient with
0.1756764704	showed few
0.1756643944	levodopa responsiveness of
0.1756363036	a significant increase in
0.1756030399	by light microscopy
0.1755684857	+ 5
0.1754991224	as part of
0.1754932082	infected patients with
0.1754615870	on days 1
0.1754574028	four weeks later
0.1753647036	previously shown to
0.1753420057	evaluated whether
0.1753262906	these data show
0.1753112331	acute pain
0.1753000845	ten minutes after
0.1752415970	but did not completely protect against
0.1752397686	reported in association with
0.1752251676	no significant change
0.1752052029	effects on
0.1752049591	effects of nicotine on
0.1751998731	to 9
0.1751014813	this observation
0.1750844210	8 + 2
0.1750600370	the stl1 and stl2 in
0.1750574202	containing quinine
0.1749821790	developed sustained
0.1749685205	the influence of pentobarbital
0.1749550992	the disease state
0.1749013853	back to normal
0.1748989699	p = 0.01
0.1748585657	effects of captopril
0.1748390930	caused by propofol
0.1748292847	44 years
0.1747983886	a unique opportunity to
0.1747664106	and 7
0.1747654899	seemed to
0.1747503586	well known side effect
0.1747469236	data on
0.1747232038	the first injection of stz
0.1747227919	both drugs
0.1747226002	suggestion of
0.1746912755	no difference
0.1746871819	a patient with chronic renal failure
0.1746714423	and 1
0.1746293930	early signs of
0.1746265168	the nigrostriatal
0.1746091262	the rats
0.1746003368	glucagon on
0.1745775478	2 occasions
0.1745731185	both strains
0.1745727532	near normal
0.1745032342	does not induce
0.1744840534	presenting with
0.1744480164	1 year serum creatinine
0.1744450819	ca 2 +
0.1744324256	10 to 15 minutes
0.1744257974	not sham stimulation
0.1743717280	d penicillamine treatment
0.1743271114	provide further
0.1742590083	an identical
0.1742384005	the nucleus accumbens
0.1741251615	analysis of
0.1741234049	14 and 20 weeks
0.1740606967	day 14
0.1740245872	a few days
0.1740234596	a rare syndrome
0.1740029393	acute renal failure after
0.1739971679	of 40
0.1739824028	the mean 24 hour heart rate
0.1738997129	from 1
0.1738849836	on period score for
0.1738660092	one way
0.1738596444	both groups of shr
0.1738008287	a projection
0.1737690709	by 2
0.1737285273	of 60
0.1736713090	after 2
0.1736448868	compared with conventional
0.1736089819	in dogs with lymphoma
0.1735849565	5 microg i
0.1735528179	this condition
0.1735225147	topical administration of
0.1735212139	or = 65 years
0.1735113154	surgical patients
0.1734784099	several recent
0.1734743308	a significant difference
0.1734600865	co administration of lidocaine
0.1734491253	2 per cent through
0.1734364518	test whether
0.1733993982	the dose of cya
0.1733807303	to 0
0.1733755081	level of activity
0.1733741916	cyclophosphamide induced cystitis in
0.1733327547	short term use
0.1733010524	2 year follow up
0.1732750200	in rats with chronic pan
0.1732742296	the authors conclude
0.1732115456	n = 25
0.1732051063	by chronic morphine administration
0.1732034095	up to 300
0.1731951396	= 0
0.1731177358	of focal nodular hyperplasia
0.1731119567	acrolein at
0.1730835111	the remaining
0.1730651004	cerebellar atrophy in
0.1729744974	three weeks
0.1729613960	did not differ significantly between
0.1729122937	diagnosis of
0.1728513003	the two
0.1728173267	as 1
0.1728162026	received lidocaine
0.1728162026	received cisplatin
0.1727910913	significantly higher in
0.1727741287	on different days
0.1726632054	g ml
0.1726208461	starting treatment with
0.1725475570	in patients with ssc
0.1725458611	coronary cta after
0.1725218068	representative of
0.1724875782	treated with warfarin during
0.1724660793	similar between
0.1724611254	at 1
0.1724339639	other sites
0.1723962905	a 34 year old
0.1723050809	possible adverse effect
0.1722614553	to 5
0.1722480866	obtained before
0.1722395759	twenty eight
0.1722066150	showed marked
0.1721771979	ceased after
0.1721134561	developed progressive
0.1721052568	the development of bradyarrhythmias
0.1720913130	c + e
0.1720796895	within 12 hours
0.1720781707	as expected
0.1720758628	a patient with decompensated
0.1720336220	effective treatment for
0.1720290361	1 mg kg
0.1719883211	+ 1.2
0.1719844897	group consisted of
0.1719797274	250 mg kg
0.1719570424	in vivo protection
0.1719137062	the myocardial
0.1718873823	on days 1 to 3
0.1718764334	the 15
0.1718278339	received intravenous
0.1717759372	increasing levels of
0.1717685355	a significant correlation
0.1717326924	this approach
0.1716432293	more than 50
0.1716300392	lasted for
0.1716281745	age 60
0.1715965276	cases of
0.1715888683	this study describes
0.1715733411	investigated in rats
0.1715474962	on bayes
0.1715377358	of mk 801 on
0.1715215555	plasma concentrations of
0.1714568694	removed for
0.1714374492	corresponding control
0.1714186393	the need of
0.1714026003	year old child with
0.1713971196	after 6 months of hyperprolactinemia
0.1713962905	a 36 year old
0.1713937562	cocaine causes
0.1713290304	a single injection of adriamycin
0.1712408311	randomized trial of
0.1712397301	the first
0.1712083067	still present
0.1711958566	seven cases
0.1711915754	and 12
0.1711797176	stimulant effects of
0.1711673130	therapeutic doses of
0.1711632322	possibly related to
0.1711318169	an inpatient
0.1710103576	+ 5 mm hg
0.1709359955	early identification of
0.1707775445	in one
0.1707414268	did not receive
0.1707262171	these two episodes
0.1707171613	n = 4
0.1707038566	n = 42
0.1706916386	in children with neuroblastoma
0.1706668768	cardiac rate and
0.1706613299	6 mmhg
0.1706575032	and or
0.1706448394	events in patients
0.1706356883	the early stage
0.1705889978	the observed
0.1705858725	95 ci 0
0.1705830540	10 month old
0.1705543655	to bpo
0.1705398458	gamma knife and
0.1705274027	in different brain
0.1705256353	most common
0.1705167808	hypotension produced by
0.1705085320	to 20
0.1705079655	these results
0.1704559815	month before
0.1704528752	most affected
0.1704346624	of hyponatremia and or
0.1704091283	an increased
0.1703962905	a 59 year old
0.1703731350	n = 20
0.1702880071	1.5 or 2
0.1702723385	further support
0.1702681236	proved to
0.1702500567	30 mg m 2
0.1702380218	significantly correlated with
0.1701801674	within one month
0.1701412633	2 1 2 years
0.1701363901	1 ng =
0.1701316429	doxorubicin administration
0.1701283650	a 47 year old woman
0.1701283650	a 57 year old woman
0.1700074503	0 mg kg
0.1699861873	treatment outcomes
0.1699812025	40 mg day
0.1699653860	the second
0.1699564398	4 hours
0.1699492464	less important
0.1698988717	a plasma
0.1698917170	prolonged apnea in
0.1698753175	dose of 500 mg
0.1698413496	not significantly changed
0.1697941118	8 to
0.1697911898	eight patients
0.1697666426	as substitutes for
0.1697543408	the oc group
0.1697446650	reversed by
0.1696532793	received infusions of
0.1695967846	the plasma
0.1695782542	of human erythrocytes induced by
0.1695309413	cause sustained
0.1694875864	a level
0.1694644880	p or = 0
0.1694163063	age group
0.1693962905	a 42 year old
0.1693797506	nephrotic syndrome in rats
0.1693206469	by mpep
0.1693061337	both isomers of propranolol
0.1692668533	a 67 year old
0.1692654020	next day
0.1692630387	and one
0.1692487417	35 years
0.1692064451	the renal
0.1691462564	mean auc
0.1691188631	significantly different from
0.1690676840	ill patients
0.1690114316	2 weeks
0.1690087691	long term therapy
0.1689690523	tumor angiogenesis in
0.1688837731	induced by pan
0.1688422530	each drug
0.1688212089	did not significantly differ between
0.1687367997	the higher dose of
0.1686724848	two case reports
0.1686616715	after magnesium administration
0.1686569160	no effect on
0.1686421736	a separate group of
0.1686389774	of dopamine
0.1686220794	this agent does
0.1686149621	degree of
0.1685910655	right and left
0.1685707823	after 4
0.1685665153	injection of
0.1685649162	three percent
0.1685426785	the muscarinic receptor
0.1685309413	more complex
0.1685261499	after completing of remd
0.1685142335	injection of human
0.1685064872	to determine sensitivity
0.1684441124	glyceryl trinitrate on
0.1683961267	30 min before
0.1683738445	decrease in
0.1683528360	n = 9
0.1683270082	new cases
0.1683035239	at presentation
0.1682878319	with low molecular weight
0.1682409401	a 35 year old woman
0.1681398173	n = 15
0.1681321567	an experimental study
0.1681306645	the drugs
0.1681205818	effects of propofol
0.1681183592	an open
0.1681110409	developed major
0.1680873533	before dox
0.1680794925	a three
0.1680719845	bacterial infections in patients with
0.1680685292	significantly lower in
0.1680472286	during spinal anesthesia
0.1680327741	group c
0.1680143514	correlates of
0.1680137388	p less than
0.1680045645	only one patient
0.1679452731	rate of
0.1678926867	a muscarinic receptor
0.1678605553	not clear whether
0.1678158181	every 6 to 8 weeks
0.1678119887	n = 32
0.1677270332	a significant
0.1677096750	response to treatment
0.1677078555	an interval of 24 h
0.1676554899	over 60 years
0.1676390385	4 months
0.1676348114	+ 1.0
0.1676306118	18 years
0.1676297855	at doses
0.1676161176	during pb administration
0.1675715823	did not show
0.1675630758	in children
0.1675405717	hypotensive effect of
0.1675382982	a period of several months
0.1674380426	induced in mice by
0.1674204579	liver failure in two
0.1674072086	proportion of
0.1673966020	of choice
0.1673900589	p greater than 0.05
0.1673500103	in 1 patient
0.1673486087	10 micrograms kg per min
0.1673129118	the kidney
0.1673087268	prone to
0.1672830805	after prolonged oral
0.1671920927	effects on cardiac
0.1671578707	did not predict
0.1671478842	by reviewing
0.1671130068	before treatment
0.1671097241	acute severe
0.1670725167	the same extent
0.1670578280	out patient
0.1670385482	2 to 5
0.1670063143	doses of ketamine
0.1669964976	treated by
0.1669846805	from exencephaly
0.1669558808	performed to evaluate
0.1669318735	activities in mice
0.1669164187	1 10 microg side
0.1669048653	this problem
0.1669004678	50 micrograms
0.1668945061	no organic
0.1668839336	with regard to
0.1668833372	the recovery room
0.1668786656	in preventing type b
0.1668119076	in rat
0.1668103162	injection immediately after
0.1667446658	of picrorrhiza kurroa
0.1667289530	the cellular level
0.1666637874	the hyperthymia component of
0.1666530799	a lithium
0.1666387709	after induction of status epilepticus
0.1666359890	22 of 62
0.1665801637	from baseline
0.1665788752	to improve blood pressure
0.1665761220	results indicate
0.1665716152	59 years
0.1665514272	3 weeks
0.1665410047	no other medications
0.1665288199	after 5 months of
0.1665247252	the 2 groups
0.1665134365	known to cause calcification of
0.1665108712	at low frequencies
0.1665074514	no change
0.1664953481	the effect of pupil dilation
0.1664630578	required treatment
0.1664432833	many years
0.1664416320	with acute
0.1664222916	ribavirin associated
0.1663880498	two consecutive
0.1663652384	5 minutes
0.1663575860	this study investigated
0.1662437090	at least in part
0.1662420749	prevented development of
0.1661972821	the treatment of spasticity
0.1661765727	woman presented with
0.1661484568	+ 6.0
0.1661378945	performed to determine
0.1661088157	group of 45 patients
0.1660849694	among users of aspirin
0.1660799714	patients with heart failure
0.1660690085	and 500 mg m2
0.1660559500	an increase in lysosomal
0.1660410039	the animals
0.1660090282	these compounds
0.1659688840	hospitals during
0.1659680964	den +
0.1659607075	maternal use
0.1659475589	a depressed patient
0.1659464242	prophylactic treatment of
0.1659280714	in rhesus monkeys
0.1659232217	side effect of amlodipine
0.1659063340	2 or 3
0.1658181431	infusions of 0
0.1657815671	such as neuropathic pain
0.1657299608	40 days
0.1657276479	four times
0.1657072268	the two groups
0.1656838359	prevalence of
0.1656512780	0.3 3
0.1656489912	not changed
0.1656286074	metabolized to
0.1656186393	and in 67 of
0.1656125588	2 hz
0.1655888778	the presence of cyanosis
0.1655588231	performed using
0.1655545827	by ah6809
0.1655065742	a reduction in glomerular number
0.1655005882	a retrospective case
0.1654803949	an 11 year old
0.1654765508	some cases
0.1654632713	visual field defects in
0.1653870309	of 0
0.1653790688	the presence of
0.1653710935	a 76 year old
0.1653487773	of treatment
0.1653211796	an oncology patient
0.1653154384	a case
0.1653058421	significantly different between
0.1652982623	a 9
0.1652873684	the bladder
0.1652700942	15 f
0.1652685404	0.25 mg kg
0.1652495966	acute renal failure secondary to
0.1652460266	about 10
0.1652044860	5 mg ml
0.1651663275	the time of examination
0.1651629004	no significant
0.1651541685	in conclusion
0.1651316888	range 5
0.1651260763	data show
0.1651172001	linked to
0.1650561854	75 mg
0.1650391067	to identify risk factors
0.1650152185	the glutamatergic system via
0.1649750826	2 4
0.1649411360	less marked
0.1648875230	of echothiophate iodide
0.1648069757	comparison with other
0.1647839305	1 and 3
0.1647728575	electrical stimulation of
0.1647621671	+ 1 mmhg
0.1647532273	expressed by
0.1647169324	for nonmalignant disease
0.1647001509	with more
0.1646911235	a poor metabolizer of
0.1646695808	the gamma aminobutyric acid
0.1646012810	in combination with other analgesics
0.1644937266	tested for susceptibility to
0.1644209640	findings consistent with
0.1644184787	range of 4
0.1643754471	significant reduction in
0.1643619569	a safe alternative
0.1643250513	year old white woman with
0.1643024468	= 42
0.1642878356	associated with clomiphene citrate
0.1642476675	dose of dox
0.1642116640	not to
0.1641593564	developed anemia
0.1640937911	20 micrograms kg
0.1640607393	dose of 0.1
0.1640130651	after drug withdrawal
0.1639980068	variations in
0.1639880392	1 2
0.1639096396	high levels
0.1638069364	in 8
0.1637822737	1 year of follow up
0.1637770628	a 3 hour
0.1637470854	high prevalence of
0.1637096244	and st segment elevation from
0.1637064811	a patient with dilated cardiomyopathy
0.1637028791	of atrial natriuretic peptide
0.1636776416	= 1.0
0.1636168336	the 25
0.1634875194	patients with atrial fibrillation
0.1633690860	3 hour infusion
0.1633641087	did not do so
0.1633480375	all infants
0.1633378176	highest risk for
0.1632874348	both skin test and rast for
0.1632068247	plus placebo
0.1631824276	the occurrence of
0.1631810096	an aminoglycoside
0.1631745917	a history of chronic urticaria and
0.1631582388	the dose
0.1631230261	the time of administration of morphine
0.1630688910	45 mg kg
0.1629734114	in combination with
0.1629347488	14 months
0.1629169214	levodopa induced dyskinesias in
0.1629045314	or alpha methyldopa
0.1628880000	a mean age of
0.1628632006	nephropathy in patients
0.1628573472	diabetic patients
0.1628477394	option for patients
0.1628463545	factors related to
0.1628446777	induced increase in
0.1628348810	described here
0.1627979832	anemia in patients
0.1627799864	this case suggests
0.1626580216	the mice
0.1626301087	used to predict
0.1626096765	defined by
0.1625915831	true for
0.1625598516	odds ratio for
0.1625088227	d tubocurarine in
0.1625065805	4 days
0.1625041313	the bbb
0.1624860178	with stage ii hypertension
0.1624099050	a significant role
0.1623796571	less than 0.05
0.1623390400	as toxic as
0.1622948970	a micturition reflex
0.1622209198	a receptor
0.1621995128	as much as
0.1621824176	100 g
0.1621776286	an option
0.1621775305	a dose
0.1621755087	received oral
0.1621637062	the central
0.1621319182	blocked by pretreatment with
0.1621302853	and 14
0.1621187046	ethambutol induced
0.1621130635	5 ht and 5 hiaa in
0.1620996145	developed transient
0.1620968524	87 +
0.1620892579	group of patients
0.1620870945	the 5 alpha
0.1620856238	of cck 8 on
0.1620560681	or by
0.1620472100	3 to 12
0.1620433703	the structural integrity of
0.1620364597	relevance to
0.1620198666	5 days
0.1619594056	the cases
0.1619584409	required for
0.1618906639	a 65 year old
0.1618745917	the pvn and
0.1618451817	than for
0.1617902784	compared between
0.1617448583	the cerebellar cortex
0.1617157537	after spinal anaesthesia
0.1616848298	the results showed
0.1616546093	recovery time
0.1616388774	and glomerular sclerosis in
0.1616309256	of 17
0.1615979227	aids patients
0.1615888839	lesion induced
0.1615849015	s angina
0.1615385018	the pilocarpine treated
0.1615239978	three compounds
0.1614982156	mean differences
0.1614872290	between 1991 and
0.1614797943	200 and 400 mg kg
0.1614600459	n = 3
0.1614555787	to quantify
0.1614516603	the 3 hydroxy group in
0.1614452120	and 40
0.1614384129	and board certified
0.1614330596	nine of 13
0.1614294086	than in controls
0.1613002784	the mean
0.1612579250	at 6 hours and
0.1612554110	a 17
0.1612413336	90 mg
0.1612337077	changes in
0.1612074706	or 0
0.1612011112	the therapeutic potential
0.1611863210	800 mg day
0.1611814270	likelihood of
0.1611659255	children without
0.1610737878	demonstration of
0.1610628790	rna content and
0.1610495917	the effects of moderate and
0.1610163045	sign of
0.1609927790	occurred in 60
0.1609616582	induced alf
0.1608811038	hormone replacement therapy in
0.1608794330	this report
0.1608656916	two cases
0.1607612267	a 38 year old
0.1607463212	due to nicergoline
0.1606971317	undertaken to
0.1606822179	systemic administration of
0.1606632893	the cardiac
0.1606586181	on vision and
0.1606536626	2 methoxy 4
0.1606037675	in 59 of patients
0.1606027483	found with
0.1605649031	the administration of methylprednisolone and gentamicin
0.1605464711	the present studies
0.1605229822	as first line therapy for
0.1605076736	without clear
0.1605019675	n = 34
0.1603062583	of vte associated with use of
0.1602819668	the mesencephalon and
0.1602707948	mg 24 h
0.1602602952	last follow up
0.1602223284	an ace inhibitor
0.1602152842	a mechanism distinct from
0.1601972825	decreased cardiac
0.1601386280	phasic and tonic pain by
0.1601140811	cisplatin plus
0.1600951314	within 1 month
0.1600664897	a model
0.1600570743	rats anesthetized with
0.1600229822	a 31 year old man with
0.1600131932	an oncology
0.1599895484	acute dose
0.1599836120	a test
0.1599643447	progressed to
0.1599643447	converted to
0.1599239800	in 95 of
0.1599022736	among groups
0.1599019033	induced by diazepam
0.1598307532	to 91
0.1597878685	1000 mg day
0.1597743639	ventricular tachycardia during
0.1597529049	the addition of sodium bicarbonate
0.1597127099	this case report
0.1596323630	to determine if
0.1596180417	in 26
0.1596019508	before dobutamine
0.1595831325	standard therapy for
0.1595648013	this population
0.1595428065	bcnu induced
0.1595139492	control levels
0.1594380031	these studies
0.1593937081	hr prior to
0.1593774667	grade 4
0.1593348855	common side effects
0.1593260244	levodopa treatment
0.1593133060	the results obtained
0.1592575046	an updated
0.1592575046	an abnormally
0.1592413895	l type
0.1592245096	a noninjurious interval of
0.1592240930	the pleural effusion
0.1592184626	the only
0.1592140294	the other three treatment groups
0.1592027449	revealed decreased
0.1591463402	the serum
0.1591213078	the safety and tolerability of
0.1590867983	32 months
0.1590245527	blockade induced
0.1590094373	2 mg kg
0.1590086441	series of patients
0.1589621430	time to peak
0.1589471318	either conventional or
0.1589453009	the hemolytic uremic syndrome
0.1589184961	of 205 patients
0.1589056492	the hypotensive effect
0.1588934896	by co administration with
0.1588462413	this difference
0.1588274187	to 15
0.1588180329	or normal saline
0.1587915734	this investigation
0.1587886457	of d
0.1587757167	a calcium channel blocker
0.1587554932	6 to 29
0.1587277546	by radioimmunoassay
0.1587152271	acute renal failure in
0.1586690675	in women
0.1586562208	of left ventricular pressure
0.1586226505	and p 0
0.1585689748	or =
0.1585594030	three men
0.1585392905	development of tolerance to
0.1585020414	0.3 mg kg
0.1584950604	dose limiting toxicity of
0.1584862055	compound 1
0.1584641768	examined in rats
0.1583005643	to find
0.1582830290	a decrease in systemic vascular resistance
0.1582813565	directed to
0.1582372322	comparable to
0.1582348411	the treatment of severe adenovirus disease
0.1582266439	an unusual case of
0.1582239972	a 35 year old
0.1582140407	these parameters
0.1581723733	a novel animal model to
0.1581723733	an antibiotic with
0.1581206643	20 micrograms
0.1581168978	pretreated with saline or
0.1581054236	an important factor
0.1581034227	18 months
0.1580975627	the onset
0.1580780054	7 days
0.1580747543	of tamoxifen as
0.1580560864	report 2 cases of
0.1580008392	not detectable
0.1580003986	the maximum effect
0.1579868376	steroids induced
0.1579808089	nik 247 on
0.1579121993	type 1
0.1578892463	a generalised
0.1578591897	the early stages of
0.1578566315	none of
0.1578301658	reported in patients
0.1578186915	absence of
0.1578088379	or = 10
0.1577948206	n = 5
0.1577467843	3 months
0.1577411738	a 73 year old
0.1576873301	by denopamine
0.1576826964	induced neutropenia
0.1576512576	a 54 year old
0.1576388632	infusions of
0.1576386689	the acute
0.1576139500	two mothers with
0.1575846509	a specific
0.1575815093	treated with lithium
0.1575691025	1 42
0.1574600840	presenting after
0.1574224718	significant differences in
0.1574161961	performed on
0.1574087719	restricted to
0.1573918213	three subjects
0.1573750307	4 weeks
0.1573580876	from days 9 to
0.1573544378	given to
0.1573509160	a greater risk
0.1573329250	the use of lmwh in
0.1573103988	25 and 50mg kg
0.1572899989	risk factor for
0.1571745917	the number of entries in
0.1571692901	in order to determine
0.1571470884	and driving simulator performance
0.1571225445	the potential
0.1570929993	the 20
0.1570674120	a strong
0.1570510685	a 46 year old
0.1570356432	abstinence from
0.1570274224	numbers of
0.1570229250	a recent increase in
0.1570128390	significant improvements in
0.1570059496	with and without mannitol
0.1569886039	the trabecular meshwork
0.1569221738	high incidence of
0.1569186814	1.7 vs
0.1569113811	vs 21
0.1568819087	tests showed
0.1568732370	+ 1.3
0.1568659028	the left
0.1568044166	the need for
0.1567951854	50 ml
0.1567808906	prevention by
0.1567797644	less likely
0.1567687782	year old man with
0.1567606719	these rats also showed
0.1567600297	urine samples for
0.1567475876	effects of bromocriptine
0.1567444642	upon discontinuation of
0.1567293190	magnetic resonance imaging and
0.1567220771	1.6 +
0.1567137985	need more evidence on
0.1567063370	the groups
0.1567008990	one or more
0.1566856819	injections of
0.1566772941	in morris water maze
0.1566335025	ligand for
0.1566228493	a 10 year
0.1565950012	of mice
0.1565672929	of symptoms
0.1565608673	single injection of
0.1565570809	the following
0.1565566603	2 years
0.1564999879	hyperalgesia induced by
0.1564980801	with severe left ventricular dysfunction
0.1564813105	reduced by
0.1564075876	the clinical
0.1564044754	effective treatment
0.1563918826	did not become
0.1563829357	5 g dl
0.1563647288	during ct
0.1563501190	no significant effects
0.1563488668	3 alpha
0.1562826121	nephropathy in rats
0.1562404404	of transient hyperammonemic encephalopathy
0.1562315809	1 8
0.1562185201	higher than normal
0.1562062023	after ovulation induction with cc
0.1561951427	the 90 htn group
0.1561745917	the son of
0.1561660042	outpatients with
0.1561415443	a given
0.1561342028	n = 29
0.1561200118	whether or not
0.1561068746	the high
0.1560956195	studied in dogs
0.1560825925	the seizures
0.1560825454	n = 38
0.1560783502	of therapy
0.1560363556	a valuable
0.1560351950	a 3 year period
0.1560125667	1 defect
0.1560113981	3 mg kg
0.1560000626	randomized into
0.1559902541	for metastatic disease
0.1559685973	the four
0.1559423370	examined using
0.1559379866	2 5
0.1559270039	the arthralgia myalgia syndrome
0.1559058607	and higher
0.1558922005	diagnosis before
0.1558364735	1 and 2
0.1558037562	and or back
0.1557912465	a total of 167
0.1557729635	days after
0.1557480261	the time of diagnosis of wegener
0.1557272462	to 4
0.1557271492	to begin
0.1557271492	to conduct
0.1557209553	significantly more often
0.1557150159	within 24 hours
0.1556871899	a 50 reduction
0.1556468819	along with
0.1556328756	benefit from
0.1556325173	brief episodes of
0.1556293783	first line treatment
0.1555816273	to 30
0.1555815990	and decreased levels of
0.1555577465	a 40 year old female
0.1555557887	the initial
0.1555506496	1 or 2
0.1555467738	experimental model of
0.1555265476	primarily because of
0.1555187705	an animal model
0.1555138572	over 1 hour
0.1554674512	randomly allocated to one of
0.1554358850	a 6 year
0.1554325646	caused by doxorubicin
0.1553945305	the pilo group
0.1553909813	the same time
0.1553768445	by bolus injection
0.1553702253	alterations in
0.1553431665	adverse effects of
0.1553249174	reported to
0.1553151797	intoxications with
0.1553058688	strategies for
0.1552395031	except for
0.1552362036	after 12 weeks of treatment
0.1552302748	6 and 12 months
0.1552260523	in 3 patients
0.1552236713	for patients
0.1552111234	12 mg m2
0.1551590825	dexamethasone therapy
0.1551549603	different doses
0.1551511829	the protection provided by
0.1551479250	g heart in
0.1550596571	the use of
0.1550552111	over 20 min
0.1550060622	the changes in
0.1549986860	in 13
0.1549961511	a family history
0.1549693502	intracranial aneurysms and
0.1549633044	a patient with
0.1549518836	high concentration of
0.1549239974	by ethinyl estradiol
0.1549129745	the probable cause of
0.1548898264	the sympathetic nervous system
0.1548689412	appropriate treatment
0.1548133651	highest dose of
0.1548043946	5 micrograms kg
0.1548007784	dex induced
0.1547814022	tubular cells on
0.1547566040	did not differ between
0.1547546178	the infusion
0.1547473681	within 4 hours
0.1547399586	new method
0.1547079024	induced by repeated
0.1546821874	with serotonin reuptake blockers
0.1546756967	treatment for
0.1546374493	mean value
0.1546269884	during programmed
0.1546161652	twenty one
0.1545681730	multiple injections of
0.1545634484	with special reference to
0.1544537548	in 4
0.1544458865	used to
0.1544404759	rate of progression of
0.1544331163	a partial response
0.1544003491	recruited from
0.1543917084	the volume density of
0.1543229376	relevance for
0.1543145521	1 10
0.1542408119	25 g
0.1542360052	the clinical and laboratory data
0.1542350946	minutes after
0.1541785150	for two
0.1541497543	a regimen of
0.1541219527	of 21
0.1541055009	this work
0.1540713698	the mixture of hpma copolymer and
0.1540585023	by dl sotalol
0.1539475983	both treatments
0.1538645305	one patient receiving
0.1538601175	back to
0.1538527677	the development of
0.1538319652	activity of thalidomide in
0.1538198771	widely used in
0.1538133651	single dose of
0.1538065437	10 000
0.1537744224	a bridge to
0.1537662537	five patients
0.1537592449	prior administration of
0.1537295411	also statistically significant
0.1537263359	the effect of injection duration on
0.1537254829	very common
0.1537157645	n = 2
0.1537014474	five patients experienced
0.1536858871	also evident
0.1536603129	allergic reaction to
0.1536399306	seven patients
0.1536308291	patients in group 1
0.1536142430	h in od vs
0.1535679268	pre treated with
0.1535623188	or qs qt
0.1535377885	did not inhibit
0.1534581850	these changes
0.1534260720	reserpine induced
0.1534077277	a significantly
0.1534048395	nephrotoxic effect of
0.1533931544	of stroke and
0.1533931544	of phenytoin and
0.1533602272	measured at
0.1533163847	effects of tamoxifen
0.1533026290	reports of
0.1532897390	serious liver
0.1532894324	22 months
0.1532858543	in two
0.1532746929	with alteplase
0.1532428580	introduced in
0.1532229250	for sedation in
0.1532100022	a similar
0.1531947146	after two doses
0.1531855158	a few minutes
0.1531768550	30 mg
0.1531482363	a short acting
0.1530869206	54 year old woman with
0.1530041511	in patients receiving heparin
0.1529998829	time of onset
0.1529743016	the duration and intensity of
0.1529565818	examined in mice
0.1529424299	and 25
0.1529092364	from 60 to
0.1529078673	a dose of 250 mg kg
0.1529002304	250 mg day
0.1528685382	microinjection of
0.1528583988	year old male patient
0.1528513359	the temporal relationship of
0.1528344768	or = 50
0.1528222531	a higher
0.1527790196	200 mg m2 d
0.1527633112	28 men and
0.1527483165	in 9 of
0.1527463744	12 months
0.1527389733	3 times
0.1527235653	a randomized
0.1527190654	a greater
0.1527062688	forty one
0.1526301304	the test
0.1525831893	the effects
0.1525820960	with quetiapine monotherapy
0.1525786192	vincristine induced
0.1525698847	an equivalent
0.1525426265	three patients
0.1525297636	associated to
0.1525257091	the pain
0.1525216949	oral treatment with
0.1525167660	even if
0.1525030570	oral dose of
0.1524560096	after transplantation
0.1524508277	no patients
0.1524094432	the effect
0.1524065990	the execution of
0.1523678860	an essential
0.1523201984	r units after
0.1523002294	in male
0.1522865165	n = 35
0.1522844852	objective assessment of
0.1522804404	a 43 year old
0.1522799389	apoptotic cell death and
0.1522495917	and in anesthetized dogs with
0.1522399466	extent than
0.1521812951	rats pretreated with
0.1521740075	with val hctz
0.1521282697	no exposure to vgb
0.1521197225	these results show
0.1520670359	in adults
0.1520500766	the patient developed
0.1520223815	after initiation of high dose
0.1519511496	new model
0.1519387312	the risk of
0.1519002440	a 50 incidence
0.1518822937	to measure
0.1518726210	effective in
0.1518509784	and glutathione reductase
0.1518483537	a differential response
0.1518450825	cyclophosphamide in combination with
0.1518147601	a double blind study
0.1518076375	an experimental model of cocaine
0.1517779590	or = 10 g dl
0.1517704002	added to
0.1517702248	19 year old
0.1517578287	the acute phase
0.1517445595	no statistically significant differences between
0.1517175228	p and n
0.1517171054	less potent
0.1517168515	13 and 14
0.1517018879	the standard deviation of
0.1516684059	rats treated
0.1516137737	a 58 year old
0.1516102297	or saline
0.1515996253	induction of
0.1515223439	amnesia induced by
0.1515185796	an uneventful
0.1515166014	after drug administration
0.1515154476	a lower incidence
0.1514899323	the treatment of acute bipolar mania
0.1514898962	11 months
0.1514409556	124 +
0.1514377668	to ns nsaids
0.1514361070	dose of
0.1514089768	and 24
0.1513986459	in man
0.1513543798	from angiograms of
0.1513442916	the epinephrine treated
0.1513334704	contrast enhancement of
0.1513073612	the treatment of
0.1512920536	vs 1.2
0.1512880082	predisposing to
0.1512475065	effect of levodopa
0.1512229250	of tamoxifen in
0.1512015499	400 mg d
0.1511965102	a therapy
0.1511846056	alkaline phosphatase and
0.1511784038	+ 15
0.1511739983	to investigate whether
0.1511599780	doxorubicin administration on
0.1511431168	the relative
0.1511376637	congestive heart failure after
0.1511320535	in controls
0.1510789036	by virtue of
0.1510717530	the mechanism of transformation
0.1510317333	responses to
0.1510247103	for 10 days
0.1510076509	for cpa ee
0.1509672893	in two patients
0.1509479334	the results suggest
0.1509477243	60 and 100 g
0.1509407034	during 1
0.1509100698	second injection
0.1508562150	study drug
0.1508439065	reported to cause
0.1508388396	mdma use on
0.1508375977	restarted on
0.1508298200	started on
0.1508068918	a higher incidence of
0.1507818346	widespread use of
0.1507141781	4 months later
0.1507070566	h in
0.1506976959	over baseline
0.1506160204	or 320
0.1505996257	as evidenced by
0.1505546178	the findings
0.1505507893	a large amount of
0.1505428331	the optimal
0.1505338466	acute study
0.1505224649	in order to investigate
0.1505215328	maintained on
0.1505105519	at 2
0.1504899674	a chronic
0.1504065990	the acidity of
0.1503880228	standard doses of
0.1503601229	subcutaneous injections of
0.1503351722	3 mg kg 1 i.v
0.1502902729	a novel
0.1502708718	the mortality rate
0.1502647802	in young
0.1502465626	rats receiving
0.1502386085	the chemotherapy
0.1502348793	all cases
0.1502258181	after starting
0.1502174927	nitroglycerin induced
0.1501927118	caused by prolonged
0.1501457501	actions on
0.1501379959	no significant difference between
0.1501279450	an increase of 1.0 mg per
0.1501243582	or = 60 years old
0.1501149828	preference for
0.1501085466	for 3
0.1501019719	to pre treatment levels
0.1500482851	less common
0.1500217878	in patients without heart
0.1500062043	only in
0.1499980718	induced dyskinesia in
0.1499848289	because of
0.1499695061	the aim of improving efficacy
0.1499431196	sacrificed after
0.1499332585	a standardized
0.1498808706	resolved after
0.1498744694	the final
0.1498533109	q 4
0.1498384967	the times to
0.1497927146	or = 65
0.1497271187	induced by cyclophosphamide
0.1497137996	antitumor efficacy of
0.1496775954	controlling for
0.1496760608	ability to
0.1496643716	a major clinical
0.1496603424	the post operative period
0.1496402188	this treatment
0.1496324166	20 mg s 1
0.1495973620	taken for at least one
0.1495845211	central and peripheral effects of
0.1495815990	the replacement of
0.1495705887	the present case
0.1495280874	to induce
0.1495170380	days after discontinuation of
0.1495165598	use of
0.1495126022	in group p than
0.1494609959	genotyped for
0.1494509006	the total
0.1494506642	the right
0.1494485614	after surgery
0.1494358072	by giving
0.1494230771	effect of glyceryl trinitrate on
0.1494148979	switched to
0.1494087779	at 400
0.1494072963	like syndrome
0.1494002040	pain mechanisms of
0.1493857120	remained unchanged in
0.1493665559	up to 150
0.1493376248	dose of 100 mg
0.1493306057	woman with
0.1493141551	other potentially
0.1492860631	2 ml
0.1492382160	for 15 days
0.1492301042	inhibitor treatment
0.1491687338	the angiotensin converting enzyme inhibitor
0.1491233443	a non
0.1491115538	a history of
0.1490946813	the ventrolateral surface of
0.1490555055	protected from
0.1489672138	and estimated glomerular filtration rate
0.1489516280	careful use of
0.1489448039	week course of
0.1489302320	the developmental origin of
0.1488935785	results support
0.1488910872	an autopsy
0.1488626358	the forestomach
0.1488513359	the propensity to
0.1488094010	the diazepam group
0.1487693342	the beta4 subunits
0.1486956395	the successful treatment of
0.1486887381	the first year
0.1486867717	stress induced
0.1486837869	known to
0.1486786261	2.3 +
0.1485821421	the case of
0.1485783376	difficulty with
0.1485783376	unresponsive with
0.1485329550	higher in group
0.1485300927	more sensitive
0.1485180417	significant improvement in
0.1484993550	during hypotension
0.1484892402	weeks after
0.1484880698	1 and 3 micrograms kg
0.1484633111	the passage through
0.1484454807	8 months
0.1484171225	compared to saline
0.1483915748	the memory
0.1483760323	activity in
0.1483605804	week treatment
0.1483558026	the syndrome
0.1483449159	at lower concentrations
0.1483293049	15 min after injection
0.1483152669	3 hydroxy 3
0.1483001680	observed in patients
0.1482841234	significantly greater than
0.1482792505	40 mg kg
0.1482185414	a case of bilateral optic neuropathy
0.1481918527	four treatment groups
0.1481784376	of hyponatremia and or siadh
0.1481613496	use of herbal products and
0.1481196356	management of patients with
0.1481088790	in most cases
0.1480839920	day for 21 days
0.1480337194	the haemodynamic changes
0.1480179153	100 and 200
0.1480148293	two cases of
0.1480071183	the present experimental
0.1479630555	neuroprotective effects of
0.1479610061	dependent on
0.1479052811	incidence and severity of
0.1478817246	the procedure
0.1478479160	3 wk
0.1477598211	of bupropion and
0.1477165072	nine percent of patients
0.1476956395	the structure and function of
0.1476915887	levels of 4
0.1476669804	under surveillance in
0.1476622609	the other
0.1476386997	in patients undergoing
0.1476274164	6.5 +
0.1476244920	7 mm hg
0.1476176380	amiodarone use
0.1476013592	the incidence of hbv reactivation
0.1475585693	in liver transplant recipients
0.1475445505	and other
0.1475310179	to warfarin induced artery calcification
0.1474970109	p difference =
0.1474928859	the absence of
0.1474602575	a new
0.1474509986	70 mg kg
0.1473902836	er stress in
0.1473718444	bradycardia induced by
0.1473377027	every 6 hours for
0.1473186760	a major contributor to
0.1473055910	and severity of adverse events
0.1472730931	a dose dependent
0.1472720166	recovered without
0.1472715892	a direct
0.1472536286	a prolonged course
0.1472348398	in 16 of patients
0.1472165939	investigated in mice
0.1472103322	a single iv
0.1471978224	a 62 year old
0.1471913583	in normal rats
0.1471538421	together with
0.1471346829	an unexpected increase in
0.1470028897	cause of
0.1469455703	an intermediate duration of
0.1468703595	retrospective review of
0.1468511367	an investigation
0.1468384967	the excitability of
0.1468327974	kg day
0.1468084052	a dual
0.1467816204	only one case
0.1467680491	cyclophosphamide therapy for
0.1467417836	5 ml 100 g
0.1467302257	11.2 +
0.1466794258	d 1 and d
0.1466516866	not at
0.1466496426	commonly encountered in
0.1466033887	given three times
0.1465960583	the long term
0.1465893918	cells l
0.1465873946	the initiation of fluconazole and
0.1465873261	a 69 year old
0.1465016765	28 mg
0.1464821961	day surgery
0.1464696884	in four
0.1464626227	8 weeks
0.1464470867	induced arrhythmias
0.1464310842	effects of clonidine
0.1463967695	a 40
0.1463737116	tested for
0.1463709875	few studies
0.1463434787	a bipolar patient
0.1463336641	each combination
0.1462941025	a result of
0.1462621701	2 to
0.1462441081	the two drugs
0.1461716639	the most
0.1460848140	25 to 75
0.1460624600	any difference
0.1460602740	on folate concentrations in
0.1460355843	subcutaneous administration of
0.1460269364	2 to 12
0.1460252756	monitored before
0.1459813413	to report
0.1459638145	no effect
0.1459550671	this group of patients
0.1459384489	in rats fed
0.1459295179	levels of
0.1458773062	associated with rls in
0.1458760083	efficacy and side effects
0.1458577939	30 micrograms
0.1458384967	the speed of
0.1458073761	patients with rheumatoid arthritis treated with
0.1457699379	liver levels of
0.1457588702	effect of heparin
0.1457310293	each course
0.1457141779	no abnormality
0.1456971503	forty two
0.1456956395	the testing of
0.1456956395	the care of
0.1456900497	the role of vasopressin
0.1456816044	a 6 year period
0.1456811185	cerebral blood flow and
0.1456350356	several days
0.1456264657	those treated with placebo
0.1456165748	the sodium
0.1455746916	of warfarin
0.1455669655	a significant decrease in
0.1455542689	by nitroglycerin in
0.1455245647	monitored using
0.1455181813	in cocaine dependent participants
0.1455120714	and review of literature
0.1454844178	more than twice
0.1454803530	the cause
0.1454790971	central role in
0.1454736845	50 mm hg
0.1454596099	eight dogs
0.1454569785	a statistically significant increase in
0.1454480203	after 96 weeks
0.1454311991	the incidence of
0.1454069700	11.5 +
0.1454023190	on entry
0.1453962072	a potentiating effect of
0.1453872043	ten patients
0.1453597030	an increased rate
0.1453591013	patients with and without
0.1453492069	the association between alcohol
0.1453074461	1.46 +
0.1453008642	prolonged administration of
0.1452799440	did not demonstrate
0.1452675712	immunostaining for
0.1452666997	a commonly used drug
0.1452612793	five times
0.1452453140	the time
0.1452437611	for five years
0.1451792689	of compounds in
0.1451690521	a lower
0.1451380466	apical targeting of
0.1450508136	the studies
0.1450237167	four groups
0.1450050279	one day after injection
0.1450034074	than controls
0.1449451554	day four
0.1449343781	antagonism on
0.1449026465	in 19
0.1448879191	the ability of
0.1448547726	no enhancement
0.1448527782	a 30 year old
0.1448476590	10 patients
0.1448243286	patient 1
0.1448202911	7 years
0.1448010067	2.4 +
0.1447772258	as consolidation therapy
0.1447701161	hours after administration of
0.1447674355	30 mg m2
0.1447592181	a targeted dosage of
0.1447492327	especially in elderly patients
0.1447358652	a six
0.1447188491	for 20 min
0.1447118060	found to
0.1447039351	the pathogenesis of
0.1446990709	the subcortex and
0.1446942718	an increase in serum creatinine
0.1446872108	30 and 60
0.1446834974	an alternate
0.1446788160	fluconazole associated
0.1446727498	more common in
0.1446569089	within 3 weeks
0.1446432385	individual patients
0.1446416386	4 month
0.1446140696	availability of
0.1446014623	computed tomography of
0.1445988547	60 mg
0.1445901876	the group receiving
0.1445610166	although somewhat
0.1445400364	activated by
0.1444923482	a 40 year old
0.1444848303	fall in
0.1444819338	greater than 50
0.1444664610	down regulation of
0.1444581746	in rodents
0.1444553451	the first case
0.1444424299	and 13
0.1444333359	the group treated with dex alone
0.1444305598	to 63 +
0.1444270481	in elderly patients
0.1444130981	effects of indomethacin
0.1443935834	to 11
0.1443847520	a report of two cases
0.1443747929	17 year old
0.1443743270	n = 19
0.1443714123	a patient with acute promyelocytic leukemia
0.1443687663	two separate
0.1443679046	no donor
0.1443678625	with hyperkinesis
0.1443250031	increased amounts of
0.1443081010	rat models of
0.1442799207	the mean + sd duration of
0.1442287342	treated with terbutaline
0.1442223104	after lv administration of
0.1441978803	induced apoptosis
0.1441978803	induced hyperalgesia
0.1441709188	+ 9
0.1441581503	this preliminary
0.1441452111	six patients
0.1441186942	olanzapine vs
0.1441086810	did not reduce
0.1441003606	and graded according to
0.1440925899	the use of omeprazole
0.1440918284	of neurological and
0.1440241062	1 month
0.1440126022	of furosemide in
0.1439996611	3.6 g of
0.1439084316	induced myopathy
0.1438626026	2 mg
0.1438523598	and 17
0.1438321421	to produce
0.1437810721	over time
0.1437531986	as early as
0.1437471927	necessary to determine
0.1437406157	n = 11
0.1437306905	delayed toxicity of
0.1437196346	also antagonized
0.1437105436	the average
0.1437055795	a tendency to
0.1436956395	the walls of
0.1436956395	and macrophages in
0.1436308713	older than
0.1436183335	sensitivity to
0.1436126260	3 and 5
0.1436095964	of lithium
0.1435902590	in 25
0.1435864335	for ipratropium and
0.1435701730	a series of
0.1435683189	after therapy
0.1435136650	obtained by
0.1435070527	in germany from
0.1434907440	tetany with
0.1434760020	second and
0.1434646369	decline in
0.1434522652	to characterize
0.1434374410	cells mm3 and
0.1433974793	also examined
0.1433967695	with 14
0.1433863971	8 hours
0.1433737135	100 mg twice daily
0.1433360678	studies using
0.1433198507	the addition of
0.1433024776	no cardiac symptoms
0.1432912477	activity of
0.1432558335	and at
0.1432465633	possible serious
0.1431892730	seem to
0.1431889129	as long as
0.1431682957	for blood and
0.1431576006	follow up study of
0.1431555543	treatment of
0.1431411384	a diet
0.1431328129	content of
0.1431290639	by lowering
0.1431255335	a significant increase
0.1431217162	followed later by
0.1430684583	a background of
0.1430573082	the safety and efficacy of combination
0.1430570350	and renal
0.1430366525	neuronal damage in
0.1430171126	the experimental
0.1430111052	of vascular endothelial growth factor
0.1430102687	the risk of esrd
0.1430091678	vpa induced
0.1430025605	treated with fluoxetine
0.1429932949	found in
0.1429930167	prior to cocaine
0.1429905811	administered 30 min before
0.1429857226	9 mg
0.1429762036	interference with
0.1429385095	consumption of
0.1429114335	the clinical presentation and
0.1429068621	the doses
0.1428884429	the blood
0.1428728633	the risk of myocardial infarction
0.1428334538	year old male received
0.1428202392	occurring after
0.1428108531	in order to prevent
0.1428021096	a progressive increase in blood pressure
0.1427882837	after trihexyphenidyl
0.1427604123	an association
0.1427503029	per week
0.1427240432	to terminate
0.1427063370	the symptoms
0.1426804801	possible mechanism
0.1426726097	not clear
0.1426288449	induced increases in
0.1425958021	after placebo to
0.1425932957	the carrageenan model and
0.1425853358	noted in
0.1425494181	the major
0.1425031986	all movements compared with
0.1424881484	a 25 year old woman with
0.1424789136	excretion of
0.1424715949	analysis of plasma
0.1424474478	8 weeks of treatment
0.1424459198	with controls
0.1423842573	given terbutaline
0.1423504602	the surgery
0.1423323548	5 and 10 mg bid
0.1422973418	scored as
0.1422628224	before transplantation
0.1422497598	no association
0.1422439854	approval for
0.1422439854	unnecessary for
0.1422439854	km for
0.1422213253	continues to
0.1422213253	intolerance to
0.1421783425	used in
0.1421682957	the expression of mrna of
0.1421619537	than on
0.1421476690	on admission
0.1421381678	of morphine
0.1421225656	aspects of
0.1421185797	ribavirin induced
0.1421175368	evaluated according to
0.1421073096	performed with
0.1420914552	the dopaminergic system
0.1420898573	the dose of 400 mg kg
0.1420797155	g d before
0.1420714935	an unusual reaction to
0.1420668799	on 2
0.1420663398	3 + 2
0.1420631644	the lateral epicondyle
0.1420440648	of nifedipine on
0.1420410204	presented to
0.1420382837	154 patients
0.1420363448	present in
0.1420184334	various experimental
0.1420044585	glomerular filtration rate and
0.1419998232	patients with dyskinesia
0.1419909008	the dose response
0.1419844948	the apical
0.1419832957	less often in
0.1419747475	single doses of
0.1419740073	appearance of
0.1419654007	of rats
0.1419598708	linked with
0.1419345162	a study
0.1419116123	developed prolonged
0.1419111220	in cancer patients
0.1419021052	the clinical and radiographic features of
0.1418981398	associated vasculitis
0.1418949167	in duchenne dystrophy
0.1418830112	a severe
0.1418798912	of treatment with azathioprine
0.1418451815	approach to
0.1418162008	the side effect profiles of
0.1418090204	calculated by
0.1418061727	low doses of
0.1418040451	all rats
0.1417963799	gene expression in
0.1417708004	accounted for by
0.1417623723	found in 10 of
0.1417377027	various regimens of
0.1417241501	than in group c
0.1417174520	of hypertension
0.1417170812	serum of patients with
0.1417143132	the possible
0.1417072720	the bupivacaine
0.1416919587	discontinuation of
0.1416727353	the protective role of
0.1416583948	responsive to
0.1416128923	20 to 40
0.1416123743	cycles of
0.1416111031	the 8
0.1415955653	with complete heart block
0.1415886908	a separate group of animals
0.1415765044	the negative chronotropic
0.1415727400	of parkinsonian motor disability
0.1415699535	vomiting and or
0.1415659206	the most striking
0.1415620642	2 and 3
0.1415435057	the hypotensive drug
0.1415296806	50 of cases
0.1415097860	and nerve conduction studies
0.1414889129	as high as
0.1414844587	in 17
0.1414356744	than in
0.1413866834	to develop
0.1413278085	almost half of
0.1413092828	the cortex
0.1413074776	grade 1
0.1412805795	to rats for
0.1412740709	and results in
0.1412325521	characterization of
0.1412235604	s to
0.1411425362	in plasma
0.1411158164	not affected
0.1411124182	other mechanism
0.1410972732	the incidence of akathisia
0.1410787320	as in
0.1410333228	administration of ketamine
0.1410326103	a substrate for
0.1410121550	within 1 week
0.1410084020	development of acute
0.1410042334	0.1 mg
0.1409782097	nausea and vomiting occurred in
0.1409727603	the other groups
0.1409608220	enhanced by
0.1409602578	both patients
0.1409549085	a 25
0.1408783508	the temporal relationship between
0.1408610265	some patients
0.1408406886	the normal
0.1408153906	doses of 50 mg
0.1407994675	one of
0.1407699684	eleven patients
0.1407603439	thrombosis in patients with
0.1407580956	betaine on
0.1407034681	adjacent to
0.1406852347	the pathophysiology of schizophrenia
0.1406818800	a history of bladder cancer
0.1406744141	2 fold
0.1406729829	but not in
0.1406726367	anticonvulsant effect of
0.1406681358	the arrhythmia
0.1406577194	did not differ significantly
0.1406442804	the human
0.1406413633	at day 5
0.1406390522	period 3
0.1405421444	+ 0.5
0.1404787255	angiosarcoma of
0.1404721303	8 + 4
0.1404583052	the 16
0.1404379151	a major
0.1404302234	with risperidone
0.1404262592	these findings show
0.1404021668	range 6
0.1403963402	the data
0.1403943867	the balb c mice
0.1403922676	nine patients showed
0.1403888162	of transient anuria
0.1403807221	21 days
0.1403667128	to 300
0.1403505667	model of
0.1403138499	twice daily for 7 days
0.1402933189	5 patients
0.1402932957	5 men and
0.1402763535	+ 3 mm hg
0.1402596400	a critical role in
0.1402566187	5 and 10 micrograms kg
0.1402422644	the normal range
0.1402317235	bmd at
0.1402058689	of amphetamine and
0.1402058689	in normal and
0.1401992816	protective action of
0.1401892083	increased resistance to
0.1401744406	in patients with renal impairment
0.1401742335	an agonist of
0.1401659796	wistar rats following
0.1401550155	the other of
0.1401542615	a useful method
0.1401485881	from day 8 to
0.1401381401	up to
0.1401058761	urinary protein excretion and
0.1400993758	age of patients
0.1400979122	few clinical
0.1400911213	an irreversible inhibitor of
0.1400735295	greater decrease in
0.1400710223	drugs in combination with other
0.1400563662	considered to
0.1400308271	co trimoxazole treatment for
0.1400241054	patients with stage
0.1400221478	the validity of
0.1400200157	three of four
0.1399835090	various forms of
0.1399786320	by pce
0.1399516955	observed in azt
0.1399493219	report on
0.1399443746	and only
0.1399013537	analgesic effect of
0.1398774333	an initial
0.1398764662	after ect
0.1398633534	higher in patients
0.1398327063	resolution of
0.1398305178	the disease
0.1398208286	12 mg kg or more
0.1398155125	infused over
0.1398063944	both substances
0.1397265087	16 ml
0.1397172089	1 g kg
0.1397138653	the effects of
0.1397101603	administered by means of
0.1397069930	the damage
0.1397029620	in organ transplant patients
0.1396994870	treatment presented
0.1396978358	a 6
0.1396779075	13 of 15
0.1396748755	to 21
0.1396657315	5 and 10
0.1396611974	a simple
0.1396469700	the magnitude of
0.1396349319	achieved only
0.1396160536	during sodium nitroprusside
0.1396111031	the 10
0.1395594356	a 21
0.1395403684	the anemia
0.1395348287	a decreased incidence of fractures and
0.1394880012	prodrug of
0.1394704081	the subjects
0.1394541203	the primary
0.1394472462	for 2 days at
0.1394270507	and less
0.1394129292	a target ce of
0.1393905986	example of
0.1393732181	the pr interval of
0.1393150729	the heart rate
0.1393112197	worsened by
0.1393007132	and higher total
0.1392992448	than in sgk1
0.1392858160	influence on
0.1392586685	a selective
0.1392255286	starting dose for
0.1391908998	augmentation of
0.1391908998	version of
0.1391526101	two consecutive days
0.1391364199	testosterone replacement in
0.1390529594	to understand
0.1390514985	removal of
0.1390082838	with hiv disease progression
0.1390022737	and three patients
0.1389932957	the utilization of
0.1389932957	the mainstay of
0.1389886532	dose of intravenous
0.1389422126	treated with tacrolimus
0.1389285592	the controls
0.1388659437	a paucity of
0.1388632195	a significant improvement
0.1388539668	mg l
0.1388159429	a positive
0.1387964339	the control group received
0.1387901342	40 and 50 mg kg
0.1387868994	increased in
0.1387512348	in patients with
0.1387509904	doses of doxorubicin
0.1387505970	few other
0.1387463229	production in patients with
0.1387347548	the li treated rats compared with
0.1387302167	n = 60
0.1387224329	the lidocaine group
0.1386931107	ns nsaids and
0.1386420826	any significant effect in
0.1386154125	the patient presented
0.1386137259	an increased incidence of seizures
0.1385906584	the past
0.1385866661	administered at
0.1385727884	known to occur
0.1385600816	mediated inhibition of
0.1385400184	acute liver failure with
0.1385211849	induced brief episodes of
0.1385170665	of 9
0.1385131320	h later
0.1384960446	the opportunity to
0.1384734888	the alpha
0.1384149010	a cause of acute
0.1383931656	treated with high dose
0.1383860111	the frequency
0.1383846736	monitored for
0.1383783367	a rare
0.1383551054	day 11
0.1383351658	dermatitis due to
0.1383248268	mean weight
0.1383146953	the first to
0.1383011907	of 3
0.1382927211	other potential causes of
0.1382807736	the most striking effect
0.1382791741	a result
0.1382596329	in groups a and b
0.1382567845	observed at
0.1382347747	reactions to
0.1382018470	for 6
0.1381804782	increased above
0.1381704812	of benefit in
0.1381517057	replaced with
0.1381492602	this response
0.1381033223	induced tachycardia
0.1380919438	not well defined
0.1380713214	and two patients
0.1380706950	the activity of p450
0.1380588832	the intestinal transit
0.1380582414	the disorder
0.1380401164	10 ng
0.1380123152	report here
0.1380055541	a past history of
0.1379973728	use in
0.1379878054	family history of
0.1379793827	g and
0.1379725769	the results of
0.1379412707	effects of meth
0.1379360357	14 mm
0.1379124294	an acute liver failure
0.1379005176	used as
0.1378846305	1 h before
0.1378579605	by way of
0.1378579605	within 20 of
0.1378471864	to 24
0.1378449552	response to cocaine
0.1378351337	did not require
0.1378268254	the expression and regulation of
0.1378131267	the most common adverse events
0.1377880641	the most effective
0.1377834587	60 mg kg
0.1377733350	the onset of jaundice
0.1377365710	between groups
0.1377322648	more often
0.1377006301	effects of testosterone
0.1376799390	relationship to
0.1376773704	patients submitted to
0.1376624311	a marked increase in
0.1376528311	120 mg kg
0.1376440371	a decrease in
0.1376292973	the mechanism of
0.1376262624	several drugs
0.1376233424	each patient received
0.1375954846	suppressed by
0.1375721755	and 18
0.1375301245	with citrate dialysate
0.1374980255	unaffected by
0.1374960446	the borderzone of
0.1374798995	in shr
0.1374657315	3 and 6
0.1374425270	12 h
0.1374347739	unlikely to
0.1374313418	the result of
0.1374212734	and in 5
0.1374168238	first 2 days
0.1373188224	did not develop
0.1373159268	four patients
0.1373056996	particularly high
0.1372837951	not hemorrhagic
0.1371814342	identical to
0.1371792604	the injection site
0.1371768918	elevated plus maze and
0.1371560079	13 days
0.1371361869	patients with thrombosis
0.1371251707	and renal tubular acidosis
0.1371242996	year period
0.1371095964	a renal
0.1371067627	not statistically significant
0.1371030158	tacrolimus associated
0.1370940522	developed chronic
0.1370734287	and clinical
0.1370492229	30 60
0.1370167019	phase ii study with
0.1369915429	as efficacious
0.1369714039	0.5 g
0.1369595769	the first case report of
0.1369190940	the effect of
0.1368825645	in 3 hours
0.1368761504	the extent of
0.1368611235	distribution of
0.1368159533	numbness in
0.1367868942	the severity of
0.1367736861	the cells
0.1367295756	amiodarone therapy for
0.1367245190	therapy with
0.1367064839	in most subjects
0.1366997513	from 10
0.1366992770	24 and 48 hours after
0.1366964390	a reduced
0.1366942334	the brainstem
0.1366530360	prolongation of
0.1365935741	this group
0.1365905100	myocardial ischemia induced by
0.1365814676	not previously
0.1365786576	years before
0.1365340652	improvements in
0.1365301004	widely used as
0.1365111458	by adding
0.1365097525	1 mm
0.1365030741	or more
0.1364960446	the vicinity of
0.1364632764	of angio oedema
0.1364119177	to 163
0.1364096187	like receptor
0.1363847142	15 and 30 minutes
0.1363841036	studied in
0.1363804169	the release rate of
0.1363742788	or vehicle
0.1363464811	taken before
0.1363383305	administered as
0.1363206655	and western blotting
0.1362985736	intravenously over
0.1362933613	a single dose of
0.1362907456	for 12 weeks
0.1362732129	12 weeks
0.1362712084	various oral
0.1362699890	induced diabetes
0.1362585963	an opioid
0.1362528268	and pilocarpine
0.1361789333	by contrast echocardiography
0.1361551759	asenapine at
0.1361351152	the first few days
0.1361182538	in rats with breast cancer
0.1361146253	the number of
0.1361124899	effective drug for
0.1361073427	two patients
0.1361038989	safety profile of
0.1360506081	and in 2
0.1360291268	admitted with
0.1360220520	on day + 7
0.1360092218	re exposure to
0.1359973728	in three
0.1359932196	western blotting and
0.1359894828	regions of
0.1359869911	seizures in mice
0.1359831376	contraindicated in
0.1359597907	inducing effect of
0.1359411875	45 minutes after
0.1359152333	incidences of
0.1359030195	effect of doxorubicin on
0.1358962167	twenty two
0.1358737362	evidence of cardiotoxicity
0.1358733807	an estimate of
0.1358459052	antioxidant effects of
0.1357701760	treatment with placebo
0.1357628796	the second group
0.1357517274	a randomized double blind
0.1357441135	the onset of
0.1357431620	the antiarrhythmic activity of
0.1357213663	by increasing
0.1357134419	the three
0.1356867436	as well as in
0.1356787503	an overall response rate of
0.1356769359	with new york heart association
0.1356709537	0 0
0.1356000093	decreased renal function in patients with
0.1355769063	the dyskinetic movements
0.1355729840	of women
0.1355698398	one cycle of
0.1355616665	to use
0.1355452092	patients with acute
0.1355165021	induced anxiety
0.1354756352	motility from
0.1354209876	understanding of
0.1354158054	during pci
0.1353794091	these cells
0.1353534551	case control study of
0.1353432176	the cardiovascular consequences of
0.1353269585	of doxorubicin
0.1353163765	anatomical or
0.1353023986	group b patients
0.1352555800	further enhanced
0.1352367822	effect of clonidine
0.1352266082	n = 23
0.1352068241	this event
0.1351930163	patients with known
0.1350902357	a normal
0.1350829837	more clearly
0.1350793127	further investigated
0.1350577373	criteria for
0.1350574839	and cocaine
0.1350435983	among elderly patients
0.1350160425	evidence of significant
0.1350012777	affected patients
0.1349725905	without concurrent
0.1349608060	does not seem to
0.1349454020	also produced
0.1349444025	of six
0.1349318956	period of 1 year
0.1349074990	5 fu cardiotoxicity
0.1348897017	40 units of
0.1348320918	s lymphoma
0.1348173614	of proteinuria
0.1348110446	s serum and in
0.1347986274	effects of long term
0.1347949642	sixty patients
0.1347808444	a very
0.1347495130	10 minutes
0.1347053360	result in serious
0.1346847633	not associated with
0.1346843446	the young group
0.1346824353	mean dose
0.1346568621	the chronic
0.1346407331	the injection
0.1346322869	the risk
0.1346317595	cyclosporine induced
0.1345913603	year old man presented with
0.1345757853	the multiple
0.1345723718	also reduced
0.1345348287	and maintained at
0.1345059150	given repeatedly
0.1344996105	intolerant to
0.1344816542	possible causes
0.1344654527	the course of
0.1344230852	these episodes
0.1344006716	potentiation of
0.1343804169	the shr treated with
0.1343750174	the third postoperative day
0.1343748287	use of cidofovir in
0.1343709527	cycle length of
0.1343611652	normalization of
0.1343428264	in preventing
0.1343375350	known to produce
0.1343058828	no serious adverse events
0.1342614259	a transient
0.1342555671	level of
0.1342167207	30 to
0.1342116188	application of
0.1341941547	increased by
0.1341879981	at 6 months
0.1341603309	epilepsy induced
0.1341596182	of rapidly progressive glomerulonephritis
0.1341035896	types of
0.1340930238	within 12 h
0.1340814518	also showed
0.1340781235	in rats with puromycin aminonucleoside
0.1340695088	and 3 remained
0.1340511672	critical for
0.1340448399	by day
0.1339963839	the hilus
0.1339387780	one kidney
0.1339316710	n = 21
0.1339129719	the english literature
0.1339111475	on day 1
0.1339087897	further long term
0.1339086797	mean hemoglobin
0.1339072869	the peripheral
0.1338977443	11 patients
0.1338793779	the facilitation of
0.1338712854	known to induce
0.1338536368	a critical
0.1338527112	of axons in
0.1338430447	renal excretion of
0.1338249631	8 week old
0.1338191332	induced dyskinesias
0.1338083383	the lesion
0.1337928683	microg kg min for
0.1337843003	to carbachol and
0.1337778126	a 21 year old
0.1337403870	and c
0.1337230319	the fractional excretion of
0.1336884751	an active
0.1336651460	sensitive to
0.1336595648	6 to 8 weeks
0.1336441074	an acute
0.1335914353	cause tdp
0.1335844348	treatment of cocaine
0.1335839864	proportion of patients
0.1335631936	or = 2
0.1335482181	the grade of
0.1335337755	these 2
0.1335336772	the toxic
0.1335281810	or = 25
0.1335227602	on 0.75 mg
0.1335079379	associated with vincristine use
0.1334793677	in thai women with
0.1334589372	10 healthy subjects
0.1334540305	in animals
0.1334485762	per min
0.1334370028	this unusual
0.1334178086	at therapeutic doses
0.1333704636	= 1
0.1333364029	consequences of
0.1333266063	a dose of 5
0.1333193462	homogenates as
0.1333120792	in six
0.1333081068	of 24
0.1332945575	at week 4
0.1332537248	of penicillamine therapy in
0.1332533390	= 2
0.1331959756	the topical application of
0.1331931190	to receive
0.1331873549	a suspected history of
0.1331815324	of 13
0.1331809648	and isotonic sodium chloride
0.1331774994	high concentrations of
0.1331744134	and in 13
0.1331681432	during 0
0.1331640885	report of
0.1331485951	in patients with end stage
0.1331182554	from day 0 to day
0.1330841119	patients with normal
0.1330698305	a cross sectional
0.1330653262	seen in
0.1330558018	the influence of
0.1330374571	correlation with
0.1330081323	during treatment
0.1330055541	of hearts from
0.1330055541	from tacrolimus to
0.1330006661	cause of death
0.1329655612	phase ii trial of
0.1329472338	most frequent cause of
0.1329099852	an autoimmune
0.1329070193	a minority of
0.1328983738	a control group
0.1328978581	a 5 year old
0.1328573043	12 patients received
0.1328143855	a rare complication
0.1328006561	in 11 patients
0.1327925431	serious side effects
0.1327833296	and after 15
0.1327823157	administration of carbamazepine
0.1327664314	features of
0.1327577517	in patients with chronic heart failure
0.1327021124	a naturalistic
0.1327021124	a multidisciplinary
0.1327021124	a nationwide
0.1327021124	a formal
0.1326962072	1 nm
0.1326892567	and apoptosis
0.1326883997	in metastatic breast cancer
0.1326785666	a common
0.1326530101	sexual desire and
0.1326365725	in control
0.1326302334	the intravenous
0.1326289915	elderly patients using
0.1326112367	comparison with
0.1326011020	formed by
0.1325938530	of collagen and
0.1325797500	neuroleptic malignant syndrome and
0.1325730918	by 3
0.1325487096	injected with
0.1325468567	in connection with
0.1325351486	and thus
0.1325326043	an inducer of
0.1325307611	a higher rate of
0.1325146073	with levodopa and
0.1325108620	or 7
0.1324902381	the time interval
0.1324613770	cessation of treatment
0.1324346955	a relatively specific
0.1324287390	after 9
0.1324062347	effect of lidocaine
0.1323952102	possible relationship between
0.1323876238	9 + 2
0.1323349358	the elderly
0.1323219645	the progression of heart failure
0.1322986993	not known
0.1322698672	the half time
0.1322680575	stratified by
0.1322539263	50 of
0.1322171834	equal to
0.1322137825	these genes
0.1321663815	this age group
0.1321493142	11 patients with severe
0.1321371551	10 microg kg
0.1321321699	8 years
0.1321310587	during lithium treatment
0.1321213803	1 to 6
0.1321012339	treatment with l dopa
0.1320934048	scored at
0.1320460753	group l
0.1320366160	to one eye and placebo to
0.1320211496	a previously healthy
0.1320177635	at 24 hours
0.1319827300	the present work
0.1319746044	high despite
0.1319469925	the hepatotoxicity of
0.1319220315	a pilot study to assess
0.1319089953	70 mg
0.1319048873	assessed in
0.1319022925	patients and 50
0.1319003214	other neurological
0.1318826622	2 3 mg day
0.1318775205	and four
0.1318603883	d ribose on
0.1318339185	this review
0.1318326476	a fixed
0.1318008359	reflex as
0.1318005595	of reactive oxygen species
0.1317895894	+ 50
0.1317747737	concentration of
0.1317679675	in 18
0.1317573920	episode of
0.1317421287	patient with
0.1316814901	action on
0.1316773333	harm associated with
0.1316757364	both cases
0.1316563498	stimulation of
0.1316443779	in magnitude to
0.1316379777	these results suggested
0.1316378776	by day 4
0.1316100266	a weak
0.1316013068	deterioration in
0.1315955106	course of events
0.1315794623	days of treatment
0.1315764954	the likely frequency of
0.1315670547	cause acute renal failure
0.1315627222	this agent
0.1315510774	than by
0.1315230745	pathological changes induced by
0.1315030072	a control
0.1314987130	this latter group
0.1314599232	on day 2
0.1314553435	recurrence of
0.1314098287	both chemotherapy and
0.1314057069	in less than
0.1313955788	in neurocritical care patients
0.1313925894	a potent antagonist of
0.1313664091	discontinued because
0.1313520275	patients with ethambutol
0.1313453700	ketamine induced
0.1313432202	1 week later
0.1313430994	an empty
0.1313120340	5 and 6
0.1312908328	hours after
0.1312893453	d 2
0.1312454238	60 of patients
0.1312397584	after 3
0.1312353607	a dramatic
0.1312114133	2 wk
0.1312079338	in five
0.1312004494	the control level
0.1311538004	no deaths
0.1311530793	the fifth day
0.1311357171	complete recovery of
0.1311074211	the cerebellum
0.1310984908	superior to
0.1310482442	t 1 2
0.1310479827	injury induced
0.1310469506	to clarify
0.1310364274	an early
0.1310352416	at least one
0.1310092376	the beck and
0.1309984650	than with
0.1309791352	8 + 1
0.1309525176	10 month
0.1309111923	reported in
0.1308804973	the children
0.1308796550	a further group of
0.1308766883	significantly less than
0.1308617125	the intact
0.1308496669	+ 11
0.1308451481	and ut a1 expression
0.1308191183	serum concentration of
0.1307594659	as indicated by
0.1307516819	identified using
0.1307289728	disease developed
0.1307250935	6 + 6
0.1306993702	born at
0.1306831399	a combination of
0.1306631156	against pilocarpine
0.1306508214	g per day for
0.1306204405	the most frequently
0.1305975501	frequently used in
0.1305804630	a significant up regulation of
0.1305367812	only 9 of
0.1305359485	apap or
0.1305215514	in line with
0.1305155910	after dexamethasone treatment
0.1305146972	out of 22
0.1305000394	haloperidol induced catalepsy and
0.1304904335	does not appear to
0.1304833514	out of
0.1304802612	d penicillamine therapy
0.1304736399	3 patients
0.1304688678	extent of
0.1304654591	at risk
0.1304370150	mean +
0.1303990520	of caffeine
0.1303743540	a typical
0.1303585128	dilated cardiomyopathy and
0.1303275447	of pain and
0.1302609122	probably because
0.1302510669	with 8 mg of
0.1301960446	on one
0.1301948149	not yet
0.1301920194	the so called
0.1301842376	in patients with uveitis treated with
0.1301589512	a pronounced
0.1301588720	+ 39
0.1301579639	course of
0.1301469521	used to assess
0.1300948162	also increased
0.1300179724	and 19
0.1300107615	in patients with coronary artery disease
0.1300065357	all groups
0.1299825710	in favor of
0.1299817198	oxidative stress and
0.1299505641	treatment and prevention of
0.1299469925	of tremor in
0.1299425599	the last
0.1299221905	attenuation of
0.1298889025	in one of
0.1298302628	the aim of improving
0.1298204912	remains to
0.1298175665	the incidence
0.1297842376	the antihyperalgesic effect of
0.1297842376	and failure of
0.1297820194	and muscle
0.1297684260	on body temperature
0.1297353782	the incidence and intensity of
0.1297338298	the visual analog scale
0.1297187748	evaluated with respect to
0.1296403465	of mannitol into
0.1296331822	these animals
0.1296062239	damage to
0.1295857387	an augmented
0.1295658339	by rhuepo treatment
0.1295404417	production of
0.1295388723	with and without
0.1295146073	for histological and
0.1295067547	frequency of
0.1294921542	than placebo
0.1294631405	causes significant
0.1294336704	switching to
0.1294216189	a small
0.1294125118	a multicenter
0.1294092376	of nimesulide and paracetamol in
0.1293355556	the hepatic
0.1293335770	9 ml
0.1293312372	a variety of factors
0.1292754952	a complete
0.1292710622	in wild type mice
0.1292638750	results of
0.1292393809	13 years
0.1292280652	20 min
0.1292097980	and pain
0.1291981685	exacerbation of
0.1291874656	of desipramine increased
0.1291796565	to suppress
0.1291627583	a and b
0.1291291595	at least as effective as
0.1291260189	in general practice in hong kong
0.1291080458	8 mg dl
0.1290944684	during amiodarone therapy
0.1290906357	a sharp
0.1290906357	a popular
0.1290799066	the time interval between monoher and
0.1290438398	pre administration of
0.1290267730	a smaller
0.1290125819	due to coronary artery spasm
0.1290003362	identified as
0.1289947035	occurred only
0.1289726913	increased from 1
0.1289614553	+ 12 years
0.1288902560	other suspected
0.1288280315	presumed to
0.1287446659	basis for
0.1287413093	on cognitive functions
0.1287334092	the protein
0.1286892902	adverse reactions to
0.1286668009	nicotine induced
0.1286174870	nephrotoxic potential of
0.1285907121	to study
0.1285449093	a change in drug
0.1285429033	or augment
0.1285279116	after three days
0.1285232358	decreased by
0.1285020828	the mean bis score corresponding to
0.1284935675	using human
0.1284909846	used for
0.1284750016	by betaine
0.1284525447	between cyclophosphamide and
0.1284493248	per 100
0.1284440534	anti oxidant and
0.1284219918	day of
0.1283821950	associated with increased
0.1283512681	man with
0.1283507619	infiltration of
0.1283333363	to 50
0.1282948983	the first reported case
0.1282925411	all animals
0.1282686725	the pilocarpine
0.1282681984	the duration of recovery
0.1282555046	therapy for
0.1282391940	and brain
0.1282357975	the cause of
0.1282299403	properties of
0.1282275530	known to influence
0.1281988169	three different
0.1281842376	the change of
0.1281734307	three consecutive
0.1281653116	induced anemia in
0.1281513796	to reach
0.1281358256	at 0
0.1281223322	the concomitant occurrence of
0.1281177493	the tests
0.1280849183	well known to cause
0.1280756509	an effect
0.1280727370	reported as
0.1280566882	response in patients
0.1280536590	induced anemia
0.1280437412	a 37 year old
0.1280195798	0.7 +
0.1280112286	in clinical trials in
0.1279917526	continued to
0.1279561379	in new hampshire
0.1279539256	erythema nodosum in
0.1279333677	recurarization in
0.1279270383	in 42
0.1278988657	the recommended dose
0.1278888802	3 days
0.1278842378	produced in rats by
0.1278379625	pan induced
0.1278359725	the fact
0.1278173769	increased levels of
0.1278142150	from 25 to
0.1277755521	to control
0.1277127634	measures from
0.1277030399	animal model of
0.1276996128	and 50 mm
0.1276574756	g daily
0.1276497658	a male
0.1276484255	in patients with parkinson
0.1276416043	day 1
0.1276355101	one patient showed
0.1276352241	studies of
0.1276278268	and urine
0.1276221898	mg per
0.1276068748	the mechanism
0.1275301353	5 to 3
0.1275237520	a contributing factor
0.1274832573	challenge with
0.1274792940	6 and 9
0.1274601898	calculated from
0.1274525447	in hl60 and
0.1274451674	for clinicians to
0.1274283295	the most common drug related
0.1274257501	pump for
0.1274184949	to highlight
0.1274151009	the a group
0.1273797901	135 +
0.1273560739	followed by vehicle
0.1273554353	47 of patients
0.1272951414	the latter group
0.1272475517	did not require treatment
0.1272353587	known adverse effect of
0.1272173884	in approximately 50 of
0.1272013095	courses of
0.1271729948	investigation of
0.1271717712	patients also received
0.1271554651	showed severe
0.1271317947	a mean
0.1271138499	antinociceptive effect of
0.1270956801	the present data
0.1270746916	of ketamine
0.1270454136	the positive
0.1270048471	30 mm hg
0.1269969162	percentage of patients with
0.1269538123	the experimental period
0.1269251444	1 microg kg
0.1269170957	the clinical course and
0.1269131586	within 30 min
0.1269130376	enhancement of
0.1268989437	three times per
0.1268481991	of 18
0.1268392904	and non
0.1268380597	following renal transplantation
0.1268379625	agonist induced
0.1268379625	carbamazepine induced
0.1268090579	the group
0.1268010112	18.9 +
0.1267844369	a common cause of
0.1267843639	a randomised
0.1267465085	intrathecal administration of
0.1267447749	the posterior
0.1267084878	a hypotensive response
0.1266348610	ten rats
0.1266328479	200 mg day
0.1266232843	with one
0.1266174521	time dependent
0.1265966759	the authors report
0.1265918055	7 to 11
0.1265899818	the risk of vte
0.1265707830	children with
0.1265535025	at 3
0.1265484169	included in
0.1265460062	from corresponding control
0.1265387133	in vivo evaluation
0.1265359200	to 204
0.1265306541	off drug
0.1265228027	year old woman presented with
0.1265062170	after acute stroke
0.1264969391	10 monkeys
0.1264918670	day 10
0.1264760245	a drug delivery system to
0.1264736620	the 48
0.1264600534	among people
0.1264549753	in four patients
0.1264438942	30 and 60 min
0.1264029038	associated with zonisamide
0.1263980979	5 ht 6
0.1263525046	roles in
0.1263392915	a follow up period of
0.1263388584	do not suggest
0.1263247029	the muscle
0.1263122107	measured in
0.1263120196	a myocardial infarction
0.1262985781	to 320
0.1262966824	at least 6 months
0.1262836379	5 or
0.1262701620	less than 50
0.1262632145	condition during
0.1262620792	use and
0.1262554010	accumulation of
0.1262518283	to establish
0.1262497879	other than
0.1262376434	of temporal lobe epilepsy
0.1262317927	in 30
0.1262056255	the possibility of
0.1262005657	an adverse
0.1261857880	onset of
0.1261554642	no other
0.1261375710	mice showed
0.1260844002	after learning of
0.1260835985	the combination
0.1260719925	by ee in
0.1260704764	low levels of
0.1260425608	s 1
0.1260284686	treatment of mice with
0.1260192937	n = 22
0.1259876165	co administered
0.1259495129	patients with major
0.1258968981	by intermittent intravenous
0.1258788614	the last dose
0.1258778896	the study group
0.1258594952	in dogs
0.1258484752	performed at
0.1258255997	useful drug
0.1258118036	this regimen
0.1258113964	6 hour
0.1257997700	but not on
0.1257976445	developed symptoms
0.1257851270	hit patients
0.1257677292	non randomized
0.1257276850	and st segment elevation
0.1256905853	side effect of quetiapine
0.1256872012	the use of clozapine
0.1256856948	three minutes
0.1256674628	in blood
0.1256570865	and treatment
0.1256543947	also suppressed
0.1256035796	a high serum
0.1255475310	changes from baseline
0.1255444670	in groups a and
0.1255416560	the entire study
0.1255326144	as compared to
0.1255128733	to reverse
0.1254944734	changes in motor activity induced by
0.1254857217	d for four days
0.1254850955	the treatment of relapsed
0.1254808013	also studied
0.1254307458	more adverse reactions
0.1254254585	developed in
0.1253679530	products using
0.1253657266	six dogs
0.1253416863	6 11
0.1253193028	six years
0.1253028330	lipid peroxidation in
0.1252964749	and sodium
0.1252788342	this disorder
0.1252736526	study of
0.1252713335	one year
0.1252668386	but not after
0.1252553647	of chemotherapy
0.1252376095	15 mg kg i
0.1252282240	these variables
0.1252028087	the mtdna encoded
0.1252017251	4 dihydroxyphenylacetic acid depletions in
0.1251951862	of serum transaminase activities
0.1251708813	despite prolonged
0.1251581931	for detecting
0.1251474845	the uk
0.1251198430	report of three
0.1251151084	10 weeks
0.1250974907	or only
0.1250856049	regulation of
0.1250112296	= 32
0.1249768299	treated with oral
0.1249565924	and 2.5 mg
0.1249526807	terbutaline on
0.1249079486	also prevented
0.1248911793	the epileptic group
0.1248736880	in preterm infants
0.1248144128	and placebo
0.1248073123	the peak
0.1248028219	other 5
0.1247983549	cardiotoxicity in patients
0.1247940375	just before
0.1247240912	or not
0.1246867884	of haloperidol on
0.1246810063	provoked by
0.1246810063	predicted by
0.1246744152	patients not previously
0.1246516380	the dose response curves
0.1246445309	second and third
0.1246374089	a placebo controlled
0.1246025607	tested in
0.1245737953	for five days
0.1245538322	the level of
0.1245496418	the 65
0.1245415978	to draw
0.1245128223	to improve
0.1245035991	other chemotherapeutic agents in
0.1244996249	the pretreatment
0.1244989698	cell proliferation in
0.1244913646	the period
0.1244827644	follow up study
0.1244777646	most serious
0.1244650731	likely to
0.1244632783	a dose dependent reduction in
0.1244611337	in neurons and
0.1244514264	rose significantly in
0.1244353209	the first 3
0.1244296017	to cause
0.1244266323	the placebo
0.1244187970	and haloperidol
0.1243770880	the activity of
0.1243704848	also showed increased
0.1243516092	6 mm
0.1243448646	the combined administration
0.1243281191	an association between
0.1243122546	a feasible
0.1242753797	group developed
0.1242753027	4 patients
0.1242719452	kept on
0.1242594953	history of
0.1242582213	treated rats compared to
0.1242354965	the pathophysiology of
0.1242343566	the later
0.1242306890	in 57
0.1241643595	patients with primary
0.1241470978	the medication
0.1241143322	the diagnosis
0.1241057098	and 100
0.1240995887	rast for
0.1240992543	the risk of venous thromboembolism
0.1240919157	in addition to
0.1240874078	a single dose of dox
0.1240768247	mechanism for
0.1240463149	this retrospective
0.1240413203	and 200
0.1239810280	the hospital
0.1239790737	longer than
0.1239731793	the blood pressure
0.1239534267	in acquired long qt syndrome
0.1238843491	the catalepsy
0.1238657250	concentrations of 10
0.1238592082	of locus coeruleus
0.1238592082	of sugar access
0.1238532142	this prospective study
0.1238451274	higher in
0.1237871752	patients at baseline
0.1237431473	the entire group
0.1237421155	the vessel wall
0.1237381773	the outer medulla
0.1237310344	on average
0.1237103975	induced by chronic
0.1236895054	a dose of
0.1236867884	of verapamil on
0.1236786982	eight courses of
0.1236692281	before initiation of therapy
0.1236451777	the selective
0.1236421759	the occurrence of nephrotoxicity
0.1236371886	60 mg m
0.1236277551	in most
0.1236082136	the action of cocaine
0.1236018000	fold higher in
0.1235963269	3 8
0.1235752149	effects of i.v
0.1235445581	than females
0.1235435958	pain during
0.1235285699	dose dependency of
0.1235066042	of renal toxicity in
0.1234980581	7 to 9
0.1234875744	in such patients
0.1234824956	and right
0.1234778970	2 +
0.1234730481	etiology of
0.1234728485	the convulsions
0.1234586984	a safe
0.1234581782	by injecting
0.1234276993	changes of blood
0.1234249754	and 28
0.1234104558	left ventricular end diastolic pressure and
0.1234060545	an effective treatment for
0.1233911396	7 + 1
0.1233780370	the c
0.1233510088	to 100
0.1233485975	the chronic phase of
0.1233303672	0 meq l
0.1233144660	a 24 year old
0.1232973013	but not by
0.1232865901	in doxorubicin
0.1232776372	chronic renal failure and
0.1232670624	female patient with
0.1232142775	three patients developed
0.1231986503	2 to 3
0.1231771667	up to 800 mg day
0.1231700070	and color vision
0.1231417269	before and during
0.1231319388	described in
0.1231167258	or endometrial cancer
0.1230805815	to lithium in
0.1230776271	in male sprague dawley rats
0.1230748296	a potential
0.1230667816	no evidence of
0.1230606002	damage produced by
0.1230537000	seizures increased
0.1230534086	treatment significantly
0.1230509769	of gestation
0.1229984213	carcinoma of
0.1229894556	to reduce
0.1229506441	similar with and without
0.1229502203	in group 4
0.1229211873	patients with confirmed
0.1229169821	with changes in
0.1229111275	in 8 patients
0.1229099108	the compound
0.1229089026	4 + 6
0.1229056361	not significant
0.1228895020	best of
0.1228833874	for one
0.1228788060	the lungs
0.1228607663	to normal
0.1228514833	phases of
0.1228022731	following discontinuation
0.1227760667	treated with doxorubicin
0.1227734581	dose of doxorubicin
0.1227658043	5 2
0.1227372689	an increased urinary
0.1227273875	guidelines for
0.1227210231	than 50 years
0.1227108003	additional patients
0.1226846806	in adult mice
0.1226782827	detection of
0.1226682713	cells in
0.1226501655	risk of
0.1226456306	applied to
0.1226092390	associated with renal
0.1225784660	and end stage renal disease
0.1225693851	for 30
0.1225254623	related to long term
0.1225190451	information on
0.1225140995	polymorphism in
0.1224387749	7 to
0.1224223142	a treatment
0.1224010223	also associated with
0.1223885167	2 3
0.1223774593	the use of amiodarone
0.1223673763	also highly
0.1223666819	to 1.5
0.1223574039	acute treatment
0.1223523166	the early
0.1223469797	restoration of
0.1223431325	before angiography
0.1223359213	to 99
0.1223227142	more marked
0.1222286145	three hours
0.1221668558	induced by cocaine
0.1221476611	with age
0.1221263621	following myocardial infarction
0.1220873688	the first reported case of
0.1220740006	more effective than
0.1220561382	the 13th day
0.1220531711	a possible cause of
0.1220410521	for 5 days
0.1219857764	third group
0.1219615798	mg kg dose of
0.1219518058	the frequency of
0.1219426824	the case
0.1219211955	interval between
0.1219151084	two weeks
0.1219026182	use with
0.1218652758	in sgk1
0.1218565879	referred to as
0.1218335489	the basal ganglia
0.1218199651	to test
0.1218149636	or d 2
0.1217884718	of animals
0.1217860524	6 mg
0.1217817923	a woman
0.1217777908	no other risk factors for
0.1217726532	the level of lipid
0.1217702175	for cocaine overdose
0.1217690198	for 18
0.1217598593	used to study
0.1217440943	the levels of dopamine
0.1217385744	convulsions induced by
0.1217215116	acute liver failure in
0.1216777072	cholestatic hepatitis after
0.1216717763	during training
0.1216629088	the brain concentration
0.1216405508	repeated doses of
0.1216398843	possibly due to
0.1216379723	at two years
0.1216352559	4 ng ml
0.1216320677	from day 0 to day 7
0.1216257302	careful observation of
0.1215945577	the electron microscope
0.1215673578	in groups
0.1215525535	9 and 12 months
0.1215369668	associative memory in
0.1215212611	20 weeks
0.1214990938	by ethanol
0.1214856389	the 50
0.1214628664	in bile diverted rats
0.1214378550	mv to
0.1214344148	doses used in
0.1213895339	a single intravenous
0.1213884927	in renal transplant recipients
0.1213684986	by calcium chloride
0.1213331024	significantly increased in
0.1213136713	up to 17
0.1212935268	the kidneys
0.1212796021	little effect
0.1212694248	per group
0.1212604214	the common
0.1212466157	day old
0.1212249768	most of
0.1212050467	patterns of
0.1211871084	all of
0.1211816923	the passive avoidance test
0.1211767353	of ce in
0.1211637437	more selective
0.1211582471	60 of
0.1211508524	patients with recurrent
0.1211506238	treatment group
0.1211065850	n = 18
0.1210748257	margin of
0.1210595425	manipulation of
0.1210335600	the analysis
0.1210323527	the fourth
0.1210117012	to delineate
0.1210099581	third of patients
0.1209866750	204 patients
0.1209865202	35 g
0.1209820150	+ 10
0.1209780060	a clinical
0.1209750883	as initial therapy
0.1208866636	one day
0.1208780198	probably due to
0.1208622951	generated during
0.1208554119	the incidence of cin
0.1208412743	involvement of
0.1208144011	during respiratory failure
0.1207893394	the prevention of
0.1207450161	+ 17
0.1207294878	of one of
0.1207197865	days of
0.1207134482	75 mg day
0.1206813231	the risk of developing
0.1206541011	0.5 h after
0.1206528845	and systemic vascular resistance
0.1206527212	most patients showed
0.1205694120	in tie2 cre
0.1205681172	in metronidazole induced encephalopathy
0.1205473241	in cancer patients receiving
0.1205353221	all 5
0.1205304010	review of
0.1204409765	3.0 +
0.1204385102	topical treatment with
0.1204231643	2 to 4
0.1204150757	form of
0.1204026949	in six of nine
0.1203880419	and complete heart block
0.1203711490	b and c
0.1203230918	after 1
0.1202989312	found between
0.1202907403	plasma concentration of
0.1202870821	bepridil at
0.1202655643	14 patients
0.1202534840	and low
0.1202397842	a possible
0.1202315327	2 p
0.1202104065	and two
0.1202028442	to two
0.1201808606	considered in patients with
0.1201749466	150 mg day
0.1201698665	during follow up
0.1201568621	the lesions
0.1201550899	a significant correlation between
0.1201492444	8 10
0.1201369628	a complete response
0.1201267351	the lower limbs
0.1201053655	stroke patients
0.1200738243	a 50 year old
0.1200523767	to manipulation
0.1200169802	did not differ significantly from
0.1199880637	percentage of
0.1199787110	more likely to
0.1199783814	induced thrombocytopenia
0.1199623586	and 10 mg
0.1199165312	of nephrotoxicity by
0.1199131737	the effect of 5
0.1198591314	impairment of
0.1198255699	and 35
0.1198218783	50 mg kg per day
0.1198051546	and seven
0.1197819830	the study involved
0.1197444022	the administration of
0.1197339178	the elderly group
0.1197217296	day old rats
0.1196885326	tested by
0.1196801109	in 10 patients
0.1196561125	toxic effects on
0.1196537862	but ranitidine
0.1196245369	than at
0.1196189157	10 or 20
0.1196104767	in adulthood
0.1195739892	only to
0.1195716113	a week
0.1195675853	the patient tolerated
0.1195619276	all mice received
0.1195388812	2 1
0.1195279261	possible to identify
0.1195159053	1 to 3
0.1195029943	the experimental group
0.1195004820	the acute period
0.1194902931	more of
0.1194834394	drug interaction with
0.1194795442	to 60
0.1194504602	the specific
0.1194359718	28 of patients
0.1194326268	hours before
0.1194322928	patient developed
0.1194243421	escalated as
0.1193764186	7 10 days
0.1193756010	mid to
0.1193554414	twenty four patients
0.1193331295	treated with ee
0.1193283127	administered to
0.1193220048	an elevated
0.1193190589	or = 20
0.1193158013	of local anesthetic induced
0.1193134733	dosage of
0.1193050053	no recurrence
0.1192185666	at 4
0.1192095586	2 to 11
0.1192058641	nicotine induced seizures and hypolocomotion in
0.1192049840	to continue
0.1191865717	any other
0.1191796290	investigated in
0.1191722773	the effects of nicotine
0.1191632337	ca o to
0.1191625131	after 10
0.1191502360	+ 19
0.1191425992	processing of
0.1190983306	no underlying
0.1190976545	3.9 +
0.1190971047	cardiac arrest after
0.1190817776	1 hz
0.1190649773	returned to baseline after
0.1190630279	14 day treatment
0.1190116557	and normal sinus rhythm
0.1189760365	sd +
0.1189589950	all dose levels
0.1189490881	no reports
0.1189236305	chronic administration of
0.1189213496	describe three patients
0.1189078460	patient showed
0.1189050735	induced arterial
0.1189043842	in 10 of patients
0.1189033611	mean arterial
0.1188936993	in vivo and in vitro
0.1188864458	the overall response rate
0.1188531372	tee with
0.1188251361	the systolic blood pressure
0.1188193788	or trimethaphan
0.1188046799	many patients
0.1187755106	to answer
0.1187606053	a direct effect
0.1187588041	18 weeks
0.1187440943	the reduction of children
0.1187324952	in men
0.1187275994	for 2 weeks
0.1187246233	activated during
0.1187231331	observed after
0.1187041239	a selective 5 ht
0.1186889032	the data suggest
0.1186858647	and liver
0.1186711812	a report
0.1186694104	with locf and mmrm
0.1186315265	the fall in blood
0.1186250498	became more
0.1186129916	a 0.5
0.1186127451	in serum
0.1186060607	the most appropriate
0.1185940178	an overall response rate of 16
0.1185443810	and four patients
0.1185428743	discontinuation of treatment
0.1185349877	the number of striatal
0.1185198438	in female
0.1184910982	cardiotoxicity in rats
0.1184874227	in 2 patients
0.1184805816	21 patients
0.1184704657	3 ng ml
0.1184653157	a second
0.1184540894	the 13 patients
0.1184416668	measure of
0.1183985098	in patients receiving lithium
0.1183873374	cholestasis in rats
0.1183720565	the original
0.1183634103	day for 4 days
0.1183621823	pegylated interferon and
0.1183374700	doses of 50
0.1183329519	effect of cocaine
0.1183306616	efficacy of
0.1183012988	to 200
0.1182998546	evaluated for
0.1182840565	the underlying
0.1182764449	the incidence of venous complications
0.1182750801	the first experiment
0.1182499821	the functional
0.1182389053	from 1986 to
0.1182313107	in auditory discrimination
0.1182295819	induced by iso
0.1182153829	a decreased
0.1181673714	significantly attenuated by
0.1181501726	in adult
0.1181445504	after 2 days of
0.1181366567	at 30
0.1181198463	20 cases
0.1181146014	of bupivacaine
0.1181023633	sg in
0.1180965600	in 37
0.1180934383	the risk of hiv seroconversion among
0.1180721002	modification of
0.1180498100	patients required
0.1180320050	45 days after
0.1180249765	the duration of
0.1180133164	and proteinuria
0.1179904418	= 0.5
0.1179899418	the development of crf or esrd
0.1179894758	a standard
0.1179698633	the direct
0.1179669780	after tdi
0.1179457122	vs placebo
0.1179147191	amiodarone resulted in
0.1179089933	after theophylline
0.1178901176	the expression
0.1178733427	a 14
0.1178702192	day 21
0.1178419058	the control animals
0.1178121186	2 bha
0.1178046281	95 confidence interval =
0.1177723933	as measured by
0.1177567644	8 patients
0.1177127323	time of
0.1177014933	the guinea pig
0.1176568757	the second patient
0.1176519404	day for 6
0.1176384436	the median
0.1176352797	increased expression of
0.1176195240	among participants
0.1174976735	aged over
0.1174975130	and levodopa induced dyskinesias
0.1174734429	concentrations of
0.1174698901	the low
0.1174615293	administration of oral
0.1174572441	and congestive heart failure
0.1174372518	used to prevent
0.1174347158	treatment of acute
0.1174256978	the combined
0.1173904710	40 years
0.1173887173	significantly more likely to
0.1173779875	found for
0.1173744394	the urinary tract
0.1173569741	induced seizure
0.1173331693	and behavioral
0.1173284240	most pronounced during
0.1173137398	the current findings on
0.1172951521	appetite suppressants in
0.1172721112	the dipyridamole induced
0.1172702965	1 + 2
0.1172035479	and wild type mice
0.1171787818	forty two patients
0.1171744422	or 0.5
0.1171639073	day for 10 days
0.1171548192	neurons in
0.1171548025	with cocaine
0.1171539864	consequence of
0.1171430624	for at least one year
0.1171359940	the basilar artery
0.1171358698	used to estimate
0.1171333541	a range of doses
0.1171084989	rates of
0.1170828092	six controls
0.1170601939	a cause
0.1170567841	a period of
0.1170495659	the development of tolerance
0.1170492829	corresponding to
0.1170406767	6 + 2
0.1170074754	more common among patients
0.1169512877	attempt to
0.1169310436	a drug challenge
0.1169211129	strategy for
0.1168945065	9 to
0.1168744211	significantly increased by
0.1168452248	cause significant
0.1168355086	nine days
0.1168191309	the time of
0.1168106455	superoxide production and
0.1167699085	the frontal cortex
0.1167638880	period 1
0.1167411259	the scopolamine
0.1167323862	and glutathione peroxidase
0.1167257409	of male sprague dawley rats
0.1167131237	on animal models
0.1166809387	duration of
0.1166763131	the effectiveness of
0.1166710588	treatment of patients with
0.1166710167	the groups treated
0.1166453879	this hypothesis
0.1165939156	0 mm
0.1165899183	induced cardiomyopathy due to
0.1165850034	6 and 1
0.1165760237	obtained during
0.1165660688	an inhibitor of
0.1165290207	the alterations
0.1165178325	increased heart rate and
0.1165078140	test for
0.1164880437	induced by single
0.1164553843	to changes in
0.1164512544	aged between
0.1164453632	the patients in
0.1164311778	to control values
0.1163836164	with diethylcarbamazine
0.1163814747	by electron microscopy
0.1163400080	deaths from
0.1163145476	this interaction
0.1163026382	case of
0.1162729524	results suggested
0.1162592182	the urinary
0.1162447509	on cpa ee
0.1162291014	the most common side effect
0.1162176257	of 16
0.1162114452	the following case
0.1161994117	in one patient
0.1161680258	the pressor effects of
0.1161515429	the delayed
0.1161458021	one of three groups
0.1161359940	the vas scores
0.1161259831	also known as
0.1161197416	and bladder
0.1161189424	of nicotine
0.1161099387	occurred in 7
0.1161010564	clinical trials in patients with
0.1160903722	all 7 patients
0.1160192868	in typical absence seizures
0.1159505129	16 years of age
0.1159392055	beta 1
0.1159366888	following paracetamol
0.1159218170	the ed
0.1159043480	most patients
0.1158944892	and plasma
0.1158906170	the development of endometrial cancer
0.1158622247	neuroleptic induced akathisia in
0.1158352800	weakly with
0.1158340601	this renal
0.1158329444	placed on
0.1158053464	effects of cocaine
0.1157978034	a previous
0.1157903312	mice leading to
0.1157875008	no differences
0.1157754658	to 67
0.1157663051	detectable on
0.1157651605	the arm
0.1157613745	and then
0.1157509013	two times per day
0.1157454968	elevations in
0.1157383395	renal failure induced by
0.1157280959	of 200
0.1157263983	79 +
0.1157188577	combined therapy with
0.1156953702	the endothelial
0.1156677480	the free
0.1156622226	a role for
0.1156454810	and 27
0.1156126968	axonal damage in
0.1156030464	as to
0.1155919797	15 and 16
0.1155630308	three months
0.1155355200	a substantial
0.1155336837	in one and
0.1155178121	the total power of pupillary oscillation
0.1155044220	the beta
0.1154901071	cause of death among
0.1154896879	combination therapy with
0.1154843010	the trial
0.1154618387	14 16
0.1154430299	50 of baseline
0.1154388242	the last dox
0.1154334846	178 +
0.1154287263	systemic vascular resistance and
0.1154125405	of cocaine induced vasoconstriction
0.1153675515	on brain function
0.1153381324	useful for
0.1153335348	with 7
0.1153313211	these manifestations
0.1153279399	on day
0.1153211520	the enhanced
0.1153053840	cells on day
0.1152730129	the patients received
0.1152645954	the baseline
0.1152515247	the present results
0.1152448546	25 and 50
0.1152235292	opening of
0.1152220116	more likely
0.1152190930	and 45
0.1151887817	a significant reduction in
0.1151052080	to control levels
0.1150986292	melphalan as
0.1150941368	recorded for
0.1150788575	a slight increase in
0.1150133987	induced memory impairment in
0.1149768780	protein expression in
0.1149487510	a kidney biopsy
0.1149379230	stz +
0.1149339360	patients in
0.1149192245	the third
0.1149088937	the use of vincristine
0.1148956141	ed 1
0.1148912507	15 + 5
0.1148693458	stages of
0.1148643547	zones in
0.1148622210	observed in patients with
0.1148264106	in combination with cyclophosphamide
0.1148048412	occurred after administration of
0.1147873242	the puromycin aminonucleoside induced
0.1147792582	even in
0.1147770830	therapy in patients with
0.1147707445	observed with
0.1147657874	appropriate therapy
0.1147609570	on experimentally induced
0.1147439373	not significantly different between
0.1147312660	reported in 3
0.1147297634	a consequent
0.1147107716	recovery of
0.1147017214	examination of
0.1146857694	conducted in
0.1146409631	for only
0.1146136981	the arterial
0.1145956559	at day 2
0.1145886198	no patient
0.1145866574	and 32
0.1145712980	prevention of
0.1145711706	predictors of
0.1145292434	the increase
0.1145220994	the anterior
0.1145089809	in summary
0.1145082564	each other
0.1144826663	nicotine gum in
0.1144805528	a first
0.1144709255	patients versus
0.1144626116	the standard
0.1144599227	this antibiotic
0.1144512689	of myxedema coma
0.1144359528	this side effect
0.1144237882	elevation in
0.1144204331	a subgroup
0.1143995171	several hours after
0.1143939975	the function of
0.1143922506	in capsaicin induced secondary hyperalgesia
0.1143684724	the incidence and severity of
0.1143502014	of 25
0.1143376957	a less
0.1143330477	no cross
0.1142671860	more than 3 months
0.1142616233	the risk for
0.1142616233	the initiation of
0.1142531543	a maximum dose of
0.1142522373	showed evidence of
0.1142437171	the administration of intrathecal
0.1141971534	with thromboembolic complications
0.1141667658	prostate cancer after
0.1141547081	all but one
0.1141422974	results from
0.1141330823	episodes of
0.1141187530	in pediatrics
0.1141099978	and mk 801
0.1140991829	a relatively
0.1140919058	performed in order to
0.1140758960	the first of
0.1140669202	and use of
0.1140423368	the changes
0.1140358944	very similar
0.1140132985	corrected by
0.1140132985	delivered by
0.1139962043	decreased in
0.1139857864	percentage of patients
0.1139772323	of sodium channel density
0.1139612982	the use of sirolimus
0.1139386065	by questionnaire
0.1139293906	more rapid
0.1139097757	ngf and pgs in
0.1139038137	the therapeutic
0.1139031876	the follow up period
0.1138991109	the cerebrospinal fluid
0.1138726290	in antagonizing
0.1138255984	less than or equal to 10
0.1138112458	prior to treatment
0.1138022299	complete heart block and
0.1137750611	the lower
0.1137485611	the combination of carboplatin
0.1137447916	a strong inhibitor of
0.1136793489	by pregnant women
0.1136641497	the reduction
0.1136543791	an earlier
0.1136412458	and apoptotic pathways
0.1136352241	toxicity of
0.1136045691	kg dose of
0.1135883397	and bradycardia
0.1135806311	day for 10
0.1135774992	the nephrotoxicity
0.1135739892	used with
0.1135711706	utility of
0.1135594626	the current
0.1135103592	a rat model
0.1134549340	at 14 and 20 weeks
0.1134492551	in mrp2 deficient
0.1134388008	a 15 year old
0.1134328367	caffeine but not
0.1134092819	positive cells in
0.1133986628	119 +
0.1133968123	causes of death
0.1133875534	a temporal relationship between
0.1133861201	for 3 days
0.1133702767	whereas in
0.1133480974	the calcium
0.1133452714	two or
0.1133444150	a low
0.1133343570	for 4 weeks caused
0.1133291078	patient 2
0.1133121016	in doses
0.1133106513	the puromycin aminonucleoside
0.1133009931	on day 9
0.1132926994	day on days 1
0.1132770217	percent of
0.1132684087	the vehicle
0.1132665653	after 12 weeks
0.1132662070	the 75
0.1132499947	after recovery from anaesthesia
0.1132473959	negatively associated with
0.1132451136	at high risk
0.1132434680	known to cause
0.1132406930	the first week
0.1131385689	in hospitalized patients
0.1131330472	6 h after injection
0.1131205376	half of
0.1131201918	given by
0.1131148574	the last dox treatment
0.1130959600	matched for
0.1130957660	a dose of 40 mg
0.1130905086	induced renal
0.1130736317	the evidence
0.1130690170	the evening before
0.1130688815	but not with
0.1130521596	to 26
0.1130262709	the development
0.1130202275	a possible involvement
0.1129909072	2 + 0
0.1129755746	a significant difference among
0.1129616267	acute interstitial nephritis in
0.1129557600	within 4 days
0.1129483080	tested using
0.1129438059	assessed for
0.1129410399	period of
0.1129350983	of new
0.1129282768	4 of 60 patients
0.1128611437	screening for
0.1128587923	to brain
0.1128440073	in 22
0.1128212864	and doxorubicin
0.1127893533	addition to
0.1127828761	alkylating agents and
0.1127727989	60 weeks
0.1127717319	occur during
0.1127468333	similar in
0.1127294582	the counter
0.1127192531	months after
0.1127170842	the 19
0.1127132407	of cisplatin
0.1127063538	a marked
0.1127012445	secretion of
0.1126990518	mean maximum
0.1126826609	cystitis in rats
0.1126825827	to treat hypertension
0.1126669588	10 to 12
0.1126610544	initiation of
0.1126192105	the parameters
0.1126183034	the gtn day
0.1126177095	examined in patients
0.1125599938	neonate with
0.1125290207	the dyskinesias
0.1125092804	the development of new
0.1124893188	for 7 days
0.1124758384	ros production and
0.1124708324	positive cells on
0.1124586764	an immunomodulatory
0.1124560200	blind to
0.1124410399	infusion of
0.1124083705	the active
0.1124036634	to 22
0.1124027606	an endogenous
0.1124002126	and death
0.1123972973	the results indicate
0.1123720255	all patients underwent
0.1123444941	clinical evaluation of
0.1123390854	the forebrain
0.1123218245	hippocampal neurons in
0.1123183021	volume retention and
0.1123135694	43 of patients
0.1122533104	extracellular matrix and
0.1122413730	in chronic puromycin aminonucleoside
0.1122257724	from 5
0.1122225130	seen between
0.1121852918	the behavioral
0.1121635541	and acute renal failure
0.1121436853	value of
0.1121433677	to doxorubicin induced cardiotoxicity
0.1121301576	after caffeine administration
0.1121182315	h after
0.1120864876	the clinical utility of
0.1120715642	on day 5
0.1120552141	in animals pretreated with
0.1120132623	at low risk
0.1120119752	especially if
0.1119882267	in 54
0.1119823646	1 to
0.1119773008	with seizures
0.1119762709	the ventricular
0.1119442975	because of concerns
0.1119341057	during 2
0.1119335904	a period
0.1119287258	urinary enzymes and
0.1119248228	hormone therapy for
0.1119151176	the efficacy
0.1118890995	as well as to
0.1118841693	system in
0.1118521324	the tumor
0.1118515055	100 and 200 mg
0.1118296985	the ketamine doc
0.1118173259	for 8 weeks
0.1118100454	of pacemaker insertion
0.1117994055	an anticonvulsant
0.1117840889	to confirm
0.1117801671	of 25 patients
0.1117757985	beginning at
0.1117604177	levels of 30
0.1117554332	no change in
0.1117504829	associated conditions
0.1117413091	the first time period
0.1117320007	the mechanisms
0.1117132407	of amiodarone
0.1116814061	co administration resulted in
0.1116673731	insulin treatment on
0.1116575761	of sm 5887
0.1116234375	no statistically significant
0.1116152434	receptor antagonists on
0.1115956873	the altered
0.1115844883	a group of
0.1115841836	an increase of
0.1115817723	induced reduction in
0.1115730006	follow up time
0.1115700790	and lower
0.1115385777	doses of 25
0.1115335417	and 54
0.1115056178	0.24 +
0.1115032897	the time of latency to
0.1114576905	to 55
0.1114524675	in five patients
0.1114486997	the stz icv
0.1114403545	the conclusion
0.1114201276	a drug
0.1114093890	9 months
0.1114066111	and 10 mg kg
0.1113882131	a 16
0.1113630506	in patients with migraine
0.1113329666	1 + 0
0.1113328220	succimer treatment of
0.1113248747	of 27
0.1113110050	the use of cocaine
0.1112922048	in rats with
0.1112873793	1.4 +
0.1112613256	the optimal dose
0.1112347804	the systemic
0.1111986778	the relationship between
0.1111520217	models of
0.1111498544	for 7
0.1111441024	a large
0.1111273458	a potent
0.1111190088	and changes in
0.1110989147	on day 8
0.1110824577	long term effects of
0.1110534730	and l dopa
0.1110281363	a review of
0.1110037459	and eight
0.1109526146	rats treated for
0.1109499744	in 41
0.1109386737	vascular resistance and
0.1109037751	the effects of continuous
0.1108766122	a 33
0.1108604903	to sodium pentobarbital
0.1108413567	the cardiotoxic effect of
0.1108389811	likely cause
0.1108388879	transplanted for
0.1108271387	administration of cocaine
0.1108075264	half life of
0.1107878992	test results
0.1107846030	and symptoms
0.1107670258	associated with statin
0.1107559008	4 mm
0.1107323294	the movement disorder
0.1107132407	of lidocaine
0.1107089010	after day 2
0.1106924973	in combination with other drugs
0.1106661432	16 mg kg
0.1106503095	on memory function
0.1106195983	less than 2
0.1105824288	an immediate
0.1105541692	dyskinesias without
0.1105243433	an excitatory
0.1105188915	given in
0.1105116524	rats showed
0.1105092394	the methamphetamine
0.1105017866	the setting of cocaine
0.1104848284	after two
0.1104275193	stress in rats
0.1103846903	3 cases
0.1103776658	after treatment
0.1103676317	all four
0.1103658399	of 20 30
0.1103527453	resistance to
0.1103506052	and thrombocytopenia
0.1103249137	mrna levels of
0.1103091295	the reports
0.1103023355	a central
0.1102774375	the national
0.1102736446	12 to
0.1102729137	administered in
0.1102702643	no longer
0.1102624662	agent for
0.1102515726	34 +
0.1102434623	on cardiac rate and ultrasound production
0.1102297028	the treatment of primary dysmenorrhea
0.1102280748	six weeks
0.1102018606	only with
0.1101981912	after 30 days
0.1101905404	doses over
0.1101824489	of subcutaneous apomorphine treatment
0.1101809387	type of
0.1101764137	artery calcification in
0.1101327324	receiving treatment for
0.1100957414	decreases in
0.1100912757	in women treated
0.1100880778	the start of
0.1100812571	per 10
0.1100627677	from 50 to
0.1100314665	2 patients
0.1100253104	the myocardium
0.1100085468	percent of patients with
0.1099876225	of 10 mice
0.1099662429	regardless of whether
0.1099424668	to 25 and 50
0.1099205009	+ 6 mm
0.1098841872	variant angina and
0.1098678517	assessed through
0.1098568751	a placebo
0.1098236157	affinity at
0.1098215122	thalidomide in patients with
0.1098190862	for seizures
0.1098169060	occurred at
0.1098153295	expression in
0.1098090034	not in
0.1097855686	the night
0.1097604244	at doses up to
0.1097399433	modulator of
0.1097049477	anesthetized with
0.1096667129	the neuropathy
0.1096439823	in parkinson
0.1096362391	in particular
0.1096159938	30 years
0.1096005676	after 12
0.1095883045	the haloperidol induced catalepsy
0.1095774992	the proteinuria
0.1095615511	and none of
0.1095519022	5 and 7
0.1095421367	cohorts with
0.1095329537	induced by 0
0.1095127779	the whole
0.1094919921	the fluocinolone acetonide
0.1094657790	in isoproterenol
0.1094540349	at day
0.1094434728	from lnna
0.1094190147	prolonged use of
0.1094166107	the increase in
0.1094114276	to examine whether
0.1094100728	0 to 2
0.1094040843	and cyclophosphamide
0.1093986628	115 +
0.1093698769	after 8 days of treatment
0.1093673922	reported with
0.1093672085	depression of
0.1093643040	with 1
0.1093629475	due to accidental
0.1093580680	and significantly
0.1093560165	a rate
0.1093488701	8 week
0.1093485377	upon withdrawal of
0.1093415344	clinical use
0.1093351377	a patient receiving
0.1093203737	0 32
0.1093117805	the non
0.1093098108	activity and
0.1093077670	on reserpine induced
0.1092903434	those taking
0.1092813958	the results of serum
0.1092658348	with end stage renal disease
0.1092442714	and 80
0.1092304396	long term use
0.1092061681	a 4 week
0.1091934524	a 6 week treatment
0.1091890953	of methamphetamine
0.1091787312	symptoms of
0.1091756728	the oral
0.1091600549	limited due to
0.1091381808	98 +
0.1091329414	occurring at
0.1091322425	an easily
0.1091296405	14 men
0.1091288757	of blood
0.1091126112	significant reductions in
0.1090954075	for use of
0.1090874581	quantified by
0.1090765386	important to
0.1090295584	and apomorphine
0.1089988356	evaluated in
0.1089986139	10 microg side
0.1089946041	approximately 7
0.1089942030	related to cocaine use
0.1089936601	a reduction in
0.1089834353	useful in
0.1089323207	n = 24
0.1089174113	the scopolamine induced amnesia
0.1088969112	20 min before
0.1088868812	increased to
0.1088542439	hypotension and
0.1088539808	useful as
0.1088509852	on day 21
0.1088208390	the first 4
0.1088187758	all three
0.1088077692	a new method
0.1088000666	in both
0.1087915667	and 37
0.1087625447	to minimize
0.1087392862	for drug induced
0.1087353377	time to first
0.1087126277	withdrawal of
0.1087040150	by sis3
0.1086606600	but not to
0.1086541897	no correlation between
0.1086212969	on day 4
0.1086204527	the inferior colliculus
0.1086084063	recorded from
0.1085995611	with coronary artery disease
0.1085774415	a significant decrease in serum
0.1085477044	a case of fatal aplastic anemia
0.1084889758	a low risk of
0.1084763791	combinations with
0.1084645828	measured with
0.1084492078	no significant effect on
0.1084384639	6 to 8
0.1084001964	observed only
0.1083570056	the second and
0.1083499894	with and without prior
0.1083461423	determined in
0.1083232660	nicotine lozenge and
0.1083215864	the development of mania
0.1083149265	and serum
0.1083108320	surgery under
0.1082993267	also significantly increased
0.1082867106	the treatment of akathisia
0.1082806441	to hepatitis b surface antigen
0.1082737038	for 14 days
0.1082487170	the sixth dose of
0.1082453312	6 x 10
0.1082193324	a brief review of
0.1082105998	loading dose of
0.1082044765	attenuated by
0.1082022812	also exhibited
0.1081967946	after renal transplantation
0.1081947351	after propranolol
0.1081739759	relating to
0.1081157986	by intravenous infusion
0.1080870636	react with
0.1080610386	on postnatal
0.1080544369	and chronic
0.1080488250	examined for
0.1080414744	and 1.0
0.1080400719	a direct relationship between
0.1080035097	and seizure
0.1079994357	also caused
0.1079984423	and 1.2
0.1079792921	the overall
0.1079768834	more potent than
0.1079640505	and chronic renal failure
0.1079521597	and neuropsychiatric like behaviors
0.1079337766	the maximum
0.1079307327	cocaine associated
0.1079212653	this case study
0.1078991862	a score of 5
0.1078859275	the type
0.1078802561	hypotension in
0.1078746732	and hypotension
0.1078468268	a high dose of
0.1078299738	alone or in combination with
0.1078241174	over 5 min
0.1077732148	this study examined
0.1077674386	normal within
0.1077659615	min after administration of
0.1077600050	hemorrhagic strokes in
0.1077542525	at 6
0.1077529886	this open
0.1077304599	4 mg
0.1077193065	of lindane induced
0.1077185909	100 mg m
0.1076994913	and in vitro
0.1076983075	and left
0.1076864151	changes in mental status
0.1076796334	for transplant free survivors of paracetamol
0.1076718268	characteristics of
0.1076669821	= 22
0.1076560294	independent of
0.1075992212	an objective response
0.1075990179	after cisplatin administration
0.1075990179	at higher doses
0.1075770880	the efficacy of
0.1075655086	induced effects
0.1075538322	the degree of
0.1075393394	the involvement of
0.1075348555	on dwi
0.1075103956	characteristic of
0.1074897214	induced prolonged
0.1074766494	of calcium channel blockers
0.1074734090	induced damage
0.1074721302	20 and 40
0.1074691134	in 5 patients
0.1074558476	0 2
0.1074459100	the response
0.1074027590	six cycles of
0.1073942763	after ouabain administration
0.1073296931	and d
0.1073255394	patients age
0.1072947988	and subsequent
0.1072536316	in less than 1
0.1072375634	in patients with graves
0.1072357243	and 31
0.1072327195	after adjustment for
0.1072176257	of 0.5
0.1072158906	a growing
0.1071883047	the expression of
0.1071650466	following se
0.1071462957	examined in
0.1071408989	an increase in acetylcholine
0.1071293750	with other
0.1071143407	in beagle dogs
0.1071054260	and potassium
0.1070991728	the ischemia
0.1070920698	t cells
0.1070868314	10 30 mg kg p
0.1070850196	6 52
0.1070577353	a low dose of amphetamine
0.1069896571	in common
0.1069853555	the importance of
0.1069844609	after administration of
0.1069732315	the 5 ht
0.1069578862	does not increase
0.1069501651	mechanisms of
0.1069499093	6 ng
0.1069440238	the use of antidepressants
0.1069407612	latency time to
0.1069179820	the underlying mechanism
0.1069068047	examined by
0.1069064784	a case of fatal
0.1068951806	24 months
0.1068853326	glucose metabolism in
0.1068849188	a randomised trial
0.1068159588	no changes in
0.1068045569	more toxic than
0.1068027997	the new
0.1067936295	less in
0.1067916790	at week 8
0.1067659777	safety and efficacy of
0.1067639074	psychotic symptoms and
0.1067638931	and toxicity
0.1067465247	significantly reduced by
0.1067208826	but only
0.1067208292	with 2 cases
0.1067030992	than in older
0.1066911413	with isolated hit
0.1066903389	in more than
0.1066806884	after insulin treatment
0.1066716693	a median follow up of
0.1066597052	the study and control
0.1066393980	a complete remission
0.1066381275	pattern of
0.1065926262	similar for
0.1065840610	induced nephrotoxicity
0.1065339379	of treated patients
0.1065104811	in group 2
0.1064943860	a cholinergic
0.1064942461	complete resolution of
0.1064374867	with placebo
0.1064043623	system of
0.1063977967	by weight
0.1063737576	the extracellular matrix
0.1063643414	results revealed
0.1063478105	the association between
0.1063451540	mg kg for
0.1063385138	and 0.5
0.1063330054	of sporadic alzheimer
0.1063275335	a liver
0.1063049749	contrast induced nephropathy in
0.1062948752	for metastatic
0.1062942875	multiple doses of
0.1062884492	treatment for patients
0.1062750932	nephrotoxic effects of
0.1062496325	of gamma aminobutyric acid
0.1062359709	observed in 2
0.1062331025	state induced by
0.1062239293	rat model of
0.1062206645	and 2.0
0.1062157283	the protocol
0.1062117455	for 7 weeks
0.1062025060	after implantation
0.1061798615	an iop
0.1061697843	from 0 to 3
0.1061690789	and nonsteroidal anti inflammatory
0.1061071817	all 3
0.1061039333	seizures in
0.1061020541	the elevated
0.1060935936	10 100 mg kg
0.1060674766	of hemolytic uremic syndrome
0.1060619747	especially in
0.1060584596	a coronary
0.1060100154	each injection
0.1059906674	sensitivity of
0.1059789245	1 6
0.1059211282	the adult
0.1059011905	on lithium induced
0.1058841964	more than one
0.1058832121	and 58
0.1058755555	divided by
0.1058473346	these 13
0.1058226214	but also
0.1058190288	report of two
0.1058168329	3 4
0.1058029535	the isoproterenol induced
0.1057802236	the dose of
0.1057761649	of ro15 1788
0.1057502014	or 4
0.1057458974	of eslicarbazepine acetate
0.1057346000	the toxic action of
0.1057194443	periods of
0.1057093870	at higher risk
0.1056998830	seizure activity due to
0.1056903336	hypertension in
0.1056852570	effects of chronic
0.1056734603	indication for
0.1056517545	died of
0.1056476807	a total of 24
0.1056434476	given after
0.1056240792	the dorsal
0.1056220009	the effects of amiodarone
0.1056118967	all strains
0.1055987706	the possible role
0.1055933457	given alone
0.1055884198	and 67
0.1055840361	greater in
0.1055671118	induced proteinuria
0.1055389700	the bile duct
0.1055382917	to 154
0.1055204156	an antipsychotic
0.1055164266	from changes in
0.1054815452	did not increase
0.1054787093	and five
0.1054733373	associated with significantly
0.1054650285	2 protocols
0.1054529667	or risperidone
0.1054522991	administered to patients
0.1054396677	these analyses
0.1054094553	during and after
0.1053905746	of calcium
0.1053831976	simultaneous administration of
0.1053781496	2 days of treatment
0.1053316031	17 10
0.1053284524	for response
0.1053007414	at six months
0.1052844507	exhibited evidence of
0.1052773882	number of patients
0.1052543937	levels in
0.1052501635	mpo anca and
0.1052499888	or through
0.1052382349	causes of
0.1052240181	only small
0.1052020189	this time
0.1051966432	mg d
0.1051777826	acute renal failure following
0.1051736043	and 39
0.1051611236	14 years
0.1051569602	a partial remission
0.1051495720	occurred in 4
0.1051425627	the iml
0.1051410739	the calcium channel blocker
0.1051279179	the amount of
0.1051203976	observed for
0.1051135408	seizures and
0.1050683777	the effects of oral
0.1050681921	as well as with
0.1050669472	of levodopa
0.1050553967	areas of
0.1050547266	and beta 2
0.1050524396	of 49
0.1050401705	improvement in
0.1050180797	by using
0.1049890282	qt interval and
0.1049872346	time course and dose
0.1049787442	time in
0.1049773688	an apparent
0.1049520248	of liver
0.1049252822	incidence of side effects
0.1049182505	the beginning of
0.1048610618	the most potent
0.1048411861	effects of acute
0.1048405382	in rats with lesions of
0.1047817526	of icrf 187
0.1047509850	five patients with
0.1047414762	the protection
0.1047278087	the onset of symptoms
0.1047103942	a 35
0.1047000832	the safety of
0.1046934572	one third
0.1046721943	a rat model of
0.1046715982	in 2 of
0.1046573392	not increased
0.1046563113	8 hr
0.1046314683	to 25
0.1046116833	and significantly reduced
0.1046082076	the efficacy and safety of
0.1046056756	of more than 2
0.1045822231	an agent
0.1045782743	these infants
0.1045658473	an emotional
0.1045175649	nonsedating doses of
0.1044687251	and 29
0.1044636895	overall disease
0.1044545641	by conventional
0.1044441578	of up to
0.1044425576	the increasing incidence of
0.1044210270	often accompanied by
0.1044121085	began to
0.1043839160	to 17
0.1043803607	recovery time of
0.1043709124	the adverse drug reaction
0.1043487534	the treatment groups
0.1043469233	five cases of
0.1043282877	preliminary results of
0.1043267260	of oral galactose treatment
0.1043081073	rats with
0.1042956581	in 15
0.1042860129	and 2.5
0.1042722973	superoxide and hydrogen peroxide production in
0.1042660818	developed signs of
0.1042424691	group a
0.1042253351	systolic blood pressure and
0.1042189794	year history of
0.1041978064	the expression analysis of
0.1041896499	more than one year
0.1041792309	in combination with l dopa
0.1041788964	to 13
0.1041311887	area of
0.1041289894	associated with cocaine
0.1041030184	and conventional spinal anaesthesia
0.1040900856	neuronal death in
0.1040605964	creatine to
0.1040494981	use of high dose
0.1040418662	the effect of risperidone
0.1040107941	day for 2 weeks
0.1040056464	before and
0.1040054541	treatment resulted in
0.1040022418	20 patients
0.1039986653	for heart
0.1039621486	no history of cardiac
0.1039215130	dopaminergic systems in
0.1039176994	and renal blood flow
0.1039103903	the anesthetic
0.1039071322	and levodopa induced
0.1039035032	the choreoathetoid movements
0.1038895139	hemoglobin level or
0.1038851832	a beta
0.1038435267	given with
0.1038346156	2 per cent
0.1038236492	mg m 2
0.1038213412	the coronary
0.1037927203	after initiation of levetiracetam treatment
0.1037867021	over 3
0.1037713991	to see
0.1037220785	to increase
0.1036857984	the aorta
0.1036646757	all three drugs
0.1036402124	10 and 30
0.1036369526	prolonged use
0.1036283528	in guinea pigs
0.1036240792	the hematoma
0.1036111427	0.98 to
0.1035870637	more prominent in
0.1035711072	and 44
0.1035590371	and in rats
0.1035535634	and 41
0.1035504577	the mean duration of therapy
0.1035493110	2 microg ml
0.1035436703	these two
0.1035364148	not different from
0.1035279866	system and
0.1035161902	decrease of
0.1035126518	+ +
0.1034777176	in response to
0.1034251969	or 10 mg kg
0.1034201268	the cardiovascular
0.1034126970	compared with 17
0.1033872668	one patients
0.1033331592	prolonged treatment with
0.1033229361	a time dependent
0.1033196400	mg d or
0.1033155563	to controls
0.1033074609	13 patients
0.1033019254	although many
0.1032997989	months since
0.1032962585	in three patients
0.1032834417	during and immediately after
0.1032763310	and 69
0.1032691597	in patients with oab
0.1032662302	necessary to
0.1032523480	5 micrograms
0.1032352006	chronic use
0.1032344333	like symptoms
0.1032216529	the changes in plasma
0.1032189391	a model of
0.1032020444	18 h after
0.1031913398	the responses
0.1031745707	in contrast to
0.1031682621	and diastolic blood pressure
0.1031583070	several new
0.1031475473	patients admitted to
0.1031274315	6 +
0.1031263907	the restricted diet
0.1031187569	use in adult
0.1031133395	a 3 hour infusion
0.1031120724	a female
0.1031102235	the recovery
0.1031086049	pathological changes in
0.1030966211	the same mechanism
0.1030849489	54 +
0.1030786376	pilocarpine in rats
0.1030450551	1 4 days
0.1030438655	day course of
0.1030434006	for mssa
0.1030327847	to present
0.1030282258	possible interaction of
0.1030241642	diastolic blood pressure and
0.1030186825	regard to
0.1030038152	3 5
0.1030023485	a useful model for
0.1029797104	two weeks before
0.1029796290	performed in
0.1029730702	with severe
0.1029647211	the effect of phenylephrine
0.1029612024	hepatic failure after
0.1029487438	associative learning in
0.1029467585	the time course of
0.1029467334	a number of
0.1029319547	the anesthetic procedure
0.1029150118	cocaine in mice
0.1028859941	on day 10
0.1028691707	associated with seizures
0.1028686251	treated with argatroban
0.1028667499	the appearance of
0.1028657433	proven by
0.1028515937	not always
0.1028422682	the patient reported
0.1028367601	10 micrograms kg 1
0.1028323783	smaller in
0.1028137153	and three
0.1028124402	many cases
0.1028076161	no further
0.1028033945	first described
0.1027917187	the well
0.1027846024	a day
0.1027764175	shape of
0.1027605829	a compensatory increase in
0.1027492111	two hours
0.1027398840	only one
0.1027133489	and possible
0.1027133236	different types of
0.1027019656	time to
0.1027017094	cardiotoxicity induced by
0.1026852220	40 of patients
0.1026765382	5 to 20
0.1026532568	the epinephrine
0.1025911734	clinical signs of
0.1025795916	resolved over
0.1025602918	the glomerular
0.1025451219	the effects of chronic
0.1025398909	the qt interval
0.1025287703	while accounting for
0.1025130221	for repeat
0.1025121302	or de novo
0.1024958715	and c57bl 6j
0.1024885239	the high dose
0.1024794117	these individuals
0.1024781296	to decrease
0.1024642767	6 h
0.1024612732	or other
0.1024053626	nine days after
0.1023803925	lesions of
0.1023640751	and timolol gellan
0.1023618284	the rate
0.1023257419	p or =
0.1023032919	blood flow to
0.1022906388	per 1
0.1022740649	risks of
0.1022709993	cardioprotective effects of
0.1022513070	survey of
0.1022513070	extravasation of
0.1022334498	danger of
0.1022334498	incidents of
0.1022305805	the experiment
0.1022184542	for chronic
0.1022167392	the treatment of alzheimer
0.1022097362	characterized as
0.1021977063	in chronic cocaine users
0.1021930450	cardiac arrest in
0.1021562532	to 40
0.1021269269	the ic
0.1021236508	the left ventricle
0.1021073640	in pms
0.1021065014	these deficits
0.1020995874	2 and 5
0.1020864401	all 24 patients
0.1020774686	at low doses
0.1020537175	the impairment
0.1020475669	the administration of lamivudine
0.1020401500	of ns 718
0.1020309936	a pre existing
0.1020302827	12 patients
0.1020101933	a one
0.1020025558	8 on
0.1019985537	serious complication of
0.1019979411	on pain responses
0.1019962631	use of cocaine
0.1019815725	and at 2
0.1019796045	p300 in
0.1019741473	injury in
0.1019593369	the long
0.1019540437	the side
0.1019433258	the age of 3
0.1019431401	associated with early life
0.1019148065	15 patients
0.1019076079	at 7
0.1018901176	the effective
0.1018853649	as compared with
0.1018758061	in 1 of
0.1018686251	treated with ethambutol
0.1018674135	heart failure in
0.1018605849	the rate of
0.1018409463	suggested to
0.1018134592	20 year
0.1018100171	the population
0.1017985927	of two groups
0.1017844640	or 11
0.1017827401	patients with chronic
0.1017679393	in 80
0.1017560177	due to drug
0.1017557985	administered to patients with
0.1017515429	the cardiomyopathy
0.1017407066	and also
0.1017132918	tgf b and
0.1016804117	for venous thromboembolism
0.1016780584	with subjects
0.1016726995	of urinary sodium excretion
0.1016545502	18 patients
0.1016420318	sensitization to
0.1016069713	lines of
0.1015925658	to deliver
0.1015925658	to adjust
0.1015791629	in patients with acute
0.1015685448	in comparison to control
0.1015667832	hallmark of
0.1015667832	eighteen of
0.1015622048	identified in
0.1015548427	to 78
0.1015274358	injection resulted in
0.1015129534	available for
0.1014732822	used to provide
0.1014673575	accompanied with
0.1014617688	more effective
0.1014607468	6 patients
0.1014386867	treatment in
0.1014206887	reported from
0.1014085753	with valproic acid
0.1013998290	granule cells of
0.1013540701	10 days of treatment
0.1013342215	the u.s
0.1013328151	change in
0.1013293217	and for patients
0.1013205695	before and 2
0.1013100858	during status epilepticus
0.1013055154	+ 16
0.1012809086	nephrotoxicity induced by
0.1012537252	the development of hypertension
0.1012121673	daily administration of
0.1011751997	a rare but severe
0.1011314328	the serum creatinine levels
0.1011298554	compared with patients without
0.1011217681	associated with reduced
0.1011217681	associated with decreased
0.1011028519	a minimum of
0.1010651409	risk of vte associated with
0.1010382219	changes with
0.1010368536	the majority of patients
0.1010351939	3 or
0.1010208019	rise in
0.1010199953	to describe
0.1010174404	the newer
0.1010128734	patients in group b
0.1010063142	a retrospective
0.1009693187	the antagonistic effect of
0.1009020875	in bladder
0.1008991577	patients enrolled in
0.1008847797	after 3 months of
0.1008703976	reduced to
0.1008463070	previous reports of
0.1008291855	performed over
0.1008213799	treated for
0.1008081643	of 5 mg
0.1007899229	latency to
0.1007435041	the bradycardia
0.1007154565	8 mm
0.1007015568	0 to
0.1006828497	the risk of stroke
0.1006672995	in cardiac surgical patients
0.1006579110	an effective and well tolerated
0.1006038970	important in
0.1005906542	during liver transplantation
0.1005669559	deficits in
0.1005556829	129 +
0.1005048603	the daily dose
0.1005004337	of hypaque 76
0.1004858325	the cocaine
0.1004706537	not only
0.1004415843	on two separate
0.1004366005	stereotypy and
0.1004363733	for patients with
0.1004335904	a daily
0.1004307235	method for
0.1004207396	of suspected myocardial infarction
0.1004149829	the rigidity
0.1004130863	activity in mice
0.1003927641	for 48 hours
0.1003837795	although generally
0.1003537559	a therapeutic dose
0.1003139639	vitamin b12 and
0.1002989939	the rapid
0.1002946614	3 mg
0.1002807870	an inhibitor of angiotensin
0.1002673234	occurred in 11
0.1002660777	of levodopa induced dyskinesia
0.1002660650	an 80
0.1002626967	the renal function
0.1002571753	induced acute
0.1002367458	part of
0.1002276878	arising in
0.1002276878	licensed in
0.1002182494	an effective method of
0.1001596435	two or three
0.1001529249	the eight
0.1001332692	the present study aimed to investigate
0.1001272527	only at
0.1001097780	phase 2
0.1000997009	a model of chronic
0.1000819026	less potent than
0.1000809059	widely prescribed in
0.1000769356	into two groups
0.1000672342	torsades de pointes in
0.1000645794	a dose dependent decrease in both
0.1000522804	did not cause
0.1000505488	than after
0.1000416554	4 and 8
0.1000413096	and 135
0.1000083713	3 months later
0.1000007268	30 patients
0.0999965132	even at
0.0999962447	at 10
0.0999788330	adverse events after
0.0999758987	chronic effects of
0.0999748817	the central nervous system
0.0999607716	a self limited
0.0999547332	the learning and memory
0.0999518822	of tumor
0.0999358003	a good
0.0999340502	the mean age
0.0999340040	odds ratio associated with
0.0999338810	and 48
0.0999276030	the first 3 weeks
0.0999193287	formation of
0.0999136837	necessary for
0.0998802245	needed for
0.0998600295	institution of
0.0998599596	n = 40
0.0998361105	with valvular heart disease
0.0998145806	0 5
0.0997992609	administration in rats
0.0997980225	of patients with
0.0997941846	and consequent
0.0997936155	control of
0.0997869141	the motor
0.0997737206	by osmotic
0.0997675457	a systematic review of
0.0997669782	particularly in
0.0997532522	than control subjects
0.0997414294	the morphine induced
0.0997408904	associated with several
0.0997343685	the amphetamine induced
0.0997255226	a modified
0.0997178318	a reduction
0.0997177522	and 36
0.0997147073	these rats
0.0997029701	qt prolongation and
0.0997023590	alone or
0.0996969263	found in rats
0.0996955877	with st elevation
0.0996646757	all three groups
0.0996452660	suspicion of
0.0996312482	some studies
0.0996270248	of death
0.0996270109	the most sensitive among
0.0996253419	3 7
0.0996126955	to divalproex sodium
0.0996110895	the emergency room
0.0996064675	by 3 hour infusion
0.0995941515	morphine in
0.0995831604	a case of acute hepatitis
0.0995614958	12 mg l
0.0995536414	in various
0.0995072424	required to
0.0995053863	delirium during
0.0994841889	the view
0.0994525017	of 5 fu
0.0994495357	a median dose of
0.0994462509	6 to
0.0994243935	at least 24 h
0.0993918022	in ldl cholesterol
0.0993627284	renal function in
0.0993599599	eads in
0.0993520786	the feasibility
0.0993435213	well to
0.0993377818	and folinic acid
0.0993220774	or longer
0.0993183279	myocardial infarction in
0.0993106446	even after
0.0992868282	5 and
0.0992810766	any time
0.0992746372	the sm 5887
0.0992707602	a dose of 0.5 mg
0.0992627280	greater than 0
0.0992531670	and up to
0.0992463369	investigated using
0.0992190125	not significantly affected by
0.0992131377	+ se
0.0991724359	in patients with schizophrenia
0.0991696973	the gastrocnemius muscle
0.0991577528	decreased renal function in
0.0991567522	induced by indomethacin
0.0991473350	the aneurysm
0.0991453289	of one
0.0991386028	no significant change in
0.0991107344	a moderate
0.0991028519	a marker of
0.0990901786	time to onset of
0.0990874108	not given
0.0990768778	the authors describe
0.0990649489	administered before
0.0990625020	a dose dependent decrease in
0.0990179966	a few
0.0989937993	g d
0.0989910281	specific to
0.0989902879	overall frequency of
0.0989722919	long term use and
0.0989614099	a particular
0.0989145731	in subjects
0.0989126303	the headache
0.0989009766	levels between
0.0988979073	of valproate induced encephalopathy
0.0988917339	the corresponding
0.0988826736	research on
0.0988581515	25 mg
0.0988260898	10 mm hg
0.0988177018	of morphine induced
0.0988077874	with congestive heart failure
0.0987691768	course of treatment
0.0987588364	case reports of
0.0987508216	liver transplantation for
0.0987459480	the control subjects
0.0987169892	24 h after
0.0986814663	the main side effects
0.0986752265	a change
0.0986678198	change in mean
0.0986354044	the decrease in
0.0986324444	observed against
0.0986036007	0 +
0.0985730373	renal failure and
0.0985686787	the six patients
0.0985676502	a few cases
0.0985417097	after 9 weeks
0.0985417097	after one week
0.0985073670	a case of acute
0.0984888382	safety of
0.0984826835	a nonselective
0.0984715527	the combination of
0.0984653235	more important
0.0984627896	lower in
0.0984570642	digoxin on
0.0984551704	a primary
0.0984408684	doses of 10
0.0984363221	system to
0.0984329331	highly effective in
0.0984022344	in cerebral blood flow
0.0983508221	1 g
0.0983380644	neurotoxic effects of
0.0983302824	report two cases of
0.0983297377	1 + 1
0.0983166681	first time
0.0983157003	use for
0.0982745950	actions of
0.0982565346	10 dogs
0.0982408437	men with
0.0982359886	the effect of chronic
0.0982302210	the first patient
0.0982247197	7 +
0.0982152658	and 3.6
0.0982070369	in 44
0.0981938433	one hundred and
0.0981749330	and warfarin
0.0981701403	3 micromol l
0.0981573956	developed in three
0.0981558941	possible role of
0.0981542415	or as
0.0981432614	need to
0.0981422504	5 years of age
0.0981302892	instances of
0.0980752792	these injections
0.0980705398	a prolonged
0.0980548529	study to investigate
0.0980201947	and serum creatinine levels
0.0980166857	and torsade de pointes
0.0979955338	to 79
0.0979924721	induced hypotension and
0.0979782235	with respect to age
0.0979679257	that cocaine induced
0.0979665611	documented in
0.0979605054	9 years
0.0979299453	adverse effects such as
0.0979227215	even less
0.0979218773	and qs qt
0.0979133626	increases in
0.0978932272	and adverse
0.0978816410	value in
0.0978800091	3.1 +
0.0978757197	3 to 6
0.0978614472	pretreatment of
0.0978578362	the dopamine
0.0978059846	increments in
0.0978059846	practices in
0.0978059846	efficiency in
0.0977924797	the first day
0.0977592340	the mean + sd
0.0977482890	yet to
0.0977466959	level in
0.0977264242	l dopa induced
0.0977243356	or 20
0.0977192169	nuclei of
0.0977127232	score 2
0.0977107057	upon cessation of
0.0977052830	induced mania in
0.0976989898	1 and 20
0.0976555635	of 65
0.0976496892	due to amiodarone treatment
0.0976359190	of side effects
0.0976025920	a 70
0.0975799268	25 30
0.0975761310	in methamphetamine induced dopaminergic
0.0975643612	and memory updating
0.0975477221	these adverse effects
0.0975429205	common side effects of
0.0975399099	at 8 days
0.0975062033	course of oral
0.0975035384	peripheral neuropathy due to
0.0974785591	effects induced by
0.0974590047	three agents
0.0974476989	in doses of 3
0.0974247465	after cc
0.0974201433	in combination
0.0973878091	in patients with cancer
0.0973817804	a patient with acute
0.0973594166	both heart and liver
0.0973518366	the complete
0.0973332336	like effects
0.0972901951	after prolonged
0.0972707044	a case of acute renal failure
0.0972572225	a mitochondrial
0.0972479889	hydrocortisone on
0.0972405582	2 minute
0.0972385865	among users of
0.0972368306	the patient received
0.0972314797	downregulation of
0.0972314797	penetration of
0.0971914123	administration of morphine
0.0971888627	after discontinuation of treatment
0.0971851543	given at
0.0971839555	in acute pain models
0.0971793598	treatment of rats
0.0971606994	minutes following
0.0971310859	analyzed by
0.0971307559	the pilocarpine induced
0.0971113484	the reaction
0.0970889461	after one hour
0.0970879046	studies on
0.0970608227	function in
0.0970446487	this adverse event
0.0970436656	4 hr
0.0970322567	aplastic anemia due to
0.0970168264	blood pressure and
0.0970060049	after oral administration
0.0969990731	a known
0.0969834111	and rate pressure product
0.0969751786	in animals treated
0.0969577908	a brief
0.0969568146	mice resulted in
0.0969334299	up to 30
0.0969268086	the clinician
0.0969228772	in bladder afferent
0.0969192784	association of
0.0969046968	toxicity in
0.0969024264	and 22
0.0968840924	by day 30
0.0968757197	0 to 3
0.0968746432	a useful
0.0968676770	and six
0.0968640238	motor function in
0.0968485334	the inhibition of
0.0968450146	of dogs
0.0967856273	this schedule
0.0967739362	1 to 20
0.0967643601	a further
0.0967274442	the remaining patients
0.0967261158	more than 10
0.0967232670	a 46
0.0967170590	site of
0.0967094569	the primary prevention of
0.0967079585	a total of 60
0.0966776261	with concurrent
0.0966681089	after ibuprofen
0.0966363068	enrolled in
0.0966284494	different from
0.0966125564	beneficial for
0.0966098919	group g
0.0965913666	compliance with
0.0965895645	a great
0.0965784554	2.5 +
0.0965687377	the injection of
0.0965543049	monitoring of
0.0965541276	the accumbens
0.0965519660	working memory and
0.0965022721	a group of women
0.0964913729	received lidocaine in
0.0964703380	of patients in
0.0964689781	seizures occurred in
0.0964669238	of propranolol
0.0964600197	the peripheral nervous system
0.0964490744	in pregnancy
0.0964430276	in contrast to controls
0.0964429540	24 weeks
0.0964207423	not reached
0.0963987266	in vitro studies
0.0963630158	and two of
0.0963557619	the arrhythmias
0.0963539988	followed for
0.0963524860	of norepinephrine transporter
0.0963448879	6 weeks of treatment
0.0963397527	significantly increased in patients with
0.0963346053	and at 30
0.0963342559	given to 10
0.0963121592	after bromocriptine treatment
0.0963081429	the sleep
0.0963006545	and in patients
0.0962714342	used to induce
0.0962469594	the incidence of myalgia
0.0962319676	markers of
0.0962316777	on bupivacaine induced
0.0961790907	day 1 and
0.0961718621	only recently
0.0961599571	the precordial pain
0.0961544151	3 and 6 months
0.0961287531	a left
0.0961059935	learning and memory as well as
0.0960968143	frequently found in
0.0960553100	odds ratios of
0.0960551955	further demonstrated
0.0960436656	also impaired
0.0960371732	with either
0.0960301102	drugs with
0.0960218640	alpha 1
0.0959902280	1 patient
0.0959774143	the use
0.0959725583	trial of
0.0959435513	in 48
0.0959407719	for 36
0.0959077805	and 85
0.0958877374	the 14 patients
0.0958699837	effects of bupivacaine
0.0958313907	the patient experienced
0.0958057386	5 months
0.0957887741	the drug and
0.0957870528	a progressive increase in
0.0957838897	while on
0.0957804081	a clear
0.0957695955	but not cortex
0.0957657267	of at least 1
0.0957650372	less than 20
0.0957543344	a drug induced
0.0957325180	and protein
0.0957263914	with tacrolimus ointment
0.0957159224	5.6 +
0.0956870788	not significantly different
0.0956747890	a decrease in hemoglobin
0.0956586307	a single blind
0.0956247394	18 h
0.0956240896	of four different
0.0956047381	the initiation of therapy
0.0956005900	the combination of cisplatin
0.0955813997	three years
0.0955770608	of 44
0.0955611981	4 5
0.0955611890	all doses
0.0955245924	these symptoms
0.0955048401	the development of lids
0.0955048128	a young
0.0954841294	anxiety like behavior in
0.0954839502	time and
0.0954831183	thirteen patients with
0.0954826814	an increased risk of
0.0954479954	all 3 patients
0.0954344685	lower doses of
0.0953980988	creatine kinase and
0.0953937566	a prior
0.0953920013	with high
0.0953815665	2 microg
0.0953780637	of serum creatinine levels
0.0953657457	s i
0.0953627976	for use in
0.0953593078	and in one
0.0953283630	and 3 mg kg
0.0953168224	after drug
0.0953130666	an increase in urinary
0.0953103557	and kidney
0.0953056398	with morphine
0.0952348646	correction of
0.0952211194	2 to 5 mg kg
0.0952009649	the affected
0.0951946062	proteinuria and
0.0951052923	analysed by
0.0951029034	each test
0.0951010328	the maximum tolerated dose
0.0950724975	of diazepam
0.0950530702	of 54
0.0950490174	treated with high doses of
0.0950462365	or ventricular fibrillation
0.0950349595	in serum and heart
0.0950319198	after administration
0.0950310164	subarachnoid hemorrhage associated with
0.0950168842	baseline within
0.0949970727	les and fps and
0.0949853902	reported cases of
0.0949760463	a common side effect of
0.0949461917	the goal of
0.0949079412	also cause
0.0948891786	the reduction of
0.0948768174	these factors
0.0948756929	the distal
0.0948753596	the migraine attack
0.0948671974	or nasal
0.0948572471	marked improvement in
0.0948455630	for 60
0.0948388319	4 to 5 days
0.0948361060	more serious
0.0948327950	= 30
0.0948302229	chronic inhibition of
0.0948059734	and surgery
0.0948022947	the serious
0.0947694963	the novel
0.0947630233	cefonicid or
0.0947525968	one patient developed
0.0947496788	light microscopy of
0.0947393809	a possible association between
0.0947325535	three drugs
0.0947185218	resulted in significant
0.0947073773	measurements of
0.0946998017	3 of patients
0.0946921775	five hours after
0.0946718163	3 weekly
0.0946691592	climbing behavior and
0.0946581471	and vital signs
0.0946377268	h in patients
0.0946167499	the regulation of
0.0945863474	in rare cases
0.0945710476	abolished by
0.0945565476	h for
0.0945518179	of 99
0.0945431889	the side effect
0.0945391008	each class of
0.0945223271	this double blind
0.0945122297	to 19
0.0944893457	the induction
0.0944889764	s ketamine
0.0944844867	the white matter
0.0944766665	the reduction in
0.0944705993	2 of patients
0.0944616763	for at least 6
0.0944481930	1 min before
0.0944458963	the test day
0.0944452572	the control patients
0.0943845527	the performance
0.0943839994	given for
0.0943767796	complications of
0.0943702599	by 12
0.0943507644	of creatine phosphokinase
0.0943470390	the lower extremities
0.0943440779	one or
0.0943439558	1 hr after
0.0943169621	the first time
0.0943147775	consistent with other
0.0943094130	and 5 mg kg
0.0942775875	the saline group
0.0942756203	in 40 and
0.0942674886	8 g
0.0942612901	sleep latency in
0.0942524602	5 8
0.0942427667	six cases of
0.0942248341	10 +
0.0942071818	in 12 patients
0.0942063185	wk after
0.0942058085	associated with clinical
0.0941516479	to carry
0.0941516479	to diagnose
0.0941516479	to localize
0.0941516479	to perform
0.0941516479	to visualize
0.0941473999	this life threatening
0.0941451545	the time of treatment
0.0941348871	the conventional
0.0941272800	increased susceptibility to
0.0940890092	and 10 of
0.0940477932	within 3
0.0940335904	with chemotherapy
0.0940250698	detected at
0.0940163859	from 15
0.0940128264	from weeks
0.0940072041	ejection fraction and
0.0939975614	than during
0.0939771321	a few hours
0.0939651263	the antihypertensive effect of
0.0939448799	significantly decreased in
0.0939384918	significantly greater in
0.0939367535	a life threatening
0.0939333167	not significantly different among
0.0939198106	a time
0.0938886793	coronary spasm in
0.0938804654	from cytotoxic
0.0938440429	this disease
0.0938421028	on off
0.0938305901	times more
0.0938071176	in children treated
0.0937950933	of 117
0.0937804081	a close
0.0937536494	associated with initial
0.0937529003	induced seizures and
0.0937411731	and laboratory
0.0937275395	a higher dose
0.0937192332	reduced in
0.0936908250	less sensitive to
0.0936789559	involved in drug
0.0936755957	at 9
0.0936699766	a generalized seizure
0.0936496558	after sevoflurane
0.0936421614	with dilated cardiomyopathy
0.0936397334	cells of
0.0936285626	reported side effects
0.0936224185	first 2 weeks of
0.0935904029	six groups
0.0935888411	versus 0
0.0935736033	a 23
0.0935707858	cell proliferation and
0.0935661409	year old woman with
0.0935645012	and heart rate
0.0935626753	estimated by
0.0935565476	changes on
0.0935565476	d for
0.0935469225	the elevated plus maze
0.0935235131	at 24
0.0935130218	more or less
0.0935079661	return to
0.0935021459	in patients with mild
0.0934826853	or 30
0.0934771731	in 29
0.0934742095	the unified parkinson
0.0934660307	these two drugs
0.0934385769	psychosis and disruptive behaviors in
0.0934125859	the sedation
0.0933883013	within or
0.0933832675	or srl
0.0933702599	by 50
0.0933587571	of copenhagen
0.0933581859	a relative
0.0933236711	the week prior to admission
0.0933161246	the eyes
0.0933141510	calculus in
0.0933015030	of 2 to 4
0.0932836623	2 mg kg 1
0.0932604629	the serotonin
0.0932566909	the role of vitamin b12 and
0.0932515905	the first group
0.0932368092	the cellular
0.0932364129	the drug in
0.0932248458	from 8
0.0932171006	the most common drug
0.0932129313	for 7h6 and zo 1
0.0932069983	after consolidation therapy
0.0932057190	3 months of treatment
0.0932000118	vulnerability of
0.0931827167	enalapril on
0.0931818439	in part
0.0931629407	the incidence of eps
0.0931599936	a lower incidence of
0.0931334299	out of 10
0.0931331851	five cases
0.0931238662	min after
0.0931011616	highly sensitive and
0.0930888749	the remaining patient
0.0930883989	to 33
0.0930773122	synthesis of
0.0930773122	influence of
0.0930560054	response in
0.0930538634	clinical significance of
0.0930432579	and one of
0.0930330449	abnormalities in
0.0930304456	+ 2 to
0.0930127158	dopamine 1
0.0930083628	five patients developed
0.0930058434	changes of
0.0929724081	symptoms with
0.0929646782	the transplant
0.0929421592	a preliminary study
0.0929414158	in comparison to
0.0929314988	study to evaluate
0.0929135772	the dose limiting
0.0929079564	30 40
0.0928953376	of 10 patients
0.0928693035	and once
0.0928685272	not with
0.0928667714	in healthy
0.0928663576	a case of ventricular
0.0928654010	between 1
0.0928615166	induced by apomorphine
0.0928558381	to observe
0.0928548234	within 3 months
0.0928483125	of 45
0.0928455630	on 50
0.0928242823	in adriamycin induced
0.0928126342	the concentration
0.0928052758	in 85
0.0928022773	fulminant hepatitis in
0.0927762946	visual acuity and
0.0927642381	of sensory fibres
0.0927444391	of nicotine induced
0.0927371850	combination of
0.0927225482	and verapamil
0.0927040416	used to identify
0.0926990996	21 day
0.0926952237	and 90
0.0926781677	the electrocardiogram
0.0926161519	a loss
0.0926017769	but not for
0.0925969213	d penicillamine induced
0.0925891786	the levels of
0.0925825714	to 28
0.0925821056	not detected
0.0925803506	a higher risk
0.0925781571	seizures within
0.0925746077	during treatment with
0.0925379177	and 2 days
0.0925127397	a potential cause of
0.0925086906	recall of
0.0925038198	as revealed by
0.0924980097	an increased risk
0.0924680928	from 76
0.0924504527	effective in patients with
0.0924270162	and t
0.0924162314	various doses of
0.0923937807	the mechanisms underlying
0.0923697959	the use of adriamycin
0.0923578328	the incidence and management of
0.0923525605	and alpha1 adrenergic
0.0923407325	of 10 20
0.0923199924	0.6 +
0.0923148975	for valdecoxib
0.0922789816	cytoplasm of
0.0922715451	morphine in rats
0.0922248341	as one
0.0922187173	in most patients
0.0922004319	and placebo groups
0.0921892804	cognitive deficits in
0.0921753862	showed changes
0.0921724257	months of
0.0921383946	the treatment of breast cancer
0.0921185630	a widely used
0.0920825061	the hyperactivity
0.0920369265	after 30
0.0920346453	mean heart rate
0.0920087876	only 1
0.0920047765	the confusion assessment method for
0.0919917417	access to
0.0919835243	the hypertensive controls
0.0919790907	the cause and
0.0919525427	also reviewed
0.0919098711	the prevalence of severe
0.0919000479	in 35
0.0918964037	patients at
0.0918572437	the former
0.0918564605	with 21
0.0918434237	cardiac toxicity in
0.0918265720	the urine
0.0918207583	a factor
0.0918035671	of podocytes
0.0918030598	a rapid
0.0917954720	effects of drugs
0.0917768513	found after
0.0917759717	fourteen of
0.0917712670	consciousness with
0.0917683861	in healthy elderly
0.0917597071	like other
0.0917570074	compared for
0.0917563017	the induction of
0.0917561538	a rat
0.0917499931	the lidocaine
0.0917496576	1 hour after
0.0917252014	with 5
0.0917140919	the 39
0.0917138894	to ace inhibitors
0.0917056950	twenty two patients
0.0917053239	not observed in
0.0916878010	of acute myocardial infarction
0.0916795065	interstitial nephritis and
0.0916756889	the day of
0.0916659624	after status epilepticus
0.0916538504	the isolated perfused
0.0916538504	the outpatient setting
0.0916429737	the health
0.0916284501	while in
0.0916192390	the patient to
0.0916066347	to 44
0.0915938519	the objectives
0.0915913005	like syndrome induced by
0.0915787985	30 day
0.0915785495	endometrial cancer and
0.0915708167	2 8
0.0915707662	resulted in severe
0.0915616074	in conscious dogs
0.0915432999	on phenobarbitone
0.0915394034	in conscious
0.0915365852	24 hr after
0.0915292244	in 50
0.0915290452	a reversible
0.0915250483	on isoproterenol induced
0.0915224125	amount of
0.0915189538	renal hemodynamics and
0.0915189538	pain intensity and
0.0915116813	a total
0.0915034144	an hbeag
0.0914936972	lipid peroxidation and
0.0914895422	associated with selective
0.0914872847	the end of treatment
0.0914807641	a fatal outcome
0.0914797998	from other causes
0.0914757442	atrial fibrillation on
0.0914595165	a risk
0.0914476481	and amphetamine
0.0914281739	two minutes
0.0914176417	associated with significant
0.0914088895	on two
0.0913969228	mj in
0.0913898534	n 4
0.0913730256	reported side effects of
0.0913721338	mg kg 1
0.0913518366	the cyclophosphamide
0.0913395354	side effects of
0.0913355534	5 mg kg 1
0.0913309752	function of
0.0913204056	the first day of treatment
0.0913075500	0 30
0.0913002586	ratios for
0.0912597228	in children with
0.0912471303	of 5 fluorouracil and folinic acid
0.0912264447	a consequence of
0.0912141552	occurred during
0.0912064814	a result of continuous
0.0911946577	the incidence of myoclonus
0.0911902229	the response of
0.0911826152	instead of
0.0911606520	the number of patients
0.0911595152	not statistically
0.0911555559	an increased incidence of
0.0911421786	the urothelium
0.0911399155	at 3 and
0.0911387847	side effects including
0.0911361785	myocardial infarctions and
0.0911185259	an oral
0.0910896116	the media of
0.0910846521	min 1 of
0.0910705884	the present study examined
0.0910527390	patients without
0.0910069198	7 patients
0.0910062947	the acute pain
0.0910046344	tolerance to
0.0909914822	the dox induced
0.0909396086	and 15 mg kg
0.0909311338	the treatment and
0.0909259722	at doses of 1
0.0909248232	to 95
0.0908987333	with 5 fu
0.0908918793	this adverse effect
0.0908721510	the lithium induced
0.0908701338	binding sites in
0.0908519528	a rise in serum creatinine
0.0908507785	following administration of
0.0908328304	a different
0.0908290246	the cytochrome p450
0.0908252850	and pentylenetetrazol
0.0908104063	associated with more
0.0908052521	a direct relationship
0.0907712032	associated with acute
0.0907667713	no significant alteration in
0.0907619219	than in users of
0.0907379044	the antidepressant fluoxetine
0.0907344129	more frequent than
0.0907311338	and induction of
0.0907264086	the serum sodium
0.0907217980	the platelet count
0.0907201899	of patients taking
0.0907162386	vasopressin as
0.0907031612	during combined therapy with
0.0906796298	to 16
0.0906702931	this period
0.0906660771	unrelated to
0.0906643256	the severity of isoproterenol
0.0906637272	the major causes of
0.0906350561	blockage of
0.0906067574	treated according to
0.0905863398	with low
0.0905804110	this potentially serious
0.0905737014	measures of
0.0905571130	associated with ciprofloxacin
0.0905433080	also suggested
0.0905403859	4 week
0.0905341107	after ppa
0.0905191883	the interaction
0.0905152727	the experiments
0.0905150704	26 months
0.0904997063	and peripheral neuropathy
0.0904912011	a common side effect
0.0904893831	the patients developed
0.0904794369	and dexamethasone
0.0904700102	other 5 ht
0.0904535808	the aim
0.0904503763	these women
0.0904134048	of young and aged mice
0.0904127024	of renal function
0.0903631169	group than in
0.0903557619	the membrane
0.0903522724	a reduction of
0.0903372488	the control groups
0.0903331144	this subject
0.0903151300	that treatment with
0.0903101699	the amphetamine
0.0902937106	4 biopsies
0.0902917847	obtained with
0.0902798622	on day 0
0.0902746739	into several
0.0902470486	the t
0.0902354516	and superoxide dismutase
0.0902225812	without reducing
0.0902196801	a patient taking
0.0902113838	three to
0.0902113838	50 to
0.0902071818	in 6 patients
0.0901949352	the treatment period
0.0901542275	by l dopa
0.0901540858	combined administration of
0.0901504698	a major role in
0.0901382687	sertraline on
0.0901369332	during sleep
0.0901316393	and headache
0.0901291739	with fatal outcome
0.0901233380	infections in
0.0901203966	the use of intravenous
0.0901135950	and 75
0.0901088706	24 h before
0.0901007927	8 days of treatment
0.0900896116	a population of
0.0900744186	but not single
0.0900609261	pathogenesis of
0.0900562708	this new
0.0900454596	metolachlor use in
0.0900443272	the changes of
0.0900419301	with mesna
0.0900280894	in doses of 4
0.0900011958	investigations of
0.0899677211	the diet
0.0899669671	the percentage of
0.0899609021	increase of
0.0899529804	antinociceptive effects of
0.0899162192	the mean plasma
0.0899150895	the vascular
0.0899106543	of 15 to
0.0898957571	to reduce mean arterial pressure
0.0898859275	the post
0.0898712664	calcification in
0.0898706569	diazepam followed by
0.0898661575	the drug effect
0.0898625368	intracerebral hemorrhage in
0.0898586858	low incidence of
0.0898509263	cocaine and ethanol in
0.0898199686	the difference
0.0898178462	10 30
0.0898115011	a hyperalgesic
0.0897801710	6 rats given
0.0897426449	the potential role of
0.0897339261	to male wistar rats
0.0897315479	at 4 weeks
0.0897287331	the artery
0.0897151221	the incidence of dementia
0.0896996801	found in patients
0.0896953876	a median of 2
0.0896940938	the incidence of ischemic
0.0896700026	as well as of
0.0896564585	weeks of
0.0896248673	or low dose
0.0896218261	1 hour
0.0896210246	white matter and
0.0896129494	the convulsant effects of
0.0896039412	and side effects of
0.0895978650	the greater
0.0895962979	myocardial injury in
0.0895917119	with hepatic impairment
0.0895880673	two patients with
0.0895807116	48 h following
0.0895806163	a combination
0.0895671875	elderly patients with
0.0895621702	for at least 2
0.0895602899	of patients and
0.0895067717	an elevation
0.0895051263	group of
0.0894991296	in control rats
0.0894978802	induced by carbamazepine
0.0894934295	the treatment of parkinsonism
0.0894866915	five weeks after
0.0894555523	the visual
0.0894389554	early changes
0.0894358924	a concomitant increase in
0.0894348101	bolus injection of
0.0894326406	not previously exposed to
0.0894299531	the administration of lidocaine
0.0894249585	in vivo study
0.0894197365	a 54
0.0893518366	the complications
0.0893508221	2 h
0.0893488530	the first 2 weeks
0.0893392870	occurred in 30
0.0893390074	even in patients with
0.0893263064	from three
0.0893166371	the inner medulla
0.0892815653	morning and evening in
0.0892800765	the post therapy
0.0892710598	with heparin
0.0892504453	all treated animals
0.0892462952	the effects of cck 8
0.0892447398	a long
0.0892253929	40 mg m
0.0892171465	a dose of 10
0.0891860098	occurs in
0.0891846751	greater than in
0.0891513284	8 8
0.0891427043	microg ml in
0.0891362900	a single 50 mg
0.0891301598	the severity of pain
0.0891089344	of 2.5
0.0890967734	days 1
0.0890828261	and 38
0.0890644398	a high incidence of
0.0890567310	seen with
0.0890539163	the increase in heart rate
0.0890533940	and group fm
0.0890485809	either as
0.0890184128	in micturition pathways
0.0890059774	attributable risk of
0.0889796784	and paresthesia
0.0889746472	for cocaine
0.0889701827	the major cause of
0.0889691168	death or
0.0889418257	in patients with progressive
0.0888954979	the various
0.0888697018	2 1 s
0.0888683863	role of
0.0888544735	blood and brain ammonia and
0.0888209483	patients with lithium
0.0888112065	15 minutes following
0.0887848175	a fall in
0.0887747755	combined effects of
0.0887708982	a 2 week
0.0887602899	and inhibition of
0.0887584100	the second day after
0.0887464911	a single injection of
0.0887446735	this study suggests
0.0887277925	of aspirin
0.0887243571	given 30 min before
0.0887228542	this clinical
0.0887178462	10 20
0.0887091841	the basal
0.0887011109	acute encephalopathy and
0.0886909063	a significant rise in
0.0886604671	protection by
0.0886591050	a retrospective analysis
0.0886589794	to measure changes
0.0886547780	as natural
0.0886459992	erectile dysfunction in
0.0886346503	between metoprolol and
0.0886061960	lesions in
0.0885946614	the two agents
0.0885891764	efficacy and
0.0885548232	ergotamine caffeine in
0.0885314941	a history of hypertension
0.0884989153	and renal insufficiency
0.0884984540	a gradual
0.0884984540	a computerized
0.0884903239	a heparin
0.0884689298	the mechanism responsible for
0.0884611656	of human
0.0884535808	and safety
0.0884535808	and induction
0.0884506512	period 2
0.0884336670	to 80
0.0884195131	randomised to
0.0884150645	also attenuated
0.0884006320	treatment on
0.0883948950	the size of
0.0883781825	the response to
0.0883505753	the setting of cocaine use
0.0883082198	kidneys from
0.0883047833	a state
0.0882788737	the mortality
0.0882713590	observed in control
0.0882700950	and neostigmine
0.0882606714	three groups
0.0882493246	significantly elevated by
0.0882361225	not affected by
0.0882221031	seconds to
0.0882160023	of 23
0.0882089143	this experience
0.0881983197	progress to
0.0881947909	the healthy subjects
0.0881131527	the formation of
0.0880946921	vs +
0.0880849408	and growth retardation
0.0880808809	the kidney and
0.0880767712	clinical improvement in
0.0880757425	the two patients
0.0880652555	the object
0.0880503697	in three of
0.0880469412	in ventilated dogs
0.0880444171	increased with
0.0880415375	after 8 weeks
0.0880369265	after 15
0.0880319394	the abnormal
0.0880317591	the liver failure
0.0880265611	a serious
0.0880123043	the gunn
0.0880049476	a key
0.0879875495	the er
0.0879702474	and blood
0.0879596301	over 30
0.0879411456	on brain edema
0.0879410025	at 12
0.0879347683	a method
0.0879279955	10 30 mg kg
0.0878912081	the patients developing
0.0878658799	the second case
0.0878641934	due to chronic
0.0878562522	experimental models of
0.0878385064	acute onset of
0.0878145350	in combination with other
0.0878071303	occurred in 1
0.0878041576	adverse reactions of
0.0878001814	10 mg and
0.0877991442	in 14 patients
0.0877795615	the hearts of patients
0.0877786245	to 75
0.0877781681	a protein
0.0877297175	phosphorylation of
0.0877099426	after exposure to
0.0877091192	with warfarin
0.0877006192	blockade by
0.0876937764	of alcohol
0.0876924147	after surgery under
0.0876837578	users than
0.0876712654	either vehicle
0.0876507183	associated with oral
0.0876460714	and also in
0.0876455473	a better
0.0876420878	and 52
0.0876417961	complaints of
0.0876369431	in doxorubicin induced
0.0876055365	also induced
0.0875969906	those observed in
0.0875815555	given for 4 weeks
0.0875706382	and risperidone
0.0875670745	bone turnover in
0.0875662189	2 micromol l
0.0875649733	a significantly increased
0.0875648197	for susceptibility to pilocarpine induced seizures
0.0875571199	a well defined
0.0875565476	for six
0.0875483154	protective effect by
0.0875433428	to follow
0.0875415682	the presence of concomitant
0.0875409711	of brain
0.0875356587	starting dose of
0.0875345870	and visual hallucinations
0.0875285170	demonstrated in
0.0875193991	10 mm
0.0875140093	induced by adriamycin
0.0874853454	the four patients
0.0874700554	60 mg day
0.0874566369	capacity to
0.0873991099	the pharmacological
0.0873644815	the 4 patients
0.0873518366	the levodopa
0.0873397696	1 or 2 mg kg
0.0873379519	a dopamine agonist
0.0873373903	in neurocritical care
0.0873327427	gene expression of
0.0873238401	followed for 2
0.0873087545	and 59
0.0873082198	intervals during
0.0872481211	for 23
0.0872466020	treated with lithium for
0.0872448729	in chickens
0.0872379044	the proliferative response
0.0872007628	of 210 cases
0.0871963650	withdrawal from
0.0871960050	the withdrawal
0.0871839343	alert to
0.0871709204	to 53
0.0871352791	20 to
0.0871349637	bradycardia caused by
0.0871343867	that aspirin
0.0871020711	proposed for
0.0870616473	the authors induced
0.0870519551	and two cases of
0.0870468089	from healthy
0.0870410680	in one case
0.0870366844	or 800 mg
0.0870251417	all dogs
0.0870250117	supplemented with
0.0870222436	the withdrawal of
0.0870181014	but not adult
0.0870049762	decreased to
0.0870005041	for valsartan
0.0869592104	following repeated
0.0869328175	the treatments
0.0869222273	measured as
0.0869123144	the effects of long term
0.0868980261	3 20
0.0868765706	or morphine
0.0868635099	subsequent to
0.0868602849	hepatocellular necrosis and
0.0868566411	the nine
0.0868295753	a total of 100
0.0868148599	to 48
0.0868118206	with high dose
0.0868117283	the combined therapy
0.0868076516	of 41
0.0868016255	as tranexamic acid
0.0867864293	patient years of
0.0867812191	the hippocampal
0.0867795809	to norepinephrine
0.0867759717	antagonism of
0.0867601707	elevated in
0.0867482370	a powerful
0.0867482306	a previously
0.0867438906	the administration of suxamethonium
0.0867083223	and extensive
0.0867040297	of 2 weeks
0.0866915780	and 3 days
0.0866915563	the diagnosis of
0.0866782149	per patient
0.0866759667	the 10 micrograms kg
0.0866708573	detected by
0.0866686347	in patients with schizophrenia treated with
0.0866537634	6 and
0.0866521877	and more likely to
0.0866343162	15 mg
0.0866074679	these events
0.0866065486	the ability
0.0866030847	on day 1 and
0.0866014951	other patients
0.0865728804	to promote
0.0865099573	on locomotion
0.0865099146	the maximal
0.0865077799	after ct
0.0864973502	compared in
0.0864912658	by morphine and fentanyl
0.0864522013	after 6 weeks of treatment
0.0864476729	the infection
0.0864450430	a role in
0.0864307622	a 6 week
0.0864095498	to baseline
0.0863955855	clinical examination and
0.0863897804	the patient remained
0.0863745958	to 50 of
0.0863699254	or 40
0.0863584635	the symptoms of
0.0863523199	given as
0.0863488324	rate in
0.0863303809	an inhibitory
0.0863214044	risk for
0.0863114163	the s group
0.0863075944	29 patients
0.0862930523	the healthy
0.0862918422	six percent of
0.0862793327	epidemiologic studies of
0.0862752810	or 25 mg
0.0862730568	1 mg kg 1
0.0862729083	s anemia
0.0862719221	nine months of
0.0862677107	as compared with controls
0.0862345082	the management of
0.0862235191	response of
0.0862125439	against renal
0.0861965106	induced hypotension on
0.0861956730	and 79
0.0861928339	a comprehensive
0.0861801917	seven patients showed
0.0861777390	reported by
0.0861729597	with time
0.0861488860	cardiac dysfunction and
0.0861354274	the exercise
0.0861243519	the adrenergic
0.0861154215	a day for 10 days
0.0861078866	a liver transplant
0.0860847940	positive for
0.0860748673	only 5
0.0860729631	no previous
0.0860727038	the urinary output
0.0860710154	and short acting
0.0860513400	in 50 of
0.0860347228	for induction of anaesthesia
0.0860161930	adverse effects during
0.0860123043	the interictal
0.0860090424	and 5 fluorouracil
0.0860070920	the mechanisms of
0.0859911265	another group
0.0859769291	the next
0.0859748575	and cerebrospinal fluid
0.0859529846	tolerability of
0.0859521224	ablation of
0.0859466964	1 week of treatment
0.0859452911	for 21
0.0859323424	with chronic
0.0859311338	and incidence of
0.0859131588	the same rate
0.0858956201	of 100 mg kg
0.0858936581	studies indicate
0.0858744997	and 42
0.0858656325	concentrations in
0.0858508530	the type of
0.0858433056	of or =
0.0858396217	therapeutic use of
0.0858311090	both agents
0.0858279377	intervention for
0.0858236572	a toxic
0.0858217542	associated with chronic
0.0857917010	30 min prior to
0.0857867423	the prolactinoma cells
0.0857863505	first with
0.0857732091	the start of treatment
0.0857501257	exclusion of
0.0857232088	the effect of treatment
0.0857127334	2.0 +
0.0857007374	ultrastructural changes in
0.0856644182	the amnesia induced by scopolamine
0.0856507183	associated with intravenous
0.0856378635	to 98
0.0856197026	at week 2 after
0.0856179677	than diazepam
0.0856055383	plasma and
0.0856036993	19 patients without
0.0856034283	and atazanavir
0.0855990950	1998 to
0.0855956019	at 1 year
0.0855948640	of cb 3717
0.0855809386	in group 1
0.0855697481	not due to
0.0855513297	the combination therapy
0.0855338031	1.9 +
0.0855228687	panic disorder and
0.0855200271	chemotherapy with
0.0855193259	the heart and
0.0855189708	ache activity in
0.0855181371	did not interfere with
0.0855028635	from doxorubicin
0.0854915013	a behavioral
0.0854883816	the clinical variables
0.0854662084	a healthy
0.0854573073	daily for
0.0854376498	significant decrease in
0.0854350752	two groups based on
0.0854337140	less severe
0.0854139218	less likely to
0.0853866463	advantages of
0.0853707168	neurotoxicity in
0.0853325360	in nine
0.0853265720	the negative
0.0853176386	with different
0.0853151300	the patients with
0.0853060145	n = 1
0.0852907078	course following
0.0852645087	of terbutaline
0.0852590764	the vocalization and fighting
0.0852506726	to show
0.0852308078	locomotor activity in
0.0852166962	an area under
0.0851976045	the triceps
0.0851943150	2 wk after
0.0851789117	infusion time of
0.0851754168	recently reported in
0.0851714746	salvage therapy in
0.0851682131	12 years
0.0851625730	t +
0.0851209396	on gd
0.0851054979	and also with
0.0850944351	profile of
0.0850930023	of 44 patients
0.0850485809	15 +
0.0850422175	intravenous injections of
0.0849969165	and 10 micrograms kg 1
0.0849907724	the methamphetamine induced
0.0849703177	the infant
0.0849611377	to recognize
0.0849376234	but did not
0.0849284903	study to
0.0848983472	the results revealed
0.0848782206	the first day of
0.0848770120	intravenous dose of
0.0848580361	selection of
0.0848562045	age =
0.0848521083	because of non
0.0848518366	the ratio
0.0848401464	associated factors
0.0848320621	return of
0.0848304961	ocular hypertension and
0.0848299875	6 24
0.0848236328	and acute renal
0.0848144173	dose of 0
0.0848131861	of four
0.0847895800	and propranolol
0.0847710833	a selective dopamine
0.0847675977	the increasing
0.0847651398	the patient underwent
0.0847580285	4.5 to
0.0847501950	a 47 year old
0.0847378929	3 min
0.0847263719	and in rats with
0.0847113838	for use
0.0847057090	by 62
0.0846553671	a statistically significant
0.0845831323	the vcm induced
0.0845599864	poisoning with
0.0845551995	both compounds
0.0845483052	2 3 times
0.0845479262	5 min before
0.0845354239	a rare but
0.0845159594	causes of acute
0.0844957244	no differences in
0.0844813195	to celecoxib
0.0844761994	patients with signs of
0.0844720785	with increasing
0.0844613364	in 21 patients
0.0844506192	controlled by
0.0844490067	a range of
0.0844447872	2 receptors
0.0844442556	fibrosis during
0.0844412974	chemotherapeutic agents in
0.0844394846	into 1
0.0843982866	these groups
0.0843944733	the sensorimotor plasticity of m1
0.0843849095	apraclonidine in
0.0843836423	four children
0.0843609659	1 mmhg
0.0843579175	in rats after
0.0843169721	most severe
0.0843137467	non significantly
0.0842765753	in 16 patients
0.0842679263	and five of
0.0842647151	1 week
0.0842496626	7 mm
0.0842491720	all p 0
0.0842243918	surgery and
0.0842177643	treatment with if
0.0841976045	the lacn
0.0841895344	in 6 of
0.0841826126	the results support
0.0841724467	in male rats
0.0841446273	the hypertensive
0.0841405608	and control rats
0.0841345226	a randomized study
0.0841343653	a causal
0.0841266153	4 + 0
0.0841117606	the beneficial effects of
0.0841049405	in patients with cocaine
0.0840958572	of n pyrimidinyl 2
0.0840891460	of adriamycin
0.0840835316	on hemodialysis
0.0840671728	and exercise
0.0840571269	the concentration of
0.0840300556	one or two
0.0840281105	this study indicate
0.0840228611	a hypotensive
0.0840228132	and fentanyl
0.0840178574	and possibly
0.0840097616	alone do not
0.0839837490	100 days
0.0839772561	or = 5
0.0839758012	in diabetic patients
0.0839699311	and survival
0.0839619835	2 h after treatment with
0.0839616851	the area
0.0839572513	potassium levels and
0.0839453791	increment in
0.0839367897	in cats
0.0839353956	for 3 weeks
0.0839334701	the next day
0.0839311625	and ischemic stroke
0.0839247776	the third patient
0.0839205802	this myalgia
0.0838995323	the present study investigated
0.0838912744	and 1 day after
0.0838864478	the core
0.0838820031	decreased significantly after
0.0838518366	the values
0.0838491913	+ + mice
0.0838488658	after treatment with
0.0838289606	and 1 year
0.0838187062	of 74
0.0838154159	days 9
0.0838130564	up to 12
0.0838101699	the volume
0.0837835506	but one of
0.0837822062	a long term
0.0837794437	not received
0.0837683029	in 20 patients
0.0837569624	first case of
0.0837420285	on behavioral
0.0837404234	and cerebellar volume
0.0837390326	this and other
0.0837370059	for aplastic anemia
0.0837076375	the procedure and
0.0836884137	the accumbal
0.0836659109	all but
0.0836609897	all patients received
0.0836567800	+ 4 to
0.0836393572	+ 5 to
0.0836142610	and also to
0.0836133733	two episodes
0.0836019413	did not respond to
0.0835826905	with olanzapine
0.0835345763	5 consecutive
0.0835288860	a phase i
0.0835285775	artery calcification and
0.0834763719	and evaluation of
0.0834749493	a high risk
0.0834709151	in mice by
0.0834549576	s role
0.0834209677	motor function and
0.0833907177	for more than one year
0.0833903468	grade 2
0.0833820365	not elevated
0.0833809309	in patients with acute liver failure
0.0833443748	mice with
0.0833386388	the medical records of
0.0833252671	for intracerebral
0.0833243892	the development of hepatotoxicity
0.0833187259	complication of
0.0833169864	insulin resistance and
0.0833119575	rating scale and
0.0833054370	induced hypotension in
0.0833018389	regimen for
0.0833001406	the migraine
0.0832934927	the treatment of many
0.0832757562	a distinct
0.0832739622	at 8 weeks
0.0832677042	this enzyme
0.0832625379	a serotonin
0.0832581904	median duration of
0.0832251902	for activities of daily living
0.0831996449	total dose of
0.0831960700	the control and
0.0831916655	the risk of bladder cancer
0.0831913404	lipids and
0.0831853435	s disease patients
0.0831818331	side effect of
0.0831810812	during iso
0.0831677174	patients presenting with
0.0831612956	no relationship
0.0831511948	and midazolam
0.0831467979	in 65
0.0831413197	in 7 of
0.0831359047	and anti hbe
0.0831292006	of taurodeoxycholic acid
0.0831152192	a 5 year
0.0831145184	the mass
0.0831135429	patient admitted to
0.0831099382	at least 1
0.0831084288	the potential of
0.0831050959	the outcome
0.0830989811	the nucleus
0.0830974847	the cumulative
0.0830893445	in eight
0.0830880703	and sodium nitroprusside
0.0830857889	treatment with high doses of
0.0830790314	and bone marrow
0.0830686050	after short term
0.0830658318	various clinical
0.0830634043	no studies
0.0830417187	35 and
0.0830197069	the skin
0.0830188964	in mice treated
0.0829983163	found with other
0.0829885930	for more than
0.0829655430	+ 6 to
0.0829647423	this randomized
0.0829604883	5 times
0.0829514267	combined with carboplatin in
0.0829493356	of 33
0.0829443275	importance of
0.0829373937	of vitamin d3
0.0829272210	such cases
0.0829232711	this risk
0.0829068747	after 15 min
0.0828978697	the bilateral
0.0828770950	mean follow up
0.0828584201	effect in
0.0828491120	the first time in
0.0828474610	propranolol in
0.0828331580	at increased risk
0.0828228811	spinal anaesthesia with
0.0828171105	the risk of reaction to
0.0828008984	the drug intake
0.0827574009	22 cases
0.0827496824	at 15
0.0827142517	2 minutes after
0.0826740382	4 weeks and then
0.0826738403	the duration
0.0826710328	with right
0.0826659630	a 45
0.0826557574	b administration
0.0826422405	observed to
0.0826321859	of migraine without aura
0.0826272149	some symptoms
0.0826004014	of hepatotoxicity
0.0825951501	selective inhibition of
0.0825938353	24 +
0.0825860288	side effects such as
0.0825695035	but not with other
0.0825692173	the association of
0.0825674472	a j
0.0825540836	associations of
0.0825303557	the adrenaline induced
0.0825234190	respiratory changes in
0.0825153260	initiated by
0.0824994247	the high frequency
0.0824937006	a single injection
0.0824932668	more severe
0.0824627922	users of
0.0824612940	the metabolism
0.0824548329	symptom onset and
0.0824547941	hospitalized for
0.0824364632	the result
0.0824271209	in 1994
0.0824125287	and 10 micrograms
0.0823872300	a continuous
0.0823660754	the short term
0.0823589078	described with
0.0823576542	also observed
0.0823446897	a decrease
0.0823412169	rats treated by
0.0823403456	after high dose
0.0823390763	documented by
0.0823308237	a clinical diagnosis of
0.0823293032	for 30 minutes
0.0823232527	significantly attenuated in
0.0823196153	5 fu and
0.0822938149	status epilepticus in
0.0822694986	preparations from
0.0822540647	+ 7 to
0.0822425473	to ergotamine caffeine
0.0822307369	treated with clonidine
0.0822194036	the tail
0.0822123010	following treatment with
0.0822092455	1 and 3 mg kg
0.0822068990	drop in
0.0822011463	day 30
0.0821794907	the spinal
0.0821612517	the 3 patients
0.0821517411	continuous infusion of
0.0821511834	week of
0.0821452756	and 100 mg kg
0.0821304840	following oral
0.0821262971	synthesis in
0.0821154185	at week 2
0.0821060479	marked changes in
0.0820962280	report 4
0.0820952710	the odds ratio
0.0820851701	the concomitant
0.0820542153	for several years
0.0820527633	of 300
0.0820515200	on epinephrine induced
0.0820427294	n 2
0.0820284740	a cocaine
0.0820217003	of liver disease
0.0820009043	no severe
0.0819967407	on days 2
0.0819881841	hypertension and
0.0819879992	the steady state
0.0819851008	administered orally in
0.0819816839	by i.c
0.0819787829	ii study of
0.0819679228	whereas 5
0.0819604996	this end
0.0819536784	of 62
0.0819519972	and 61
0.0819421866	in unanesthetized
0.0819384293	the ribavirin
0.0819201816	the genetic
0.0819028632	no change in cardiac
0.0818951297	a 27
0.0818902806	injected over
0.0818788737	the block
0.0818640627	a target
0.0818394452	+ mice
0.0818201168	and more
0.0818087981	and testosterone
0.0818029865	sirolimus as
0.0817987585	2 mm hg
0.0817943506	those not
0.0817800164	during dipyridamole
0.0817755097	on day 6
0.0817717626	the partial
0.0817453345	the risk of serious
0.0817336331	by metformin
0.0817065276	associated with fulminant hepatic failure
0.0817065014	on days
0.0816788563	for biochemical analysis
0.0816763719	and development of
0.0816630808	ejection fraction of
0.0816428602	of 42
0.0816224361	like drugs
0.0816150386	segment of
0.0816085587	the 6 patients
0.0815961765	by phenylephrine
0.0815753986	sulfate for
0.0815643515	developed after administration of
0.0815449160	in 9 patients
0.0815401792	to treatment with
0.0815364277	and ribavirin
0.0815303227	little effect on
0.0815201070	after 24 h
0.0815163420	cognitive function and
0.0815142004	that seen in
0.0814834251	pulmonary hypertension in
0.0814712421	the incidence of cardiovascular
0.0814667303	a 14 day
0.0814630548	the biochemical
0.0814619716	the decrease
0.0814592532	in approximately 50 of patients
0.0814401472	and elevation of
0.0814349094	of epilepsy
0.0814067145	sensory neurons and
0.0814028856	for 30 min
0.0813898028	all participants
0.0813866653	the evaluation of
0.0813755439	clinical symptoms of
0.0813621480	increasingly associated with
0.0813619615	in ns 718 treated rats
0.0813572360	by puromycin aminonucleoside
0.0813380598	also assessed
0.0813275083	of bladder
0.0813166791	due to ethambutol
0.0813136711	calculated for
0.0813052758	in 59
0.0812963241	the molecular
0.0812916422	for two consecutive days
0.0812459652	in group ii
0.0812304622	due to 5 fu
0.0812256744	and motor
0.0812024516	+ 24
0.0811823002	for treatment of
0.0811653265	for 25 months
0.0811336138	a consolidation therapy
0.0811072260	significantly greater with
0.0811018034	to further
0.0810868451	the locomotor activity
0.0810798073	the participants
0.0810773946	no changes
0.0810744268	64 patients
0.0810741372	value for
0.0810569905	a warfarin
0.0810403990	mg day for
0.0810402172	revealed further
0.0810391643	acute administration of
0.0810370590	inhibitor resulted in
0.0810368388	patients than in
0.0809875591	to dopaminergic neurons
0.0809828422	therapy in
0.0809712282	in patients with ethambutol
0.0809506774	that observed
0.0809421510	with newer
0.0809284799	as for
0.0809166676	death from
0.0808971737	this study to
0.0808860044	the effects of central
0.0808734255	commonly used to
0.0808720755	the latter also
0.0808666309	the gtn
0.0808665930	the rat brain
0.0808388353	12 mg
0.0808376353	not found in
0.0808322136	patient treated with
0.0808316555	hypoxia in
0.0808023503	in antiplatelet users
0.0807969831	1 x 10
0.0807941524	in female rats
0.0807907508	less than 10
0.0807875012	other groups
0.0807825607	the patients experienced
0.0807817181	and atrial flutter
0.0807735330	the most common cause of
0.0807652219	the protective
0.0807558562	on five patients
0.0807505645	as determined by
0.0807430385	the disruption of
0.0807407491	induction of anaesthesia with
0.0807372139	most likely due to
0.0807077347	to 4 days
0.0807056920	seen in animals
0.0807042172	with ergotamine caffeine
0.0807006348	clinical manifestations of
0.0806969595	or vitamin e
0.0806899573	the overall incidence of
0.0806842431	no prior
0.0806789713	27 patients
0.0806764263	induced by 6
0.0806732298	kg +
0.0806728859	the induction of anesthesia
0.0806552775	in vivo characterization of
0.0806334620	documentation of
0.0806088744	two patients suffering from
0.0806066083	the study period
0.0805997709	the saline treated
0.0805604445	specifically to
0.0805270684	day 2
0.0805177867	a high affinity
0.0805175207	the diagnostic
0.0805157317	adjusted for
0.0805088437	of more than
0.0804949491	prophylactic administration of lamivudine in
0.0804947299	to 61
0.0804878098	then treated
0.0804496902	at repeat
0.0804486752	the morphological
0.0804163321	the effects of drug
0.0804098644	and heart rate and decreased
0.0803963076	the form of
0.0803667526	performed under
0.0803405420	in six patients
0.0803399159	in pd patients
0.0803387955	a protective
0.0803377265	a cerebral
0.0803312234	the first postoperative
0.0803297532	6 patients with
0.0803239715	pain in
0.0803159059	the incidence of lidocaine
0.0803099547	to rofecoxib
0.0803077818	by tam
0.0803034269	a voiding
0.0803034269	a reasonable
0.0803034269	a triggering
0.0803034269	a mildly
0.0802948140	seven out of
0.0802937764	the young
0.0802891612	components of
0.0802835712	the 12 patients
0.0802514669	to 32
0.0802444226	of lindane
0.0802381333	the nascis
0.0802286046	or bicuculline
0.0802286046	or pruritus
0.0802252132	the ketamine
0.0802251968	in patients with atrial fibrillation
0.0802203982	rechallenge with
0.0802130611	blood pressure and heart rate and
0.0802083490	one class of
0.0801889909	of 5 fluorouracil
0.0801799421	decreased with
0.0801657321	and ten
0.0801598607	clinical use of
0.0801565146	a marked reduction in
0.0801512883	with blindness
0.0801471932	in vitro in
0.0801351434	and 81
0.0801337466	between 15
0.0801249983	erectile dysfunction and
0.0801162455	toxicity due to
0.0801092082	of 30 patients receiving
0.0800865499	nephrotoxicity in rats
0.0800771439	those patients
0.0800724400	a major role
0.0800589403	60 years
0.0800559803	and mortality
0.0800511366	morphine with
0.0800430473	of isg
0.0800225946	obtained for
0.0800149691	induced seizures in
0.0800091550	addition of
0.0800044452	compared with one of
0.0799924596	an excessive
0.0799861003	rate and
0.0799763719	the bladder and
0.0799712282	in patients with chronic
0.0799710942	these mechanisms
0.0799644312	the loss of
0.0799438921	used to determine
0.0799278201	used alone or
0.0799215579	of 70
0.0799146718	did not seem to
0.0799136943	and 24 h after
0.0799089001	both p 0.01
0.0798789804	7 days later
0.0798789164	the creatinine concentration
0.0798777109	the prevalence of
0.0798552120	treated with cisplatin
0.0798541601	occurs at
0.0798445137	the timolol
0.0798373757	those receiving
0.0798333853	the seven
0.0798249011	of 60 patients
0.0798043065	the primary efficacy
0.0797817842	and duration
0.0797809406	of bupivacaine induced
0.0797714666	mean time of
0.0797665615	both groups of
0.0797515606	the tubular
0.0797476029	observed during
0.0797324047	the recommended
0.0797262822	peripheral neuropathy in
0.0797258615	the alterations in
0.0796975306	for 18 months
0.0796753435	to november
0.0796733937	the patient with
0.0796526736	with kainic acid
0.0796357574	an indicator of
0.0796342841	nature of
0.0796258959	the muscarinic
0.0796231486	a hypertensive
0.0796192487	in new
0.0796178973	year of
0.0796118937	the incidence of postoperative
0.0796034630	a 38
0.0795991126	no plays
0.0795940187	evaluation of patients
0.0795894504	estimated from
0.0795810412	weeks following
0.0795777109	the majority of
0.0795727119	variation in
0.0795377810	to call
0.0795338860	of prostaglandin d2
0.0794824073	the toxicity of
0.0794694327	postoperative nausea and vomiting and
0.0794180219	recognized as
0.0794131934	of sodium
0.0794117586	both in vivo and in vitro
0.0794083769	the 24 hour heart rate
0.0793856839	a mean of
0.0793556146	with d
0.0793391064	four doses
0.0793379810	not indicated for
0.0793259131	steroids with
0.0793257759	an interaction
0.0793240471	a novel drug
0.0793175486	the neurotoxic
0.0793137192	the accompanying
0.0792958065	to 27
0.0792655085	related increase in
0.0792502244	administration resulted in
0.0792317525	k +
0.0792225326	110 patients
0.0792171887	20 mg kg day
0.0792165939	used during
0.0792145843	the early development of
0.0792033726	warranted in
0.0792011724	chronic treatment with
0.0791988666	with desipramine and 6 ohda
0.0791906813	of 11 patients
0.0791837715	the safety and efficacy of
0.0791786289	describe two
0.0791705543	a ventricular
0.0791582972	factor for
0.0791562367	drugs in
0.0791507400	parkinsonian patients with
0.0791384292	8 ml
0.0791377074	abnormalities on
0.0791249053	but not in rats treated with
0.0791239003	after amiodarone
0.0791138481	subject to
0.0791138481	changed to
0.0791122386	maintained during
0.0791072991	in mice treated with dox
0.0791015707	a 2 minute
0.0790956491	more than 20
0.0790928579	within 2
0.0790356262	10 to
0.0790300592	an allergic
0.0790185977	liver transplantation with
0.0790112555	hyperprolactinemia and
0.0790001499	use by
0.0789894504	srl as
0.0789870029	groups of
0.0789739038	both in vitro and in vivo
0.0789726473	than in patients
0.0789633139	levodopa treatment and
0.0789569594	after heparin exposure
0.0789519574	the dosage
0.0789404411	a report of
0.0789203374	many of
0.0789193208	evaluable patients with
0.0789107322	one case
0.0789075941	2 hours
0.0788941853	a score of
0.0788668517	four cases
0.0788525713	of astrocytes
0.0788379616	causes for
0.0788355095	this trial
0.0788292623	the most common form of
0.0787972014	while one
0.0787922916	this technique
0.0787906439	monitored by
0.0787689954	further episodes of
0.0787636260	in individual patients
0.0787625385	all mice
0.0787578919	every 3
0.0787385498	therapy in patients with or
0.0787149685	physical examination and
0.0786955008	with one of
0.0786798718	the muscarinic cholinergic
0.0786626978	trial in
0.0786516745	statistically significant for
0.0786382384	by 25
0.0786342841	abundance of
0.0786167773	possibly associated with
0.0786079273	after exercise
0.0786054163	or 21 days
0.0785776925	the medical literature
0.0785637965	the ketoprofen group
0.0785582176	6 hr
0.0785530369	the median duration of response
0.0785445100	degeneration in
0.0785430650	the incidence of cardiac
0.0785331752	observed only in
0.0785281132	induced convulsions and
0.0785264714	in 4 patients
0.0785231132	neurotoxicity of
0.0785101190	an elderly
0.0784770730	changes associated with
0.0784711137	h following
0.0784670427	the dyskinesia score
0.0784593161	the percent
0.0784375436	of hearing loss
0.0784191625	to hypothesize
0.0784033944	1 h
0.0783541949	treatment outcomes of
0.0783541949	ml kg of
0.0783541949	induced apoptosis of
0.0783518366	the nicotine
0.0783455609	calcitonin on
0.0783404009	a calcineurin inhibitor
0.0783314849	the prevalence
0.0783258035	placebo day
0.0783245422	by phenobarbital
0.0783065767	in patients treated with
0.0782896318	also determined
0.0782883698	30 +
0.0782815146	a significant proportion of
0.0782809759	the prophylactic
0.0782762237	or ropivacaine
0.0782740899	patients treated for
0.0782670427	the venous sinus
0.0782636035	16 days
0.0782452474	the dexamethasone
0.0782441092	or clozapine
0.0782366920	in 27
0.0782251848	with cyclooxygenase inhibitors
0.0782222370	for 24 weeks
0.0782149890	significantly different
0.0782130126	in rat brain
0.0782104453	severity of
0.0781877421	for most
0.0781647392	of treatment with
0.0781584413	the most sensitive
0.0781567053	the ingestion of
0.0781545227	4 days of
0.0781511177	the role
0.0781496362	in conscious shr
0.0781397494	the cerebral
0.0781370203	fanft in
0.0781202492	appropriate for
0.0781169339	rats exposed to
0.0781096509	a significantly greater
0.0780834813	of levodopa therapy
0.0780564472	the 32
0.0780562917	on period
0.0780516555	the opposite
0.0780404411	side effect in
0.0780362715	by 30 to
0.0780323337	the concentration of gaba
0.0780281878	the response and toxicity
0.0780280029	5 + 0
0.0780201757	the same as
0.0780148952	the impact of
0.0780140763	in patients in
0.0780094725	with physiological saline
0.0779933326	associated with initial treatment
0.0779912235	proteinuria after
0.0779874346	not receive
0.0779830110	without additional
0.0779665388	after 4 weeks
0.0779649745	31 and
0.0779576511	the first reported
0.0779538616	in two cases
0.0779463510	for atrial fibrillation
0.0779326850	associated with prolonged
0.0779049532	and wild type
0.0778955285	this myopathy
0.0778869675	with heart failure
0.0778788021	in two of
0.0778680321	1 day
0.0778641210	both p 0
0.0778614737	agent in
0.0778598048	of 20 mg
0.0778456849	a 15 year old boy with
0.0778429718	diagnostic value of
0.0778260627	h 2
0.0778208463	the technique
0.0778151991	by drugs
0.0778128833	the first dose
0.0778121857	and 30 mg
0.0778035453	31 +
0.0778016715	changes in renal
0.0777977425	activities of
0.0777931948	impairments in
0.0777927890	side effects than
0.0777909895	to 65
0.0777887877	with chest pain
0.0777853964	associated with significantly greater
0.0777828730	effects in rats
0.0777691586	in seven
0.0777628353	of 128
0.0777628353	of 17.5
0.0777590552	therefore examined
0.0777458640	the standard dose
0.0777318097	5 d
0.0777268972	mm hg in
0.0777255254	returned to normal by
0.0777122345	and dose related
0.0777083617	this dose
0.0777004840	of group b patients
0.0776895553	a favorable
0.0776851209	of 20 patients
0.0776826304	by clonidine
0.0776822085	studied in two
0.0776655608	and significantly lower
0.0776642356	2 ml kg of
0.0776619380	oxygen consumption and
0.0776574900	reactivity of
0.0776507860	recall after
0.0776501612	given to rats
0.0776388786	76 +
0.0776358098	the switch
0.0776342677	and liposomal doxorubicin
0.0776312752	search for
0.0776215344	the structural
0.0776189780	the data indicate
0.0776186563	16 years
0.0776179154	on bruising and pain
0.0776150779	5 20
0.0776150779	5 15
0.0775754628	persisted for
0.0775716826	also causes
0.0775572222	the fourth patient
0.0775307585	a mechanism
0.0775197208	of 92
0.0775079743	a 65
0.0774928728	those experienced
0.0774897305	and zidovudine
0.0774839867	either intravenous
0.0774786782	for more than 3
0.0774728750	the drug administered
0.0774556297	an nmda receptor
0.0774501101	15 d
0.0774389102	in older patients
0.0774361505	in adult patients
0.0774320388	3 h
0.0774213060	of torsade de pointes
0.0774118766	and in one case
0.0774092830	n = 30
0.0774079289	of substantia nigra
0.0774076135	in amphetamine induced
0.0773970305	acute treatment of
0.0773873330	sinus rhythm and
0.0773774094	reduction during
0.0773715071	the liver and
0.0773683837	a computer
0.0773681662	observed even
0.0773616702	animal model in
0.0773539235	period using
0.0773276011	in 90
0.0773065113	in monkeys
0.0772946929	the literature on
0.0772898321	in comparison with
0.0772590119	and prednisone
0.0772560031	following i.p
0.0772478243	one week after
0.0772470890	received 0.5
0.0772372799	in neonates
0.0772362405	obtained in
0.0772318531	of bladder irrigation
0.0772213513	the discharge
0.0772015251	five groups
0.0771957716	of abnormal eeg
0.0771870810	all treatments
0.0771811151	induced by doxorubicin
0.0771771846	a median of
0.0771610552	in ten patients
0.0771405105	several years
0.0771348577	the day after
0.0771334271	after switch to
0.0771253783	that seen
0.0771154365	the pressor response to
0.0770953782	on state
0.0770816774	oxidative stress in
0.0770801398	but did
0.0770424342	different groups
0.0770357796	the qt
0.0770332502	induced by injection of
0.0769957226	different methods
0.0769885928	during long term
0.0769733679	the protective effect of
0.0769721053	more side effects
0.0769523296	only for
0.0769451251	literature on
0.0769242244	an overall
0.0769224820	at least 6
0.0769063884	changes in rats
0.0768921175	the lack of
0.0768831522	animals indicate
0.0768764950	+ 0.7 to
0.0768705400	levodopa therapy for
0.0768426375	the lipid
0.0768375634	after cessation of
0.0768347747	a semi
0.0768278357	protective effects of
0.0768218528	the detection of
0.0768127823	32 patients
0.0768115499	induced by morphine
0.0768056136	l 3h nicotine binding sites and
0.0768024885	electron microscopy of
0.0767955014	the hormone
0.0767812843	0.03 to
0.0767792207	the antinociception
0.0767782690	after 6 months of
0.0767759326	on stimulus induced
0.0767500584	significantly reduced in
0.0767484674	for assessing
0.0767478988	to result in
0.0767434484	to 25 of
0.0767267409	1 10 micrograms
0.0767042351	cause for
0.0766992963	of 85
0.0766988316	on bupivacaine
0.0766901472	the signs of
0.0766889274	and finally
0.0766856271	of 31
0.0766851209	or 2 mg
0.0766831243	to 38
0.0766701333	a risk factor for
0.0766687107	of 78
0.0766615284	in conscious rats
0.0766427450	the administration of intravenous
0.0766377282	toxicity by
0.0766371112	a mild
0.0766123652	a non specific
0.0766115620	a systematic
0.0766062736	of lipopolysaccharide
0.0765914442	0.17 to
0.0765743089	other known
0.0765684111	the 5 micrograms kg
0.0765618622	the cohort
0.0765594170	and pulmonary
0.0765583851	induced by gentamicin
0.0765555124	women with
0.0765165537	admitted for
0.0765158874	by renal biopsy
0.0764923519	a 62
0.0764759595	either group
0.0764697972	in relation to
0.0764520070	and then at
0.0763860783	four out of
0.0763855897	the visual acuity
0.0763835552	and diazepam
0.0763738852	myocardial damage in
0.0763333726	as well as on
0.0763160198	the odds ratios
0.0763143253	and verbal memory
0.0763134860	28 +
0.0763109558	the duration of action
0.0763089372	5 mm hg
0.0763078695	an experimental model of
0.0763072630	a random
0.0762891436	the brain stem
0.0762796975	the important
0.0762790108	with haloperidol
0.0762663651	the lateral
0.0762523771	and head and neck cancers
0.0762462780	the spv
0.0762452474	and tissue
0.0762418931	a dyskinesia
0.0762418931	a maximum
0.0762395513	the nodules
0.0762286307	the completion of chemotherapy
0.0762197577	revealed loss of
0.0762136623	for one week
0.0762105544	15 months
0.0762052370	age and
0.0762049172	pressure and
0.0762014806	of learning and memory
0.0761871641	the case control
0.0761760800	9 vs
0.0761751023	5 year
0.0761635078	four courses of
0.0761567681	a massive
0.0761453865	of drug treatment
0.0761443657	9 patients
0.0761376914	and ca
0.0761195669	two minutes after
0.0761153183	as salvage therapy in
0.0761004381	a complication of
0.0760979112	the low dose
0.0760896413	found in children
0.0760869764	not significantly
0.0760706194	but did not significantly
0.0760657535	induced by propranolol
0.0760645432	and reduced glutathione
0.0760546625	45 +
0.0760509896	the number
0.0760458559	of ifosfamide
0.0760431757	3 patients with
0.0760208867	this result
0.0760128120	the dog
0.0760032712	bladder cancer in
0.0759954128	the average time from
0.0759758615	the differences in
0.0759688755	after atenolol
0.0759612224	for elective
0.0759480955	the intracellular
0.0759350091	the same dose
0.0759301241	mice treated with
0.0759250866	for patients with advanced
0.0759041106	acute hypertension in
0.0758954190	observed among
0.0758926981	the first case of
0.0758689891	some central
0.0758626396	the above
0.0758606310	at regular intervals for
0.0758239957	studies in
0.0758165603	did not appear to
0.0758052644	the frequencies
0.0757966835	morphine did not
0.0757841365	discontinued because of
0.0757819288	these experiments
0.0757785372	at 10 and
0.0757751596	with acceptable
0.0757655430	+ 8 to
0.0757492014	exposure of
0.0757467861	for detection of
0.0757311112	the brain and
0.0757123199	adverse effect on
0.0757104431	the tonic
0.0757061898	symptoms in
0.0757053416	the criteria
0.0757052261	100 mg day
0.0756947356	cocaine and or
0.0756899698	for initiation
0.0756866544	the renin angiotensin system in
0.0756795029	induced seizures after
0.0756653596	with first episode schizophrenia
0.0756573337	the pattern of kidney
0.0756492282	levels compared to
0.0756456603	induced convulsions in
0.0756281097	administered for
0.0756231271	of 39
0.0756114789	in mice and
0.0756092120	switch to
0.0756073198	and stroke
0.0756007951	the outcome of
0.0755700706	the beta 2
0.0755678379	from 100
0.0755546947	such as haloperidol
0.0755507185	an average of
0.0755501312	5 g
0.0755482209	in association with
0.0755479297	and st segment
0.0755418931	of propofol
0.0755394909	after recovery from
0.0755349718	and cancer incidence
0.0755349462	with hearing loss
0.0755214142	nephrotoxicity in
0.0755119993	only 5 of
0.0755087696	and severe hypotension
0.0755024747	an example of
0.0755019251	associated with dysfunction
0.0755005711	an analysis of
0.0754948715	that observed in
0.0754931236	further reduction in
0.0754905381	the 38
0.0754747858	groups compared with
0.0754693885	in 18 patients
0.0754638296	within one
0.0754531161	the rats treated with
0.0754351726	an antagonist of
0.0754253814	treated with pilocarpine
0.0754244183	after 10 days
0.0754144969	cumulative dose of
0.0754132358	patients in group a
0.0754119141	the prolonged
0.0754084252	reorganization of
0.0753957014	as one of
0.0753945401	aspirin for
0.0753847926	a rare complication of
0.0753820688	by contrast
0.0753726674	with epo and il 3
0.0753615072	all patients with
0.0753485259	of plasma lipoproteins
0.0753218419	s disease patient
0.0753138997	mortality after
0.0753056260	50 of patients
0.0752935613	interaction of
0.0752907723	the resting
0.0752890525	67 +
0.0752890525	38 +
0.0752870661	also decreased
0.0752727650	a single agent
0.0752628581	the introduction of
0.0752625298	diabetic rats with
0.0752517089	to 49
0.0752457613	in four children
0.0752452474	the abnormalities
0.0752444886	6 h after
0.0752292386	patients with risk factors for
0.0752256690	and 30 min
0.0752216855	demonstrated by
0.0752140611	to complete
0.0752137231	no significant difference in
0.0752129455	after delivery
0.0752113169	only after
0.0752074941	renin angiotensin system in
0.0751951331	at high doses
0.0751875048	in patients with mechanical heart valves
0.0751851209	the 5 patients
0.0751681323	reactions in
0.0751595474	to 1998
0.0751549660	given simultaneously
0.0751405667	the threshold
0.0751392834	very effective in
0.0751305845	a tertiary
0.0751284894	49 +
0.0751255737	activation in
0.0751217434	for 13 days
0.0751063771	an adverse effect on
0.0751055996	on seizures
0.0750977819	on isoproterenol
0.0750928782	related to treatment
0.0750843732	the concept
0.0750843732	the orthopaedic
0.0750843732	the detrusor
0.0750843732	the anaesthetist
0.0750843732	the sg145r
0.0750813350	the poor
0.0750669954	of biomembranes
0.0750632945	also received
0.0750604223	the high risk
0.0750410186	the hypotensive
0.0750404411	the ability to
0.0750404411	5 days of
0.0750338021	the mother
0.0750230035	complete remission and
0.0750071078	the recovery of
0.0750068741	ingestion of
0.0749911018	no more
0.0749872514	in men and women
0.0749869716	and severity
0.0749733925	limited to
0.0749622791	experience with
0.0749566846	treated groups in
0.0749328534	19 vs
0.0749238370	after bupivacaine
0.0749124295	after receiving
0.0749110557	five days after
0.0749108213	of 76
0.0749076994	a recognized complication
0.0749054965	11 years
0.0748998413	a patient developed
0.0748895317	the enzyme
0.0748879526	25 years
0.0748856148	76 cases of
0.0748853868	with loss of
0.0748851423	the non mi group
0.0748768458	a rare and
0.0748655801	the liver in
0.0748504531	possible to
0.0748409486	than seen with
0.0748326696	the mouse
0.0748318404	an overdose of
0.0748222256	induced anemia and
0.0748221021	in patients on long term
0.0748087589	these values
0.0748055943	3 ng
0.0748021615	especially in patients
0.0747934568	patients with pd and
0.0747919971	22 patients
0.0747868833	by about
0.0747801368	anticonvulsant activity and
0.0747729598	to 52
0.0747727650	s renal function
0.0747613236	the scopolamine induced
0.0747511938	the protective effect
0.0747497030	clinical symptoms and
0.0747369735	a significant impairment of
0.0747144371	although most
0.0747068347	indicated by
0.0747050458	and sexual dysfunction
0.0747038016	assessed during
0.0747033568	cyclosporin a and
0.0747004970	and metabolism
0.0746975840	the heart of
0.0746960074	to 39
0.0746900513	the cardiotoxicity of
0.0746894484	produced in rats
0.0746867281	and 200 mg
0.0746665910	recorded as
0.0746505328	+ 0.1
0.0746430538	by up to
0.0746216544	in 1985
0.0746206692	five controls
0.0746150797	after heart transplantation
0.0746133425	increased activity of
0.0746066545	and bone
0.0746043931	of hbv
0.0746036383	administered with
0.0745963958	followed by 1
0.0745834520	discharged from
0.0745781553	in clinical practice
0.0745751381	of cocaine administration
0.0745545202	a lower risk of
0.0745456681	from cells
0.0745407438	in 67
0.0745346968	and tremors
0.0745171273	to reduce bf by
0.0745162680	20 years
0.0745137539	of hbv dna
0.0745087740	perfused with
0.0745025753	tubular dysfunction and
0.0744912551	tranexamic acid in
0.0744897725	of 46
0.0744803801	and 2 patients
0.0744790997	48 h of
0.0744595387	of creatine kinase
0.0744568815	the present study aimed to
0.0744530172	h with
0.0744445219	the acute stage
0.0744422876	of d penicillamine induced aplastic anemia
0.0744334867	factors in
0.0744125649	with lithium
0.0744122898	older age and
0.0744056501	the medical
0.0744028994	as effective as
0.0743768458	and for patients with
0.0743644777	a single high
0.0743617417	1 agonist
0.0743607728	a clinical trial
0.0743599020	the hippocampus in
0.0743571810	by 60
0.0743499668	a marker for
0.0743335465	the mesna
0.0743313253	that apomorphine
0.0743277889	even with
0.0743269546	for 30 days
0.0743202463	in 22 patients
0.0743087589	these responses
0.0743072704	the liver of
0.0743062910	the immediate
0.0743042848	appeared in
0.0742989481	a negative
0.0742926879	h after treatment
0.0742863559	related to either
0.0742635657	desogestrel with
0.0742540446	in fischer 344 rats
0.0742519196	occur following
0.0742502887	at 1 month
0.0742096706	third to
0.0742081736	the activities of
0.0742057880	day 3
0.0741920575	found to cause
0.0741906261	day by
0.0741735190	toxic effects of
0.0741729231	profiles of
0.0741713550	33 +
0.0741586250	of prostaglandin synthesis
0.0741497682	died after
0.0741416921	experimental study in
0.0741408947	only two
0.0741399340	side of
0.0741352054	the 80 patients
0.0741308123	no direct
0.0741210510	to p and n
0.0741083749	forty patients with
0.0741020659	the anti
0.0740937502	from 86
0.0740919870	also observed in
0.0740812336	a side effect
0.0740795848	day 9
0.0740762968	among various
0.0740723727	adjustment of
0.0740719039	70 +
0.0740574252	mania associated with
0.0740561718	these children
0.0740516573	+ + +
0.0740500156	pain responses in
0.0740407718	at least in
0.0740338319	= 6
0.0739950238	the three compounds
0.0739945985	of artery calcification in rats
0.0739865565	allow for
0.0739843152	either vehicle or
0.0739769604	of intrathecal methotrexate
0.0739656969	the administration of levobupivacaine
0.0739621752	occurrence of
0.0739504295	mm hg or
0.0739330440	12 days
0.0739315505	with autonomic neuropathy
0.0739097052	the blood and
0.0739017592	of developing
0.0739015677	in patients after
0.0738942028	dogs with
0.0738885371	with long term use
0.0738751499	used by
0.0738738340	predominance of
0.0738738340	indicators of
0.0738648788	the value
0.0738567761	to protect
0.0738552646	after 8 weeks of treatment
0.0738495504	use in patients with
0.0738462241	in 30 patients
0.0738413333	the other patients
0.0738405179	women over
0.0738281703	of bile salt
0.0738099699	the median number of
0.0738087589	these lesions
0.0738064551	on treatment with
0.0738029078	86 +
0.0737966480	cohort of
0.0737908966	the sinus node
0.0737908707	non drug
0.0737841217	5 of patients
0.0737784775	correlated to
0.0737754116	of na
0.0737669449	in 4 of
0.0737634407	subjective effects and
0.0737612423	with major depression
0.0737530370	the hospital for
0.0737525886	no adverse effects
0.0737501618	for 2 months
0.0737478040	of cyclosporine
0.0737453960	in 24 patients
0.0737451330	the activation of
0.0737440270	a paradoxical
0.0737127603	and 120
0.0737085465	the areas
0.0736928508	night of
0.0736820021	the muscle rigidity
0.0736780172	during gestation
0.0736654692	of alpha enac
0.0736579722	of 5 x 10
0.0736215021	a low dose
0.0736114789	and treatment with
0.0736107391	the renal injury
0.0735934202	units of
0.0735828866	with bipolar disorder
0.0735715144	the drug on
0.0735435976	or renal cortical
0.0735408502	patients with or without
0.0735352463	free of
0.0735340512	the medical records
0.0735224119	the prolactin
0.0735199960	the median time to
0.0735048788	receptors in
0.0735043931	with ketamine
0.0734974788	women on
0.0734771672	at six
0.0734614479	start of
0.0734591302	the effective dose
0.0734495040	interaction with
0.0734460944	by 26
0.0734340805	characteristics at
0.0734200027	on two different
0.0734119141	the lithium
0.0734016804	only during
0.0733824147	of conduction defects
0.0733748049	remained on
0.0733746526	6 groups
0.0733660893	in heparin products
0.0733629863	mg kg day in
0.0733532807	within 2 to
0.0733392250	on lidocaine induced
0.0733370726	prostate cancer in
0.0733343048	does not cause
0.0733157080	boluses of
0.0733046068	5 mg kg day
0.0732891951	a day for
0.0732558425	glial activation and
0.0732544005	the acute and
0.0732502894	the respiratory
0.0732462780	the anticonvulsive
0.0732388032	the ca1 region of
0.0732373980	about 30
0.0732337094	the degeneration of dopaminergic neurons
0.0732303605	failure in
0.0732289566	to 70 mg
0.0732279981	at concentrations
0.0732079480	on qt interval
0.0731974252	with cyclophosphamide
0.0731910354	this laboratory
0.0731881854	not clearly
0.0731855316	a progressive
0.0731747121	no difference in
0.0731734413	a well known
0.0731721671	medical records of
0.0731713497	and interstitial fibrosis
0.0731703917	the small
0.0731664767	of 72
0.0731654513	et 1 and
0.0731634542	concentration in
0.0731616661	more toxic
0.0731456571	an improvement in
0.0731383592	such treatment
0.0731376914	and generally
0.0731362630	on various
0.0731296272	a once daily
0.0731231470	the molecular weight
0.0730933440	the need to
0.0730693979	100 mg kg day
0.0730581759	the acute onset
0.0730578004	the introduction
0.0730501755	the latter two
0.0730458653	those previously
0.0730445705	of kidney function
0.0730376100	of 1 apraclonidine
0.0730314786	an attempt to
0.0730244520	or haloperidol
0.0729843040	of podocyte injury
0.0729676174	extension of
0.0729642221	at least 2
0.0729557945	25 months
0.0729393935	in young women
0.0729352421	in primary culture
0.0729123196	the recurrence of
0.0729114757	course and
0.0728871007	and development
0.0728868861	the potential to
0.0728755592	test with
0.0728574895	in patients with various
0.0728415490	elimination of
0.0728174798	3 mg dl
0.0728150588	the history
0.0728099203	the combined administration of
0.0727942915	and myalgia
0.0727733301	in 11 of
0.0727729598	to 59
0.0727701426	c mice
0.0727692483	the ph
0.0727659518	by use of
0.0727593947	by comparing
0.0727495342	other potential
0.0727478988	to activation of
0.0727400647	scores during
0.0727083109	aggravation of
0.0726999793	found at
0.0726876694	the serum and
0.0726837864	use on
0.0726775499	and 50 mg kg
0.0726755533	to ampicillin
0.0726752167	and 600
0.0726576164	and 49
0.0726567681	a depressed
0.0726527670	bradycardia and
0.0726427799	values of
0.0726388262	dosages of
0.0726375595	different concentrations of
0.0726222629	and 47
0.0726153211	the reflex
0.0726085579	not necessary
0.0726041372	the high and
0.0725931204	of cyclophosphamide
0.0725527150	and alcohol
0.0725015344	analyzed from
0.0724929503	12 hours after
0.0724796630	of 10 days
0.0724751711	24 days
0.0724585563	a median
0.0724576968	sinus bradycardia and
0.0724379147	not sustained
0.0724323687	and heart
0.0724055125	proliferation of
0.0724014948	more normal
0.0723959561	after withdrawal of
0.0723907490	the results demonstrate
0.0723797307	gentamicin +
0.0723638351	in patients with sah
0.0723607226	at risk for
0.0723604219	ocular hypertension in
0.0723497479	a complication
0.0723380857	a living
0.0722906198	an adjunct to
0.0722889033	21 +
0.0722858986	17 +
0.0722803095	major depression with
0.0722774003	resolved with
0.0722745909	a single 50
0.0722712104	randomization and
0.0722616244	widely used by
0.0722501965	outcome in
0.0722432365	all patients developed
0.0722284071	the effects of ouabain
0.0722283470	the association
0.0722256441	mean dose of
0.0722018240	an adenosine
0.0721894035	12 cases
0.0721856105	5 ht and
0.0721732335	clinical characteristics and
0.0721696855	dopamine d2 and
0.0721678915	200 mg day for
0.0721638599	the association with
0.0721546664	glutamate and
0.0721456892	+ 13 to
0.0721237745	2 weeks of
0.0721125226	of hyperprolactinemia
0.0721113716	and respiratory depression
0.0721109928	2 weeks of treatment
0.0720974252	a medical
0.0720924814	for breast cancer
0.0720846132	the tricyclic antidepressant
0.0720788038	studied on
0.0720782482	visual loss and
0.0720755392	for up to
0.0720534541	treated with warfarin
0.0720435852	the minimum effective plasma concentrations of
0.0720144780	the change in
0.0719993761	in 60 of
0.0719914636	in patients taking
0.0719801404	this study suggest
0.0719759882	to warfarin
0.0719719236	several cases
0.0719717680	after 30 min
0.0719623362	and renal injury
0.0719612625	the blood pressure and
0.0719564854	course after
0.0719474277	onset of symptoms and
0.0719448242	higher than in
0.0719245429	many other
0.0719142500	and deterioration of renal function
0.0719132024	to 0.50
0.0719086417	associated with higher
0.0718876818	in rats treated
0.0718591452	terminals of
0.0718404411	the decrease of
0.0718404411	in studies of
0.0718281438	toxic effect of
0.0718110773	the incidence of severe
0.0718089735	number of patients with
0.0718005792	in patients with rheumatoid arthritis
0.0717906439	rigidity after
0.0717836760	for 5 years
0.0717793315	the rat by
0.0717653289	catatonia in
0.0717574349	a total dose
0.0717551726	greater in patients with
0.0717507139	this complication and
0.0717486146	the second time
0.0717468065	known as
0.0717294114	of postural hypotension
0.0717236722	and generally well tolerated
0.0717104431	the rise
0.0716913851	than women
0.0716886087	a peak
0.0716837748	in users of third generation
0.0716698480	and cost effective
0.0716615241	drug therapy in
0.0716602227	improved at
0.0716464369	a component of
0.0716453332	the day
0.0716399587	performance status of
0.0716361223	locomotor hyperactivity in
0.0716314804	hypotension following
0.0716118430	appeared after
0.0716114436	38 patients
0.0716007951	the density of
0.0715980586	the potential for
0.0715898138	period following
0.0715885067	bacteremia with
0.0715800505	associated with cpa ee
0.0715796807	in anesthetized dogs
0.0715706382	and behavior
0.0715606231	studied using
0.0715487476	living in
0.0715361446	the medulla
0.0715101965	damage in
0.0715086536	all cases of
0.0715085190	and liver function
0.0715060954	this study assessed
0.0714997541	the analysis of
0.0714983370	and diastolic bp
0.0714822707	the endothelial cells
0.0714816317	a diagnosis
0.0714729625	nausea and
0.0714703872	the acetaminophen group
0.0714585581	a significant difference in
0.0714507952	the effects of n
0.0714388494	the haloperidol induced
0.0714352215	that lindane
0.0714284737	bradycardia due to
0.0714248494	one side
0.0714054788	even in patients
0.0714037472	2 receptor
0.0714032605	or 10 mg
0.0713949147	and better
0.0713607589	of adenosine in cerebrospinal fluid
0.0713583161	the third group
0.0713567250	the adverse drug
0.0713360726	a role
0.0713254013	all therapy
0.0712919077	a surgical
0.0712900817	and tranexamic acid
0.0712868025	also recorded
0.0712849532	increased significantly in
0.0712811595	and 17 and
0.0712630711	of desipramine
0.0712146835	the brain damage
0.0712116268	and skeletal
0.0712017514	reversibility of
0.0712000168	by 21
0.0711957638	bradycardia in
0.0711880716	the total dose
0.0711850262	in dba 2 mice
0.0711840835	efficacy and tolerability of
0.0711835530	a significantly higher
0.0711697092	the patient continued
0.0711674413	5 patients with
0.0711612735	subjects with
0.0711515378	to control rats
0.0711515372	and 0.8
0.0711316800	urinary ngf and
0.0711295994	dysfunction in
0.0711282293	for thrombosis
0.0711109141	adenovirus disease in
0.0711109141	protein excretion in
0.0711052726	less than 1
0.0710984490	headache in
0.0710954588	the mechanism of action
0.0710716893	again after
0.0710680437	and clinical studies
0.0709951204	but only in
0.0709945296	treatment did not
0.0709934450	and activation of
0.0709870584	the survival
0.0709846913	cure of
0.0709832840	in 111
0.0709826659	the magnitude
0.0709773782	of exposure to
0.0709694140	at or
0.0709580479	with rizatriptan
0.0709554444	a significant prolongation of
0.0709487317	and 21 of
0.0709242003	a loading dose of
0.0709226583	the cumulative incidence of
0.0709077625	6 8
0.0709075603	through 4
0.0709063871	a 15 minute
0.0708869907	study in
0.0708848208	in alcohol withdrawal
0.0708846937	latency in
0.0708660621	and 14 of
0.0708649348	adverse reactions associated with
0.0708570545	in patients with heart failure
0.0708319837	and potentially
0.0708319837	and water
0.0708231417	reductions of
0.0708194449	a tumor
0.0708100129	the same diet
0.0707792808	8 mg kg
0.0707732411	the controls and
0.0707668093	of borderline subjects
0.0707561712	analyses of
0.0707546884	the development of severe
0.0707499739	the underlying mechanisms
0.0707439596	also to
0.0707439596	4 to
0.0707326308	37 patients
0.0707237453	of 30 patients
0.0707160507	the observation period
0.0707073807	nephrotoxicity of
0.0707015879	either by
0.0706900386	two groups of
0.0706544795	group p
0.0706465449	the nerve
0.0706399587	structural damage of
0.0706334471	and 15.0
0.0706313860	apoptosis in
0.0706271172	epileptiform activity in
0.0706194515	the development of cardiac
0.0706183076	at week
0.0705971418	a group of patients
0.0705955822	this way
0.0705928773	time for
0.0705860314	in humans and
0.0705797082	in 84
0.0705413883	a 56
0.0705326192	following discontinuation of
0.0705237273	nicergoline and
0.0705235529	11 cases
0.0705073987	collected on
0.0705032842	of hit
0.0704923309	a case in
0.0704822606	8 days of
0.0704815766	induced model of
0.0704678710	receptor antagonist in
0.0704584208	also negative
0.0704533288	from 16
0.0704507074	randomized to
0.0704244447	either blood pressure
0.0704150050	blood pressures of
0.0704094504	the activity
0.0704061415	with most of
0.0704014251	these patients with
0.0703999122	a metabolic
0.0703961886	after reduction of ribavirin
0.0703816207	a 12 week
0.0703788142	a grade
0.0703741746	a steroid injection
0.0703580211	of uric acid
0.0703505316	associated or not
0.0703377338	the animals of
0.0703158225	again in
0.0703066253	specific inhibitor of
0.0703000797	adjusted or
0.0702955443	in 13 patients
0.0702953373	in postmenopausal women
0.0702861832	a pure
0.0702785097	obtained after
0.0702713328	10 hours
0.0702624083	cognitive impairment and
0.0702388842	the first report of
0.0702274587	retrieval of
0.0702270039	of vincristine sulfate
0.0702202056	nine patients
0.0702127088	drugs such as
0.0701992338	disorientation and
0.0701992338	electroencephalographic and
0.0701975969	those following
0.0701940380	the oxytocin
0.0701940380	the donor
0.0701840832	made in
0.0701836458	to et 1
0.0701773982	in ecstasy users
0.0701745222	hearing loss in
0.0701662357	0 mg
0.0701469754	in 14 of
0.0701317989	considered in
0.0701286489	the first report
0.0701258232	widely available and
0.0701243729	after birth
0.0701223488	and sparteine
0.0701098117	three cases
0.0701052943	the excretion
0.0700995152	with hepatitis c virus
0.0700758619	progression of
0.0700597393	throughout treatment
0.0700287806	in most of
0.0700258285	of cocaine and
0.0700069149	9 10
0.0699976160	the action of
0.0699939049	and 12 months
0.0699928822	induced by propranolol and
0.0699870584	the series
0.0699786507	a maintenance dose
0.0699741599	thalidomide in
0.0699712205	the treatment of severe
0.0699618638	the discontinuation of
0.0699579488	seizure associated
0.0699473537	for 2 weeks and
0.0699358228	evaluated with
0.0699048588	the mean age of
0.0698780098	the saline
0.0698659005	hypothalamus and
0.0698582311	also improved
0.0698571689	for children
0.0698448428	with snhl
0.0698448428	with tolazamide
0.0698404411	in plasma and
0.0698391606	a comparison of
0.0698173455	food and drug administration and
0.0697895185	studied with
0.0697863312	2 h after
0.0697862679	the pineal
0.0697733301	in 90 of
0.0697658868	and exercise induced
0.0697454340	and creatinine
0.0697439356	the first 2 days
0.0697424720	mg dl or
0.0697309008	the site of
0.0697258285	the period of
0.0696922859	to 135
0.0696685759	all exhibited
0.0696582864	increment of
0.0696563063	levels at
0.0696466892	degeneration of
0.0696457791	the efficacy and safety
0.0696419545	4.2 to
0.0696377543	such as in
0.0696340048	the treatment of parkinson
0.0696323773	the inner
0.0696313860	binding in
0.0696186585	importance in
0.0696179840	the antiepileptic drugs
0.0696118430	limited by
0.0696080787	a case report and
0.0696025053	time course and
0.0696024798	the fall in
0.0695721425	and activity of
0.0695571118	a case of severe
0.0695569860	toxicity associated with
0.0695555204	30 mg kg day
0.0695515527	the decrease in blood pressure
0.0695264057	by 19
0.0695258285	the infusion of
0.0695248236	the neuromuscular
0.0695193079	the passive avoidance
0.0695113138	examined with
0.0695074004	an additive
0.0695032538	and response to
0.0694970117	comprised of
0.0694936870	u l and
0.0694927120	the dopaminergic
0.0694926355	associations of ozone and
0.0694871938	following surgery
0.0694750896	the improvement in
0.0694681068	cause severe
0.0694656665	a bolus
0.0694427067	conversion to
0.0694357499	week 2
0.0694340266	impaired by
0.0694335830	region of
0.0694308820	the site
0.0694290089	a few minutes after
0.0694238165	out patients
0.0694068977	range of
0.0694060442	and ax
0.0694042357	an anticholinergic
0.0693931105	1 day after
0.0693844423	the anticonvulsant
0.0693827014	the patients at
0.0693736359	disappeared after
0.0693709953	12 mg kg
0.0693687935	43 of
0.0693652361	the symptoms of rls
0.0693596990	the first and
0.0693483206	a 47
0.0693402386	and cisplatin induced
0.0693398089	by real time
0.0693164289	the hemorrhagic
0.0693149407	the japanese population
0.0693090803	and clinical evidence
0.0693044704	the hemodynamic
0.0693041932	of cardiac arrest
0.0693001789	a routine
0.0692922723	a 47 year old woman with
0.0692922723	a 57 year old woman with
0.0692806149	of methyldopa
0.0692705832	remain to
0.0692677356	hepatitis following
0.0692661099	by mechanisms
0.0692564811	glomeruli with
0.0692478889	a peripheral
0.0692381003	serum level of
0.0692335544	and 0.7
0.0692287589	47 patients
0.0692216558	a dopamine
0.0692096376	and well
0.0692054710	4 hr after
0.0691764438	a short
0.0691762115	developed in rats
0.0691750440	the patient died
0.0691744536	greater than for
0.0691740165	a significant reduction of
0.0691716358	immediately following
0.0691638599	and regulation of
0.0691530230	of dopaminergic
0.0691499845	a specific inhibitor
0.0691447177	this reduction
0.0691377044	responsiveness of
0.0691225679	+ 0.2 to
0.0691016829	for hypertension
0.0690854498	significant changes in
0.0690748005	the cerebral cortex
0.0690535877	in rats given
0.0690475996	and levels of
0.0690396742	paroxetine and
0.0690384835	the ischemic
0.0690304600	the effects on
0.0690286524	a visual
0.0690044622	of 2 chloroprocaine ce
0.0690015021	32 +
0.0689746614	and cerebral edema
0.0689588114	dose reduction or
0.0689316243	95 ci 1
0.0689315029	the topical
0.0689298336	in learning and memory
0.0689249087	the hypersensitivity
0.0689171101	the pituitary
0.0689160473	the gpi
0.0689148995	and control groups
0.0688931105	within 3 to
0.0688812058	one third of
0.0688653675	no significant differences between
0.0688425653	and depression
0.0688422133	b and
0.0688406564	odds ratio of
0.0688382883	use of aspirin
0.0688277021	a 24 hour
0.0688273957	and areas of
0.0688009147	8 12
0.0687976160	the blockade of
0.0687976030	in 13 of
0.0687733301	and 22 of
0.0687697688	in ovariectomized rats
0.0687511951	median age of
0.0687416616	recorded in
0.0687136629	on blood pressure
0.0687111149	developed from
0.0687101791	both patients and
0.0687028783	in wky and shr
0.0686819913	occurred in only
0.0686628629	the effect of long term
0.0686590703	seen by
0.0686544725	after one
0.0686287867	at 13
0.0686199795	the stimulation of
0.0686123831	well with
0.0686116019	the day before
0.0685970956	of da neurons
0.0685924251	of eight dogs
0.0685837194	the ventrolateral
0.0685750903	in 19 patients
0.0685691313	use of more
0.0685656398	a protocol
0.0685621122	protection for
0.0685555971	the non selective
0.0685455821	maintained with
0.0685446764	and weight
0.0685427777	the measurement of
0.0685364498	reaction with
0.0685292529	in 71 of
0.0685269182	access of
0.0685193079	the local anesthetic
0.0685036383	the hepatitis
0.0684789289	the gamma
0.0684654081	mm hg and
0.0684555789	the percentage
0.0684540792	22 patients with
0.0684414635	metabolism in
0.0684332485	those given
0.0684265979	reaction to
0.0684165653	channels by
0.0684137936	this study provides
0.0684074096	and urea
0.0683935392	the curve
0.0683929481	in rats and mice
0.0683795422	the time course
0.0683765876	three doses of
0.0683759811	and complications of
0.0683749546	of striatal
0.0683581570	the consolidation
0.0683472071	h prior to
0.0683408447	concomitant administration of
0.0683390600	three doses
0.0683315137	describe 2
0.0683243639	ml of
0.0683202602	the cardioprotective
0.0683184304	findings in
0.0682981930	and migraine
0.0682901925	a minimum
0.0682866472	6 12
0.0682532678	also performed
0.0682415027	on renal function
0.0682225519	analogs of
0.0682225519	separation of
0.0682225519	classification of
0.0682225519	discovery of
0.0682181562	and decrease in
0.0682080519	predictive of
0.0682032539	published in
0.0681816002	an activation
0.0681327602	the ouabain
0.0681323967	weeks 4
0.0681299836	in australia
0.0681250901	parameters of
0.0681136995	nag activity and
0.0681089505	the fetus
0.0680929221	metabolites in
0.0680903894	of carbachol
0.0680661709	the first injection
0.0680643196	two children
0.0680537670	the striatum of
0.0680489085	this drug in
0.0680475472	of steroids induced
0.0680396742	syncope and
0.0680359876	but much
0.0680280214	10 mg dose of
0.0680256087	associated with ketoconazole
0.0679962062	on four
0.0679849382	the three groups
0.0679842143	the baby
0.0679842143	the lc
0.0679842143	the 10th
0.0679842143	the neuropathological
0.0679753335	on time
0.0679742230	chemotherapy for
0.0679650886	increased at
0.0679593945	discussed in
0.0679515801	myopathy due to
0.0679473813	the enhancement
0.0679364546	of carboplatin at
0.0679032441	6 subjects
0.0678884646	and cdt with alteplase
0.0678763344	for theophylline
0.0678571689	on brain
0.0678518599	the clinical and laboratory
0.0678462671	observed on
0.0678280310	at baseline and
0.0678216463	an infusion of
0.0678185486	mg per day of
0.0678106925	depletion of
0.0678080010	measured by using
0.0678068943	of snr
0.0678043646	stained with
0.0677981930	the fetal
0.0677649046	in submitochondrial particles of
0.0677549018	all subjects
0.0677472613	per 5
0.0677407249	animals with
0.0677256877	a cardiac arrest
0.0677179805	the sensitivity
0.0677159104	a non selective
0.0677121791	rise in blood pressure in
0.0676949200	on lv
0.0676868382	only by
0.0676761890	but also to
0.0676619510	the optic nerve
0.0676593807	the rats in
0.0676584729	intake of
0.0676557017	changes in brain
0.0676471139	a lesser
0.0676367870	did not change in
0.0676356162	no significant differences in
0.0676116382	compared to only
0.0676113989	in modulating
0.0676103880	of seizure development
0.0675996373	s disease with
0.0675946458	during training or
0.0675922089	the antiviral therapy
0.0675864284	of six cases of
0.0675726427	and 400 mg kg
0.0675605520	three hours after
0.0675334720	alone or with
0.0675265938	6 min
0.0675226225	aplastic anemia in
0.0675225321	or moderate
0.0675100371	day period
0.0674589296	the tissues
0.0674495750	in 42 of
0.0674162009	11 days
0.0674162009	25 days
0.0673983115	a questionnaire
0.0673937029	did not change during
0.0673815263	and platelet
0.0673794273	and 48 h
0.0673762428	the proximal
0.0673636302	for patients in
0.0673625433	50 mg kg day
0.0673426562	the evaluation
0.0673298896	no differences between
0.0673212117	in vitro and in vivo results
0.0673204835	done in
0.0673143976	born to
0.0672986688	the risk factors
0.0672890065	the water
0.0672728893	2 weeks later
0.0672567350	of deglutition
0.0672395818	elevated levels of
0.0672387406	retrospective analysis of
0.0672338401	in patients with diabetes
0.0672208369	the 51 patients
0.0672155940	15 cases
0.0671893858	and dose dependently
0.0671881662	a preoperative
0.0671880466	the future
0.0671832365	this action
0.0671821414	responses of
0.0671802973	signs and symptoms of
0.0671774249	the sensitivity of
0.0671772624	help in
0.0671764113	for various
0.0671663624	in less than 20
0.0671592817	the surgery and
0.0671559210	17 vs
0.0671519388	5 mg kg i
0.0671476382	and s 23121
0.0671355546	the periods
0.0671180205	those treated with
0.0671174221	following treatments
0.0671119779	a cause of
0.0671118538	the intestine
0.0671008036	this toxicity
0.0670964061	those patients receiving
0.0670947509	directly to
0.0670902494	twenty three patients
0.0670853185	six days
0.0670849868	in relatively healthy women
0.0670831894	blood pressure by
0.0670801475	these medications
0.0670742185	an analysis
0.0670720912	30 mg kg 1
0.0670607803	risk factors associated with
0.0670484054	the cognitive
0.0670376585	an asymptomatic
0.0670326655	children than in
0.0670154264	a case series
0.0670147971	ratio of
0.0670129744	antagonist of
0.0670099252	a clinically
0.0670029232	iu l and
0.0670010899	a history of nsaid
0.0669932514	directly on
0.0669919919	only occurred after
0.0669904774	after one year
0.0669877562	c57bl 6 and
0.0669826324	developed after
0.0669743932	an intact
0.0669724046	weight but
0.0669721596	deletion of
0.0669686755	aim of
0.0669447507	suspected of
0.0669377047	method of
0.0669368241	as demonstrated by
0.0669329156	low dose of
0.0669159784	no association between
0.0669141982	given on
0.0669097390	an 18
0.0669037251	the subcutaneous
0.0669029838	+ 0.5 mg
0.0668957182	with intravenous ribavirin
0.0668802801	baseline and
0.0668705371	the general
0.0668506773	3 ml
0.0668460912	ligands of
0.0668438731	in patients with chronic kidney disease
0.0668435668	knowledge of
0.0668423073	the same age
0.0668350609	and ctnt
0.0668292548	a lipid
0.0668266976	for 6 months
0.0668262846	of liver function
0.0668174744	this finding
0.0668172433	as assessed by
0.0668108199	the long term administration of
0.0668073750	that pretreatment with
0.0668005864	the unilateral
0.0668001789	a solution
0.0667762452	noted with
0.0667687566	the drug for
0.0667419106	in female patients
0.0667296697	of breast cancer
0.0667154347	median 5
0.0667140675	forgetting of
0.0667140675	spread of
0.0667140675	chance of
0.0667140675	fractions of
0.0667140675	durations of
0.0666981165	of high doses of
0.0666917612	influences on
0.0666912144	and 87
0.0666741395	a mean follow up of
0.0666664216	the possible role of
0.0666614421	either drug
0.0666607516	controlled trial of
0.0666534705	the other two
0.0666446709	5 ml
0.0666378943	the side effects of
0.0666349638	of estrogen to
0.0666329034	the noradrenaline
0.0666296245	later found to
0.0666258727	assessed as
0.0666119204	and toxicity of
0.0666098819	the word
0.0666048205	of 200 microg
0.0665986008	18 rats
0.0665953755	p 0.01 for
0.0665924666	with cyp treatment
0.0665890403	the market
0.0665741700	to 69
0.0665741607	this receptor
0.0665263643	and il 6
0.0665156422	and cisplatin
0.0665008727	evaluated as
0.0664954747	for three
0.0664778952	twelve patients with
0.0664721425	a patient in
0.0664626249	and 1990
0.0664456309	six cases
0.0664290628	20 mg day
0.0664006848	2.7 to
0.0663974251	and 6 h after injection
0.0663847050	demonstrated to
0.0663739569	to address
0.0663712731	the liver biopsy
0.0663543492	inhibition of no
0.0663532295	developmental toxicity of
0.0663524087	in male ds
0.0663391268	effects such as
0.0663386667	among patients
0.0663386602	two week
0.0663349844	of two patients with
0.0663299617	lorazepam in
0.0663291841	50 years
0.0663277800	use of dexamethasone
0.0663175878	the plasma level
0.0663078810	the sole sedative for
0.0662842358	from third to
0.0662519707	of esrd
0.0662382536	the function
0.0662270068	but reversible
0.0662037534	and clinical findings
0.0661960024	rare side effect of
0.0661941636	with uric acid
0.0661909967	this area
0.0661835614	second dose of
0.0661701743	in males
0.0661697759	the most significant
0.0661690428	an urgent need to
0.0661556156	an objective
0.0661530230	of ribavirin
0.0661501947	activity by
0.0661485324	this severe
0.0661448314	after 4 days
0.0661426130	tolerance and
0.0661402277	a general
0.0661396457	the l arginine
0.0661038109	subjects treated with
0.0660917988	the first part of
0.0660893833	the first study
0.0660848928	medication by
0.0660807647	stage of
0.0660674561	4.5 +
0.0660598905	for cimetidine
0.0660581637	a pretreatment
0.0660560318	5 500 mg
0.0660419155	the tinnitus
0.0660378348	died from
0.0660274858	discontinued after
0.0660180623	of cbz
0.0659986618	significantly associated with
0.0659930961	in patients with essential hypertension
0.0659891266	the use of oral contraceptives
0.0659873825	with primary
0.0659865030	the acquisition
0.0659770556	a combined
0.0659761039	to enhance
0.0659700505	the bleeding
0.0659346479	changes occurred in
0.0659289147	at least 5
0.0659232059	60 s
0.0659117729	to 5 days
0.0658995320	of hbsag positive
0.0658928157	of spinal block
0.0658918719	depletions in
0.0658799510	and 16 of
0.0658745930	a greater decrease in
0.0658743424	therapy on
0.0658722099	qt interval in
0.0658637123	uptake of
0.0658560919	a japanese
0.0658275082	6 rats
0.0658076150	3 h after
0.0658009706	shown by
0.0657999297	users with
0.0657975998	not considered
0.0657411928	on warfarin
0.0657380110	19 patients
0.0657249635	the hypothesis of
0.0657243838	a stable
0.0657193576	the propofol infusion
0.0657069977	the event
0.0656884506	in mean arterial pressure
0.0656756506	in doses of
0.0656752913	commonly used in
0.0656581291	albino rats of
0.0656573498	no significant changes in
0.0656535527	of group b
0.0656533337	the 24 h
0.0656489236	the 1 hour
0.0656394307	carbimazole and
0.0656140122	a very rare
0.0656000245	first day
0.0655971319	the episode
0.0655770419	an enhanced
0.0655534580	results indicated
0.0655489842	4 mg kg day
0.0655308445	and blood transfusion
0.0655297019	in cases of
0.0655061404	the sn
0.0654824575	a year
0.0654765470	the group treated with
0.0654698410	the last 2
0.0654695838	improvement of
0.0654666763	and sudden death
0.0654659558	the rat model
0.0654643389	and at least
0.0654495569	improved by
0.0654486199	in parp 1
0.0654417883	of antithyroid drugs
0.0654350224	associated with desvenlafaxine
0.0654220482	day 0
0.0654199894	of nfs
0.0654161229	or paracetamol
0.0654116159	in azt treated
0.0654109251	no proteinuria
0.0654105321	suggested by
0.0653790595	differential diagnosis of
0.0653674221	s condition
0.0653523290	of 29 patients
0.0653498320	and none
0.0653462968	dysfunction and
0.0653427637	on days 2 and
0.0653376919	a mixed
0.0653344610	the interstitial
0.0653284210	an interaction between
0.0653219524	further evaluation of
0.0652931807	and ropivacaine
0.0652915390	at 300 mg
0.0652435516	and treatment of
0.0652307623	in three patients with
0.0652215237	also with
0.0652177542	like syndrome after
0.0652084081	a man
0.0652045897	the recurrence of hepatitis
0.0652014537	also suggest
0.0651921221	both drug
0.0651840433	for 1 month
0.0651475578	renal failure in
0.0651464883	2 mmhg
0.0651427509	all but one of
0.0651404966	ability of
0.0651265340	edema and
0.0651252046	10 mg kg day
0.0651207901	a host
0.0651128770	domain of
0.0651128770	configuration of
0.0651128770	quantities of
0.0651088802	and literature review
0.0650995338	at 2 h
0.0650816935	a negligible
0.0650722796	mainly in
0.0650702602	the les
0.0650702602	the pilo
0.0650598492	the optimal treatment
0.0650542547	for 10 to
0.0650506728	the liver damage
0.0650432893	the most likely
0.0650403200	after 2 weeks
0.0650350965	a mouse
0.0650300226	the dipyridamole
0.0650296778	24 h prior to
0.0650233072	in cyclophosphamide induced cystitis in
0.0650184305	on cpa
0.0650059990	the ipsilateral
0.0650051982	pilocarpine on
0.0649988739	also experienced
0.0649857349	the pressor effect
0.0649501818	clinical trials of
0.0649330440	20 days
0.0649295409	carbamazepine therapy in
0.0649279770	rats by
0.0649139925	blinded to
0.0649135097	the striatum to
0.0649131072	twice as
0.0649100032	a block
0.0648894835	and pre test
0.0648718430	15 patients in
0.0648717737	hypersensitivity to
0.0648536005	the body
0.0648324628	to 120
0.0648222813	of eight
0.0648060827	the follow up
0.0648057330	in experimental animals
0.0648031590	the need for further
0.0647941469	the target
0.0647903327	the analgesic
0.0647884942	in pd
0.0647764692	following treatment
0.0647707351	the combination of paclitaxel
0.0647656440	patients on
0.0647540492	a scale
0.0647433965	the increased use of
0.0647298943	the iso
0.0647248230	treatment with d
0.0647234602	db after
0.0647064395	but physicians
0.0647056394	an inhibitory effect on
0.0646958180	segments of
0.0646927400	in susceptible patients
0.0646897112	in parkinsonian patients
0.0646535527	3 weeks of
0.0646513500	the myocardial cell
0.0646476495	of bone marrow
0.0646420415	the median survival
0.0646377444	and receptor binding
0.0646346610	the surrounding
0.0646192211	a 24 h
0.0646170331	the most severe
0.0646109389	to 6 months
0.0646104113	prospective study of
0.0646103880	of inflammatory cells
0.0646036206	in dexamethasone induced hypertension in
0.0645989853	in six of
0.0645889057	more sensitive to
0.0645792379	medication associated
0.0645601579	catalepsy in
0.0645581817	significantly lower than in
0.0645414117	the glial
0.0645410383	the production of reactive oxygen species
0.0645379012	evaluated before
0.0645186343	not altered by
0.0645149268	inhibitor of
0.0645071736	and post
0.0645054968	mechanisms for
0.0644849101	adult male and
0.0644815028	often associated with
0.0644771825	other types of
0.0644686641	the 24 hour
0.0644665791	by streptozotocin
0.0644549994	conducted at
0.0644434441	associated with heroin
0.0644434441	associated with hiccups
0.0644433438	on seizures produced by pilocarpine
0.0644162645	and pre
0.0644152039	the mean change in
0.0644113264	for tdf
0.0644040357	the exception of
0.0644002094	= 7
0.0643934926	the multivariate analysis
0.0643863696	all four patients
0.0643839642	defects associated with
0.0643775805	an important cause of
0.0643582182	in plasma potassium
0.0643411218	more than 5
0.0643391015	9 days
0.0643371923	and gallbladder disease
0.0643202602	the co2
0.0643167320	and mental
0.0643159399	the tubular damage
0.0643044265	such patients
0.0642914550	l noarg and
0.0642866323	all tested
0.0642862007	the contribution of
0.0642811168	with essential hypertension
0.0642654230	4 cases of
0.0642615878	levels during
0.0642499853	the early and
0.0642452041	systemic toxicity of
0.0642396774	in users of
0.0642363877	studied for
0.0642350151	describe 3
0.0642306677	in group b
0.0642137319	in parallel
0.0642114425	during phenylephrine
0.0642103909	48 and
0.0641899522	of bupropion hcl 120 mg kg
0.0641795812	pre treatment of
0.0641687369	administration in
0.0641673653	not treated with
0.0641391247	as revealed
0.0641359937	induction by
0.0641265065	the acetylcholine
0.0641188573	for 4 weeks
0.0641158129	a once
0.0641031128	89 of
0.0640869716	the daily
0.0640862174	after parenteral
0.0640656026	the survival of
0.0640632870	the last two
0.0640532886	the maximum tolerated dose of
0.0640336042	limitations in
0.0640333173	the hearts of
0.0640073644	a migraine
0.0639955895	from seizure
0.0639830956	the white
0.0639726650	of antianginal
0.0639706364	the isoflurane
0.0639638553	day 6
0.0639499033	as at least
0.0639478576	after 24 hours
0.0639332120	and not
0.0639228349	clinical studies with
0.0639195753	the compounds
0.0639136764	50 or
0.0639020017	and 12 weeks
0.0638983094	the glomeruli
0.0638981584	sensitivity in
0.0638931807	and amoxicillin
0.0638931807	and irradiation
0.0638717737	relevant to
0.0638636857	the most important
0.0638564057	release of
0.0638550790	in 1 patient and
0.0638452086	the development of glomerular sclerosis
0.0638399874	at 3 min after
0.0638373190	of at least
0.0638301070	refractory to
0.0638262107	13 to
0.0638207159	a transplant
0.0638163130	for identifying
0.0638158520	of venous thromboembolism
0.0638084569	at 24 h
0.0638068908	damage caused by
0.0638063492	center for
0.0637868861	of rats with
0.0637763997	of learning
0.0637758351	10 mg day
0.0637699628	to 76
0.0637616199	and 6 h after
0.0637501475	the globus pallidus after
0.0636874609	the lozenge
0.0636666078	for antidepressants
0.0636621988	a sustained
0.0636574856	20 mg kg i
0.0636446372	and e antigen
0.0636434356	read to
0.0636434356	sensitivities to
0.0636427509	in 24 of
0.0636412313	as many
0.0636412164	monitoring during
0.0636397618	change during
0.0636367238	did not differ from
0.0636256661	of risperidone
0.0636195718	in 40 of
0.0636105584	a 30 min
0.0636024820	myocardial infarction by
0.0635920127	the test conditions
0.0635839042	the gradual
0.0635732411	and lesions of
0.0635604787	participating in
0.0635562596	for 6 weeks
0.0635394542	the antiepileptic drug
0.0635296106	but calcium
0.0635294607	in patients with or =
0.0635086296	in behavioral studies
0.0635080763	and time course of
0.0634996059	of 14.1
0.0634843190	one of three
0.0634635450	a single high dose of
0.0634626249	and 3.7
0.0634616799	previously treated with
0.0634420257	the diazepam
0.0634293193	the proportion of patients
0.0634207094	the isolated hit
0.0634199446	formed in
0.0634117517	measured for
0.0634050868	in several patients
0.0633922906	a postdose
0.0633890490	the estrogen
0.0633736985	management of
0.0633652120	increased in urothelium and
0.0633585392	14 day
0.0633372049	and psychiatric
0.0633364284	the hyperactivity induced by
0.0633270750	although in
0.0633232759	in organ transplantation
0.0633220549	in six dogs
0.0633215836	significantly less with
0.0633158687	without prior
0.0633080555	these side effects
0.0632991246	a 77
0.0632970946	3 +
0.0632871007	the short
0.0632739776	first report of
0.0632624946	the hemoglobin concentration
0.0632607282	control rats in
0.0632581558	tacrolimus as
0.0632569270	mortality in
0.0632503721	l dopa on
0.0632432088	and sometimes
0.0632400739	also effective
0.0632288081	for further
0.0631937969	the rostral
0.0631855554	a population based
0.0631846848	after one year of
0.0631497098	model for
0.0631469222	and nag
0.0631460573	7 months
0.0631457879	of apap
0.0631401523	not only in
0.0631206765	in children and adolescents
0.0631103909	indicated in
0.0631096333	e and
0.0631016247	no report
0.0631016247	but severe
0.0630956917	12 days after
0.0630943901	or altered
0.0630872279	or = 4
0.0630846452	200 to
0.0630828846	the right and left
0.0630809991	and acetylcholine
0.0630682219	doxorubicin on
0.0630574824	foci of
0.0630550981	and salt
0.0630485324	by doxorubicin
0.0630471814	matched by
0.0630462388	effect caused by
0.0630462175	the threshold for pilocarpine
0.0630350965	a steroid
0.0630298956	the sexual side effects
0.0630069052	and adrenaline induced
0.0630004285	to provide
0.0629952674	and capsaicin induced
0.0629922089	the positive and negative syndrome scale
0.0629837031	5 x 10
0.0629789577	or systemic
0.0629788026	of cocaine and ethanol
0.0629706764	and impairment of
0.0629670754	the time course and
0.0629652020	two subsequent
0.0629569763	found on
0.0629488440	the initial dose of
0.0629388364	a safer
0.0629305807	and pai 1
0.0629289066	the evening
0.0629187841	episodes associated with
0.0629135097	of patients on
0.0629045836	action but
0.0628990956	a side effect of
0.0628898323	day 21 of
0.0628889699	with diazepam for
0.0628746749	after discontinuation of
0.0628654094	a concomitant
0.0628506967	after pediatric
0.0628498356	one or more of
0.0628355698	suspected to
0.0628314043	or 2.0 mg
0.0628229634	a partial
0.0628217358	the behavioural
0.0628209805	the clinical and
0.0628171531	altered by
0.0628148204	by amantadine in
0.0628131523	and height
0.0627948187	a poor
0.0627937193	12.5 or
0.0627916453	and 300 mg kg
0.0627753590	the dyskinesia
0.0627732411	and decrease of
0.0627633001	no drug
0.0627307297	induced amnesia and
0.0627306099	an index of
0.0627274769	alterations of
0.0627128559	the first few
0.0626937881	other causes
0.0626919155	the complement
0.0626869969	adult patients with
0.0626674831	without pain
0.0626552405	from four
0.0626460401	both medications
0.0626373430	the cortex and
0.0626355098	a greater risk of
0.0626319111	to monitor
0.0626195831	electroshock or
0.0626102909	and 61 of
0.0625836309	of children with
0.0625627292	and cortex
0.0625616725	and aggression
0.0625515611	and management of riha
0.0625405746	renal injury in
0.0625329347	the progressive
0.0625329347	the carbamazepine
0.0625228053	and in patients with
0.0625215990	the dlt
0.0625214093	efficacy and safety of
0.0625177793	and focal
0.0624929573	made to
0.0624862870	cardiac function and
0.0624776808	after dipyridamole
0.0624716923	to overcome
0.0624712664	further reduction of
0.0624557011	40 patients
0.0624530308	one of four
0.0624495039	in elderly
0.0624434444	and gsh
0.0624391015	any significant
0.0624248672	action with
0.0624245615	and 4 aminopyridine
0.0624240026	in people
0.0624201716	at two
0.0624182426	to review
0.0624149993	lidocaine for
0.0624141878	the mitochondria
0.0624088675	a 2 h
0.0624001789	serum concentrations of
0.0623962553	on ca
0.0623929517	a maximum of
0.0623601504	for autism
0.0623035881	measurements from
0.0623034869	or even
0.0622929225	as confirmed
0.0622697133	in 2 separate
0.0622603960	the dgc
0.0622532538	and evidence of
0.0622494794	24 patients
0.0622262346	the close
0.0622218430	involvement in
0.0622148393	strategy to
0.0622023636	anaemia in
0.0622001420	the perioperative
0.0621956570	the bche
0.0621869333	the 90 htn
0.0621861474	rather than to
0.0621539130	administration in patients with
0.0621427547	binding of
0.0621351117	this change
0.0621339667	a process
0.0621251273	s group
0.0621248726	as potential
0.0621205895	both doses
0.0621056099	at baseline and at
0.0621051127	with eventual
0.0620934726	the first dose of
0.0620767574	capacity for
0.0620702602	the brains
0.0620689208	evident in
0.0620641299	of mrp2
0.0620612472	combination therapy of
0.0620477557	quality of
0.0620369820	derivative of
0.0620123093	vitamin e and
0.0620079610	and cardiac troponin
0.0620048758	the c + e
0.0620011277	the bolus
0.0619968430	the cortex of
0.0619848719	uveitis in
0.0619751309	a 1 month
0.0619726685	six days after
0.0619722330	a therapeutic
0.0619699327	of symptom onset
0.0619690915	in group a
0.0619545173	those reported
0.0619522929	on both
0.0619463581	of vessels
0.0619324975	first line treatment of
0.0619307610	a group and
0.0619142213	syndrome of
0.0619121659	frequently associated with
0.0619061745	distinct from
0.0619013768	and morphology
0.0618989694	and liver biopsy
0.0618961908	the mean arterial pressure
0.0618937303	a newborn with
0.0618896446	infusion with
0.0618847137	taken from
0.0618819854	blood pressure without
0.0618765281	sensation in
0.0618697144	after verapamil
0.0618636148	safe at
0.0618562484	toxic than
0.0618421760	at 48
0.0618386277	the basis
0.0618325487	dyskinesias in
0.0618101542	and vsd
0.0618013695	and 3.1
0.0617964614	no evidence
0.0617828860	the finding
0.0617566540	not effective for
0.0617451406	of cases
0.0617429586	changes suggestive of
0.0617426233	on haloperidol induced
0.0617396697	role as
0.0617231340	a newborn
0.0617159680	or almost
0.0617101310	two years
0.0617046570	safety and
0.0617040492	with diazepam
0.0616800605	decreased after
0.0616743176	of capsaicin
0.0616696536	a differential
0.0616661321	a pressor
0.0616659934	the first two
0.0616619525	the steroid
0.0616557921	of dopamine receptors
0.0616457182	in group ps
0.0616427509	only 1 of
0.0616379536	3 children
0.0616355098	the plasma level of
0.0616325734	a need to
0.0616309693	and optic nerve
0.0616303418	pharmacokinetics of
0.0615836309	this group of
0.0615779573	by decreasing
0.0615696711	to suppression of
0.0615632917	the rabbit syndrome
0.0615569205	with effects on
0.0615457091	in higher doses
0.0615364451	heart failure during
0.0615222301	investigated changes in
0.0615104337	or higher
0.0615092443	injected in
0.0615077810	and hepatic dysfunction
0.0614956086	receptor agonist with
0.0614928773	0.5 to
0.0614585400	with dysfunction in
0.0614522464	in other studies
0.0614503490	a significant number of
0.0614488883	individuals with
0.0614412164	noted during
0.0614199446	barrier in
0.0614082996	to extend
0.0614040357	the brains of
0.0614026363	every 2
0.0614015317	adverse effects associated with
0.0613932793	of muscle fasciculations
0.0613860923	schedule for
0.0613695212	and acidosis
0.0613593045	this hypotension
0.0613518244	and up
0.0613499430	three days
0.0613281708	injection with
0.0612914971	a depression
0.0612821843	this increase
0.0612744514	during nitroprusside
0.0612597270	for monitoring
0.0612494840	a compensatory
0.0612473908	2 specific
0.0612340116	of pethidine
0.0612192371	toxic to
0.0612151333	and oxidative damage
0.0612114908	not observed
0.0612109346	twelve patients
0.0612065980	in only one of
0.0612031444	trazodone at
0.0612009583	s syndrome
0.0611790485	a subgroup of patients
0.0611735532	the food and drug administration
0.0611697617	the women on
0.0611457879	of suprofen
0.0611261615	in reversing
0.0611143986	of 37 patients
0.0611027301	from control
0.0610969657	4 neutropenia
0.0610950240	7 weeks
0.0610889636	the examination
0.0610646675	the mu
0.0610646675	the glycine
0.0610540097	the concentrations of
0.0610471533	with stable
0.0610455385	of 175
0.0610391247	as controls
0.0610246937	23 patients
0.0610246181	to affect
0.0610043185	and well tolerated
0.0609981446	hyperprolactinemia induced by
0.0609959710	hemolytic anemia in
0.0609933984	in fluctuating patients
0.0609928213	variations of
0.0609921791	located in
0.0609907568	with thrombosis
0.0609877816	rates for
0.0609774168	more than 3
0.0609755267	after i.v
0.0609396840	also decreased but
0.0609331417	presumably due to
0.0609302041	a hemoglobin
0.0609284369	2 separate
0.0608969368	the bruising
0.0608934273	deficient in
0.0608907297	and impotence
0.0608851832	amphetamine or
0.0608482964	the characteristic
0.0608340472	a clinical and
0.0608186598	recommended in
0.0608158278	2 3 of
0.0608005356	size of
0.0607897844	or angioedema
0.0607881903	of three
0.0607836760	in schizophrenic patients
0.0607748648	for acetaminophen
0.0607744465	for almost
0.0607715042	of 50 mg of
0.0607569277	a late
0.0607516603	of inducible no synthase
0.0607489332	dose levels of
0.0607341195	a synergistic
0.0607338641	neuropsychiatric side effects in
0.0607308790	and did not recur
0.0607270622	the igm
0.0607212337	and regional
0.0607103909	2.5 and
0.0607050790	the reversal of
0.0606860214	clinical features of
0.0606770438	during anaesthesia
0.0606705910	a persistent
0.0606481316	intensity of
0.0606334335	combination with
0.0606296231	in advanced
0.0606092643	in brain tissue
0.0606011463	three rats
0.0605922154	the regulation
0.0605818971	the artery media in
0.0605812505	for 21 days
0.0605789262	treatment because of
0.0605787425	of cases of
0.0605783056	with vnr
0.0605717659	on serum calcium
0.0605677430	in animals of
0.0605449385	a unique
0.0605442875	the classical
0.0605384425	a vagal
0.0605324992	to support
0.0605317600	renal dysfunction in
0.0605261471	recorded with
0.0605246937	by cisplatin
0.0605049834	with hiv
0.0605029802	collection for
0.0604970363	and management
0.0604834783	occurred in four
0.0604763997	a population
0.0604642933	a later
0.0604616378	by repeated
0.0604528141	two days after
0.0604483493	the subjective effects
0.0604472813	or without
0.0604412987	a model for
0.0604374980	with l noarg
0.0604335317	early detection and
0.0604325622	1995 to
0.0604201716	at one
0.0604190396	the half life
0.0604169999	these disorders
0.0604142324	reported during
0.0604090458	for chronic hepatitis c
0.0603930316	13 patients in
0.0603912065	observed using
0.0603910552	2 days
0.0603849807	a useful drug
0.0603694467	use of medication
0.0603685184	deterioration of
0.0603620051	this potential
0.0603532255	a child
0.0603396876	an improved
0.0603323611	the heavy
0.0603309332	both liver
0.0603173465	and other drugs
0.0603163773	used at
0.0603147055	before or
0.0603068423	the histologic
0.0602890065	and older
0.0602627918	the amount and
0.0602611687	pain intensity in
0.0602588820	for ten
0.0602526780	both acute
0.0602460585	lethargy and
0.0602440445	for attention
0.0602329912	the long term effects of
0.0602263388	the terminal
0.0602193405	assessed with
0.0602155711	by imipramine
0.0602155711	by azithromycin
0.0602061649	to stimulate
0.0602061649	to mimic
0.0602053537	a study on
0.0602049425	rebound of
0.0602049425	relevance of
0.0601789734	technique for
0.0601632256	of 115
0.0601575018	weight of
0.0601528300	nmda receptors in
0.0601437063	cholestasis with
0.0601288081	only on
0.0601242408	9 mg kg
0.0601229495	this rare
0.0601204340	the pre
0.0601203887	and picrotoxin
0.0601166031	but further studies
0.0600997170	day after
0.0600619464	in one patient and
0.0600567216	mechanism of
0.0600485324	by lithium
0.0600485324	this rat
0.0600352682	and beta adrenergic
0.0600352557	eleven of
0.0600346922	no other evidence of
0.0600322783	and psychotic symptoms
0.0600299678	effects of n
0.0600217419	fold at
0.0600164043	symptoms within
0.0599983814	beneficial effects in
0.0599969368	the cx3cr1
0.0599789577	or aspirin
0.0599755267	after taking
0.0599735090	the antiviral
0.0599697617	the prevalence and
0.0599570070	on behaviors
0.0599498636	the model group
0.0599475876	protection from
0.0599396078	a functional
0.0599349523	to demonstrate
0.0599335317	protein excretion and
0.0599321632	type 2
0.0599321380	in precipitating
0.0599321380	in ems
0.0599282745	30 min after
0.0599198644	with argatroban
0.0598769521	to 12 months
0.0598762646	mainly to
0.0598759424	in drug intoxication
0.0598692276	a probable
0.0598582113	enrolled on
0.0598536628	this side effect of
0.0598426562	the pulmonary
0.0598386277	the cholinergic
0.0598362058	the investigation
0.0598300981	the iron
0.0598204572	the training
0.0598198644	a strain
0.0598039270	dysfunction induced by
0.0597972620	activator of
0.0597965816	group 4
0.0597828261	further increase in
0.0597787778	also used
0.0597584944	likely due to
0.0597479361	the features of
0.0597469368	the list
0.0597436657	to occur
0.0597364966	confused with
0.0597364966	insecticide with
0.0597311855	into 6
0.0597272368	continued in
0.0597241266	these drugs in
0.0597215969	presented for
0.0597153055	did not significantly
0.0597118846	series of
0.0597008722	usage of
0.0596936951	analyzed for
0.0596848640	taken with
0.0596812695	and susceptibility to
0.0596754763	the higher doses
0.0596624960	the risk associated with
0.0596613854	awareness of
0.0596613854	yield of
0.0596397494	the mitochondrial
0.0596388997	a potassium
0.0596384212	after completion of
0.0596368835	a convenient
0.0596312828	after dexamethasone
0.0596245784	close to
0.0596162981	this method
0.0596103909	so in
0.0596044039	of cocaine in mice
0.0596024930	the renin angiotensin system
0.0595968921	on metoprolol
0.0595926481	the elevation of
0.0595691436	modifications in
0.0595641921	a need
0.0595473908	2 week
0.0595461553	hemodynamic effects of
0.0595442959	identified with
0.0595373123	and high doses of
0.0595312720	two courses of
0.0595215990	the vasodilating
0.0595122811	that administration of
0.0595086661	the cardiovascular effects of
0.0595058411	tolerability of nimesulide and paracetamol in
0.0595056303	the epileptic
0.0594858943	of vasopressin
0.0594800466	during treatment of
0.0594779655	the assessment of
0.0594748104	the expression and
0.0594688493	of convulsive activity
0.0594675992	to methadone dose
0.0594447409	drug for
0.0594417099	for fever
0.0594282197	of vascular events
0.0594277076	due to local
0.0594172593	an appropriate
0.0594152383	with varying
0.0593840311	of renal function and
0.0593795592	and cardiovascular effects
0.0593748905	in six cases
0.0593693423	the muscular
0.0593688432	the latency of
0.0593585733	a history
0.0593485872	with symptoms of
0.0593402262	a reliable
0.0593390740	the effects of i
0.0593362094	the rise in
0.0593345194	after oltx
0.0593285939	in hemoglobin concentrations
0.0593115447	in children and
0.0593086897	for epilepsy
0.0592995858	glomeruli of
0.0592851700	events during
0.0592829647	this purpose
0.0592719462	any effect on
0.0592674831	either control
0.0592594388	a risk factor
0.0592540205	of fibrin
0.0592515333	alpha5 and
0.0592493040	to three weeks
0.0592446149	by histology
0.0592390081	caffeine in
0.0592369786	results show
0.0592349082	scores on
0.0592276877	three women
0.0592168594	discontinuation or
0.0592048025	appeared as
0.0591947027	finding for
0.0591894841	follow up of
0.0591812695	and upregulation of
0.0591787912	women using
0.0591762714	of valproate
0.0591675685	3 women
0.0591642587	acute treatment with
0.0591514452	occur in
0.0591344237	sedation for
0.0591248081	other side effects
0.0591213483	the as ks group
0.0591143986	in three cases
0.0591096557	to 77
0.0591096557	to 3.8
0.0591048524	the numbers of
0.0590905257	the pressure dynamic
0.0590900688	or bradycardia
0.0590899076	in france
0.0590885470	stroke in
0.0590792636	without side effects
0.0590715042	the mean doses of
0.0590666894	a widely
0.0590649473	lesion of
0.0590646568	effects of i
0.0590612951	of inappropriate
0.0590567414	taken by
0.0590412277	with parkinson
0.0590286512	80 patients
0.0590262123	of hyperbaric 5 lignocaine
0.0590127254	patients with various
0.0589976134	death in
0.0589968906	expected to
0.0589834611	the light of
0.0589789577	or subsequent
0.0589772368	delirium in
0.0589735090	the probable
0.0589735090	the structure
0.0589712433	in mice lacking
0.0589517947	of mice with
0.0589506227	a slow
0.0589499910	of 16 patients
0.0589461222	of vision
0.0589396078	a delayed
0.0589335317	highly effective and
0.0589244620	a cyp2d6
0.0589222204	and placebo on
0.0589202537	brain damage in
0.0589144235	side effects attributable to
0.0589127052	of caa
0.0589106302	the striatal
0.0589086019	enflurane and
0.0588978663	year old girl with
0.0588933760	no evidence for
0.0588925981	the frontal
0.0588837666	of csa and fk506
0.0588672919	for parkinson
0.0588626979	the results show
0.0588573455	thalidomide at
0.0588292304	2 lidocaine
0.0588271654	the toxic effects of
0.0588222040	the overall effect of
0.0588162906	and quality
0.0588065972	given during
0.0588042465	reduced from
0.0587969817	in 85 patients
0.0587954144	a low incidence of
0.0587945081	with mild
0.0587933030	the case also
0.0587823503	and pain in
0.0587809772	analyzed at
0.0587697759	than 1 year
0.0587526617	volume of
0.0587458370	sensation of
0.0587376681	other symptoms
0.0587312774	greater with
0.0587266516	with other drugs
0.0587209315	occur after
0.0587200275	that inhibition of
0.0587141149	given before
0.0587088652	neutropenia after
0.0586945933	the possible mechanisms
0.0586936808	on acetaminophen
0.0586916235	dysfunction associated with
0.0586899764	51 patients with
0.0586865310	of nrf2
0.0586832952	the findings suggest
0.0586763997	of carboplatin
0.0586693828	the difficulty
0.0586558960	the icu for
0.0586547907	potential of
0.0586496752	mania in
0.0586465059	of calcium and
0.0586390626	fold increase in
0.0586388997	a multiple
0.0586387189	charge and
0.0586336912	index of
0.0586216308	but significantly
0.0585424623	reported after
0.0585406854	with epilepsy
0.0585381587	assessed on
0.0585366752	aetiology of
0.0585334196	slices of
0.0585327988	a mood
0.0585295512	little or
0.0585257827	30 d
0.0585161999	psychosis in
0.0585017174	the days of
0.0585017174	the efficacy and
0.0584945391	slope of
0.0584945391	prescription of
0.0584945391	breakdown of
0.0584748104	the frequency and
0.0584538014	production and
0.0584528278	values in
0.0584473608	pain on
0.0584357435	of cisplatin and amifostine
0.0584112046	with fluoxetine
0.0583894179	side effect of treatment with
0.0583384337	treatment discontinuation in
0.0583370568	heart hypertrophy in
0.0583262107	for five
0.0583222109	contact with
0.0583215836	an association with
0.0583187922	hypokalemia and
0.0583130197	after phenytoin
0.0583109260	the epm
0.0582914971	a paclitaxel
0.0582883287	any treatment
0.0582859169	occur at
0.0582839525	the cpu
0.0582825465	in women with
0.0582409620	but prolonged
0.0582393021	15 days
0.0582347270	on scopolamine
0.0582345411	changes leading to
0.0582271648	amnesia for
0.0582265822	a second group
0.0582033727	on electrocardiogram
0.0581914308	in such patients and
0.0581773557	to ptz
0.0581725940	of patients with congestive heart failure
0.0581687362	in animals and humans
0.0581550286	by morphine in
0.0581505857	a calcium channel
0.0581471232	after controlling for
0.0581403444	min for
0.0581399445	of succinylcholine associated myalgia
0.0581395045	at higher risk for
0.0581195212	and hematoma
0.0581179315	in lnna rats
0.0581152701	and laboratory studies
0.0581124631	received only
0.0580924834	of sevoflurane
0.0580870623	after intravenous
0.0580707317	in individuals
0.0580681418	and interleukin 6
0.0580518463	the suppression
0.0580370362	associated with enhanced
0.0580313291	observation of
0.0580235470	size and
0.0580213069	biochemical and
0.0580129975	independently of
0.0580072586	a minor
0.0580007555	a mean arterial pressure
0.0579962841	monitored with
0.0579914676	and after administration of
0.0579841759	out patients and
0.0579834611	the benefit of
0.0579740169	of group a
0.0579735090	the extracellular
0.0579735090	the potency
0.0579700618	renal toxicity of
0.0579697617	of doxorubicin and
0.0579688432	the urinary bladder of
0.0579651089	and neurotoxicity in
0.0579621181	to srl
0.0579410606	a putative
0.0579366497	the occurrence
0.0579353785	the concentration time curve
0.0579345533	the volume of
0.0579200744	and 0.4
0.0579095424	this apparent
0.0578937852	the progression of
0.0578932805	difference in
0.0578797606	also compared with
0.0578788141	among patients with
0.0578783664	one month after
0.0578778849	neuropathy using
0.0578740310	of cyclosporin
0.0578659711	two events
0.0578614853	a relevant
0.0578614444	associated with sirolimus
0.0578576825	formulations of
0.0578521404	this test
0.0578463672	higher with
0.0578430394	four cases of
0.0578346744	and furosemide
0.0578316149	the hypotensive response
0.0578300981	the intermediate
0.0578300981	the electrophysiological
0.0578199415	drug administration and
0.0577988880	tachycardia in
0.0577987365	a challenge
0.0577832859	for approximately
0.0577811503	a larger
0.0577730388	with if
0.0577670169	in vitro showed
0.0577663367	to play
0.0577561499	tremors and
0.0577512538	seizure associated with
0.0577512415	the central venous
0.0577481302	the beginning
0.0577455408	restriction of
0.0577455408	spectrum of
0.0577336101	the incidence and
0.0577296741	while at
0.0577209315	continued after
0.0577177176	5 week
0.0577152038	also presented
0.0577063685	with therapeutic doses of
0.0577035100	occurred with
0.0576958597	also demonstrated
0.0576956535	this compound
0.0576865310	of clentiazem
0.0576791186	followed by increased
0.0576713324	the pathophysiology
0.0576689163	at increased risk for
0.0576556929	and 300 mg
0.0576496761	a review
0.0576447500	weight loss in
0.0576440617	refractory or
0.0576402610	increasing from
0.0576357015	with mdp
0.0576108103	indication of
0.0576081467	due to severe
0.0576028314	proven to
0.0575970301	and 1200
0.0575919531	of contrast induced nephropathy in
0.0575730309	presented in
0.0575556929	and 400 mg
0.0575467436	a 69
0.0575361567	or ethanol
0.0575304365	further support to
0.0575011853	of forces
0.0575011853	of remd
0.0574763997	a sensitive
0.0574641923	a dopaminergic
0.0574641923	a pre
0.0574599412	the occurrence of serious
0.0574504443	thrombosis in
0.0574490169	and dyskinesias in
0.0574476017	first reported
0.0574398726	compared on
0.0574380820	to onset of
0.0574332860	cyclosporin a
0.0574061220	a commonly
0.0574041250	and serotonergic
0.0574038141	12 patients with
0.0573990722	only 15
0.0573940891	the fractional
0.0573750758	crossover study of
0.0573713945	bmd of
0.0573457772	the atria
0.0573435565	ppi in
0.0573390857	safe and effective in
0.0573390549	and immunohistochemical
0.0573358035	of 5 fu cardiotoxicity
0.0573240651	done at
0.0573190890	taken for
0.0573154491	a selective and
0.0573139648	several patients
0.0573130197	by estrogen
0.0573125168	administered after
0.0572634167	the adjusted
0.0572429619	findings on
0.0572394553	a generalized
0.0572169981	24 h of
0.0572133045	level 2
0.0572098214	proteinuria associated with
0.0572059962	the syndrome of
0.0571919604	without evidence of
0.0571848828	anticonvulsant effects of
0.0571814825	postulated to
0.0571811736	and adrenaline
0.0571731245	those found in
0.0571617581	to test whether
0.0571566548	during snp
0.0571526846	variability and
0.0571493870	effectiveness of
0.0571493870	sensitization of
0.0571383588	increased during
0.0571345533	the range of
0.0571240496	amphetamine in
0.0571157122	to manage
0.0571131247	emergence of
0.0571122749	baseline for
0.0571033465	considered with
0.0570947477	by administration of
0.0570938027	of methylergonovine
0.0570835975	heart rate in
0.0570822593	experiments with
0.0570772741	in earlier studies
0.0570606467	measured on
0.0570597082	targets of
0.0570593560	the neural
0.0570587391	3 months of
0.0570564924	the cessation of
0.0570511519	to six months
0.0570511203	the cases of
0.0570376261	comparable with
0.0570218681	of lovastatin
0.0570175449	9 weeks
0.0570143644	and oxygen
0.0570135444	a twice daily
0.0570121351	in mice treated with
0.0570042195	problem with
0.0570018847	after follow up
0.0570009997	after 8 weeks of
0.0569978280	of sfas
0.0569944972	from one
0.0569907083	the application of
0.0569859347	the classic
0.0569823770	and discontinuation of
0.0569800527	with caffeine in
0.0569789577	or functional
0.0569789577	or tacrolimus
0.0569757907	identified from
0.0569608497	and blood coagulation
0.0569585455	pre and
0.0569483985	two days
0.0569483985	10 days
0.0569452122	for evidence of
0.0569440031	mean duration of
0.0569326092	for 12 days
0.0569225447	+ gentamicin
0.0569119715	a phase ii trial of
0.0569096678	dependence in
0.0569015511	a case report of
0.0569002126	other drugs
0.0568967330	also reported
0.0568940473	in subjects with
0.0568887734	the morbidity and mortality
0.0568848918	a genetic
0.0568776942	to exclude
0.0568770890	week 3
0.0568648546	62 +
0.0568575811	of non specific
0.0568521404	1 years
0.0568515828	followed by infusion
0.0568493204	the observation
0.0568487087	to adenomyosis
0.0568479361	and prevention of
0.0568449086	with acne
0.0568372401	3.4 +
0.0568364284	of lidocaine in
0.0568300981	the barium
0.0568300981	the net
0.0568271654	the plasma concentration of
0.0568207904	and 1200 mg day
0.0568073684	with carcinoma
0.0568005989	deposits of
0.0567793601	a relatively high
0.0567375515	the substrate
0.0567340948	using enzyme
0.0567338324	the capillary
0.0567231881	6 ohda and
0.0567209315	occurs after
0.0567155697	for 30 s
0.0567125597	90 and
0.0567095030	p greater than
0.0567042054	in either
0.0566890678	the benzodiazepines
0.0566886155	and 26 of
0.0566882100	the 8 week
0.0566838918	the onset and
0.0566818828	using different
0.0566722268	at week 2 and
0.0566721025	2 months
0.0566615824	a very low
0.0566604987	the ratio of
0.0566604987	the generation of
0.0566542357	an iron
0.0566506101	in nine patients
0.0566395013	hydration and
0.0566184395	over 20
0.0566155330	96 +
0.0566148352	a long acting
0.0566146278	in neurons in
0.0566130933	and seizure frequency
0.0565999968	for untreated
0.0565912189	determined as
0.0565868864	the hematologic
0.0565793811	with glibenclamide
0.0565690465	27 to
0.0565675895	diagnosed by
0.0565656744	efficacy and safety in
0.0565546674	7 days prior to
0.0565487354	expressed in
0.0565385801	lower than in
0.0565169750	presenting for
0.0565032659	the breast
0.0565032659	the prevention
0.0565024097	by 15 min
0.0564984914	during prolonged
0.0564903537	in 29 patients
0.0564763997	a frequently
0.0564688733	anxiety and
0.0564605326	of 210 patients
0.0564507312	as seen in
0.0564416448	effective to
0.0564382536	the use of amiodarone in
0.0564336659	2 or more
0.0564321009	the hypotensive response to
0.0564316807	or not with
0.0564216523	introduction of
0.0564209262	the second day
0.0564208914	probably related to
0.0564188183	67 of
0.0564091555	but without
0.0563880413	under control
0.0563859022	a suspected
0.0563818583	a susceptible
0.0563788229	the nociceptive
0.0563727440	and 30 minutes
0.0563717737	learning and
0.0563587836	recording of
0.0563532158	more than 1
0.0563401507	associated with release of
0.0563322616	administered by
0.0563316172	to 800 mg
0.0563060315	of 114
0.0563026094	the area of
0.0562888875	to return
0.0562793767	5 weeks of
0.0562707703	performed for
0.0562643421	3 cases and
0.0562547809	the patients without
0.0562475812	the month
0.0562397939	compared to controls in
0.0562369786	rare but
0.0562264192	low to
0.0562154348	sodium 2
0.0562143162	and second generation
0.0561853263	the black
0.0561845234	54 patients
0.0561677390	without effect on
0.0561640666	the stomach
0.0561637346	the inferior
0.0561628110	the ma
0.0561285467	after 4 days of
0.0561196062	dilatation of
0.0561184937	the rat to
0.0561180189	small for
0.0561167327	convulsive dose of
0.0560952628	in dogs with partial coronary stenosis
0.0560939644	the t +
0.0560734415	and review of
0.0560712553	to mediate
0.0560711680	and thereby
0.0560597061	the group with
0.0560495832	further cardiac
0.0560448961	10 minutes after
0.0560377908	relation to
0.0560330429	these abnormalities
0.0560306900	disturbances in
0.0560282933	no episodes of
0.0560262689	a microdialysis
0.0560248965	the open field
0.0560180526	at doses of
0.0560171813	the placebo group during
0.0560141442	diagnoses of
0.0560138133	in anesthetized rats
0.0560131887	and asystole after
0.0560121123	and mucositis
0.0560119704	hours following
0.0560018503	the increase of
0.0559993294	on l dopa
0.0559975812	the management
0.0559931020	10 mg of
0.0559713370	compared to other
0.0559695790	the painful
0.0559650470	within 10 to
0.0559647916	hypertension with
0.0559543519	with flushing
0.0559397718	this small
0.0559393574	the mean peak
0.0559385330	the protective effects of
0.0559326092	for 9 days
0.0559301769	9 days after
0.0559275098	as well as during
0.0559255488	the beneficial
0.0559196764	the improvement
0.0559132371	a lateral
0.0559024541	and weight loss
0.0558925537	the mechanism by
0.0558891412	anaesthesia with
0.0558780138	each treatment
0.0558758558	the convulsant
0.0558736091	defects in
0.0558705604	dogs by
0.0558593570	30 mg kg p
0.0557982973	shown at
0.0557870178	in wky and
0.0557866438	two months after
0.0557832859	on aspirin
0.0557830128	maintenance dose of
0.0557651089	and latency to
0.0557536088	hepatitis due to
0.0557438019	not shown
0.0557326934	a profound
0.0557210033	to re
0.0557134309	to erythropoietin
0.0556927794	a half
0.0556917880	the average time
0.0556891649	compared using
0.0556890678	the ultrastructural
0.0556858325	two seizure
0.0556856302	and 3h
0.0556847092	common in
0.0556842326	year old male with
0.0556834141	or less
0.0556770010	syndrome in
0.0556710004	single agent in
0.0556688473	all transplant
0.0556647073	or 75 mg kg
0.0556507276	and lethality
0.0556453387	in animals treated with
0.0556440800	swelling and
0.0556412895	200 mg of
0.0556297543	16 patients
0.0556231139	and 26
0.0556021648	detected on
0.0556000872	of oxidative
0.0555899130	of cardiac complications
0.0555868735	persisted to
0.0555697027	collected for
0.0555633041	while animals
0.0555625776	the modulation of
0.0555531761	a potentially
0.0555453889	with generalized seizures
0.0555448644	with azathioprine
0.0555372874	two months
0.0555370594	taken at
0.0555345152	factors associated with
0.0555305785	the liver with
0.0555301680	for symptomatic
0.0555279028	carcinogenesis in
0.0555270020	the damaged
0.0555240351	after nitroglycerin
0.0555172252	side effect and
0.0555128942	the excess
0.0555116849	not significantly different from
0.0555102630	means of
0.0555035901	objectives of
0.0555025166	or amphetamine
0.0554928965	in others
0.0554921620	pathway of
0.0554916148	and intensity of
0.0554848640	enhancement by
0.0554846048	the extent
0.0554823052	corrected with
0.0554753752	receptor 1
0.0554592438	a probe
0.0554449560	the cardiovascular system
0.0554430673	of ephedrine to
0.0554321722	with phenobarbitone and carbamazepine
0.0554313628	and weakness
0.0554274638	those patients with
0.0554239307	of pill
0.0554199052	no history of
0.0554198644	with phenobarbital
0.0554165124	the difference in
0.0554098039	the comparison
0.0554073191	the p10
0.0554045769	well tolerated in
0.0554023505	the present study indicates
0.0553980005	this possible
0.0553958566	lowered after
0.0553939639	and 48 hours
0.0553874249	parameters in
0.0553846028	a decrease of
0.0553838952	shown on
0.0553812757	to 3 times
0.0553803550	all p
0.0553639499	and caspase 3 activity
0.0553556303	the cycle
0.0553350209	in pilocarpine induced seizure in
0.0553300620	the degree
0.0553239151	or lymphoma
0.0553130824	this system
0.0553074815	with l dopa
0.0553059466	effective than
0.0553032890	also evaluated
0.0552969106	seizure but
0.0552923296	heart rate by
0.0552869414	decreased during
0.0552839697	6 days
0.0552836270	only group
0.0552804034	8 hours after
0.0552778879	a peak of
0.0552695079	the behavioral and
0.0552633032	at 200 mg day
0.0552621905	brain injury and
0.0552312561	a retrospective study
0.0552255328	rats from
0.0552239338	of insufficient
0.0552220753	a venlafaxine
0.0552134276	and electron
0.0552043918	cytoskeleton and
0.0552043918	dysarthria and
0.0552043918	ensued and
0.0552006882	whereas none of
0.0552005467	and further
0.0551876189	after dosing
0.0551863463	associated with oral contraceptives
0.0551834611	of utility in
0.0551745058	of carbachol in
0.0551693851	an important factor in
0.0551634497	oxidation of
0.0551522665	a fulminant
0.0551492312	2 hours after
0.0551410390	the pathological
0.0551300509	the second injection
0.0551084611	the lvef of
0.0551080158	toxicities associated with
0.0551045047	in hospitalised patients with cancer
0.0551042569	among several
0.0551035702	used in combination with
0.0551007318	groups than in
0.0550999015	s use
0.0550926298	a single 10
0.0550728588	in mice with
0.0550526986	seizures at
0.0550512617	the decision
0.0550512617	the psychostimulant
0.0550507935	a protective role for
0.0550479118	for 6 hours
0.0550391019	previously associated with
0.0550315995	the last two doses of mesna
0.0550203237	the ammonia
0.0550172038	and glu
0.0550172038	and aversive
0.0550172038	and e4031
0.0550172038	and economic
0.0550172038	and amphetamines
0.0550107176	2 mm
0.0550102630	calcification of
0.0550039066	but does not
0.0550015758	the dosage of
0.0549842688	the field
0.0549796157	factor in
0.0549644293	s effects
0.0549599430	with asenapine
0.0549487807	the offspring
0.0549456899	required in
0.0549359635	from moderate to severe
0.0549248312	an interval of
0.0549192529	a j and
0.0549191437	for 3 days after
0.0549165124	the latency to
0.0549149423	not found
0.0549105939	this potentially
0.0549009630	of amantadine
0.0548925916	the 24 h retention
0.0548893099	a co
0.0548803864	and occasionally
0.0548773881	2 mg kg s
0.0548680412	by cocaine and
0.0548320757	by intraperitoneal
0.0548295199	18 to
0.0548266348	twenty patients
0.0548209404	5 ml of
0.0548072671	with sumatriptan
0.0547982973	amiodarone at
0.0547968313	changes after
0.0547903290	rate for
0.0547888993	the local
0.0547859432	for at least 24 h
0.0547840834	for rizatriptan
0.0547774049	finding in
0.0547582561	to october
0.0547515590	the mammalian
0.0547438106	the laboratory
0.0547434582	and examined for
0.0547397007	s ability to
0.0547349197	a finding
0.0547221605	gender on
0.0547174488	the region of
0.0547110606	the mouth
0.0547103909	in ten
0.0547070547	the correlation between
0.0546803655	5 versus
0.0546786776	the currently
0.0546785945	the actions of
0.0546779136	loss of vision in
0.0546761277	with suspected
0.0546737230	5 day
0.0546676881	the rates of
0.0546626696	with quetiapine
0.0546600888	one week
0.0546380045	developed during
0.0546348355	the iodixanol group and
0.0546284837	lesion in
0.0546139054	performance on
0.0546125474	and histopathological
0.0545997320	fibrosis in
0.0545966391	consecutive patients with
0.0545829127	two doses of
0.0545747222	cardiotoxicity of
0.0545692199	the visual field
0.0545572463	control for
0.0545570772	a rate of
0.0545483385	remission after
0.0545468638	drugs on
0.0545448644	with ketoconazole
0.0545414457	most cases of
0.0545406312	all cause mortality in
0.0545339339	the plasma concentration
0.0545229495	by meth
0.0545217538	this process
0.0545045685	hypercalcemia and
0.0544993048	a word
0.0544990456	the quality of life
0.0544972502	determined from
0.0544923187	for eight
0.0544819226	the determination of
0.0544804346	with cessation of
0.0544660329	the synthesis
0.0544590945	the improvement of
0.0544528278	impaired in
0.0544507606	with radiotherapy
0.0544430673	to theophylline in
0.0544389605	other causes of
0.0544320420	as relevant
0.0544247739	in contrast with
0.0544192306	media for
0.0544116071	mainly as
0.0544095941	a measure of
0.0543908101	the participation of
0.0543859022	a lesion
0.0543838800	200 and
0.0543803038	a cause for
0.0543790688	conditions associated with
0.0543678441	particles of
0.0543556303	the lung
0.0543464133	two weeks after
0.0543430663	of norepinephrine
0.0543393381	and increase of
0.0543392402	the second dose of
0.0543331461	hemolysis during
0.0543174709	and quality of life
0.0542946764	the depression
0.0542765549	and asystole
0.0542752585	nephropathy in
0.0542705844	15 min after
0.0542698109	both therapeutic
0.0542601883	an effect of
0.0542425184	a substantially
0.0542308249	s duration
0.0542250176	in inflamed
0.0542182438	trimester of
0.0542182438	exception of
0.0542164665	the patient continued to
0.0542080303	resolved in
0.0541859410	with 5 fu and
0.0541834611	25 mg of
0.0541832260	the spectrum of
0.0541762520	in drg
0.0541494568	7 days following
0.0541489710	at 4 weeks in
0.0541477805	a 50 reduction in
0.0541330413	growth and
0.0541078869	not essential for
0.0540943256	the well known
0.0540752161	and vomiting
0.0540642479	and accumulation
0.0540606706	the animals treated with
0.0540573151	in patients on
0.0540522208	in serum and
0.0540293834	a dose dependent manner with
0.0540193709	and stroke in
0.0540089287	determined on
0.0540083604	a correlation
0.0540027783	the initiation
0.0539973722	given i.v
0.0539917958	resuscitation with
0.0539877775	renal failure during
0.0539867447	of des treatment
0.0539861822	or infection
0.0539793451	with uveitis
0.0539654216	for 1 year
0.0539640967	not more than
0.0539481475	in elderly patients with
0.0539376388	33 patients
0.0539367844	4 min
0.0539307610	the mechanism and
0.0539214624	the problems
0.0539145124	renal impairment in
0.0539027964	or expression of
0.0538937852	the intensity of
0.0538918281	t + a
0.0538865355	absent in
0.0538806743	for 48 h
0.0538710084	and prevention
0.0538670409	in alzheimer
0.0538559145	the neuronal
0.0538422359	each time
0.0538414998	9 +
0.0538362653	to discuss
0.0538306861	the efficacy and tolerability of
0.0538300981	the oc
0.0538213741	for nearly
0.0538153099	a serotonergic
0.0537983391	of sulphasalazine treatment
0.0537980808	73 patients
0.0537968313	by four
0.0537827396	a hypersensitivity
0.0537807023	use as
0.0537790178	during 5 fu
0.0537696764	the higher
0.0537685970	for 24 h
0.0537622395	by propranolol
0.0537400377	necrosis in
0.0537307526	developed to
0.0537263386	days 4
0.0537049288	the intravenous administration of
0.0536961088	in epileptogenesis and
0.0536960900	the presence
0.0536927518	for at least
0.0536880933	complication in
0.0536838918	and frequency of
0.0536717201	as tolerated
0.0536681296	vasodilation and
0.0536681296	vldl and
0.0536649012	of tacrolimus as
0.0536627389	the rats with
0.0536602053	the reuptake of
0.0536601497	goal of
0.0536548376	a change of
0.0536532980	the significance of
0.0536520039	the genes
0.0536489169	and melatonin
0.0536325811	60 patients
0.0536299037	avp and
0.0536222932	67 patients
0.0536112975	the pharmacokinetics of
0.0536001350	and mortality in
0.0535872874	each dose
0.0535850721	slower in
0.0535823118	showed only
0.0535813488	a pediatric
0.0535764206	the convulsive
0.0535702592	for induction
0.0535634640	observations on
0.0535560003	and oxidized
0.0535539734	anticoagulation for
0.0535521690	five rats
0.0535423494	relief of
0.0535423494	resection of
0.0535279184	and on pod 7
0.0535044253	and end stage
0.0535004484	and ibuprofen
0.0534994037	at three
0.0534976947	concomitantly with
0.0534944435	in improving
0.0534807810	given only
0.0534799602	an eight
0.0534497794	not used
0.0534408538	41 patients
0.0534222268	the disappearance of
0.0534211076	physiologic and
0.0534192121	or near
0.0534142497	the test and
0.0534136074	mean loss of
0.0534114544	at 4 months
0.0534068099	patients after
0.0533952258	the increase with
0.0533624525	with pph
0.0533565133	in vivo by
0.0533505371	and hva
0.0533505371	and neuroradiologic
0.0533505371	and ganaxolone
0.0533434973	estimated for
0.0533343432	studied at
0.0533237217	and serum potassium
0.0533104773	and capsaicin
0.0533104773	the norepinephrine
0.0533080624	or in combination with
0.0533072418	administration during
0.0532927855	staining for
0.0532893832	after 7 days
0.0532880823	side effects from
0.0532437726	in common with
0.0532344679	without impairment of
0.0532244578	no age
0.0532214193	dexmedetomidine and
0.0532157841	in dogs with
0.0532101392	of renal hemodynamics and
0.0532014089	blood pressure during
0.0532010203	of d pen
0.0531850436	the release of
0.0531795088	and small coronary arteries and
0.0531704456	by atropine
0.0531580965	than without
0.0531497589	reported on
0.0531472618	of vitamin e and
0.0531389474	clearance of
0.0531388708	1 week after
0.0531256064	a rapid and
0.0531246937	after diazepam
0.0531229301	the disruption
0.0531078435	the efficacy and toxicity of
0.0530763168	of 3 hydroxy
0.0530665927	trial with
0.0530661331	d after
0.0530644472	a function of
0.0530601051	manifestations of
0.0530576413	per day for
0.0530551601	of phospholipid
0.0530551601	of hypocellular
0.0530520554	for lowering
0.0530496865	on fetal
0.0530298602	several cases of
0.0530004607	the antioxidant
0.0529687445	these agents or
0.0529680920	mean arterial pressure in
0.0529647938	the tolerance
0.0529549662	also present
0.0529487807	the internal
0.0529446847	memory for
0.0529395436	the international
0.0529376388	after dox
0.0529367844	s plasma
0.0529347271	often with
0.0529338860	induced lethality in
0.0529177249	but not saline
0.0529170192	the cost
0.0529133103	the hemodynamic and
0.0529055268	during induction
0.0528839627	necessary in
0.0528821720	a control group of
0.0528817985	hospitalized in
0.0528805541	for comparison
0.0528782812	binding to
0.0528738417	for malignant
0.0528720405	common to
0.0528709688	phenotype and
0.0528706530	the plasma and
0.0528675542	the protection from
0.0528672216	the enhancement of
0.0528620785	anemia in
0.0528614030	the subject
0.0528484565	first day of
0.0528414998	20 +
0.0528312956	an effective and
0.0528285939	a woman with
0.0528171044	of sodium and
0.0528113381	one day after
0.0528064354	altered in
0.0528062521	given either
0.0528055298	renal failure associated with
0.0528028927	three patients with
0.0528012200	the nature of
0.0527982973	responses at
0.0527975284	after hydrocortisone
0.0527891320	a follow up
0.0527838289	in diabetic
0.0527807023	from other
0.0527776230	complications associated with
0.0527747648	in hippocampus and cortex
0.0527738471	sections with
0.0527733490	melatonin on
0.0527530171	one case of
0.0527426716	the pharmacokinetics
0.0527347061	no signs of
0.0527335349	scores for
0.0527162725	probably associated with
0.0527134355	the intensity
0.0527088316	but none
0.0527067045	with tropicamide
0.0526885655	the off
0.0526868902	a female patient with
0.0526845839	120 min after
0.0526806770	inhibition with
0.0526768059	of propranolol and
0.0526706473	after prolonged use
0.0526681033	on inhaled
0.0526681033	on psychological
0.0526450202	these doses of
0.0526447235	different among
0.0526171408	or isoflurane
0.0526171044	the number and
0.0526036842	the upper and lower
0.0526033100	needed in
0.0525995298	after map
0.0525913566	to allow
0.0525865409	hypothesized to
0.0525844664	formation in
0.0525837993	not other
0.0525720753	a disulfiram
0.0525709001	a synthetic
0.0525634640	caution for
0.0525613535	5 fluorouracil and
0.0525578086	intervals after
0.0525525755	after commencement of
0.0525306206	exhibited by
0.0525042919	leukemia after
0.0524918455	but not all
0.0524701331	and tnfalpha
0.0524694415	attention to
0.0524664118	syndrome from
0.0524655909	production in
0.0524641156	of d penicillamine treatment
0.0524559585	recovered after
0.0524530001	sub effective doses of ketamine and
0.0524459869	or diltiazem
0.0524390529	compliance to
0.0524388118	the serum concentrations of
0.0524270767	described by
0.0524199700	a physiological
0.0524165401	cells from
0.0524067856	techniques with
0.0524030479	none in
0.0523940891	the base
0.0523861203	delirium or
0.0523795650	a longer
0.0523741725	noted on
0.0523723772	of three women
0.0523633208	a statistically
0.0523617851	established in
0.0523559529	62 patients
0.0523558562	the findings of
0.0523497580	the cardioprotective effect of
0.0523487792	other cases
0.0523478200	of levodopa treatment and
0.0523436676	memory in
0.0523357633	in most patients with
0.0523266348	48 patients
0.0523240290	on adriamycin
0.0523188825	the maintenance of
0.0523156289	changes from
0.0523104773	the untreated
0.0523104773	and carboplatin
0.0523072415	the risks
0.0522928223	a diagnosis of
0.0522837711	the urinary bladder and
0.0522782893	17 patients
0.0522774769	degrees of
0.0522721469	distributed in
0.0522641340	lid and
0.0522612300	this model of
0.0522601694	between 15 and
0.0522507441	1 month after
0.0522445623	available to
0.0522430513	and pathological findings
0.0522191471	1 mg day
0.0522118800	10 days of
0.0522064142	after cocaine use
0.0522025025	an alpha
0.0522014089	blood pressure from
0.0522005730	incidence and severity and
0.0521973925	to salt
0.0521923581	2 g
0.0521888515	died in
0.0521845234	28 patients
0.0521831782	for recurrent
0.0521811208	depressed in
0.0521803651	hyperkalemia and
0.0521776898	to december
0.0521652174	interval of
0.0521612069	conversion from
0.0521583736	in mice after
0.0521377270	a commonly used
0.0521307416	an isolated
0.0521153963	a decline in
0.0521074946	the cingulate
0.0521043369	the synergistic
0.0520996215	the final 2
0.0520869258	on memory
0.0520862480	but not significantly
0.0520739710	associated with cocaine use
0.0520705844	6 hours after
0.0520679395	with unexplained
0.0520562538	the first 24 h
0.0520484588	without chronic
0.0520300712	6 vs
0.0520268987	an adult
0.0519999358	loss in
0.0519891878	syndrome with
0.0519522605	by genetic
0.0519519325	the same animals
0.0519515139	an excess
0.0519368149	36 patients
0.0519337090	for determination of
0.0518905796	treated on
0.0518849725	during surgery
0.0518748905	to four groups
0.0518711672	more frequent in
0.0518704414	of ten
0.0518640967	also seen in
0.0518498679	a stronger
0.0518497793	a median age of
0.0518494864	the order
0.0518422133	the different
0.0518300981	and amisulpride
0.0518170091	the studies of left ventricular dysfunction
0.0518089527	history of hypertension and
0.0518012642	following pilocarpine
0.0517954827	prophylaxis with
0.0517813671	the improvements in
0.0517796138	the early phase of
0.0517790995	eight patients with
0.0517731505	dexmedetomidine as
0.0517680360	the increases in
0.0517658595	hypertension in patients with
0.0517624223	a food
0.0517523512	a whole
0.0517474211	35 +
0.0517449558	14 patients with
0.0517418045	system or
0.0517371027	the electrophysiologic
0.0517237150	50 mg kg for
0.0517181698	anemia after
0.0517134728	and duration of
0.0517097108	higher than after
0.0516867170	the residual
0.0516826393	with zonisamide
0.0516774001	effective for
0.0516672505	after injection of
0.0516533161	and ototoxicity
0.0516532094	of estrogen
0.0516532094	of captopril
0.0516393832	after 6 weeks
0.0516371546	to 120 mg
0.0516349725	an increasing
0.0516292992	a phenomenon
0.0516225743	the carcinogen
0.0516213854	hospital for
0.0516209522	after atropine
0.0516177314	by directly
0.0516164953	as shown by
0.0516159069	chronic use of
0.0516139054	stable for
0.0515848428	by insulin
0.0515740686	a complete recovery of
0.0515674111	obtained using
0.0515427950	the rcts
0.0515158171	the platelet
0.0515130339	lower with
0.0515085548	in many tissues
0.0514967831	step in
0.0514904925	with reductions in
0.0514678202	exposure during
0.0514677581	for prophylaxis
0.0514653871	deficiency in
0.0514527933	the serum of
0.0514492337	of choice for
0.0514406450	seen at
0.0514342473	in patients without
0.0514270740	in rodents and
0.0514194593	in alleviating
0.0514194593	in distinguishing
0.0514194593	in agriculture
0.0514146060	mainly related to
0.0513903476	the operating
0.0513800778	or tamoxifen
0.0513708748	and pirenzepine
0.0513672515	the explanation
0.0513533453	or 60 min after
0.0513427211	higher for
0.0513221261	analyzed in
0.0513170820	subunit of
0.0513105020	the last follow up
0.0513040681	no different
0.0512884523	after rizatriptan
0.0512783590	5 d of
0.0512720753	with ibuprofen
0.0512662300	an infant
0.0512633173	an altered
0.0512585871	to ameliorate
0.0512511016	from acetaminophen
0.0512453039	the cbd
0.0512414863	with nelarabine
0.0512390139	the papillary
0.0512379011	and seemed to
0.0512359712	associated with vigabatrin
0.0512322597	and elevated plus maze
0.0512228136	1995 and
0.0512187000	dysfunction after
0.0512137940	a relative risk
0.0512079742	the differential
0.0511994317	the nephrotoxic
0.0511860669	the li
0.0511631338	and drug abuse
0.0511591709	associated with fewer
0.0511577961	the procedure at
0.0511529147	as well as cardiac
0.0511520328	for autoantibodies
0.0511431246	a defect in
0.0511343105	clinic with
0.0511307707	treated patients with
0.0511295941	in vitro using
0.0511178276	stable or
0.0511075205	this mechanism
0.0511054955	the long term use of
0.0511049104	among women on
0.0510991631	inhibition on
0.0510918709	or duration
0.0510901906	to protect against
0.0510608705	by pentobarbital
0.0510593330	the amnesia induced by
0.0510572463	dose for
0.0510243133	recorded on
0.0510163246	every other day for
0.0510153674	during periods of
0.0510130098	an anti
0.0509941409	a placebo and
0.0509916137	found during
0.0509892533	rats compared to
0.0509878175	a higher dose of
0.0509847498	and vitamin d
0.0509756933	a fixed dose
0.0509751313	after beginning
0.0509746244	associated with increases in
0.0509746055	analgesic and
0.0509697237	the subjects with
0.0509637755	managed with
0.0509541093	scan of
0.0509354535	this low
0.0509337428	erythropoietin in
0.0509336449	the locomotor
0.0509219838	greater for
0.0509216558	this series
0.0509174283	administered on
0.0509053807	an experimental
0.0508989710	the length of
0.0508777924	in order to evaluate
0.0508482186	dexamethasone for
0.0508442641	61 +
0.0508424064	after conversion to
0.0508382740	16 patients with
0.0508350513	the media
0.0508119929	in warfarin users with
0.0508084521	pain after
0.0508031785	assay in
0.0507763864	the outcomes
0.0507703295	of rats in
0.0507642582	to september
0.0507580413	triglycerides and
0.0507580413	cataract and
0.0507364503	the event of
0.0507364503	the finding of
0.0507299814	for hemorrhage
0.0507283531	pretreatment on
0.0507223404	support for
0.0507186369	other symptoms of
0.0507092367	hyperalgesia and
0.0507089301	dosed to
0.0507050991	treatments for
0.0506931881	the physiological
0.0506931687	and intramuscularly
0.0506868902	a high prevalence of
0.0506813488	with caution
0.0506813488	with metformin
0.0506776558	not related to
0.0506761283	in inhibiting
0.0506730394	of erythrocytes
0.0506709059	in 24 patients with
0.0506548376	of fluconazole and
0.0506513545	from 100 to
0.0506405073	the qrs
0.0506405073	the haemolytic
0.0506384486	if not
0.0506333995	51 patients
0.0506171351	the transformation
0.0506170650	the deficit
0.0506117158	those seen in
0.0506100784	in chinese
0.0505991631	conditions for
0.0505840160	analogues of
0.0505840160	assessments of
0.0505787805	the hepatocytes
0.0505728640	the mean duration of therapy with
0.0505707719	no such
0.0505551192	the hemolytic
0.0505539810	of castrated and noncastrated
0.0505387419	of sorafenib
0.0505387419	of dilevalol
0.0505270457	selective for
0.0505244283	during experimental
0.0505219672	the mitral
0.0505130339	male with
0.0504905083	and paroxetine
0.0504871862	implications of
0.0504710898	a totally
0.0504710898	a true
0.0504710898	a striking
0.0504606941	at less than
0.0504537407	an adjusted
0.0504452959	of experimentally induced
0.0504326691	elevated by
0.0504271649	treated with one
0.0504251753	nine patients with
0.0504182257	the locus
0.0504146767	performed during
0.0503977805	in excess of
0.0503861550	and hence
0.0503825102	kg i
0.0503801021	the pattern
0.0503785467	a difference in
0.0503707147	velocity of
0.0503693284	those injected with
0.0503606265	the procoagulant
0.0503443803	sepsis and
0.0503416097	the mechanisms by
0.0503366935	rats compared with
0.0503240290	for infection
0.0503218791	not receiving
0.0503218791	2 min
0.0503191436	consolidation of
0.0502946764	the range
0.0502940409	further studies on
0.0502894727	in 1 patient with
0.0502878587	in presence of
0.0502860219	on blood pressure and
0.0502774769	metabolite of
0.0502773166	four patients with
0.0502688315	site for
0.0502583559	in prevention of
0.0502567307	morphine but
0.0502439801	of patients treated with
0.0502364503	the pituitary of
0.0502285555	and atenolol
0.0502186316	by amphetamine
0.0502176021	the superoxide
0.0502176021	the cerebellar
0.0502013296	thickness in
0.0502004204	intravenously during
0.0501953313	associated with longer
0.0501915041	recommended to
0.0501860669	the hilar
0.0501860669	the replication
0.0501769658	benztropine in
0.0501769658	bdl and
0.0501755708	and neuroinflammatory
0.0501694412	the beneficial effects
0.0501601460	for preventing
0.0501561507	of 24 hour
0.0501494262	the predominant
0.0501311550	the co administration of
0.0501291988	the gum
0.0501226720	for advanced
0.0501198360	during isoflurane induced hypotension in
0.0501183449	generation of
0.0500951208	after pilocarpine
0.0500909280	from local
0.0500886252	the dominant
0.0500823423	the central nervous system and
0.0500537748	fasciculations in
0.0500409267	no cases
0.0500326995	the light
0.0500238099	of hospitalization for ami
0.0500206173	and 6 months after
0.0500144867	of blood pressure during
0.0500090684	support to
0.0499871670	a study of
0.0499690933	infusion at
0.0499525486	the patient described
0.0499497893	the basic
0.0499475254	a third
0.0499458293	the age of
0.0499456189	anticoagulation with
0.0499394059	cytotoxicity in
0.0499392397	the utility of
0.0499320027	one group
0.0499295909	the stn
0.0499124960	the development of tolerance to
0.0499059687	other studies
0.0499055161	those induced by
0.0499030344	s action
0.0498894722	and management of
0.0498831620	the narrow
0.0498773123	placebo on
0.0498772543	the co administration
0.0498462130	with good
0.0498424618	the antihypertensive
0.0498157889	the mechanisms for
0.0498147888	the infusions
0.0498138619	the most commonly
0.0498075536	of denopamine
0.0498025620	cells treated with
0.0498009977	the data of
0.0497999370	elevations of
0.0497965823	and csf
0.0497891779	usually associated with
0.0497832255	probably as
0.0497799440	a ten
0.0497760920	estimated in
0.0497704456	by reducing
0.0497624223	a permanent
0.0497454361	in tr
0.0497427141	probably caused by
0.0497382986	phenotype of
0.0497335349	testing for
0.0497288720	250 and
0.0497176643	the kidneys of
0.0497136257	fraction of
0.0497087079	68 and
0.0497031716	the biochemical and
0.0496903706	in belgium
0.0496872840	and 30 min after
0.0496829249	and distribution of
0.0496810879	employed to
0.0496738070	arrest associated with
0.0496699129	3 weeks after
0.0496531348	after intravenous administration of
0.0496514471	the head and neck
0.0496503420	in half of
0.0496480658	in recreational
0.0496378359	not mediated by
0.0496268794	while using
0.0496208177	and cognition
0.0496192898	in vivo injection of
0.0496168709	a highly
0.0495959422	associated with topical
0.0495609730	in aminotransferase levels
0.0495350145	85 patients
0.0495286480	a need for
0.0495277452	the latency
0.0495096015	performed by
0.0495009652	capsaicin in
0.0494969852	and fibrosis
0.0494870785	events in
0.0494841943	injection for
0.0494713345	done on
0.0494676643	the cases with
0.0494664825	arrhythmias in
0.0494450392	the proper
0.0494442129	speed and
0.0494393847	other possible
0.0494390036	1 min
0.0494372938	the synergy between
0.0494368966	allopregnanolone and
0.0494253475	a proven
0.0494203627	before surgery and
0.0494170192	the etoricoxib
0.0494146767	hypertension during
0.0494049146	time from
0.0493999752	female with
0.0493948880	function as
0.0493937285	and third
0.0493937285	novel and
0.0493802944	of indinavir
0.0493726963	different doses of
0.0493650901	in rats using
0.0493461012	and d4
0.0493428426	the challenge
0.0493284298	even for
0.0493239721	umb24 and
0.0493239721	perception and
0.0493110727	with history of
0.0493086741	or ecstasy
0.0493079929	demonstrated after
0.0492947479	the enzymes
0.0492918011	this study aimed to
0.0492894561	children treated with
0.0492703985	and concentration dependent
0.0492700508	and diastolic dysfunction
0.0492683747	with intermittent
0.0492658712	sensitive and
0.0492638637	not sufficient to
0.0492546261	12 weeks after
0.0492543166	an abnormal
0.0492458293	the diameter of
0.0492394146	ratings of
0.0492383924	component of
0.0492217790	arteriolar and
0.0492084733	quetiapine in
0.0492084733	disappeared in
0.0491884441	injections for
0.0491854730	with standard doses of
0.0491848840	these behavioral
0.0491770010	neuropathy in
0.0491450750	determination of
0.0491450109	session of
0.0491432174	6 week
0.0491034300	well tolerated by
0.0490905830	4 weeks of
0.0490823254	and nf
0.0490641979	a gamma
0.0490641979	a cumulative
0.0490611051	no serious
0.0490233841	to attenuate
0.0490188126	role for
0.0490054822	an impaired
0.0490053841	the muscimol
0.0489985334	with valproate
0.0489907083	one patient in
0.0489907083	of treatment for
0.0489676230	and levofloxacin
0.0489667849	thalidomide for
0.0489592420	platform in
0.0489459667	after liver transplantation and
0.0489456189	monkeys with
0.0489308766	jaundice with
0.0489303414	slowing of
0.0489303414	source of
0.0489303414	isomer of
0.0489216394	smokers with
0.0489215097	after multiple
0.0489213449	after caffeine
0.0489166233	with lung
0.0489154582	6 months after
0.0489106805	and greatly
0.0489059687	30 days
0.0488937136	and lidocaine on
0.0488851343	1.5 to
0.0488826671	administered during
0.0488811842	due to inhibition of
0.0488744332	channels in
0.0488709642	in combination with cnsb002
0.0488544362	the absolute risk
0.0488497423	and iohexol
0.0488382740	13 patients with
0.0488299989	both indomethacin
0.0488276217	the simultaneous
0.0488169874	4 years
0.0488133008	with etoricoxib
0.0488013110	with netilmicin
0.0487999370	interpretation of
0.0487999370	instillation of
0.0487942415	waves and
0.0487917889	changes produced by
0.0487760920	unchanged in
0.0487735036	of 0.5 mg dl
0.0487681582	3 min after
0.0487643215	any effect
0.0487643215	one rat
0.0487435916	one hour or
0.0487421472	lidocaine or
0.0487316715	negative for
0.0487219575	for control of
0.0487203737	solution of
0.0487166037	length of
0.0487166037	hyperplasia of
0.0487146822	a reversal
0.0487136250	the inclusion criteria for
0.0487111538	more severe in
0.0487093371	a repeat
0.0487059654	signals in
0.0487014560	available on
0.0486931881	the newborn
0.0486753734	affinity of
0.0486713449	this toxic
0.0486713449	by monitoring
0.0486667940	exposures to
0.0486653667	for severity of
0.0486643288	and shorter
0.0486594316	in lnna
0.0486173187	indicated for
0.0486172831	by pilocarpine
0.0486171751	the aetiology of
0.0486162264	also found
0.0486136411	a role of
0.0486109600	a biphasic
0.0485987245	applied by
0.0485957566	specificity of
0.0485894466	the vessel
0.0485812057	9 weeks of
0.0485785555	and conversely
0.0485714937	3 mmhg
0.0485604301	the extension
0.0485511120	occurred only in
0.0485464380	and ca o
0.0485405985	also significantly
0.0485287321	the cardiovascular and
0.0485273428	co administration of
0.0485219672	the sinoatrial
0.0485219672	the japanese
0.0485174216	assays of
0.0485015036	after heparin
0.0484971009	the emergency department at
0.0484842182	the temporal
0.0484804926	alteration in
0.0484780985	4 cases
0.0484757362	the platform
0.0484679374	the urinary bladder
0.0484633801	a patient on
0.0484543854	a real
0.0484476744	the increased risk of
0.0484447061	in fluctuating
0.0484380790	made by
0.0484367175	and aged mice
0.0484327983	but returned to
0.0484260405	of oxidative stress and
0.0484198884	the protective activity of loreclezole and
0.0483866270	and paracetamol in
0.0483853343	lidocaine in
0.0483790799	the dgc and
0.0483790107	and trough
0.0483733998	delivered in
0.0483619317	and tolerability
0.0483617681	of triazolam
0.0483588687	the benefit
0.0483495915	and normalization of
0.0483489129	reported for
0.0483431291	and other organs
0.0483428426	the opioid
0.0483416097	the commencement of
0.0483339171	after pretreatment with
0.0483240290	for prolactin
0.0483213449	at therapeutic
0.0483174217	the naranjo
0.0483110727	with infusion of
0.0483101770	the data show
0.0483043724	naloxone on
0.0482990154	the absence
0.0482937285	available in
0.0482898075	in higher doses in young children
0.0482684676	done to
0.0482662531	on anxiety
0.0482566118	diazepam or
0.0482275734	with cinacalcet
0.0482275734	with platinum
0.0482248002	effects by
0.0482245118	a step
0.0482106242	4 weeks in
0.0482087907	the neonate
0.0482034926	placebo for
0.0481965064	in face
0.0481872000	s disease after
0.0481854335	by electrical
0.0481776073	with vancomycin
0.0481758371	of cytosine
0.0481713449	by scopolamine
0.0481654395	2 cases of
0.0481630643	mutation in
0.0481559598	to explain
0.0481525271	in no deficient rats
0.0481524809	treated from
0.0481356117	a full
0.0481338308	and cyclophosphamide in
0.0481271047	the subjective
0.0481152093	and pulmonary hypertension in
0.0480823254	the cows
0.0480790799	the cpu and
0.0480790799	and detachment of
0.0480695678	the second case of
0.0480695678	of 13 patients with
0.0480633850	started with
0.0480296581	ct and
0.0480292585	prognosis in
0.0480196378	especially at
0.0480145291	the enalapril
0.0480092664	the emergency room with
0.0479930128	for breast cancer in
0.0479909693	1994 to
0.0479732186	tested on
0.0479731608	patient did not
0.0479650902	the recommended dose of
0.0479561299	6 mg day
0.0479333178	in carriers of
0.0479072786	of rats treated with
0.0478998377	morning of
0.0478954116	the results indicated
0.0478900974	the pattern of
0.0478674163	shift of
0.0478673832	the pressor effect of
0.0478669874	s symptoms
0.0478516882	an incidence of
0.0478515068	to better
0.0478452925	and increased levels of
0.0478382740	most patients with
0.0478290607	investigated by
0.0478038218	the threshold for
0.0477996759	the potency of
0.0477992377	failure with
0.0477929780	a benign
0.0477919084	matched to
0.0477896309	oih in
0.0477872419	the allele
0.0477835004	the sole
0.0477835004	the likelihood
0.0477730388	mainly of
0.0477682518	the hippocampus following
0.0477641187	on cyclosporine
0.0477582703	impact of
0.0477568600	to form
0.0477513656	discovered in
0.0477486046	completely after
0.0477421472	ketamine or
0.0477250524	1 year after
0.0477250524	after 1 year
0.0477191859	structures of
0.0477168709	with topical
0.0476994981	populations of
0.0476992122	with enalapril
0.0476918698	the behavioral effects of
0.0476904375	of bortezomib
0.0476543709	with methadone
0.0476469035	after initiation of
0.0476433164	a basic
0.0476350500	angiography after
0.0476325448	during ischemia
0.0475912214	the impairment of
0.0475864932	in slices from
0.0475840104	in comparison
0.0475702251	class of
0.0475575974	55 +
0.0475333236	with grade 3
0.0475277452	the head
0.0475213032	period after
0.0475200759	of amphotericin b
0.0475149637	in surviving
0.0475112112	also able to
0.0474911311	the co
0.0474780985	those treated
0.0474748518	for prevention
0.0474738836	a relationship
0.0474708378	the literature as
0.0474698613	and 60 min after
0.0474681524	s disease +
0.0474546544	the diagnosis before
0.0474422021	and intervention
0.0474376751	and tonic
0.0474344388	after induction of
0.0474340467	the same dose of
0.0474290184	in subjects treated with
0.0474233082	beginning on
0.0474187220	events following
0.0474182257	the gastrocnemius
0.0474140668	and caspase 3
0.0474065869	metabolism by
0.0474048089	the experimental model of
0.0473957903	elicited in
0.0473760038	a histamine
0.0473719230	relapse of
0.0473669874	into rats
0.0473457138	three times in
0.0473333195	of patients from
0.0473318550	repeated on
0.0473173302	the superior
0.0473136354	the adverse effects of
0.0473118889	and gemcitabine
0.0473055859	more often with
0.0473005697	50 incidence of
0.0472937713	and isoflurane
0.0472929709	and nine
0.0472759488	bed and
0.0472684676	57 to
0.0472555407	arthralgia and
0.0472527048	described as
0.0472492433	and resolution of
0.0472362971	and predictors of
0.0472293176	also used for
0.0472285591	in platinum
0.0472285591	in macrophages
0.0472262017	for tuberculosis
0.0472259511	2009 and
0.0472196369	as well
0.0472080868	applied in
0.0471997698	the morphological changes
0.0471837713	prominent in
0.0471795597	these well
0.0471791832	a possible involvement of
0.0471753937	and death in
0.0471672476	not detected in
0.0471608402	a change in
0.0471531957	syndromes in
0.0471478780	for quality
0.0471395749	a special
0.0471393013	database of
0.0471337463	both cell
0.0471274159	of reperfusion
0.0471271047	the contralateral
0.0471271047	and sudden
0.0471034926	concentration for
0.0470952443	a broad
0.0470952443	a trigger
0.0470869805	in 21 patients with
0.0470858162	evident at
0.0470853935	a treatment for
0.0470784499	as markers
0.0470767308	both growth
0.0470767308	from observations
0.0470767308	from general
0.0470750390	the dark
0.0470615793	later developed
0.0470473192	in neurons and astrocytes
0.0470435183	from baseline to
0.0470365049	the distribution of
0.0470339181	the caudate
0.0470279047	the pathogenic
0.0470172538	all children
0.0470022947	tendency of
0.0470022947	adenocarcinoma of
0.0469995487	at onset
0.0469890392	associated with persistent
0.0469840900	the plasma levels of
0.0469805274	and placebo for
0.0469751170	of hypertension and
0.0469367456	due to activation of
0.0469242876	the hippocampus of
0.0469154658	a comparison
0.0469131356	at different
0.0469090829	repair of
0.0469069725	also resulted in
0.0469048428	complication after
0.0468998377	centre of
0.0468900974	the production of
0.0468660077	of facial
0.0468346799	to inhibit
0.0468271258	s effects on
0.0468200052	on local
0.0468119384	between three
0.0467983009	after intrathecal
0.0467870956	twice daily for
0.0467673960	years after
0.0467655796	administration for
0.0467612023	the area under
0.0467582703	recognition of
0.0467309384	to predict
0.0467228179	the tibialis
0.0467208482	in models of
0.0467142865	patients become
0.0467134362	and superoxide
0.0466937687	a detailed
0.0466902452	the atypical
0.0466902452	the perfusion
0.0466827763	during infusion of
0.0466825718	and extension
0.0466784499	from altered
0.0466711921	and tolerability of
0.0466670631	of venlafaxine
0.0466545310	the sympathetic
0.0466537576	with levofloxacin
0.0466508421	moderate to
0.0466507814	the anaemia
0.0466315163	bromocriptine for
0.0466229200	teams and
0.0465989750	the hh
0.0465989750	the hem
0.0465945487	to correct
0.0465905681	recurrence after
0.0465726281	at concentrations of
0.0465712501	in otherwise
0.0465659772	for future
0.0465627376	and 900 mg kg
0.0465548086	morbidity and mortality of
0.0465340499	a short period of
0.0465277452	the bile
0.0465265080	training on
0.0465244323	the synthesis of
0.0465224379	with pericarditis
0.0465221143	the beta4
0.0465180338	overdose of
0.0465035505	stimulation on
0.0464900216	n n =
0.0464824560	at lower
0.0464573800	in control and
0.0464551042	an inflammatory
0.0464467269	the tendency
0.0464467269	the exencephaly
0.0464422021	and chronically
0.0464361262	present with
0.0464322463	administration on
0.0464214958	changes induced by
0.0464182598	with halothane
0.0464182257	the passage
0.0464123440	achieved with
0.0463937651	hearts of
0.0463715365	mutations in
0.0463696920	cause seizures
0.0463672216	the manifestation of
0.0463605991	options in
0.0463478060	with signs of
0.0463451728	shortening of
0.0463388364	mmhg to
0.0463344114	a chronic hepatitis c
0.0463282533	a fall
0.0463273829	the epicardial
0.0463273829	the catheterization
0.0463138607	a relationship to
0.0463099831	a sudden
0.0463051043	by oral administration of
0.0462940317	and aldosterone
0.0462901396	in f344 rats
0.0462790602	occurring in
0.0462641187	on thalidomide
0.0462548302	and glutathione
0.0462441100	and stomatitis
0.0462304804	time course of
0.0462260670	well tolerated at
0.0462245118	a worsening
0.0462206625	the control value
0.0462202986	and theoretical
0.0462202986	and ataxia
0.0462079621	the na k
0.0462073255	eosinophilia and
0.0461973216	reverse or
0.0461758371	of antimicrobial
0.0461699325	in order
0.0461648539	but does
0.0461574233	this prospective
0.0461430818	a significant increase of
0.0461274829	curve at
0.0461239698	14 days of
0.0461052965	to exhibit
0.0461045614	and electrophysiological
0.0460763888	an electrocardiogram
0.0460611162	both anti
0.0460368434	score of
0.0460361006	of progesterone
0.0460333027	given alone and
0.0459860382	11 +
0.0459828612	ptz and
0.0459790995	some patients with
0.0459790995	10 patients with
0.0459776522	strain of
0.0459650902	the haemodynamic effects of
0.0459618170	of endometrial
0.0459537858	or pulmonary
0.0459429099	the last dose of
0.0459428157	content and
0.0459422021	the hearts
0.0459403404	those animals
0.0459390878	of chemotherapy with
0.0459242876	the kidney of
0.0459179737	these three
0.0459153808	structure and
0.0459151561	the seriousness of
0.0459133008	a competitive
0.0459119002	the cataleptic
0.0459119002	the diaphragm
0.0459031957	crocin in
0.0459031957	equally in
0.0458737019	and eosinophilia
0.0458737019	and electrolyte
0.0458726160	3 days of
0.0458454572	a comparative
0.0458432777	and eventually
0.0458386429	1 h after
0.0458278947	with increases in
0.0458081701	for factors associated with
0.0458078258	and minimum
0.0458016708	with classical
0.0457952019	without seizures
0.0457800427	a phase ii study of
0.0457462329	after treatment for
0.0457458568	with omeprazole
0.0457395041	thrombosis at
0.0457353787	with gradual
0.0457333495	or metabolism
0.0457317281	both eyes with
0.0457269867	12.5 and
0.0457251978	kinases and
0.0457238123	the study because of
0.0457224379	or des
0.0457154299	a daily dose of
0.0457123818	0.57 to
0.0456801764	mean =
0.0456799814	on tumor
0.0456785259	a similar increase in
0.0456784499	no clinically
0.0456688507	the lymphocytes
0.0456635345	and october
0.0456630937	from 1 year
0.0456630406	as treatment for
0.0456616961	of pinprick
0.0456583187	the incidence or
0.0456507814	the intrarenal
0.0456395749	a final
0.0456307119	16 +
0.0456298909	the signs and symptoms of
0.0455882690	impairment in
0.0455688507	the benzodiazepine
0.0455658761	the most frequent cause of
0.0455456187	a patient treated with
0.0455308753	the patient nor
0.0455215423	42 +
0.0455116168	without effect
0.0454983768	a return of
0.0454942343	the susceptibility to
0.0454866015	the hilus of
0.0454695823	at sites
0.0454568233	probably induced
0.0454518079	no statistically significant differences in
0.0454391982	the stage of
0.0454244862	a mean follow up
0.0454172505	an inhibition of
0.0454093348	or treatment of
0.0453821519	a model to
0.0453821519	or severity of
0.0453821519	before treatment to
0.0453730484	mean arterial pressure of
0.0453723762	the pathophysiologic
0.0453723762	the fda
0.0453719230	changed in
0.0453689606	a retrospective study of
0.0453653674	another group of
0.0453556217	after ingestion
0.0453520654	for studies on
0.0453479258	to become
0.0453397124	the exact
0.0453369619	or absence of
0.0453037822	metoprolol or
0.0452997291	4 patients in
0.0452949233	by 24 h
0.0452809946	for 6 weeks and
0.0452763015	during continuous
0.0452684664	but few
0.0452580092	the epidemiology of
0.0452532340	effects through
0.0452424155	the cholinergic system
0.0452366102	the alteration in
0.0452271047	and partially
0.0451917308	the pre and
0.0451878574	and amitriptyline
0.0451738035	by alfentanil
0.0451598311	after eight
0.0451509877	during sodium
0.0451377156	before surgery and on
0.0451337463	but evidence
0.0451211354	in group c
0.0451034926	potential for
0.0450865106	in rabbits
0.0450759058	thrombocytopenia with
0.0450634441	score for
0.0450471693	also shown
0.0450432598	with diffuse
0.0450410074	both selective
0.0450400221	and parathyroid
0.0450339181	the cytostatic
0.0450304305	for at least one
0.0450285259	the differential effects of
0.0450283441	controlled with
0.0450275992	at 48 h
0.0450225513	the ca1
0.0450178465	and retained
0.0450178465	and hypomagnesemia
0.0450178465	and dyspnea
0.0450019517	the proportion
0.0449929715	during fluoxetine
0.0449916072	side effects after
0.0449833495	or untreated
0.0449828612	prilocaine and
0.0449812452	for four weeks
0.0449743248	not consistent with
0.0449738916	with antineoplastic
0.0449667091	and cold
0.0449637944	in rats treated with
0.0449554822	an adriamycin
0.0449432598	a busulfan
0.0449431674	the emergency department with
0.0449422021	the routine
0.0449384121	through changes in
0.0449129428	of visual function in
0.0448860593	motility and
0.0448837215	catecholamines and
0.0448774868	a remarkably
0.0448751078	at risk of
0.0448571636	the frequency and severity of
0.0448308685	utility in
0.0448308685	proportion in
0.0448146822	with etomidate
0.0448130141	the widespread use of
0.0448032310	61 and
0.0447863818	used with caution in
0.0447664144	the intervention
0.0447642659	for patients treated with
0.0447560070	because toxicity
0.0447467805	the pressor
0.0447450202	an effect on
0.0447438273	status of
0.0447428921	irritability and
0.0447388070	30 s
0.0447271794	8 h
0.0447110503	10 g
0.0447063555	and severity of
0.0447031716	the interaction of
0.0446944136	tissues from
0.0446918698	the catalepsy induced by
0.0446846905	with diclofenac
0.0446676056	after start of
0.0446513042	and therefore
0.0446406274	transformation of
0.0446211356	necrosis at
0.0446163029	associated with nitric oxide
0.0446130629	the minimum
0.0446023749	82 patients
0.0445833133	the risks of
0.0445804989	on argatroban
0.0445554822	by fentanyl
0.0445463687	and hypothermia
0.0445324053	from previous
0.0445078392	in normotensive and
0.0445042560	with iopamidol
0.0444964190	with hydrocortisone
0.0444964190	with pergolide
0.0444960393	the outflow
0.0444956667	associated with proteinuria and
0.0444793728	risk associated with
0.0444601586	absorption of
0.0444551042	an evaluation
0.0444549406	attenuated after
0.0444445994	in parkinsonian patients with
0.0444353172	for cocaine or
0.0444326188	this patient also
0.0444215429	8 cases
0.0444115532	of loreclezole
0.0444072153	23 +
0.0444004338	1 hr
0.0443997242	the training session of
0.0443961694	convulsions in
0.0443878650	an early and
0.0443866270	the food and
0.0443839892	undertaken in
0.0443832837	achieved in
0.0443804989	on dialysis
0.0443804989	on isoniazid
0.0443719230	efficacious in
0.0443715365	pathology in
0.0443415756	a concentration of
0.0443351900	and galactosamine
0.0443308685	modulation in
0.0443249216	not usually
0.0443158184	1 patient with
0.0443075515	not noted
0.0443032310	the best
0.0442947702	60 min after
0.0442931263	and deferoxamine
0.0442900077	with cocaine associated
0.0442897634	with saline or
0.0442829954	the restoration of
0.0442826770	difficulty in
0.0442819744	the interaction between
0.0442754655	for 24 hours
0.0442731882	ventilation and
0.0442728661	of platelets
0.0442575278	24 hours after
0.0442454853	and leucovorin
0.0442370508	between two
0.0442141445	suggested for
0.0442141445	specific for
0.0441954018	neurocognitive and
0.0441927202	reliability of
0.0441726351	power to
0.0441506771	in metastatic
0.0441441037	in men and
0.0441408194	the incidences of
0.0441387235	cystitis in
0.0441198049	pretreatment for
0.0441107521	the subcutaneous administration of
0.0440939193	the periphery of
0.0440794659	of alkylxanthines
0.0440794659	of menopause
0.0440732860	an action
0.0440732860	by echocardiography
0.0440641187	for vte
0.0440387235	resistance and
0.0440255855	also seen
0.0440156047	syndrome associated with
0.0439988236	alone decreased
0.0439976661	37 patients with
0.0439968791	2 expression
0.0439892649	on dobutamine
0.0439661646	up regulation of
0.0439617985	the results also
0.0439557098	with preexisting
0.0439557098	with classic
0.0439465077	not correlated with
0.0439277393	with decreases in
0.0439272457	with proven
0.0439271452	most commonly in
0.0439249070	also occurred in
0.0439155540	the etiology of
0.0439131137	of myocardial damage in
0.0439123841	stable during
0.0438766041	unchanged after
0.0438681183	need for
0.0438582019	by sex
0.0438438868	year old boy with
0.0438287765	kanamycin and
0.0438215429	8 days
0.0438215429	without significant
0.0438090703	for treating
0.0438081165	5 children
0.0437717791	observed as
0.0437666553	the messenger
0.0437666553	the adaptive
0.0437666553	the adjunctive
0.0437577005	the renal cortex and
0.0437445287	this class of
0.0437345285	and seventh
0.0437162229	marker of
0.0436939673	s effect on
0.0436779494	collected in
0.0436778510	the subjects treated with
0.0436775310	on renal function in
0.0436748005	and usually
0.0436737611	function than
0.0436670345	the qt interval in
0.0436512304	any clinical
0.0436406274	abilities of
0.0436293854	the neck
0.0436158592	and self
0.0436089907	diet or
0.0436075246	and six months after
0.0435815653	increased only
0.0435806284	after angiography
0.0435799028	bupropion as
0.0435664005	ratios of
0.0435655006	the bmc
0.0435643940	and 3 days later
0.0435629131	5 mg kg per day
0.0435393737	carefully for
0.0435213475	in relationship to
0.0434900441	in 16 patients with
0.0434867643	4 days after
0.0434553536	and tonic pain
0.0434463687	and dizziness
0.0434458836	the therapeutic potential of
0.0434378361	improved in
0.0434273829	the bha
0.0434006079	rats given
0.0433868287	retention on
0.0433747478	the predictive
0.0433307716	and functionally
0.0433307716	and hyperlipidemia
0.0433307716	and pathologically
0.0433269678	alternative to
0.0433236931	no cases of
0.0433190258	benefits of
0.0433190258	alteration of
0.0433141657	of 200 mg m2
0.0433075515	not required
0.0433054822	an improvement
0.0432948561	toxicity after
0.0432821343	infection in
0.0432817071	6 days after
0.0432805765	of metolachlor use
0.0432679344	after induction
0.0432657038	with histologically
0.0432644398	teratogenic in
0.0432636367	the cardiotoxic
0.0432584503	to lack of
0.0432343464	not completely
0.0432289490	discontinuation in
0.0432141445	considered for
0.0432141445	medication for
0.0432136802	the semi
0.0432135605	occurs during
0.0432120604	or reflex
0.0432015268	after adequate
0.0431918659	trigger of
0.0431821343	confirmed in
0.0431651092	the usual
0.0431579926	and determination of
0.0431495970	on measures
0.0431436558	values for
0.0431418722	a shorter
0.0431357168	survival from
0.0431353454	a group of patients with
0.0431348984	of abs
0.0431348984	of normotension
0.0431311770	the list of
0.0431293940	a medline
0.0431253052	of procainamide
0.0431253052	of newborns
0.0430970885	the rat model of
0.0430908550	the difference between
0.0430578763	and placebo in
0.0430513257	a potential for
0.0430414719	the natural history of
0.0430414719	a recognized complication of
0.0430386171	with thiopentone
0.0430097268	following exposure
0.0430019517	the mentioned
0.0429728233	a marker
0.0429713449	this initial
0.0429633057	after admission
0.0429627772	vehicle or
0.0429534935	the glutamatergic
0.0429534935	the vas
0.0429439262	during infusions of
0.0429427436	these doses
0.0429397124	the immunological
0.0429271091	somnolence and
0.0429245642	4 weeks after
0.0429181619	the dentate gyrus in
0.0429155540	the antagonism of
0.0429145328	the dramatic
0.0429145328	the hazard
0.0429093114	a protocol of
0.0428898184	of visual acuity and
0.0428824311	seizures during
0.0428463449	by carbamazepine
0.0428258901	immediate but
0.0427799814	for management
0.0427746593	and renal injury in
0.0427693954	an animal model of
0.0427438273	hours of
0.0427273197	by echocardiography and
0.0427179923	12 weeks of
0.0427093519	3 days after
0.0427091716	to control value
0.0427034638	the mtd
0.0427014517	way to
0.0426732702	1 month and
0.0426696764	the acetaminophen
0.0426424206	dilevalol and
0.0426424206	radiographic and
0.0426389536	more effective in
0.0426285768	reversed to
0.0426051912	in indian
0.0425963009	and tnf
0.0425858786	7 vs
0.0425823391	hippocampus after
0.0425815653	increased while
0.0425714808	and widely used
0.0425607913	the pharmacodynamic
0.0425556767	with paroxetine and
0.0425530860	did not differ in
0.0425483842	four hours after
0.0425431084	a convulsant
0.0425362348	and hepatoma
0.0425218210	the central nervous system to
0.0425143867	for prevention of
0.0425072465	ptcr and
0.0425028030	a targeted
0.0424957306	with ampicillin
0.0424957306	with cabergoline
0.0424852072	angina and
0.0424461989	to normal within
0.0424424531	of hematuria
0.0424198383	and depletion of
0.0424195410	release from
0.0424154474	with risperidone at
0.0424084572	medline and
0.0424072153	but many
0.0424039127	the beneficial effect of
0.0424003005	a useful drug in
0.0423992122	with cirrhosis
0.0423880491	infrequent and
0.0423738719	the etiology
0.0423726715	an alternative to
0.0423713449	by attention
0.0423458485	associated changes
0.0423409605	58 patients
0.0423381336	600 and
0.0423249281	after recovery of
0.0423113039	result of
0.0423009647	in animals with
0.0422992122	a nephrotoxic
0.0422969206	a percutaneous
0.0422760213	dependence of
0.0422739404	by determination of
0.0422686413	the acute phase of
0.0422636367	the dietary
0.0422296803	amb and
0.0422296803	atrophy in
0.0422237019	and neurochemical
0.0422178836	not clinically
0.0422158788	of salbutamol
0.0422141445	ketamine for
0.0421964272	crocin on
0.0421847225	than control
0.0421792052	d penicillamine in
0.0421783105	and extent of
0.0421783105	and measures of
0.0421748570	through inhibition of
0.0421688098	and h2
0.0421687060	a rise in
0.0421687060	a percentage of
0.0421571458	and qtc
0.0421437191	the respective
0.0421437191	the natural
0.0421394548	suxamethonium in
0.0421376192	in paediatric
0.0421198049	concentration on
0.0421140647	a reliable and
0.0420938057	and 7 days following
0.0420778564	and ulcer
0.0420751942	the locomotor hyperactivity induced by
0.0420456689	sites in
0.0420432219	and adam
0.0419885096	after succinylcholine
0.0419728542	of d2r
0.0419728211	and 45 minutes after
0.0419713449	by diazepam
0.0419708163	killed on
0.0419355372	a potentially serious
0.0419290242	after 6 weeks of
0.0419185909	and leukopenia
0.0418908682	different than
0.0418871331	of noradrenaline
0.0418841524	alone than
0.0418574288	a drop
0.0418418324	the effect of pretreatment with
0.0418269138	14 days after
0.0418257937	women without
0.0418126984	68 of
0.0417933183	also compared
0.0417929709	and often
0.0417901785	during treatment but
0.0417796808	and doxorubicin and
0.0417760213	plasticity of
0.0417760213	formulation of
0.0417746593	in convulsions induced by
0.0417718039	maintenance of
0.0417434093	the glomeruli of
0.0417409605	by reserpine
0.0417278847	and readily
0.0417236216	with low doses of
0.0416857988	and platelets
0.0416857988	and mucosal
0.0416812850	a modification of
0.0416809757	placed in
0.0416804989	on ct
0.0416762675	in childhood
0.0416759080	layer of
0.0416678187	s disease patients with
0.0416202308	with asa
0.0416060048	2 weeks after
0.0415885096	by isoniazid
0.0415811995	the limbs
0.0415595076	the nephrotoxic effects of
0.0415442276	different treatment
0.0415273358	a manifestation of
0.0415041192	infusion while
0.0415001281	the high incidence of
0.0414996362	and perhaps
0.0414960393	the trigeminal
0.0414868018	the patient recovered after
0.0414658788	of pemoline
0.0414641187	on mouse
0.0414593903	resection and
0.0414570366	three cases of
0.0414330265	a relative risk in
0.0414267687	tablets for
0.0414243828	phase of
0.0414100817	from exposure to
0.0414021830	the abundance of
0.0413951887	the lesioned
0.0413801135	15 cases of
0.0413596807	tachycardia associated with
0.0413490783	a relationship between
0.0413477283	from baseline in
0.0413362672	atrophy with
0.0413293388	patients under
0.0412760213	pituitary of
0.0412663744	and erythromycin
0.0412636367	the institution
0.0412636367	and spironolactone
0.0412509037	more pronounced in
0.0412034638	the alpha3
0.0412016333	and zinc
0.0411740102	in maintaining
0.0411728155	caa on
0.0411697867	replacement in
0.0411400085	ctni and
0.0411394415	hepatotoxicity associated with
0.0411324053	but remained
0.0411188971	3 l
0.0411187516	the hippocampus after
0.0411070603	of status epilepticus in
0.0410865049	and attenuated by
0.0410578763	the resolution of
0.0410490971	indices of
0.0410419219	the danish
0.0410363123	and disappearance of
0.0410353102	in f344
0.0410218782	hours during
0.0409949122	only if
0.0409922261	cerebellum and
0.0409908312	anatomical and
0.0409789778	the amounts of
0.0409752742	only three
0.0409682829	a steroid injection in
0.0409655540	the aorta and
0.0409353907	a total dose of
0.0409329361	not blocked by
0.0409120236	and returned to baseline after
0.0408987474	block with
0.0408576462	vnr and
0.0408576462	bendrofluazide and
0.0408513307	the number of patients with
0.0408395227	presentation with
0.0408233991	due to possible
0.0408072710	3 days later
0.0408020175	of erk
0.0407889196	the mini
0.0407799814	on dopaminergic
0.0407777018	selected to
0.0407600614	and propranolol for
0.0407366375	compounds at
0.0407092105	only one case of
0.0406878119	a faster
0.0406860890	the pharmacodynamics
0.0406835219	anesthesia with
0.0406784670	manic or
0.0406766163	a significant role in
0.0406439157	or tobramycin
0.0406396315	1986 to
0.0406146663	the cross
0.0406011247	using oral
0.0405632277	to respond to
0.0405578120	after 2 weeks of
0.0405154094	after 4 weeks of
0.0404992122	with streptozotocin
0.0404992122	with cyp
0.0404642713	4 h
0.0404538622	the cyclooxygenase
0.0404538622	the power
0.0404445678	the timing of
0.0404439483	four groups of
0.0404436258	a considerable
0.0404401665	the fifth
0.0404400778	3 months after
0.0404168787	records of
0.0404100631	stability and
0.0404055080	hypertension at
0.0404053536	and electrolytes
0.0404025768	for anticoagulation
0.0403924148	a specific inhibitor of
0.0403899722	the hypotensive effect of
0.0403897271	after conversion from
0.0403763893	in dbh +
0.0403628369	ciprofloxacin and
0.0403448143	5 days after
0.0403430935	given intravenously in
0.0403346615	initiated at
0.0403020776	vt or
0.0402948593	the proportion of
0.0402936245	pain at
0.0402890316	ten patients with
0.0402665697	per cent of
0.0402581380	2005 to
0.0402366102	the emergence of
0.0402202999	no recurrence of
0.0402141445	dexamethasone on
0.0402141445	lesions on
0.0402134465	a syndrome of
0.0401910250	of syncope
0.0401878612	the face
0.0401870902	glomerulonephritis in
0.0401849265	of wilson
0.0401750055	two different
0.0401606351	at various
0.0401598952	and pathologic
0.0401465688	the elevations of
0.0401137794	a shift
0.0400777877	membranes of
0.0400754054	and radiofrequency
0.0400734642	the implications of
0.0400594623	the dyskinetic
0.0400381627	a self
0.0400368092	a relation between
0.0400318107	haemorrhage in
0.0400144548	lethality in
0.0400144548	glaucoma in
0.0400144548	pallidotomy in
0.0400144548	anticoagulation in
0.0399948104	the cumulative dose of
0.0399718076	a wilson
0.0399455720	lt for
0.0399169874	s serum
0.0399096757	than normal
0.0399000161	of cytokine
0.0398897271	12 months after
0.0398881949	only five
0.0398766651	500 mg of
0.0398537568	interferon and
0.0398513572	of mu
0.0398513572	of energy
0.0398510023	on learning and
0.0398422518	with mesna for
0.0398279297	one month to
0.0398278564	the ptra
0.0398216745	induction with
0.0398188584	eyes from
0.0397913686	the optimal dose of
0.0397873166	outcome of
0.0397868329	a week for
0.0397777018	occurs to
0.0397423558	and june
0.0397102124	force in
0.0396950573	both types of
0.0396728080	and electrocardiography
0.0396653515	sedation with
0.0396618554	the pool
0.0396607913	the lp
0.0396603818	various degrees of
0.0396546306	hypotension due to
0.0396287718	the medulla but not in
0.0396186821	drugs used
0.0396059538	frequent but
0.0395892432	of cataract and
0.0395838763	course or
0.0395624394	the completion of
0.0395414464	and memory in
0.0395376672	therapies for
0.0395003984	but serious
0.0394733055	the median duration of
0.0394646939	cholestasis after
0.0394568164	six months after
0.0394538622	and inos
0.0394473529	variants of
0.0394263651	and maintenance of
0.0394142040	a shift of
0.0394111210	thromboembolism with
0.0394055080	prolonged after
0.0394055080	test at
0.0393739886	s space and
0.0393739886	and electrocardiographic changes
0.0393501207	and totally
0.0393381782	stabilized in
0.0393350193	assessed at
0.0393188584	infection during
0.0393171146	the annual
0.0392637335	and safety profile of
0.0392636367	and tiapride
0.0392565999	glaucoma or
0.0392500153	hydroxylase and
0.0392330671	thyroxine and
0.0392291061	the protection by
0.0392220020	the antinociceptive and
0.0391893779	the outcomes of
0.0391769705	with particular
0.0391666506	the incorporation of
0.0391465688	the safety and
0.0391135441	dysfunction due to
0.0390987428	of thalidomide in
0.0390699436	the recognition of
0.0390617270	second injection of
0.0390596616	the mean arterial pressure and
0.0390318107	benefits in
0.0390185677	contractility and
0.0390123575	of ouabain in
0.0390009556	nephritis and
0.0389933063	the requirement for
0.0389817402	with placebo in
0.0389788973	days during
0.0389780596	ltp in
0.0389780596	pseudolithiasis in
0.0389749166	occur with
0.0389734139	and vitamin e
0.0389698675	facility of
0.0389636468	functions by
0.0389380114	incorporation of
0.0389298943	immediate headache and
0.0389148825	following cessation of
0.0389143317	not subjected to
0.0389108314	hoarseness and
0.0388809018	calculated to
0.0388661840	histochemistry and
0.0388623389	a resurgence in
0.0388487033	this form of
0.0388422518	a return to
0.0387959678	arrhythmia as
0.0387833495	or matched
0.0387463558	not very
0.0387237033	2 days after
0.0387044740	later by
0.0387029790	the lozenge and
0.0386960084	dronedarone and
0.0386466610	organs with
0.0386415715	the management of patients with
0.0386179493	the criteria of
0.0386179493	a factor of
0.0386133021	that ouabain
0.0386026855	potential as
0.0385810251	evidence from
0.0385756589	of tobramycin and
0.0385518747	of nociception
0.0385432165	the epithelial
0.0385112183	imaging with
0.0385000161	of remoxipride
0.0384976567	suggested as
0.0384959409	in tumor size and
0.0384949868	daunorubicin and
0.0384934048	for clinical use
0.0384747224	a subgroup of
0.0384729911	a wide
0.0384343990	orally for
0.0384293701	nicotine on
0.0384235671	to evaluate whether
0.0384021991	an episode of
0.0383992122	a separate
0.0383912453	overload and
0.0383900083	a correlation between
0.0383537568	rna and
0.0383403699	a derivative of
0.0383341278	a direct effect of
0.0383261325	the slope of
0.0383087724	the alpha3 and
0.0383005094	and ex
0.0382810872	although several
0.0382599149	the records of
0.0382581838	the diagnostic value of
0.0382423255	the replication of
0.0382417991	to interfere with
0.0382317522	and shape of
0.0382251624	recovery from
0.0382101997	of choice in
0.0381902872	in od vs
0.0381864393	forces and
0.0381861262	age of
0.0381795319	power of
0.0381482903	a child with
0.0381449551	synthesis by
0.0381218076	with vcm
0.0381026855	common as
0.0380976567	hypotension during
0.0380906566	30 micrograms kg and
0.0380680425	triglyceride and
0.0380680425	night and
0.0380594623	and prompt
0.0380594623	and hemodynamics
0.0380404146	the key
0.0380404146	the erythrocyte
0.0380404146	the secretory
0.0380106999	most frequently in
0.0379935996	and erythropoietin
0.0379568697	mortality from
0.0379492888	last two doses of mesna with
0.0379343990	evidence on
0.0379222805	of opioids
0.0379222805	of prochlorperazine
0.0379163947	a subset of
0.0379097172	few cases of
0.0379093153	this type of
0.0378823604	the systemic toxicity of
0.0378438057	the cytoplasm of
0.0378395227	simultaneously with
0.0378368380	the treatment and prevention of
0.0377969326	combinations of
0.0377833495	with iodixanol
0.0377833495	with hypothyroidism
0.0377833495	with echocardiographic
0.0377458839	in parallel with
0.0377245519	the antiplatelet
0.0377245519	the epidemiological
0.0377181168	in hospitalized
0.0377156371	1 week of
0.0377083534	the cochlear
0.0376795319	morphology of
0.0376542007	increased among
0.0376501361	atracurium in
0.0376465688	the deficit in
0.0376414472	the causative
0.0376410251	syndrome during
0.0376220047	of atracurium in
0.0376055669	a face
0.0375736248	due to lack of
0.0375577588	of visceral
0.0375009468	in individuals with
0.0374534766	thrombosis associated with
0.0374306349	of vascular endothelial growth factor and
0.0374293701	values on
0.0373697010	from various
0.0373422518	to participate in
0.0373407592	in populations
0.0373132355	less severe in
0.0372978509	like effects in
0.0372925439	a cohort of
0.0372833581	and continued for
0.0372658788	of sulphasalazine
0.0372578976	4 months after
0.0372419529	a clinical trial of
0.0372271607	after ingestion of
0.0371962614	latencies to
0.0371521802	electrodes in
0.0371406115	in mean arterial pressure in
0.0371354945	of paranoid
0.0370987428	the urine of
0.0370944540	the associations
0.0370898843	and triglycerides
0.0370898843	and bmd
0.0370898843	and february
0.0370870593	and polymorphic
0.0370720590	of ketamine or
0.0370700453	developed within
0.0370680425	amantadine in
0.0370404146	the icu
0.0370257625	remained at
0.0370257625	reversed after
0.0369990543	adjusted to
0.0369762658	advantage of
0.0369745519	and allodynia
0.0369166620	average of
0.0369028404	a metabolite of
0.0369001326	derivatives of
0.0368819079	excitability in
0.0368631538	the analgesic effect of
0.0368368219	of oral d
0.0368360306	and oxidative damage in
0.0368340189	in dosages of
0.0368214534	the advantage of
0.0368200434	the relation between
0.0367839438	2.0 to
0.0367227113	of pheochromocytoma
0.0367062280	or saline for
0.0366920912	in rats pretreated with
0.0366735099	the underlying mechanism of
0.0366641021	action at
0.0366548204	the prolonged depletion of dopamine in
0.0366404790	the standard of care for
0.0366207336	concentrations at
0.0365603907	the differential diagnosis of
0.0365432165	the stimulant
0.0365257625	monitoring after
0.0365112183	pattern with
0.0364974267	of danazol
0.0364837231	after switching to
0.0364837228	density and
0.0364343990	safe for
0.0364265816	the pharmacology and
0.0363936674	an elevation in
0.0363867799	isoproterenol on
0.0363823604	the cardioprotective effects of
0.0363416617	200 micrograms of
0.0363415171	the domains of
0.0362969326	monotherapy with
0.0362861053	target of
0.0362697288	diagnosed in
0.0362525612	registry of
0.0362464290	information to
0.0362370177	in lag
0.0362112914	in hospitalised
0.0361867367	65 years with
0.0361676222	matrix and
0.0361666506	the benefits of
0.0361653270	120 min of
0.0361582899	feasible and
0.0361237435	as indicated
0.0361179099	by suppression of
0.0361116992	and inattention
0.0361116992	and reappeared
0.0361111050	in adolescents
0.0360952221	a correlation of
0.0360944540	the phenobarbitone
0.0360819371	in adult smokers with
0.0360404146	and etiology
0.0360182851	strains with
0.0359950696	of responders
0.0359911486	and castration
0.0359911486	and neurogenic
0.0359907125	the suspicion
0.0359907125	the electromyographic
0.0359907125	the slices
0.0359749166	diameter of
0.0359725371	increases during
0.0359684481	the antagonistic
0.0359606526	and morphological changes
0.0358977333	and alcohol use
0.0358929061	hyperalgesia in
0.0358929061	hyperactivity in
0.0358929061	defined in
0.0358892318	a slight
0.0358867799	recommended for
0.0358834510	the anatomical and
0.0358808930	of maternal smoking on
0.0358651376	and cannabis
0.0358502436	ethambutol for
0.0358310162	times during
0.0358117504	a deterioration of
0.0357839438	0.6 to
0.0357435996	and rubella
0.0357350277	deposition of
0.0357263228	one month of
0.0357149257	achieved at
0.0357008778	reduction or
0.0356741440	pirenzepine and
0.0355905324	of progestagen
0.0355905324	of milrinone
0.0355535504	outcomes of
0.0355314228	mechanisms by
0.0354915390	1984 and
0.0354861033	with disappearance of
0.0354416071	score at
0.0354343990	activation on
0.0353851182	and lr132
0.0353814851	a beneficial effect in
0.0352894743	anesthesia but
0.0352861053	membrane of
0.0352651491	recovery in
0.0352561972	thrombosis by
0.0352402231	co morbidity and
0.0352331203	effective as
0.0352201132	antagonists on
0.0351755357	recurrent or
0.0351706344	lasting for
0.0351701713	the cost of
0.0351554083	trained to
0.0351487466	the complete disappearance of
0.0351416531	pressures of
0.0351257625	reversible after
0.0351093236	and c3
0.0351093236	and musculoskeletal
0.0350648337	reports on
0.0350630100	the lvef
0.0350162957	recovered to
0.0350112183	origin of
0.0349907125	the racemic
0.0349749166	thrombosis or
0.0349337033	of nmdar and
0.0349323265	curve of
0.0349141039	calculi in
0.0349141039	immunoreactivity in
0.0349058245	alternative for
0.0348680620	significance of
0.0348505578	the benefits
0.0348505578	the nature
0.0348291223	detection and
0.0348200728	that microinjection of
0.0348144303	implantation of
0.0347613691	of mglur5
0.0347613691	of serological
0.0347245519	the swedish
0.0347245519	and chronotropic
0.0347245519	the preceding
0.0347245519	the neutral
0.0347245519	and pinacidil
0.0347245519	and pharmacodynamic
0.0346314406	proliferation and
0.0346229418	produced in
0.0345956063	persisted in
0.0345956063	potentiated in
0.0345821996	48 hours of
0.0345722805	of msg
0.0345098738	epileptogenesis and
0.0344181718	cost of
0.0343803807	weakness in
0.0343803807	disturbance in
0.0343291706	the superficial
0.0342721927	48 weeks of
0.0342561972	completely by
0.0342561972	recovery after
0.0341103803	attack with
0.0340956724	chick and
0.0340781434	abnormalities after
0.0340112183	pharmacology of
0.0340018716	frequent in
0.0339721010	and gynecologic
0.0339543844	of product use
0.0339416071	noted at
0.0338230659	systolic and
0.0337468163	and morphometric
0.0336416531	carriers of
0.0336260240	density of
0.0335956063	added in
0.0335956063	problem in
0.0335693927	extract of
0.0335490167	once daily for
0.0335461376	expressions of
0.0335252273	pronounced in
0.0335062955	proliferation in
0.0334806783	dexmedetomidine for
0.0334799455	longer with
0.0333803807	theophylline in
0.0333803807	examinations in
0.0333803807	normalized in
0.0333803807	technique in
0.0333803807	reabsorption and
0.0333803807	hyperkalemia in
0.0333803807	benign and
0.0333639651	plasticity in
0.0333540931	hypokalemia by
0.0333337487	diuresis and
0.0332656598	documented with
0.0332611268	walls and
0.0332561972	outcome after
0.0332211877	captopril on
0.0331778414	pregnancy or
0.0331730264	tolerance of
0.0331707058	in autism
0.0331268716	hemorrhage in
0.0331239232	in almost half of
0.0331123119	people with
0.0331103803	surveillance of
0.0330492401	behavior in
0.0330355265	changed with
0.0330181840	initiated in
0.0330018716	hepatotoxicity in
0.0329799455	potency of
0.0329799455	excess of
0.0329548947	encountered in
0.0329354132	volumes of
0.0328316717	amplitudes of
0.0327658639	and paf
0.0327489710	exercise on
0.0327452727	hypercholesterolemia and
0.0327396691	naproxen and
0.0327396691	avoided in
0.0326798278	consciousness and
0.0326496111	behaviors in
0.0326359277	selegiline and
0.0325314282	in tgr
0.0325305219	to focus on
0.0325297436	hyponatremia and
0.0325102670	limit of
0.0325091639	in genetically
0.0324799455	schedules of
0.0324799455	tablets of
0.0324458256	nh4ac and
0.0323803807	ineffective in
0.0323803807	picrotoxin in
0.0323676350	fields and
0.0322950130	dehydration and
0.0322656598	prescribed with
0.0321009714	acquisition of
0.0320956724	gastrocnemius and
0.0319354132	thresholds of
0.0318511532	tma and
0.0318092371	rosacea and
0.0317396691	bilaterally in
0.0316610512	iopamidol and
0.0316006352	defect in
0.0316006352	ouabain in
0.0316006352	deficit in
0.0315530161	substance in
0.0315262249	leakage of
0.0313803807	normotensive and
0.0313349112	entity in
0.0313349112	lymphadenopathy and
0.0313349112	polydipsia and
0.0313349112	metamizol in
0.0312375236	recognized in
0.0311758252	property of
0.0311255002	benzoylecgonine in
0.0311255002	vigilance in
0.0311255002	abundant in
0.0311006352	turnover in
0.0311006352	potentials in
0.0310114509	polymyositis and
0.0310102670	thickness of
0.0308798322	pathology of
0.0307396691	glycopyrrolate and
0.0307310699	delay in
0.0303863495	ca1 and
0.0303676350	aqp2 and
0.0303676350	piroxicam and
0.0302569892	myositis in
0.0302375236	monotherapy in
0.0302310699	vision in
0.0301469146	p53 in
0.0301006352	mutants in
0.0301006352	nerves in
0.0301006352	leg and
0.0300530161	neurotransmission in
0.0294950655	balance in
0.0294950655	discharges in
0.0294123045	trihexyphenidyl and
0.0293863495	hemodynamics and
0.0291265902	ulcers in
0.0290402704	route and
0.0290366073	vinorelbine in
0.0288021941	simple and
0.0288021941	fa and
0.0287985311	audiograms in
0.0287985311	progress in
0.0287985311	prostaglandins in
0.0287545561	mexiletine and
0.0286819341	clotting and
0.0286655465	preparation of
0.0286655465	comparisons of
